PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Seaman, J; Maguire, S				Seaman, J; Maguire, S			ABC of conflict and disaster - The special needs of children and women	BMJ-BRITISH MEDICAL JOURNAL			English	Review												s_r_maguire@yahoo.co.uk						Bracken Patrick., 1998, RETHINKING TRAUMA WA; The Sphere Project, 2004, HUM CHART MIN STAND	2	14	15	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	2005	331	7507					34	36		10.1136/bmj.331.7507.34	http://dx.doi.org/10.1136/bmj.331.7507.34			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947TD	15994690	Green Published			2022-12-28	WOS:000230668500020
J	Elitzur, M				Elitzur, M			Masers in the sky	SCIENCE			English	Editorial Material							REGION		Univ Kentucky, Dept Phys & Astron, Lexington, KY 40506 USA	University of Kentucky	Elitzur, M (corresponding author), Univ Kentucky, Dept Phys & Astron, Lexington, KY 40506 USA.	moshe@pa.uky.edu		Elitzur, Moshe/0000-0001-8143-3550				Crovisier J, 2002, ASTRON ASTROPHYS, V393, P1053, DOI 10.1051/0004-6361:20020673; Kanekar N, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.051302; MIYOSHI M, 1995, NATURE, V373, P127, DOI 10.1038/373127a0; Pestalozzi MR, 2004, ASTROPHYS J, V603, pL113, DOI 10.1086/383127; RIEU NO, 1976, ASTRON ASTROPHYS, V46, P413; Weisberg JM, 2005, SCIENCE, V309, P106, DOI 10.1126/science.1112494	6	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					71	72		10.1126/science.1114855	http://dx.doi.org/10.1126/science.1114855			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994519				2022-12-28	WOS:000230212800036
J	Hersch, GL; Burton, RE; Bolon, DN; Baker, TA; Sauer, RT				Hersch, GL; Burton, RE; Bolon, DN; Baker, TA; Sauer, RT			Asymmetric interactions of ATP with the AAA+ ClpX(6) unfoldase: Allosteric control of a protein machine	CELL			English	Article							MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; DEPENDENT PROTEOLYSIS; DEGRADATION MACHINE; HYDROLYSIS; BINDING; DNA; MECHANISM; HELICASE; HEXAMER	ATP hydrolysis by AAA+ ClpX hexamers powers protein unfolding and translocation during ClpXP degradation. Although ClpX is a homohexamer, positive and negative allosteric interactions partition six potential nucleotide binding sites into three classes with asymmetric properties. Some sites release ATP rapidly, others release ATP slowly, and at least two sites remain nucleotide free. Recognition of the degradation tag of protein substrates requires ATP binding to one set of sites and ATP or ADP binding to a second set of sites, suggesting a mechanism that allows repeated unfolding attempts without substrate release over multiple ATPase cycles. Our results rule out concerted hydrolysis models involving ClPX6 center dot ATP(6) or ClPX6 center dot ADP(6) and highlight structures of hexameric AAA+ machines with three or four nucleotides as likely functional states. These studies further emphasize commonalities between distant AAA+ family members, including protein and DNA translocases, helicases, motor proteins, clamp loaders, and other ATP-dependent enzymes.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Sauer, RT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	bobsauer@mit.edu		Sauer, Robert/0000-0002-1719-5399; Bolon, Daniel/0000-0001-5857-6676	NIAID NIH HHS [AI-15706] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015706, R37AI015706] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bolon DN, 2004, MOL CELL, V16, P343, DOI 10.1016/j.molcel.2004.10.001; Bolon DN, 2004, MOL CELL, V13, P443, DOI 10.1016/S1097-2765(04)00027-9; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Burton RE, 2005, NAT STRUCT MOL BIOL, V12, P245, DOI 10.1038/nsmb898; Burton RE, 2003, PROTEIN SCI, V12, P893, DOI 10.1110/ps.0237603; Burton RE, 2001, EMBO J, V20, P3092, DOI 10.1093/emboj/20.12.3092; Flynn JM, 2001, P NATL ACAD SCI USA, V98, P10584, DOI 10.1073/pnas.191375298; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Glover JR, 2001, BIOCHEM CELL BIOL, V79, P557, DOI 10.1139/bcb-79-5-557; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Hishida T, 2004, P NATL ACAD SCI USA, V101, P9573, DOI 10.1073/pnas.0403584101; Jeong YJ, 2002, J BIOL CHEM, V277, P43778, DOI 10.1074/jbc.M208634200; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Joshi SA, 2004, NAT STRUCT MOL BIOL, V11, P404, DOI 10.1038/nsmb752; Kenniston JA, 2005, P NATL ACAD SCI USA, V102, P1390, DOI 10.1073/pnas.0409634102; Kenniston JA, 2004, J STRUCT BIOL, V146, P130, DOI 10.1016/j.jsb.2003.10.023; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Kon T, 2004, BIOCHEMISTRY-US, V43, P11266, DOI 10.1021/bi048985a; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Marrione PE, 1996, BIOCHEMISTRY-US, V35, P11228, DOI 10.1021/bi960316c; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; Orelle C, 2003, J BIOL CHEM, V278, P47002, DOI 10.1074/jbc.M308268200; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; PATEL SS, 1995, BIOPHYS J, V68, pS186; Piszczek G, 2005, J BIOL CHEM, V280, P12221, DOI 10.1074/jbc.M411733200; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Segel IH, 1976, BIOCH CALCULATIONS; Siddiqui SM, 2004, GENE DEV, V18, P369, DOI 10.1101/gad.1170304; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Stitt BL, 2001, BIOCHEMISTRY-US, V40, P2276, DOI 10.1021/bi002253a; STITT BL, 1988, J BIOL CHEM, V263, P11130; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wah DA, 2002, CHEM BIOL, V9, P1237, DOI 10.1016/S1074-5521(02)00268-5; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Zalk R, 2003, BIOCHEM J, V374, P473, DOI 10.1042/BJ20030219	44	133	133	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	2005	121	7					1017	1027		10.1016/j.cell.2005.05.024	http://dx.doi.org/10.1016/j.cell.2005.05.024			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989952	Bronze			2022-12-28	WOS:000230448000009
J	Maione, D; Margarit, I; Rinaudo, CD; Masignani, V; Mora, M; Scarselli, M; Tettelin, H; Brettoni, C; Iacobini, ET; Rosini, R; D'Agostino, N; Miorin, L; Buccato, S; Mariani, M; Galli, G; Nogarotto, R; Nardi-Dei, V; Vegni, F; Fraser, C; Mancuso, G; Teti, G; Madoff, LC; Paoletti, LC; Rappuoli, R; Kasper, DL; Telford, JL; Grandi, G				Maione, D; Margarit, I; Rinaudo, CD; Masignani, V; Mora, M; Scarselli, M; Tettelin, H; Brettoni, C; Iacobini, ET; Rosini, R; D'Agostino, N; Miorin, L; Buccato, S; Mariani, M; Galli, G; Nogarotto, R; Nardi-Dei, V; Vegni, F; Fraser, C; Mancuso, G; Teti, G; Madoff, LC; Paoletti, LC; Rappuoli, R; Kasper, DL; Telford, JL; Grandi, G			Identification of a universal group B Streptococcus vaccine by multiple genome screen	SCIENCE			English	Article							PROTECTIVE IMMUNITY; INFECTIONS; ANTIBODY; PROTEIN; IMMUNIZATION; PATHOGEN; SEQUENCE; WOMEN	Group B Streptococcus (CBS) is a multiserotype bacterial pathogen representing a major cause of life-threatening infections in newborns. To develop a broadly protective vaccine, we analyzed the genome sequences of eight GBS isolates and cloned and tested 312 surface proteins as vaccines. Four proteins elicited protection in mice, and their combination proved highly protective against a large panel of strains, including all circulating serotypes. Protection also correlated with antigen accessibility on the bacterial surface and with the induction of opsonophagocytic antibodies. Multigenome analysis and screening described here represent a powerful strategy for identifying potential vaccine candidates against highly variable pathogens.	Chiron Srl, I-53100 Siena, Italy; Inst Genome Res, Rockville, MD 20850 USA; Univ Messina, Sch Med, Dept Pathol & Expt Microbiol, I-98125 Messina, Italy; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, Boston, MA 02125 USA	Novartis; J. Craig Venter Institute; University of Messina; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Grandi, G (corresponding author), Chiron Srl, Via Fiorentina 1, I-53100 Siena, Italy.	guido_grandi@chiron.com	D'Agostino, Nunzio/A-6071-2017; Telford, John Laird/ABG-8144-2020	D'Agostino, Nunzio/0000-0001-9840-3817; Mancuso, Giuseppe/0000-0001-5454-3228; Grandi, Guido/0000-0001-9724-2185; Fraser, Claire/0000-0003-1462-2428	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI060603] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI060603, AI-060603] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BAKER CJ, 1976, NEW ENGL J MED, V294, P753, DOI 10.1056/NEJM197604012941404; Brodeur BR, 2000, INFECT IMMUN, V68, P5610, DOI 10.1128/IAI.68.10.5610-5618.2000; Cheng Q, 2001, INFECT IMMUN, V69, P2302, DOI 10.1128/IAI.69.4.2302-2308.2001; Gibbs RS, 2004, OBSTET GYNECOL, V104, P1062, DOI 10.1097/01.AOG.0000144128.03913.c2; Jones N, 2003, J CLIN MICROBIOL, V41, P2530, DOI 10.1128/JCM.41.6.2530-2536.2003; Lachenauer CS, 1999, J INFECT DIS, V179, P1030, DOI 10.1086/314666; Lauer P, 2005, SCIENCE, V309, P105, DOI 10.1126/science.1111563; Lin FYC, 2004, J INFECT DIS, V190, P928, DOI 10.1086/422756; MADOFF LC, 1992, INFECT IMMUN, V60, P4989, DOI 10.1128/IAI.60.12.4989-4994.1992; Paoletti Lawrence C, 2002, Semin Neonatol, V7, P315, DOI 10.1053/siny.2002.0114; Paoletti LC, 2003, EXPERT OPIN BIOL TH, V3, P975, DOI 10.1517/14712598.3.6.975; Paoletti LC, 2001, VACCINE, V19, P2118, DOI 10.1016/S0264-410X(00)00437-0; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; Schuchat A, 1999, LANCET, V353, P51, DOI 10.1016/S0140-6736(98)07128-1; STALHAMMARCARLEMALM M, 1993, J EXP MED, V177, P1593, DOI 10.1084/jem.177.6.1593; Tettelin H, 2002, P NATL ACAD SCI USA, V99, P12391, DOI 10.1073/pnas.182380799	18	410	475	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 1	2005	309	5731					148	150		10.1126/science.1109869	http://dx.doi.org/10.1126/science.1109869			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994562	Green Accepted			2022-12-28	WOS:000230212800081
J	Joyal, F; Margaroli, P				Joyal, F; Margaroli, P			Calcific arteriopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Montreal, Notre Dame Hosp, Ctr Hosp, Montreal, PQ H2L 4M1, Canada	Universite de Montreal	Joyal, F (corresponding author), Univ Montreal, Notre Dame Hosp, Ctr Hosp, Montreal, PQ H2L 4M1, Canada.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					E24	E24		10.1056/NEJMicm040777	http://dx.doi.org/10.1056/NEJMicm040777			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	940HH	15987912				2022-12-28	WOS:000230133800011
J	Jacobson, MZ; Colella, WG; Golden, DM				Jacobson, MZ; Colella, WG; Golden, DM			Cleaning the air and improving health with hydrogen fuel-cell vehicles	SCIENCE			English	Article							GATOR-GCMM; POLLUTION; ECONOMY; US; STRATOSPHERE; TROPOSPHERE; WEATHER; BUDGET; IMPACT; OZONE	Converting all U.S. onroad vehicles to hydrogen fuel-cell vehicles (HFCVs) may improve air quality, health, and climate significantly, whether the hydrogen is produced by steam reforming of natural gas, wind electrolysis, or coal gasification. Most benefits would result from eliminating current vehicle exhaust. Wind and natural gas HFCVs offer the greatest potential health benefits and could save 3700 to 6400 U.S. lives annually. Wind HFCVs should benefit climate most. An all-HFCV fleet would hardly affect tropospheric water vapor concentrations. Conversion to coal HFCVs may improve health but would damage climate more than fossil/electric hybrids. The real cost of hydrogen from wind electrolysis may be below that of U.S. gasoline.	Stanford Univ, Dept Civil & Environm Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA	Stanford University; Stanford University	Jacobson, MZ (corresponding author), Stanford Univ, Dept Civil & Environm Engn, Stanford, CA 94305 USA.	jacobson@stanford.edu		Jacobson, Mark/0000-0002-4315-4128				Archer CL, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002076; BOLINGER M, SUMMARY POWER AUTHOR; COLELLA WC, IN PRESS J POWER SOU; Delucchi MA, 2000, J TRANSP ECON POLICY, V34, P135; Demirdoven N, 2004, SCIENCE, V305, P974, DOI 10.1126/science.1093965; Derwent RG, 2001, CLIMATIC CHANGE, V49, P463, DOI 10.1023/A:1010648913655; Heywood J.B., 2018, INTERNAL COMBUSTION; Jacobson MZ, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004945; Jacobson MZ, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018448; Jacobson MZ, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD002044; Jacobson MZ, 2001, J GEOPHYS RES-ATMOS, V106, P5385, DOI 10.1029/2000JD900560; Jacobson MZ, 2001, J GEOPHYS RES-ATMOS, V106, P5403, DOI 10.1029/2000JD900559; Jacobson MZ, 2001, SCIENCE, V293, P1438, DOI 10.1126/science.1063376; LEE K, 2004, WORLD REN EN C, V8; McCubbin DR, 1999, J TRANSP ECON POLICY, V33, P253; Myers DB, 2003, HYDROGEN RENEWABLE E; National Academy of Science, 2004, HYDR EC OPP COSTS BA; Novelli PC, 1999, J GEOPHYS RES-ATMOS, V104, P30427, DOI 10.1029/1999JD900788; *NREL, 2004, FS56036705 NREL; Rahn T, 2003, NATURE, V424, P918, DOI 10.1038/nature01917; Schultz MG, 2003, SCIENCE, V302, P624, DOI 10.1126/science.1089527; Service RF, 2004, SCIENCE, V305, P958, DOI 10.1126/science.305.5686.958; Tromp TK, 2003, SCIENCE, V300, P1740, DOI 10.1126/science.1085169; Turner JA, 2004, SCIENCE, V305, P972, DOI 10.1126/science.1103197; *US EPA, 2003, CLEAR INV EM FACT; Warwick NJ, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019224; 1998, EXTERNE EXTERNALITIE, V7	27	741	753	12	426	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	2005	308	5730					1901	1905		10.1126/science.1109157	http://dx.doi.org/10.1126/science.1109157			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976300				2022-12-28	WOS:000230120000038
J	Little, P; Rumsby, K; Kelly, J; Watson, L; Moore, M; Warner, G; Fahey, T; Williamson, I				Little, P; Rumsby, K; Kelly, J; Watson, L; Moore, M; Warner, G; Fahey, T; Williamson, I			Information leaflet and antibiotic prescribing strategies for acute lower respiratory tract infection - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; ACUTE COUGH; ACUTE BRONCHITIS; PNEUMONIA; ILLNESS; COMPLICATIONS; COMMUNITY; DIAGNOSIS; ETIOLOGY; PLACEBO	Context Acute lower respiratory tract infection is the most common condition treated in primary care. Many physicians still prescribe antibiotics; however, systematic reviews of the use of antibiotics are small and have diverse conclusions. Objective To estimate the effectiveness of 3 prescribing strategies and an information leaflet for acute lower respiratory tract infection. Design, Setting, and Patients A randomized controlled trial conducted from August 18, 1998, to July 30, 2003, of 80 patients presenting in a primary care setting with acute uncomplicated lower respiratory tract infection. Patients were assigned to 1 of 6 groups by a factorial design: leaflet or no leaflet and 1 of 3 antibiotic groups (immediate antibiotics, no offer of antibiotics, and delayed antibiotics). Intervention Three strategies, immediate antibiotics (n = 262), a delayed antibiotic prescription (n = 272), and no offer of antibiotics (n = 273), were prescribed. Approximately half of each group received an information leaflet (129 for immediate antibiotics, 136 for delayed antibiotic prescription, and 140 for no antibiotics)., Main Outcome Measures Symptom duration and severity. Results A total of 562 patients (70%) returned complete diaries and 78 (10%) provided information about both symptom duration and severity. Cough rated at least "a slight problem" lasted a mean of 11.7 days (25% of patients had a cough lasting >= 17 days). An information leaflet had no effect on the main outcomes. Compared with no offer of antibiotics, other strategies did not alter cough duration (delayed, 0.75 days; 95% confidence intervals [CI], -0.37 to 1.88; immediate, 0.11 days; 95% Cl, -1.01 to 1.24) or other primary outcomes. Compared with the immediate antibiotic group, slightly fewer patients in the delayed and control groups used antibiotics (96%, 20%, and 16%, respectively; P<.001) fewer patients were "very satisfied" (86%, 77%, and 72%, respectively; P=.005), and fewer patients believed in the effectiveness of antibiotics (75%, 40%, and 47%, respectively; P<.001). There were lower reattendances within a month with antibiotics (mean attendances for no antibiotics, 0.19; delayed, 0.12; and immediate, 0.11; P=.04) and higher attendance with a leaflet (mean attendances for no leaflet, 0.11; and leaflet, 0.17; P=.02). Conclusion No offer or a delayed offer of antibiotics for acute uncomplicated lower. respiratory tract infection is acceptable, associated with little difference in symptom resolution, and is likely to considerably reduce antibiotic use and beliefs in the effectiveness of antibiotics.	Univ Southampton, Aldermoor Hlth Ctr, Primary Med Care Grp, Southampton SO16 5ST, Hants, England; Nightingale Surg, Romsey, Hants, England; Three Swans Surg, Salisbury, England; Univ Dundee, Dept Primary Care, Dundee, Scotland	University of Southampton; University of Dundee	Little, P (corresponding author), Univ Southampton, Aldermoor Hlth Ctr, Primary Med Care Grp, Aldermoor Close, Southampton SO16 5ST, Hants, England.	p.little@soton.ac.uk	Moore, Michael/C-3447-2011; Fahey, Tom/C-9367-2012	Moore, Michael/0000-0002-5127-4509; Fahey, Tom/0000-0002-5896-5783; Rumsby, Kate/0000-0002-8573-3718; Little, Paul/0000-0003-3664-1873				Arroll B, 2002, J FAM PRACTICE, V51, P324; Cornford CS, 1998, BRIT J GEN PRACT, V48, P1751; DIEHR P, 1984, J CHRON DIS, V37, P215, DOI 10.1016/0021-9681(84)90149-8; Dowell J, 2001, BRIT J GEN PRACT, V51, P200; Fahey T, 1998, BRIT MED J, V316, P906, DOI 10.1136/bmj.316.7135.906; Flanders SA, 2004, AM J MED, V116, P529, DOI 10.1016/j.amjmed.2003.11.023; Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1; Gonzales R, 2003, JAMA-J AM MED ASSOC, V289, P2701, DOI 10.1001/jama.289.20.2701; Gonzales R, 2001, Eff Clin Pract, V4, P105; GONZALES R, 1995, LANCET, V345, P665, DOI 10.1016/S0140-6736(95)90861-7; Gonzales R, 2001, ANN EMERG MED, V37, P720, DOI 10.1067/mem.2001.em376720; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; Gonzales R, 2000, ANN INTERN MED, V133, P981, DOI 10.7326/0003-4819-133-12-200012190-00014; Hopstaken RM, 2003, BRIT J GEN PRACT, V53, P358; Huchon GJ, 1996, EUR RESPIR J, V9, P1590, DOI 10.1183/09031936.96.09081590; Little P, 2002, BRIT J GEN PRACT, V52, P187; Little P, 1997, BRIT MED J, V315, P350; Little P, 2001, BRIT J GEN PRACT, V51, P987; Macfarlane J, 2002, BRIT MED J, V324, P91, DOI 10.1136/bmj.324.7329.91; Macfarlane J, 2001, THORAX, V56, P109, DOI 10.1136/thorax.56.2.109; Macfarlane JT, 1997, BRIT J GEN PRACT, V47, P719; MACFARLANE JT, 1993, LANCET, V341, P511, DOI 10.1016/0140-6736(93)90275-L; MELBYE H, 1992, Scandinavian Journal of Primary Health Care, V10, P226, DOI 10.3109/02813439209014066; Melbye H., 1995, Tidsskrift for den Norske Laegeforening, V115, P1610; Melbye H, 1988, Scand J Prim Health Care, V6, P111, DOI 10.3109/02813438809009300; Office of Population Censuses and Surveys, 1994, MORB STAT GEN PRACT; Price D, 2003, RESP MED, V97, P12, DOI 10.1053/rmed.2002.1426; *SMAC, 1998, STAND MED ADV COMM S; Smith SM, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858, DOI 10.1002/14651858.CD000245.PUB2]; Spurling GKP, 2004, COCHRANE DB SYST REV; VERHEIJ TJM, 1994, BRIT J GEN PRACT, V44, P400; Watson L, 2001, FAM PRACT, V18, P553, DOI 10.1093/fampra/18.5.553; 1998, HOUSE LORDS SELECT C	33	185	186	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 22	2005	293	24					3029	3035		10.1001/jama.293.24.3029	http://dx.doi.org/10.1001/jama.293.24.3029			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937SG	15972565	Bronze			2022-12-28	WOS:000229945200018
J	Baba, D; Maita, N; Jee, JG; Uchimura, Y; Saitoh, H; Sugasawa, K; Hanaoka, F; Tochio, H; Hiroaki, H; Shirakawa, M				Baba, D; Maita, N; Jee, JG; Uchimura, Y; Saitoh, H; Sugasawa, K; Hanaoka, F; Tochio, H; Hiroaki, H; Shirakawa, M			Crystal structure of thymine DNA glycosylase conjugated to SUMO-1	NATURE			English	Article							UBIQUITIN; RECOGNITION; PROTEINS; NUCLEAR; COMPLEX	Members of the small ubiquitin-like modifier ( SUMO) family can be covalently attached to the lysine residue of a target protein through an enzymatic pathway similar to that used in ubiquitin conjugation(1), and are involved in various cellular events that do not rely on degradative signalling via the proteasome or lysosome(2-5). However, little is known about the molecular mechanisms of SUMO-modification-induced protein functional transfer. During DNA mismatch repair, SUMO conjugation of the uracil/ thymine DNA glycosylase TDG promotes the release of TDG from the abasic (AP) site created after base excision, and coordinates its transfer to AP endonuclease 1, which catalyses the next step in the repair pathway(6). Here we report the crystal structure of the central region of human TDG conjugated to SUMO-1 at 2.1 angstrom resolution. The structure reveals a helix protruding from the protein surface, which presumably interferes with the product DNA and thus promotes the dissociation of TDG from the DNA molecule. This helix is formed by covalent and non-covalent contacts between TDG and SUMO-1. The non-covalent contacts are also essential for release from the product DNA, as verified by mutagenesis.	Yokohama City Univ, Grad Sch Integrated Sci, Yokohama, Kanagawa 2300045, Japan; Japan Biol Informat Consortium, Tokyo 1040032, Japan; RIKEN Genom Sci Ctr, Kanagawa 2300045, Japan; Kumamoto Univ, Inst Mol Embryol & Genet, Dept Regenerat Med, Kumamoto 8600811, Japan; RIKEN, Discovery Res Inst, Cellular Physiol Lab, Wako, Saitama 3510198, Japan; Japan Sci & Technol Univ, SORST, Kawaguchi, Saitama 3320012, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Kyoto Univ, Grad Sch Engn, Kyoto 6158510, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Yokohama City University; RIKEN; Kumamoto University; RIKEN; Japan Science & Technology Agency (JST); Osaka University; Kyoto University; Japan Science & Technology Agency (JST)	Shirakawa, M (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Yokohama, Kanagawa 2300045, Japan.	shirakawa@moleng.kyoto-u.ac.jp	Maita, Nobuo/J-1443-2012; HIROAKI, HIDEKAZU/N-1658-2019; Hiroaki, Hidekazu/G-9564-2012; Tochio, Hidehito/F-6109-2011	Maita, Nobuo/0000-0003-2260-5783; HIROAKI, HIDEKAZU/0000-0003-1621-5893; Tochio, Hidehito/0000-0003-3843-3330				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W, 2002, PYMOL 0 99; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Hardeland U, 2000, J BIOL CHEM, V275, P33449, DOI 10.1074/jbc.M005095200; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Hardeland U, 2001, PROG NUCLEIC ACID RE, V68, P235; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Uchimura Y, 2004, ANAL BIOCHEM, V331, P204, DOI 10.1016/j.ab.2004.04.034; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67	25	177	187	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					979	982		10.1038/nature03634	http://dx.doi.org/10.1038/nature03634			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959518				2022-12-28	WOS:000229799700054
J	van Es, JH; van Gijn, ME; Riccio, O; van den Born, M; Vooijs, M; Begthel, H; Cozijnsen, M; Robine, S; Winton, DJ; Radtke, F; Clevers, H				van Es, JH; van Gijn, ME; Riccio, O; van den Born, M; Vooijs, M; Begthel, H; Cozijnsen, M; Robine, S; Winton, DJ; Radtke, F; Clevers, H			Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells	NATURE			English	Article							COLORECTAL-CANCER; NOTCH; RECOMBINATION; COMMITMENT; EXPRESSION; ENHANCER; COMPLEX; SPLIT; DELTA; FATE	The self-renewing epithelium of the small intestine is ordered into stem/progenitor crypt compartments and differentiated villus compartments. Recent evidence indicates that the Wnt cascade is the dominant force in controlling cell fate along the crypt-villus axis(1). Here we show a rapid, massive conversion of proliferative crypt cells into post-mitotic goblet cells after conditional removal of the common Notch pathway transcription factor CSL/RBP-J (ref. 2). We obtained a similar phenotype by blocking the Notch cascade with a gamma-secretase inhibitor. The inhibitor also induced goblet cell differentiation in adenomas in mice carrying a mutation of the Apc tumour suppressor gene. Thus, maintenance of undifferentiated, proliferative cells in crypts and adenomas requires the concerted activation of the Notch and Wnt cascades. Our data indicate that gamma-secretase inhibitors, developed for Alzheimer's disease, might be of therapeutic benefit in colorectal neoplastic disease.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland; Inst Curie, CNRS, UMR 144, F-75248 Paris, France; Addenbrookes Hosp, Cambridge Inst Med Res, Canc Res UK Dept Oncol, Cambridge CB2 2XY, England	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Ludwig Institute for Cancer Research; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; Cancer Research UK; University of Cambridge	Clevers, H (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	clevers@niob.knaw.nl	Radtke, Freddy/Q-3198-2017; van+Es, Johan/ABD-5411-2021; Vooijs, Marc/K-3522-2019	Radtke, Freddy/0000-0003-4315-4045; 				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Citron M, 2004, NAT REV NEUROSCI, V5, P677, DOI 10.1038/nrn1495; Crosnier C, 2005, DEVELOPMENT, V132, P1093, DOI 10.1242/dev.01644; DE SB, 1999, NATURE, V398, P518; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Heitzler P, 1996, DEVELOPMENT, V122, P161; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Moorman AFM, 2001, J HISTOCHEM CYTOCHEM, V49, P1, DOI 10.1177/002215540104900101; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Sander GR, 2004, J HISTOCHEM CYTOCHEM, V52, P509, DOI 10.1177/002215540405200409; Schroeder Natalia, 2002, Gene Expression Patterns, V2, P247, DOI 10.1016/S1567-133X(02)00060-1; Searfoss GH, 2003, J BIOL CHEM, V278, P46107, DOI 10.1074/jbc.M307757200; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Zheng JL, 2000, DEVELOPMENT, V127, P4551	28	1206	1258	5	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					959	963		10.1038/nature03659	http://dx.doi.org/10.1038/nature03659			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959515				2022-12-28	WOS:000229799700050
J	Frank, KT; Petrie, B; Choi, JS; Leggett, WC				Frank, KT; Petrie, B; Choi, JS; Leggett, WC			Trophic cascades in a formerly cod-dominated ecosystem	SCIENCE			English	Article							FOOD WEBS; FISHERIES; DYNAMICS	Removal of top predators from ecosystems can result in cascading effects through the trophic levels below, completely restructuring the food Web. Cascades have been observed in small-scale or simple food webs, but not in large, complex, open-ocean ecosystems. Using data spanning many decades from a once cod-dominated northwest Atlantic ecosystem, we demonstrate a trophic cascade in a large marine ecosystem. Several cod stocks in other geographic areas have also collapsed without recovery, suggesting the existence of trophic cascades in these systems.	Fisheries & Oceans Canada, Bedford Inst Oceanog, Ocean Sci Div, Dartmouth, NS B2Y 4A2, Canada; Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada	Bedford Institute of Oceanography; Fisheries & Oceans Canada; Queens University - Canada	Frank, KT (corresponding author), Fisheries & Oceans Canada, Bedford Inst Oceanog, Ocean Sci Div, POB 1006, Dartmouth, NS B2Y 4A2, Canada.	frankk@mar.dfo-mpo.gc.ca	Leggett, William C/F-6009-2011					Bowen WD, 2003, ICES J MAR SCI, V60, P1265, DOI 10.1016/S1054-3139(03)00147-4; Choi JS, 2005, OCEANOGR MAR BIOL, V43, P47; Choi JS, 2004, CAN J FISH AQUAT SCI, V61, P505, DOI 10.1139/F04-079; Estes JA, 1998, SCIENCE, V282, P473, DOI 10.1126/science.282.5388.473; FANNING LP, 2003, 27 CAN SCI ADV; Frank KT, 2000, ICES J MAR SCI, V57, P1023, DOI 10.1006/jmsc.2000.0587; Frank KT, 2000, CAN J FISH AQUAT SCI, V57, P513, DOI 10.1139/cjfas-57-3-513; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Jackson JBC, 2001, SCI MAR, V65, P273, DOI 10.3989/scimar.2001.65s2273; Micheli F, 1999, SCIENCE, V285, P1396, DOI 10.1126/science.285.5432.1396; Pace ML, 1999, TRENDS ECOL EVOL, V14, P483, DOI 10.1016/S0169-5347(99)01723-1; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; Polis GA, 2000, TRENDS ECOL EVOL, V15, P473, DOI 10.1016/S0169-5347(00)01971-6; Reid PC, 2000, ICES J MAR SCI, V57, P495, DOI 10.1006/jmsc.2000.0740; Scheffer M, 2001, NATURE, V413, P591, DOI 10.1038/35098000; Shurin JB, 2002, ECOL LETT, V5, P785, DOI 10.1046/j.1461-0248.2002.00381.x; Steele J. H., 2004, GLOBAL COASTAL OCEAN, V13; STRONG DR, 1992, ECOLOGY, V73, P747, DOI 10.2307/1940154; Terborgh J, 2001, SCIENCE, V294, P1923, DOI 10.1126/science.1064397; Worm B, 2003, ECOLOGY, V84, P162, DOI 10.1890/0012-9658(2003)084[0162:MAOCSI]2.0.CO;2	20	867	908	7	620	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 10	2005	308	5728					1621	1623		10.1126/science.1113075	http://dx.doi.org/10.1126/science.1113075			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947186				2022-12-28	WOS:000229827000055
J							US Preventive Serv Task Force	Screening for HIV: Recommendation statement	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; RISK; INFECTION; METAANALYSIS; TRANSUDATE; DIAGNOSIS; TYPE-1	This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on screening for HIV infection and the supporting scientific evidence, and updates the 1996 recommendations on this topic. The complete information on which this statement is based, including evidence tables and references, is included in the summaries of the evidence and evidence syntheses on this topic, available through the USPSTF Web site (www.preventiveservices.ahrq.gov). The recommendation is also posted on the Web site of the National Guideline Clearinghouse (www.guideline.gov).	US Prevent Serv Task Force Agcy Healthcare Res &, Rockville, MD USA				Abrams, William R/A-5782-2008					Aberg JA, 2004, CLIN INFECT DIS, V39, P609, DOI 10.1086/423390; ACOG Committee on Obstetric Practice, 2004, Obstet Gynecol, V104, P1119; *AM AC FAM PHYS, 2005, HIV INF STAT POL; *AM COLL NURS MIDW, 2000, ACNM POS STAT HUM IM; *AM MED ASS, 2005, UN ROUT SCREEN PREGN; Bucher HC, 1997, J ACQ IMMUN DEF SYND, V15, P104, DOI 10.1097/00042560-199706010-00002; Bulterys M, 2004, JAMA-J AM MED ASSOC, V292, P219, DOI 10.1001/jama.292.2.219; BULTERYS M, 2002, AIDSCIENCE, V2; CELUM CL, 1994, ARCH INTERN MED, V154, P1129, DOI 10.1001/archinte.154.10.1129; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P538; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P380; Crepaz N, 2004, JAMA-J AM MED ASSOC, V292, P224, DOI 10.1001/jama.292.2.224; *CTR DIS CONTR PRE, 2005, HIV AIDS SURV REP, V14; *DEP HLTH HUM SERV, 2004, GUID US ANT AG HIV; Dybul M, 2002, J INFECT DIS, V185, P1818, DOI 10.1086/340650; EICKHOFF TC, 1994, ANN INTERN MED, V120, P310; FLEMING PL, 2002, 9 C RETR OPP INF SEA; Frank AP, 1997, ARCH INTERN MED, V157, P309, DOI 10.1001/archinte.157.3.309; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Gallo D, 1997, JAMA-J AM MED ASSOC, V277, P254, DOI 10.1001/jama.277.3.254; Gielen AC, 1997, WOMEN HEALTH, V25, P19, DOI 10.1300/J013v25n03_02; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Ioannidis JPA, 1996, ARCH INTERN MED, V156, P177, DOI 10.1001/archinte.156.2.177; Klein D, 2003, JAIDS-J ACQ IMM DEF, V32, P143, DOI 10.1097/00126334-200302010-00005; Kleinman S, 1998, JAMA-J AM MED ASSOC, V280, P1080, DOI 10.1001/jama.280.12.1080; Kline MW, 2001, PEDIATRICS, V107, P188, DOI 10.1542/peds.107.1.188; KOCHANEK KD, 2004, DEATHS PRELIMINARY D, V52; Lee L M, 2001, J Am Med Womens Assoc (1972), V56, P94; Martinez PM, 1999, J CLIN MICROBIOL, V37, P1100; McNaghten AD, 1999, AIDS, V13, P1687, DOI 10.1097/00002030-199909100-00012; O'Connell RJ, 2003, J CLIN MICROBIOL, V41, P2153, DOI 10.1128/JCM.41.5.2153-2155.2003; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; Peterman TA, 1996, J ACQ IMMUN DEF SYND, V12, P69, DOI 10.1097/00042560-199605010-00010; Reynolds SJ, 2002, INT J STD AIDS, V13, P171, DOI 10.1258/0956462021924857; Sanders GD, 2005, NEW ENGL J MED, V352, P570, DOI 10.1056/NEJMsa042657; Tuomala RE, 2002, NEW ENGL J MED, V346, P1863, DOI 10.1056/NEJMoa991159; *US PREV SERV TAK, 1996, GUID CLIN PREV SERV; Walensky RP, 2002, ARCH INTERN MED, V162, P887, DOI 10.1001/archinte.162.8.887; 1992, CMAJ, V147, P867; 2004, MMWR MORB MORTAL WKL, V53, P523; 1999, PEDIATRICS, V104, P128; 2003, MMWR MORB MORTAL WKL, V52, P1145; 2001, MMWR MORB MORTAL WKL, V50, P6; 2000, MMWR MORB MORTAL WKL, V49, P512	46	54	55	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 5	2005	143	1					32	37		10.7326/0003-4819-143-1-200507050-00008	http://dx.doi.org/10.7326/0003-4819-143-1-200507050-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941XB	15998753				2022-12-28	WOS:000230246400005
J	Bystryn, JC; Rudolph, JL				Bystryn, JC; Rudolph, JL			Pemphigus	LANCET			English	Article							ANTI-CD20 MONOCLONAL-ANTIBODY; DRUG-INDUCED PEMPHIGUS; HIGH-DOSE CYCLOPHOSPHAMIDE; FOLIACEUS FOGO SELVAGEM; TOPICAL TACROLIMUS; MYCOPHENOLATE-MOFETIL; INTRAVENOUS IMMUNOGLOBULINS; PATHOGENIC AUTOANTIBODIES; AMERINDIAN RESERVATION; PLASMAPHERESIS THERAPY	Pemphigus is a rare autoimmune disease that results in blistering of the skin and oral cavity. It is caused by autoantibodies directed against cell-surface antigens on keratinocytes, which when targeted lose their cellular adhesion properties and separate from one another to form blisters within the epidermis. Differences in the particular antigens targeted by the antibodies and in the distribution of these antigens in the different regions of the body and in the separate layers of the epidermis result in different clinical manifestations of the disease. The disease is diagnosed based on its clinical manifestations (flaccid blisters and erosions on skin and oral mucosa), histology (epidermal acantholysis), and immunological abnormalities (circulating and tissue-fixed antibodies against keratinocyte surface antigens). Pemphigus, which if left untreated is almost always fatal, is generally managed with topical, oral, or intralesional corticosteroids. Other options include plasmapheresis and intravenous immunoglobulin (IVIg), coupled with cytotoxic drugs. Immunosupressants, anti-inflammatory drugs, and antibiotics are used as adjuvants, but apart from IVIg, these therapy options are non-specific and more research is needed to develop treatments with improved side-effect profiles.	NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY 10016 USA	New York University	Bystryn, JC (corresponding author), NYU, Sch Med, Ronald O Perelman Dept Dermatol, 560 1st Ave, New York, NY 10016 USA.	bystryn@nyu.edu						Aboobaker J, 2001, INT J DERMATOL, V40, P115, DOI 10.1046/j.1365-4362.2001.01124.x; AHMED AR, 1990, P NATL ACAD SCI USA, V87, P7658, DOI 10.1073/pnas.87.19.7658; AHMED AR, 1991, P NATL ACAD SCI USA, V88, P5056, DOI 10.1073/pnas.88.11.5056; Ahmed AR, 2001, J AM ACAD DERMATOL, V45, P679, DOI 10.1067/mjd.2001.116339; AKMAN A, 2002, ARCH DERMATOL, V138, P1252; Amagai M, 2000, NAT MED, V6, P1275, DOI 10.1038/81385; AMAGAI M, 1995, J INVEST DERMATOL, V104, P895, DOI 10.1111/1523-1747.ep12606168; Amagai M, 1999, J AM ACAD DERMATOL, V40, P167, DOI 10.1016/S0190-9622(99)70183-0; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; Amagai M, 1996, J INVEST DERMATOL, V106, P351, DOI 10.1111/1523-1747.ep12343081; Amagai M, 1999, J DERMATOL SCI, V20, P92, DOI 10.1016/S0923-1811(99)00016-X; AMAGAI M, 2002, DERMATOLOGY, P449; ANHALT CL, 1982, NEW ENGL J MED, V306, P1190; ANHALT GJ, 2003, FITZPATRICKS DERMATO; Aoyama Y, 1999, J INVEST DERMATOL, V112, P67, DOI 10.1046/j.1523-1747.1999.00463.x; AUERBACH R, 1979, ARCH DERMATOL, V115, P728, DOI 10.1001/archderm.115.6.728; BASSET N, 1987, ARCH DERMATOL, V123, P783, DOI 10.1001/archderm.123.6.783; BEUTNER EH, 1964, P SOC EXP BIOL MED, V117, P505; Brenner S, 1997, J AM ACAD DERMATOL, V36, P919, DOI 10.1016/S0190-9622(97)80273-3; Brenner S, 1998, CLIN DERMATOL, V16, P393, DOI 10.1016/S0738-081X(98)00010-8; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; BYSTRYN JC, 1978, J CLIN INVEST, V61, P339, DOI 10.1172/JCI108944; BYSTRYN JC, 1984, ARCH DERMATOL, V120, P941, DOI 10.1001/archderm.120.7.941; Bystryn JC, 2002, J AM ACAD DERMATOL, V47, P358, DOI 10.1067/mjd.2002.122735; Bystryn JC, 2002, J EUR ACAD DERMATOL, V16, P562, DOI 10.1046/j.1468-3083.2002.00412.x; Bystryn JC, 1996, ARCH DERMATOL, V132, P203, DOI 10.1001/archderm.132.2.203; BYSTRYN JC, 1988, ARCH DERMATOL, V124, P1702, DOI 10.1001/archderm.124.11.1702; Bystryn JC, 1985, PROG DERMATOL, V19, P1; BYSTRYN JC, J INVEST DERMATOL, V121, pC96; Caldelari R, 2001, J CELL BIOL, V153, P823, DOI 10.1083/jcb.153.4.823; Chrysomallis Fotis, 1994, International Journal of Dermatology, V33, P803, DOI 10.1111/j.1365-4362.1994.tb01003.x; Cooper HL, 2003, CLIN EXP DERMATOL, V28, P366, DOI 10.1046/j.1365-2230.2003.01283.x; DIAZ LA, 1989, J AM ACAD DERMATOL, V20, P657, DOI 10.1016/S0190-9622(89)70079-7; Ding X, 1999, J INVEST DERMATOL, V112, P739, DOI 10.1046/j.1523-1747.1999.00585.x; Dupuy A, 2004, ARCH DERMATOL, V140, P91, DOI 10.1001/archderm.140.1.91; Dutz JP, 1998, DERMATOL CLIN, V16, P235, DOI 10.1016/S0733-8635(05)70006-1; Eaton DP, 1998, J MED ENTOMOL, V35, P120, DOI 10.1093/jmedent/35.2.120; Engineer L, 2000, J AM ACAD DERMATOL, V43, P1049, DOI 10.1067/mjd.2000.108366; Enk AH, 1997, LANCET, V350, P494, DOI 10.1016/S0140-6736(05)63084-X; Espana A, 2004, J AM ACAD DERMATOL, V50, P974, DOI 10.1016/j.jaad.2003.08.021; FUNTEI YM, 2000, J INVEST DERMATOL, V115, P829; Gach JE, 2004, CLIN EXP DERMATOL, V29, P271, DOI 10.1111/j.1365-2230.2004.01499.x; Hacker MK, 2002, CLIN IMMUNOL, V105, P64, DOI 10.1006/clim.2002.5259; Hale EK, 2001, J AM ACAD DERMATOL, V44, P609, DOI 10.1067/mjd.2001.112225; Hanakawa Y, 2002, J INVEST DERMATOL, V119, P27, DOI 10.1046/j.1523-1747.2002.01780.x; Hans G, 1996, J INVEST DERMATOL, V107, P68, DOI 10.1111/1523-1747.ep12298213; Harman KE, 2003, BRIT J DERMATOL, V149, P926, DOI 10.1111/j.1365-2133.2003.05665.x; Hayag MV, 2000, J AM ACAD DERMATOL, V43, P1065, DOI 10.1067/mjd.2000.110397; Herbst A, 2000, J AM ACAD DERMATOL, V42, P422, DOI 10.1016/S0190-9622(00)90213-5; Herrmann G, 2003, BRIT J DERMATOL, V148, P602, DOI 10.1046/j.1365-2133.2003.05209_10.x; Hodgson TA, 2003, EUR J DERMATOL, V13, P142; HU CH, 1978, AM J PATHOL, V90, P345; Ioannides D, 2000, ARCH DERMATOL, V136, P868, DOI 10.1001/archderm.136.7.868; IOANNIDES D, 1991, J INVEST DERMATOL, V96, P159, DOI 10.1111/1523-1747.ep12460927; JABLONSKA S, 1975, INT J DERMATOL, V14, P83; Kricheli D, 2000, BRIT J DERMATOL, V143, P337, DOI 10.1046/j.1365-2133.2000.03659.x; Landau M, 1997, AM J DERMATOPATH, V19, P411, DOI 10.1097/00000372-199708000-00017; LEIBOLD AM, 1994, J CUTAN PATHOL, V21, P200, DOI 10.1111/j.1600-0560.1994.tb00261.x; Lester RS, 1998, DERMATOL CLIN, V16, P277, DOI 10.1016/S0733-8635(05)70010-3; Loiseau P, 2000, J AUTOIMMUN, V15, P67, DOI 10.1006/jaut.2000.0388; Luftl M, 2003, BRIT J DERMATOL, V149, P598, DOI 10.1046/j.1365-2133.2003.05513.x; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; Mimouni D, 2003, ARCH DERMATOL, V139, P739, DOI 10.1001/archderm.139.6.739; Mizrachi A., 2003, Journal of Investigative Dermatology, V121, P0320; MORAES JR, 1991, IMMUNOGENETICS, V33, P388, DOI 10.1007/BF00216698; Morrison LH, 2004, J AM ACAD DERMATOL, V51, P817, DOI 10.1016/j.jaad.2004.06.007; Mutasim DE, 2004, J AM ACAD DERMATOL, V51, P859, DOI 10.1016/j.jaad.2004.02.013; Nguyen VT, 2000, J CLIN INVEST, V106, P1467, DOI 10.1172/JCI10305; Nguyen VT, 1998, ARCH DERMATOL, V134, P971, DOI 10.1001/archderm.134.8.971; Nishimura J, 2000, J BONE MINER METAB, V18, P350, DOI 10.1007/s007740070008; Nousari CH, 2003, J AM ACAD DERMATOL, V49, P148, DOI 10.1067/mjd.2003.581; Powell AM, 2003, BRIT J DERMATOL, V149, P138, DOI 10.1046/j.1365-2133.2003.05269.x; ROCK B, 1989, NEW ENGL J MED, V320, P1463, DOI 10.1056/NEJM198906013202206; Ruach M, 1995, Obstet Gynecol Surv, V50, P755, DOI 10.1097/00006254-199510000-00023; Ruocco E, 2001, DERMATOLOGY, V203, P201, DOI 10.1159/000051749; Rutter A, 2001, J AM ACAD DERMATOL, V44, P1010, DOI 10.1067/mjd.2001.112325; Schmidt E, 2003, BRIT J DERMATOL, V148, P1222, DOI 10.1046/j.1365-2133.2003.05302.x; SHIMIZU H, 1995, J INVEST DERMATOL, V105, P153, DOI 10.1111/1523-1747.ep12316695; SISONFONACIER L, 1987, ARCH DERMATOL, V123, P1507, DOI 10.1001/archderm.123.11.1507; SISONFONACIER S, 1986, J EXP MED, V164, P2125, DOI 10.1084/jem.164.6.2125; Smith TJ, 1999, ARCH DERMATOL, V135, P1275, DOI 10.1001/archderm.135.10.1275; Stanley JR, 1999, FITZPATRICKS DERMATO, P654; TANLIM R, 1990, J AM ACAD DERMATOL, V22, P35, DOI 10.1016/0190-9622(90)70004-2; Termeer CC, 2004, J EUR ACAD DERMATOL, V18, P636, DOI 10.1111/j.1468-3083.2004.00980.x; Turner MS, 2000, J AM ACAD DERMATOL, V43, P1058, DOI 10.1067/mjd.2000.109297; Vecchietti G, 2003, BRIT J DERMATOL, V148, P833, DOI 10.1046/j.1365-2133.2003.05260.x; Veldman C, 2003, J IMMUNOL, V170, P635, DOI 10.4049/jimmunol.170.1.635; Warren SJP, 2003, J INVEST DERMATOL, V120, P104, DOI 10.1046/j.1523-1747.2003.12017.x; WASSERSTRUM N, 1983, JAMA-J AM MED ASSOC, V249, P1480; Werth VP, 1996, ARCH DERMATOL, V132, P1435, DOI 10.1001/archderm.132.12.1435; WOLF R, 1991, DERMATOLOGICA, V182, P207, DOI 10.1159/000247795	91	291	300	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	2005	366	9479					61	73		10.1016/S0140-6736(05)66829-8	http://dx.doi.org/10.1016/S0140-6736(05)66829-8			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993235				2022-12-28	WOS:000230277600036
J	Rothwell, PM; Giles, MF; Flossmann, E; Lovelock, CE; Redgrave, JNE; Warlow, CP; Mehta, Z				Rothwell, PM; Giles, MF; Flossmann, E; Lovelock, CE; Redgrave, JNE; Warlow, CP; Mehta, Z			A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack	LANCET			English	Article							SYMPTOMATIC CAROTID STENOSIS; ACUTE CORONARY SYNDROMES; PROGNOSIS; OXFORDSHIRE; ENDARTERECTOMY; CLOPIDOGREL; PREVENTION; MANAGEMENT; SUBGROUPS; MORTALITY	Background Effective early management of patients with transient ischaemic attacks (TIA) is undermined by an inability to predict who is at highest early risk of stroke. Methods We derived a score for 7-day risk of stroke in a population-based cohort of patients (n=209) with a probable or definite TIA (Oxfordshire Community Stroke Project; OCSP), and validated the score in a similar population-based cohort (Oxford Vascular Study; OXVASC, n=190). We assessed likely clinical usefulness to front-line health services by using the score to stratify all patients with suspected TIA referred to OXVASC (n=378, outcome: 7-day risk of stroke) and to a hospital-based weekly TIA clinic (n=210; outcome: risk of stroke before appointment) Results A six-point score derived in the OCSP (age [>= 60 years=1], blood pressure [systolic >140 mm Hg and/or diastolic >= 90 mm Hg=1], clinical features [unilateral weakness=2, speech disturbance without weakness=1, other=0], and duration of symptoms in min [>= 60=2,10-59=1, <10=0]; ABCD) was highly predictive of 7-day risk of stroke in OXVASC patients with probable or definite TIA (p<0.0001), in the OXVASC population-based cohort of all referrals with suspected TIA (p<0.0001), and in the hospital-based weekly TIA clinic-referred cohort (p=0.006). In the OXVASC suspected TIA cohort, 19 of 20 (95%) strokes occurred in 101 (27%) patients with a score of 5 or greater: 7-day risk was 0.4% (95% CI 0-1.1) in 274 (73%) patients with a score less than 5, 12.1% (4.2-20.0) in 66 (18%) with a score of 5, and 31.4% (16.0-46.8) in 35 (9%) with a score of 6. In the hospital-referred clinic cohort, 14 (7.5%) patients had a stroke before their scheduled appointment, all with a score of 4 or greater. Conclusions Risk of stroke during the 7 days after TIA seems to be highly predictable. Although further validations and refinements are needed, the ABCD score can be used in routine clinical practice to identify high-risk individuals who need emergency investigation and treatment.	Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England; Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland	Radcliffe Infirmary; University of Oxford; University of Edinburgh	Rothwell, PM (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England.	peter.rothwell@clneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	Medical Research Council [G0500987] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5; Bond R, 2003, STROKE, V34, P2290, DOI 10.1161/01.STR.0000087785.01407.CC; Coull AJ, 2004, STROKE, V35, P2041, DOI 10.1161/01.STR.0000137605.48864.2f; Coull AJ, 2004, STROKE, V35, P1925, DOI 10.1161/01.STR.0000133129.58126.67; Coull AJ, 2004, BMJ-BRIT MED J, V328, P326, DOI 10.1136/bmj.37991.635266.44; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; GILES MF, 2004, CEREBROVASC DIS, V17, P6; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; Goldstein LB, 2000, ARCH INTERN MED, V160, P2941, DOI 10.1001/archinte.160.19.2941; Gubitz G, 1999, CEREBROVASC DIS, V9, P210, DOI 10.1159/000015957; Hacke W, 2004, LANCET, V363, P768; HANKEY GJ, 1992, J NEUROL NEUROSUR PS, V55, P640, DOI 10.1136/jnnp.55.8.640; HATANO S, 1976, B WORLD HEALTH ORGAN, V56, P541; Hill MD, 2004, NEUROLOGY, V62, P2015, DOI 10.1212/01.WNL.0000129482.70315.2F; *INT STROK TRIAL C, 1977, LANCET, V349, P1569; Intercollegiate working Party for Stroke, 2004, NAT CLIN GUID STROK; Johnston SC, 2003, NEUROLOGY, V60, P1429, DOI 10.1212/01.WNL.0000063309.41867.0F; Johnston SC, 1999, EUR NEUROL, V42, P105, DOI 10.1159/000069419; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; KENNEDY J, 2003, SEMIN CEREBROVASC DI, V3, P25; Kernan WN, 2000, STROKE, V31, P456, DOI 10.1161/01.STR.31.2.456; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lisabeth LD, 2004, STROKE, V35, P1842, DOI 10.1161/01.STR.0000134416.89389.9d; Lovett JK, 2004, NEUROLOGY, V62, P569, DOI 10.1212/01.WNL.0000110311.09970.83; Lovett JK, 2003, STROKE, V34, pE138, DOI 10.1161/01.STR.0000080935.01264.91; Markus HS, 2005, CIRCULATION, V111, P2233, DOI 10.1161/01.CIR.0000163561.90680.1C; Ovbiagele B, 2004, STROKE, V35, P2879, DOI 10.1161/01.STR.0000147967.49567.d6; Pearce LA, 2000, AM J MED, V109, P45, DOI 10.1016/S0002-9343(00)00440-X; Purroy F, 2004, STROKE, V35, P2313, DOI 10.1161/01.STR.0000141703.21173.91; Rothwell PM, 2004, LANCET, V363, P915, DOI 10.1016/S0140-6736(04)15785-1; Rothwell PM, 2005, NEUROLOGY, V64, P817, DOI 10.1212/01.WNL.0000152985.32732.EE; Rothwell PM, 2003, CEREBROVASC DIS, V16, P2, DOI 10.1159/000070271; Rothwell PM, 2005, LANCET, V365, P256; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Wolf PA, 1999, STROKE, V30, P1991, DOI 10.1161/01.STR.30.9.1991; Yusuf S, 2001, NEW ENGL J MED, V345, P494	39	436	495	4	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	2005	366	9479					29	36		10.1016/S0140-6736(05)66702-5	http://dx.doi.org/10.1016/S0140-6736(05)66702-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993230				2022-12-28	WOS:000230277600031
J	Gardner, MJ; Bishop, R; Shah, T; de Villiers, EP; Carlton, JM; Hall, N; Ren, QH; Paulsen, IT; Pain, A; Berriman, M; Wilson, RJM; Sato, S; Ralph, SA; Mann, DJ; Xiong, ZK; Shallom, SJ; Weidman, J; Jiang, LX; Lynn, J; Weaver, B; Shoaibi, A; Domingo, AR; Wasawo, D; Crabtree, J; Wortman, JR; Haas, B; Angiuoli, SV; Creasy, TH; Lu, C; Suh, B; Silva, JC; Utterback, TR; Feldblyum, TV; Pertea, M; Allen, J; Nierman, WC; Taracha, ELN; Salzberg, SL; White, OR; Fitzhugh, HA; Morzaria, S; Venter, JC; Fraser, CM; Nene, V				Gardner, MJ; Bishop, R; Shah, T; de Villiers, EP; Carlton, JM; Hall, N; Ren, QH; Paulsen, IT; Pain, A; Berriman, M; Wilson, RJM; Sato, S; Ralph, SA; Mann, DJ; Xiong, ZK; Shallom, SJ; Weidman, J; Jiang, LX; Lynn, J; Weaver, B; Shoaibi, A; Domingo, AR; Wasawo, D; Crabtree, J; Wortman, JR; Haas, B; Angiuoli, SV; Creasy, TH; Lu, C; Suh, B; Silva, JC; Utterback, TR; Feldblyum, TV; Pertea, M; Allen, J; Nierman, WC; Taracha, ELN; Salzberg, SL; White, OR; Fitzhugh, HA; Morzaria, S; Venter, JC; Fraser, CM; Nene, V			Genome sequence of Theileria parva, a bovine pathogen that transforms lymphocytes	SCIENCE			English	Article							PARASITE PLASMODIUM-FALCIPARUM; PYRUVATE-DEHYDROGENASE COMPLEX; OPEN READING FRAMES; ENCODED PROTEINS; MALARIA; GENES; DNA; APICOMPLEXAN; MITOCHONDRIA; TELOMERES	We report the genome sequence of Theileria parva, an apicomplexan pathogen causing economic losses to smallholder farmers in Africa. The parasite chromosomes exhibit limited conservation of gene synteny with Plasmodium falciparum, and its plastid-like genome represents the first example where all apicoplast genes are encoded on one DNA strand. We tentatively identify proteins that facilitate parasite segregation during host cell cytokinesis and contribute to persistent infection of transformed host cells. Several biosynthetic pathways are incomplete or absent, suggesting substantial metabolic dependence on the host cell. One protein family that may generate parasite antigenic diversity is not telomere-associated.	Inst Genom Res TIGR, Rockville, MD 20850 USA; Int Livestock Res Inst, Nairobi, Kenya; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Natl Inst Med Res, London NW7 1AA, England; Inst Pasteur, F-75724 Paris, France; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Venter Inst, Rockville, MD 20850 USA	J. Craig Venter Institute; CGIAR; International Livestock Research Institute (ILRI); Wellcome Trust Sanger Institute; MRC National Institute for Medical Research; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Imperial College London; J. Craig Venter Institute	Gardner, MJ (corresponding author), Inst Genom Res TIGR, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	gardner@tigr.org	Paulsen, Ian T/K-3832-2012; Silva, Joana/GVT-6441-2022; Salzberg, Steven/Q-6514-2019; Salzberg, Steven L/F-6162-2011; Angiuoli, Samuel V/H-7340-2014; Berriman, Matthew/A-7618-2011; Pertea, Mihaela/AAT-2705-2021; Pain, Arnab/L-5766-2015; Silva, Joana/GYQ-9526-2022; Hall, Neil/A-8717-2013; Ralph, Stuart/C-8590-2014; Sato, Shigeharu/K-9464-2013	Paulsen, Ian T/0000-0001-9015-9418; Salzberg, Steven/0000-0002-8859-7432; Salzberg, Steven L/0000-0002-8859-7432; Berriman, Matthew/0000-0002-9581-0377; Pertea, Mihaela/0000-0003-0762-8637; Pain, Arnab/0000-0002-1755-2819; Hall, Neil/0000-0002-7995-3810; Sato, Shigeharu/0000-0003-2738-430X; Wortman, Jennifer/0000-0002-8713-1227; Nene, Vishvanath/0000-0001-7066-4169; de Villiers, Etienne/0000-0001-9878-1009; Shah, Trushar/0000-0002-0091-7981; Fraser, Claire/0000-0003-1462-2428; Gardner, Malcolm/0000-0003-2180-5089; Hall, Neil/0000-0003-2808-0009; Angiuoli, Samuel/0000-0001-9525-4350; Ralph, Stuart/0000-0003-0114-7808; Allen, Jonathan/0000-0002-4359-8263; Sato, Shigeharu/0000-0001-9559-7580				Abrahamsen MS, 2004, SCIENCE, V304, P441, DOI 10.1126/science.1094786; ANDERS RF, 1986, PARASITE IMMUNOL, V8, P529, DOI 10.1111/j.1365-3024.1986.tb00867.x; Barry JD, 2003, INT J PARASITOL, V33, P29, DOI 10.1016/S0020-7519(02)00247-3; BAYLIS HA, 1991, MOL BIOCHEM PARASIT, V49, P133, DOI 10.1016/0166-6851(91)90136-T; Bishop R, 1997, MOL CELL BIOL, V17, P1666, DOI 10.1128/MCB.17.3.1666; Bishop R, 2000, MOL BIOCHEM PARASIT, V110, P359, DOI 10.1016/S0166-6851(00)00291-7; BISHOP R, UNPUB; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Cheeseman IM, 2004, CURR BIOL, V14, pR70, DOI 10.1016/j.cub.2003.12.048; ESCALANTE AA, 1995, P NATL ACAD SCI USA, V92, P5793, DOI 10.1073/pnas.92.13.5793; Foth BJ, 2005, MOL MICROBIOL, V55, P39, DOI 10.1111/j.1365-2958.2004.04407.x; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Goedert M, 2004, SEMIN CELL DEV BIOL, V15, P45, DOI 10.1016/j.semcdb.2003.12.015; GRAHAM SV, UNPUB; GUNDERSON JH, 1987, SCIENCE, V238, P933, DOI 10.1126/science.3672135; KAIRO A, 1994, EMBO J, V13, P898, DOI 10.1002/j.1460-2075.1994.tb06333.x; Leon S, 2003, BIOCHEM J, V371, P823, DOI 10.1042/BJ20021946; MCCOLM AA, 1984, ANN TROP MED PARASIT, V78, P345, DOI 10.1080/00034983.1984.11811831; Norval R.A.I., 1992, EPIDEMIOLOGY THEILER, P481; Pain A, 2005, SCIENCE, V309, P131, DOI 10.1126/science.1110418; Ralph SA, 2005, MOL MICROBIOL, V55, P1, DOI 10.1111/j.1365-2958.2004.04314.x; Seeber F, 2002, INT J PARASITOL, V32, P1207, DOI 10.1016/S0020-7519(02)00022-X; Sohanpal B, 2000, GENE, V255, P401, DOI 10.1016/S0378-1119(00)00284-5; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Walter RF, 2005, CURR ISSUES MOL BIOL, V7, P57, DOI 10.21775/cimb.007.057; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; Xu XM, 2004, P NATL ACAD SCI USA, V101, P9143, DOI 10.1073/pnas.0400799101	29	255	308	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					134	137		10.1126/science.1110439	http://dx.doi.org/10.1126/science.1110439			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994558	Bronze			2022-12-28	WOS:000230212800076
J	Maeda, S; Kamata, H; Luo, JL; Leffert, H; Karin, M				Maeda, S; Kamata, H; Luo, JL; Leffert, H; Karin, M			IKK beta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis	CELL			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; HEPATOCELLULAR-CARCINOMA; NUCLEAR-FACTOR; TRANSGENIC MICE; LIVER-REGENERATION; JNK ACTIVATION; MOUSE-LIVER; CELL-DEATH; TNF-ALPHA	I kappa B kinase beta (IKK beta), required for NF-kappa B activation, links chronic inflammation with carcinogenesis. We investigated whether IKK beta is involved in chemically induced liver cancer, a model not involving overt inflammation. Surprisingly, mice lacking IKK beta only in hepatocytes (Ikk beta(Delta hep) mice) exhibited a marked increase in hepatocarcinogenesis caused by diethylnitrosamine (DEN). This correlated with enhanced reactive oxygen species (ROS) production, increased JNK activation, and hepatocyte death, giving rise to augmented compensatory proliferation of surviving hepatocytes. Brief oral administration of an antioxidant around the time of DEN exposure blocked prolonged JNK activation and compensatory proliferation and prevented excessive DEN-induced carcinogenesis in Ikk beta(Delta hep) mice. Decreased hepatocarcinogenesis was also found in mice lacking IKKP in both hepatocytes and hematopoietic-derived Kupffer cells. These mice exhibited reduced hepatocyte regeneration and diminished induction of hepatomitogens, which were unaltered in Ikk beta(Delta hep) mice. IKK beta, therefore, orchestrates inflammatory crosstalk between hepatocytes and hematopoietic-derived cells that promotes chemical hepatocarcinogenesis.	Univ Calif San Diego, Sch Med, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr,MC 0723, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Kamata, Hideaki/N-3907-2017	Luo, Jun-Li/0000-0002-7625-4766	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337, R01ES006376] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43477] Funding Source: Medline; NIEHS NIH HHS [ES06376, ES010337] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BERENBLUM I, 1954, ADV CANCER RES, V2, P129, DOI 10.1016/S0065-230X(08)60493-5; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Cavin LG, 2004, CANCER RES, V64, P7030, DOI 10.1158/0008-5472.CAN-04-1647; CHISARI FV, 1995, HEPATOLOGY, V22, P1316, DOI 10.1016/0270-9139(95)90645-2; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; DYROFF MC, 1986, CARCINOGENESIS, V7, P241, DOI 10.1093/carcin/7.2.241; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Factor VM, 2000, P NATL ACAD SCI USA, V97, P2196, DOI 10.1073/pnas.040428797; FARBER J L, 1984, Pharmacological Reviews, V36, p71S; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fausto N, 1999, SEMIN LIVER DIS, V19, P243, DOI 10.1055/s-2007-1007114; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hara A, 2000, BRIT J CANCER, V82, P467; HARDONK MJ, 1992, J LEUKOCYTE BIOL, V52, P296, DOI 10.1002/jlb.52.3.296; Horiguchi N, 2002, ONCOGENE, V21, P1791, DOI 10.1038/sj.onc.1205248; Hsu LC, 2004, NATURE, V428, P341, DOI 10.1038/nature02405; Im YH, 2001, CANCER RES, V61, P6665; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; Kobayashi A, 2004, METHOD ENZYMOL, V378, P273; KORSMEYER SJ, 1992, BLOOD, V80, P879; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; LIAO WSL, 1980, J BIOL CHEM, V255, P36; Lieber A, 1997, J VIROL, V71, P8798, DOI 10.1128/JVI.71.11.8798-8807.1997; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; MAUAD TH, 1994, AM J PATHOL, V145, P1237; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Pierce RH, 2002, AM J PATHOL, V160, P1555, DOI 10.1016/S0002-9440(10)61101-7; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; SARMA DSR, 1986, CANCER SURV, V5, P781; Satoh K, 2002, CARCINOGENESIS, V23, P457, DOI 10.1093/carcin/23.3.457; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schirmacher P, 1993, EXS, V65, P285; SELL S, 1982, HEPATOLOGY, V2, P77; Tai DI, 2000, CANCER, V89, P2274, DOI 10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.0.CO;2-2; TALBOT D, 1994, NUCLEIC ACIDS RES, V22, P756, DOI 10.1093/nar/22.5.756; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Thorgeirsson SS, 2000, TOXICOL LETT, V112, P553, DOI 10.1016/S0378-4274(99)00224-6; Verna L, 1996, PHARMACOL THERAPEUT, V71, P57, DOI 10.1016/0163-7258(96)00062-9; WILLIAMS GM, 1993, TOXICOL IND HEALTH, V9, P303, DOI 10.1177/0748233793009001-222; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; Zhou ZX, 2004, AM J PATHOL, V164, P1547, DOI 10.1016/S0002-9440(10)63713-3	54	914	958	4	52	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	2005	121	7					977	990		10.1016/j.cell.2005.04.014	http://dx.doi.org/10.1016/j.cell.2005.04.014			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989949	Bronze			2022-12-28	WOS:000230448000006
J	Masson-Delmotte, V; Jouzel, J; Landais, A; Stievenard, M; Johnsen, SJ; White, JWC; Werner, M; Sveinbjornsdottir, A; Fuhrer, K				Masson-Delmotte, V; Jouzel, J; Landais, A; Stievenard, M; Johnsen, SJ; White, JWC; Werner, M; Sveinbjornsdottir, A; Fuhrer, K			GRIP deuterium excess reveals rapid and orbital-scale changes in Greenland moisture origin	SCIENCE			English	Article							NORTH-ATLANTIC OCEAN; ABRUPT CLIMATE-CHANGE; VOSTOK ICE CORE; TEMPERATURE-CHANGES; VARIABILITY; AIR; PRECIPITATION; ACCUMULATION; RECORD; CYCLE	The Northern Hemisphere hydrological cycle is a key factor coupling ice sheets, ocean circulation, and polar amplification of climate change. Here we present a Northern Hemisphere deuterium excess profile covering one climatic cycle, constructed with the use of delta O-18 and delta D Greenland Ice Core Project (GRIP) records. Past changes in Greenland source and site temperatures are quantified with precipitation seasonality taken into account. The imprint of obliquity is evidenced in the site-to-source temperature gradient at orbital scale. At the millennial. time scale, GRIP source temperature changes reflect southward shifts of the geographical locations of moisture sources during cold events, and these rapid shifts are associated with large-scale changes in atmospheric circulation.	CEA Saclay, UMR CEA CNRS, IPSL LSCE, F-91191 Gif Sur Yvette, France; Univ Copenhagen, Dept Geophys, DK-2100 Copenhagen, Denmark; Univ Iceland, Inst Sci, IS-107 Reykjavik, Iceland; Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA; Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA; Max Planck Inst Biogeochem, D-07701 Jena, Germany; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland	UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); University of Copenhagen; University of Iceland; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Max Planck Society; University of Bern	Masson-Delmotte, V (corresponding author), CEA Saclay, UMR CEA CNRS, IPSL LSCE, F-91191 Gif Sur Yvette, France.	valerie.masson@cea.fr	Werner, Martin/C-8067-2014; Masson-Delmotte, Valerie L/G-1995-2011; White, James W.C./A-7845-2009	Werner, Martin/0000-0002-6473-0243; Masson-Delmotte, Valerie L/0000-0001-8296-381X; White, James W.C./0000-0001-6041-4684; LANDAIS, Amaelle/0000-0002-5620-5465				Andersen KK, 2004, NATURE, V431, P147, DOI 10.1038/nature02805; Armengaud A, 1998, J GEOPHYS RES-ATMOS, V103, P8947, DOI 10.1029/98JD00274; BERGER A, 1977, CELESTIAL MECH, V15, P53, DOI 10.1007/BF01229048; Boyle EA, 1997, GEOPHYS RES LETT, V24, P273, DOI 10.1029/97GL00081; CHAPPELLAZ J, 1993, NATURE, V366, P443, DOI 10.1038/366443a0; CIAIS P, 1994, J GEOPHYS RES-ATMOS, V99, P16793, DOI 10.1029/94JD00412; *CLIMAP, 1981, GSA MAP CHART SER; Cortijo E, 1997, EARTH PLANET SC LETT, V146, P29, DOI 10.1016/S0012-821X(96)00217-8; Cortijo E, 1999, PALEOCEANOGRAPHY, V14, P23, DOI 10.1029/1998PA900004; Cortijo E, 2000, QUATERNARY SCI REV, V19, P227, DOI 10.1016/S0277-3791(99)00063-3; Cuffey KM, 1997, J GEOPHYS RES-OCEANS, V102, P26383, DOI 10.1029/96JC03981; CUFFEY KM, 1995, SCIENCE, V270, P455, DOI 10.1126/science.270.5235.455; Cuffey KM, 2001, NATURE, V412, P523, DOI 10.1038/35087544; DahlJensen D, 1998, SCIENCE, V282, P268, DOI 10.1126/science.282.5387.268; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; DANSGAARD W, 1964, TELLUS, V16, P436; Fuhrer K, 1999, J GEOPHYS RES-ATMOS, V104, P31043, DOI 10.1029/1999JD900929; Grachev AM, 2003, J PHYS CHEM A, V107, P4636, DOI 10.1021/jp027817u; Hoffmann G, 2001, J GEOPHYS RES-ATMOS, V106, P14265, DOI 10.1029/2000JD900585; Hoffmann G., 1998, INT S IS TECHN STUD, P591; Johnsen SJ, 1989, TELLUS B, V41, P452, DOI 10.1111/j.1600-0889.1989.tb00321.x; JOHNSEN SJ, 1995, TELLUS B, V47, P624, DOI 10.1034/j.1600-0889.47.issue5.9.x; JOUZEL J, 1987, NATURE, V329, P403, DOI 10.1038/329403a0; JOUZEL J, 2003, M EUR GEOPH SOC NIC; Kageyama M, 2000, GEOPHYS RES LETT, V27, P1515, DOI 10.1029/1999GL011274; Krinner G, 1997, GEOPHYS RES LETT, V24, P2825, DOI 10.1029/97GL52891; Landais A, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004193; Landais A, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021193; Landais A, 2004, EARTH PLANET SC LETT, V225, P221, DOI 10.1016/j.epsl.2004.06.009; LANG C, 1999, SCIENCE; Liu Z, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000819; LORIUS C, 1977, ISOTOPES IMPURITIES, P125; Loutre MF, 2004, EARTH PLANET SC LETT, V221, P1, DOI 10.1016/S0012-821X(04)00108-6; Masson-Delmotte V, 2004, HOLOCENE, V14, P145, DOI 10.1191/0959683604hl697ft; MASSONDELMOTTE V, IN PRESS J GEOPHYS R; Peterson LC, 2000, SCIENCE, V290, P1947, DOI 10.1126/science.290.5498.1947; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Severinghaus JP, 1999, SCIENCE, V286, P930, DOI 10.1126/science.286.5441.930; SHUMAN CA, 1995, J GEOPHYS RES-ATMOS, V100, P9165, DOI 10.1029/95JD00560; Stenni B, 2001, SCIENCE, V293, P2074, DOI 10.1126/science.1059702; Vimeux F, 2002, EARTH PLANET SC LETT, V203, P829, DOI 10.1016/S0012-821X(02)00950-0; Waelbroeck C, 2002, QUATERNARY SCI REV, V21, P295, DOI 10.1016/S0277-3791(01)00101-9; Werner M, 2000, GEOPHYS RES LETT, V27, P723, DOI 10.1029/1999GL006075	43	216	222	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					118	121		10.1126/science.1108575	http://dx.doi.org/10.1126/science.1108575			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994553	Green Submitted			2022-12-28	WOS:000230212800071
J	Wagers, AJ				Wagers, AJ			Stem cell grand SLAM	CELL			English	Editorial Material							BONE-MARROW NICHE; HEMATOPOIETIC STEM; SIZE	Stem cells in both embryonic and adult tissues are defined by their unique ability to balance self-renewal and differentiation such that mature cells necessary for tissue function can be generated and replaced without depletion of the stem cell pool. In this issue of Cell, Kiel et al. (2005) report a major step forward for studying the mechanisms and regulation of such stem cell fate decisions in the blood-forming (hematopoietic) system by providing a simple and broadly applicable method to isolate these cells and to visualize them in their normal environment.	Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.	Wagers, AJ (corresponding author), Joslin Diabet Ctr, Boston, MA 02215 USA.							Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Engel P, 2003, NAT REV IMMUNOL, V3, P813, DOI 10.1038/nri1202; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Li WM, 2004, EXP HEMATOL, V32, P1226, DOI 10.1016/j.exphem.2004.09.001; Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293; NILSSON SK, 2005, BLOOD; Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992; Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood-2003-11-4011; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	13	18	18	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 1	2005	121	7					967	970		10.1016/j.cell.2005.06.017	http://dx.doi.org/10.1016/j.cell.2005.06.017			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989946	Bronze			2022-12-28	WOS:000230448000003
J	Steddon, S; Cunningham, J				Steddon, S; Cunningham, J			Calcimimetics and calcilytics - fooling the calcium receptor	LANCET			English	Review							STAGE RENAL-DISEASE; SECONDARY HYPERPARATHYROIDISM; PARATHYROID-HORMONE; CA2+-SENSING RECEPTOR; HEMODIALYSIS-PATIENTS; CINACALCET HCL; CA2+ RECEPTOR; HYPOPARATHYROIDISM; CALCIFICATION; METABOLISM	Context just a decade after the the calcium-sensing receptor (CaR) was identified, pharmacological manipulation of the CaR is about to enter routine practice. For hyperparathyroid states, calcimimetics, which increase activation of the CaR, have been licensed in Europe and the USA. Calcilytics, which decrease CaR function and increase secretion of parathyroid hormone (PTH), might allow the anabolic effects of PTH on bone to be harnessed for the prevention and treatment of osteoporosis. Starting point In a multicentre randomised double-blind placebo-controlled study, Munro Peacock and colleagues recently confirmed the efficacy of the oral calcimimetic cinacalcet for achieving long-term reductions in serum calcium and PTH concentrations in primary hyperparathyroidism (J Clin Endocrinol Metab 2005; 90: 135-41). The arrival of a non-surgical option for this common disorder is important. What next? Study in primary and uraemic secondary hyperparathyroidism will indicate whether the efficacy of calcimimetic agents extends into the longer term. The extracellular relation between the CaR and its ligands and the intracellular signalling cascades that modify PTH gene transcription and secretion need further study. Drugs acting on the CaR might treat other disorders of bone remodelling, including osteoporosis. CaR expression in tissues beyond those involved in mineral ion homoeostasis should remain an important focus of research.	Royal Free Hosp, Ctr Nephrol, London NW3 2PF, England; Barts & London NHS Trust, Dept Renal Med & Transplantat, London, England; UCL, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Barts Health NHS Trust; University of London; University College London	Cunningham, J (corresponding author), Royal Free Hosp, Ctr Nephrol, London NW3 2PF, England.	drjohncunningham@aol.com	Centeno, Patricia Pacios/O-8368-2016					Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; CUNNINHAM J, IN PRESS KIDNEY INT; DeLuca F, 1997, J CLIN ENDOCR METAB, V82, P2710, DOI 10.1210/jc.82.8.2710; Eknoyan G, 2003, AM J KIDNEY DIS S, V42, pS1; Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Goodman WG, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341017; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Li YX, 1996, J CLIN INVEST, V97, P910, DOI 10.1172/JCI118513; Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523-1755.2005.67139.x; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323; Nemeth EF, 2004, J PHARMACOL EXP THER, V308, P627, DOI 10.1124/jpet.103.057273; Peacock M, 2005, J CLIN ENDOCR METAB, V90, P135, DOI 10.1210/jc.2004-0842; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; Ribeiro S, 1998, NEPHROL DIAL TRANSPL, V13, P2037, DOI 10.1093/ndt/13.8.2037; Shoback DM, 2003, J CLIN ENDOCR METAB, V88, P5644, DOI 10.1210/jc.2002-021597; SILVERBERG SJ, 2004, J BONE MINER RES, V19, pS186; Wada M, 1998, KIDNEY INT, V53, P448, DOI 10.1046/j.1523-1755.1998.00782.x; Wada M, 2003, NEPHROL DIAL TRANSPL, V18, P13, DOI 10.1093/ndt/gfg1004; Young EW, 2004, AM J KIDNEY DIS, V44, pS34, DOI 10.1053/j.ajkd.2004.08.009	24	57	62	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 25	2005	365	9478					2237	2239		10.1016/S0140-6736(05)66782-7	http://dx.doi.org/10.1016/S0140-6736(05)66782-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978932				2022-12-28	WOS:000230034800034
J	Vaughan, DG				Vaughan, DG			How does the antarctic ice sheet affect sea level rise?	SCIENCE			English	Editorial Material							WEST ANTARCTICA; PINE ISLAND; GLACIER		British Antarctic Survey, NERC, Cambridge CB3 0ET, England	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey	Vaughan, DG (corresponding author), British Antarctic Survey, NERC, Madingley Rd, Cambridge CB3 0ET, England.	dgv@bas.ac.uk	Vaughan, David/C-8348-2011	Vaughan, David/0000-0002-9065-0570				CHURCH JA, 2001, CLIMATE CHANGE 2001, P583; Davis CH, 2005, SCIENCE, V308, P1898, DOI 10.1126/science.1110662; De Angelis H, 2003, SCIENCE, V299, P1560, DOI 10.1126/science.1077987; Joughin I, 2002, SCIENCE, V295, P476, DOI 10.1126/science.1066875; Payne AJ, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021284; Rignot E, 2002, ANN GLACIOL, V34, P189, DOI 10.3189/172756402781817950; Shepherd A, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014183; Shepherd A, 2001, SCIENCE, V291, P862, DOI 10.1126/science.291.5505.862; Smith AM, 1998, ANN GLACIOL, V27, P113; Stone JO, 2003, SCIENCE, V299, P99, DOI 10.1126/science.1077998; Thomas R, 2004, SCIENCE, V306, P255, DOI 10.1126/science.1099650; Wingham DJ, 1998, SCIENCE, V282, P456, DOI 10.1126/science.282.5388.456	12	27	30	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 24	2005	308	5730					1877	1878		10.1126/science.1114670	http://dx.doi.org/10.1126/science.1114670			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976294				2022-12-28	WOS:000230120000029
J	Biswas, T; Aihara, H; Radman-Livaja, M; Filman, D; Landy, A; Ellenberger, T				Biswas, T; Aihara, H; Radman-Livaja, M; Filman, D; Landy, A; Ellenberger, T			A structural basis for allosteric control of DNA recombination by lambda integrase	NATURE			English	Article							SITE-SPECIFIC RECOMBINATION; CRYSTAL-STRUCTURE; INT PROTEIN; COMPLEX; ORDER; IHF; ARCHITECTURE; FLEXIBILITY; MUTATIONS; VANADATE	Site-specific DNA recombination is important for basic cellular functions including viral integration, control of gene expression, production of genetic diversity and segregation of newly replicated chromosomes, and is used by bacteriophage lambda to integrate or excise its genome into and out of the host chromosome. lambda recombination is carried out by the bacteriophage-encoded integrase protein (lambda-int) together with accessory DNA sites and associated bending proteins that allow regulation in response to cell physiology. Here we report the crystal structures of lambda-int in higher-order complexes with substrates and regulatory DNAs representing different intermediates along the reaction pathway. The structures show how the simultaneous binding of two separate domains of lambda-int to DNA facilitates synapsis and can specify the order of DNA strand cleavage and exchange. An intertwined layer of amino-terminal domains bound to accessory (arm) DNAs shapes the recombination complex in a way that suggests how arm binding shifts the reaction equilibrium in favour of recombinant products.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Brown Univ, Div Biol & Med, Providence, RI 02912 USA	Harvard University; Harvard Medical School; Brown University	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	tome@hms.harvard.edu		Radman-Livaja, Marta/0000-0003-4987-0608; filman, david/0000-0002-8714-1644	NIGMS NIH HHS [R01 GM033928, R01 GM062723] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062723, R01GM033928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aihara H, 2003, MOL CELL, V12, P187, DOI 10.1016/S1097-2765(03)00268-5; Azaro MA, 1997, EMBO J, V16, P3744, DOI 10.1093/emboj/16.12.3744; Azaro MA., 2002, MOBILE DNA-UK, P118, DOI DOI 10.1128/9781555817954.CH7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bankhead TM, 2003, J BACTERIOL, V185, P2653, DOI 10.1128/JB.185.8.2653-2666.2003; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSHMAN W, 1985, SCIENCE, V230, P906, DOI 10.1126/science.2932798; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Chen Y, 2003, ANNU REV BIOPH BIOM, V32, P135, DOI 10.1146/annurev.biophys.32.110601.141732; Crisona NJ, 1999, J MOL BIOL, V289, P747, DOI 10.1006/jmbi.1999.2771; Davies DR, 2003, CHEM BIOL, V10, P139, DOI 10.1016/S1074-5521(03)00021-8; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DEVARGAS LM, 1989, SCIENCE, V244, P1457; FRANZ B, 1995, EMBO J, V14, P397, DOI 10.1002/j.1460-2075.1995.tb07014.x; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kazmierczak RA, 2002, NUCLEIC ACIDS RES, V30, P5193, DOI 10.1093/nar/gkf652; KIM S, 1992, SCIENCE, V256, P198, DOI 10.1126/science.1533056; KITTS PA, 1988, J MOL BIOL, V204, P95, DOI 10.1016/0022-2836(88)90602-X; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Martin SS, 2003, BIOCHEM BIOPH RES CO, V308, P529, DOI 10.1016/S0006-291X(03)01437-2; MIZUUCHI K, 1978, J MOL BIOL, V121, P375, DOI 10.1016/0022-2836(78)90370-4; NASH HA, 1996, CELLULAR MOL BIOL, P2263; NUMRYCH TE, 1990, NUCLEIC ACIDS RES, V18, P3953, DOI 10.1093/nar/18.13.3953; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Radman-Livaja M, 2005, P NATL ACAD SCI USA, V102, P3913, DOI 10.1073/pnas.0500844102; Radman-Livaja M, 2003, MOL CELL, V11, P783, DOI 10.1016/S1097-2765(03)00111-4; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; ROSS W, 1979, CELL, V18, P297, DOI 10.1016/0092-8674(79)90049-7; ROSS W, 1982, P NATL ACAD SCI-BIOL, V79, P7724, DOI 10.1073/pnas.79.24.7724; Sam MD, 2004, J MOL BIOL, V338, P229, DOI 10.1016/j.jmb.2004.02.053; Sarkar D, 2002, J MOL BIOL, V324, P775, DOI 10.1016/S0022-2836(02)01199-3; Segall AM, 1996, GENES CELLS, V1, P453, DOI 10.1046/j.1365-2443.1996.d01-254.x; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Swinger KK, 2004, CURR OPIN STRUC BIOL, V14, P28, DOI 10.1016/j.sbi.2003.12.003; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; THOMPSON JF, 1987, J MOL BIOL, V195, P481, DOI 10.1016/0022-2836(87)90177-X; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; Tirumalai RS, 1998, J MOL BIOL, V279, P513, DOI 10.1006/jmbi.1998.1786; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87; Warren D, 2005, MOL MICROBIOL, V55, P1104, DOI 10.1111/j.1365-2958.2004.04447.x; Wojciak JM, 2002, P NATL ACAD SCI USA, V99, P3434, DOI 10.1073/pnas.052017999	48	131	137	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1059	1066		10.1038/nature03657	http://dx.doi.org/10.1038/nature03657			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973401	Green Accepted			2022-12-28	WOS:000229970400040
J	Guo, QF				Guo, QF			Plant communities - Ecosystem maturity and performance	NATURE			English	Editorial Material							STABILITY; FORESTS		US Geol Survey, NPWRC, Jamestown, ND 58401 USA	United States Department of the Interior; United States Geological Survey	Guo, QF (corresponding author), US Geol Survey, NPWRC, Jamestown, ND 58401 USA.	qguo@usgs.gov						[Anonymous], 1975, COMMUNITIES ECOSYSTE; Bai YF, 2004, NATURE, V431, P181, DOI 10.1038/nature02850; COLLINS SL, 1995, TRENDS ECOL EVOL, V10, P95, DOI 10.1016/S0169-5347(00)88998-3; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; GIBSON DJ, 1987, VEGETATIO, V72, P175; GRIME JP, 1973, NATURE, V242, P344, DOI 10.1038/242344a0; Guo QF, 2003, AMBIO, V32, P428, DOI 10.1639/0044-7447(2003)032[0428:DLHAOM]2.0.CO;2; Guo QF, 2003, J VEG SCI, V14, P121, DOI 10.1111/j.1654-1103.2003.tb02134.x; Huston M.A., 1994, BIOL DIVERSITY; Lichter J, 1998, ECOL MONOGR, V68, P487, DOI 10.1890/0012-9615(1998)068[0487:PSAFDO]2.0.CO;2; ODUM EP, 1969, SCIENCE, V164, P262, DOI 10.1126/science.164.3877.262; Ryan MG, 2004, ECOL MONOGR, V74, P393, DOI 10.1890/03-4037; Yang LH, 2004, SCIENCE, V306, P1565, DOI 10.1126/science.1103114	13	10	12	4	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 23	2005	435	7045					E6	E6		10.1038/nature03583	http://dx.doi.org/10.1038/nature03583			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973361				2022-12-28	WOS:000229970400036
J	Reguera, G; McCarthy, KD; Mehta, T; Nicoll, JS; Tuominen, MT; Lovley, DR				Reguera, G; McCarthy, KD; Mehta, T; Nicoll, JS; Tuominen, MT; Lovley, DR			Extracellular electron transfer via microbial nanowires	NATURE			English	Article							INSOLUBLE FE(III) OXIDE; GEOBACTER-METALLIREDUCENS; PSEUDOMONAS-AERUGINOSA; IV PILI; REDUCTION; SULFURREDUCENS; RESPIRATION; BIOGENESIS; METABOLISM; MOTILITY	Microbes that can transfer electrons to extracellular electron acceptors, such as Fe(III) oxides, are important in organic matter degradation and nutrient cycling in soils and sediments(1,2). Previous investigations on electron transfer to Fe(III) have focused on the role of outer-membrane c-type cytochromes(1,3). However, some Fe(III) reducers lack c-cytochromes(4). Geobacter species, which are the predominant Fe(III) reducers in many environments(1), must directly contact Fe(III) oxides to reduce them(5), and produce monolateral pili(6) that were proposed(1,2), on the basis of the role of pili in other organisms(7,8), to aid in establishing contact with the Fe(III) oxides. Here we report that a pilus-deficient mutant of Geobacter sulfurreducens could not reduce Fe(III) oxides but could attach to them. Conducting-probe atomic force microscopy revealed that the pili were highly conductive. These results indicate that the pili of G. sulfurreducens might serve as biological nanowires, transferring electrons from the cell surface to the surface of Fe(III) oxides. Electron transfer through pili indicates possibilities for other unique cell-surface and cell-cell interactions, and for bioengineering of novel conductive materials.	Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Phys, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Lovley, DR (corresponding author), Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA.	dlovley@microbio.umass.edu	Reguera, Gemma/AAZ-5864-2020; Tuominen, Mark/A-6129-2012	Reguera, Gemma/0000-0003-4317-7933; 				AHO EL, 1987, INFECT IMMUN, V55, P1009, DOI 10.1128/IAI.55.4.1009-1013.1987; Alm RA, 1997, GENE, V192, P89, DOI 10.1016/S0378-1119(96)00805-0; BUTLER JE, UNPUB J BACTERIOL; Childers SE, 2002, NATURE, V416, P767, DOI 10.1038/416767a; CHILDERS SE, 2003, 103 GEN M, P361; Coppi MV, 2001, APPL ENVIRON MICROB, V67, P3180, DOI 10.1128/AEM.67.7.3180-3187.2001; Davis JJ, 2003, PHILOS T R SOC A, V361, P2807, DOI 10.1098/rsta.2003.1270; DOIG P, 1988, INFECT IMMUN, V56, P1641, DOI 10.1128/IAI.56.6.1641-1646.1988; Holmes DE, 2004, INT J SYST EVOL MICR, V54, P1591, DOI 10.1099/ijs.0.02958-0; Lonergan DJ, 1996, J BACTERIOL, V178, P2402, DOI 10.1128/jb.178.8.2402-2408.1996; Lovley DR, 2003, NAT REV MICROBIOL, V1, P35, DOI 10.1038/nrmicro731; LOVLEY DR, 1995, APPL ENVIRON MICROB, V61, P2132, DOI 10.1128/AEM.61.6.2132-2138.1995; LOVLEY DR, 1988, APPL ENVIRON MICROB, V54, P1472, DOI 10.1128/AEM.54.6.1472-1480.1988; Lovley DR, 1996, NATURE, V382, P445, DOI 10.1038/382445a0; LOVLEY DR, 2004, ADV MICROBIAL PHYSL, V49; Merz AJ, 2000, NATURE, V407, P98, DOI 10.1038/35024105; Methe BA, 2003, SCIENCE, V302, P1967, DOI 10.1126/science.1088727; Nassif X, 1997, GENE, V192, P149, DOI 10.1016/S0378-1119(96)00802-5; Nevin KP, 2000, APPL ENVIRON MICROB, V66, P2248, DOI 10.1128/AEM.66.5.2248-2251.2000; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; Richardson DJ, 2000, MICROBIOL-SGM, V146, P551, DOI 10.1099/00221287-146-3-551; Sahu SN, 2003, MOL CELL BIOCHEM, V253, P167, DOI 10.1023/A:1026028930203; Sayler GS, 2004, CURR OPIN MICROBIOL, V7, P267, DOI 10.1016/j.mib.2004.04.003; STROM MS, 1993, ANNU REV MICROBIOL, V47, P565, DOI 10.1146/annurev.micro.47.1.565; Wall D, 1999, MOL MICROBIOL, V32, P1, DOI 10.1046/j.1365-2958.1999.01339.x	25	1705	1848	74	1286	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1098	1101		10.1038/nature03661	http://dx.doi.org/10.1038/nature03661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973408				2022-12-28	WOS:000229970400049
J	Cain, FE; Benjamin, RM; Thompson, JN				Cain, FE; Benjamin, RM; Thompson, JN			GMC and the future of revalidation - Obstacles to maintaining licensure in the United States	BRITISH MEDICAL JOURNAL			English	Article									Federat State Med Boards, Dallas, TX 75261 USA; Bayou La Batre Rural Hlth Clin, Bayou La Batre, AL 36509 USA		Cain, FE (corresponding author), Federat State Med Boards, POB 619850, Dallas, TX 75261 USA.	fcain@fsmb.org						FINOCCHIO LJ, 1995, REF HLTH CAR WORKF R; *I MED, 1999, TO ERR IS HUM BUILD; LEBUHN RA, 2001, P CIT ADV CTR C JUN; WILSON JA, 2002, J MED LICENSURE DISC, V88, P76	4	7	7	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 18	2005	330	7505					1443	1445		10.1136/bmj.330.7505.1443	http://dx.doi.org/10.1136/bmj.330.7505.1443			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938NP	15961820	Green Published			2022-12-28	WOS:000230010400023
J	Hargreaves, EL; Rao, G; Lee, I; Knierim, JJ				Hargreaves, EL; Rao, G; Lee, I; Knierim, JJ			Major dissociation between medial and lateral entorhinal input to dorsal hippocampus	SCIENCE			English	Article							POSITIONAL FIRING PROPERTIES; FREELY MOVING RATS; HEAD-DIRECTION CELLS; PLACE CELLS; POSTRHINAL CORTEX; PERIRHINAL CORTEX; MEMORY; PARASUBICULUM; NEURONS; PRESUBICULUM	Hippocampal place cells are a model system of how the brain constructs cognitive representations and of how these representations support complex behavior, teaming, and memory. There is, however, a lack of detailed knowledge about the properties of hippocampal afferents. We recorded multiple single units from the hippocampus and the medial and lateral entorhinal areas of behaving rats. Although many medial entorhinal neurons had highly specific place fields, Lateral entorhinal neurons displayed weak spatial specificity. This finding demonstrates a fundamental dissociation between the information conveyed to the hippocampus by its major input streams, with spatial information represented by the medial and nonspatial information represented by the lateral entorhinal cortex.	Univ Texas, Med Sch Houston, WM Keck Ctr Neurobiol Learning & Memory, Dept Neurobiol & Anat, Houston, TX 77225 USA; NYU, Ctr Neural Sci, New York, NY 10003 USA	University of Texas System; University of Texas Health Science Center Houston; New York University	Knierim, JJ (corresponding author), Univ Texas, Med Sch Houston, WM Keck Ctr Neurobiol Learning & Memory, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	james.j.knierim@uth.tmc.edu	Hargreaves, Eric/H-4891-2011	Hargreaves, Eric/0000-0001-5311-9804	NIMH NIH HHS [K02 MH63297] Funding Source: Medline; NINDS NIH HHS [R01 NS039456] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH063297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039456] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNES CA, 1990, PROG BRAIN RES, V83, P287; Burwell RD, 1998, NEUROREPORT, V9, P3013, DOI 10.1097/00001756-199809140-00017; Burwell RD, 2003, NEUROSCIENCE, V119, P577, DOI 10.1016/S0306-4522(03)00160-X; Burwell RD, 2000, ANN NY ACAD SCI, V911, P25; CABALLEROBLEDA M, 1993, J COMP NEUROL, V328, P115, DOI 10.1002/cne.903280109; CHEN LL, 1994, EXP BRAIN RES, V101, P8, DOI 10.1007/BF00243212; Davachi L, 2003, P NATL ACAD SCI USA, V100, P2157, DOI 10.1073/pnas.0337195100; Dolorfo CL, 1998, J COMP NEUROL, V398, P25; Eichenbaum H, 2004, NEURON, V44, P109, DOI 10.1016/j.neuron.2004.08.028; Frank LM, 2000, NEURON, V27, P169, DOI 10.1016/S0896-6273(00)00018-0; Fyhn M, 2004, SCIENCE, V305, P1258, DOI 10.1126/science.1099901; Gaffan D, 1998, EXP BRAIN RES, V123, P201, DOI 10.1007/s002210050562; JUNG MW, 1994, J NEUROSCI, V14, P7347; MIZUMORI SJY, 1992, BRAIN RES, V570, P188, DOI 10.1016/0006-8993(92)90581-S; Moita MAP, 2003, NEURON, V37, P485, DOI 10.1016/S0896-6273(03)00033-3; Moser MB, 1998, HIPPOCAMPUS, V8, P608, DOI 10.1002/(SICI)1098-1063(1998)8:6<608::AID-HIPO3>3.0.CO;2-7; Muller R, 1996, NEURON, V17, P813, DOI 10.1016/S0896-6273(00)80214-7; Norman G, 2005, BEHAV NEUROSCI, V119, P557, DOI 10.1037/0735-7044.119.2.557; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; QUIRK GJ, 1992, J NEUROSCI, V12, P1945; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; Suzuki WA, 1997, J NEUROPHYSIOL, V78, P1062, DOI 10.1152/jn.1997.78.2.1062; Taube JS, 1995, HIPPOCAMPUS, V5, P569, DOI 10.1002/hipo.450050608; TAUBE JS, 1995, J NEUROSCI, V15, P70; VANGROEN T, 1990, BRAIN RES, V518, P227, DOI 10.1016/0006-8993(90)90976-I; Witter M., 2004, RAT NERVOUS SYSTEM, V3, P635, DOI [10.1016/B978-012547638-6/50022-5, DOI 10.1016/B978-012547638-6/50022-5]; Wood ER, 1999, NATURE, V397, P613, DOI 10.1038/17605	28	447	456	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1792	1794		10.1126/science.1110449	http://dx.doi.org/10.1126/science.1110449			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961670				2022-12-28	WOS:000229926800056
J	Udvardi, MK; Scheible, WR				Udvardi, MK; Scheible, WR			GRAS genes and the symbiotic Green Revolution	SCIENCE			English	Editorial Material							RECEPTOR KINASE GENE; SIGNAL-TRANSDUCTION; BACTERIAL; FUNGAL; IDENTIFICATION; PROTEINS; NITROGEN; CALCIUM; FAMILY		Max Planck Inst Mol Plant Physiol, D-14476 Golm, Germany	Max Planck Society	Udvardi, MK (corresponding author), Max Planck Inst Mol Plant Physiol, Muhlenberg 1, D-14476 Golm, Germany.	udvardi@mpimp-golm.mpg.de; scheible@mpimp-golm.mpg.de	Udvardi, Michael/GPX-4653-2022; Scheible, Wolf-Rudiger/A-7764-2015	Udvardi, Michael/0000-0001-9850-0828; Scheible, Wolf-Rudiger/0000-0003-4363-4196				Ane JM, 2004, SCIENCE, V303, P1364, DOI 10.1126/science.1092986; Bolle C, 2004, PLANTA, V218, P683, DOI 10.1007/s00425-004-1203-z; Catoira R, 2000, PLANT CELL, V12, P1647, DOI 10.1105/tpc.12.9.1647; Ehrhardt DW, 1996, CELL, V85, P673, DOI 10.1016/S0092-8674(00)81234-9; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; Imaizumi-Anraku H, 2005, NATURE, V433, P527, DOI 10.1038/nature03237; Kalo P, 2005, SCIENCE, V308, P1786, DOI 10.1126/science.1110951; Kistner C, 2002, TRENDS PLANT SCI, V7, P511, DOI 10.1016/S1360-1385(02)02356-7; Krusell L, 2005, PLANT CELL, V17, P1625, DOI 10.1105/tpc.104.030106; Levy J, 2004, SCIENCE, V303, P1361, DOI 10.1126/science.1093038; Limpens E, 2003, SCIENCE, V302, P630, DOI 10.1126/science.1090074; Madsen EB, 2003, NATURE, V425, P637, DOI 10.1038/nature02045; Mitra RM, 2004, P NATL ACAD SCI USA, V101, P4701, DOI 10.1073/pnas.0400595101; Oldroyd GED, 2005, PLANT PHYSIOL, V137, P1205, DOI 10.1104/pp.104.057661; Oldroyd GED, 2004, NAT REV MOL CELL BIO, V5, P566, DOI 10.1038/nrm1424; Oldroyd GED, 2003, PLANT PHYSIOL, V131, P1027, DOI 10.1104/pp.102.010710; Radutoiu S, 2003, NATURE, V425, P585, DOI 10.1038/nature02039; Schauser L, 1999, NATURE, V402, P191, DOI 10.1038/46058; Smil V, 1999, NATURE, V400, P415, DOI 10.1038/22672; Smil V, 1999, GLOBAL BIOGEOCHEM CY, V13, P647, DOI 10.1029/1999GB900015; Smit P, 2005, SCIENCE, V308, P1789, DOI 10.1126/science.1111025; Stracke S, 2002, NATURE, V417, P959, DOI 10.1038/nature00841	22	12	12	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1749	1750		10.1126/science.1114217	http://dx.doi.org/10.1126/science.1114217			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961658				2022-12-28	WOS:000229926800040
J	Willoughby, RE; Tieves, KS; Hoffman, GM; Ghanayem, NS; Amlie-Lefond, CM; Schwabe, MJ; Chusid, MJ; Rupprecht, CE				Willoughby, RE; Tieves, KS; Hoffman, GM; Ghanayem, NS; Amlie-Lefond, CM; Schwabe, MJ; Chusid, MJ; Rupprecht, CE			Brief report - Survival after treatment of rabies with induction of coma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-INFECTION; MICE; MANAGEMENT; GLUTAMATE; KETAMINE; HUMANS; UPDATE	We report the survival of a 15-year-old girl in whom clinical rabies developed one month after she was bitten by a bat. Treatment included induction of coma while a native immune response matured; rabies vaccine was not administered. The patient was treated with ketamine, midazolam, ribavirin, and amantadine. Probable drug-related toxic effects included hemolysis, pancreatitis, acidosis, and hepatotoxicity. Lumbar puncture after eight days showed an increased level of rabies antibody, and sedation was tapered. Paresis and sensory denervation then resolved. The patient was removed from isolation after 31 days and discharged to her home after 76 days. At nearly five months after her initial hospitalization, she was alert and communicative, but with choreoathetosis, dysarthria, and an unsteady gait.	Med Coll Wisconsin, Res Ctr, Dept Pediat Infect Dis, Midwest Athletes Childhood Canc Fund, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Pediat Crit Care Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Pediat Anesthesiol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Pediat Neurol, Milwaukee, WI 53226 USA; Ctr Dis Control & Prevent, Atlanta, GA USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Centers for Disease Control & Prevention - USA	Willoughby, RE (corresponding author), Med Coll Wisconsin, Res Ctr, Dept Pediat Infect Dis, Midwest Athletes Childhood Canc Fund, 8701 Watertown Plank Rd,Suite 3019, Milwaukee, WI 53226 USA.	rewillou@mail.mcw.edu	Hoffman, George M/C-1036-2008; Rupprecht, Charles/AAI-1544-2020; Chusid, Michael/R-4947-2019	Hoffman, George M/0000-0001-6501-2940; Tieves, Kelly/0000-0002-9756-3859				Beilin B, 1998, ANESTHESIOLOGY, V89, P1133, DOI 10.1097/00000542-199811000-00013; BELL JF, 1974, INFECT IMMUN, V10, P510, DOI 10.1128/IAI.10.3.510-515.1974; BHATT DR, 1974, AM J DIS CHILD, V127, P862, DOI 10.1001/archpedi.1974.02110250088013; EMMONS R W, 1973, Intervirology, V1, P60, DOI 10.1159/000148833; Fleischer R, 2004, CLIN INFECT DIS, V38, pE79, DOI 10.1086/383151; GODE GR, 1988, INDIAN J MED RES, V88, P564; GODE GR, 1976, LANCET, V2, P6; HATTWICK MA, 1972, ANN INTERN MED, V76, P931, DOI 10.7326/0003-4819-76-6-931; Hoffman GM, 2004, J THORAC CARDIOV SUR, V127, P223, DOI 10.1016/j.jtcvs.2003.08.021; Jackson AC, 1999, LAB INVEST, V79, P945; Jackson AC, 2003, J NEUROVIROL, V9, P253, DOI 10.1080/13550280390193975; Jackson AC, 2003, CLIN INFECT DIS, V36, P60, DOI 10.1086/344905; Jogai S, 2002, NEUROPATH APPL NEURO, V28, P334, DOI 10.1046/j.1365-2990.2002.00400.x; LOCKHART BP, 1992, ANTIMICROB AGENTS CH, V36, P1750, DOI 10.1128/AAC.36.8.1750; LODMELL DL, 1969, J INFECT DIS, V119, P569, DOI 10.1093/infdis/119.6.569; MATON PN, 1976, BRIT MED J, V1, P1038, DOI 10.1136/bmj.1.6017.1038; MRAK RE, 1994, J NEUROPATH EXP NEUR, V53, P1, DOI 10.1097/00005072-199401000-00001; Nargi-Aizenman JL, 2004, ANN NEUROL, V55, P541, DOI 10.1002/ana.20033; PORTER RHP, 1995, J NEUROCHEM, V64, P614; REICH DL, 1989, CAN J ANAESTH, V36, P186, DOI 10.1007/BF03011442; RUBIN RH, 1970, J INFECT DIS, V122, P318, DOI 10.1093/infdis/122.4.318; SUPERTI F, 1985, DRUG EXP CLIN RES, V11, P69; Wang XY, 2001, NEUROSCI LETT, V313, P121, DOI 10.1016/S0304-3940(01)02262-5; WARRELL DA, 1976, AM J MED, V60, P180, DOI 10.1016/0002-9343(76)90427-7; WILLOUGHBY RE, 2005, MMWR-MORBID MORTAL W, V53, P1171	25	350	387	1	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2005	352	24					2508	2514		10.1056/NEJMoa050382	http://dx.doi.org/10.1056/NEJMoa050382			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935RH	15958806				2022-12-28	WOS:000229798900006
J	Raitt, MH; Connor, WE; Morris, C; Kron, J; Halperin, B; Chugh, SS; McClelland, J; Cook, J; MacMurdy, K; Swenson, R; Connor, SL; Gerhard, G; Kraemer, DF; Oscran, D; Marchant, C; Calhoun, D; Shnider, R; McAnulty, J				Raitt, MH; Connor, WE; Morris, C; Kron, J; Halperin, B; Chugh, SS; McClelland, J; Cook, J; MacMurdy, K; Swenson, R; Connor, SL; Gerhard, G; Kraemer, DF; Oscran, D; Marchant, C; Calhoun, D; Shnider, R; McAnulty, J			Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYUNSATURATED FATTY-ACIDS; SUDDEN CARDIAC DEATH; MYOCARDIAL-INFARCTION; N-3; PREVENTION; OMEGA-3-FATTY-ACIDS; ERYTHROCYTES; ARRHYTHMIAS; CONSUMPTION; PLASMA	Context Clinical studies of omega-3 polyunsaturated fatty acids (PUFAs) have shown a reduction in sudden cardiac death, suggesting that omega-3 PUFAs may have antiarrhythmic effects. Objective To determine whether omega-3 PUFAs have beneficial antiarrhythmic effects in patients with a history of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF). Design and Setting Randomized, double-blind, placebo-controlled trial performed at 6 US medical centers with enrollment from February 1999 until January 2003. Patients Two hundred patients with an implantable cardioverter defibrillator (ICD) and a recent episode of sustained VT or VF Intervention Patients were randomly assigned to receive fish oil, 1.8 g/d, 72% omega-3 PUFAs, or placebo and were followed up for a median of 718 days (range, 20-828 days). Main Outcome Measures Time to first episode of ICD treatment for VT/VF, changes in red blood cell concentrations of omega-3 PUFAs, frequency of recurrent VT/VF events, and predetermined subgroup analyses. Results Patients randomized to receive fish oil had an increase in the mean percentage of omega-3 PUFAs in red blood cell membranes from 4.7% to 8.3% (P<.001), with no change observed in patients receiving placebo. At 6, 12, and 24 months, 46% (SE, 5%), 51% (5%), and 65% (5%) of patients randomized to receive fish oil had ICD therapy for VT/VF compared with 36% (5%), 41% (5%), and 59% (5%) for patients randomized to receive placebo (P=.19). In the subset of 133 patients whose qualifying arrhythmia was VT, 61% (SE, 6%), 66% (6%), and 79% (6%) of patients in the fish oil group had VT/VF at 6, 12, and 24 months compared with 37% (6%), 43% (6%), and 65% (6%) of patients in the control group (P=.007). Recurrent VT/VF events were more common in patients randomized to receive fish oil (P<.001). Conclusion Among patients with a recent episode of sustained ventricular arrhythmia and an ICD, fish oil supplementation does not reduce the risk of VT/VF and may be proarrhythmic in some patients.	Portland VA Med Ctr, Portland, OR 97239 USA; Baystate Med Ctr, Springfield, MA USA; SW Med Ctr, Vancouver, WA USA; Sacred Heart Med Ctr, Eugene, OR USA; Oregon State Univ, Portland, OR USA; St Vincents Med Ctr, Portland, OR USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Baystate Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; Oregon State University; Oregon Health & Science University	Raitt, MH (corresponding author), Portland VA Med Ctr, 3710 SW US Vet Rd,P-3-CARD, Portland, OR 97239 USA.	merritt.raitt@med.va.gov		Raitt, Merritt/0000-0001-5638-7732	NCRR NIH HHS [5 M01 RR00334] Funding Source: Medline; NHLBI NIH HHS [R01HL61682] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000334] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061682] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert CM, 2002, NEW ENGL J MED, V346, P1113, DOI 10.1056/NEJMoa012918; Albert CM, 1998, JAMA-J AM MED ASSOC, V279, P23, DOI 10.1001/jama.279.1.23; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; BANG HO, 1971, LANCET, V1, P1143, DOI 10.1016/S0140-6736(71)91658-8; Billman GE, 1997, LIPIDS, V32, P1161, DOI 10.1007/s11745-997-0149-2; Billman GE, 1999, CIRCULATION, V99, P2452, DOI 10.1161/01.CIR.99.18.2452; BURR ML, 1989, LANCET, V2, P757; Burr ML, 2003, EUR J CLIN NUTR, V57, P193, DOI 10.1038/sj.ejcn.1601539; CONNOR WE, 1990, J LIPID RES, V31, P237; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; EPSTEIN AE, 1993, JAMA-J AM MED ASSOC, V270, P2451, DOI 10.1001/jama.270.20.2451; Harris WS, 2004, CIRCULATION, V110, P1645, DOI 10.1161/01.CIR.0000142292.10048.B2; KANG JX, 1994, P NATL ACAD SCI USA, V91, P9886, DOI 10.1073/pnas.91.21.9886; Kang JX, 1996, EUR J PHARMACOL, V297, P97, DOI 10.1016/0014-2999(95)00701-6; Klein Richard C, 2003, J Cardiovasc Electrophysiol, V14, P940, DOI 10.1046/j.1540-8167.2003.01554.x; Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94; KROMANN N, 1980, ACTA MED SCAND, V208, P401; Leaf A, 2003, CIRCULATION, V107, P2646, DOI 10.1161/01.CIR.0000069566.78305.33; Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; MCLENNAN PL, 1993, AM J CLIN NUTR, V58, P666, DOI 10.1093/ajcn/58.5.666; Raitt MH, 2003, AM J CARDIOL, V91, P812, DOI 10.1016/S0002-9149(03)00015-8; Singh RB, 1997, CARDIOVASC DRUG THER, V11, P485, DOI 10.1023/A:1007757724505; SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363; U.S. Food and Drug Administration, 2004, FDA ANN QUAL HLTH CL; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Xiao YF, 1998, P NATL ACAD SCI USA, V95, P2680, DOI 10.1073/pnas.95.5.2680	27	282	349	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	2005	293	23					2884	2891		10.1001/jama.293.23.2884	http://dx.doi.org/10.1001/jama.293.23.2884			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935MD	15956633	Bronze			2022-12-28	WOS:000229785500023
J	Dauphinee, WD				Dauphinee, WD			GMC and the future of revalidation - Self regulation must be made to work	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BOARD CERTIFICATION; DOCTORS	Several high profile cases of poor medical practice in the United Kingdom have brought self regulation into question. Pressure for change is great, but experience from other Western countries suggests that abandoning the existing systems is not the best way forward. The United States and Canada both have well established systems of self regulation that are being gradually adapted to include a requirement for regular recertification. Although the healthcare environment in the UK is somewhat different, North America presents important lessons on how to ensure doctors are competent.	Med Council Canada, Ottawa, ON K1G 3H7, Canada		Dauphinee, WD (corresponding author), Med Council Canada, POB 8234, Ottawa, ON K1G 3H7, Canada.	dale.dauphinee@mcc.ca						American Board of Internal Medicine, MAINT CERT; Brennan TA, 2004, JAMA-J AM MED ASSOC, V292, P1038, DOI 10.1001/jama.292.9.1038; Dauphinee WD, 1999, BMJ-BRIT MED J, V319, P1188, DOI 10.1136/bmj.319.7218.1188; Dauphinee WD, 2002, INT HDB RES MED ED, P835; Evans R, 2004, BMJ-BRIT MED J, V328, P1240, DOI 10.1136/bmj.328.7450.1240; FRANK J, 2004, EVOLUTION SPECIALTY, P109; Horowitz SD, 2004, MED EDUC, V38, P10, DOI 10.1046/j.1365-2923.2004.01702.x; Irvine D, 1997, BRIT MED J, V314, P1613, DOI 10.1136/bmj.314.7094.1613; JACQUES A, 2003, B KUWAIT I MED SPECI, V2, P5; Leach DC, 2002, JAMA-J AM MED ASSOC, V287, P243, DOI 10.1001/jama.287.2.243; Oneill O., 2002, QUESTION TRUST BBC R; Paul C, 2000, BRIT MED J, V320, P499, DOI 10.1136/bmj.320.7233.499; RIEDSON E, 1994, PROFESSIONALISM REBO; STACEY M, 1997, FED B, V84, P17; Violato C, 2003, BMJ-BRIT MED J, V326, P546, DOI 10.1136/bmj.326.7388.546	15	11	11	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 11	2005	330	7504					1385	1387		10.1136/bmj.330.7504.1385	http://dx.doi.org/10.1136/bmj.330.7504.1385			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936FE	15947404	Green Published			2022-12-28	WOS:000229840100033
J	Kingston, J				Kingston, J			Thyroid cancer after neck irradiation during childhood	LANCET			English	Editorial Material							CARCINOMA; NEOPLASMS; MALIGNANCIES; RADIATION; RISK		Royal London Hosp, London E1 1BB, England	Barts Health NHS Trust; Royal London Hospital	Kingston, J (corresponding author), Royal London Hosp, London E1 1BB, England.	j.e.kingston@qmul.ac.uk						Acharya S, 2003, CANCER-AM CANCER SOC, V97, P2397, DOI 10.1002/cncr.11362; Bhatia S, 2003, J CLIN ONCOL, V21, P4386, DOI 10.1200/JCO.2003.11.059; Black P, 1998, MED PEDIATR ONCOL, V31, P91, DOI 10.1002/(SICI)1096-911X(199808)31:2<91::AID-MPO8>3.0.CO;2-U; Cohen A, 2001, BONE MARROW TRANSPL, V28, P1125, DOI 10.1038/sj.bmt.1703290; Gow KW, 2003, J PEDIATR SURG, V38, P1574, DOI 10.1016/S0022-3468(03)00563-3; GRAY LH, 1964, CELLULAR RAD BIOL, P7; Inskip PD, 2001, MED PEDIATR ONCOL, V36, P568, DOI 10.1002/mpo.1132; Mahoney MC, 2004, INT J EPIDEMIOL, V33, P1025, DOI 10.1093/ije/dyh201; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; Rubino C, 2003, INT J CANCER, V107, P791, DOI 10.1002/ijc.11455	10	1	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 11	2005	365	9476					1986	1987		10.1016/S0140-6736(05)66675-5	http://dx.doi.org/10.1016/S0140-6736(05)66675-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950701				2022-12-28	WOS:000229701400005
J	Asvany, O; Kumar, P; Redlich, B; Hegemann, I; Schlemmer, S; Marx, D				Asvany, O; Kumar, P; Redlich, B; Hegemann, I; Schlemmer, S; Marx, D			Understanding the infrared spectrum of bare CH5+	SCIENCE			English	Article							DENSITY-FUNCTIONAL THEORY; POTENTIAL-ENERGY SURFACE; LASER-INDUCED REACTIONS; 22-POLE ION-TRAP; PROTONATED METHANE; QUANTUM; DYNAMICS; CHEMISTRY; SPECTROSCOPY; HYDROGEN	Protonated methane, CH5+, continues to elude definitive structural assignment, as large-amplitude vibrations and hydrogen scrambling challenge both theory,and experiment. Here, the infrared spectrum of bare CH5+ is presented, as detected by reaction with carbon dioxide gas after resonant excitation by the free electron laser at the FELIX facility in the Netherlands. Comparison of the experimental spectrum at similar to 110 kelvin to finite-temperature infrared spectra, calculated by ab initio molecular dynamics, supports fluxionality of bare CH5+ under experimental conditions and provides a dynamical mechanism for exchange of hydrogens between CH3 tripod positions and the three-center bonded H-2 moiety, which eventually leads to full hydrogen scrambling. The possibility of artificially freezing out scrambling and internal rotation in the simulations allowed assignment of the infrared spectrum despite this pronounced fluxionality.	Ruhr Univ Bochum, Lehrstuhl Theoret Chem, D-44780 Bochum, Germany; Leiden Observ, NL-2300 RA Leiden, Netherlands; EURATOM, FOM, Inst Plasma Phys Rijnhuizen, FELIX Facil, NL-3430 BE Nieuwegein, Netherlands; Univ Cologne, Inst Phys 1, D-50937 Cologne, Germany	Ruhr University Bochum; Leiden University; Leiden University - Excl LUMC; Euratom; University of Cologne	Marx, D (corresponding author), Ruhr Univ Bochum, Lehrstuhl Theoret Chem, D-44780 Bochum, Germany.	dominik.marx@theochem.rub.de	Schlemmer, Stephan/E-2903-2015; Redlich, Britta/F-9689-2015; Padmanabhan, Padma Kumar/ABI-7465-2020; Padmanabhan, Padma Kumar/H-5886-2013	Schlemmer, Stephan/0000-0002-1421-7281; Padmanabhan, Padma Kumar/0000-0001-9502-6251; Padmanabhan, Padma Kumar/0000-0001-9502-6251				Asvany O, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.073001; BOO DW, 1995, SCIENCE, V269, P57, DOI 10.1126/science.269.5220.57; Brown A, 2004, J CHEM PHYS, V121, P4105, DOI 10.1063/1.1775767; Brown A, 2003, J CHEM PHYS, V119, P8790, DOI 10.1063/1.1622379; DYCZMONS V, 1974, THEOR CHIM ACTA, V33, P239, DOI 10.1007/BF00551258; Gerlich D, 2005, PHYS CHEM CHEM PHYS, V7, P1583, DOI 10.1039/b419328h; HECK AJR, 1991, J AM SOC MASS SPECTR, V2, P453, DOI 10.1016/1044-0305(91)80030-B; HUTTER J, 1995, CPMD SOFTWARE PACKAG; Marx D, 1996, SCIENCE, V271, P179, DOI 10.1126/science.271.5246.179; MARX D, 1995, NATURE, V375, P216, DOI 10.1038/375216a0; Marx D, 1997, Z PHYS D ATOM MOL CL, V41, P253, DOI 10.1007/s004600050320; Marx D, 1997, ANGEW CHEM INT EDIT, V36, P2077, DOI 10.1002/anie.199720771; Marx D, 1999, SCIENCE, V284, P59, DOI 10.1126/science.284.5411.59; Marx D., 2000, MODERN METHODS ALGOR, P301; Marx D., 1999, SCIENCE, V286, P1051; McCoy AB, 2004, J PHYS CHEM A, V108, P4991, DOI 10.1021/jp0487096; Muller H, 1997, J CHEM PHYS, V106, P1863, DOI 10.1063/1.473340; OEPTS D, 1995, INFRARED PHYS TECHN, V36, P297, DOI 10.1016/1350-4495(94)00074-U; OKA T, 1988, PHILOS T R SOC A, V324, P81, DOI 10.1098/rsta.1988.0002; OLAH GA, 1995, ANGEW CHEM INT EDIT, V34, P1393, DOI 10.1002/anie.199513931; Olah GA, 1997, ACCOUNTS CHEM RES, V30, P245, DOI 10.1021/ar960103f; Ramirez R, 2004, J CHEM PHYS, V121, P3973, DOI 10.1063/1.1774986; SAYKALLY RJ, 1988, SCIENCE, V239, P157, DOI 10.1126/science.239.4836.157; Schlemmer S, 2005, J PHYS CONF SER, V4, P134, DOI 10.1088/1742-6596/4/1/018; Schlemmer S, 2002, J CHEM PHYS, V117, P2068, DOI 10.1063/1.1487373; Schlemmer S, 1999, INT J MASS SPECTROM, V185, P589, DOI 10.1016/S1387-3806(98)14141-6; Schreiner PR, 2000, ANGEW CHEM INT EDIT, V39, P3239, DOI 10.1002/1521-3773(20000915)39:18<3239::AID-ANIE3239>3.3.CO;2-F; SCHREINER PR, 1993, J CHEM PHYS, V99, P3716, DOI 10.1063/1.466147; Scott AP, 1996, J PHYS CHEM-US, V100, P16502, DOI 10.1021/jp960976r; SCUSERIA GE, 1993, NATURE, V366, P512, DOI 10.1038/366512a0; TALBI D, 1992, ASTRON ASTROPHYS, V261, P671; Thompson KC, 2005, J AM CHEM SOC, V127, P4954, DOI 10.1021/ja0482280; TSE JS, 1995, PHYS REV LETT, V74, P876, DOI 10.1103/PhysRevLett.74.876; White ET, 1999, SCIENCE, V284, P135, DOI 10.1126/science.284.5411.135	35	165	165	4	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	2005	309	5738					1219	1222		10.1126/science.1113729	http://dx.doi.org/10.1126/science.1113729			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	15994376				2022-12-28	WOS:000231395400039
J	Fox, N; Ward, K				Fox, N; Ward, K			Global consumption and the challenge to pharmaceutical governance in the United Kingdom	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENETICS	Analysis of governance, based on research into the views of stakeholders, can show the ways in which systems for regulation of technology evolve in the face of changes such as globalisation.	Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England	University of Sheffield	Fox, N (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England.	nj.fox@shefac.uk		Fox, Nick/0000-0003-2037-2664				BYNOE R, 1999, ZDNET           0406; CHILDS M, 1998, NEW LAW J, V148, P1840; *EUR FED PHARM IND, 2001, GUID INT WEB SIT AV; FOX NJ, IN PRESS SOC SCI MED; FOX NJ, IN PRESS SOCIOLOGY; Jones M, 2003, NEW GENET SOC, V22, P21, DOI 10.1080/1463677032000069691; Kerr A, 2003, NEW GENET SOC, V22, P111, DOI 10.1080/1463677032000102611; LENK K, 1997, GOVERNANCE CYBERSPAC, P126; *MED CONTR AG, 1999, ADV PROM MED UK; Pines WL, 2000, ANN PHARMACOTHER, V34, P1341; Queau P., 2002, DEVELOPMENT, V45, P10, DOI [10.1057/palgrave.development.1110398, DOI 10.1057/PALGRAVE.DEVELOPMENT.1110398]; Rosenau J., 1997, DOMESTIC FOREIGN FRO; Rosenau J. N., 2002, TECHNOLOGY DEV DEMOC; *ROYAL PHARM SOC G, 2005, COD ETH STAND; Shaw J, 2004, BMJ-BRIT MED J, V328, P723, DOI 10.1136/bmj.328.7442.723; SMART A, 2003, SOCIOLOGY HLTH ILLNE, V25, P408	16	4	4	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	2005	331	7507					40	42		10.1136/bmj.331.7507.40	http://dx.doi.org/10.1136/bmj.331.7507.40			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947TD	15994692	Green Published			2022-12-28	WOS:000230668500022
J	Beck, P; Gillet, P; El Goresy, A; Mostefaoui, S				Beck, P; Gillet, P; El Goresy, A; Mostefaoui, S			Timescales of shock processes in chondritic and martian meteorites	NATURE			English	Article							METAMORPHISM; DIFFUSION; MINERALS; OLIVINE; TEMPERATURE; CONSTRAINTS; SHERGOTTY; PHASES; ZAGAMI; VEINS	The accretion of the terrestrial planets from asteroid collisions and the delivery to the Earth of martian and lunar meteorites has been modelled extensively(1,2). Meteorites that have experienced shock waves from such collisions can potentially be used to reveal the accretion process at different stages of evolution within the Solar System. Here we have determined the peak pressure experienced and the duration of impact in a chondrite and a martian meteorite, and have combined the data with impact scaling laws to infer the sizes of the impactors and the associated craters on the meteorite parent bodies. The duration of shock events is inferred from trace element distributions between coexisting high-pressure minerals in the shear melt veins of the meteorites. The shock duration and the associated sizes of the impactor are found to be much greater in the chondrite (similar to 1 s and 5 km, respectively) than in the martian meteorite (similar to 10 ms and 100 m). The latter result compares well with numerical modelling studies of cratering on Mars, and we suggest that martian meteorites with similar, recent ejection ages (10(5) to 10(7) years ago)(3) may have originated from the same few square kilometres on Mars.	Ecole Normale Super Lyon, CNRS, UMR 5570, Lab Sci Terre, F-69364 Lyon, France; Univ Lyon 1, F-69364 Lyon, France; Max Planck Inst Chem, D-55128 Mainz, Germany	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Max Planck Society	Beck, P (corresponding author), Ecole Normale Super Lyon, CNRS, UMR 5570, Lab Sci Terre, 46 Allee Italie, F-69364 Lyon, France.	pbeck@ens-lyon.fr	Beck, Pierre/F-3149-2011					AGEE CB, 1995, J GEOPHYS RES-SOL EA, V100, P17725, DOI 10.1029/95JB00049; Ahrens TJ, 2002, AIP CONF PROC, V620, P1393; AKAOGI M, 1989, J GEOPHYS RES-SOLID, V94, P15671, DOI 10.1029/JB094iB11p15671; Barrat JA, 2001, METEORIT PLANET SCI, V36, P23, DOI 10.1111/j.1945-5100.2001.tb01807.x; Beck P, 2004, EARTH PLANET SC LETT, V219, P1, DOI 10.1016/S0012-821X(03)00695-2; BLUNDY J, 1994, NATURE, V372, P452, DOI 10.1038/372452a0; Chen M, 1996, SCIENCE, V271, P1570, DOI 10.1126/science.271.5255.1570; DODSON MH, 1973, CONTRIB MINERAL PETR, V40, P259, DOI 10.1007/BF00373790; FREER R, 1981, CONTRIB MINERAL PETR, V76, P440, DOI 10.1007/BF00371486; Gillet P, 2000, SCIENCE, V287, P1633, DOI 10.1126/science.287.5458.1633; Gladman BJ, 1996, SCIENCE, V274, P161; Head JN, 2002, SCIENCE, V298, P1752, DOI 10.1126/science.1077483; JUREWICZ AJG, 1988, CONTRIB MINERAL PETR, V99, P186, DOI 10.1007/BF00371460; Kerschhofer L, 2000, PHYS EARTH PLANET IN, V121, P59, DOI 10.1016/S0031-9201(00)00160-6; LANGENHORST F, 1995, GEOCHIM COSMOCHIM AC, V59, P1835, DOI 10.1016/0016-7037(95)00086-F; Langenhorst F, 2000, EARTH PLANET SC LETT, V184, P37, DOI 10.1016/S0012-821X(00)00317-4; Langenhorst F, 2000, EARTH PLANET SC LETT, V176, P259, DOI 10.1016/S0012-821X(00)00028-5; LOWRY RK, 1982, CONTRIB MINERAL PETR, V80, P254, DOI 10.1007/BF00371355; Malavergne V, 2001, METEORIT PLANET SCI, V36, P1297, DOI 10.1111/j.1945-5100.2001.tb01825.x; Melosh H.J., 1989, OXFORD MONOGRAPHS GE; Nyquist LE, 2001, SPACE SCI REV, V96, P105, DOI 10.1023/A:1011993105172; Ohtani E, 2004, EARTH PLANET SC LETT, V227, P505, DOI 10.1016/j.epsl.2004.08.018; PUTNIS A, 1979, NATURE, V280, P217, DOI 10.1038/280217a0; Steel D, 1998, PLANET SPACE SCI, V46, P473, DOI 10.1016/S0032-0633(97)00232-8; STOFFLER D, 1986, GEOCHIM COSMOCHIM AC, V50, P889, DOI 10.1016/0016-7037(86)90371-6; STOFFLER D, 1991, GEOCHIM COSMOCHIM AC, V55, P3845, DOI 10.1016/0016-7037(91)90078-J; Tomioka N, 1997, SCIENCE, V277, P1084, DOI 10.1126/science.277.5329.1084; Wang WY, 1999, AM MINERAL, V84, P357; WARREN PH, 1994, ICARUS, V111, P338, DOI 10.1006/icar.1994.1149; WETHERILL GW, 1980, ANNU REV ASTRON ASTR, V18, P77, DOI 10.1146/annurev.aa.18.090180.000453	30	110	114	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1071	1074		10.1038/nature03616	http://dx.doi.org/10.1038/nature03616			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973403				2022-12-28	WOS:000229970400042
J	Wilson, JF				Wilson, JF			Liver cancer on the rise	ANNALS OF INTERNAL MEDICINE			English	News Item							HEPATOCELLULAR-CARCINOMA; DIABETES INCREASES; UNITED-STATES; HEPATITIS-C; DISEASE					jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136				Adams PC, 2004, HEPATOLOGY, V39, P1204, DOI 10.1002/hep.20169; Caldwell SH, 2004, GASTROENTEROLOGY, V127, pS97, DOI 10.1053/j.gastro.2004.09.021; Davila JA, 2005, GUT, V54, P533, DOI 10.1136/gut.2004.052167; Di Bisceglie AM, 2004, GASTROENTEROLOGY, V127, pS104, DOI 10.1053/j.gastro.2004.09.022; El-Serag HB, 2004, GASTROENTEROLOGY, V126, P460, DOI 10.1053/j.gastro.2003.10.065; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; Ikai I, 2004, HEPATOL RES, V28, P21, DOI 10.1016/j.hepres.2003.08.002; Kojiro Masamichi, 2004, Liver Transpl, V10, pS3, DOI 10.1002/lt.20042; Lencioni R, 2005, RADIOLOGY, V234, P961, DOI 10.1148/radiol.2343040350; Morgan TR, 2004, GASTROENTEROLOGY, V127, pS87, DOI 10.1053/j.gastro.2004.09.020; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; Shiratori Y, 2003, ANN INTERN MED, V138, P299, DOI 10.7326/0003-4819-138-4-200302180-00008	12	44	46	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	1				1029	1032		10.7326/0003-4819-142-12_Part_1-200506210-00024	http://dx.doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00024			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937IN	15968025				2022-12-28	WOS:000229917900019
J	Minamimoto, T; Hori, Y; Kimura, M				Minamimoto, T; Hori, Y; Kimura, M			Complementary process to response bias in the centromedian nucleus of the thalamus	SCIENCE			English	Article							CM-PF COMPLEX; BASAL GANGLIA; ANTERIOR CINGULATE; NEURONAL SIGNALS; DOPAMINE NEURONS; PARIETAL CORTEX; REWARD; PREDICTION; MOTIVATION; DECISION	Activity in several areas of the human brain and the monkey brain increases when a subject anticipates events associated with a reward, implicating a role for bias of decision and action. However, in real life, events do not always appear as expected, and we must choose an undesirable action, More than half of the neurons in the monkey centromedian (CM) thalamus were selectively activated when a small-reward action was required but a Large-reward option was anticipated. Electrical stimulation of the CM after a large-reward action request substituted a brisk performance with a sluggish performance. These results suggest involvement of the CM in a mechanism complementary to decision and action bias.	Kyoto Prefectural Univ Med, Dept Physiol, Kamigyo Ku, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine	Kimura, M (corresponding author), Kyoto Prefectural Univ Med, Dept Physiol, Kamigyo Ku, Kyoto 6028566, Japan.	mkimura@koto.kpu-m.ac.jp	Minamimoto, Takafumi/AAD-8726-2020; Minamimoto, Takafumi/D-6610-2012	Minamimoto, Takafumi/0000-0003-4305-0174; Minamimoto, Takafumi/0000-0003-4305-0174				Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; GROENEWEGEN HJ, 1994, TRENDS NEUROSCI, V17, P52, DOI 10.1016/0166-2236(94)90074-4; Hatanaka N, 2003, J COMP NEUROL, V462, P121, DOI 10.1002/cne.10720; HERMSTEIN RJ, 1961, J EXPT ANAL BEHAV, V4, P267; Kimura M, 2004, NEUROSCI RES, V48, P355, DOI 10.1016/j.neures.2003.12.002; Lauwereyns J, 2002, NATURE, V418, P413, DOI 10.1038/nature00892; Leon MI, 1999, NEURON, V24, P415, DOI 10.1016/S0896-6273(00)80854-5; Matsumoto N, 2001, J NEUROPHYSIOL, V85, P960, DOI 10.1152/jn.2001.85.2.960; Minamimoto T, 2002, J NEUROPHYSIOL, V87, P3090, DOI 10.1152/jn.2002.87.6.3090; Nakahara H, 2004, NEURON, V41, P269, DOI 10.1016/S0896-6273(03)00869-9; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; Redgrave P, 1999, TRENDS NEUROSCI, V22, P146, DOI 10.1016/S0166-2236(98)01373-3; Roesch MR, 2004, SCIENCE, V304, P307, DOI 10.1126/science.1093223; Satoh T, 2003, J NEUROSCI, V23, P9913; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563; Shidara M, 1998, J NEUROSCI, V18, P2613; Shidara M, 2002, SCIENCE, V296, P1709, DOI 10.1126/science.1069504; Smith Y, 2004, TRENDS NEUROSCI, V27, P520, DOI 10.1016/j.tins.2004.07.004; STERIADE M, 1997, THALAMUS, V1, P55; Sugrue LP, 2004, SCIENCE, V304, P1782, DOI 10.1126/science.1094765; THORNDIKE EL, 1898, ANIMAL INTELLIGENCE; Watanabe M, 2001, EXP BRAIN RES, V140, P511, DOI 10.1007/s002210100856	24	97	102	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1798	1801		10.1126/science.1109154	http://dx.doi.org/10.1126/science.1109154			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961671				2022-12-28	WOS:000229926800058
J	Rehren, T; Pusch, EB				Rehren, T; Pusch, EB			Late Bronze Age glass production at Qantir-Piramesses, Egypt	SCIENCE			English	Article								It has been uncertain whether the glass produced during the Late Bronze Age (LBA) originated in Egypt or Mesopotamia. Here we present evidence for the production of glass from its raw materials in the eastern Nile Delta during the LBA. Glass was made in workshops that were separate from where the production of objects took place. The initial melting of the raw materials to semi-finished glass was done at temperatures of 900 degrees to 950 degrees C, followed by coloration and ingot production at 1000 degrees to 1100 degrees C.	UCL, Archaeol Inst, London WC1H 0PY, England; Pelizaeus Museum Hildesheim, D-31124 Hildesheim, Germany	University of London; University College London	Rehren, T (corresponding author), UCL, Archaeol Inst, 31-34 Gordon Sq, London WC1H 0PY, England.	th.rehren@uct.ac.uk	Rehren, Thilo/C-1567-2008	Rehren, Thilo/0000-0002-9169-1198				Aston D. A., 1998, KERAMIK GRABUNGSPL 1 KERAMIK GRABUNGSPL 1, V1; Brill R.H., 1999, CHEM ANAL EARLY GLAS, V2; NICHOLSON P, 1993, SHIRE EGYPTOLOGY SER; Nicholson PT, 1997, J EGYPT ARCHAEOL, V83, P143, DOI 10.2307/3822462; PUALK C, 1997, RES MARITIMAE, P233; PUSCH EB, 1996, PELIZAEUS MUSEUM HIL, P126; Rehren T, 1998, CERAM CIVIL, P227; Rehren T, 1997, J EGYPT ARCHAEOL, V83, P127, DOI 10.2307/3822461; Rehren T, 1997, ARCHAEOMETRY, V39, P355, DOI 10.1111/j.1475-4754.1997.tb00812.x; Shugar A., 2002, GLASS TECHNOLOGY C, V43C, P145; Turner W. E. S., 1954, J SOC GLASS TECHNOL, V38, P436	11	63	63	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1756	1758		10.1126/science.1110466	http://dx.doi.org/10.1126/science.1110466			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961663				2022-12-28	WOS:000229926800045
J	Bergman, L				Bergman, L			Damned if you don't	NATURE			English	Editorial Material																			0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 16	2005	435	7044					1002	1002		10.1038/4351002a	http://dx.doi.org/10.1038/4351002a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959527	Bronze			2022-12-28	WOS:000229799700057
J	Muto, MG; O'Neill, MJ; Oliva, E; Harris, NL; Schiff, I; Scully, RE				Muto, MG; O'Neill, MJ; Oliva, E; Harris, NL; Schiff, I; Scully, RE			A 45-year-old woman with a painful mass in the abdomen - Endometriosis associated with a surgical scar.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CLEAR-CELL-CARCINOMA; EXTRAPELVIC ENDOMETRIOSIS; ABDOMINAL-WALL; MALIGNANCY; DIAGNOSIS; OVARIAN; CANCER		Dana Farber Canc Inst, Div Gynecol Oncol, Gillette Ctr Womens Canc, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Obstet, Boston, MA USA; Harvard Univ, Sch Med, Dept Gynecol, Boston, MA USA; Harvard Univ, Sch Med, Dept Reprod Biol, Boston, MA USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Muto, MG (corresponding author), Dana Farber Canc Inst, Div Gynecol Oncol, Gillette Ctr Womens Canc, Boston, MA 02115 USA.							AHN GH, 1991, CANCER-AM CANCER SOC, V67, P116, DOI 10.1002/1097-0142(19910101)67:1<116::AID-CNCR2820670121>3.0.CO;2-E; Blanco RG, 2003, AM J SURG, V185, P596, DOI 10.1016/S0002-9610(03)00072-2; Brinton LA, 1997, AM J OBSTET GYNECOL, V176, P572, DOI 10.1016/S0002-9378(97)70550-7; Campbell IG, 2001, HUM REPROD UPDATE, V7, P15, DOI 10.1093/humupd/7.1.15; CHATTERJEE SK, 1980, OBSTET GYNECOL, V56, P81; CLEMENT PB, 1990, PATHOL ANNU, V25, P245; FIRILAS A, 1994, AM SURGEON, V60, P259; FRANKLIN RR, 1990, PROG CLIN BIOL RES, V323, P289; Gucer F, 1998, EUR J GYNAECOL ONCOL, V19, P39; Honore GM, 1999, CLIN OBSTET GYNECOL, V42, P699, DOI 10.1097/00003081-199909000-00021; Isbister WH, 2002, ANZ J SURG, V72, P314, DOI 10.1046/j.1445-2197.2002.02382.x; Markopoulos C., 1996, European Journal of Gynaecological Oncology, V17, P520; MICHOWITZ M, 1983, DERMATOLOGICA, V167, P326, DOI 10.1159/000249810; Ness RB, 2003, AM J OBSTET GYNECOL, V189, P280, DOI 10.1067/mob.2003.408; Nirula R, 2000, J AM COLL SURGEONS, V190, P404, DOI 10.1016/S1072-7515(99)00286-0; OLIVE DL, 1993, NEW ENGL J MED, V328, P1759, DOI 10.1056/NEJM199306173282407; Park SW, 1999, J KOREAN MED SCI, V14, P217, DOI 10.3346/jkms.1999.14.2.217; Redwine DB, 2002, FERTIL STERIL, V78, P686, DOI 10.1016/S0015-0282(02)03329-0; Roncoroni L., 2001, Archives of Gynecology and Obstetrics, V265, P165, DOI 10.1007/s004040000153; Sampson JA, 1925, ARCH SURG-CHICAGO, V10, P1, DOI 10.1001/archsurg.1925.01120100007001; Seli E, 2003, OBSTET GYN CLIN N AM, V30, P43; Seydel AS, 1996, AM J SURG, V171, P239, DOI 10.1016/S0002-9610(97)89557-8; Shields CJ, 2001, EUR J SURG ONCOL, V27, P701, DOI 10.1053/ejso.2001.1169; SINGH KK, 1995, BRIT J SURG, V82, P1349, DOI 10.1002/bjs.1800821017; SPEROFF L, 1999, CLIN GYNECOLOGIC END, P1057; STECK WILLARD D., 1966, CLIN OBSTET GYNECOL, V9, P373, DOI 10.1097/00003081-196606000-00007; Stern RC, 2001, INT J GYNECOL PATHOL, V20, P133, DOI 10.1097/00004347-200104000-00004; Suleiman S, 2001, AM FAM PHYSICIAN, V64, P431; Todd RW, 2000, INT J GYNECOL CANCER, V10, P170, DOI 10.1046/j.1525-1438.2000.00024.x; Vinatier D, 2001, EUR J OBSTET GYN R B, V96, P21, DOI 10.1016/S0301-2115(00)00405-X; Wolf G C, 1989, Obstet Gynecol Surv, V44, P89, DOI 10.1097/00006254-198902000-00003; Wolf Y, 1996, AM SURGEON, V62, P1042; Ying AJ, 1998, GYNECOL ONCOL, V68, P301, DOI 10.1006/gyno.1998.4952	33	11	11	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2005	352	24					2535	2542		10.1056/NEJMcpc059013	http://dx.doi.org/10.1056/NEJMcpc059013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935RH	15958810				2022-12-28	WOS:000229798900011
J	Sipkins, DA; Wei, XB; Wu, JW; Runnels, JM; Cote, D; Means, TK; Luster, AD; Scadden, DT; Lin, CP				Sipkins, DA; Wei, XB; Wu, JW; Runnels, JM; Cote, D; Means, TK; Luster, AD; Scadden, DT; Lin, CP			In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment	NATURE			English	Article							CHEMOKINE RECEPTOR CXCR4; STEM-CELLS; ADHESION MOLECULES; NOD/SCID MICE; CANCER-CELLS; PRECURSOR-B; EXPRESSION; LEUKEMIA; MICROVESSELS; VOLUNTEERS	The organization of cellular niches is known to have a key role in regulating normal stem cell differentiation and regeneration, but relatively little is known about the architecture of microenvironments that support malignant metastasis(1,2). Using dynamic in vivo confocal imaging, here we show that murine bone marrow contains unique anatomic regions defined by specialized endothelium. This vasculature expresses the adhesion molecule E-selectin and the chemoattractant stromal-cell-derived factor 1 (SDF-1) in discrete, discontinuous areas that influence the homing of a variety of tumour cell lines. Disruption of the interactions between SDF-1 and its receptor CXCR4 inhibits the homing of Nalm-6 cells (an acute lymphoblastic leukaemia cell line) to these vessels. Further studies revealed that circulating leukaemic cells can engraft around these vessels, suggesting that this molecularly distinct vasculature demarcates a microenvironment for early metastatic tumour spread in bone marrow. Finally, purified haematopoietic stem/progenitor cells and lymphocytes also localize to the same microdomains, indicating that this vasculature might also function in benign states to demarcate specific portals for the entry of cells into the marrow space. Specialized vascular structures therefore appear to delineate a microenvironment with unique physiology that can be exploited by circulating malignant cells.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med & Technol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Hematol Oncol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Ctr Immunol & Inflammatory Dis, Charlestown, MA 02129 USA; Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard University	Lin, CP (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, 55 Fruit St, Boston, MA 02114 USA.	dsipkins1@partners.org; lin@helix.mgh.harvard.edu	Côté, Daniel/D-5185-2011; Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912	NCI NIH HHS [T32 CA071345, P50 CA086355] Funding Source: Medline; NEI NIH HHS [R01 EY014106] Funding Source: Medline; NIBIB NIH HHS [R01 EB000664] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY014106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000664] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Burger JA, 2002, LEUKEMIA LYMPHOMA, V43, P461, DOI 10.1080/10428190290011921; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Cao YA, 2004, P NATL ACAD SCI USA, V101, P221, DOI 10.1073/pnas.2637010100; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; CRISTY M, 1981, PHYS MED BIOL, V26, P389, DOI 10.1088/0031-9155/26/3/003; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014-5793(02)03143-5; Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000; HONN KV, 1992, CANCER METAST REV, V11, P353, DOI 10.1007/BF01307187; Jo DY, 2003, BRIT J HAEMATOL, V121, P649, DOI 10.1046/j.1365-2141.2003.04326.x; Liles WC, 2003, BLOOD, V102, P2728, DOI 10.1182/blood-2003-02-0663; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mastro AM, 2003, CLIN EXP METASTAS, V20, P275, DOI 10.1023/A:1022995403081; Mazo IB, 1999, J LEUKOCYTE BIOL, V66, P25, DOI 10.1002/jlb.66.1.25; Mazo IB, 1998, J EXP MED, V188, P465, DOI 10.1084/jem.188.3.465; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113; Novak J, 2004, OPT LETT, V29, P77, DOI 10.1364/OL.29.000077; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; REUSSBORST MA, 1995, LEUKEMIA, V9, P869; Shen HM, 2001, J IMMUNOL, V166, P5027, DOI 10.4049/jimmunol.166.8.5027; Shen W, 2001, EXP HEMATOL, V29, P1439, DOI 10.1016/S0301-472X(01)00741-X; Spano JP, 2004, ANN ONCOL, V15, P613, DOI 10.1093/annonc/mdh136; Spiegel A, 2004, BLOOD, V103, P2900, DOI 10.1182/blood-2003-06-1891; Tavor S, 2004, CANCER RES, V64, P2817, DOI 10.1158/0008-5472.CAN-03-3693	30	640	679	3	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					969	973		10.1038/nature03703	http://dx.doi.org/10.1038/nature03703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959517	Green Accepted			2022-12-28	WOS:000229799700052
J	Butler, D				Butler, D			China rejects Internet claims of human cases	NATURE			English	News Item								Reports that the outbreak of avian influenza among wild birds in Qinghai has resulted in any human cases of the disease are being denied by China. Rumours that people had been infected began when the ProMED-mail Internet alert system relayed a translation of an article from the independent Chinese website BoxunNews, which is based in the United States. ProMED warned that the informationwas unofficial and needed to be confirmed.											0	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 2	2005	435	7042					542	543						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15954220				2022-12-28	WOS:000229476200005
J	Maier, PC; Funk, J; Schwarzer, G; Antes, G; Falck-Ytter, YT				Maier, PC; Funk, J; Schwarzer, G; Antes, G; Falck-Ytter, YT			Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TIMOLOL THERAPY; NO TREATMENT; PROGRESSION; NUMBER; ONSET	Objective Open angle glaucoma is one of the most common causes of blindness in industrialised nations. Treatments to lower ocular pressure are widely used in glaucoma prevention and treatment, despite conflicting evidence. Design We performed meta-analyses to reassess the effectiveness of pressure lowering treatment to delay the development of glaucoma in ocular hypertension, as well as progression of manifest open angle glaucoma. Data sources Medline, Embase, and the Cochrane Library. Selection of studies Eligible studies were randomised controlled trials with a concurrent untreated control group and information on time to glaucomatous changes to visual field and optic disc. Trial reports were reviewed independently by two investigators in an unblinded standardised manner. Results Meta-analysis of trials in ocular hypertension showed a significant preventive effect of reducing intraocular pressure on progression to glaucoma (hazard ratio 0.56, 95%) confidence interval 0.39 to 0.81, P = 0.01; number needed to treat 12). Pooled data of studies in manifest glaucoma showed a significant delay of visual field deterioration (0.65, 0.49 to 0.87, P = 0.003; NNT = 7), with subgroup analysis showing a larger effect in patients with raised pressure and a reduced effect in normal tension glaucoma (subgroup comparison: not significant). Conclusions Lowering intraocular pressure in patients with ocular hypertension or manifest glaucoma is beneficial in reducing the risk of visual field loss in the long term.	Univ Hosp Freiburg, Dept Ophthalmol, D-79106 Freiburg, Germany; Univ Hosp Freiburg, Inst Med Biometry & Med Informat, German Cochrane Ctr, D-79106 Freiburg, Germany; Case Western Reserve Univ, Louis Stokes VA Med Ctr, Cleveland, OH 44106 USA	University of Freiburg; University of Freiburg; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Maier, PC (corresponding author), Univ Hosp Freiburg, Dept Ophthalmol, Killianstr 5, D-79106 Freiburg, Germany.	maierphi@aug.ukl.uni-freiburg.de	Falck-Ytter, Yngve/GZH-0993-2022; Schwarzer, Guido/A-8168-2009; Yngve Falck-Ytter, AGAF/AAC-5362-2019	Schwarzer, Guido/0000-0001-6214-9087; Yngve Falck-Ytter, AGAF/0000-0002-4688-3211				Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Alward WL, 1998, AM J OPHTHALMOL, V126, P498; DIELEMANS I, 1994, OPHTHALMOLOGY, V101, P1851; EPSTEIN DL, 1989, OPHTHALMOLOGY, V96, P1460; Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714; Heijl A, 2000, GRAEF ARCH CLIN EXP, V238, P877, DOI 10.1007/s004170000189; Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HOLMIN C, 1988, ACTA OPHTHALMOL, V66, P170; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Kamal D, 2003, GRAEF ARCH CLIN EXP, V241, P196, DOI 10.1007/s00417-002-0614-4; KARNAL D, 2003, GRAEFES ARCH CLIN EX, V241, P196; Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701; KASS MA, 1989, ARCH OPHTHALMOL-CHIC, V107, P1590, DOI 10.1001/archopht.1989.01070020668025; KITAZAWA Y, 1977, ARCH OPHTHALMOL-CHIC, V95, P1180, DOI 10.1001/archopht.1977.04450070078004; Kitazawa Y, 1981, Trans Ophthalmol Soc N Z, V33, P30; Leske MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P48; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; ROSSETTI L, 1993, ARCH OPHTHALMOL-CHIC, V111, P96, DOI 10.1001/archopht.1993.01090010100034; SCHULZER M, 1991, OPHTHALMOLOGY, V98, P301; SHIN DH, 1976, ARCH OPHTHALMOL-CHIC, V94, P2059	23	157	161	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 16	2005	331	7509					134	136B		10.1136/bmj.38506.594977.E0	http://dx.doi.org/10.1136/bmj.38506.594977.E0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947GV	15994659	Bronze, Green Published			2022-12-28	WOS:000230632300014
J	Cook, NR; Lee, IM; Gaziano, JM; Gordon, D; Ridker, PM; Manson, JE; Hennekens, CH; Buring, JE				Cook, NR; Lee, IM; Gaziano, JM; Gordon, D; Ridker, PM; Manson, JE; Hennekens, CH; Buring, JE			Low-dose aspirin in the primary prevention of cancer the women's health study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MUCOSAL PROSTAGLANDIN E-2; BREAST-CANCER; COLORECTAL ADENOMAS; CARDIOVASCULAR-DISEASE; LUNG-CANCER; PHYSICIANS HEALTH; RISK; CYCLOOXYGENASE-2; CHEMOPREVENTION	Context Basic research and observational evidence as well as results from trials of colon polyp recurrence suggest a role for aspirin in the chemoprevention of cancer. Objective To examine the effect of aspirin on the risk of cancer among healthy women. Design, Setting, and Participants In the Women's Health Study, a randomized 2 X 2 factorial trial of aspirin and vitamin E conducted between September 1992 and March 2004, 39 876 US women aged at least 45 years and initially without previous history of cancer, cardiovascular disease, or other major chronic illness were randomly assigned to receive either aspirin or aspirin placebo and followed up for an average of 10.1 years. Intervention A dose of 100 mg of aspirin (n=19 934) or aspirin placebo (n=19942) administered every other day. Main Outcome Measures Confirmed newly diagnosed invasive cancer at any site, except for nonmelanoma skin cancer. Incidence of breast, colorectal, and lung cancer were secondary end points. Results No effect of aspirin was observed on total cancer (n=2865; relative risk [RR], 1.01; 95% confidence interval [CI], 0.94-1.08; P=.87), breast cancer (n =1230; RR, 0.98;.95% Cl, 0.87-1.09; P=.68), colorectal cancer (n=269; RR, 0.97; 95% Cl, 0.77-1.24; P=.83), or cancer of any other site, with the exception of lung cancer for which there was a trend toward reduction in risk (n=205; RR, 0.78; 95% Cl,-0.59-1.03; P=.08). There was also no reduction in cancer mortality either overall (n=583; RR, 0.95; 95% Cl, 0.81-1.11; P=.51) or by site, except for lung cancer mortality (n=140; RR, 0.70; 95% Cl, 0.50-0.99; P=.04). No evidence of differential effects of aspirin by follow-up time or interaction with vitamin E was found. Conclusions Results from this large-scale, long-term trial suggest that alternate day use of low-dose aspirin (100 mg) for an average 10 years of treatment does not lower risk of total, breast, colorectal, or other site-specific cancers. A protective effect on lung cancer or a benefit of higher doses of aspirin cannot be ruled out.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Prevent Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Cardiovasc Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Aging, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Vet Affairs Boston Healthcare Syst, Boston, MA USA; Univ Miami, Sch Med, Dept Med, Miami, FL USA; Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL USA; Florida Atlantic Univ, Ctr Excellence, Dept Biomed Sci, Boca Raton, FL 33431 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System; University of Miami; University of Miami; State University System of Florida; Florida Atlantic University	Cook, NR (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.	ncook@rics.bwh.harvard.edu	Lee, I-Min/ABD-5409-2021		NATIONAL CANCER INSTITUTE [R01CA047988] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043851] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47988] Funding Source: Medline; NHLBI NIH HHS [HL-43851] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhmedkhanov A, 2002, BRIT J CANCER, V87, P49, DOI 10.1038/sj.bjc.6600370; Anderson JR, 1985, MUIRS TXB PATHOLOGY, P20; Asano TK, 2004, DIS COLON RECTUM, V47, P665, DOI 10.1007/s10350-003-0111-9; Awtry EH, 2000, CIRCULATION, V101, P1206, DOI 10.1161/01.CIR.101.10.1206; Baron JA, 2003, PROG EXP TUMOR RES, V37, P1; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Benamouzig R, 2003, GASTROENTEROLOGY, V125, P328, DOI 10.1016/S0016-5085(03)00887-4; Chan AT, 2004, ANN INTERN MED, V140, P157, DOI 10.7326/0003-4819-140-3-200402030-00006; Cook NR, 2000, ARCH INTERN MED, V160, P921, DOI 10.1001/archinte.160.7.921; COX DR, 1972, J R STAT SOC B, V34, P187; GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; Gonzalez-Perez A, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-28; Harris RE, 2002, ONCOL REP, V9, P693; Harris RE, 2003, CANCER RES, V63, P6096; Holick CN, 2003, BRIT J CANCER, V89, P1705, DOI 10.1038/sj.bjc.6601343; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; Khuder SA, 2001, BRIT J CANCER, V84, P1188, DOI 10.1054/bjoc.2000.1709; Krishnan K, 2001, CANCER EPIDEM BIOMAR, V10, P447; Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102; Muscat JE, 2003, CANCER, V97, P1732, DOI 10.1002/cncr.11242; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; Patrono C, 2001, CHEST, V119, p39S, DOI 10.1378/chest.119.1_suppl.39S; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; Rexrode KM, 2000, J WOMEN HEALTH GEN-B, V9, P19, DOI 10.1089/152460900318911; Ridker P M, 1996, J Cardiovasc Risk, V3, P209, DOI 10.1097/00043798-199604000-00013; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Rodriguez LAG, 2000, EPIDEMIOLOGY, V11, P376, DOI 10.1097/00001648-200007000-00003; Rodriguez LAG, 2004, BRIT J CANCER, V91, P525, DOI 10.1038/sj.bjc.6602003; Rodriguez LAG, 2001, EPIDEMIOLOGY, V12, P88, DOI 10.1097/00001648-200101000-00015; Sample D, 2002, CANCER EPIDEM BIOMAR, V11, P275; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Sturmer T, 1998, ANN INTERN MED, V128, P713, DOI 10.7326/0003-4819-128-9-199805010-00003; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Tangrea JA, 2003, CANCER CAUSE CONTROL, V14, P403, DOI 10.1023/A:1024990617158; Terry MB, 2004, JAMA-J AM MED ASSOC, V291, P2433, DOI 10.1001/jama.291.20.2433; Thun MJ, 2000, EPIDEMIOLOGY, V11, P371, DOI 10.1097/00001648-200007000-00001	38	620	632	0	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2005	294	1					47	55		10.1001/jama.294.1.47	http://dx.doi.org/10.1001/jama.294.1.47			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941JD	15998890	Bronze			2022-12-28	WOS:000230210200024
J	Dennis, CL				Dennis, CL			Psychosocial and psychological interventions for prevention of postnatal depression: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTPARTUM DEPRESSION	Objective To assess the effects of psychosocial and psychological interventions compared with usual antepartum, intrapartum, or postpartum care on the risk of postnatal depression. Data sources Medline, Embase, CINAHL, Cochrane central register of controlled trials, Cochrane pregnancy and childbirth group trials register, Cochrane depression, anxiety, and neurosis trials register, secondary references and review articles, and experts in the field. Study selection All published and unpublished randomised controlled trials of preventive psychosocial or psychological interventions in which the primary or secondary aim was a reduction in the risk of postnatal depression. All trials recruited pregnant women or new mothers less than six weeks postpartum. Eligible studies were abstracted, assessed for methodological quality, and pooled with relative risk for categorical data and weighted mean difference for continuous data. Results Fifteen trials with 7697 women were included. Although there was no overall statistically significant effect on the prevention of postnatal depression in the meta-analysis of all types of interventions (15 trials, n = 7697; relative risk 0.81, 95% confidence interval 0.65 to 1.02), these results suggest a potential reduction in postnatal depression. ne only intervention to have a clear preventive effect was intensive postpartum support provided by a health professional (0.68,0.55 to 0.84). Identifying women "at risk" assisted in the prevention of postnatal depression (0.67, 0.51 to 0.89). Interventions with only a postnatal component were more beneficial (0.76, 0.58 to 0.98) than interventions that incorporated an antenatal component. In addition, individually based interventions were more effective (0.76,0.59 to 1.00) than group based interventions (1.03, 0.65 to 1.63). Conclusions Diverse psychosocial or psychological interventions do not significantly reduce the number of women who develop postnatal depression. The most promising intervention is the provision of intensive, professionally based postpartum support.	Univ Toronto, Fac Nursing, Toronto, ON M5S 3H4, Canada	University of Toronto	Dennis, CL (corresponding author), Univ Toronto, Fac Nursing, 50 St George St, Toronto, ON M5S 3H4, Canada.	cindylee.dennis@utoronto.ca	Dennis, Cindy-Lee/ABA-2860-2020	Dennis, Cindy-Lee/0000-0002-0135-7242				Austin MP, 2003, ACTA PSYCHIAT SCAND, V107, P10, DOI 10.1034/j.1600-0447.2003.02024.x; Beck CT, 2001, NURS RES, V50, P275, DOI 10.1097/00006199-200109000-00004; Cooper PJ, 1997, ARCH DIS CHILD, V77, P97, DOI 10.1136/adc.77.2.97; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Dennis CL, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006309; Dennis CLE, 2004, CAN J PSYCHIAT, V49, P526, DOI 10.1177/070674370404900804; Dennis CLE, 2004, CAN J PSYCHIAT, V49, P467, DOI 10.1177/070674370404900708; Dennis CLE, 2004, J CLIN PSYCHIAT, V65, P1252, DOI 10.4088/JCP.v65n0915; Lumley J, 2004, INT J TECHNOL ASSESS, V20, P128, DOI 10.1017/S0266462304000911; OHara MW, 1996, INT REV PSYCHIATR, V8, P37, DOI 10.3109/09540269609037816	10	208	213	1	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	2005	331	7507					15	18		10.1136/bmj.331.7507.15	http://dx.doi.org/10.1136/bmj.331.7507.15			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	947TD	15994688	Green Published, Bronze			2022-12-28	WOS:000230668500015
J	Qin, LD; Park, S; Huang, L; Mirkin, CA				Qin, LD; Park, S; Huang, L; Mirkin, CA			On-wire lithography	SCIENCE			English	Article							DIP-PEN NANOLITHOGRAPHY; ELECTROCHEMICAL FABRICATION; METALLIC ELECTRODES	We report a high-throughput procedure for lithographically processing one-dimensional nanowires. This procedure, termed on-wire lithography, combines advances in temptate-directed synthesis of nanowires with electrochemical deposition and wet-chemical etching and allows routine fabrication of face-to-face disk arrays and gap structures in the range of five to several hundred nanometers. We studied the transport properties of 13-nanometer gaps with and without nanoscopic amounts of conducting polymers deposited within by dip-pen nanotithography.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Inst Nanotechnol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Mirkin, CA (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	chadnano@northwestern.edu		Mirkin, Chad/0000-0002-6634-7627				Gates BD, 2005, CHEM REV, V105, P1171, DOI 10.1021/cr030076o; Ginger DS, 2004, ANGEW CHEM INT EDIT, V43, P30, DOI 10.1002/anie.200300608; Kovtyukhova NI, 2002, CHEM-EUR J, V8, P4355, DOI 10.1002/1521-3765(20021004)8:19<4354::AID-CHEM4354>3.0.CO;2-1; Li CZ, 2000, APPL PHYS LETT, V77, P3995, DOI 10.1063/1.1332406; Maier SA, 2003, NAT MATER, V2, P229, DOI 10.1038/nmat852; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137; Park H, 1999, APPL PHYS LETT, V75, P301, DOI 10.1063/1.124354; Park S, 2004, SCIENCE, V303, P348, DOI 10.1126/science.1093276; Park S, 2004, J AM CHEM SOC, V126, P11772, DOI 10.1021/ja046077v; Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Reichert J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.176804; Routkevitch D, 1996, J PHYS CHEM-US, V100, P14037, DOI 10.1021/jp952910m; Salem AK, 2004, NANO LETT, V4, P1163, DOI 10.1021/nl049462r; Xiang J, 2005, ANGEW CHEM INT EDIT, V44, P1265, DOI 10.1002/anie.200461797	16	326	339	8	155	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					113	115		10.1126/science.1112666	http://dx.doi.org/10.1126/science.1112666			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994551				2022-12-28	WOS:000230212800069
J	Won, J; Kim, M; Yi, YW; Kim, YH; Jung, N; Kim, TK				Won, J; Kim, M; Yi, YW; Kim, YH; Jung, N; Kim, TK			RETRACTED: A magnetic nanoprobe technology for detecting molecular interactions in live cells (Retracted article. See vol. 324, pg. 463, 2009)	SCIENCE			English	Article; Retracted Publication							TAT-FUSION PROTEINS; QUANTUM DOTS; IDENTIFICATION; MICROARRAYS; DELIVERY; RECEPTOR; INHIBITORS; TRACKING; CLONING; SYSTEM	Technologies to assess the molecular targets of biomolecules in living cells are lacking. We have developed a technology called magnetism-based interaction capture (MAGIC) that identifies molecular targets on the basis of induced movement of superparamagnetic nanoparticles inside living cells. Efficient intracellular uptake of superparamagnetic nanoparticles (coated with a small molecule of interest) was mediated by a transducible fusogenic peptide. These nanoprobes captured the small molecule's labeled target protein and were translocated in a direction specified by the magnetic field. Use of MAGIC in genome-wide expression screening identified multiple protein targets of a drug. MAGIC was also used to monitor signal-dependent modification and multiple interactions of proteins.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; CGK Co Ltd, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Kim, TK (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	tkkim@kaist.ac.kr						Alexiou C, 2000, CANCER RES, V60, P6641; Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Baatz JE, 2001, BBA-MOL BASIS DIS, V1535, P100, DOI 10.1016/S0925-4439(00)00084-3; Burdine L, 2004, CHEM BIOL, V11, P593, DOI 10.1016/j.chembiol.2004.05.001; Caron NJ, 2004, BIOCHEM BIOPH RES CO, V319, P12, DOI 10.1016/j.bbrc.2004.04.180; Clardy J, 2004, NATURE, V432, P829, DOI 10.1038/nature03194; Derfus AM, 2004, ADV MATER, V16, P961, DOI 10.1002/adma.200306111; Gonzalez-Gaitan Marcos, 2003, Cell, V115, P513, DOI 10.1016/S0092-8674(03)00932-2; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; JIN YJ, 1992, J BIOL CHEM, V267, P10942; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kuruvilla FG, 2002, NATURE, V416, P653, DOI 10.1038/416653a; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817; Liu JO, 2003, BIOCHEM BIOPH RES CO, V311, P1103, DOI 10.1016/j.bbrc.2003.10.020; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; MacBeath G, 2000, SCIENCE, V289, P1760; Mack A, 2000, J IMMUNOL METHODS, V241, P19, DOI 10.1016/S0022-1759(00)00195-2; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Oda Y, 2003, ANAL CHEM, V75, P2159, DOI 10.1021/ac026196y; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Sche PP, 1999, CHEM BIOL, V6, P707, DOI 10.1016/S1074-5521(00)80018-6; Stockwell BR, 2004, NATURE, V432, P846, DOI 10.1038/nature03196; Strausberg RL, 2003, SCIENCE, V300, P294, DOI 10.1126/science.1083395; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996	27	126	140	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					121	125		10.1126/science.1112869	http://dx.doi.org/10.1126/science.1112869			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994554				2022-12-28	WOS:000230212800072
J	Lau, GKK; Piratvisuth, T; Luo, KX; Marcellin, P; Thongsawat, S; Cooksley, G; Gane, E; Fried, MW; Chow, WC; Paik, SW; Chang, WY; Berg, T; Flisiak, R; McCloud, P; Pluck, N				Lau, GKK; Piratvisuth, T; Luo, KX; Marcellin, P; Thongsawat, S; Cooksley, G; Gane, E; Fried, MW; Chow, WC; Paik, SW; Chang, WY; Berg, T; Flisiak, R; McCloud, P; Pluck, N		Peginterferon Alfa-2A HBeAg-Posit	Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM FOLLOW-UP; CONSENSUS STATEMENT; ADEFOVIR DIPIVOXIL; INTERFERON-ALPHA; CONTROLLED TRIAL; DRUG-RESISTANCE; ANTI-HBE; 40 KDA; THERAPY; INFECTION	BACKGROUND: Current treatments for chronic hepatitis B are suboptimal. In the search for improved therapies, we compared the efficacy and safety of pegylated interferon alfa plus lamivudine, pegylated interferon alfa without lamivudine, and lamivudine alone for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. METHODS: A total of 814 patients with HBeAg-positive chronic hepatitis B received either peginterferon alfa-2a (180 microg once weekly) plus oral placebo, peginterferon alfa-2a plus lamivudine (100 mg daily), or lamivudine alone. The majority of patients in the study were Asian (87 percent). Most patients were infected with hepatitis B virus (HBV) genotype B or C. Patients were treated for 48 weeks and followed for an additional 24 weeks. RESULTS: After 24 weeks of follow-up, significantly more patients who received peginterferon alfa-2a monotherapy or peginterferon alfa-2a plus lamivudine than those who received lamivudine monotherapy had HBeAg seroconversion (32 percent vs. 19 percent [P<0.001] and 27 percent vs. 19 percent [P=0.02], respectively) or HBV DNA levels below 100,000 copies per milliliter (32 percent vs. 22 percent [P=0.01] and 34 percent vs. 22 percent [P=0.003], respectively). Sixteen patients receiving peginterferon alfa-2a (alone or in combination) had hepatitis B surface antigen (HBsAg) seroconversion, as compared with 0 in the group receiving lamivudine alone (P=0.001). The most common adverse events were those known to occur with therapies based on interferon alfa. Serious adverse events occurred in 4 percent, 6 percent, and 2 percent of patients receiving peginterferon alfa-2a monotherapy, combination therapy, and lamivudine monotherapy, respectively. Two patients receiving lamivudine monotherapy had irreversible liver failure after the cessation of treatment -- one underwent liver transplantation, and the other died. CONCLUSIONS: In patients with HBeAg-positive chronic hepatitis B, peginterferon alfa-2a offers superior efficacy over lamivudine, on the basis of HBeAg seroconversion, HBV DNA suppression, and HBsAg seroconversion.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Songklanakarin Hosp, Dept Med, Songkhla, Thailand; Nangfang Hosp, Dept Infect Dis, Guangzhou, Peoples R China; Hop Beaujon, INSERM, U481, Serv Hepatol, Clichy, France; Hop Beaujon, Ctr Rech Claude Bernard Hepatites Virales, Clichy, France; Chiang Mai Univ, Dept Internal Med, Chiang Mai 50000, Thailand; Univ Queensland, Royal Brisbane Hosp, Dept Clin Res, Herston, Qld, Australia; Middlemore Hosp, Dept Gastroenterol, Otahuhu, New Zealand; Univ N Carolina, Liver Program, Chapel Hill, NC USA; Singapore Gen Hosp, Dept Gastroenterol, Singapore 0316, Singapore; Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Div Gastroenterol, Seoul, South Korea; Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan; Univ Med Berlin, Charite, Med Klin Schwerpunkt Hepatol & Gastroenterol, Berlin, Germany; Med Univ Bialystok, Dept Infect Dis, Bialystok, Poland; Roche, Dee Why, Australia; Roche, Welwyn Garden City, Herts, England	University of Hong Kong; Prince of Songkla University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Chiang Mai University; Royal Brisbane & Women's Hospital; University of Queensland; University of North Carolina; University of North Carolina Chapel Hill; Singapore General Hospital; Sungkyunkwan University (SKKU); Samsung Medical Center; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Medical University of Bialystok; Roche Holding; Roche Holding	Lau, GKK (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Rm 1838,Block K, Hong Kong, Hong Kong, Peoples R China.	gkklau@netvigator.com	cooksley, william ge/G-7742-2011; Lau, George/AAQ-2085-2021; Flisiak, Robert/S-5356-2018	Flisiak, Robert/0000-0003-3394-1635; Berg, Thomas/0000-0003-0003-6241; Thongsawat, Satawat/0000-0003-3302-3930				Bailon P, 2001, BIOCONJUGATE CHEM, V12, P195, DOI 10.1021/bc000082g; Barbaro G, 2001, J HEPATOL, V35, P406, DOI 10.1016/S0168-8278(01)00145-3; Cooksley WGE, 2003, J VIRAL HEPATITIS, V10, P298, DOI 10.1046/j.1365-2893.2003.00450.x; Craxi A, 2003, J HEPATOL, V39, pS99, DOI 10.1016/S0168-8278(03)00154-5; de Franchis R, 2003, J HEPATOL, V39, pS3, DOI 10.1016/S0168-8278(03)00378-7; Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702; FATTOVICH G, 1986, HEPATOLOGY, V6, P167, DOI 10.1002/hep.1840060203; Fattovich G, 1998, AM J GASTROENTEROL, V93, P896, DOI 10.1111/j.1572-0241.1998.00272.x; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Janssen HLA, 2005, LANCET, V365, P123, DOI 10.1016/S0140-6736(05)17701-0; Kao JH, 2002, J GASTROEN HEPATOL, V17, P643, DOI 10.1046/j.1440-1746.2002.02737.x; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lai CL, 2003, LANCET, V362, P2089, DOI 10.1016/S0140-6736(03)15108-2; Liaw YF, 2005, LIVER INT, V25, P472, DOI 10.1111/j.1478-3231.2005.01134.x; Liaw YF, 2003, J HEPATOL, V39, pS111, DOI 10.1016/S0168-8278(03)00155-7; Liaw YF, 2003, J GASTROEN HEPATOL, V18, P246, DOI 10.1046/j.1440-1746.2003.02976.x; LOK AS, 2003, AASLD PRACTICE GUIDE; LOK ASF, 1993, GASTROENTEROLOGY, V105, P1833, DOI 10.1016/0016-5085(93)91082-S; Lok ASF, 2004, HEPATOLOGY, V39, P857, DOI 10.1002/hep.20110; LOK ASF, 1988, LANCET, V2, P298; Lok ASF, 2002, J CLIN MICROBIOL, V40, P3729, DOI 10.1128/JCM.40.10.3729-3734.2002; Marcellin P, 2004, NEW ENGL J MED, V351, P1206, DOI 10.1056/NEJMoa040431; Marcellin P, 2003, NEW ENGL J MED, V348, P808, DOI 10.1056/NEJMoa020681; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; Perry CM, 2001, DRUGS, V61, P2263, DOI 10.2165/00003495-200161150-00013; QI X, 2004, J HEPATOL, V40, pA57; Richman DD, 2000, HEPATOLOGY, V32, P866, DOI 10.1053/jhep.2000.18194; Santantonio T, 2002, J HEPATOL, V36, P799, DOI 10.1016/S0168-8278(02)00056-9; Schalm SW, 2000, GUT, V46, P562, DOI 10.1136/gut.46.4.562; Tangkijvanich Pisit, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P452; Westland C, 2003, GASTROENTEROLOGY, V125, P107, DOI 10.1016/S0016-5085(03)00700-5; Yuen MF, 2003, ANTIVIR THER, V8, P531; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301	35	1131	1291	1	90	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					2682	2695		10.1056/NEJMoa043470	http://dx.doi.org/10.1056/NEJMoa043470			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	940HH	15987917	Green Published			2022-12-28	WOS:000230133800005
J	Theise, ND				Theise, ND			Now you see it, now you don't	NATURE			English	Editorial Material									Beth Israel Med Ctr, Div Digest Dis, New York, NY 10003 USA	Harvard University; Beth Israel Deaconess Medical Center	Theise, ND (corresponding author), Beth Israel Med Ctr, Div Digest Dis, 1st Ave & 16th St, New York, NY 10003 USA.							Kurakin A, 2005, DEV GENES EVOL, V215, P46, DOI 10.1007/s00427-004-0448-7; Theise ND, 2004, BLOOD CELL MOL DIS, V32, P17, DOI 10.1016/j.bcmd.2003.09.010; Theise ND, 2002, LEUKEMIA, V16, P542, DOI 10.1038/sj.leu.2402445	3	14	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 30	2005	435	7046					1165	1165		10.1038/4351165a	http://dx.doi.org/10.1038/4351165a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988502				2022-12-28	WOS:000230140500021
J	Thomas, DSG; Knight, M; Wiggs, GFS				Thomas, DSG; Knight, M; Wiggs, GFS			Remobilization of southern African desert dune systems by twenty-first century global warming	NATURE			English	Article							SOUTHWEST KALAHARI DESERT; DUNEFIELD ACTIVITY; MOBILITY; VARIABILITY; RAINFALL	Although desert dunes cover 5 per cent of the global land surface and 30 per cent of Africa, the potential impacts of twenty-first century global warming on desert dune systems are not well understood(1). The inactive Sahel and southern African dune systems, which developed in multiple arid phases since the last interglacial period(2), are used today by pastoral and agricultural systems(3,4) that could be disrupted if climate change alters twenty-first century dune dynamics. Empirical data and model simulations have established that the interplay between dune surface erodibility ( determined by vegetation cover and moisture availability) and atmospheric erosivity ( determined by wind energy) is critical for dunefield dynamics(5). This relationship between erodibility and erosivity is susceptible to climate-change impacts. Here we use simulations with three global climate models and a range of emission scenarios to assess the potential future activity of three Kalahari dunefields. We determine monthly values of dune activity by modifying and improving an established dune mobility index(6) so that it can account for global climate model data outputs. We find that, regardless of the emission scenario used, significantly enhanced dune activity is simulated in the southern dunefield by 2039, and in the eastern and northern dunefields by 2069. By 2099 all dunefields are highly dynamic, from northern South Africa to Angola and Zambia. Our results suggest that dunefields are likely to be reactivated ( the sand will become significantly exposed and move) as a consequence of twenty-first century climate warming.	Univ Oxford, Ctr Environm, Sch Geog & Environm, Oxford OX1 3QY, England; Univ Salford, Dept Earth & Life Sci, Manchester M5 4WT, Lancs, England	University of Oxford; University of Salford	Thomas, DSG (corresponding author), Univ Oxford, Ctr Environm, Sch Geog & Environm, S Parks Rd, Oxford OX1 3QY, England.	david.thomas@ouce.ox.ac.uk		Thomas, David/0000-0001-6867-5504; Wiggs, Giles/0000-0002-2131-0724				Bauer BO, 1998, J ARID ENVIRON, V39, P345, DOI 10.1006/jare.1998.0380; Bullard JE, 1997, EARTH SURF PROC LAND, V22, P165, DOI 10.1002/(SICI)1096-9837(199702)22:2&lt;165::AID-ESP687&gt;3.0.CO;2-9; CHEPIL W. S., 1963, ADVAN AGRON, V15, P211, DOI 10.1016/S0065-2113(08)60400-9; Hulme M., 1996, CLIMATE CHANGE SO AF; IPCC, 2001, CLIM CHANG 2001; KAR A, 1993, J ARID ENVIRON, V25, P83, DOI 10.1006/jare.1993.1044; Knight M, 2004, GEOMORPHOLOGY, V59, P197, DOI 10.1016/j.geomorph.2003.07.017; Korner C, 2000, ECOL APPL, V10, P1590, DOI 10.2307/2641226; LANCASTER N, 1988, J ARID ENVIRON, V14, P233; Lancaster N, 2000, EARTH SURF PROC LAND, V25, P197, DOI [10.1002/(SICI)1096-9837(200002)25:2&lt;197::AID-ESP82&gt;3.0.CO;2-H, 10.1002/(SICI)1096-9837(200002)25:2<197::AID-ESP82>3.0.CO;2-H]; Livingstone I., 1993, GEOLOGICAL SOC SPECI, V720, P91; Muhs D.R., 1993, J ARID ENVIRON, V25, P905; Nakicenovic N., 2000, IPCC SPECIAL REPORT; Nicholson SE, 1997, INT J CLIMATOL, V17, P117, DOI 10.1002/(SICI)1097-0088(199702)17:2<117::AID-JOC84>3.0.CO;2-O; RINGROSE S, 1991, INT J REMOTE SENS, V12, P1023, DOI 10.1080/01431169108929708; SCANLON TM, 2002, REMOTE SENS ENVIRON, V13, P419; Sporton D., 2002, SUSTAINABLE LIVELIHO; Stokes S, 1997, NATURE, V388, P154, DOI 10.1038/40596; SUMMER G, 2001, INT J CLIMATOL, V21, P211; TALBOT MR, 1984, PALAEOECOL AFR, V16, P203; Thomas DSG, 2005, GEOMORPHOLOGY, V64, P117, DOI 10.1016/j.geomorph.2004.06.004; Thomas DSG, 2002, QUATERNARY SCI REV, V21, P783, DOI 10.1016/S0277-3791(01)00127-5; THOMAS DSG, 1998, ARID ZONE GEOMORPHOL, P373; Tsoar H., 2020, AEOLIAN GEOMORPHOLOG, P75; Turner MD, 1999, J ARID ENVIRON, V41, P277, DOI 10.1006/jare.1998.0485; WASSON RJ, 1986, EARTH SURF PROCESSES, V11, P505, DOI 10.1002/esp.3290110505; WIGGS GFS, 1995, EARTH SURF PROC LAND, V20, P515, DOI 10.1002/esp.3290200604; WOODRUFF WP, 1968, J SOIL WATER CONSERV, V23, P103	28	219	234	4	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 30	2005	435	7046					1218	1221		10.1038/nature03717	http://dx.doi.org/10.1038/nature03717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988522				2022-12-28	WOS:000230140500040
J	Feigin, VL				Feigin, VL			Stroke epidemiology in the developing world	LANCET			English	Editorial Material							CASE-FATALITY; RISK-FACTORS; CEREBROVASCULAR-DISEASE; MONICA PROJECT; TRENDS; MORTALITY; SUBTYPES		Univ Auckland, Dept Med, Clin Trials Res Unit, Auckland, New Zealand; Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand	University of Auckland; University of Auckland	Feigin, VL (corresponding author), Univ Auckland, Dept Med, Clin Trials Res Unit, Private Bag 92019, Auckland, New Zealand.	v.feigin@.auckland.ac.nz	Feigin, Valery/AAF-2313-2019	Feigin, Valery L./0000-0002-6372-1740				AHO K, 1980, B WORLD HEALTH ORGAN, V58, P113; Feigin VL, 2004, STROKE, V35, P2045; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; Gorelick PB, 1998, STROKE, V29, P2656, DOI 10.1161/01.STR.29.12.2656; Haheim LL, 2004, SCAND CARDIOVASC J, V38, P216, DOI 10.1080/14017430410014910; Hajat C, 2001, STROKE, V32, P37, DOI 10.1161/01.STR.32.1.37; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; Sacco RL, 2001, STROKE, V32, P1725, DOI 10.1161/01.STR.32.8.1725; Smadja D, 2001, STROKE, V32, P2741, DOI 10.1161/hs1201.099385; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; Terent A, 2003, STROKE, V34, P1353, DOI 10.1161/01.STR.0000074038.71700.1C; Thorogood M, 2004, B WORLD HEALTH ORGAN, V82, P503; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; Truelsen T, 2003, STROKE, V34, P1346, DOI 10.1161/01.STR.0000069724.36173.4D; Zhang LF, 2003, STROKE, V34, P2091, DOI 10.1161/01.STR.0000087149.42294.8C	15	301	325	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 25	2005	365	9478					2160	2161		10.1016/S0140-6736(05)66755-4	http://dx.doi.org/10.1016/S0140-6736(05)66755-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978910				2022-12-28	WOS:000230034800008
J	Lin, JF; Sturhahn, W; Zhao, JY; Shen, GY; Mao, HK; Hemley, RJ				Lin, JF; Sturhahn, W; Zhao, JY; Shen, GY; Mao, HK; Hemley, RJ			Sound velocities of hot dense iron: Birch's law revisited	SCIENCE			English	Article							DIAMOND-ANVIL CELL; SITU X-RAY; NUCLEAR RESONANT SCATTERING; EARTHS INNER-CORE; HIGH-PRESSURE; GRUNEISEN-PARAMETER; OF-STATES; 300 GPA; EPSILON-IRON; TEMPERATURE	Sound velocities of hexagonal close-packed iron (hcp-Fe) were measured at pressures up to 73 gigapascals and at temperatures up to 1700 kelvin with nuclear inelastic x-ray scattering in a laser-heated diamond anvil cell. The compressional-wave velocities (V-p) and shear-wave velocities (V-S) of hcp-Fe decreased significantly with increasing temperature under moderately high pressures. V-P and V-S under high pressures and temperatures thus cannot be fitted to a linear relation, Birch's law, which has been used to extrapolate measured sound velocities to densities of iron in Earth's interior. This result means that there are more light elements in Earth's core than have been inferred from linear extrapolation at room temperature.	Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA; Univ Chicago, Chicago, IL 60637 USA	Carnegie Institution for Science; United States Department of Energy (DOE); Argonne National Laboratory; University of Chicago	Lin, JF (corresponding author), Carnegie Inst Washington, Geophys Lab, 5251 Broad Branch Rd NW, Washington, DC 20015 USA.	j.lin@gl.ciw.edu	Shen, Guoyin/D-6527-2011; Lin, Jung-Fu/B-4917-2011	Shen, Guoyin/0000-0001-5146-1147; Lin, Jung-Fu/0000-0002-0163-5329				Alfe D, 2000, NATURE, V405, P172, DOI 10.1038/35012056; Anderson OL, 2001, GEOPHYS RES LETT, V28, P399, DOI 10.1029/2000GL008544; Antonangeli D, 2004, EARTH PLANET SC LETT, V225, P243, DOI 10.1016/j.epsl.2004.06.004; Bass J.D, 1987, HIGH PRESSURE RES MI, P393, DOI DOI 10.1029/GM039; BIRCH F, 1961, GEOPHYS J ROY ASTR S, V4, P295, DOI 10.1111/j.1365-246X.1961.tb06821.x; BIRCH F, 1952, J GEOPHYS RES, V57, P227, DOI 10.1029/JZ057i002p00227; BIRCH F, 1978, J GEOPHYS RES, V83, P1257, DOI 10.1029/JB083iB03p01257; BROWN JM, 1986, J GEOPHYS RES-SOLID, V91, P7485, DOI 10.1029/JB091iB07p07485; CAMPBELL AJ, 1992, SCIENCE, V257, P66, DOI 10.1126/science.257.5066.66; Dubrovinsky LS, 2000, PHYS REV LETT, V84, P1720, DOI 10.1103/PhysRevLett.84.1720; Dubrovinsky LS, 1998, PHYS CHEM MINER, V25, P434, DOI 10.1007/s002690050133; Dubrovinsky LS, 2000, AM MINERAL, V85, P386, DOI 10.2138/am-2000-2-318; Dubrovinsky LS, 2001, P NATL ACAD SCI USA, V98, P9484, DOI 10.1073/pnas.161583398; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Fiquet G, 2001, SCIENCE, V291, P468, DOI 10.1126/science.291.5503.468; HEINZ DL, 1990, GEOPHYS RES LETT, V17, P1161, DOI 10.1029/GL017i008p01161; Hu MY, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.094304; LIEBERMANN RC, 1973, J GEOPHYS RES, V78, P6926, DOI 10.1029/JB078i029p06926; Lin JF, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020599; Lin JF, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018405; Lin JF, 2004, EARTH PLANET SC LETT, V226, P33, DOI 10.1016/j.epsl.2004.07.018; Lubbers R, 2000, SCIENCE, V287, P1250, DOI 10.1126/science.287.5456.1250; Mao HK, 1998, NATURE, V396, P741, DOI 10.1038/25506; MAO HK, 1990, J GEOPHYS RES-SOLID, V95, P21737, DOI 10.1029/JB095iB13p21737; Mao HK, 2001, SCIENCE, V292, P914, DOI 10.1126/science.1057670; Mao WL, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020541; NGUYEN JH, 2004, NATURE, V306, P2239; Shen G, 2004, PHYS CHEM MINER, V31, P353, DOI 10.1007/s00269-004-0403-1; Steinle-Neumann G, 1999, PHYS REV B, V60, P791, DOI 10.1103/PhysRevB.60.791; Steinle-Neumann G, 2001, NATURE, V413, P57, DOI 10.1038/35092536; STURHAHN W, 1995, PHYS REV LETT, V74, P3832, DOI 10.1103/PhysRevLett.74.3832; Sturhahn W, 1999, HYPERFINE INTERACT, V123, P367, DOI 10.1023/A:1017071806895	32	121	128	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 24	2005	308	5730					1892	1894		10.1126/science.1111724	http://dx.doi.org/10.1126/science.1111724			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976298				2022-12-28	WOS:000230120000035
J	Headrick, JM; Diken, EG; Walters, RS; Hammer, NI; Christie, RA; Cui, J; Myshakin, EM; Duncan, MA; Johnson, MA; Jordan, KD				Headrick, JM; Diken, EG; Walters, RS; Hammer, NI; Christie, RA; Cui, J; Myshakin, EM; Duncan, MA; Johnson, MA; Jordan, KD			Spectral signatures of hydrated proton vibrations in water clusters	SCIENCE			English	Article							INFRARED-LASER SPECTROSCOPY; GAS-PHASE; AQUEOUS-SOLUTIONS; HYDRONIUM ION; EXCESS PROTON; HYDROGEN-BOND; RESOLUTION; MECHANISM; DYNAMICS; SYSTEM	The ease with which the pH of water is measured obscures the fact that there is presently no clear molecular description for the hydrated proton. The mid-infrared spectrum of bulk aqueous acid, for example, is too diffuse to establish the roles of the putative Eigen (H3O+) and Zundel (H5O2+) ion cores. To expose the local environment of the excess charge, we report how the vibrational spectrum of protonated water clusters evolves in the size range from 2 to 11 water molecules. Signature bands indicating embedded Eigen or Zundel limiting forms are observed in all of the spectra with the exception of the three- and five-membered clusters. These unique species display bands appearing at intermediate energies, reflecting asymmetric solvation of the core ion. Taken together, the data reveal the pronounced spectral impact of subtle changes in the hydration environment.	Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA; Yale Univ, Sterling Chem Lab, New Haven, CT 06520 USA	University System of Georgia; University of Georgia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yale University	Duncan, MA (corresponding author), Univ Georgia, Dept Chem, Athens, GA 30602 USA.	maduncan@uga.edu; mark.johnson@yale.edu; jordan@pitt.edu	Christie, Richard/E-5144-2015	Christie, Richard/0000-0001-8603-5834; Hammer, Nathan/0000-0002-6221-2709				AGMON N, 1995, CHEM PHYS LETT, V244, P456, DOI 10.1016/0009-2614(95)00905-J; Asmis KR, 2003, SCIENCE, V299, P1375, DOI 10.1126/science.1081634; BEGEMANN MH, 1985, J CHEM PHYS, V82, P3570, DOI 10.1063/1.448914; Borgis D, 1996, J PHYS CHEM-US, V100, P1118, DOI 10.1021/jp9522324; Chaban GM, 1999, J CHEM PHYS, V111, P1823, DOI 10.1063/1.479452; Chen KS, 2000, NATURE, V405, P814, DOI 10.1038/35015610; Ciobanu CV, 2000, J CHEM PHYS, V113, P5321, DOI 10.1063/1.1288918; Duncan MA, 2003, INT REV PHYS CHEM, V22, P407, DOI 10.1080/0144235031000095201; EIGEN M, 1958, PROC R SOC LON SER-A, V247, P505, DOI 10.1098/rspa.1958.0208; FALK M, 1957, CAN J CHEM, V35, P1195, DOI 10.1139/v57-160; Fridgen TD, 2004, J PHYS CHEM A, V108, P9008, DOI 10.1021/jp040486w; Frisch M.J., 2009, GAUSSIAN 09 LINUX VE; Gerhards M, 2002, PHYS CHEM CHEM PHYS, V4, P5563, DOI 10.1039/b208304c; Grotthuss C. J. T., 1806, ANN CHIM PHYS, V58, P54; GRUEBELE M, 1987, J CHEM PHYS, V87, P3347, DOI 10.1063/1.453029; HAMMER NI, IN PRESS J CHEM PHYS; Headrick JM, 2004, J CHEM PHYS, V121, P11523, DOI 10.1063/1.1834566; HEBERLE J, 1994, NATURE, V370, P379, DOI 10.1038/370379a0; Jiang JC, 2000, J AM CHEM SOC, V122, P1398, DOI 10.1021/ja990033i; JOHNSON MA, 1988, TECHNIQUES CHEM, V20, P591; KENDALL RA, 1992, J CHEM PHYS, V96, P6796, DOI 10.1063/1.462569; Kim J, 2002, J CHEM PHYS, V116, P737, DOI 10.1063/1.1423327; KUNST M, 1980, NATURE, V288, P465, DOI 10.1038/288465a0; LIBROVICH NB, 1979, CHEM PHYS, V39, P351, DOI 10.1016/0301-0104(79)80155-X; Lin CK, 2005, PHYS CHEM CHEM PHYS, V7, P938, DOI 10.1039/b412281j; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Marx D, 1999, NATURE, V397, P601, DOI 10.1038/17579; Miyazaki M, 2004, SCIENCE, V304, P1134, DOI 10.1126/science.1096037; OKUMURA M, 1986, J CHEM PHYS, V85, P2328, DOI 10.1063/1.451079; Rini M, 2003, SCIENCE, V301, P349, DOI 10.1126/science.1085762; SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112; Shin JW, 2004, SCIENCE, V304, P1137, DOI 10.1126/science.1096466; Sobolewski AL, 2002, J PHYS CHEM A, V106, P4158, DOI 10.1021/jp013835k; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wang YS, 2003, J PHYS CHEM A, V107, P4217, DOI 10.1021/jp022156m; YEH LI, 1989, J CHEM PHYS, V91, P7319, DOI 10.1063/1.457305; YEH LI, 1994, J MOL SPECTROSC, V164, P473, DOI 10.1006/jmsp.1994.1090	38	640	661	11	267	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1765	1769		10.1126/science.1113094	http://dx.doi.org/10.1126/science.1113094			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961665				2022-12-28	WOS:000229926800048
J	Wara, MW; Ravelo, AC; Delaney, ML				Wara, MW; Ravelo, AC; Delaney, ML			Permanent El Nino-like conditions during the Pliocene warm period	SCIENCE			English	Article							OXYGEN ISOTOPIC COMPOSITION; PLANKTONIC-FORAMINIFERA; THERMAL STRUCTURE; CIRCULATION; MODULATIONS; VARIABILITY; EVOLUTION; AMPLITUDE; ENSO	During the warm early Pliocene (similar to 4.5 to 3.0 million years ago), the most recent interval with a climate warmer than today, the eastern Pacific thermocline was deep and the average west-to-east sea surface temperature difference across the equatorial Pacific was only 1.5 +/- 0.9 degrees C, much like it is during a modern El Nino event. Thus, the modern strong sea surface temperature gradient across the equatorial Pacific is not a stable and permanent feature. Sustained El Nino-like conditions, including relatively weak zonal atmospheric (Walker) circulation, could be a consequence of, and play an important role in determining, global warmth.	Univ Calif Santa Cruz, Ocean Sci Dept, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Ravelo, AC (corresponding author), Univ Calif Santa Cruz, Ocean Sci Dept, Santa Cruz, CA 95064 USA.	acr@es.ucsc.edu		Ravelo, Ana Christina/0000-0003-3929-677X				Andreasen DJ, 1997, PALEOCEANOGRAPHY, V12, P395, DOI 10.1029/97PA00822; BATTISTI DS, 1989, J ATMOS SCI, V46, P1687, DOI 10.1175/1520-0469(1989)046<1687:IVIATA>2.0.CO;2; Bemis BE, 1998, PALEOCEANOGRAPHY, V13, P150, DOI 10.1029/98PA00070; BJERKNES J, 1969, MON WEATHER REV, V97, P163, DOI 10.1175/1520-0493(1969)097<0163:ATFTEP>2.3.CO;2; Boccaletti G, 2004, J PHYS OCEANOGR, V34, P888, DOI 10.1175/1520-0485(2004)034<0888:TTSOTU>2.0.CO;2; Cane MA, 1998, SCIENCE, V282, P59, DOI 10.1126/science.282.5386.59; Cane MA, 2005, EARTH PLANET SC LETT, V230, P227, DOI 10.1016/j.epsl.2004.12.003; Cannariato KG, 1997, PALEOCEANOGRAPHY, V12, P805, DOI 10.1029/97PA02514; Chaisson WP, 2000, PALEOCEANOGRAPHY, V15, P497, DOI 10.1029/1999PA000442; Cubasch U., 2001, PROJECTIONS FUTURE C, P525; Dekens PS, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000200; Dowsett H, 1996, MAR MICROPALEONTOL, V27, P13, DOI 10.1016/0377-8398(95)00050-X; Fedorov AV, 2000, SCIENCE, V288, P1997, DOI 10.1126/science.288.5473.1997; Fedorov AV, 2004, J PHYS OCEANOGR, V34, P1949, DOI 10.1175/1520-0485(2004)034<1949:TEOSOT>2.0.CO;2; Fedorov AV, 2001, J CLIMATE, V14, P3086, DOI 10.1175/1520-0442(2001)014<3086:ASAOTO>2.0.CO;2; Haywood AM, 2005, GEOCHEM GEOPHY GEOSY, V6, DOI 10.1029/2004GC000799; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Marlow JR, 2000, SCIENCE, V290, P2288; McPhaden MJ, 2002, NATURE, V415, P603, DOI 10.1038/415603a; Molnar P, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2001PA000663; Philander SG, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000837; Ravelo AC, 1992, PALEOCEANOGRAPHY, V7, P815, DOI 10.1029/92PA02092; Ravelo AC, 2004, NATURE, V429, P263, DOI 10.1038/nature02567; RAVELO AC, 2004, OCEANOGRAPHY, V17, P22; Rickaby REM, 2005, SCIENCE, V307, P1948, DOI 10.1126/science.1104666; Rodgers KB, 2004, J CLIMATE, V17, P3761, DOI 10.1175/1520-0442(2004)017<3761:TPDVAI>2.0.CO;2; Schwing FB, 2002, PROG OCEANOGR, V53, P115, DOI 10.1016/S0079-6611(02)00027-7; Sun DZ, 2004, J CLIMATE, V17, P3786, DOI 10.1175/1520-0442(2004)017<3786:TEOSCO>2.0.CO;2; Sun DZ, 2003, J CLIMATE, V16, P2425, DOI 10.1175/2786.1; Sun DZ, 2003, J CLIMATE, V16, P185, DOI 10.1175/1520-0442(2003)016<0185:APEOAI>2.0.CO;2; Timmermann A, 2003, GLOBAL PLANET CHANGE, V37, P135, DOI 10.1016/S0921-8181(02)00194-7; Trenberth KE, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000298; Yin JH, 2001, J CLIMATE, V14, P565, DOI 10.1175/1520-0442(2001)014<0565:TIOTSS>2.0.CO;2	33	402	425	11	160	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 29	2005	309	5735					758	761		10.1126/science.1112596	http://dx.doi.org/10.1126/science.1112596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951NU	15976271				2022-12-28	WOS:000230938200046
J	Zhao, Y; Samal, E; Srivastava, D				Zhao, Y; Samal, E; Srivastava, D			Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis	NATURE			English	Article							BHLH TRANSCRIPTION FACTOR; C-ELEGANS; CAENORHABDITIS-ELEGANS; POSTTRANSCRIPTIONAL REGULATION; CARDIAC DEVELOPMENT; GENE-EXPRESSION; SMALL RNAS; HEART; PREDICTION; MYOCARDIN	Gradients of signalling and transcription factors govern many aspects of embryogenesis, highlighting the need for spatiotemporal control of regulatory protein levels. MicroRNAs are phylogenetically conserved small RNAs that regulate the translation of target messenger RNAs, providing a mechanism for protein dose regulation. Here we show that microRNA-1-1 (miR-1-1) and miR-1-2 are specifically expressed in cardiac and skeletal muscle precursor cells. We found that the miR-1 genes are direct transcriptional targets of muscle differentiation regulators including serum response factor, MyoD and Mef2. Correspondingly, excess miR-1 in the developing heart leads to a decreased pool of proliferating ventricular cardiomyocytes. Using a new algorithm for microRNA target identification that incorporates features of RNA structure and target accessibility, we show that Hand2, a transcription factor that promotes ventricular cardiomyocyte expansion, is a target of miR-1. This work suggests that miR-1 genes titrate the effects of critical cardiac regulatory proteins to control the balance between differentiation and proliferation during cardiogenesis.	Univ Texas, SW Med Ctr, Dept Pediat Cardiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Childrens Med Ctr Dallas, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Srivastava, D (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, 1650 Owens St, San Francisco, CA 94158 USA.	dsrivastava@gladstone.ucsf.edu						Abrahante JE, 2003, DEV CELL, V4, P625, DOI 10.1016/S1534-5807(03)00127-8; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chang S, 2004, NATURE, V430, P785, DOI 10.1038/nature02752; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Dsouza M, 1997, TRENDS GENET, V13, P497, DOI 10.1016/S0168-9525(97)01347-4; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; Grosshans H, 2005, DEV CELL, V8, P321, DOI 10.1016/j.devcel.2004.12.019; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Kelly RG, 2002, TRENDS GENET, V18, P210, DOI 10.1016/S0168-9525(02)02642-2; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; McFadden DG, 2005, DEVELOPMENT, V132, P189, DOI 10.1242/dev.01562; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Miano JM, 2004, P NATL ACAD SCI USA, V101, P17132, DOI 10.1073/pnas.0406041101; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Vella MC, 2004, GENE DEV, V18, P132, DOI 10.1101/gad.1165404; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang DZ, 2004, CURR OPIN GENET DEV, V14, P558, DOI 10.1016/j.gde.2004.08.003; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Yamagishi H, 2003, GENE DEV, V17, P269, DOI 10.1101/gad.1048903; Yamagishi H, 2001, DEV BIOL, V239, P190, DOI 10.1006/dbio.2001.0417; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Yelon D, 2000, DEVELOPMENT, V127, P2573; Zhou JL, 2005, J BIOL CHEM, V280, P10861, DOI 10.1074/jbc.M411586200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	49	1278	1440	5	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	2005	436	7048					214	220		10.1038/nature03817	http://dx.doi.org/10.1038/nature03817			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	944VR	15951802				2022-12-28	WOS:000230459500031
J	Bell, JF; Lemmon, MT; Duxbury, TC; Hubbard, MYH; Wolff, MJ; Squyres, SW; Craig, L; Ludwinski, JM				Bell, JF; Lemmon, MT; Duxbury, TC; Hubbard, MYH; Wolff, MJ; Squyres, SW; Craig, L; Ludwinski, JM			Solar eclipses of Phobos and Deimos observed from the surface of Mars	NATURE			English	Article							SATELLITES; LOCALIZATION; SPACECRAFT; ORBITS	The small martian satellites Phobos and Deimos orbit in synchronous rotation with inclinations of only 0.01 degrees and 0.92 degrees, respectively, relative to the planet's equatorial plane. Thus, an observer at near-equatorial latitudes on Mars could occasionally observe solar eclipses by these satellites (see ref. 1, for example). Because the apparent angular diameter of the satellites is much smaller than that of the Sun, however, such events are more appropriately referred to as transits. Transit data can be used for correcting and refining the orbital ephemerides of the moons. For example, Phobos is known to exhibit a secular acceleration that is caused by tidal dissipation within Mars(2-4). Long-term, accurate measurements are needed to refine the magnitude and origin of this dissipation within the martian interior as well as to refine the predicted orbital evolution of both satellites(5,6). Here we present observations of six transits of Phobos and Deimos across the solar disk from cameras on Mars aboard the Mars Exploration Rovers Spirit and Opportunity(7,8). These are the first direct imaging observations of satellites transiting the Sun from the surface of another planet.	Cornell Univ, Ithaca, NY 14853 USA; Texas A&M Univ, College Stn, TX 77843 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Space Sci Inst, Boulder, CO 80301 USA	Cornell University; Texas A&M University System; Texas A&M University College Station; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Bell, JF (corresponding author), Cornell Univ, Ithaca, NY 14853 USA.	jfb8@cornell.edu	Lemmon, Mark T/E-9983-2010; Lemmon, Mark/X-2333-2019	Lemmon, Mark T/0000-0002-4504-5136; Lemmon, Mark/0000-0002-4504-5136				Arvidson RE, 2004, SCIENCE, V306, P1730, DOI 10.1126/science.1104211; Arvidson RE, 2004, SCIENCE, V305, P821, DOI 10.1126/science.1099922; Bell JF, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002070; BETTS BH, 1995, J GEOPHYS RES-PLANET, V100, P5285, DOI 10.1029/95JE00226; BILLS BG, IN PRESS J GEOPHYS R; BILLS BG, 2003, EOS T AGU S, V84; BORN GH, 1975, CELESTIAL MECH, V12, P77, DOI 10.1007/BF01228626; DUXBURY TC, 1978, SCIENCE, V199, P1201, DOI 10.1126/science.199.4334.1201; JACOBSON RA, 1989, ASTRON ASTROPHYS, V225, P548; Ledger E., 1879, OBSERVATORY, V3, P191; MIGNARD F, 1981, MON NOT R ASTRON SOC, V194, P365, DOI 10.1093/mnras/194.2.365; NEUMANN GA, 2004, LUNAR PLANET SCI C, V35; SINCLAIR AT, 1989, ASTRON ASTROPHYS, V220, P321; SMITH JC, 1976, ICARUS, V27, P51, DOI 10.1016/0019-1035(76)90183-4; Squyres SW, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002121; *VIK LAND IM TEAM, 1978, NASA	16	19	20	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 7	2005	436	7047					55	57		10.1038/nature03437	http://dx.doi.org/10.1038/nature03437			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	942QJ	16001060				2022-12-28	WOS:000230296600037
J	Kurz, T; Ozlu, N; Rudolf, F; O'Rourke, SM; Luke, B; Hofmann, K; Hyman, AA; Bowerman, B; Peter, M				Kurz, T; Ozlu, N; Rudolf, F; O'Rourke, SM; Luke, B; Hofmann, K; Hyman, AA; Bowerman, B; Peter, M			The conserved protein DCN-1/Dcn1p is required for cullin neddylation in C-elegans and S-cerevisiae	NATURE			English	Article							FUNCTIONAL GENOMIC ANALYSIS; MODIFICATION PATHWAY; UBIQUITIN LIGASES; NEDD8; CUL1; DEGRADATION; COMPLEX; SCF; DESTRUCTION; CLEAVAGE	SCF-type E3 ubiquitin ligases are multi-protein complexes required for polyubiquitination and subsequent degradation of target proteins by the 26S proteasome(1). Cullins, together with the RING-finger protein Rbx1, form the catalytic core of the ligase, and recruit the substrate-recognition module(1-4). Cycles of covalent modification of cullins by the ubiquitin-like molecule Nedd8 (neddylation)(5) and removal of Nedd8 by the COP9 signalosome (deneddylation) positively regulate E3 ligase activity(6,7). Here we report the identification and analysis of a widely conserved protein that is required for cullin neddylation in the nematode Caenorhabditis elegans and the yeast Saccharomyces cerevisiae. C. elegans DCN-1 and S. cerevisiae Dcn1p ( defective in cullin neddylation) are characterized by a novel UBA-like ubiquitin-binding domain and a DUF298 domain of unknown function. Consistent with their requirements for neddylation, DCN-1 and Dcn1p directly bind Nedd8 and physically associate with cullins in both species. Moreover, overexpression of Dcn1p in yeast results in the accumulation of Nedd8-modified cullin Cdc53p. Both in vivo and in vitro experiments indicate that Dcn1p does not inhibit deneddylation of Cdc53p by the COP9 signalosome, but greatly increases the kinetics of the neddylation reaction.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; ETH Honggerberg, Inst Biochem, CH-8093 Zurich, Switzerland; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Memorec Biotec GmbH, D-50829 Cologne, Germany	University of Oregon; Swiss Federal Institutes of Technology Domain; ETH Zurich; Max Planck Society	Peter, M (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	matthias.peter@bc.biol.ethz.ch	Hyman, Tony/F-1923-2011; Hyman, Anthony A/B-3917-2017; Kurz, Thimo/E-4116-2012; Hofmann, Kay/D-6714-2011	Hyman, Anthony A/0000-0003-3664-154X; Hofmann, Kay/0000-0002-2289-9083; Kurz, Thimo/0000-0003-0700-6993; Peter, Matthias/0000-0002-2160-6824; Luke, Brian/0000-0002-1648-5511				Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dharmasiri S, 2003, EMBO J, V22, P1762, DOI 10.1093/emboj/cdg190; Dow MR, 1998, GENETICS, V150, P119; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Guthrie C, 1991, GUIDE YEAST GENETICS; Hofmann K, 2000, Brief Bioinform, V1, P167, DOI 10.1093/bib/1.2.167; Jaquenoud M, 1998, EMBO J, V17, P5360, DOI 10.1093/emboj/17.18.5360; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; MCNALLY FJ, 1993, CELL, V75, P419, DOI 10.1016/0092-8674(93)90377-3; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Morimoto M, 2003, BIOCHEM BIOPH RES CO, V301, P392, DOI 10.1016/S0006-291X(02)03051-6; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1; Srayko M, 2000, GENE DEV, V14, P1072; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Verma R, 1997, METHOD ENZYMOL, V283, P366; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0	29	146	159	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1257	1261		10.1038/nature03662	http://dx.doi.org/10.1038/nature03662			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988528				2022-12-28	WOS:000230140500048
J	Bhandawat, V; Reisert, J; Yau, KW				Bhandawat, V; Reisert, J; Yau, KW			Elementary response of olfactory receptor neurons to odorants	SCIENCE			English	Article							RETINAL RODS; CELLS; CALCIUM; DESENSITIZATION; TRANSDUCTION; PHOTOTRANSDUCTION; ADAPTATION; SALAMANDER; MECHANISM; MAGNESIUM	Signaling by heterotrimeric GTP-binding proteins (G proteins) drives numerous cellular processes. The number of G protein molecules activated by a single membrane receptor is a determinant of signal amplification, although in most cases this parameter remains unknown. In retinal rod photoreceptors, a long-lived photoisomerized rhodopsin molecule activates many G protein molecules (transducins), yielding substantial amplification and a large elementary (single-photon) response, before rhodopsin activity is terminated. Here we report that the elementary response in olfactory transduction is extremely small. A ligand-bound odorant receptor has a low probability of activating even one G protein molecule because the odorant dwell-time is very brief. Thus, signal amplification in olfactory transduction appears fundamentally different from that of phototransduction.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Bhandawat, V (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Room 907,Preclin Teaching Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	vbhanda@mail.jhmi.edu; kwyau@mail.jhmi.edu			NEI NIH HHS [R01 EY006837-18, R01 EY014596, R01 EY014596-03, R37 EY006837-15S1, R01 EY014596-01, R01 EY006837-17, R01 EY006837, R37 EY006837, R01 EY006837-16A1, R01 EY014596-02, R37 EY006837-15] Funding Source: Medline; NIDCD NIH HHS [R01 DC006904, DC06904, R01 DC006904-01] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006837, R01EY014596, R37EY006837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006904] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; Buck LB, 2000, CELL, V100, P611, DOI 10.1016/S0092-8674(00)80698-4; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; GOLD GH, 1995, NATURE, V376, P27, DOI 10.1038/376027a0; KLEENE SJ, 1995, NEUROSCIENCE, V66, P1001, DOI 10.1016/0306-4522(94)00634-H; LAMB TD, 1981, J PHYSIOL-LONDON, V319, P463, DOI 10.1113/jphysiol.1981.sp013921; Leskov IB, 2000, NEURON, V27, P525, DOI 10.1016/S0896-6273(00)00063-5; Lewcock JW, 2004, P NATL ACAD SCI USA, V101, P1069, DOI 10.1073/pnas.0307986100; LOWE G, 1995, P NATL ACAD SCI USA, V92, P7864, DOI 10.1073/pnas.92.17.7864; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; Matthews HR, 2003, CURR OPIN NEUROBIOL, V13, P469, DOI 10.1016/S0959-4388(03)00097-7; MENINI A, 1995, NATURE, V373, P435, DOI 10.1038/373435a0; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P695, DOI 10.1113/jphysiol.1988.sp016942; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; Peppel K, 1997, J BIOL CHEM, V272, P25425, DOI 10.1074/jbc.272.41.25425; Reisert J, 1998, J GEN PHYSIOL, V112, P529, DOI 10.1085/jgp.112.5.529; Schild D, 1998, PHYSIOL REV, V78, P429, DOI 10.1152/physrev.1998.78.2.429; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9	24	110	114	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	2005	308	5730					1931	1934		10.1126/science.1109886	http://dx.doi.org/10.1126/science.1109886			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976304	Green Accepted			2022-12-28	WOS:000230120000046
J	Waxman, HA				Waxman, HA			The lessons of Vioxx - Drug safety and sales	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Dai CL, 2005, ARCH INTERN MED, V165, P171, DOI 10.1001/archinte.165.2.171; *FDA ADV COMM, 2001, 21042S007 NDA FDA AD; Graham DJ, 2005, LANCET, V365, P475, DOI 10.1016/S0140-6736(05)17864-7; ROSE JL, 2002, PHYS EXPECTATIONS IN; *US HOUS REPR COMM, MERCK DOC SHOW AGGR	5	80	83	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					2576	2578		10.1056/NEJMp058136	http://dx.doi.org/10.1056/NEJMp058136			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972862				2022-12-28	WOS:000229953700003
J	Bates, D; Kleckner, N				Bates, D; Kleckner, N			Chromosome and replisome dynamics in E. coli: Loss of sister cohesion triggers global chromosome movement and mediates chromosome segregation	CELL			English	Article							CELL-CYCLE EVENTS; ESCHERICHIA-COLI; DNA-REPLICATION; INITIATION; LOCALIZATION; ORGANIZATION; GROWTH; MODEL	Chromosome and replisome dynamics were examined in synchronized E. coli cells undergoing a eukaryotic-like cell cycle. Sister chromosomes remain tightly colocalized for much of S phase and then separate, in a single coordinate transition. Origin and terminus regions behave differently, as functionally independent domains. During separation, sister loci move far apart and the nucleoid becomes bilobed. Origins and terminus regions also move. We infer that sisters are initially linked and that loss of cohesion triggers global chromosome reorganization. This reorganization creates the 2-fold symmetric, ter-inlori-out conformation which, for E. coh, comprises sister segregation. Analogies with eukaryotic prometaphase suggest that this could be a primordial segregation mechanism to which microtubule-based processes were later added. We see no long-lived replication "factory"; replication initiation timing does not covary with cell mass, and we identify changes in nucleoid position and state that are tightly linked to cell division. We propose that cell division licenses the next round of replication initiation via these changes.	Harvard Univ, Sch Med, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Bates, D (corresponding author), Harvard Univ, Sch Med, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	bates2@fas.harvard.edu		Bates, David/0000-0002-0870-055X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020627, R37GM025326, R01GM025326] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25326, R01 GM025326, R37 GM025326, GM20627, F32 GM020627-01, R01 GM025326-31, F32 GM020627-02, F32 GM020627] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATES D, 2005, IN PRESS MOL MICROBI, V13, P2097; Ben-Yehuda S, 2003, SCIENCE, V299, P532, DOI 10.1126/science.1079914; Boye E, 2003, EMBO REP, V4, P757, DOI 10.1038/sj.embor.embor895; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; CoskunAri FF, 1997, J BIOL CHEM, V272, P26448, DOI 10.1074/jbc.272.42.26448; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; Donachie WD, 2003, CURR OPIN MICROBIOL, V6, P146, DOI 10.1016/S1369-5274(03)00026-2; Gordon GS, 2002, MOL MICROBIOL, V44, P501, DOI 10.1046/j.1365-2958.2002.02901.x; Hunter N, 2001, CELL, V106, P59, DOI 10.1016/S0092-8674(01)00430-5; Kleckner N, 2004, P NATL ACAD SCI USA, V101, P12592, DOI 10.1073/pnas.0402724101; Lau IF, 2003, MOL MICROBIOL, V49, P731, DOI 10.1046/j.1365-2958.2003.03640.x; Lemon KP, 2001, GENE DEV, V15, P2031, DOI 10.1101/gad.913301; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Li YF, 2003, MOL MICROBIOL, V50, P825, DOI 10.1046/j.1365-2958.2003.03746.x; Migocki MD, 2004, MOL MICROBIOL, V54, P452, DOI 10.1111/j.1365-2958.2004.04267.x; Niki H, 2000, GENE DEV, V14, P212; Roos M, 2001, MOL MICROBIOL, V39, P633, DOI 10.1046/j.1365-2958.2001.02263.x; Sunako Y, 2001, MOL MICROBIOL, V42, P1233, DOI 10.1046/j.1365-2958.2001.02680.x; Viollier PH, 2004, P NATL ACAD SCI USA, V101, P9257, DOI 10.1073/pnas.0402606101; Weitao T, 1999, MOL MICROBIOL, V34, P157, DOI 10.1046/j.1365-2958.1999.01589.x; WOLD S, 1994, EMBO J, V13, P2097, DOI 10.1002/j.1460-2075.1994.tb06485.x	21	249	250	1	27	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 17	2005	121	6					899	911		10.1016/j.cell.2005.04.013	http://dx.doi.org/10.1016/j.cell.2005.04.013			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960977	Green Accepted, Bronze			2022-12-28	WOS:000230011200012
J	Curry, R; Mauritzen, C				Curry, R; Mauritzen, C			Dilution of the northern North Atlantic Ocean in recent decades	SCIENCE			English	Article							THERMOHALINE CIRCULATION; FRESH-WATER; SIMULATION; INCREASE; CHANNEL; MODEL; SEA; ICE	Declining salinities signify that large amounts of fresh water have been added to the northern North Atlantic Ocean since the mid-1960s. We estimate that the Nordic Seas and Subpolar Basins were diluted by an extra 19,000 5000 cubic kilometers of freshwater input between 1965 and 1995. Fully half of that additional fresh water-about 10,000 cubic kilometers-infiltrated the system in the late 1960s at an approximate rate of 2000 cubic kilometers per year. Patterns of freshwater accumulation observed in the Nordic Seas suggest a century time scale to reach freshening thresholds critical to that portion of the Atlantic meridional overturning circulation.	Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Norwegian Meteorol Inst, N-0313 Oslo, Norway	Woods Hole Oceanographic Institution; Norwegian Meteorological Institute	Curry, R (corresponding author), Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA.	rcurry@whoi.edu	Mauritzen, Cecilie/G-7682-2019	Mauritzen, Cecilie/0000-0001-5956-8811				AAGAARD K, 1989, J GEOPHYS RES-OCEANS, V94, P14485, DOI 10.1029/JC094iC10p14485; Belkin IM, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019334; Bersch M, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2001JC000901; Blindheim J, 2000, DEEP-SEA RES PT I, V47, P655, DOI 10.1016/S0967-0637(99)00070-9; Dickson B, 2002, NATURE, V416, P832, DOI 10.1038/416832a; DICKSON RR, 1988, PROG OCEANOGR, V20, P103, DOI 10.1016/0079-6611(88)90049-3; FICHEFET T, 2003, GEOPHYS RES LETT, V30, DOI DOI 10.1029/2003GL017826; HAKKINEN S, 1993, J GEOPHYS RES-OCEANS, V98, P16397, DOI 10.1029/93JC01504; Hansen B, 2001, NATURE, V411, P927, DOI 10.1038/35082034; Houghton J. T., 2001, CLIMATE CHANGE 2001; LAZIER JRN, 1995, NATURAL CLIMATE VARI, P295; MANABE S, 1995, NATURE, V378, P165, DOI 10.1038/378165a0; MANABE S, 1994, J CLIMATE, V7, P5, DOI 10.1175/1520-0442(1994)007<0005:MCROAC>2.0.CO;2; Rahmstorf S, 1999, CLIMATIC CHANGE, V43, P353, DOI 10.1023/A:1005474526406; Russell GL, 1999, J CLIMATE, V12, P531, DOI 10.1175/1520-0442(1999)012<0531:RTCTII>2.0.CO;2; Schaeffer M, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015254; Schiermeier Q, 2004, NATURE, V428, P114, DOI 10.1038/428114a; SCHMITZ WJ, 1995, REV GEOPHYS, V33, P151, DOI 10.1029/95RG00879; Stocker TF, 1997, NATURE, V388, P862, DOI 10.1038/42224; Turrell WR, 1999, DEEP-SEA RES PT I, V46, P1, DOI 10.1016/S0967-0637(98)00067-3; Vellinga M, 2002, CLIMATIC CHANGE, V54, P251, DOI 10.1023/A:1016168827653; Whitehead JA, 1998, REV GEOPHYS, V36, P423, DOI 10.1029/98RG01014; Wood RA, 1999, NATURE, V399, P572, DOI 10.1038/21170; Wu PL, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018584; Wu PL, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021570	25	258	266	2	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1772	1774		10.1126/science.1109477	http://dx.doi.org/10.1126/science.1109477			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961666				2022-12-28	WOS:000229926800050
J	Kuzuyama, T; Noel, JP; Richard, SB				Kuzuyama, T; Noel, JP; Richard, SB			Structural basis for the promiscuous biosynthetic prenylation of aromatic natural products	NATURE			English	Article							FARNESYL DIPHOSPHATE SYNTHASE; CRYSTAL-STRUCTURE; PROTEIN FARNESYLTRANSFERASE; POLYKETIDE SYNTHASE; BINDING PROTEIN; RESOLUTION; PRENYLTRANSFERASE; IDENTIFICATION; MECHANISM; ENZYMES	The anti-oxidant naphterpin is a natural product containing a polyketide-based aromatic core with an attached 10-carbon geranyl group derived from isoprenoid ( terpene) metabolism(1-3). Hybrid natural products such as naphterpin that contain 5-carbon ( dimethylallyl), 10-carbon ( geranyl) or 15-carbon ( farnesyl) isoprenoid chains possess biological activities distinct from their non-prenylated aromatic precursors(4). These hybrid natural products represent new anti-microbial, anti-oxidant, anti-inflammatory, anti-viral and anti-cancer compounds. A small number of aromatic prenyltransferases (PTases) responsible for prenyl group attachment have only recently been isolated and characterized(5,6). Here we report the gene identification, biochemical characterization and high-resolution X-ray crystal structures of an architecturally novel aromatic PTase, Orf2 from Streptomyces sp. strain CL190, with substrates and substrate analogues bound. In vivo, Orf2 attaches a geranyl group to a 1,3,6,8-tetrahydroxynaphthalene-derived polyketide during naphterpin biosynthesis. In vitro, Orf2 catalyses carbon-carbon-based and carbon-oxygen-based prenylation of a diverse collection of hydroxyl-containing aromatic acceptors of synthetic, microbial and plant origin. These crystal structures, coupled with in vitro assays, provide a basis for understanding and potentially manipulating the regio-specific prenylation of aromatic small molecules using this structurally unique family of aromatic PTases.	Salk Inst Biol Studies, Jack Skirball Chem Biol & Proteom Lab, La Jolla, CA 92037 USA; Univ Tokyo, Biotechnol Res Ctr, Lab Cell Biotechnol, Tokyo 1138657, Japan	Salk Institute; University of Tokyo	Richard, SB (corresponding author), Salk Inst Biol Studies, Jack Skirball Chem Biol & Proteom Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	richard@salk.edu	Noel, Joseph P/A-9459-2009	Kuzuyama, Tomohisa/0000-0002-7221-5858	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Botta B, 2005, CURR MED CHEM, V12, P713, DOI 10.2174/0929867053202241; Branden C., 1999, INTRO PROTEIN STRUCT; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNO M, 1985, HETEROCYCLES, V23, P1147, DOI 10.3987/R-1985-05-1147; CANE DE, 1998, ISOPRENOIDS INCLUDIN; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Edwards DJ, 2004, J AM CHEM SOC, V126, P11432, DOI 10.1021/ja047876g; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; Gerlt JA, 2003, CURR OPIN CHEM BIOL, V7, P252, DOI 10.1016/S1367-5931(03)00019-X; Izumikawa M, 2003, J IND MICROBIOL BIOT, V30, P510, DOI 10.1007/s10295-003-0075-8; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kharel Y, 2003, NAT PROD REP, V20, P111, DOI 10.1039/b108934j; Koyama T, 1996, BIOCHEMISTRY-US, V35, P9533, DOI 10.1021/bi960137v; Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432-1033.2002.03014.x; Long SB, 2002, NATURE, V419, P645, DOI 10.1038/nature00986; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Pojer F, 2003, P NATL ACAD SCI USA, V100, P2316, DOI 10.1073/pnas.0337708100; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SCHUTZ BA, 1995, PHYTOCHEMISTRY, V40, P1273, DOI 10.1016/0031-9422(95)00508-5; Seto H, 1996, TETRAHEDRON LETT, V37, P7979, DOI 10.1016/0040-4039(96)01787-X; SHIN-YA K, 1990, Tetrahedron Letters, V31, P6025, DOI 10.1016/S0040-4039(00)98019-5; SHINYA K, 1990, J ANTIBIOT, V43, P444, DOI 10.7164/antibiotics.43.444; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Taura F, 1996, J BIOL CHEM, V271, P17411, DOI 10.1074/jbc.271.29.17411; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; XU ZH, 1993, J BIOL CHEM, V268, P7874	29	238	252	2	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					983	987		10.1038/nature03668	http://dx.doi.org/10.1038/nature03668			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959519	Green Accepted, Green Submitted			2022-12-28	WOS:000229799700055
J	Zachos, JC; Rohl, U; Schellenberg, SA; Sluijs, A; Hodell, DA; Kelly, DC; Thomas, E; Nicolo, M; Raffi, I; Lourens, LJ; McCarren, H; Kroon, D				Zachos, JC; Rohl, U; Schellenberg, SA; Sluijs, A; Hodell, DA; Kelly, DC; Thomas, E; Nicolo, M; Raffi, I; Lourens, LJ; McCarren, H; Kroon, D			Rapid acidification of the ocean during the Paleocene-Eocene thermal maximum	SCIENCE			English	Article							CIRCUM-CARIBBEAN VOLCANISM; HIGH-RESOLUTION RECORDS; PLANKTONIC-FORAMINIFERA; METHANE HYDRATE; DISSOCIATION; CLIMATE; CARBON; END; EXTINCTIONS	The Pateocene-Eocene thermal maximum (PETM) has been attributed to the rapid release of similar to 2000 x 10(9) metric tons of carbon in the form of methane. in theory, oxidation and ocean absorption of this carbon should have lowered deep-sea pH, thereby triggering a rapid (<10,000-year) shoaling of the calcite compensation depth (CCD), followed by gradual recovery. Here we present geochemical data from five new South Atlantic deep-sea sections that constrain the timing and extent of massive sea-floor carbonate dissolution coincident with the PETM. The sections, from between 2.7 and 4.8 kilometers water depth, are marked by a prominent clay layer, the character of which indicates that the CCD shoaled rapidly (<10,000 years) by more than 2 kilometers and recovered gradually (>100,000 years). These findings indicate that a large mass of carbon (>>2000 x 10(9) metric tons of carbon) dissolved in the ocean at the Paleocene-Eocene boundary and that permanent sequestration of this carbon occurred through silicate weathering feedback.	Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA; Univ Bremen, Deutsch Forschungsgemeinschaft Res Ctr Ocean Marg, D-28359 Bremen, Germany; San Diego State Univ, Dept Geol Sci, San Diego, CA 92182 USA; Univ Utrecht, Dept Palaeoecol, Palaeobot & Palynol Lab, NL-3584 CD Utrecht, Netherlands; Univ Utrecht, Fac Geosci, Dept Earth Sci, NL-3584 CD Utrecht, Netherlands; Univ Florida, Dept Geol Sci, Gainesville, FL 32611 USA; Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA; Wesleyan Univ, Middletown, CT 06459 USA; Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; Rice Univ, Dept Earth Sci, Houston, TX 77005 USA; Univ G DAnnunzio, Dipartimento Sci Terra, I-66013 Chieti, Italy; Vrije Univ Amsterdam, Fac Earth & Life Sci, NL-1081 HV Amsterdam, Netherlands	University of California System; University of California Santa Cruz; University of Bremen; California State University System; San Diego State University; Utrecht University; Utrecht University; State University System of Florida; University of Florida; University of Wisconsin System; University of Wisconsin Madison; Wesleyan University; Yale University; Rice University; G d'Annunzio University of Chieti-Pescara; Vrije Universiteit Amsterdam	Zachos, JC (corresponding author), Univ Calif Santa Cruz, Dept Earth Sci, Earth & Marine Sci Bldg, Santa Cruz, CA 95064 USA.	jzachos@emerald.uscs.edu	Zachos, James C/A-7674-2008; Sluijs, Appy/B-3726-2009; Raffi, Isabella/AAY-5505-2020; Röhl, Ursula/G-5986-2011; Thomas, Ellen/E-5573-2011	Zachos, James C/0000-0001-8439-1886; Sluijs, Appy/0000-0003-2382-0215; Raffi, Isabella/0000-0002-5192-7477; Röhl, Ursula/0000-0001-9469-7053; Hodell, David/0000-0001-8537-1588; Kelly, Clay/0000-0002-3241-1635; Thomas, Ellen/0000-0002-7141-9904				Archer D, 1997, GEOPHYS RES LETT, V24, P405, DOI 10.1029/97GL00168; Bains S, 1999, SCIENCE, V285, P724, DOI 10.1126/science.285.5428.724; Bowen GJ, 2004, NATURE, V432, P495, DOI 10.1038/nature03115; Bralower TJ, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2002PA000832; Bralower TJ, 1998, GEOLOGY, V26, P671; Bralower TJ, 1997, GEOLOGY, V25, P963, DOI 10.1130/0091-7613(1997)025<0963:HRROTL>2.3.CO;2; BRALOWER TJ, 2002, P ODP INIT REP, V198; Caldeira K, 2003, NATURE, V425, P365, DOI 10.1038/425365a; Coccioni Rodolfo, 1995, Palaeopelagos, V4, P87; Dickens G, 2001, GEOCHEM GEOPHY GEOSY, V2; Dickens GR, 1997, GEOLOGY, V25, P259, DOI 10.1130/0091-7613(1997)025<0259:ABOGIT>2.3.CO;2; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; Dickens GR, 2000, B SOC GEOL FR, V171, P37; Farley KA, 2003, EARTH PLANET SC LETT, V208, P135, DOI 10.1016/S0012-821X(03)00017-7; Feely RA, 2004, SCIENCE, V305, P362, DOI 10.1126/science.1097329; Kelly DC, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2002PA000761; Kelly DC, 1996, GEOLOGY, V24, P423; KENNETT JP, 1991, NATURE, V353, P225, DOI 10.1038/353225a0; Kurtz AC, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2003PA000908; MOORE TCJ, 1984, LEG, V74; Ortiz N, 1995, MAR MICROPALEONTOL, V26, P341, DOI 10.1016/0377-8398(95)00039-9; Rohl U, 2000, GEOLOGY, V28, P927, DOI 10.1130/0091-7613(2000)28<927:NCFTLP>2.0.CO;2; Schmitz B, 1996, GEOLOGY, V24, P347, DOI 10.1130/0091-7613(1996)024<0347:LPBEEO>2.3.CO;2; Schmitz B, 2001, PALAEOGEOGR PALAEOCL, V165, P299, DOI 10.1016/S0031-0182(00)00167-X; Svensen H, 2004, NATURE, V429, P542, DOI 10.1038/nature02566; Thomas DJ, 1999, PALEOCEANOGRAPHY, V14, P561, DOI 10.1029/1999PA900031; Thomas DJ, 2002, GEOLOGY, V30, P1067, DOI 10.1130/0091-7613(2002)030<1067:WTFFTF>2.0.CO;2; THOMAS E, 1996, CORRELATION EARLY PA, V0101; Thomas E, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P214; Tripati AK, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2003GC000631; Zachos JC, 2003, SCIENCE, V302, P1551, DOI 10.1126/science.1090110; ZACHOS JC, 2004, P ODP INIT REP, V208	32	763	811	8	532	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1611	1615		10.1126/science.1109004	http://dx.doi.org/10.1126/science.1109004			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947184	Green Submitted			2022-12-28	WOS:000229827000052
J	Chendrimada, TP; Gregory, RI; Kumaraswamy, E; Norman, J; Cooch, N; Nishikura, K; Shiekhattar, R				Chendrimada, TP; Gregory, RI; Kumaraswamy, E; Norman, J; Cooch, N; Nishikura, K; Shiekhattar, R			TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing	NATURE			English	Article							RNA-BINDING-PROTEIN; MICROPROCESSOR COMPLEX; C-ELEGANS; INTERFERENCE; INITIATION; ARGONAUTE2; CELLS	MicroRNAs ( miRNAs) are generated by a two-step processing pathway to yield RNA molecules of approximately 22 nucleotides that negatively regulate target gene expression at the post-transcriptional level(1). Primary miRNAs are processed to precursor miRNAs (pre-miRNAs) by the Microprocessor complex(2-4). These pre-miRNAs are cleaved by the RNase III Dicer(5-8) to generate mature miRNAs that direct the RNA-induced silencing complex ( RISC) to messenger RNAs with complementary sequence(9). Here we show that TRBP ( the human immunodeficiency virus transactivating response RNA-binding protein(10)), which contains three double-stranded, RNA-binding domains, is an integral component of a Dicer-containing complex. Biochemical analysis of TRBP-containing complexes revealed the association of Dicer - TRBP with Argonaute 2 (Ago2)(11,12), the catalytic engine of RISC. The physical association of Dicer - TRBP and Ago2 was confirmed after the isolation of the ternary complex using Flag-tagged Ago2 cell lines. In vitro reconstitution assays demonstrated that TRBP is required for the recruitment of Ago2 to the small interfering RNA ( siRNA) bound by Dicer. Knockdown of TRBP results in destabilization of Dicer and a consequent loss of miRNA biogenesis. Finally, depletion of the Dicer - TRBP complex via exogenously introduced siRNAs diminished RISC-mediated reporter gene silencing. These results support a role of the Dicer - TRBP complex not only in miRNA processing but also as a platform for RISC assembly.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Shiekhattar, R (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	shiekhattar@wistar.org	Chan, Edward K. L./B-5671-2009	Chan, Edward K. L./0000-0003-3938-9503	NATIONAL CANCER INSTITUTE [P01CA072765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040536] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA072765-050002, P01 CA072765] Funding Source: Medline; NHLBI NIH HHS [R01 HL070045-03, R01 HL070045] Funding Source: Medline; NIGMS NIH HHS [R01 GM040536-15, R01 GM040536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Zhang HD, 2004, CELL, V118, P57, DOI 10.1016/j.cell.2004.06.017; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684	19	1458	1557	1	172	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2005	436	7051					740	744		10.1038/nature03868	http://dx.doi.org/10.1038/nature03868			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951XA	15973356	Green Accepted			2022-12-28	WOS:000230964500052
J	Berliner, JA; Watson, AD				Berliner, JA; Watson, AD			A role for oxidized phospholipids in artherosclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Berliner, JA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA.							Berliner JA, 2001, TRENDS CARDIOVAS MED, V11, P142, DOI 10.1016/S1050-1738(01)00098-6; BINDER DJ, IN PRESS J LIPID RES; Leitinger N, 2003, CURR OPIN LIPIDOL, V14, P421, DOI 10.1097/00041433-200310000-00002; Navab M, 2004, J LIPID RES, V45, P993, DOI 10.1194/jlr.R400001-JLR200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200	5	194	223	3	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2005	353	1					9	11		10.1056/NEJMp058118	http://dx.doi.org/10.1056/NEJMp058118			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942FC	16000351				2022-12-28	WOS:000230267300003
J	Horton, R				Horton, R			In defence of Roy Meadow	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, London NW1 7BY, England.							BRAID M, 2005, SUNDAY TIMES    0619, P10; CAVENDISH C, 2005, TIMES LOND      0620, P18; Le Fanu James, 2005, SUNDAY TELEGRAP 0619; Meadow R, 1997, ABC CHILD ABUSE; *ROYAL COLL PATH R, 2004, SUDD UN DEATH INF; Watkins SJ, 2000, BRIT MED J, V320, P2, DOI 10.1136/bmj.320.7226.2; 1998, LANCET, V352, P335	7	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 2	2005	366	9479					3	5		10.1016/S0140-6736(05)66798-0	http://dx.doi.org/10.1016/S0140-6736(05)66798-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993209				2022-12-28	WOS:000230277600004
J	de Ruiter, PC; Wolters, V; Moore, JC; Winemiller, KO				de Ruiter, PC; Wolters, V; Moore, JC; Winemiller, KO			Food web ecology: Playing Jenga and beyond	SCIENCE			English	Editorial Material							COMMUNITY DESCRIPTION; SPECIES ABUNDANCE; BODY-SIZE; STABILITY; BIODIVERSITY; DYNAMICS		Univ Utrecht, Dept Environm Sci, Copernicus Res Inst Sustainable Dev & Innovat, NL-3508 TC Utrecht, Netherlands; Univ Giessen, Dept Anim Ecol, D-35392 Giessen, Germany; Univ No Colorado, Sch Biol Sci, Greeley, CO 80639 USA; Texas A&M Univ, Dept Wildlife & Fisheries Sci, Sect Ecol & Evolutionary Biol, College Stn, TX 77843 USA	Utrecht University; Justus Liebig University Giessen; University of Northern Colorado; Texas A&M University System; Texas A&M University College Station	de Ruiter, PC (corresponding author), Univ Utrecht, Dept Environm Sci, Copernicus Res Inst Sustainable Dev & Innovat, NL-3508 TC Utrecht, Netherlands.	p.deruiter@geo.uu.nl; Volkmar.Wolters@allzool.bio.uni-giessen.de; john.moore@unco.edu; k-winemiller@tamu.edu	Wolters, Volkmar/B-4635-2010; Moore, John/E-9802-2011	Wolters, Volkmar/0000-0002-7556-4578; Winemiller, Kirk/0000-0003-0236-5129				Brose U, 2004, NATURE, V428, P167, DOI 10.1038/nature02297; Cohen JE, 2003, P NATL ACAD SCI USA, V100, P1781, DOI 10.1073/pnas.232715699; De Roos AM, 2002, P NATL ACAD SCI USA, V99, P12907, DOI 10.1073/pnas.192174199; DEANGELIS DL, 1992, DYNAMICS FOOD WEBS N; Downing AL, 2002, NATURE, V416, P837, DOI 10.1038/416837a; Elton C., 1927, ANIMAL ECOLOGY; Jonsson T, 2005, ADV ECOL RES, V36, P1, DOI 10.1016/S0065-2504(05)36001-6; Kondoh M, 2003, SCIENCE, V299, P1388, DOI 10.1126/science.1079154; Krause AE, 2003, NATURE, V426, P282, DOI 10.1038/nature02115; MACARTHUR R, 1955, ECOLOGY, V36, P533, DOI 10.2307/1929601; May R.M., 1973, STABILITY COMPLEXITY; McCann KS, 2005, ECOL LETT, V8, P513, DOI 10.1111/j.1461-0248.2005.00742.x; Moore JC, 2004, ECOL LETT, V7, P584, DOI 10.1111/j.1461-0248.2004.00606.x; MOORE JC, 1988, NATURE, V333, P261, DOI 10.1038/333261a0; Neutel AM, 2002, SCIENCE, V296, P1120, DOI 10.1126/science.1068326; Odum H.T., 1983, SYSTEMS ECOLOGY INTR; PAINE RT, 1980, J ANIM ECOL, V49, P667; Polis G.A., 1996, FOOD WEBS INTEGRATIO; Thebault E, 2003, P NATL ACAD SCI USA, V100, P14949, DOI 10.1073/pnas.2434847100; Williams RJ, 2000, NATURE, V404, P180, DOI 10.1038/35004572	20	96	103	0	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 1	2005	309	5731					68	+		10.1126/science.1096112	http://dx.doi.org/10.1126/science.1096112			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994518				2022-12-28	WOS:000230212800035
J	Martin, CR; Baker, LA				Martin, CR; Baker, LA			Expanding the molecular electronics toolbox	SCIENCE			English	Editorial Material							NANOMETER SEPARATION; FABRICATION; JUNCTIONS		Univ Florida, Dept Chem, Gainesville, FL 32611 USA; Univ Florida, Ctr Res BioNano Interface, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Martin, CR (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.	crmartin@chem.ufl.edu	Martin, Charles/AAA-1040-2019; Baker, Lane/B-6452-2008	Baker, Lane/0000-0001-5127-507X				Deshmukh MM, 2003, NANO LETT, V3, P1383, DOI 10.1021/nl034538p; Hipps KW, 2001, SCIENCE, V294, P536, DOI 10.1126/science.1065708; James DK, 2004, CHEM MATER, V16, P4423, DOI 10.1021/cm049648r; KLEIN JD, 1993, CHEM MATER, V5, P902, DOI 10.1021/cm00031a002; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; Mbindyo JKN, 2002, J AM CHEM SOC, V124, P4020, DOI 10.1021/ja016696t; Metzger RM, 2003, CHEM REV, V103, P3803, DOI 10.1021/cr020413d; Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137; Nitzan A, 2003, SCIENCE, V300, P1384, DOI 10.1126/science.1081572; Park H, 1999, APPL PHYS LETT, V75, P301, DOI 10.1063/1.124354; Qin LD, 2005, SCIENCE, V309, P113, DOI 10.1126/science.1112666; Service RF, 2001, SCIENCE, V294, P2442, DOI 10.1126/science.294.5551.2442	12	18	19	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 1	2005	309	5731					67	68		10.1126/science.1114663	http://dx.doi.org/10.1126/science.1114663			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994517				2022-12-28	WOS:000230212800034
J	Sun, F; Huo, X; Zhai, YJ; Wang, AJ; Xu, JX; Su, D; Bartlam, M; Rao, ZH				Sun, F; Huo, X; Zhai, YJ; Wang, AJ; Xu, JX; Su, D; Bartlam, M; Rao, ZH			Crystal structure of mitochondrial respiratory membrane protein complex II	CELL			English	Article							SUCCINATE-UBIQUINONE REDUCTASE; CYTOCHROME BC(1) COMPLEX; BOVINE HEART-MITOCHONDRIA; COLI FUMARATE REDUCTASE; ANCHORING SUBUNIT QPS3; QUINONE-BINDING-SITES; ESCHERICHIA-COLI; FAMILIAL PHEOCHROMOCYTOMA; NECK PARAGANGLIOMAS; FLAVOPROTEIN GENE	The mitochondrial respiratory Complex II or succinate: ubiquinone oxidoreductase (SQR) is an integral membrane protein complex in both the tricarboxylic acid cycle and aerobic respiration. Here we report the first crystal structure of Complex II from porcine heart at 2.4 angstrom resolution and its complex structure with inhibitors 3-nitropropionate and 2-thenoyltrifluoroacetone (TTFA) at 3.5 angstrom resolution. Complex II is comprised of two hydrophilic proteins, flavoprotein (Fp) and ironsulfur protein (Ip), and two transmembrane proteins (CybL and CybS), as well as prosthetic groups required for electron transfer from succinate to ubiquinone. The structure correlates the protein environments around prosthetic groups with their unique midpoint redox potentials. Two ubiquinone binding sites are discussed and elucidated by TTFA binding. The Complex II structure provides a bona fide model for study of the mitochondrial respiratory system and human mitochondrial diseases related to mutations in this complex.	Tsinghua Univ, Tsing Hua IBP Joint Res Grp Struct Biol, Beijing 100084, Peoples R China; Chinese Acad Sci, Inst Biophys IBP, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Tsinghua University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Rao, ZH (corresponding author), Tsinghua Univ, Tsing Hua IBP Joint Res Grp Struct Biol, Beijing 100084, Peoples R China.	raozh@xtal.tsinghua.edu.cn	Su, Dan/F-8177-2010; Sun, Fei/C-4190-2015; Rao, Zihe/HCH-6944-2022; Sun, Fei/AAR-3186-2020	Sun, Fei/0000-0002-0351-5144; Sun, Fei/0000-0002-0351-5144; Bartlam, Mark/0000-0001-5173-5080				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ackrell BAC, 2002, MOL ASPECTS MED, V23, P369, DOI 10.1016/S0098-2997(02)00012-2; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Bauters C, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.6.e75; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; Birch-Machin MA, 2000, ANN NEUROL, V48, P330, DOI 10.1002/1531-8249(200009)48:3<330::AID-ANA7>3.0.CO;2-A; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dekker PBD, 2003, J PATHOL, V201, P480, DOI 10.1002/path.1461; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Guo J, 2003, J BIOL CHEM, V278, P47629, DOI 10.1074/jbc.M306312200; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; INGLEDEW WJ, 1976, ARCH BIOCHEM BIOPHYS, V177, P176, DOI 10.1016/0003-9861(76)90427-6; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; Lemos RS, 2002, BBA-BIOENERGETICS, V1553, P158, DOI 10.1016/S0005-2728(01)00239-0; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; Maklashina E, 1999, ARCH BIOCHEM BIOPHYS, V369, P223, DOI 10.1006/abbi.1999.1359; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; Milunsky JM, 2001, AM J MED GENET, V100, P311, DOI 10.1002/ajmg.1270; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oyedotun KS, 2001, J BIOL CHEM, V276, P16936, DOI 10.1074/jbc.M100184200; Oyedotun KS, 1999, J BIOL CHEM, V274, P23956, DOI 10.1074/jbc.274.34.23956; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Parfait B, 2000, HUM GENET, V106, P236, DOI 10.1007/s004390051033; Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6; RUZICKA FJ, 1975, P NATL ACAD SCI USA, V72, P2886, DOI 10.1073/pnas.72.8.2886; SALERNO JC, 1977, FEBS LETT, V82, P179, DOI 10.1016/0014-5793(77)80579-6; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Shenoy SK, 1999, J BIOL CHEM, V274, P8717, DOI 10.1074/jbc.274.13.8717; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; Taschner PEM, 2001, GENE CHROMOSOME CANC, V31, P274, DOI 10.1002/gcc.1144; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Van Coster R, 2003, AM J MED GENET A, V120A, P13, DOI 10.1002/ajmg.a.10202; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; XU Y, 1987, BIOCHEM BIOPH RES CO, V144, P315, DOI 10.1016/S0006-291X(87)80512-0; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020; YU L, 1987, J BIOL CHEM, V262, P1137; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	57	554	581	15	165	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	2005	121	7					1043	1057		10.1016/j.cell.2005.05.025	http://dx.doi.org/10.1016/j.cell.2005.05.025			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989954	Bronze			2022-12-28	WOS:000230448000011
J	Andreae, MO; Jones, CD; Cox, PM				Andreae, MO; Jones, CD; Cox, PM			Strong present-day aerosol cooling implies a hot future	NATURE			English	Article							CLIMATE-CHANGE; TEMPERATURE-CHANGE; UNCERTAINTIES; SENSITIVITY; FEEDBACK	Atmospheric aerosols counteract the warming effects of anthropogenic greenhouse gases by an uncertain, but potentially large, amount. This in turn leads to large uncertainties in the sensitivity of climate to human perturbations, and therefore also in carbon cycle feedbacks and projections of climate change. In the future, aerosol cooling is expected to decline relative to greenhouse gas forcing, because of the aerosols' much shorter lifetime and the pursuit of a cleaner atmosphere. Strong aerosol cooling in the past and present would then imply that future global warming may proceed at or even above the upper extreme of the range projected by the Intergovernmental Panel on Climate Change.	Max Planck Inst Chem, D-55131 Mainz, Germany; Met Off, Hadley Ctr Climate Predict & Res, Exeter EX1 3PB, Devon, England; Ctr Ecol & Hydrol, Winfrith DT2 8ZD, Dorset, England	Max Planck Society; Met Office - UK; Hadley Centre; UK Centre for Ecology & Hydrology (UKCEH)	Andreae, MO (corresponding author), Max Planck Inst Chem, POB 3060, D-55131 Mainz, Germany.	andreae@mpch-mainz.mpg.de	Andreae, Meinrat O./B-1068-2008; Cox, Peter Michae;/B-3299-2012; Jones, Chris/I-2983-2014	Andreae, Meinrat O./0000-0003-1968-7925; Cox, Peter Michae;/0000-0002-0679-2219; Jones, Chris/0000-0002-7141-9285				Allen MR, 2000, NATURE, V407, P617, DOI 10.1038/35036559; Alley RB, 2003, PHILOS T R SOC A, V361, P1831, DOI 10.1098/rsta.2003.1236; Anderson TL, 2003, SCIENCE, V300, P1103, DOI 10.1126/science.1084777; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; Cox PM, 2000, NATURE, V408, P184, DOI 10.1038/35041539; Folland CK, 2001, GEOPHYS RES LETT, V28, P2621, DOI 10.1029/2001GL012877; Forest CE, 2002, SCIENCE, V295, P113, DOI 10.1126/science.1064419; Friedlingstein P, 2003, TELLUS B, V55, P692, DOI 10.1034/j.1600-0889.2003.01461.x; Friedlingstein P, 2001, GEOPHYS RES LETT, V28, P1543, DOI 10.1029/2000GL012015; Gregory JM, 2002, J CLIMATE, V15, P3117, DOI [10.1175/1520-0442(2002)015<3117:AOBEOT>2.0.CO;2, 10.1175/1520-0442(2002)015&lt;3117:AOBEOT&gt;2.0.CO;2]; Hansen J, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001143; Hansen JE, 2005, CLIMATIC CHANGE, V68, P269, DOI 10.1007/s10584-005-4135-0; Haywood J, 2000, REV GEOPHYS, V38, P513, DOI 10.1029/1999RG000078; Houghton J. T., 2001, CLIMATE CHANGE 2001; Intergovt Panel Climate Change, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P1; Jenkyns HC, 2004, NATURE, V432, P888, DOI 10.1038/nature03143; Jones CD, 2003, TELLUS B, V55, P642, DOI 10.1034/j.1600-0889.2003.01440.x; Jones CD, 2001, ATMOS SCI LETT, V2, P166, DOI 10.1006/asle.2001.0041; Knorr W, 2005, NATURE, V433, P298, DOI 10.1038/nature03226; Knutti R, 2002, NATURE, V416, P719, DOI 10.1038/416719a; Koch D, 2001, J GEOPHYS RES-ATMOS, V106, P20311, DOI 10.1029/2001JD900038; Levitus S, 2000, SCIENCE, V287, P2225, DOI 10.1126/science.287.5461.2225; Lohmann U, 2005, ATMOS CHEM PHYS, V5, P715, DOI 10.5194/acp-5-715-2005; Murphy JM, 2004, NATURE, V430, P768, DOI 10.1038/nature02771; Nakicenovic N., 2000, SPECIAL REPORT EMISS; O'Neill BC, 2002, SCIENCE, V296, P1971, DOI 10.1126/science.1071238; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Powlson D, 2005, NATURE, V433, P204, DOI 10.1038/433204a; Stainforth DA, 2005, NATURE, V433, P403, DOI 10.1038/nature03301; Stott PA, 2001, CLIM DYNAM, V17, P1, DOI 10.1007/PL00007924	30	431	448	4	136	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1187	1190		10.1038/nature03671	http://dx.doi.org/10.1038/nature03671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988515				2022-12-28	WOS:000230140500033
J	Becks, L; Hilker, FM; Malchow, H; Jurgens, K; Arndt, H				Becks, L; Hilker, FM; Malchow, H; Jurgens, K; Arndt, H			Experimental demonstration of chaos in a microbial food web	NATURE			English	Article							PREDATOR-PREY SYSTEM; LYAPUNOV EXPONENTS; DYNAMICS; CYCLES; POPULATIONS; BIFURCATION; DIVERSITY; BACTERIA	Discovering why natural population densities change over time and vary with location is a central goal of ecological and evolutional disciplines. The recognition that even simple ecological systems can undergo chaotic behaviour has made chaos a topic of considerable interest among theoretical ecologists(1-4). However, there is still a lack of experimental evidence that chaotic behaviour occurs in the real world of coexisting populations in multi-species systems. Here we study the dynamics of a defined predator - prey system consisting of a bacterivorous ciliate and two bacterial prey species. The bacterial species preferred by the ciliate was the superior competitor. Experimental conditions were kept constant with continuous cultivation in a one-stage chemostat. We show that the dynamic behaviour of such a two-prey, one-predator system includes chaotic behaviour, as well as stable limit cycles and coexistence at equilibrium. Changes in the population dynamics were triggered by changes in the dilution rates of the chemostat. The observed dynamics were verified by estimating the corresponding Lyapunov exponents. Such a defined microbial food web offers a new possibility for the experimental study of deterministic chaos in real biological systems.	Univ Cologne, Inst Zool, Dept Gen Ecol & Limnol, D-50923 Cologne, Germany; Univ Osnabruck, Inst Environm Syst Res, Dept Math & Comp Sci, D-49069 Osnabruck, Germany; Max Planck Inst Limnol, D-24302 Plon, Germany; Balt Sea Res Inst, D-18119 Rostock, Germany	University of Cologne; University Osnabruck; Max Planck Society	Arndt, H (corresponding author), Univ Cologne, Inst Zool, Dept Gen Ecol & Limnol, D-50923 Cologne, Germany.	hartmut.arndt@uni-koeln.de	Becks, Lutz/I-8256-2012; Hilker, Frank/B-8624-2008; Arndt, Hartmut/K-9364-2017	Hilker, Frank/0000-0001-5470-8889; Arndt, Hartmut/0000-0003-2811-3595; Jurgens, Klaus/0000-0002-7999-9368				Arndt H., 2000, FLAGELLATES, P240; BEGON M, 2002, ECOLOGY; CARON DA, 1982, SCIENCE, V218, P795, DOI 10.1126/science.218.4574.795; Christoffersen K, 1997, AQUAT MICROB ECOL, V13, P127, DOI 10.3354/ame013127; Costantino RF, 1997, SCIENCE, V275, P389, DOI 10.1126/science.275.5298.389; Dennis B, 1997, J ANIM ECOL, V66, P704, DOI 10.2307/5923; Eisenmann H, 1998, APPL ENVIRON MICROB, V64, P1264; ELLNER S, 1995, AM NAT, V145, P343, DOI 10.1086/285744; Fussmann GF, 2000, SCIENCE, V290, P1358, DOI 10.1126/science.290.5495.1358; GILPIN ME, 1979, AM NAT, V113, P306, DOI 10.1086/283389; HASTINGS A, 1991, ECOLOGY, V72, P896, DOI 10.2307/1940591; HEERKLOSS R, 1993, VERH INT VEREIN LIMN, V25, P995; Hegger R, 1999, CHAOS, V9, P413, DOI 10.1063/1.166424; Huisman J, 1999, NATURE, V402, P407, DOI 10.1038/46540; Jessup CM, 2004, TRENDS ECOL EVOL, V19, P189, DOI 10.1016/j.tree.2004.01.008; JOST JL, 1973, J BACTERIOL, V113, P834, DOI 10.1128/JB.113.2.834-840.1973; KANTZ H, 1994, PHYS LETT A, V185, P77, DOI 10.1016/0375-9601(94)90991-1; Kooi BW, 2003, DYNAM CONT DIS SER B, V10, P259; LUCKINBILL LS, 1978, ECOLOGY, V59, P1271, DOI 10.2307/1938241; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; Nelson WA, 2005, NATURE, V433, P413, DOI 10.1038/nature03212; PORTER KG, 1980, LIMNOL OCEANOGR, V25, P943, DOI 10.4319/lo.1980.25.5.0943; Rainey PB, 2000, TRENDS ECOL EVOL, V15, P243, DOI 10.1016/S0169-5347(00)01871-1; ROSENSTEIN MT, 1993, PHYSICA D, V65, P117, DOI 10.1016/0167-2789(93)90009-P; TAKEUCHI Y, 1983, B MATH BIOL, V45, P877, DOI 10.1007/BF02458820; Turchin Peter, 2003, Monographs in Population Biology, V35, pi; Vayenas DV, 1999, MATH BIOSCI, V162, P69, DOI 10.1016/S0025-5564(99)00044-9; Volterra V, 1926, NATURE, V118, P558, DOI 10.1038/118558a0; WOLF A, 1985, PHYSICA D, V16, P285, DOI 10.1016/0167-2789(85)90011-9; Yoshida T, 2003, NATURE, V424, P303, DOI 10.1038/nature01767	30	162	168	2	76	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1226	1229		10.1038/nature03627	http://dx.doi.org/10.1038/nature03627			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988524				2022-12-28	WOS:000230140500042
J	Goncharenko, I; Loubeyre, P				Goncharenko, I; Loubeyre, P			Neutron and X-ray diffraction study of the broken symmetry phase transition in solid deuterium	NATURE			English	Article							ORTHO-PARA CONVERSION; INTEGRAL MONTE-CARLO; MOLECULAR-HYDROGEN; HIGH-PRESSURE; ORIENTATIONAL ORDER; MEGABAR PRESSURES; QUANTUM; EXCITATIONS; STATE	The solid hydrogen compounds D-2, HD and H-2 remain quantum molecular solids up to pressures in the 100 GPa range(1). A remarkable macroscopic consequence is the existence of a pressure-induced broken symmetry phase transition(2-4), in which the molecules go from a spherical rotational state to an anisotropic rotational state. Theoretical understanding of the broken symmetry phase structure remains controversial, despite numerous studies(5-10). Some open questions concern the existence of long- or short-range orientational order; whether a strong isotopic shift on the transition pressure should be assigned to the nuclear zero-point motion or to quantum localization; and whether the structures are cubic, hexagonal or orthorhombic. Here we present experimental data on the structure of the broken symmetry phase in solid D-2, obtained by a combination of neutron and X-ray diffraction up to 60 GPa. Our data are incompatible with orthorhombic structures predicted by recent theoretical works. We find that the broken symmetry phase structure is incommensurate with local orientational order, being similar to that found in metastable cubic para-D-2.	CEA Saclay, CNRS, Lab Leon Brillouin, F-91191 Gif Sur Yvette, France; CEA, Dept Phys Theor & Applicat, F-91680 Bruyeres Le Chatel, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA	Goncharenko, I (corresponding author), CEA Saclay, CNRS, Lab Leon Brillouin, F-91191 Gif Sur Yvette, France.	gonch@llb.saclay.cea.fr; paul.loubeyre@cea.fr						CUI LJ, 1994, PHYS REV LETT, V72, P3048, DOI 10.1103/PhysRevLett.72.3048; Cui T, 1997, PHYS REV B, V55, P12253, DOI 10.1103/PhysRevB.55.12253; Eggert JH, 1999, P NATL ACAD SCI USA, V96, P12269, DOI 10.1073/pnas.96.22.12269; Freiman YA, 2003, J LOW TEMP PHYS, V133, P251, DOI 10.1023/A:1026031107293; Goncharenko IN, 2004, HIGH PRESSURE RES, V24, P193, DOI 10.1080/08957950410001661882; Goncharov AF, 1998, PHYS REV LETT, V80, P101, DOI 10.1103/PhysRevLett.80.101; Goncharov AF, 1996, PHYS REV B, V54, P15590, DOI 10.1103/PhysRevB.54.R15590; Hetenyi B, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.125503; JAMES HM, 1968, PHYS REV, V167, P862, DOI 10.1103/PhysRev.167.862; Johnson KA, 2000, NATURE, V403, P632, DOI 10.1038/35001024; KAXIRAS E, 1994, PHYS REV B, V49, P11822, DOI 10.1103/PhysRevB.49.11822; Kitamura H, 2000, NATURE, V404, P259, DOI 10.1038/35005027; Kohanoff J, 1997, PHYS REV LETT, V78, P2783, DOI 10.1103/PhysRevLett.78.2783; LORENZANA HE, 1989, PHYS REV LETT, V63, P2080, DOI 10.1103/PhysRevLett.63.2080; Loubeyre P, 1996, NATURE, V383, P702, DOI 10.1038/383702a0; Mazin II, 1997, PHYS REV LETT, V78, P1066, DOI 10.1103/PhysRevLett.78.1066; MIYAGI H, 1967, PROG THEOR PHYS, V37, P641, DOI 10.1143/PTP.37.641; MOSHARY F, 1993, PHYS REV LETT, V71, P3814, DOI 10.1103/PhysRevLett.71.3814; Nagao K, 1999, PHYS REV B, V59, P13741, DOI 10.1103/PhysRevB.59.13741; Pravica MG, 1998, PHYS REV LETT, V81, P4180, DOI 10.1103/PhysRevLett.81.4180; Raich JC, 1972, J LOW TEMP PHYS, V6, P229, DOI 10.1007/BF00628309; SILVERA IF, 1981, PHYS REV LETT, V47, P39, DOI 10.1103/PhysRevLett.47.39; Stadele M, 2000, PHYS REV LETT, V84, P6070, DOI 10.1103/PhysRevLett.84.6070; Van Kranendonk J., 1983, SOLID HYDROGEN THEOR	24	85	90	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1206	1209		10.1038/nature03699	http://dx.doi.org/10.1038/nature03699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988519				2022-12-28	WOS:000230140500037
J	Liu, JG; Diamond, J				Liu, JG; Diamond, J			China's environment in a globalizing world	NATURE			English	Article							ACID DEPOSITION; TRADE		Michigan State Univ, Dept Fisheries & Wildlife, Ctr Syst Integrat & Sustainabil, E Lansing, MI 48824 USA; Chinese Acad Sci, Ecoenvironm Sci Res Ctr, Beijing, Peoples R China; Fudan Univ, Shanghai 200433, Peoples R China; Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA	Michigan State University; Chinese Academy of Sciences; Research Center for Eco-Environmental Sciences (RCEES); Fudan University; University of California System; University of California Los Angeles	Liu, JG (corresponding author), Michigan State Univ, Dept Fisheries & Wildlife, Ctr Syst Integrat & Sustainabil, E Lansing, MI 48824 USA.	jliu@panda.msu.edu; jdiamond@geog.ucla.edu	liang, jiwang/A-5334-2009; Liu, Jianguo/G-5211-2015	Liu, Jianguo/0000-0001-6344-0087	NICHD NIH HHS [R01 HD39789] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039789] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS M, 2001, ITTO NEWSLETTER; Brown L.R., 1995, WHO WILL FEED CHINA; Chai JCH, 2002, SUSTAIN DEV, V10, P25, DOI 10.1002/sd.174; DAI Q, 1998, RIVER DRAGON HAS COM, P3; Dean JM, 2002, CAN J ECON, V35, P819, DOI 10.1111/0008-4085.00155; *ED BOARD, 2000, ENV PROT CHIN; *ED BOARD, 2001, ATL POP ENV SUST DEV; Feng ZW, 2002, J ENVIRON SCI-CHINA, V14, P227; GUO X, 2004, CHINA ENV DEV REV, V2, P53; Holden C, 2001, SCIENCE, V294, P2457; Johnson Todd M., 1997, CLEAR WATER BLUE SKI; Liu JG, 2003, SCIENCE, V300, P1240, DOI 10.1126/science.1078868; Liu JG, 2003, NATURE, V421, P530, DOI 10.1038/nature01359; *NAT BUR STAT CHIN, 2000, CHIN STAT YB 2000; National Bureau of Statistics of China, 2004, CHIN STAT YB 2003; Pauly D, 2003, SCIENCE, V302, P1359, DOI 10.1126/science.1088667; QU G, 2000, DREAM EXPECTATION PA; *SEPA, 1999, REP CHIN EC ISS; United Nations Center for Human Settlement (HABITAT), 2001, CIT GLOB WORLD GLOB; World Bank, 2001, CHIN AIR LAND WAT; Xie Y, 2001, BIODIVERS CONSERV, V10, P1317, DOI 10.1023/A:1016695609745; XIE Z, 1997, GREENING STRATEGY, P44; Xu XP, 1998, ECOSYST HEALTH, V4, P199, DOI 10.1046/j.1526-0992.1998.98096.x; Yang L, 2002, PHYTON-ANN REI BOT A, V42, P255; YE R, 2001, ENV TRADE; ZHANG P, INTRO NATURAL FOREST, P99	26	1205	1325	28	650	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1179	1186		10.1038/4351179a	http://dx.doi.org/10.1038/4351179a			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988514	Bronze			2022-12-28	WOS:000230140500032
J	Greenhalgh, RM; Brown, LC; Epstein, D; Kwong, GPS; Powell, JT; Sculpher, MJ; Thompson, SG				Greenhalgh, RM; Brown, LC; Epstein, D; Kwong, GPS; Powell, JT; Sculpher, MJ; Thompson, SG		EVAR Participants	Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial	LANCET			English	Article							MORTALITY; SURGERY; RUPTURE	Background Endovascular aneurysm repair (EVAR) to exclude abdominal aortic aneurysm (AAA) was introduced for patients of poor health status considered unfit for major surgery. We instigated EVAR trial 2 to identify whether EVAR improves survival compared with no intervention in patients unfit for open repair of aortic aneurysm. Methods We did a randomised controlled trial of 338 patients aged 60 years or older who had aneurysms of at least 5.5 cm in diameter and who had been referred to one of 31 hospitals in the UK. We assigned patients to receive either EVAR (n=166) or no intervention (n=172). Our primary endpoint was all-cause mortality, with secondary endpoints of aneurysm-related mortality, health-related quality of life (HRQL), postoperative complications, and hospital costs. Analyses were by intention to treat. Findings 197 patients underwent aneurysm repair (47 assigned no intervention) and 80% of patients adhered to protocol. The 30-day operative mortality in the EVAR group was 9% (13 of 150, 95% CI 5-15) and the no intervention group had a rupture rate of 9.0 per 100 person years (95% CI 6.0-13.5). By end of follow up 142 patients had died, 42 of aneurysm-related factors; overall mortality after 4 years was 64%. There was no significant difference between the EVAR group and the no intervention group for all-cause mortality (hazard ratio 1.21, 95% CI 0.87-1.69, p=0.25). There was no difference in aneurysm-related mortality. The mean hospital costs per patient over 4 years were UK 13632 pound in the EVAR group and 4983 pound in the no intervention group (mean difference 8649 pound, SE 1248), with no difference in HRQL scores. Interpretation EVAR had a considerable 30-day operative mortality in patients already unfit for open repair of their aneurysm. EVAR did not improve survival over no intervention and was associated with a need for continued surveillance and reinterventions, at substantially increased cost. Ongoing follow-up and improved fitness of these patients is a priority.	Univ London Imperial Coll Sci Technol & Med, Dept Vasc Surg, London W6 8RP, England	Imperial College London	Greenhalgh, RM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Vasc Surg, Charing Cross Campus, London W6 8RP, England.		Epstein, David/I-2839-2019; Morgan, Robert Anthony/AAH-9104-2021; Russell, Ian T/H-1181-2012	Epstein, David/0000-0002-2275-0916; Morgan, Robert Anthony/0000-0002-8108-5258; 				Brown LC, 2004, EUR J VASC ENDOVASC, V27, P372, DOI 10.1016/j.ejvs.2003.12.019; Brown LC, 1999, ANN SURG, V230, P289, DOI 10.1097/00000658-199909000-00002; DUBOST C, 1951, Mem Acad Chir (Paris), V77, P381; Greenhalgh RM, 2005, LANCET, V365, P2179, DOI 10.1016/S0140-6736(05)66627-5; Greenhalgh RM, 2004, LANCET, V364, P843, DOI 10.1016/S0140-6736(04)16979-1; Kertai MD, 2004, EUR J VASC ENDOVASC, V28, P343, DOI 10.1016/j.ejvs.2004.07.008; Kertai MD, 2004, AM J MED, V116, P96, DOI 10.1016/j.amjmed.2003.08.029; Lederle FA, 2002, JAMA-J AM MED ASSOC, V287, P2968, DOI 10.1001/jama.287.22.2968; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; Powell JT, 2003, NEW ENGL J MED, V348, P1895, DOI 10.1056/NEJMcp012641; Prinssen M, 2004, NEW ENGL J MED, V351, P1607, DOI 10.1056/NEJMoa042002; Thomas SM, 2001, EUR J VASC ENDOVASC, V21, P57, DOI 10.1053/ejvs.2000.1268; VOLODOS NL, 1986, VESTN KHIR IM GREKOV, V137, P123	13	538	558	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	2005	365	9478					2187	2192		10.1016/S0140-6736(05)66628-7	http://dx.doi.org/10.1016/S0140-6736(05)66628-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978926				2022-12-28	WOS:000230034800028
J	Escher, P; Lacazette, E; Courtet, M; Blindenbacher, A; Landmann, L; Bezakova, G; Lloyd, KC; Mueller, U; Brenner, HR				Escher, P; Lacazette, E; Courtet, M; Blindenbacher, A; Landmann, L; Bezakova, G; Lloyd, KC; Mueller, U; Brenner, HR			Synapses form in skeletal muscles lacking neuregulin receptors	SCIENCE			English	Article							ACETYLCHOLINE-RECEPTOR; NEUROMUSCULAR-JUNCTION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; IN-VIVO; DIFFERENTIATION; SUBUNIT; ERBB4; MICE; PROTEIN	The formation of the neuromuscular junction (NMJ) is directed by reciprocal interactions between motor neurons and muscle fibers. Neuregulin (NRG) and Agrin from motor nerve terminals are both implicated. Here, we demonstrate that NMJs can form in the absence of the NRG receptors ErbB2 and ErbB4 in mouse muscle. Postsynaptic differentiation is, however, induced by Agrin. We therefore conclude that NRG signaling to muscle is not required for NMJ formation. The effects of NRG signaling to muscle may be mediated indirectly through Schwann cells.	Univ Basel, Inst Physiol, CH-4056 Basel, Switzerland; Univ Basel, Inst Anat, Dept Clin Biol Sci, CH-4056 Basel, Switzerland; Univ Basel, Div Pharmacol, Biozentrum, CH-4056 Basel, Switzerland; Univ Calif Davis, Ctr Comparat Med, Sch Vet Med, Davis, CA 95616 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Inst Childhood & Neglected Dis, La Jolla, CA 92037 USA	University of Basel; University of Basel; University of Basel; University of California System; University of California Davis; Scripps Research Institute; Scripps Research Institute	Escher, P (corresponding author), Univ Basel, Inst Physiol, CH-4056 Basel, Switzerland.	Hans-Rudolf.Brenner@unibas.ch	Lacazette, eric/M-7168-2014	lacazette, eric/0000-0003-1234-5260				BEZAKOVA G, UNPUB; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; Cossins J, 2004, HUM MOL GENET, V13, P2947, DOI 10.1093/hmg/ddh320; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; ESCHER P, UNPUB; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Garratt AN, 2000, BIOESSAYS, V22, P987, DOI 10.1002/1521-1878(200011)22:11<987::AID-BIES5>3.0.CO;2-5; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; Hashemolhosseini S, 2000, MOL CELL NEUROSCI, V16, P697, DOI 10.1006/mcne.2000.0911; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Leu M, 2003, DEVELOPMENT, V130, P2291, DOI 10.1242/dev.00447; Lin WC, 2001, NATURE, V410, P1057, DOI 10.1038/35074025; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Marques MJ, 2000, J NEUROSCI, V20, P3663, DOI 10.1523/JNEUROSCI.20-10-03663.2000; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Meier T, 1997, J NEUROSCI, V17, P6534; Missias AC, 1996, DEV BIOL, V179, P223, DOI 10.1006/dbio.1996.0253; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; Ozaki M, 1997, NATURE, V390, P691, DOI 10.1038/37795; Rimer M, 2004, MOL CELL NEUROSCI, V26, P271, DOI 10.1016/j.mcn.2004.02.002; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Schwander M, 2003, DEV CELL, V4, P673, DOI 10.1016/S1534-5807(03)00118-7; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Witzemann V, 1996, P NATL ACAD SCI USA, V93, P13286, DOI 10.1073/pnas.93.23.13286; Yang X, 2001, NEURON, V30, P399, DOI 10.1016/S0896-6273(01)00287-2	28	93	95	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	2005	308	5730					1920	1923		10.1126/science.1108258	http://dx.doi.org/10.1126/science.1108258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976301				2022-12-28	WOS:000230120000043
J	Solomon, SD; Zelenkofske, S; McMurray, JJV; Finn, PV; Velazquez, E; Ertl, G; Harsanyi, A; Rouleau, JL; Maggioni, A; Kober, L; White, H; Van de Werf, F; Pieper, K; Califf, RM; Pfeffer, MA				Solomon, SD; Zelenkofske, S; McMurray, JJV; Finn, PV; Velazquez, E; Ertl, G; Harsanyi, A; Rouleau, JL; Maggioni, A; Kober, L; White, H; Van de Werf, F; Pieper, K; Califf, RM; Pfeffer, MA		VALIANT Investigators	Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; CARDIAC DEATH; RISK STRATIFICATION	Background The risk of sudden death from cardiac causes is increased among survivors of acute myocardial infarction with reduced left ventricular systolic function. We assessed the risk and time course of sudden death in high-risk patients after myocardial infarction. Methods We studied 14,609 patients with left ventricular dysfunction, heart failure, or both after myocardial infarction to assess the incidence and timing of sudden unexpected death or cardiac arrest with resuscitation in relation to the left ventricular ejection fraction. Results Of 14,609 patients, 1067 (7 percent) had an event a median of 180 days after myocardial infarction: 903 died suddenly, and 164 were resuscitated after cardiac arrest. The risk was highest in the first 30 days after myocardial infarction -- 1.4 percent per month (95 percent confidence interval, 1.2 to 1.6 percent) -- and decreased to 0.14 percent per month (95 percent confidence interval, 0.11 to 0.18 percent) after 2 years. Patients with a left ventricular ejection fraction of 30 percent or less were at highest risk in this early period (rate, 2.3 percent per month; 95 percent confidence interval, 1.8 to 2.8 percent). Nineteen percent of all sudden deaths or episodes of cardiac arrest with resuscitation occurred within the first 30 days after myocardial infarction, and 83 percent of all patients who died suddenly did so in the first 30 days after hospital discharge. Each decrease of 5 percentage points in the left ventricular ejection fraction was associated with a 21 percent adjusted increase in the risk of sudden death or cardiac arrest with resuscitation in the first 30 days. Conclusions The risk of sudden death is highest in the first 30 days after myocardial infarction among patients with left ventricular dysfunction, heart failure, or both. Thus, earlier implementation of strategies for preventing sudden death may be warranted in selected patients.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Novartis Pharmaceut, E Hanover, NJ USA; Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland; Duke Univ, Med Ctr, Durham, NC USA; Univ Wurzburg, Wurzburg, Germany; Natl Ctr Hlth Serv, Budapest, Hungary; Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada; Assoc Nazl Med Cardiol Osped Res Ctr, Florence, Italy; Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark; Green Lane Hosp, Dept Cardiol, Auckland 3, New Zealand; Leuven Coordinating Ctr, Louvain, Belgium	Harvard University; Brigham & Women's Hospital; Novartis; University of Glasgow; Duke University; University of Wurzburg; Universite de Montreal; Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO); Rigshospitalet; University of Copenhagen; KU Leuven	Solomon, SD (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	ssolomon@rics.bwh.harvard.edu	mcmurray, John/B-2467-2013; Maggioni, Aldo Pietro/AAL-5334-2020; Solomon, Scott/I-5789-2013	mcmurray, John/0000-0002-6317-3975; Maggioni, Aldo Pietro/0000-0003-2764-6779; Van de Werf, Frans/0000-0001-9479-7767; Patt, Mitchell/0000-0001-9696-4477; Kober, Lars/0000-0002-6635-1466				ALKHATIB SM, IN PRESS AM HEART J; Antman Elliott M., 2004, J Am Coll Cardiol, V44, pE1, DOI 10.1016/j.jacc.2004.07.014; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Buxton AE, 2000, NEW ENGL J MED, V343, P1813; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; CALIFF RM, 1982, AM J CARDIOL, V50, P23, DOI 10.1016/0002-9149(82)90004-2; Every N, 2002, AM HEART J, V144, P390, DOI 10.1067/mhj.2002.125495; Hohnloser SH, 2000, AM HEART J, V140, P735, DOI 10.1067/mhj.2000.110088; Hohnloser SH, 2004, NEW ENGL J MED, V351, P2481, DOI 10.1056/NEJMoa041489; Huikuri HV, 2003, J AM COLL CARDIOL, V42, P652, DOI 10.1016/S0735-1097(03)00783-6; Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; MYERBURG RJ, 1993, ANN INTERN MED, V119, P1187, DOI 10.7326/0003-4819-119-12-199312150-00006; Naccarella F, 2000, CURR OPIN CARDIOL, V15, P1, DOI 10.1097/00001573-200001000-00001; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Savard P, 1997, CIRCULATION, V96, P202; STEINBERG JS, 1992, AM J CARDIOL, V69, P13, DOI 10.1016/0002-9149(92)90669-P; Uretsky BF, 2000, CIRCULATION, V102, P611, DOI 10.1161/01.CIR.102.6.611; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334	23	549	569	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					2581	2588		10.1056/NEJMoa043938	http://dx.doi.org/10.1056/NEJMoa043938			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972864				2022-12-28	WOS:000229953700005
J	Reed, D; Price, EG; Windish, DM; Wright, SM; Gozu, A; Hsu, EB; Beach, MC; Kern, D; Bass, EB				Reed, D; Price, EG; Windish, DM; Wright, SM; Gozu, A; Hsu, EB; Beach, MC; Kern, D; Bass, EB			Challenges in systematic reviews of educational intervention studies	ANNALS OF INTERNAL MEDICINE			English	Article							EVIDENCE MEDICAL-EDUCATION; PATIENT EDUCATION; CRITICAL-APPRAISAL; OUTCOMES RESEARCH; CLINICAL-TRIALS; GUIDE; METAANALYSIS; PROGRAMS; INFORMATION; PREVENTION	Educators have recognized the need to apply evidence-based approaches to medical training. To do so, medical educators must have access to reliable evidence on the impact of educational interventions. This paper describes 5 methodologic challenges to performing systematic reviews of educational interventions for health care professionals: finding reports of medical education interventions, assessing quality of study designs, assessing the scope of interventions, assessing the evaluation of interventions, and synthesizing the results of educational interventions. We offer suggestions for addressing these challenges and make recommendations for reporting, reviewing, and appraising interventions in medical education.	Johns Hopkins Univ, Baltimore, MD USA	Johns Hopkins University	Reed, D (corresponding author), Mayo Clin Coll Med, 200 1st St SW, Rochester, MN 55905 USA.	reed.darcy@mayo.edu	Price-Haywood, Eboni/L-5527-2014	Price-Haywood, Eboni/0000-0003-2901-3852; Beach, Mary Catherine/0000-0002-1112-6309; Bass, Eric/0000-0001-9106-527X				BEACH MC, 2005, IN PRESS MED CARE; BEACH MC, 2004, AHRQ PUBLICATION; BERKMAN N, 2004, AHRQ PUBLICATION; Biffl W, 2002, AM J SURG, V184, P641; Bowen JL, 2002, ACAD MED, V77, P621, DOI 10.1097/00001888-200207000-00006; Carline JD, 2004, ACAD MED, V79, P918, DOI 10.1097/00001888-200410000-00004; Carney PA, 2004, JAMA-J AM MED ASSOC, V292, P1044, DOI 10.1001/jama.292.9.1044; Cauffman Joy Garrison, 2002, J Contin Educ Health Prof, V22, P214, DOI 10.1002/chp.1340220405; Chang JT, 2004, BRIT MED J, V328, P680, DOI 10.1136/bmj.328.7441.680; Chart P, 2001, J CANCER EDUC, V16, P129; Chen FM, 2004, ACAD MED, V79, P955, DOI 10.1097/00001888-200410000-00010; Coomarasamy A, 2003, MED TEACH, V25, P77, DOI 10.1080/0142159021000061468; Coren E, 2003, J ADOLESCENCE, V26, P79, DOI 10.1016/S0140-1971(02)00119-7; Dauphinee WD, 2004, ACAD MED, V79, P925, DOI 10.1097/00001888-200410000-00005; Dillner L, 1999, BRIT MED J, V318, P1265; Ellis SE, 2004, PATIENT EDUC COUNS, V52, P97, DOI 10.1016/S0738-3991(03)00016-8; Gozu A, 2004, J GEN INTERN MED, V19, P234; Green ML, 2001, ANN INTERN MED, V135, P889, DOI 10.7326/0003-4819-135-10-200111200-00009; Haig A, 2003, MED TEACH, V25, P463, DOI 10.1080/01421590310001608667; Haig A, 2003, MED TEACH, V25, P352, DOI 10.1080/0142159031000136815; Harden RM, 1999, MED TEACH, V21, P553, DOI 10.1080/01421599978960; Hebert RS, 2003, ACAD MED, V78, P61, DOI 10.1097/00001888-200301000-00012; Holtzman J, 2004, AHRQ PUBLICATION; HSU EB, 2004, AHRQ PUBLICATION; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Kern D, 1998, CURRICULUM DEV MED E; Lang TA, 2004, ACAD MED, V79, P1067, DOI 10.1097/00001888-200411000-00011; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Loveman E, 2003, HEALTH TECHNOL ASSES, V7, P1, DOI DOI 10.3310/HTA7220; Mazmanian PE, 1998, ACAD MED, V73, P882, DOI 10.1097/00001888-199808000-00013; Morrison JM, 1999, MED EDUC, V33, P890, DOI 10.1046/j.1365-2923.1999.00479.x; MORTON SC, 2004, AHRQ PUBLICATION; Mulrow C, 1997, ANN INTERN MED, V127, P989, DOI 10.7326/0003-4819-127-11-199712010-00008; Mytton JA, 2002, ARCH PEDIAT ADOL MED, V156, P752, DOI 10.1001/archpedi.156.8.752; Niedermann K, 2004, ARTHRIT RHEUM-ARTHR, V51, P388, DOI 10.1002/art.20399; PRICE E, 2005, IN PRESS ACAD MED; Prideaux D, 2002, BRIT MED J, V324, P126, DOI 10.1136/bmj.324.7330.126; Prystowsky JB, 2001, MED EDUC, V35, P331, DOI 10.1046/j.1365-2923.2001.00910.x; Riemsma RP, 2004, ARTHRIT RHEUM-ARTHR, V51, P1045, DOI 10.1002/art.20823; Smits PB, 2003, SCAND J WORK ENV HEA, V29, P280, DOI 10.5271/sjweh.732; Stone EG, 2002, ANN INTERN MED, V136, P641, DOI 10.7326/0003-4819-136-9-200205070-00006; Sudre P, 1999, THORAX, V54, P681, DOI 10.1136/thx.54.8.681; Taylor R, 2000, MED EDUC, V34, P120, DOI 10.1046/j.1365-2923.2000.00574.x; Thomas J, 2004, BRIT MED J, V328, P1010, DOI 10.1136/bmj.328.7446.1010; Thomas PA, 2004, J GEN INTERN MED, V19, P599, DOI 10.1111/j.1525-1497.2004.99999.x; Torgerson C.J., 2002, J RES READ, V25, P129, DOI [10.1111/1467-9817.00164, DOI 10.1111/1467-9817.00164, DOI 10.1111/1467-9817]; Torgerson CJ, 2002, MED EDUC, V36, P1002, DOI 10.1046/j.1365-2923.2002.01335.x; Valk GD, 2002, ENDOCRIN METAB CLIN, V31, P633, DOI 10.1016/S0889-8529(02)00021-X; Viswanathan M, 2004, AHRQ PUBLICATION; Warsi A, 2004, ARCH INTERN MED, V164, P1641, DOI 10.1001/archinte.164.15.1641; West S, 2002, AHRQ PUBLICATION, V02-E016; Wilkes M, 1999, BRIT MED J, V318, P1269; WINEMILLER DR, 1993, J CLIN PSYCHOL, V49, P638, DOI 10.1002/1097-4679(199309)49:5<638::AID-JCLP2270490505>3.0.CO;2-7	53	121	125	1	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1080	1089		10.7326/0003-4819-142-12_Part_2-200506211-00008	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938CN	15968033				2022-12-28	WOS:000229977600008
J	Einterz, EM				Einterz, EM			Apollo at the front	LANCET			English	Editorial Material									Hop Dist Kolofata, Mora, Extreme Nord, Cameroon		Einterz, EM (corresponding author), Hop Dist Kolofata, BP111, Mora, Extreme Nord, Cameroon.			Einterz, Ellen/0000-0002-0818-847X					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 18	2005	365	9477					2147	2148		10.1016/S0140-6736(05)66739-6	http://dx.doi.org/10.1016/S0140-6736(05)66739-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964453				2022-12-28	WOS:000229858800033
J	Obermann, K				Obermann, K			When the patient comes back	LANCET			English	Editorial Material									CHD Eastern Visayas, GTZ Hlth Sector Philippines, Palo 6501, Leyte, Philippines		Obermann, K (corresponding author), CHD Eastern Visayas, GTZ Hlth Sector Philippines, Palo 6501, Leyte, Philippines.	obermannk@gmx.de							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 18	2005	365	9477					2149	2149		10.1016/S0140-6736(05)66741-4	http://dx.doi.org/10.1016/S0140-6736(05)66741-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964454				2022-12-28	WOS:000229858800035
J	Agterof, MJ; Biesma, DH				Agterof, MJ; Biesma, DH			Bortezomib-induced skin lesions	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									St Antonius Hosp, NL-3435 CM Nieuwegein, Netherlands	St. Antonius Hospital Utrecht	Agterof, MJ (corresponding author), St Antonius Hosp, NL-3435 CM Nieuwegein, Netherlands.		Biesma, Douwe H./AAV-6343-2020	Biesma, Douwe H./0000-0001-8334-3057					0	28	28	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2005	352	24					2534	2534		10.1056/NEJMicm041166	http://dx.doi.org/10.1056/NEJMicm041166			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935RH	15958809				2022-12-28	WOS:000229798900009
J	Shekelle, PG; Delitto, AM				Shekelle, PG; Delitto, AM			Treating low back pain	LANCET			English	Editorial Material							THERAPY		Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA; Univ Pittsburgh, Pittsburgh, PA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Shekelle, PG (corresponding author), Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA.	shekelle@rand.org						Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; Childs JD, 2004, ANN INTERN MED, V141, P920, DOI 10.7326/0003-4819-141-12-200412210-00008; Deyo RA, 2004, ANN INTERN MED, V141, P957, DOI 10.7326/0003-4819-141-12-200412210-00012; Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508; Fritz JM, 2001, PAIN, V94, P7, DOI 10.1016/S0304-3959(01)00333-5; George SZ, 2003, SPINE, V28, P2551, DOI 10.1097/01.BRS.0000096677.84605.A2; HART IG, 1995, SPINE, V20, P11	7	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 11	2005	365	9476					1987	1989		10.1016/S0140-6736(05)66676-7	http://dx.doi.org/10.1016/S0140-6736(05)66676-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950702				2022-12-28	WOS:000229701400006
J	Ahmad, OB				Ahmad, OB			Managing medical migration from poor countries	BRITISH MEDICAL JOURNAL			English	Article								Migration of health workers from poorer to richer nations is unlikely to stop, but we can and must put policies in place to minimise the damage it causes.	Univ Ghana, Coll Hlth Sci, Sch Publ Hlth, Dept Biostat, Legon, Accra, Ghana	University of Ghana	Ahmad, OB (corresponding author), Univ Ghana, Coll Hlth Sci, Sch Publ Hlth, Dept Biostat, POB LG13, Legon, Accra, Ghana.	oahmad@ug.edu.gh						ADAMS O, 1998, PUBLIC HLTH PERSPETI; [Anonymous], 2001, MIGRATION NEWS, V8; BLONDAL S, 1999, OECD EC STUDIES; Buchan J., 2004, INT RECRUITMENT HLTH; Buchan James, 2003, INT NURSE MOBILITY T; Carrington WJ., 1999, FINANC DEV, V36, P46; Commonwealth Secretariat, 2003, COMP DOC COMM COD PR; Couper I, 2002, Rural Remote Health, V2, P196; *DEP HLTH, 2001, COD PRACT NHS EMPL I; *DEP HLTH AG, 2001, HLTH WORKF RUR MED B; Detragiache E, 1998, WP98102 INT MON FUND; Diallo K, 2004, B WORLD HEALTH ORGAN, V82, P601; *GHAN MIN HLTH, 1999, IN DEPTH REV HUM RES; GOLDCARE M, 1998, BRIT MED J, V316, P1847; *INT COUNC NURS, 2001, POS STAT ETH NURS RE; *INT ORG MIGR, 1999, RET QUAL AFR NAT PRO; International Labour Organization, 2002, SOC DIAL HLTH SERV I; Kandela P, 1998, LANCET, V352, P123, DOI 10.1016/S0140-6736(98)85035-6; Lowell B.Lindsay., 2001, SYNTHESIS REPORT; Mejia A., 1979, PHYS NURSE MIGRATION; *ORG EC COOP DEV, 2000, OECD EC STUDIES, V30, P149; Organisation for Economic Co-Operation and Development, 2002, INT MOB HIGHL SKILL; Organisation for Economic Co-operation and Development, 1997, TRENDS INT MIGR; Organisation for Economic Co-operation and Development, 1998, MAINT PROSP AG SOC; Pang T, 2002, BMJ-BRIT MED J, V324, P499, DOI 10.1136/bmj.324.7336.499; REGETS M, 2001, 366 NAT SCI FDN; Sullivan P, 2001, CAN MED ASSOC J, V164, P1334; *UN POP DIV, 2003, INT MIGR REP 2002; United States Department of Health and Human Services, 2002, PROJ SUPPL DEM SHORT; Willets A., 2004, ETHICAL INT RECRUITM; 2005, FINANCIAL EXPRE 0208	31	67	68	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 2	2005	331	7507					43	45		10.1136/bmj.331.7507.43	http://dx.doi.org/10.1136/bmj.331.7507.43			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947TD	15994693	Green Published			2022-12-28	WOS:000230668500023
J	Normann, EK				Normann, EK			Conjunctivitis in children	LANCET			English	Editorial Material							BACTERIAL CONJUNCTIVITIS; DROPS; ACID		Akershus Univ Hosp, NO-1478 Lorenskog, Norway	University of Oslo	Normann, EK (corresponding author), Akershus Univ Hosp, NO-1478 Lorenskog, Norway.	erik@normann.no						Hwang DG, 2003, BRIT J OPHTHALMOL, V87, P1004, DOI 10.1136/bjo.87.8.1004; Jackson WB, 2002, CAN J OPHTHALMOL, V37, P228, DOI 10.1016/S0008-4182(02)80114-4; Normann EK, 2002, ACTA OPHTHALMOL SCAN, V80, P183, DOI 10.1034/j.1600-0420.2002.800212.x; ORDEN MB, 2004, ANN PEDIAT, V61, P32; Rose PW, 2005, LANCET, V366, P37, DOI 10.1016/S0140-6736(05)66709-8; Tveten Y, 2002, J ANTIMICROB CHEMOTH, V50, P873, DOI 10.1093/jac/dkf217	6	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	2005	366	9479					6	7		10.1016/S0140-6736(05)66799-2	http://dx.doi.org/10.1016/S0140-6736(05)66799-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993210				2022-12-28	WOS:000230277600005
J	Gleich, B; Weizenecker, R				Gleich, B; Weizenecker, R			Tomographic imaging using the nonlinear response of magnetic particles	NATURE			English	Article							CONTRAST AGENTS; IRON-OXIDE; IN-VIVO	The use of contrast agents and tracers in medical imaging has a long history(1-7). They provide important information for diagnosis and therapy, but for some desired applications, a higher resolution is required than can be obtained using the currently available medical imaging techniques. Consider, for example, the use of magnetic tracers in magnetic resonance imaging: detection thresholds for in vitro(8) and in vivo(9) imaging are such that the background signal from the host tissue is a crucial limiting factor. A sensitive method for detecting the magnetic particles directly is to measure their magnetic fields using relaxometry(10); but this approach has the drawback that the inverse problem ( associated with transforming the data into a spatial image) is ill posed and therefore yields low spatial resolution. Here we present a method for obtaining a high-resolution image of such tracers that takes advantage of the nonlinear magnetization curve of small magnetic particles. Initial 'phantom' experiments are reported that demonstrate the feasibility of the imaging method. The resolution that we achieve is already well below 1 mm. We evaluate the prospects for further improvement, and show that the method has the potential to be developed into an imaging method characterized by both high spatial resolution as well as high sensitivity.	Philips Res Hamburg, D-22335 Hamburg, Germany	Philips; Philips Research	Gleich, B (corresponding author), Philips Res Hamburg, Rontgenstr 24-26, D-22335 Hamburg, Germany.	bernhard.gleich@philips.com; juergen.weizenecker@philips.com						Chikazumi S., 1964, PHYS MAGNETISM; Czernin J, 2002, ANNU REV MED, V53, P89, DOI 10.1146/annurev.med.53.082901.104028; FYE WB, 2002, CIRCULATION, V106, P752; GLEICH B, 2004, Patent No. 200418039; GOLDBERG BB, 1994, ULTRASOUND MED BIOL, V20, P319, DOI 10.1016/0301-5629(94)90001-9; Haschek E., 1896, WIEN KLIN WOCHENSCHR, V9, P63; HENDRICK RE, 1993, JMRI-J MAGN RESON IM, V3, P137, DOI 10.1002/jmri.1880030126; HEVESY G, 1913, CHEM NEWS J PHYS SCI, V108, P166; Heyn C, 2005, MAGN RESON MED, V53, P312, DOI 10.1002/mrm.20356; Jordan A, 1997, INT J HYPERTHER, V13, P587, DOI 10.3109/02656739709023559; Lawaczeck R, 1997, ACTA RADIOL, V38, P584, DOI 10.1080/02841859709174391; Nunn A D, 1997, Q J Nucl Med, V41, P155; PRESS WH, 1992, NUMERICAL RECIPES; Romanus E, 2002, J MAGN MAGN MATER, V252, P387, DOI 10.1016/S0304-8853(02)00645-5; VLAARDINGERBROE.MT, 2003, MAGNETIC RESONANCE I; WEISSLEDER R, 1989, AM J ROENTGENOL, V152, P167, DOI 10.2214/ajr.152.1.167; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123	17	1271	1361	16	243	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 30	2005	435	7046					1214	1217		10.1038/nature03808	http://dx.doi.org/10.1038/nature03808			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988521				2022-12-28	WOS:000230140500039
J	Schramke, V; Sheedy, DM; Denli, AM; Bonila, C; Ekwall, K; Hannon, GJ; Allshire, RC				Schramke, V; Sheedy, DM; Denli, AM; Bonila, C; Ekwall, K; Hannon, GJ; Allshire, RC			RETRACTED: RNA-interference-directed chromatin modification coupled to RNA polymerase II transcription (Retracted article. See vol. 437, pg. 1057, 2005)	NATURE			English	Article; Retracted Publication							GENOME REARRANGEMENT; GENE-EXPRESSION; DNA METHYLATION; HUMAN-CELLS; HETEROCHROMATIN; YEAST; RITS; MAINTENANCE; TETRAHYMENA; COMPLEX	RNA interference (RNAi) acts on long double-stranded RNAs (dsRNAs) in a variety of eukaryotes to generate small interfering RNAs that target homologous messenger RNA, resulting in their destruction. This process is widely used to 'knock-down' the expression of genes of interest to explore phenotypes(1-3). In plants(3-5), fission yeast(6-8), ciliates(9,10), flies(11) and mammalian cells(12,13), short interfering RNAs (siRNAs) also induce DNA or chromatin modifications at the homologous genomic locus, which can result in transcriptional silencing or sequence elimination(14). siRNAs may direct DNA or chromatin modification by siRNA - DNA interactions at the homologous locus(4,5). Alternatively, they may act by interactions between siRNA and nascent transcript(15,16). Here we show that in fission yeast ( Schizosaccharomyces pombe), chromatin modifications are only directed by RNAi if the homologous DNA sequences are transcribed. Furthermore, transcription by exogenous T7 polymerase is not sufficient. Ago1, a component of the RNAi effector RISC/RITS complex, associates with target transcripts and RNA polymerase II. Truncation of the regulatory carboxy-terminal domain (CTD) of RNApol II disrupts transcriptional silencing, indicating that, like other RNA processing events(17-19), RNAi-directed chromatin modification is coupled to transcription.	Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; Univ Coll Sodertorn, Karolinska Inst, Dept Biosci, Dept Nat Sci, S-14189 Huddinge, Sweden	University of Edinburgh; Cold Spring Harbor Laboratory; Karolinska Institutet; Sodertorn University	Allshire, RC (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.	robin.allshire@ed.ac.uk	Hannon, Gregory/AAB-3568-2019	Allshire, Robin/0000-0002-8005-3625; Ekwall, Karl/0000-0002-3029-4041	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aranda A, 2001, MOL CELL, V7, P1003, DOI 10.1016/S1097-2765(01)00235-0; Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Herr AJ, 2005, SCIENCE, V308, P118, DOI 10.1126/science.1106910; Jones L, 2001, CURR BIOL, V11, P747, DOI 10.1016/S0960-9822(01)00226-3; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; Lippman Z, 2004, NATURE, V431, P364, DOI 10.1038/nature02875; Martienssen RA, 2003, NAT GENET, V35, P213, DOI 10.1038/ng1252; Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500; Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872; Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194; Mochizuki K, 2004, CURR OPIN GENET DEV, V14, P181, DOI 10.1016/j.gde.2004.01.004; Mochizuki K, 2002, CELL, V110, P689, DOI 10.1016/S0092-8674(02)00909-1; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Motamedi MR, 2004, CELL, V119, P789, DOI 10.1016/j.cell.2004.11.034; Noma K, 2004, NAT GENET, V36, P1174, DOI 10.1038/ng1452; Onodera Y, 2005, CELL, V120, P613, DOI 10.1016/j.cell.2005.02.007; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Partridge JF, 2000, GENE DEV, V14, P783; Partridge JF, 2002, CURR BIOL, V12, P1652, DOI 10.1016/S0960-9822(02)01177-6; Pidoux AL, 2003, J CELL BIOL, V161, P295, DOI 10.1083/jcb.200212110; Proudfoot N, 2004, CURR OPIN CELL BIOL, V16, P272, DOI 10.1016/j.ceb.2004.03.007; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Sugiyama T, 2005, P NATL ACAD SCI USA, V102, P152, DOI 10.1073/pnas.0407641102; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973	30	56	72	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1275	1279		10.1038/nature03652	http://dx.doi.org/10.1038/nature03652			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15965464				2022-12-28	WOS:000230140500052
J	Savitz, SI; Caplan, LR				Savitz, SI; Caplan, LR			Current concepts: Vertebrobasilar disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EXTRACRANIAL VERTEBRAL ARTERY; CEREBROVASCULAR-DISEASE; THROMBOLYTIC THERAPY; CONSECUTIVE PATIENTS; STROKE REGISTRY; CIRCULATION; PREVENTION; DIAGNOSIS; WARFARIN; ASPIRIN		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Cerebrovasc Dis, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Savitz, SI (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Cerebrovasc Dis, Palmer 127,330 Brookline Ave, Boston, MA 02215 USA.	ssavitz@bidmc.harvard.edu						ACKERSTAFF RGA, 1993, VASCULAR DIAGNOSIS, P315; Berguer R, 2000, J VASC SURG, V31, P9, DOI 10.1016/S0741-5214(00)70063-2; BOGOUSSLAVSKY J, 1993, NEUROLOGY, V43, P1528, DOI 10.1212/WNL.43.8.1528; BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083; Brandt T, 1996, STROKE, V27, P875, DOI 10.1161/01.STR.27.5.875; Brandt T, 1999, STROKE, V30, P606, DOI 10.1161/01.STR.30.3.606; Caplan L, 2000, STROKE, V31, P2011, DOI 10.1161/01.STR.31.8.2011; Caplan L.R., 1996, POSTERIOR CIRCULATIO; CAPLAN LR, 1976, J NEUROL NEUROSUR PS, V39, P385, DOI 10.1136/jnnp.39.4.385; CAPLAN LR, 1990, NEUROLOGY, V40, P696, DOI 10.1212/WNL.40.4.696; CAPLAN LR, 1986, STROKE, V17, P648, DOI 10.1161/01.STR.17.4.648; CAPLAN LR, 1992, NEUROLOGY, V42, P1505, DOI 10.1212/WNL.42.8.1505; CAPLAN LR, 1989, NEUROLOGY, V39, P1246, DOI 10.1212/WNL.39.9.1246; Caplan LR, 2004, ANN NEUROL, V56, P389, DOI 10.1002/ana.20204; CAPLAN LR, 1980, NEUROLOGY, V30, P72, DOI 10.1212/WNL.30.1.72; CAPLAN LR, 1988, NEUROLOGY, V38, P868, DOI 10.1212/WNL.38.6.868; CAPLAN LR, 2005, THROMBOLYTIC THERAPY, P203; CHIMOWITZ MI, 1995, NEUROLOGY, V45, P1488, DOI 10.1212/WNL.45.8.1488; Chimowitz MI, 2005, NEW ENGL J MED, V352, P1305, DOI 10.1056/NEJMoa043033; FELDMANN E, 1990, NEUROLOGY, V40, P1541, DOI 10.1212/wnl.40.10.1540; Ferro JM, 1998, STROKE, V29, P1106, DOI 10.1161/01.STR.29.6.1106; FISHER CM, 1971, NEUROLOGY, V21, P900, DOI 10.1212/WNL.21.9.900; FISHER CM, 1969, ACTA NEUROPATHOL, V12, P1, DOI 10.1007/BF00685305; Glass TA, 2002, ARCH NEUROL-CHICAGO, V59, P369, DOI 10.1001/archneur.59.3.369; Gobin YP, 2004, STROKE, V35, P2848, DOI 10.1161/01.STR.0000147718.12954.60; GORELICK PB, 1985, STROKE, V16, P785, DOI 10.1161/01.STR.16.5.785; Grond M, 1998, ARCH NEUROL-CHICAGO, V55, P466, DOI 10.1001/archneur.55.4.466; GROTTA JC, 1992, NEUROLOGY, V42, P111, DOI 10.1212/WNL.42.1.111; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Gupta R, 2003, NEUROLOGY, V61, P1729, DOI 10.1212/01.WNL.0000103900.65021.5B; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; HUTCHINSON EC, 1957, LANCET, V1, P2; Kidwell CS, 1999, STROKE, V30, P1174, DOI 10.1161/01.STR.30.6.1174; KUBIK CS, 1946, BRAIN, V69, P73, DOI 10.1093/brain/69.2.73; Lee H, 2003, J NEUROL NEUROSUR PS, V74, P1644, DOI 10.1136/jnnp.74.12.1644; Linfante I, 2001, ARCH NEUROL-CHICAGO, V58, P621, DOI 10.1001/archneur.58.4.621; Linzer M, 1997, ANN INTERN MED, V126, P989, DOI 10.7326/0003-4819-126-12-199706150-00012; Lutsep HL, 2003, STROKE, V34, P253; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marx JJ, 2002, J NEUROL NEUROSUR PS, V72, P572, DOI 10.1136/jnnp.72.5.572; MEHLER MF, 1989, NEUROLOGY, V39, P9, DOI 10.1212/WNL.39.1.9; MILLIKAN CH, 1955, P STAFF M MAYO CLIN, V30, P61; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; MOKRI B, 1988, NEUROLOGY, V38, P880, DOI 10.1212/WNL.38.6.880; Montavont A, 2004, NEUROLOGY, V62, P1854, DOI 10.1212/01.WNL.0000125330.06520.0D; Moulin T, 2000, CEREBROVASC DIS, V10, P261, DOI 10.1159/000016068; Oppenheim C, 2000, AM J NEURORADIOL, V21, P1434; PESSIN MS, 1987, ANN NEUROL, V21, P290, DOI 10.1002/ana.410210311; SAVAGE DD, 1985, STROKE, V16, P626, DOI 10.1161/01.STR.16.4.626; Schievink WI, 2001, NEW ENGL J MED, V344, P898, DOI 10.1056/NEJM200103223441206; Shin HK, 1999, ARCH NEUROL-CHICAGO, V56, P1353, DOI 10.1001/archneur.56.11.1353; SIVENIUS J, 1991, ANN NEUROL, V29, P596, DOI 10.1002/ana.410290605; Vemmos KN, 2000, CEREBROVASC DIS, V10, P133, DOI 10.1159/000016042; Voetsch B, 2004, ARCH NEUROL-CHICAGO, V61, P496, DOI 10.1001/archneur.61.4.496; von Kummer R, 1991, THROMBOLYTIC THERAPY, P161; WENTZ KU, 1994, RADIOLOGY, V190, P105, DOI 10.1148/radiology.190.1.8259384; Wityk RJ, 1998, ARCH NEUROL-CHICAGO, V55, P470, DOI 10.1001/archneur.55.4.470; Yamamoto Y, 1999, ARCH NEUROL-CHICAGO, V56, P824, DOI 10.1001/archneur.56.7.824	58	268	341	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					2618	2626		10.1056/NEJMra041544	http://dx.doi.org/10.1056/NEJMra041544			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972868				2022-12-28	WOS:000229953700009
J	Smalley, R; Ellis, MA; Paul, J; Van Arsdale, RB				Smalley, R; Ellis, MA; Paul, J; Van Arsdale, RB			Space geodetic evidence for rapid strain rates in the New Madrid seismic zone of central USA	NATURE			English	Article							EARTHQUAKES; DEFORMATION; KINEMATICS; HAZARD	In the winter of 1811-1812, near the town of New Madrid in the central United States and more than 2,000 km from the nearest plate boundary, three earthquakes within three months shook the entire eastern half of the country and liquefied the ground over distances far greater than any historic earthquake in North America(1,2). The origin and modern significance of these earthquakes, however, is highly contentious(3). Geological evidence demonstrates that liquefaction due to strong ground shaking, similar in scale to that generated by the New Madrid earthquakes, has occurred at least three and possibly four times in the past 2,000 years (refs 4-6), consistent with recurrence statistics derived from regional seismicity(7). Here we show direct evidence for rapid strain rates in the area determined from a continuously operated global positioning system (GPS) network. Rates of strain are of the order of 10(-7) per year, comparable in magnitude to those across active plate boundaries, and are consistent with known active faults within the region. These results have significant implications for the definition of seismic hazard and for processes that drive intraplate seismicity.	Univ Memphis, Ctr Earthquake Res & Informat, Memphis, TN 38152 USA; Univ Memphis, Dept Earth Sci, Memphis, TN 38152 USA	University of Memphis; University of Memphis	Ellis, MA (corresponding author), Univ Memphis, Ctr Earthquake Res & Informat, Memphis, TN 38152 USA.	mellis@memphis.edu	Ellis, Michael Alexander A/M-4505-2018; Ellis, Michael/AAP-2039-2020	Ellis, Michael Alexander A/0000-0002-6613-3565; Ellis, Michael/0000-0002-6613-3565				Battaglia M, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019723; England P, 1997, SCIENCE, V278, P647, DOI 10.1126/science.278.5338.647; FREED A, 2004, EOS FALL M S, V85; Fuller ML, 1912, US GEOL SURV B, V494, P119; Grollimund B, 2001, GEOLOGY, V29, P175, DOI 10.1130/0091-7613(2001)029<0175:DDTISI>2.0.CO;2; HUDNUT K., 2002, SEISMOTECTONICS CONV, P167; Hudnut KW, 2002, B SEISMOL SOC AM, V92, P1403, DOI 10.1785/0120000912; Johnston AC, 1996, ANNU REV EARTH PL SC, V24, P339, DOI 10.1146/annurev.earth.24.1.339; JOHNSTON AC, 1985, J GEOPHYS RES-SOLID, V90, P6737, DOI 10.1029/JB090iB08p06737; Kelson KI, 1996, J GEOPHYS RES-SOL EA, V101, P6151, DOI 10.1029/95JB01815; Kenner SJ, 2000, SCIENCE, V289, P2329, DOI 10.1126/science.289.5488.2329; Langbein J, 1997, J GEOPHYS RES-SOL EA, V102, P591, DOI 10.1029/96JB02945; McClusky S, 2000, J GEOPHYS RES-SOL EA, V105, P5695, DOI 10.1029/1999JB900351; Newman A, 1999, SCIENCE, V284, P619, DOI 10.1126/science.284.5414.619; NEWMAN AV, 1999, EOS T AM GEOPHYS UN, V80, P199; NEWMAN AV, 1999, EOS T AM GEOPHYS UN, V80, P197; NUTTLI OW, 1973, B SEISMOL SOC AM, V63, P227; Pollitz FF, 2001, B SEISMOL SOC AM, V91, P1882, DOI 10.1785/0120000277; RUSS DP, 1982, 1236H US GEOL SURV; SCHWEIG ES, 1999, EOS T AM GEOPHYS UN, V80, P197, DOI DOI 10.1029/99EO00146; SEGALL P, 2004, EOS FALL M S, V85; Stein S, 2004, SEISMOL RES LETT, V75, P173, DOI 10.1785/gssrl.75.2.173; Stein S., 2003, EOS T, V84, P184; Tuttle MP, 2002, B SEISMOL SOC AM, V92, P2080, DOI 10.1785/0120010227; TUTTLE MP, 1995, GEOLOGY, V23, P253, DOI 10.1130/0091-7613(1995)023<0253:AAPEFL>2.3.CO;2; Tuttle MP, 2001, J SEISMOL, V5, P361, DOI 10.1023/A:1011423525258; TUTTLE MP, IN PRESS SEISMOL RES; Van Arsdale RB, 1998, GEOLOGY, V26, P515; Weber J, 1998, TECTONICS, V17, P250, DOI 10.1029/97TC03550; Zoback MD, 1999, SCIENCE, V285, P664; 2000, EOS, V81, P397	31	47	47	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1088	1090		10.1038/nature03642	http://dx.doi.org/10.1038/nature03642			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973405				2022-12-28	WOS:000229970400046
J	Mehta, SR; Cannon, CP; Fox, KAA; Wallentin, L; Boden, WE; Spacek, R; Widimsky, P; McCullough, PA; Hunt, D; Braunwald, E; Yusuf, S				Mehta, SR; Cannon, CP; Fox, KAA; Wallentin, L; Boden, WE; Spacek, R; Widimsky, P; McCullough, PA; Hunt, D; Braunwald, E; Yusuf, S			Routine vs selective invasive strategies in patients with acute coronary syndromes - A collaborative meta-analysis of randomized trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ST-SEGMENT ELEVATION; WAVE MYOCARDIAL-INFARCTION; HIGH-RISK PATIENTS; PLATELET GLYCOPROTEIN IIB/IIIA; UNSTABLE ANGINA-PECTORIS; ARTERY-DISEASE; CONSERVATIVE TREATMENT; UNFRACTIONATED HEPARIN; ANTIPLATELET THERAPY; TROPONIN-T	Context Patients with unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI) can be cared for with a routine invasive strategy involving coronary angiography and revascularization or more conservatively with a selective invasive strategy in which only those with recurrent or inducible ischemia are referred for acute intervention. Objective To conduct a meta-analysis that compares benefits and risks of routine invasive vs selective invasive strategies. Data Sources Randomized controlled trials identified through search of MEDLINE and the Cochrane databases (1970 through June 2004) and hand searching of cross-references from original articles and reviews. Study Selection Trials were included that involved patients with unstable angina or NSTEMI who received a routine invasive or a selective invasive strategy. Data Extraction Major outcomes of death and myocardial infarction (MI) occurring from initial hospitalization to the end of follow-up were extracted from published results of eligible trials. Data Synthesis A total of 7 trials (N = 9212 patients) were eligible. Overall, death or MI was reduced from 663 (14.4%) of 4604 patients in the selective invasive group to 561 (12.2%) of 4608 patients in the routine invasive group (odds ratio [OR], 0.82; 95% confidence interval [Cl], 0.72-0.93; P=.001). There was a nonsignificant trend toward fewer deaths (6.0% vs 5.5%; OR, 0.92; 95% Cl, 0.77-1.09; P=.33) and a significant reduction in MI alone (9.4% vs 7.3%; OR, 0.75; 95% CI, 0.65-0.88; P<.001). Higher-risk patients with elevated cardiac biomarker levels at baseline benefited more from routine intervention, with no significant benefit observed in lower-risk patients with negative baseline marker levels. During the initial hospitalization, a routine invasive strategy was associated with a significantly higher early mortality (1.1% vs 1.8% for selective vs routine, respectively; OR, 1.60; 95% Cl, 1.14-2.25; P=.007) and the composite of death or MI (3.8% vs 5.2%; OR, 1.36; 95% CI, 1.12-1.66; P = .002). But after discharge, the routine invasive strategy was associated with fewer subsequent deaths (4.9% vs 3.8%; OR, 0.76; 95% Cl, 0.62-0.94; P = .01) and the composite of death or MI (11.0% vs 7.4%; OR, 0.64; 95% CI, 0.56-0.75; P<.001). At the end of follow-up, there was a 33% reduction in severe angina (14.0% vs 11.2%; OR, 0.77; 95% CI, 0.68-0.87; P<.001) and a 34% reduction in rehospitalization (41.3% vs 32.5%; OR, 0.66; 95% CI, 0.60-0.72; P<.001) with a routine invasive strategy. Conclusions A routine invasive strategy exceeded a selective invasive strategy in reducing MI, severe angina, and rehospitalization over a mean follow-up of 17 months. But routine intervention was associated with a higher early mortality hazard and a trend toward a mortality reduction at follow-up. Future strategies should explore ways to minimize the early hazard and enhance later benefits by focusing on higher-risk patients and optimizing timing of intervention and use of proven therapies.	McMaster Univ, Dept Med, Hamilton, ON L6K 1B8, Canada; Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; Royal Melbourne Hosp, Melbourne, Vic, Australia; William Beaumont Hosp, Royal Oak, MI 48072 USA; Charles Univ, Sch Med 3, Cardioctr, Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; Hartford Hosp, Div Cardiol, Hartford, CT 06115 USA; Hartford Hosp, Henry Low Heart Ctr, Hartford, CT 06115 USA; Univ Uppsala Hosp, Uppsala Clin Res Ctr, Uppsala, Sweden; Royal Infirm, Dept Med, Edinburgh, Midlothian, Scotland; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA	McMaster University; McMaster University; Population Health Research Institute; Royal Melbourne Hospital; Beaumont Health; Charles University Prague; University Hospital Vinohrady; Hartford Hospital; Hartford Hospital; Uppsala University; Uppsala University Hospital; Royal Infirmary of Edinburgh; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Mehta, SR (corresponding author), McMaster Univ, Dept Med, 237 Barton St E,Room 508, Hamilton, ON L6K 1B8, Canada.	smehta@mcmaster.ca	Fox, keith A A/I-3742-2013; Widimsky, Petr/P-8088-2016	Widimsky, Petr/0000-0001-5686-7752; Fox, Keith/0000-0002-0140-2752; Yusuf, Salim/0000-0003-4776-5601				Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Bhatt DL, 2004, JAMA-J AM MED ASSOC, V292, P2096, DOI 10.1001/jama.292.17.2096; Blazing MA, 2004, JAMA-J AM MED ASSOC, V292, P55, DOI 10.1001/jama.292.1.55; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; BRAUNWALD E, 1994, CIRCULATION, V89, P1545; Braunwald E, 2002, CIRCULATION, V106, P1893, DOI 10.1161/01.CIR.0000037106.76139.53; BROWN CA, 1981, AM HEART J, V102, P959, DOI 10.1016/0002-8703(81)90477-4; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; DEBONO DP, 1991, BMJ-BRIT MED J, V302, P555; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEWINTER RJ, 2004, EUR SOC CARD C AUG 2; Diderholm E, 2002, AM HEART J, V143, P760, DOI 10.1067/mhj.2002.121733; Ellis SG, 1997, CIRCULATION, V95, P2479, DOI 10.1161/01.CIR.95.11.2479; Ferguson JJ, 2004, JAMA-J AM MED ASSOC, V292, P45; Fox KAA, 2002, EUR HEART J, V23, P1177, DOI 10.1053/euhj.2001.3081; Fox KAA, 2002, LANCET, V360, P743, DOI 10.1016/S0140-6736(02)09894-X; Lagerqvist B, 2002, J AM COLL CARDIOL, V40, P1902, DOI 10.1016/S0735-1097(02)02572-X; LUCHI RJ, 1987, NEW ENGL J MED, V316, P977, DOI 10.1056/NEJM198704163161603; Madsen JK, 1997, CIRCULATION, V96, P748; MANTEL N, 1959, J NATL CANCER I, V22, P719; McCullough PA, 1998, J AM COLL CARDIOL, V32, P596, DOI 10.1016/S0735-1097(98)00284-8; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Michalis LK, 2000, EUR HEART J, V21, P1954, DOI 10.1053/euhj.2000.2397; Morrow DA, 2001, JAMA-J AM MED ASSOC, V286, P2405, DOI 10.1001/jama.286.19.2405; Neumann FJ, 2003, JAMA-J AM MED ASSOC, V290, P1593, DOI 10.1001/jama.290.12.1593; Russell RO., 1978, AM J CARDIOL, V42, P839; SCOTT SM, 1994, CIRCULATION, V90, P120; Spacek R, 2002, EUR HEART J, V23, P230, DOI 10.1053/euhj.2001.2735; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Topol E, 1998, NEW ENGL J MED, V339, P436; VANDEWERF F, 2005, BMJ             0124; Wallentin L, 1999, LANCET, V354, P708; Wallentin L, 2000, LANCET, V356, P9, DOI 10.1016/S0140-6736(00)02427-2; Yusuf S, 1998, LANCET, V352, P507, DOI 10.1016/S0140-6736(97)11162-X; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; Yusuf S, 2003, CIRCULATION, V107, P966, DOI 10.1161/01.CIR.0000051362.96946.15; Yusuf S, 2001, NEW ENGL J MED, V345, P494	39	577	612	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	2005	293	23					2908	2917		10.1001/jama.293.23.2908	http://dx.doi.org/10.1001/jama.293.23.2908			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935MD	15956636				2022-12-28	WOS:000229785500026
J	Jeffcoate, W				Jeffcoate, W			Thomas Addison: one of the three "Giants" of Guy's Hospital	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Jeffcoate, W (corresponding author), Lancet, London NW1 7BY, England.	william.jeffcoate@lancet.com						ADDISON T, 1836, ELEMENTS PRACTICE ME; Addison T., 1855, CONSTITUTIONAL LOCAL; Eliot George, 1972, MIDDLEMARCH; FIRKIN BG, 1987, DICT MED EPONYMS, P3	4	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 11	2005	365	9476					1989	1990		10.1016/S0140-6736(05)66677-9	http://dx.doi.org/10.1016/S0140-6736(05)66677-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950703				2022-12-28	WOS:000229701400007
J	Raynaud, D; Barnola, JM; Souchez, R; Lorrain, R; Petit, JR; Duval, P; Lipenkov, VY				Raynaud, D; Barnola, JM; Souchez, R; Lorrain, R; Petit, JR; Duval, P; Lipenkov, VY			Palaeoclimatology - The record for marine isotopic stage 11	NATURE			English	Editorial Material							CLIMATE		CNRS, Lab Glaciol & Geophys Environm, F-38402 St Martin Dheres, France; Univ Libre Bruxelles, Lab Glaciol, B-1050 Brussels, Belgium; Arctic & Antarctic Res Inst, St Petersburg 199397, Russia	Centre National de la Recherche Scientifique (CNRS); Universite Libre de Bruxelles; Arctic & Antarctic Research Institute	Raynaud, D (corresponding author), CNRS, Lab Glaciol & Geophys Environm, F-38402 St Martin Dheres, France.	raynaud@lgge.obs.ujf-grenoble.fr	Lipenkov, Vladimir Y/Q-8262-2016; Raynaud, Dominique/H-9626-2016; raynaud, dominique/ABG-4718-2020	Lipenkov, Vladimir Y/0000-0003-4221-5440; 				Augustin L, 2004, NATURE, V429, P623, DOI 10.1038/nature02599; Berger A, 2003, SURV GEOPHYS, V24, P117, DOI 10.1023/A:1023233702670; Berger A., 2003, GEOPHYS MONOGR SER, P17, DOI DOI 10.1029/137GM02); Cuffey KM, 2001, NATURE, V412, P523, DOI 10.1038/35087544; CUNNINGHAM J, 1990, J GLACIOL, V36, P269, DOI 10.3189/002214390793701336; Droxler A. W., 2003, EARTHS CLIMATE ORBIT; Goujon C, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003319; Pepin L, 2001, J GEOPHYS RES-ATMOS, V106, P31885, DOI 10.1029/2001JD900117; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Ramsay J.G., 1967, FOLDING FRACTURING R; Raynaud D, 2003, EARTHS CLIMATE ORBIT, P27, DOI DOI 10.1029/137GM03; Ruddiman WF, 2003, CLIMATIC CHANGE, V61, P261, DOI 10.1023/B:CLIM.0000004577.17928.fa	12	72	76	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 7	2005	436	7047					39	40		10.1038/43639b	http://dx.doi.org/10.1038/43639b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	942QJ	16001055				2022-12-28	WOS:000230296600033
J	Qin, P; Xu, HL; Laursen, TM; Vestergaard, M; Mortensen, PB				Qin, P; Xu, HL; Laursen, TM; Vestergaard, M; Mortensen, PB			Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To investigate whether age at onset of epilepsy, type of epilepsy, family history of psychosis, or family history of epilepsy affect the risk of schizophrenia or schizophrenia-like psychosis among patients with epilepsy. Design Comparison of population based data. Setting Danish longitudinal registers. Subjects The cohort comprised 2.27 million people. Main outcome measures Epilepsy, psychosis, personal birth data. Results We found an increased risk of schizophrenia (relative risk 2.48, 95% confidence interval 2.20 to 2.80) and schizophrenia-like psychosis (2.93, 2.69 to 3.20) in people with a history of epilepsy. The effect of epilepsy was the same in men and in women and increased with age. Family history of psychosis and a family history of epilepsy were significant risk factors for schizophrenia and schizophrenia-like psychosis, and the effect of epilepsy, both in cases and families, was greater among people with no family history of psychosis. In addition, the increased risk for schizophrenia or schizophrenia-like psychosis did not differ by type of epilepsy but increased with increasing number of admissions to hospital and, particularly, was significantly greater for people first admitted for epilepsy at later ages. Conclusions There is a strong association between epilepsy and schizophrenia or schizophrenia-like psychosis. The two conditions may share common genetic or environmental causes.	Aarhus Univ, Natl Ctr Register Based Res, DK-8000 Aarhus, Denmark; Cent S Univ, Sch Publ Hlth, Dept Social Med & Hlth Management, Changsha, Peoples R China; Univ Aarhus, Inst Publ Hlth, Dept Epidemiol, DK-8000 Aarhus, Denmark	Aarhus University; Central South University; Aarhus University	Qin, P (corresponding author), Aarhus Univ, Natl Ctr Register Based Res, Taasingegade 1, DK-8000 Aarhus, Denmark.	pq@ncrr.dk	Laursen, Thomas Munk/AFQ-8066-2022; Mortensen, Preben B/D-2358-2015; Vestergaard, Mogens/M-9333-2014	Mortensen, Preben B/0000-0002-5230-9865; Vestergaard, Mogens/0000-0001-8830-2174; Laursen, Thomas Munk/0000-0001-6934-1784				Adachi N, 2000, NEUROLOGY, V55, P1310, DOI 10.1212/WNL.55.9.1310; Cardno AG, 2002, AM J PSYCHIAT, V159, P539, DOI 10.1176/appi.ajp.159.4.539; Huang JA, 2003, AM J HUM GENET, V72, P949, DOI 10.1086/374568; MAIER W, 1993, ARCH GEN PSYCHIAT, V50, P871; McDonald C, 2003, PSYCHIAT CLIN N AM, V26, P41, DOI 10.1016/S0193-953X(02)00030-8; Sachdev P, 1998, AM J PSYCHIAT, V155, P325, DOI 10.1176/ajp.155.3.325; SLATER E, 1969, BRIT J PSYCHIAT, V115, P599, DOI 10.1192/bjp.115.522.599; Stafstrom CE, 2002, PROG BRAIN RES, V135, P377; Toone BK, 2000, J NEUROL NEUROSUR PS, V69, P1, DOI 10.1136/jnnp.69.1.1	9	157	159	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	2005	331	7507					23	25		10.1136/bmj.38488.462037.8F	http://dx.doi.org/10.1136/bmj.38488.462037.8F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947TD	15964859	Green Published, Bronze			2022-12-28	WOS:000230668500017
J	Dauphas, N				Dauphas, N			The U/Th production ratio and the age of the Milky Way from meteorites and Galactic halo stars	NATURE			English	Article							R-PROCESS; CHEMICAL EVOLUTION; SOLAR-SYSTEM; CS 31082-001; COSMOCHRONOLOGY; ELEMENTS; NEIGHBORHOOD; HIPPARCOS; DENSITY; GALAXY	Some heavy elements ( with atomic number A > 69) are produced by the 'rapid' (r)-process of nucleosynthesis, where lighter elements are bombarded with a massive flux of neutrons(1-8). Although this is characteristic of supernovae and neutron star mergers, uncertainties in where the r-process occurs persist because stellar models are too crude to allow precise quantification of this phenomenon. As a result, there are many uncertainties and assumptions in the models used to calculate the production ratios of actinides ( like uranium-238 and thorium-232). Current estimates of the U/Th production ratio range from similar to 0.4 to 0.7. Here I show that the U/Th abundance ratio in meteorites(9) can be used, in conjunction with observations of low-metallicity stars in the halo of the Milky Way(10-12), to determine the U/Th production ratio very precisely (0.571(-0.031)(+0.037)). This value can be used in future studies to constrain the possible nuclear mass formulae used in r- process calculations(5,6), to help determine the source of Galactic cosmic rays, and to date circumstellar grains(5). I also estimate the age of the Milky Way (14.5(-2.2)(+2.8) Gyr) in a way that is independent of the uncertainties associated with fluctuations in the microwave background(13) or models of stellar evolution(14,15).	Univ Chicago, Enrico Fermi Inst, Dept Geophys Sci, Origins Lab, Chicago, IL 60637 USA; Univ Chicago, Chicago Ctr Cosmochem, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Dauphas, N (corresponding author), Univ Chicago, Enrico Fermi Inst, Dept Geophys Sci, Origins Lab, 5734 S Ellis Ave, Chicago, IL 60637 USA.	dauphas@uchicago.edu	Dauphas, Nicolas/E-4568-2011					Argast D, 2000, ASTRON ASTROPHYS, V356, P873; BURBIDGE EM, 1957, REV MOD PHYS, V29, P547, DOI 10.1103/RevModPhys.29.547; Cayrel R, 2001, NATURE, V409, P691, DOI 10.1038/35055507; Chang RX, 1999, ASTRON ASTROPHYS, V350, P38; CHEN JH, 1993, LUNAR PLANET SCI, V24, P277; CLAYTON DD, 1988, MON NOT R ASTRON SOC, V234, P1; Cowan JJ, 2002, ASTROPHYS J, V572, P861, DOI 10.1086/340347; Dauphas N, 2003, NUCL PHYS A, V719, p287C, DOI 10.1016/S0375-9474(03)00934-5; Goriely S, 2001, ASTRON ASTROPHYS, V379, P1113, DOI 10.1051/0004-6361:20011368; Hansen BMS, 2004, ASTROPHYS J SUPPL S, V155, P551, DOI 10.1086/424832; Hill V, 2002, ASTRON ASTROPHYS, V387, P560, DOI 10.1051/0004-6361:20020434; Holmberg J, 2004, MON NOT R ASTRON SOC, V352, P440, DOI 10.1111/j.1365-2966.2004.07931.x; Holmberg J, 2000, MON NOT R ASTRON SOC, V313, P209, DOI 10.1046/j.1365-8711.2000.02905.x; Kennicutt RC, 1998, ASTROPHYS J, V498, P541, DOI 10.1086/305588; Lodders K, 2003, ASTROPHYS J, V591, P1220, DOI 10.1086/375492; Meyer BS, 2000, PHYS REP, V333, P1, DOI 10.1016/S0370-1573(00)00012-0; Nordstrom B, 2004, ASTRON ASTROPHYS, V418, P989, DOI 10.1051/0004-6361:20035959; Otsuki K, 2003, NEW ASTRON, V8, P767, DOI 10.1016/S1384-1076(03)00065-4; Pagel B.E.J., 1997, NUCLEOSYNTHESIS CHEM; Pfeiffer B, 1997, Z PHYS A-HADRON NUCL, V357, P235, DOI 10.1007/s002180050237; Rutherford E, 1929, NATURE, V123, P313, DOI 10.1038/123313b0; Schatz H, 2002, ASTROPHYS J, V579, P626, DOI 10.1086/342939; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; Tinsley B. M., 1980, Fundamentals of Cosmic Physics, V5, P287; Wakker BP, 1999, NATURE, V402, P388, DOI 10.1038/46498; Wanajo S, 2002, ASTROPHYS J, V577, P853, DOI 10.1086/342230; YOKOI K, 1983, ASTRON ASTROPHYS, V117, P65	30	33	34	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 30	2005	435	7046					1203	1205		10.1038/nature03645	http://dx.doi.org/10.1038/nature03645			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988518				2022-12-28	WOS:000230140500036
J	McGinn, CG				McGinn, CG			Close calls with club drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mt Auburn Hosp, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Mount Auburn Hospital; Harvard University; Harvard Medical School	McGinn, CG (corresponding author), Mt Auburn Hosp, Cambridge, MA 02138 USA.								0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					2671	2672		10.1056/NEJMp058107	http://dx.doi.org/10.1056/NEJMp058107			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	940HH	15987915				2022-12-28	WOS:000230133800003
J	Gratzer, W; Nathan, DG				Gratzer, W; Nathan, DG			Fred S. Rosen (1930-2005) - Immunologist, paediatrician and polymath	NATURE			English	Biographical-Item									Univ London Kings Coll, Randall Div, London SE1 1UL, England; Childrens Hosp Boston, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of London; King's College London; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Gratzer, W (corresponding author), Univ London Kings Coll, Randall Div, Guys Campus,New Hunts House, London SE1 1UL, England.	wbg@helios.rai.kcl.ac.uk; David_Nathan@dfci.harvard.edu							0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1044	1044		10.1038/4351044a	http://dx.doi.org/10.1038/4351044a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973397				2022-12-28	WOS:000229970400032
J	Kao, AY; Munandar, R; Ferrara, SL; Systrom, DM; Sheridan, RL; Cash, SS; Ryan, ET; Ronan, L; Harris, NL; Llewellyn, M				Kao, AY; Munandar, R; Ferrara, SL; Systrom, DM; Sheridan, RL; Cash, SS; Ryan, ET; Ronan, L; Harris, NL; Llewellyn, M			Respiratory distress and hemiparesis after a tsunami - Tsunami-related aspiration pneumonia with lung and brain abscesses, probably polymicrobial	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Chelsea Hlth Ctr, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Infect Dis, Trop & Geog Med Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Project HOPE, Task Force HOPE Mercy, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Zainoel Abidin Univ Hosp, Dept Med, Banda Aceh, Sumatra, Indonesia; US Naval Ship Mercy TAH19, Dept Radiol, San Diego, CA USA; Naval Med Ctr, Dept Radiol, San Diego, CA USA; Massachusetts Gen Hosp, Burn Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Trauma Serv, Boston, MA 02114 USA; Shriners Hosp Children, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; United States Department of Defense; United States Navy; Naval Medical Center San Diego; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Kao, AY (corresponding author), Massachusetts Gen Hosp, Chelsea Hlth Ctr, Dept Med, Boston, MA 02114 USA.			Systrom, David/0000-0002-9610-6330				Bernardini Gary L, 2004, Curr Neurol Neurosci Rep, V4, P448, DOI 10.1007/s11910-004-0067-8; Chadwick DR, 2002, T ROY SOC TROP MED H, V96, P72, DOI 10.1016/S0035-9203(02)90248-8; CHUN CH, 1986, MEDICINE, V65, P415, DOI 10.1097/00005792-198611000-00006; Colicc GL, 2000, CHEST, V118, P1158, DOI 10.1378/chest.118.4.1158; Colice, 2001, CHEST, V119, P319; Davis, 1999, Curr Treat Options Neurol, V1, P157, DOI 10.1007/s11940-999-0015-7; DWORZACK DL, 1989, MEDICINE, V68, P218, DOI 10.1097/00005792-198907000-00004; Einstein HE, 2001, CHEST, V120, P696, DOI 10.1378/chest.120.3.696; Ender PT, 1997, CLIN INFECT DIS, V25, P896, DOI 10.1086/515532; Idris AH, 2003, CIRCULATION, V108, P2565, DOI 10.1161/01.CIR.0000099581.70012.68; Kim BY, 2004, AM J SURG, V188, P321, DOI 10.1016/j.amjsurg.2004.06.009; LEE N, 1985, J CLIN MICROBIOL, V22, P352, DOI 10.1128/JCM.22.3.352-354.1985; NICOLOSI A, 1991, NEUROEPIDEMIOLOGY, V10, P122, DOI 10.1159/000110257; PRUEKPRASERT P, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P276; Rosenblum M L, 1986, Clin Neurosurg, V33, P603; SIMS JK, 1983, ANN EMERG MED, V12, P212, DOI 10.1016/S0196-0644(83)80597-6; Thourani VH, 2003, ANN THORAC SURG, V76, P401, DOI 10.1016/S0003-4975(03)00470-3; WAGENSTEEN OH, 1978, RISE SURG EMPIRIC CR, P187; WIJDICKS E, 2000, NEUROLOGIC CATASTROP, P183; YANG SY, 1993, SURG NEUROL, V39, P290, DOI 10.1016/0090-3019(93)90008-O	20	17	17	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					2628	2636		10.1056/NEJMcpc059015	http://dx.doi.org/10.1056/NEJMcpc059015			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972870				2022-12-28	WOS:000229953700012
J	Bastien, GJ; Schepens, B; Willems, PA; Heglund, NC				Bastien, GJ; Schepens, B; Willems, PA; Heglund, NC			Energetics of load carrying in Nepalese porters	SCIENCE			English	Article							HUMAN WALKING; COST		Catholic Univ Louvain, Fac Med, Unite Physiol & Biomecan Locomot, B-3000 Louvain, Belgium	Universite Catholique Louvain	Heglund, NC (corresponding author), Catholic Univ Louvain, Fac Med, Unite Physiol & Biomecan Locomot, B-3000 Louvain, Belgium.	norman.heglund@loco.ucl.ac.be						Bastien GJ, 2005, EUR J APPL PHYSIOL, V94, P76, DOI 10.1007/s00421-004-1286-z; Cavagna GA, 2002, J EXP BIOL, V205, P3413; HEGLUND NC, 1995, NATURE, V375, P52, DOI 10.1038/375052a0; MALOIY GMO, 1986, NATURE, V319, P668, DOI 10.1038/319668a0	4	68	69	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1755	1755		10.1126/science.1111513	http://dx.doi.org/10.1126/science.1111513			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961662				2022-12-28	WOS:000229926800044
J	Sangrithi, MN; Bernal, JA; Madine, M; Philpott, A; Lee, J; Dunphy, WG; Venkitaraman, AR				Sangrithi, MN; Bernal, JA; Madine, M; Philpott, A; Lee, J; Dunphy, WG; Venkitaraman, AR			Initiation of DNA replication requires the RECQL4 protein mutated in Rothmund-Thomson syndrome	CELL			English	Article							SISTER-CHROMATID COHESION; S-PHASE; WERNER-SYNDROME; FISSION YEAST; HELICASE; PHOSPHORYLATION; COMPLEX; BRCA2; CDC45; RECOMBINATION	How the replication machinery is loaded at origins of DNA replication is poorly understood. Here, we implicate in this process the Xenopus laevis homolog (xRTS) of the RECOL4 helicase mutated in Rothmund-Thomson syndrome. xRTS, which bears homology to the yeast replication factors SId2/DRC1, is essential for DNA replication in egg extracts. xRTS can be replaced in extracts by its human homolog, while RECOL4 depletion from mammalian cells induces proliferation failure, suggesting an evolutionarily conserved function. xRTS accumulates on chromatin during replication initiation, after prereplication-complex (pre-RC) proteins, Cut5, SId5, or Cdc45 but before replicative polymerases. xRTS depletion suppresses the loading of RPA, the ssDNA binding protein that marks unwound origins before polymerase recruitment. However, xRTS is unaffected by xRPA depletion. Thus, xRTS functions after pre-RC formation to promote loading of replication factors at origins, a previously unrecognized activity necessary for initiation. This role connects defective replication initiation to a chromosome-fragility disorder.	Univ Cambridge, Canc Res UK Dept Oncol, Cambridge CB2 2XZ, England; Hutchison MRC Res Ctr, MRC, Canc Cell Unit, Cambridge CB2 2XZ, England; CALTECH, Div Biol, Pasadena, CA 91125 USA	Cancer Research UK; University of Cambridge; California Institute of Technology	Venkitaraman, AR (corresponding author), Univ Cambridge, Canc Res UK Dept Oncol, Hills Rd, Cambridge CB2 2XZ, England.	arv22@cam.ac.uk	Bernal, Juan A/N-4544-2014	Bernal, Juan A/0000-0002-9933-5550; Philpott, Anna/0000-0003-3789-2463; Sangrithi, Mahesh/0000-0002-0008-4588	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070891] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM070891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COX LS, 1990, J CELL SCI, V97, P177; Davies SL, 2004, MOL CELL BIOL, V24, P1279, DOI 10.1128/MCB.24.3.1279-1291.2004; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; Hashimoto Y, 2003, EMBO J, V22, P2526, DOI 10.1093/emboj/cdg238; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hoki Y, 2003, HUM MOL GENET, V12, P2293, DOI 10.1093/hmg/ddg254; Ichikawa Koji, 2002, Nihon Yakurigaku Zasshi, V119, P219; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003; Laskey RA, 2003, EMBO REP, V4, P26, DOI 10.1038/sj.embor.embor706; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Li WH, 2004, J CELL BIOL, V165, P801, DOI 10.1083/jcb.200402095; Liao SR, 2000, GENE DEV, V14, P2570, DOI 10.1101/gad.822400; Lindor NM, 2000, AM J MED GENET, V90, P223, DOI 10.1002/(SICI)1096-8628(20000131)90:3<223::AID-AJMG7>3.0.CO;2-Z; Lomonosov M, 2003, GENE DEV, V17, P3017, DOI 10.1101/gad.279003; Mann MB, 2005, HUM MOL GENET, V14, P813, DOI 10.1093/hmg/ddi075; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; MILLS AD, 1989, J CELL SCI, V94, P471; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Noguchi E, 2002, CURR BIOL, V12, P599, DOI 10.1016/S0960-9822(02)00739-X; Pacek M, 2004, EMBO J, V23, P3667, DOI 10.1038/sj.emboj.7600369; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pichierri P, 2001, MOL BIOL CELL, V12, P2412, DOI 10.1091/mbc.12.8.2412; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Siitonen HA, 2003, HUM MOL GENET, V12, P2837, DOI 10.1093/hmg/ddg306; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Tanaka K, 2000, MOL CELL BIOL, V20, P3459, DOI 10.1128/MCB.20.10.3459-3469.2000; VENNOS EM, 1995, DERMATOL CLIN, V13, P143, DOI 10.1016/S0733-8635(18)30117-7; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Wang H, 1999, P NATL ACAD SCI USA, V96, P3824, DOI 10.1073/pnas.96.7.3824; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yin JH, 2004, HUM MOL GENET, V13, P2421, DOI 10.1093/hmg/ddh269; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	41	216	219	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	2005	121	6					887	898		10.1016/j.cell.2005.05.015	http://dx.doi.org/10.1016/j.cell.2005.05.015			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960976	Bronze			2022-12-28	WOS:000230011200011
J	Snyder, C; Anderson, G				Snyder, C; Anderson, G			Do quality improvement organizations improve the quality of hospital care for medicare beneficiaries?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COOPERATIVE CARDIOVASCULAR PROJECT; ACUTE MYOCARDIAL-INFARCTION	Context Quality improvement organizations (QIOs) are charged with improving the quality of medical care for Medicare beneficiaries. Objective To explore whether the quality of hospital care for Medicare beneficiaries improves more in hospitals that voluntarily participate with Medicare's QIOs compared with nonparticipating hospitals. Design, Setting, and Data Data from 4 QIOs charged with improving the quality of care in 5 states (Maryland, Nevada, New York, Utah, and Washington) and the District of Columbia were used. Hospitals participate with the QIOs on quality improvement on a voluntary basis. A retrospective study was conducted comparing improvement in the quality of care of patients in hospitals that actively participated with the QIOs vs hospitals that did not. The medical records of approximately 750 Medicare beneficiaries per state in each of 5 clinical areas (atrial fibrillation, acute myocardial infarction, heart failure, pneumonia, and stroke) were abstracted at baseline (1998) and follow-up (2000-2001). Main Outcome Measure Fifteen quality indicators associated with improved outcomes in the prevention or treatment of the 5 clinical areas were used as quality of care measures. These 15 indicators were specifically targeted by the QIOs for quality improvement during the study period. Results Hospitals that voluntarily participate with the QIOs are more likely to be larger than nonparticipating hospitals (P<.05). At baseline, there were statistically significant (P<.05) differences between participating and nonparticipating hospitals on 5 of 15 quality indicators, with participating hospitals performing better on 3 of 5. There was no statistically significant difference in change from baseline to follow-up between participating and nonparticipating hospitals on 14 of 15 quality indicators. The one exception was that participating hospitals improved more on the pneumonia immunization indicator than nonparticipating hospitals (P=.005). Conclusion Hospitals that participate with the QIO program are not more likely to show improvement on quality indicators than hospitals that do not participate.	Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Snyder, C (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, 624 N Broadway,6th Floor, Baltimore, MD 21205 USA.	claire.snyder@alumni.duke.edu			AHRQ HHS [T32 HS 00029, 1 R36 HS014509] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R36HS014509, T32HS000029] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1990, MED STRAT QUAL ASS; Cleves M A, 1997, Jt Comm J Qual Improv, V23, P550; DANS PE, 1985, NEW ENGL J MED, V313, P1131, DOI 10.1056/NEJM198510313131806; Devereaux PJ, 2002, CAN MED ASSOC J, V166, P1399; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; *I MED, RED HLTH INS BEN PAY; *I MED, 2002, LEAD EX; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; JENCKS SF, 1995, JOINT COMM J QUAL IM, V21, P343, DOI 10.1016/S1070-3241(16)30160-2; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; LUFT HS, 1987, HEALTH SERV RES, V22, P157; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; RUBENSTEIN LV, 1990, JAMA-J AM MED ASSOC, V264, P1974, DOI 10.1001/jama.264.15.1974; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; Silver MP, 2004, AM J MED QUAL, V19, P93, DOI 10.1177/106286060401900302; SMITS HL, 1981, NEW ENGL J MED, V305, P253, DOI 10.1056/NEJM198107303050504	19	52	52	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	2005	293	23					2900	2907		10.1001/jama.293.23.2900	http://dx.doi.org/10.1001/jama.293.23.2900			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	935MD	15956635	Bronze			2022-12-28	WOS:000229785500025
J	Boyle, P; Ariyaratne, MAY; Bartelink, H; Baselga, J; Berns, A; Brawley, OW; Burns, H; Davidov, MH; Dinshaw, KA; Dresler, C; Eggermont, AMM; Gajurel, D; Gordina, G; Gray, N; Kakizoe, T; Karki, BS; Kasler, M; Kerr, DJ; Khayat, D; Kiselev, A; Khuhaprema, T; Klocker, H; Levshin, V; Martin-Moreno, JM; McVie, JG; Mendelsohn, J; Napalkov, NP; Ngoma, TA; Park, JG; Philip, T; Potschke-Langer, M; Poudal, HN; Rajan, B; Ringborg, U; Rodger, A; Seffrin, JR; Shanta, V; Shrestha, MM; Thomas, R; Tursz, T; de Valeriola, D; Veronesi, U; Wiestler, OD; Zaridze, D; Zatonski, W; Zeng, YX				Boyle, P; Ariyaratne, MAY; Bartelink, H; Baselga, J; Berns, A; Brawley, OW; Burns, H; Davidov, MH; Dinshaw, KA; Dresler, C; Eggermont, AMM; Gajurel, D; Gordina, G; Gray, N; Kakizoe, T; Karki, BS; Kasler, M; Kerr, DJ; Khayat, D; Kiselev, A; Khuhaprema, T; Klocker, H; Levshin, V; Martin-Moreno, JM; McVie, JG; Mendelsohn, J; Napalkov, NP; Ngoma, TA; Park, JG; Philip, T; Potschke-Langer, M; Poudal, HN; Rajan, B; Ringborg, U; Rodger, A; Seffrin, JR; Shanta, V; Shrestha, MM; Thomas, R; Tursz, T; de Valeriola, D; Veronesi, U; Wiestler, OD; Zaridze, D; Zatonski, W; Zeng, YX			Curbing tobacco's toll starts with the professionals: World No Tobacco Day	LANCET			English	Editorial Material									Int Agcy Res Canc, F-69372 Lyon, France; Govt Canc Inst, Canc Control Programme, Maharagamma, Sri Lanka; Federat European Canc Soc, Brussels, Belgium; Hosp Gen Univ Vall dHebron, Barcelona, Spain; Netherlands Canc Inst, Amsterdam, Netherlands; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Greater Glasgow Hlth Board, Glasgow, Lanark, Scotland; Russian Canc Res Ctr, Moscow, Russia; Tata Mem Hosp, Bombay, Maharashtra, India; European Org Res Treatment Canc, Brussels, Belgium; Natl Canc Ctr, Tokyo 104, Japan; BP Koirala Mem Canc Hosp, Bharatpur, Chitwan, Nepal; Natl Inst Oncol, Budapest, Hungary; Natl Translat Canc Res Network, Oxford, England; Natl Canc Inst, Paris, France; Natl Canc Inst, Bangkok, Thailand; Innsbruck Med Univ, Innsbruck, Austria; Russian NN Blokhin Canc Res Ctr, Inst Carcinogenesis, Moscow, Russia; Univ Valencia, Fac Med, Valencia, Spain; European Inst Oncol, Milan, Italy; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; NN Petrov Oncol Res Inst, St Petersburg, Russia; Ocean Rd Canc Inst, Dar Es Salaam, Tanzania; Natl Canc Ctr, Seoul, South Korea; Ctr Leon Berard, F-69373 Lyon, France; Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany; Reg Canc Ctr, Trivandrum 695011, Kerala, India; Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; Beatson Oncol Ctr, Glasgow, Lanark, Scotland; Amer Canc Soc, Geneva, Switzerland; Int Union Canc, Geneva, Switzerland; Madras Metropolitan Tumour Registry, Inst Canc, Madras, Tamil Nadu, India; Peter MacCallum Canc Inst, Melbourne, Vic, Australia; Inst Gustave Roussy, Villejuif, France; Org European Canc Inst, Villejuif, France; Inst Jules Bordet, B-1000 Brussels, Belgium; Maria Sklodowska Curie Inst Oncol, Warsaw, Poland; Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China	World Health Organization; International Agency for Research on Cancer (IARC); Hospital Universitari Vall d'Hebron; Netherlands Cancer Institute; Emory University; Tata Memorial Centre (TMC); Tata Memorial Hospital; European Organisation for Research & Treatment of Cancer; National Cancer Center - Japan; National Institute of Oncology Hungary; University of Oxford; Institut National du Cancer (INCA) France; National Cancer Institute - Thailand; Medical University of Innsbruck; N.N. Blokhin Russian Cancer Research Center; University of Valencia; IRCCS European Institute of Oncology (IEO); University of Texas System; UTMD Anderson Cancer Center; N.N. Petrov Research Institute of Oncology; National Cancer Center - Korea (NCC); UNICANCER; Centre Leon Berard; Helmholtz Association; German Cancer Research Center (DKFZ); Karolinska Institutet; Beatson Oncology Centre; Peter Maccallum Cancer Center; UNICANCER; Gustave Roussy; Institut Jules Bordet; Maria Sklodowska-Curie National Research Institute of Oncology; Sun Yat Sen University	Boyle, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	BOYLE@IARC.FR	Boyle, Peter/A-4380-2014; Park, Jae-Gahb/J-5494-2012; Klocker, Helmut/AAI-7130-2020; Ngoma, Twalib/L-7874-2019; Martin-Moreno, Jose M./S-7733-2016	Boyle, Peter/0000-0001-6251-0610; Martin-Moreno, Jose M./0000-0002-8648-5541				Doll R, 2004, BMJ-BRIT MED J, V328, P1507; Howell F, 2005, TOB CONTROL, V14, P73, DOI 10.1136/tc.2005.011304; IARC, 2004, IARC MON EV CARC RIS, V83; Jha P., 1999, CURBING EPIDEMIC GOV; *NEW YORK CIT DEP, 2004, NEW YORK CIT SMOK RA; *WHO, TOB FREE IN WHY IS T	6	1	1	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 11	2005	365	9476					1990	1992		10.1016/S0140-6736(05)66590-7	http://dx.doi.org/10.1016/S0140-6736(05)66590-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950704				2022-12-28	WOS:000229701400008
J	Harrison, CN; Campbell, PJ; Buck, G; Wheatley, K; East, CL; Bareford, D; Wilkins, BS; van der Walt, JD; Reilly, JT; Grigg, AP; Revell, P; Woodcock, BE; Green, AR; Pearson, TC; Conneally, E; Crawley, C; Cross, NCP; Hall, G; Hunt, B; Lucas, G; Ludlam, C; McMullin, MF; Oscier, D; Radia, D; Reilly, JT; Robinson, G; Culligan, DJ; Tighe, J; Watson, HG; Warren, AJ; Awaad, MO; Obeid, D; Cuthbert, RJG; Kyle, A; Chan-Lam, D; Paul, B; Cuthbert, RJG; McMullin, MF; Morris, TCM; Johnson, RJ; Fegan, C; Milligan, DW; Galloway, MJ; Williamson, PJ; Newton, LJ; Williams, AT; Abboudi, Z; Ryan, K; Lush, R; Blundell, E; Dalton, RG; Wright, JG; Wood, M; Beard, J; Clough, JV; Rhodes, E; Boyd, HK; Ozanne, CC; Mitchell, DC; Mayne, S; Chapple, MR; Dang, RKB; Stark, A; Toolis, F; Jones, L; Wallis, JP; Abdul-Cader, AHM; Narayanan, M; McQuaker, G; Lush, R; Ropner, J; Hamilton, MS; Jobanputra, SM; Tucker, J; Blesing, NE; Gray, AG; Green, ES; McEvoy, MW; Gaminara, EJ; Harrison, JFM; Willoughby, SJB; Jan-Mohamed, R; Kaczmarski, R; Hoggarth, CE; Rege, K; Carter, C; Patil, K; Patmore, RD; Shields, ML; Ali, S; Ellis, DL; Ademokun, JA; Chalmers, IHM; Hudson, JG; Wood, AC; Jeha, MT; Sadullah, S; Leahy, M; Pocock, CFE; Lewis, ML; Shirley, JA; Arya, R; Auger, M; Smith, GM; Hutchinson, RM; Pasi, J; Chapman, CS; Hunter, AE; Mitchell, VE; Snowden, JA; Wood, JK; Adelman, MA; Tew, C; Jacob, A; Pollard, CM; Miller, EJ; Murphy, JA; Soutar, R; Watson, W; Habboush, HW; Robinson, GTM; Donohue, SM; Deane, AM; Turner, GE; Wimperis, JZ; Attock, B; Aston, DL; Milne, AE; Nokes, TJC; Kumaran, T; Chasty, RC; Allard, S; Reid, CDL; Brownell, A; Lewis, D; Littlewood, TJ; Gillett, DS; Wright, D; Bell, AJ; Jack, F; Oxley, V; Hill, PR; De Lord, CFM; Lakhani, AK; Vadher, B; Murray, JA; Mahendra, P; Keidan, J; Coates, P; Summerfield, GP; Voke, JM; Evan-Wong, A; Forsyth, P; Murray, W; Barker, HF; Taylor, PC; McKay, P; BritoBabapulle, FB; Grech, H; Hamblin, TJ; Oscier, DG; Collin, R; Stewart, R; Wodzinski, M; Creagh, MD; Kruger, AR; Noble, R; Lee, R; Pocock, MA; Rudin, CE; Potter, MN; Mehta, AB; Jackson, HA; Moffat, EH; Reilly, JT; Winfield, DA; Horn, EH; Johnson, PRE; Ludlam, CA; Gorst, DW; Clark, RE; Pettitt, AR; Chu, P; Cavenagh, JD; Douglas, IDC; Robbins, G; Knechtli, CJC; Harrison, P; Neilson, J; Houghton, JB; Cullis, JO; Parry, HF; Handa, SI; Hasan, Y; Stableforth, PJ; Ezekwesili, RA; Jalihal, S; Al-Ismail, S; Lewis, MS; Hendrick, AM; Duncombe, A; Manson, LM; Morrison, AE; Woodcock, BE; Behrens, J; Mercieca, J; Cook, MK; Bain, BJ; Shlebak, AA; Bevan, PC; Janes, SL; Stross, P; Messinezy, M; Pearson, TC; Phaure, TAJ; Jowitt, S; Leggat, HM; Sheerin, SM; Watson, A; Bolam, S; Davies, SV; Booth, F; Rymes, N; Smith, SR; Turner, DL; El-Agnaf, M; Olujohungbe, A; Mir, N; Tillyer, ML; Robinson, GTM; Burnett, AK; Poynton, C; Clarke, P; McCallum, CJ; Rogers, SY; Neilly, I; Hughes, RG; Sekhar, M; Ganly, P; Johnson, PRE; Mackie, MJ; Parker, AC; Roddie, PH; Bienz, N; Mackie, PH; DeSilva, C; Parker, NE; Saleem, AKN; Rist, CL; Roques, AWW; Duguid, J; Aitchison, R; Kelly, S; Pattinson, JK; Gilleece, M; Korn, HET; Parry, DH; Seale, JRC; Cooney, JP; Cordingley, F; Leahy, MF; Januszewicz, H; Prince, M; Young, R; Grigg, A; Murray, M				Harrison, CN; Campbell, PJ; Buck, G; Wheatley, K; East, CL; Bareford, D; Wilkins, BS; van der Walt, JD; Reilly, JT; Grigg, AP; Revell, P; Woodcock, BE; Green, AR; Pearson, TC; Conneally, E; Crawley, C; Cross, NCP; Hall, G; Hunt, B; Lucas, G; Ludlam, C; McMullin, MF; Oscier, D; Radia, D; Reilly, JT; Robinson, G; Culligan, DJ; Tighe, J; Watson, HG; Warren, AJ; Awaad, MO; Obeid, D; Cuthbert, RJG; Kyle, A; Chan-Lam, D; Paul, B; Cuthbert, RJG; McMullin, MF; Morris, TCM; Johnson, RJ; Fegan, C; Milligan, DW; Galloway, MJ; Williamson, PJ; Newton, LJ; Williams, AT; Abboudi, Z; Ryan, K; Lush, R; Blundell, E; Dalton, RG; Wright, JG; Wood, M; Beard, J; Clough, JV; Rhodes, E; Boyd, HK; Ozanne, CC; Mitchell, DC; Mayne, S; Chapple, MR; Dang, RKB; Stark, A; Toolis, F; Jones, L; Wallis, JP; Abdul-Cader, AHM; Narayanan, M; McQuaker, G; Lush, R; Ropner, J; Hamilton, MS; Jobanputra, SM; Tucker, J; Blesing, NE; Gray, AG; Green, ES; McEvoy, MW; Gaminara, EJ; Harrison, JFM; Willoughby, SJB; Jan-Mohamed, R; Kaczmarski, R; Hoggarth, CE; Rege, K; Carter, C; Patil, K; Patmore, RD; Shields, ML; Ali, S; Ellis, DL; Ademokun, JA; Chalmers, IHM; Hudson, JG; Wood, AC; Jeha, MT; Sadullah, S; Leahy, M; Pocock, CFE; Lewis, ML; Shirley, JA; Arya, R; Auger, M; Smith, GM; Hutchinson, RM; Pasi, J; Chapman, CS; Hunter, AE; Mitchell, VE; Snowden, JA; Wood, JK; Adelman, MA; Tew, C; Jacob, A; Pollard, CM; Miller, EJ; Murphy, JA; Soutar, R; Watson, W; Habboush, HW; Robinson, GTM; Donohue, SM; Deane, AM; Turner, GE; Wimperis, JZ; Attock, B; Aston, DL; Milne, AE; Nokes, TJC; Kumaran, T; Chasty, RC; Allard, S; Reid, CDL; Brownell, A; Lewis, D; Littlewood, TJ; Gillett, DS; Wright, D; Bell, AJ; Jack, F; Oxley, V; Hill, PR; De Lord, CFM; Lakhani, AK; Vadher, B; Murray, JA; Mahendra, P; Keidan, J; Coates, P; Summerfield, GP; Voke, JM; Evan-Wong, A; Forsyth, P; Murray, W; Barker, HF; Taylor, PC; McKay, P; BritoBabapulle, FB; Grech, H; Hamblin, TJ; Oscier, DG; Collin, R; Stewart, R; Wodzinski, M; Creagh, MD; Kruger, AR; Noble, R; Lee, R; Pocock, MA; Rudin, CE; Potter, MN; Mehta, AB; Jackson, HA; Moffat, EH; Reilly, JT; Winfield, DA; Horn, EH; Johnson, PRE; Ludlam, CA; Gorst, DW; Clark, RE; Pettitt, AR; Chu, P; Cavenagh, JD; Douglas, IDC; Robbins, G; Knechtli, CJC; Harrison, P; Neilson, J; Houghton, JB; Cullis, JO; Parry, HF; Handa, SI; Hasan, Y; Stableforth, PJ; Ezekwesili, RA; Jalihal, S; Al-Ismail, S; Lewis, MS; Hendrick, AM; Duncombe, A; Manson, LM; Morrison, AE; Woodcock, BE; Behrens, J; Mercieca, J; Cook, MK; Bain, BJ; Shlebak, AA; Bevan, PC; Janes, SL; Stross, P; Messinezy, M; Pearson, TC; Phaure, TAJ; Jowitt, S; Leggat, HM; Sheerin, SM; Watson, A; Bolam, S; Davies, SV; Booth, F; Rymes, N; Smith, SR; Turner, DL; El-Agnaf, M; Olujohungbe, A; Mir, N; Tillyer, ML; Robinson, GTM; Burnett, AK; Poynton, C; Clarke, P; McCallum, CJ; Rogers, SY; Neilly, I; Hughes, RG; Sekhar, M; Ganly, P; Johnson, PRE; Mackie, MJ; Parker, AC; Roddie, PH; Bienz, N; Mackie, PH; DeSilva, C; Parker, NE; Saleem, AKN; Rist, CL; Roques, AWW; Duguid, J; Aitchison, R; Kelly, S; Pattinson, JK; Gilleece, M; Korn, HET; Parry, DH; Seale, JRC; Cooney, JP; Cordingley, F; Leahy, MF; Januszewicz, H; Prince, M; Young, R; Grigg, A; Murray, M		United Kingdom Med Res Council Prim	Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYCYTHEMIA-VERA; DIAGNOSTIC-CRITERIA; THROMBOTIC COMPLICATIONS; INHIBITION; MYELOFIBROSIS; LEUKEMIA; TRIAL; DRUG	Background: We conducted a randomized comparison of hydroxyurea with anagrelide in the treatment of essential thrombocythemia. Methods: A total of 809 patients with essential thrombocythemia who were at high risk for vascular events received low-dose aspirin plus either anagrelide or hydroxyurea. The composite primary end point was the actuarial risk of arterial thrombosis (myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, or peripheral arterial thrombosis), venous thrombosis (deep-vein thrombosis, splanchnic-vein thrombosis, or pulmonary embolism), serious hemorrhage, or death from thrombotic or hemorrhagic causes. Results: After a median follow-up of 39 months, patients in the anagrelide group were significantly more likely than those in the hydroxyurea group to have reached the primary end point (odds ratio, 1.57; 95 percent confidence interval, 1.04 to 2.37; P=0.03). As compared with hydroxyurea plus aspirin, anagrelide plus aspirin was associated with increased rates of arterial thrombosis (P=0.004), serious hemorrhage (P=0.008), and transformation to myelofibrosis (P=0.01) but with a decreased rate of venous thromboembolism (P=0.006). Patients receiving anagrelide were more likely to withdraw from their assigned treatment (P<0.001). Equivalent long-term control of the platelet count was achieved in both groups. Conclusions: Hydroxyurea plus low-dose aspirin is superior to anagrelide plus low-dose aspirin for patients with essential thrombocythemia at high risk for vascular events.	Univ Cambridge, Dept Haematol, Cambridge, England; Addenbrookes Natl Hlth Serv Trust, Cambridge, England; St Thomas Hosp, Dept Haematol, London SE1 7EH, England; St Thomas Hosp, Dept Histopathol, London SE1 7EH, England; Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Univ Birmingham, Birmingham Clin Trials Unit, Birmingham, W Midlands, England; City Hosp Natl Hlth Serv Trust, Dept Haematol, Birmingham, W Midlands, England; Royal Victoria Infirm, Dept Histopathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Sheffield, Dept Haematol, Sheffield, S Yorkshire, England; Staffordshire Gen Hosp, Dept Haematol, Stafford, England; Southport & Formby Dist Gen Hosp, Dept Haematol, Southport, Qld, Australia; Royal Melbourne Hosp, Dept Haematol, Melbourne, Vic, Australia	University of Cambridge; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Radcliffe Infirmary; University of Oxford; University of Birmingham; Newcastle University - UK; University of Sheffield; Royal Melbourne Hospital	Green, AR (corresponding author), Cambridge Inst Med Res, Dept Haematol, Hills Rd, Cambridge CB2 2XY, England.	arg1000@cam.ac.uk	Cross, Nicholas/B-4817-2009; Mehta, Atul/GPC-7364-2022; McMullin, Mary Frances/AAG-6078-2021; Deane, Adam/AAF-7370-2020; McMullin, Mary F/AAF-6472-2020	Cross, Nicholas/0000-0001-5481-2555; McMullin, Mary Frances/0000-0002-0773-0204; Deane, Adam/0000-0002-7620-5577; van der Walt, Jon/0000-0002-2667-7752; Buck, Georgina/0000-0001-5909-4265; Green, Anthony/0000-0002-9795-0218; SNOWDEN, JOHN/0000-0001-6819-3476	Wellcome Trust [088340] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDES WA, 1984, THROMB HAEMOSTASIS, V52, P325; Barbui T, 2003, SEMIN HEMATOL, V40, P22, DOI 10.1053/shem.2003.50030; Barosi G, 1999, BRIT J HAEMATOL, V104, P730, DOI 10.1046/j.1365-2141.1999.01262.x; Bellucci S, 1999, BRIT J HAEMATOL, V104, P886, DOI 10.1046/j.1365-2141.1999.01234.x; Besses C, 1999, LEUKEMIA, V13, P150, DOI 10.1038/sj.leu.2401270; Bouchard BA, 2001, CURR OPIN HEMATOL, V8, P263, DOI 10.1097/00062752-200109000-00001; Brun M, 2003, PHARMACOGENOMICS J, V3, P215, DOI 10.1038/sj.tpj.6500176; BRUNNING RD, 2001, WHO CLASSIFICATION T, V3, P75; Cacciola RR, 2004, BRIT J HAEMATOL, V126, P885, DOI 10.1111/j.1365-2141.2004.05139.x; Cannon CP, 2000, CIRCULATION, V102, P149, DOI 10.1161/01.CIR.102.2.149; CORTELAZZO S, 1995, NEW ENGL J MED, V332, P1132, DOI 10.1056/NEJM199504273321704; CORTELAZZO S, 1990, J CLIN ONCOL, V8, P556, DOI 10.1200/JCO.1990.8.3.556; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1, P6; Ellenberg SS., 2002, DATA MONITORING COMM; Falanga A, 2000, BLOOD, V96, P4261; Finazzi G, 2000, BRIT J HAEMATOL, V110, P577, DOI 10.1046/j.1365-2141.2000.02188.x; FLEMING JS, 1979, THROMB RES, V15, P373, DOI 10.1016/0049-3848(79)90145-2; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; Harrison CN, 2003, HEMATOL ONCOL CLIN N, V17, P1175, DOI 10.1016/S0889-8588(03)00082-0; Jantunen R, 2001, ANN HEMATOL, V80, P74, DOI 10.1007/s002770000244; Landolfi R, 2004, NEW ENGL J MED, V350, P114, DOI 10.1056/NEJMoa035572; LOFVENBERG E, 1990, EUR J HAEMATOL, V44, P33; MAZUR EM, 1992, BLOOD, V79, P1931, DOI 10.1182/blood.V79.8.1931.bloodjournal7981931; Murphy S, 1997, SEMIN HEMATOL, V34, P29; Nahavandi M, 2002, BRIT J HAEMATOL, V119, P855, DOI 10.1046/j.1365-2141.2002.03919.x; Pearson TC, 2001, SEMIN HEMATOL, V38, P21, DOI 10.1053/shem.2001.23043; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SILVERSTEIN MN, 1988, NEW ENGL J MED, V318, P1292, DOI 10.1056/NEJM198805193182002; Solberg LA, 1997, BRIT J HAEMATOL, V99, P174, DOI 10.1046/j.1365-2141.1997.3503164.x; Spivak Jerry L, 2003, Hematology Am Soc Hematol Educ Program, P200; Sterkers Y, 1998, BLOOD, V91, P616, DOI 10.1182/blood.V91.2.616.616_616_622; TANG SS, 1980, J LAB CLIN MED, V95, P241; Tefferi A, 2001, BLOOD REV, V15, P121, DOI 10.1054/blre.2001.0158; Thiele J, 2000, BRIT J HAEMATOL, V108, P64, DOI 10.1046/j.1365-2141.2000.01819.x; Tomer A, 2002, BLOOD, V99, P1602, DOI 10.1182/blood.V99.5.1602; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124; Wilkins, 2001, BONE MARROW PATHOLOG	37	624	653	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2005	353	1					33	45		10.1056/NEJMoa043800	http://dx.doi.org/10.1056/NEJMoa043800			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942FC	16000354				2022-12-28	WOS:000230267300006
J	Chou, R; Huffman, LH; Fu, RW; Smits, AK; Korthuis, PT				Chou, R; Huffman, LH; Fu, RW; Smits, AK; Korthuis, PT			Screening for HIV: A review of the evidence for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; MYCOBACTERIUM-AVIUM COMPLEX; PNEUMOCYSTIS-CARINII-PNEUMONIA; QUALITY-OF-LIFE; SEXUALLY-TRANSMITTED-DISEASES; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; RANDOMIZED CLINICAL-TRIAL; CORONARY-HEART-DISEASE; 6-YEAR FOLLOW-UP	Background: HIV infection affects 850 000 to 950 000 persons in the United States. The management and outcomes of HIV infection have changed substantially since the U.S. Preventive Services Task Force issued recommendations in 1996. Purpose: To synthesize the evidence on risks and benefits of screening for HIV infection. Data Sources: MEDLINE, the Cochrane Library, reference lists, and experts. Study Selection: Studies of screening, risk factor assessment, accuracy of testing, follow-up testing, and efficacy of interventions. Data Extraction: Data on settings, patients, interventions, and outcomes were abstracted for included studies; quality was graded according to criteria developed by the Task Force. Data Synthesis: No trials directly link screening for HIV with clinical outcomes. Many HIV-infected persons in the United States currently receive diagnosis at advanced stages of disease, and almost all will progress to AIDS if untreated. Screening based on risk factors could identify persons at substantially higher risk but would miss a substantial proportion of those infected. Screening tests for HIV are extremely (> 99%) accurate. Acceptance rates for screening and use of recommended interventions vary widely. Highly active antiretroviral therapy (HAART) substantially reduces the risk for clinical progression or death in patients with immunologically advanced disease. Along with other adverse events, HAART is associated with an increased risk for cardiovascular complications, although absolute rates are low after 3 to 4 years. Limitations: Data are insufficient to estimate the effects of screening and interventions on transmission rates or in patients with less immunologically advanced disease. Long-term data on adverse events associated with HAART are not yet available. Conclusions: Benefits of HIV screening appear to outweigh harms. The yield from screening higher-prevalence populations would be substantially higher than that from screening the general population.	Oregon Hlth & Sci Univ, Portland, OR 97239 USA; Oregon Evidence Based Practice Ctr, Portland, OR 97239 USA	Oregon Health & Science University	Chou, R (corresponding author), Oregon Hlth & Sci Univ, Mail Code BICC,3181 SW Sam Jackson Rd, Portland, OR 97239 USA.	chour@ohsu.edu		Korthuis, Philip/0000-0001-5556-3597	PHS HHS [290-02-0024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABMA JC, 2001, VITAL HLTH STAT 23, V0023; ABMA JC, 1997, VITAL HLTH STAT; Ahdieh-Grant L, 2003, AM J EPIDEMIOL, V157, P738, DOI 10.1093/aje/kwg036; ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; Alpert PL, 1996, ANN EMERG MED, V28, P159, DOI 10.1016/S0196-0644(96)70056-2; Anastos K, 2002, ARCH INTERN MED, V162, P1973, DOI 10.1001/archinte.162.17.1973; Anderson JE, 2000, AM J PUBLIC HEALTH, V90, P1089, DOI 10.2105/AJPH.90.7.1089; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; [Anonymous], [No title captured], DOI DOI 10.1023/A:1022359307814; Antoni MH, 2000, J CONSULT CLIN PSYCH, V68, P31, DOI 10.1037/0022-006X.68.1.31; Asch SM, 1997, AM J RESP CRIT CARE, V155, P378, DOI 10.1164/ajrccm.155.1.9001340; Barbaro G, 2003, CLIN THER, V25, P2405, DOI 10.1016/S0149-2918(03)80283-7; Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006; Belzer M, 2001, J ADOLESCENT HEALTH, V29, P93, DOI 10.1016/S1054-139X(01)00282-8; Benson CA, 2000, J INFECT DIS, V181, P1289, DOI 10.1086/315380; Beral V, 2004, AIDS, V18, P51, DOI [10.1097/00002030-200401020-00006, 10.1097/01.aids.0000096908.73209.5d]; Bindman AB, 1998, JAMA-J AM MED ASSOC, V280, P1416, DOI 10.1001/jama.280.16.1416; Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; Braitstein P, 2003, AIDS, V17, P2071, DOI 10.1097/00002030-200309260-00008; Branson BM, 1998, JAMA-J AM MED ASSOC, V280, P1699, DOI 10.1001/jama.280.19.1699; Breiman RF, 2000, ARCH INTERN MED, V160, P2633, DOI 10.1001/archinte.160.17.2633; Brosgart CL, 1998, AIDS, V12, P269, DOI 10.1097/00002030-199803000-00004; Bucciardini R, 2000, AIDS, V14, P2567, DOI 10.1097/00002030-200011100-00020; Bucher HC, 1999, AIDS, V13, P501, DOI 10.1097/00002030-199903110-00009; Bucher HC, 1997, J ACQ IMMUN DEF SYND, V15, P104, DOI 10.1097/00042560-199706010-00002; Bulterys M, 2004, JAMA-J AM MED ASSOC, V292, P219, DOI 10.1001/jama.292.2.219; CALSYN DA, 1992, AM J PUBLIC HEALTH, V82, P573, DOI 10.2105/AJPH.82.4.573; Castrucci Brian C, 2002, J Public Health Manag Pract, V8, P30; Celentano DD, 2001, DRUG ALCOHOL DEPEN, V61, P315, DOI 10.1016/S0376-8716(00)00154-X; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P891; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P538; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P380; Chamot E, 1999, AIDS, V13, P971, DOI 10.1097/00002030-199905280-00014; Chen RY, 2003, CLIN INFECT DIS, V37, P714, DOI 10.1086/377271; Chen Z, 1998, SEX TRANSM DIS, V25, P539, DOI 10.1097/00007435-199811000-00008; Chene G, 2003, LANCET, V362, P679, DOI 10.1016/S0140-6736(03)14229-8; Chesney MA, 2003, PSYCHOSOM MED, V65, P1038, DOI 10.1097/01.PSY.0000097344.78697.ED; Chou R, 2005, ANN INTERN MED, V143, P38, DOI 10.7326/0003-4819-143-1-200507050-00009; Chou R, SCREENING HUMAN IMMU; CLEARY PD, 1995, AIDS, V9, P1271, DOI 10.1097/00002030-199511000-00009; COATES TJ, 1989, AM J PUBLIC HEALTH, V79, P885, DOI 10.2105/AJPH.79.7.885; Cohen M, 2000, AM J PUBLIC HEALTH, V90, P560, DOI 10.2105/AJPH.90.4.560; Colfax GN, 2002, AIDS, V16, P1529, DOI 10.1097/00002030-200207260-00010; Coplan PM, 2003, AIDS RES HUM RETROV, V19, P449, DOI 10.1089/088922203766774487; Coplan PM, 2004, CLIN INFECT DIS, V39, P426, DOI 10.1086/422520; COTE TR, 1992, JAMA-J AM MED ASSOC, V268, P2066, DOI 10.1001/jama.268.15.2066; Crepaz N, 2004, JAMA-J AM MED ASSOC, V292, P224, DOI 10.1001/jama.292.2.224; Cruess DG, 2000, HEALTH PSYCHOL, V19, P12, DOI 10.1037/0278-6133.19.1.12; Cunningham WE, 2000, J ACQ IMMUN DEF SYND, V25, P115, DOI 10.1097/00126334-200010010-00005; Currier JS, 2003, JAIDS-J ACQ IMM DEF, V33, P506, DOI 10.1097/00126334-200308010-00012; DANGELO LJ, 1991, PEDIATRICS, V88, P982; Dannenberg AL, 1996, JAMA-J AM MED ASSOC, V276, P1743, DOI 10.1001/jama.276.21.1743; DESAI S, 1991, LANCET, V337, P183, DOI 10.1016/0140-6736(91)90855-J; DESENCLOS JC, 1993, AIDS, V7, P1371, DOI 10.1097/00002030-199310000-00011; DesJarlais DC, 1996, AM J PUBLIC HEALTH, V86, P1780, DOI 10.2105/AJPH.86.12.1780; Detels R, 2001, AIDS, V15, P347, DOI 10.1097/00002030-200102160-00008; Do AN, 2001, AIDS, V15, P1149, DOI 10.1097/00002030-200106150-00010; Donovan BJ, 2004, ANN PHARMACOTHER, V38, P670, DOI 10.1345/aph.1D314; Dube MP, 2000, CLIN INFECT DIS, V31, P1216; Dunne MW, 1999, LANCET, V354, P891, DOI 10.1016/S0140-6736(98)10328-8; Dworkin MS, 2001, CLIN INFECT DIS, V32, P794, DOI 10.1086/319218; Dybul M, 2002, J INFECT DIS, V185, P1818, DOI 10.1086/340650; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; El-Sadr WM, 1998, NEW ENGL J MED, V339, P1889, DOI 10.1056/NEJM199812243392604; ERICKSON B, 1990, SEX TRANSM DIS, V17, P194, DOI 10.1097/00007435-199010000-00009; FEHRS LJ, 1988, LANCET, V2, P379; Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3; FLEMING PL, 2002, 9 C RETR OPP INF SEA; Fogarty LA, 2001, PUBLIC HEALTH REP, V116, P103, DOI 10.1093/phr/116.S1.103; Frank AP, 1997, ARCH INTERN MED, V157, P309, DOI 10.1001/archinte.157.3.309; French N, 2000, LANCET, V355, P2106, DOI 10.1016/S0140-6736(00)02377-1; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Gallo D, 1997, JAMA-J AM MED ASSOC, V277, P254, DOI 10.1001/jama.277.3.254; Garcia F, 2004, JAIDS-J ACQ IMM DEF, V36, P702, DOI 10.1097/00126334-200406010-00007; Gebo KA, 1996, J INFECT DIS, V173, P857, DOI 10.1093/infdis/173.4.857; Gibson DR, 1999, AIDS, V13, P1807, DOI 10.1097/00002030-199910010-00002; Gibson DR, 2001, AIDS, V15, P1329, DOI 10.1097/00002030-200107270-00002; Gielen AC, 1997, WOMEN HEALTH, V25, P19, DOI 10.1300/J013v25n03_02; Goggin MA, 2000, J EMERG MED, V19, P13, DOI 10.1016/S0736-4679(00)00175-X; Granade TC, 1998, CLIN DIAGN LAB IMMUN, V5, P171, DOI 10.1128/CDLI.5.2.171-175.1998; GROSECLOSE SL, 1994, SEX TRANSM DIS, V21, P31, DOI 10.1097/00007435-199401000-00007; Guerrero M, 1999, AIDS, V13, P1971, DOI 10.1097/00002030-199910010-00021; Gulick RM, 2003, AIDS, V17, P2345, DOI 10.1097/00002030-200311070-00009; HARRIS RL, 1990, INFECT CONT HOSP EP, V11, P628; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Havlir DV, 1996, NEW ENGL J MED, V335, P392, DOI 10.1056/NEJM199608083350604; Herek GM, 2002, AM J PUBLIC HEALTH, V92, P371, DOI 10.2105/AJPH.92.3.371; HertzPicciotto I, 1996, AM J PUBLIC HEALTH, V86, P1446, DOI 10.2105/AJPH.86.10.1446; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; Hightow LB, 2003, AIDS EDUC PREV, V15, P282, DOI 10.1521/aeap.15.4.282.23826; HIRANO D, 1994, AM J PUBLIC HEALTH, V84, P2008, DOI 10.2105/AJPH.84.12.2008; Holmberg SD, 2004, NEW ENGL J MED, V350, P730, DOI 10.1056/NEJM200402123500719; Holmberg SD, 2002, LANCET, V360, P1747, DOI 10.1016/S0140-6736(02)11672-2; Holtgrave DR, 2004, JAIDS-J ACQ IMM DEF, V35, P89, DOI 10.1097/00126334-200401010-00013; Hoxworth T, 2003, SEX TRANSM DIS, V30, P83, DOI 10.1097/00007435-200301000-00016; Hoxworth Tamara, 1994, AIDS Public Policy J, V9, P182; HUTCHINSON CM, 1991, JAMA-J AM MED ASSOC, V266, P253, DOI 10.1001/jama.266.2.253; Ioannidis JPA, 1996, ARCH INTERN MED, V156, P177, DOI 10.1001/archinte.156.2.177; Irwin KL, 1996, AIDS, V10, P1707, DOI 10.1097/00002030-199612000-00016; Janssen RS, 2001, AM J PUBLIC HEALTH, V91, P1019, DOI 10.2105/AJPH.91.7.1019; Janssen RS, 2004, JAIDS-J ACQ IMM DEF, V37, pS119, DOI 10.1097/01.qai.0000140610.82134.e3; Jordan R, 2002, BMJ-BRIT MED J, V324, P757, DOI 10.1136/bmj.324.7340.757; Jutte A, 1999, AIDS, V13, P1796, DOI 10.1097/00002030-199909100-00034; Kalichman SC, 2001, AM J PREV MED, V21, P84, DOI 10.1016/S0749-3797(01)00324-5; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; Kaplan EH, 2000, J ACQ IMMUN DEF SYND, V23, P339; Kaplan JE, 2003, CLIN INFECT DIS, V37, P951, DOI 10.1086/377606; Kaplan JE, 1999, J ACQ IMMUN DEF SYND, V21, P228, DOI 10.1097/00126334-199907010-00008; Kaplan Jonathan E, 2002, MMWR Recomm Rep, V51, P1; KASSLER WJ, 1994, AIDS, V8, P351, DOI 10.1097/00002030-199403000-00009; Kassler WJ, 1997, AIDS EDUC PREV, V9, P27; Katz MH, 2002, AM J PUBLIC HEALTH, V92, P388, DOI 10.2105/AJPH.92.3.388; KATZ MH, 1992, ARCH INTERN MED, V152, P1501, DOI 10.1001/archinte.152.7.1501; Kaufmann GR, 2003, ARCH INTERN MED, V163, P2187, DOI 10.1001/archinte.163.18.2187; KAZEMPOUR K, 1995, J ACQ IMMUN DEF SYND, V10, pS97; Keenan PA, 2001, AIDS EDUC PREV, V13, P541, DOI 10.1521/aeap.13.6.541.21439; Kelen GD, 1999, ANN EMERG MED, V33, P147, DOI 10.1016/S0196-0644(99)70387-2; Kelen GD, 1996, ANN EMERG MED, V27, P687, DOI 10.1016/S0196-0644(96)70184-1; Kellerman SE, 2003, J INFECT DIS, V188, P571, DOI 10.1086/377135; Kellerman SE, 2002, JAIDS-J ACQ IMM DEF, V31, P202, DOI 10.1097/00126334-200210010-00011; Kendrick SR, 2004, AIDS, V18, P2208, DOI 10.1097/00002030-200411050-00017; Kilmarx PH, 1998, SEX TRANSM DIS, V25, P28, DOI 10.1097/00007435-199801000-00007; Kirkland KB, 1999, AIDS PATIENT CARE ST, V13, P473, DOI 10.1089/108729199318200; Kissinger PJ, 2003, SEX TRANSM DIS, V30, P75, DOI 10.1097/00007435-200301000-00015; Klein D, 2002, J ACQ IMMUN DEF SYND, V30, P471, DOI 10.1097/00126334-200208150-00002; Klein D, 2003, JAIDS-J ACQ IMM DEF, V32, P143, DOI 10.1097/00126334-200302010-00005; Kleinman S, 1998, JAMA-J AM MED ASSOC, V280, P1080, DOI 10.1001/jama.280.12.1080; KOCHANEK KD, 2004, DEATHS PRELIMINARY D, V52; Koenig L J, 2000, Matern Child Health J, V4, P103; Lee LM, 2001, JAMA-J AM MED ASSOC, V285, P1308, DOI 10.1001/jama.285.10.1308; LEPORT C, 2002, 9 C RETR OPP INF SEA; Lepri AC, 2001, AIDS, V15, P983, DOI 10.1097/00002030-200105250-00006; Liddicoat RV, 2004, J GEN INTERN MED, V19, P349, DOI 10.1111/j.1525-1497.2004.21251.x; Lindenburg CEA, 2001, AIDS, V15, P1315, DOI 10.1097/00002030-200107060-00017; Louie JK, 2002, J INFECT DIS, V186, P1023, DOI 10.1086/343862; LUBY S, 1994, AM J PUBLIC HEALTH, V84, P377, DOI 10.2105/AJPH.84.3.377; MACDONALD KL, 1989, ANN INTERN MED, V110, P617, DOI 10.7326/0003-4819-110-8-617; Margolin A, 2003, HEALTH PSYCHOL, V22, P223, DOI 10.1037/0278-6133.22.2.223; Martinez PM, 1999, J CLIN MICROBIOL, V37, P1100; Mary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010; MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; McCusker Jane, 1994, Annals of Epidemiology, V4, P466; McNaghten AD, 2003, JAIDS-J ACQ IMM DEF, V32, P499, DOI 10.1097/00126334-200304150-00006; McNaghten AD, 1999, AIDS, V13, P1687, DOI 10.1097/00002030-199909100-00012; McQuitty M, 1999, J ACQ IMMUN DEF SYND, V21, P417; Meehan TM, 1997, AM J PUBLIC HEALTH, V87, P1338, DOI 10.2105/AJPH.87.8.1338; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Molitor F, 1999, AIDS EDUC PREV, V11, P1; Monforte AD, 2004, AIDS, V18, P1811, DOI 10.1097/00002030-200409030-00010; Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017; Murphy DA, 2001, J ADOLESCENT HEALTH, V29, P57, DOI 10.1016/S1054-139X(01)00287-7; Murphy G, 2004, AIDS, V18, P265, DOI 10.1097/00002030-200401230-00016; MUSICCO M, 1994, ARCH INTERN MED, V154, P1971, DOI 10.1001/archinte.154.17.1971; Mylonakis E, 2000, ARCH INTERN MED, V160, P2386, DOI 10.1001/archinte.160.15.2386; Nakashima AK, 1998, JAMA-J AM MED ASSOC, V280, P1421, DOI 10.1001/jama.280.16.1421; Nieuwkerk PT, 2000, AIDS, V14, P181, DOI 10.1097/00002030-200001280-00014; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; O'Brien ME, 2003, JAIDS-J ACQ IMM DEF, V34, P407, DOI 10.1097/00126334-200312010-00008; O'Connell RJ, 2003, J CLIN MICROBIOL, V41, P2153, DOI 10.1128/JCM.41.5.2153-2155.2003; Oldfield EC, 1998, CLIN INFECT DIS, V26, P611, DOI 10.1086/514566; Opravil M, 2002, AIDS, V16, P1371, DOI 10.1097/00002030-200207050-00009; Osmond DH, 1999, ANN INTERN MED, V131, P775, DOI 10.7326/0003-4819-131-10-199911160-00010; OTTEN MW, 1993, AM J PUBLIC HEALTH, V83, P529, DOI 10.2105/AJPH.83.4.529; PADIAN NS, 1993, J ACQ IMMUN DEF SYND, V6, P1043; Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088; Parsons JT, 2000, HAEMOPHILIA, V6, P181, DOI 10.1046/j.1365-2516.2000.00404.x; Patterson TL, 2003, ANN BEHAV MED, V25, P137, DOI 10.1207/S15324796ABM2502_10; Payen MC, 1997, BIOMED PHARMACOTHER, V51, P439, DOI 10.1016/S0753-3322(97)82322-0; PERRY S, 1991, ARCH GEN PSYCHIAT, V48, P143; PERRY SW, 1990, AIDS, V4, P145, DOI 10.1097/00002030-199002000-00008; Peterman TA, 1996, J ACQ IMMUN DEF SYND, V12, P69, DOI 10.1097/00042560-199605010-00010; Pezzotti P, 1999, AIDS, V13, P249, DOI 10.1097/00002030-199902040-00013; Phillips AN, 2003, AIDS, V17, P1863, DOI 10.1097/00002030-200309050-00004; Pierce M, 1996, NEW ENGL J MED, V335, P384, DOI 10.1056/NEJM199608083350603; Pinkerton SD, 1997, SOC SCI MED, V44, P1303, DOI 10.1016/S0277-9536(96)00258-4; Pugatch DL, 2001, J ACQ IMMUN DEF SYND, V27, P135, DOI 10.1097/00126334-200106010-00007; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Revicki DA, 1999, AIDS, V13, P851, DOI 10.1097/00002030-199905070-00016; Reynolds SJ, 2002, INT J STD AIDS, V13, P171, DOI 10.1258/0956462021924857; Richardson JL, 2004, AIDS, V18, P1179, DOI 10.1097/00002030-200405210-00011; Rickerts V, 2000, Eur J Med Res, V5, P329; ROSENBERG PS, 1994, NEW ENGL J MED, V330, P789, DOI 10.1056/NEJM199403173301114; Rotheram-Borus MJ, 2004, JAIDS-J ACQ IMM DEF, V37, pS68, DOI 10.1097/01.qai.0000140604.57478.67; Rotheram-Borus MJ, 2001, AM J PUBLIC HEALTH, V91, P400, DOI 10.2105/AJPH.91.3.400; RUNDELL JR, 1992, PSYCHOSOMATICS, V33, P24, DOI 10.1016/S0033-3182(92)72017-9; Saha S, 2001, AM J PREV MED, V20, P36, DOI 10.1016/S0749-3797(01)00260-4; Samet JH, 1998, ARCH INTERN MED, V158, P734, DOI 10.1001/archinte.158.7.734; Samet JH, 2001, AIDS, V15, P77, DOI 10.1097/00002030-200101050-00012; Sanders GD, 2005, NEW ENGL J MED, V352, P570, DOI 10.1056/NEJMsa042657; Sayre KR, 1996, TRANSFUSION, V36, P45, DOI 10.1046/j.1537-2995.1996.36196190514.x; Schambelan M, 2002, JAIDS-J ACQ IMM DEF, V31, P257, DOI 10.1097/00126334-200211010-00001; Scheer S, 2001, LANCET, V357, P432, DOI 10.1016/S0140-6736(00)04007-1; Schlumberger MG, 1999, EUR J EPIDEMIOL, V15, P207, DOI 10.1023/A:1007578402083; SCHNELL DJ, 1992, AM J PUBLIC HEALTH, V82, P1675, DOI 10.2105/AJPH.82.12.1675; Schopper D, 1996, AIDS, V10, P1455, DOI 10.1097/00002030-199611000-00002; Semba RD, 2002, CLIN INFECT DIS, V34, P260, DOI 10.1086/338151; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; Spielberg F, 2000, AIDS, V14, P1819, DOI 10.1097/00002030-200008180-00018; Stall R, 2001, AM J PUBLIC HEALTH, V91, P767, DOI 10.2105/AJPH.91.5.767; Stanley B, 2003, BMJ-BRIT MED J, V326, P1174, DOI 10.1136/bmj.326.7400.1174; Sterling TR, 2003, J INFECT DIS, V188, P1659, DOI 10.1086/379741; Sterling TR, 2003, CLIN INFECT DIS, V36, P812, DOI 10.1086/367934; Sterling TR, 2001, AIDS, V15, P2251, DOI 10.1097/00002030-200111230-00006; Sy FS, 1998, SEX TRANSM DIS, V25, P211, DOI 10.1097/00007435-199804000-00006; Tarwater PM, 2001, AM J EPIDEMIOL, V154, P675, DOI 10.1093/aje/154.7.675; Tasker SA, 1999, ANN INTERN MED, V131, P430, DOI 10.7326/0003-4819-131-6-199909210-00006; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; Torre D, 2002, CLIN INFECT DIS, V35, P631, DOI 10.1086/341308; Turner BJ, 2000, ARCH INTERN MED, V160, P2614, DOI 10.1001/archinte.160.17.2614; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; VANHAASTRECHT HJA, 1994, AIDS, V8, P1721, DOI 10.1097/00002030-199412000-00013; Vittinghoff E, 1999, J INFECT DIS, V179, P717, DOI 10.1086/314623; Wai CT, 2002, AM J MED, V112, P737, DOI 10.1016/S0002-9343(02)01113-0; Walensky RP, 2002, ARCH INTERN MED, V162, P887, DOI 10.1001/archinte.162.8.887; Wang CL, 2004, J INFECT DIS, V190, P1046, DOI 10.1086/422848; Watera C, 2004, AIDS, V18, P1210, DOI 10.1097/00002030-200405210-00018; Weinhardt LS, 1999, AM J PUBLIC HEALTH, V89, P1397, DOI 10.2105/AJPH.89.9.1397; WELLER S, 2004, CONDOM EFFECTIVENESS; WILKINSON D, 2003, DRUGS PREVENTING TUB; Wingood GM, 2004, JAIDS-J ACQ IMM DEF, V37, pS58, DOI 10.1097/01.qai.0000140603.57478.a9; Wolitski RJ, 1997, AIDS EDUC PREV, V9, P52; Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008; Wood E, 2003, AIDS, V17, P711, DOI 10.1097/00002030-200303280-00009; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251; 2004, HIV AIDS SURVIELLANC, P1; 2002, HIV TESTING SURVEY; 1988, MMWR MORB MORTAL WKL, V36, P833; 2004, MMWR MORB MORTAL WKL, V53, P523; 2005, GUIDELINES USE ANTIR; 2004, J ACQUIR IMMUNE DEFI, V35, P511; 2004, MMWR MORB MORTAL WKL, V53, P1110; 2004, J ACQUIR IMMUNE DEFI, V36, P1057; 2002, HIV ASSAYS OPERATION; 2004, RAPID HIV ANTIBODY T; 1988, MMWR MORB MORTAL WKL, V36, P845; 2000, MMWR MORB MORTAL WKL, V49, P1062; 2003, MMWR MORB MORTAL WKL, V52, P1145; 1989, JAMA-J AM MED ASSOC, V262, P3395; 2001, MMWR MORB MORTAL WKL, V50, P262; 2003, HIV AIDS SURVEILLANC; 2002, MMWR MORB MORTAL WKL, V51, P592; 2000, MMWR MORB MORTAL WKL, V49, P512	250	85	88	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 5	2005	143	1					55	73		10.7326/0003-4819-143-1-200507050-00010	http://dx.doi.org/10.7326/0003-4819-143-1-200507050-00010			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	941XB	15998755				2022-12-28	WOS:000230246400007
J	Ali, M; Emch, M; von Seidlein, L; Yunus, M; Sack, DA; Rao, M; Holmgren, J; Clemens, JD				Ali, M; Emch, M; von Seidlein, L; Yunus, M; Sack, DA; Rao, M; Holmgren, J; Clemens, JD			Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis	LANCET			English	Article							FIELD TRIAL; IMMUNIZATION	Background Decisions about the use of killed oral cholera vaccines, which confer moderate levels of direct protection to vaccinees, can depend on whether the vaccines also provide indirect (herd) protection when high levels of vaccine coverage are attained. We reanalysed data from a field trial in Bangladesh to ascertain whether there is evidence of indirect protection from killed oral cholera vaccines. Methods We analysed the first year of surveillance data from a placebo-controlled trial of B subunit-killed whole-cell and killed whole-cell-only oral cholera vaccines in children and adult women in Bangladesh. We calculated whether there was an inverse, monotonic trend for the relation between the level of vaccine coverage in a residential cluster and the incidence of cholera in individual vaccine recipients or placebo recipients residing in the cluster after controlling for potential confounding variables. Findings Vaccine coverage of the targeted population ranged from 4% to 65%. Incidence rates of cholera among placebo recipients were inversely related to levels of vaccine coverage (7.01 cases per 1000 in the lowest quintile of coverage vs 1.47 cases per 1000 in the highest quintile; p<0.0001 for trend). Receipt of vaccine by an individual and the level of vaccine coverage of the individual's cluster were independently related to a reduced risk of cholera. Moreover, after adjustment for the level of vaccine coverage of the cluster, vaccine protective efficacy remained significant (55% [95% CI 41-66], p<0.0001). Interpretation in addition to providing direct protection to vaccine recipients, killed oral cholera vaccines confer significant herd protection to neighbouring non-vaccinated individuals. Use of these vaccines could have a major effect on the burden of cholera in endemic settings.	Int Vaccine Inst, Seoul 151818, South Korea; Portland State Univ, Dept Geog, Portland, OR 97207 USA; ICDDR B, Ctr Hlth & Populat Res, Dhaka, Bangladesh; NIAID, NIH, Bethesda, MD 20892 USA; Univ Gothenburg, Dept Med Microbiol & Immunol, Gothenburg, Sweden; NICHHD, Bethesda, MD 20892 USA	International Vaccine Institute; Portland State University; International Centre for Diarrhoeal Disease Research (ICDDR); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Gothenburg; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Clemens, JD (corresponding author), Int Vaccine Inst, SNU Res Pk,San 4-8 Bongcheon 7 Dong, Seoul 151818, South Korea.	jclemens@ivi.int	Ali, Mohammad/E-2365-2017	Ali, Mohammad/0000-0003-1410-388X; Holmgren, Jan/0000-0003-1784-5918	NIAID NIH HHS [1R03AI53214-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI053214] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali M, 2001, J HEALTH POPUL NUTR, V19, P100; Anderson R M, 1990, Lancet, V335, P641; BLACK RE, 1987, INFECT IMMUN, V55, P1116, DOI 10.1128/IAI.55.5.1116-1120.1987; CLEMENS JD, 1986, LANCET, V2, P124; CLEMENS JD, 1987, J INFECT DIS, V155, P79, DOI 10.1093/infdis/155.1.79; CLEMENS JD, 1992, AM J EPIDEMIOL, V135, P865, DOI 10.1093/oxfordjournals.aje.a116382; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1988, J INFECT DIS, V158, P60, DOI 10.1093/infdis/158.1.60; CLEMENS JD, 1990, AM J EPIDEMIOL, V131, P400, DOI 10.1093/oxfordjournals.aje.a115515; CLEMENS JD, 1992, J INFECT DIS, V166, P1029, DOI 10.1093/infdis/166.5.1029; Cox D., 1958, PLANNING EXPT; FINE PEM, 1993, EPIDEMIOL REV, V15, P265, DOI 10.1093/oxfordjournals.epirev.a036121; FOX JP, 1995, AM J EPIDEMIOL, V141, P187, DOI 10.1093/oxfordjournals.aje.a117420; GLASS RI, 1985, J INFECT DIS, V151, P236, DOI 10.1093/infdis/151.2.236; GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498; GREENLAND S, 1988, INT J EPIDEMIOL, V17, P456, DOI 10.1093/ije/17.2.456; Longini IM, 2002, STAT MED, V21, P481, DOI 10.1002/sim.994; MURPHY TV, 1993, JAMA-J AM MED ASSOC, V269, P246, DOI 10.1001/jama.269.2.246; Snedecor GW, 1980, STAT METHODS, V7th; *WHO GLOB TASK FOR, 2002, WHO M 10 11 DEC 2002; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	21	228	236	1	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	2005	366	9479					44	49		10.1016/S0140-6736(05)66550-6	http://dx.doi.org/10.1016/S0140-6736(05)66550-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993232				2022-12-28	WOS:000230277600033
J	Hershberger, RE; Starling, RC; Eisen, HJ; Bergh, CH; Kormos, RL; Love, RB; Van Bakel, A; Gordon, RD; Popat, R; Cockey, L; Mamelok, RD				Hershberger, RE; Starling, RC; Eisen, HJ; Bergh, CH; Kormos, RL; Love, RB; Van Bakel, A; Gordon, RD; Popat, R; Cockey, L; Mamelok, RD			Daclizumab to prevent rejection after cardiac transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Meetin of the International-Society-of-Heart-and-Lung-Transplantation	APR 09-12, 2003	Vienna, AUSTRIA	Int Soc Heart Lung Transplantation			HEART-TRANSPLANTATION; INTERLEUKIN-2-RECEPTOR; BLOCKADE	BACKGROUND: Daclizumab, a humanized monoclonal antibody against the interleukin-2 receptor, reduced the risk of rejection without increasing the risk of infection among renal-transplant recipients and, in a single-center trial, among cardiac-transplant recipients. We conducted a multicenter, placebo-controlled, double-blind study to confirm these results in cardiac-transplant patients. METHODS: We randomly assigned 434 recipients of a first cardiac transplant treated with standard immunosuppression (cyclosporine, mycophenolate mofetil, and corticosteroids) to receive five doses of daclizumab or placebo. The primary end point was a composite of moderate or severe cellular rejection, hemodynamically significant graft dysfunction, a second transplantation, or death or loss to follow-up within six months. RESULTS: By six months, 104 of 218 patients in the placebo group had reached the primary end point, as compared with 77 of the 216 patients in the daclizumab group (47.7 percent vs. 35.6 percent, P=0.007), a 12.1 percent absolute risk reduction and a 25 percent relative reduction. The rate of rejection was lower in the daclizumab group than in the placebo group (41.3 percent vs. 25.5 percent). Among patients reaching the primary end point, the median time to the end point was almost three times as long in the daclizumab group as in the placebo group during the first 6 months (61 vs. 21 days) and at 1 year (96 vs. 26 days). More patients in the daclizumab group than in the placebo group died of infection (6 vs. 0) when they received concomitant cytolytic therapy. CONCLUSIONS: Daclizumab was efficacious as prophylaxis against acute cellular rejection after cardiac transplantation. Because of the excess risk of death, concurrent or anticipated use of cytolytic therapy with daclizumab should be avoided.	Oregon Hlth & Sci Univ, Dept Med Cardiol, Portland, OR 97239 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Temple Univ, Sch Med, Philadelphia, PA 19122 USA; Sahlgrenska Univ Hosp, Gothenburg, Sweden; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA; Med Univ S Carolina, Charleston, SC 29425 USA; Roche Labs, Nutley, NJ USA	Oregon Health & Science University; Cleveland Clinic Foundation; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Sahlgrenska University Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wisconsin System; University of Wisconsin Madison; Medical University of South Carolina; Roche Holding	Hershberger, RE (corresponding author), Oregon Hlth & Sci Univ, Dept Med Cardiol, UHN-62,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	hershber@ohsu.edu	Mattos, Beatriz A/D-2432-2011	Hershberger, Ray/0000-0001-5683-6526				Beniaminovitz A, 2000, NEW ENGL J MED, V342, P613, DOI 10.1056/NEJM200003023420902; Billingham M E, 1990, J Heart Transplant, V9, P587; Carswell CI, 2001, BIODRUGS, V15, P745, DOI 10.2165/00063030-200115110-00005; Kobashigawa J, 1998, TRANSPLANTATION, V66, P507, DOI 10.1097/00007890-199808270-00016; MILLER LW, 1994, J HEART LUNG TRANSPL, V13, P381; Nashan B, 1999, TRANSPLANTATION, V67, P110, DOI 10.1097/00007890-199901150-00019; *NOS, 2005, ORG PROC TRANSPL NET; Smart FW, 1996, J HEART LUNG TRANSPL, V15, P329; Taylor DO, 2003, J HEART LUNG TRANSPL, V22, P616, DOI 10.1016/S1053-2498(03)00186-4; Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304	10	143	149	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					2705	2713		10.1056/NEJMoa032953	http://dx.doi.org/10.1056/NEJMoa032953			9	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	940HH	15987919				2022-12-28	WOS:000230133800007
J	Mulshine, JL; Sullivan, DC				Mulshine, JL; Sullivan, DC			Lung cancer screening	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HELICAL COMPUTED-TOMOGRAPHY; SMALL PULMONARY NODULES; SPIRAL CT; BASE-LINE; COST-EFFECTIVENESS; SMOKING-CESSATION; ACTION PROJECT; ADULT SMOKERS; CARCINOMA; SURVIVAL		NCI, Intervent Sect, Cell & Canc Biol Branch, Lung Canc & Aerodigest Chemoprevent Fac,Ctr Canc, Bethesda, MD 20892 USA; NCI, Canc Imaging Program, Div Canc Treatment & Diag, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mulshine, JL (corresponding author), NIH, Ctr Clin, Cell & Canc Biol Branch, Rm 12N226, Bethesda, MD 20892 USA.	mulshinj@mail.nih.gov						Ambrogi V, 2003, EUR J CARDIO-THORAC, V23, P811, DOI 10.1016/S1010-7940(03)00093-9; Asamura H, 2003, ANN THORAC SURG, V76, P1016, DOI 10.1016/S0003-4975(03)00835-X; Bach PB, 2003, JNCI-J NATL CANCER I, V95, P470, DOI 10.1093/jnci/95.6.470; Bianchi F, 2004, CLIN CANCER RES, V10, P6023, DOI 10.1158/1078-0432.CCR-04-0619; Brenner DJ, 2004, RADIOLOGY, V231, P440, DOI 10.1148/radiol.2312030880; Clarke LP, 2001, ACAD RADIOL, V8, P447, DOI 10.1016/S1076-6332(03)80555-X; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Cox LS, 2003, CANCER, V98, P2495, DOI 10.1002/cncr.11813; Enstrom JE, 1999, EPIDEMIOLOGY, V10, P500, DOI 10.1097/00001648-199909000-00007; FLEHINGER BJ, 1992, CHEST, V101, P1013, DOI 10.1378/chest.101.4.1013; Fontana RS, 2000, CANCER, V89, P2352, DOI 10.1002/1097-0142(20001201)89:11+<2352::AID-CNCR7>3.0.CO;2-5; Gohagan JK, 2005, LUNG CANCER, V47, P9, DOI 10.1016/j.lungcan.2004.06.007; Henschke CI, 2001, CANCER, V92, P153, DOI 10.1002/1097-0142(20010701)92:1<153::AID-CNCR1303>3.0.CO;2-S; Henschke CI, 2004, CLIN IMAG, V28, P317, DOI 10.1016/j.clinimag.2004.05.001; Henschke CI, 2004, RADIOLOGY, V231, P164, DOI 10.1148/radiol.2311030634; Henschke CI, 2003, LUNG CANCER-J IASLC, V39, P327, DOI 10.1016/S0169-5002(02)00503-2; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Humphrey LL, 2004, ANN INTERN MED, V140, P740, DOI 10.7326/0003-4819-140-9-200405040-00015; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; KAKINUMA R, 2003, P INT ASS STUD LUNG, P18; Kaneko M, 2000, CANCER, V89, P2485, DOI 10.1002/1097-0142(20001201)89:11+<2485::AID-CNCR28>3.0.CO;2-T; Kiessling F, 2004, NAT MED, V10, P1133, DOI 10.1038/nm1101; Kostis WJ, 2003, IEEE T MED IMAGING, V22, P1259, DOI 10.1109/TMI.2003.817785; Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507; Mahadevia PJ, 2003, JAMA-J AM MED ASSOC, V289, P313, DOI 10.1001/jama.289.3.313; Mulshine JL, 2004, CLIN CANCER RES, V10, P5973, DOI 10.1158/1078-0432.CCR-04-1154; Mulshine JL, 2003, NAT REV CANCER, V3, P65, DOI 10.1038/nrc972; MULSHINE JL, 1989, J NATL CANCER I, V81, P900, DOI 10.1093/jnci/81.12.900; Nawa T, 2002, CHEST, V122, P15, DOI 10.1378/chest.122.1.15; Okada M, 2001, ANN THORAC SURG, V71, P956, DOI 10.1016/S0003-4975(00)02223-2; Ostroff JS, 2001, PREV MED, V33, P613, DOI 10.1006/pmed.2001.0935; Pastorino U, 2003, LANCET, V362, P593, DOI 10.1016/S0140-6736(03)14188-8; Patel JD, 2004, JAMA-J AM MED ASSOC, V291, P1763, DOI 10.1001/jama.291.14.1763; Sackett DL, 1997, BRIT MED J, V315, P1636, DOI 10.1136/bmj.315.7123.1636; Skuladottir H, 2002, LUNG CANCER-J IASLC, V37, P127, DOI 10.1016/S0169-5002(02)00080-6; Smith RA, 2004, CA-CANCER J CLIN, V54, P41, DOI 10.3322/canjclin.54.1.41; Smith RA, 2004, ONCOLOGY-NY, V18, P578; Sobue T, 2002, J CLIN ONCOL, V20, P911, DOI 10.1200/JCO.2002.20.4.911; SOBUE T, 1992, CANCER, V69, P685, DOI 10.1002/1097-0142(19920201)69:3<685::AID-CNCR2820690315>3.0.CO;2-W; Sugarbaker DJ, 2000, CANCER, V89, P2432, DOI 10.1002/1097-0142(20001201)89:11+<2432::AID-CNCR17>3.0.CO;2-A; Swensen SJ, 2003, RADIOLOGY, V226, P756, DOI 10.1148/radiol.2263020036; Swensen SJ, 2003, MAYO CLIN PROC, V78, P1187, DOI 10.4065/78.9.1187; Swensen SJ, 2005, RADIOLOGY, V235, P259, DOI 10.1148/radiol.2351041662; Timins Julie K, 2005, N J Med, V102, P45; Tong LZ, 1996, CANCER, V78, P1004, DOI 10.1002/(SICI)1097-0142(19960901)78:5<1004::AID-CNCR10>3.0.CO;2-6; Tsushima Y, 2004, MED SCI MONITOR, V10, pMT65; van Klaveren RJ, 2002, LUNG CANCER, V38, P243, DOI 10.1016/S0169-5002(02)00222-2; Warner EE, 2003, J SURG ONCOL, V84, P1, DOI 10.1002/jso.10280; Warner EE, 2004, ONCOLOGY-NY, V18, P564; Wisnivesky JP, 2003, CHEST, V124, P614, DOI 10.1378/chest.124.2.614; Yankelevitz DF, 2000, RADIOLOGY, V217, P251, DOI 10.1148/radiology.217.1.r00oc33251; 2002, MMWR MORB MORTAL WKL, V51, P300	52	165	176	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					2714	2720		10.1056/NEJMcp042630	http://dx.doi.org/10.1056/NEJMcp042630			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	940HH	15987920				2022-12-28	WOS:000230133800008
J	Ballard, C				Ballard, C			Hodgkin's disease: are you the type?	LANCET			English	Editorial Material							EPSTEIN-BARR-VIRUS; REGULATORY T-CELLS		Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Texas Children's Cancer Center	Ballard, C (corresponding author), Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA.	cmbollar@texaschildrenshospital.org						Alexander FE, 2001, CANCER EPIDEM BIOMAR, V10, P705; Bollard CM, 2004, J EXP MED, V200, P1623, DOI 10.1084/jem.20040890; Bollard CM, 2004, J IMMUNOTHER, V27, P317, DOI 10.1097/00002371-200407000-00008; Marshall NA, 2004, BLOOD, V103, P1755, DOI 10.1182/blood-2003-07-2594; Voo KS, 2005, CANCER RES, V65, P1577, DOI 10.1158/0008-5472.CAN-04-2552	5	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	2005	365	9478					2162	2163		10.1016/S0140-6736(05)66756-6	http://dx.doi.org/10.1016/S0140-6736(05)66756-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978911				2022-12-28	WOS:000230034800009
J	Baxter, PJ				Baxter, PJ			Commentary: Evacuation decisions in chemical incidents benefit from expert health advice	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Cambridge, Dept Publ Hlth & Primary Care, Inst Publ Hlth, Cambridge CB2 2SR, England	University of Cambridge	Baxter, PJ (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Inst Publ Hlth, Cambridge CB2 2SR, England.	Pjb21@medschl.cam.ac.uk						BAXTER PJ, 1995, OCCUP ENVIRON MED, V52, P694, DOI 10.1136/oem.52.10.694; BAXTER PJ, 1990, INT C S SERIES, V155, P7; *DEP ENV FOOD RUR, 2005, GUID HAL HYDR HAL AM; *HLTH SAF EX, CONTR MAJ ACC HAZ CO; Kinra S, 2005, BMJ-BRIT MED J, V330, P1471, DOI 10.1136/bmj.330.7506.1471	5	2	2	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 25	2005	330	7506					1474	1475		10.1136/bmj.330.7506.1474	http://dx.doi.org/10.1136/bmj.330.7506.1474			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942NR	15976420	Green Published, Bronze			2022-12-28	WOS:000230289600016
J	Kim, J; Wu, HH; Lander, AD; Lyons, KM; Matzuk, MM; Calof, AL				Kim, J; Wu, HH; Lander, AD; Lyons, KM; Matzuk, MM; Calof, AL			GDF11 controls the timing of progenitor cell competence in developing retina	SCIENCE			English	Article							GANGLION-CELLS; RAT RETINA; NEURAL RETINA; FROG RETINA; BHLH GENES; DIFFERENTIATION; MOUSE; AUTOREGULATION; RETINOGENESIS; EXPRESSION	The orderly generation of cell types in the developing retina is thought to be regulated by changes in the competence of multipotent progenitors. Here, we show that a secreted factor, growth and differentiation factor 11 (GDF11), controls the numbers of retinal ganglion cells (RGCs), as well as amacrine and photoreceptor cells, that form during development. GDF11 does not affect proliferation of progenitors-a major mode of GDF11 action in other tissues-but instead controls duration of expression of Maths, a gene that confers competence for RGC genesis, in progenitor cells. Thus, GDF11 governs the temporal windows during which multipotent progenitors retain competence to produce distinct neural progeny.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Dev Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; Univ Calif Los Angeles, Dept Mol Cellular & Dev Biol, Los Angeles, CA 90095 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Los Angeles; Baylor College of Medicine	Calof, AL (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	alcalof@uci.edu	Kim, Joon/C-1833-2011; Calof, Anne/A-8644-2013; Lander, Arthur D/C-9008-2011; Lander, Arthur/L-2827-2019	Calof, Anne/0000-0003-3676-2499; Lander, Arthur D/0000-0002-4380-5525; Lander, Arthur/0000-0002-4380-5525	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD032067] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD038761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003583] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44528] Funding Source: Medline; NICHD NIH HHS [HD32067, HD38761] Funding Source: Medline; NIDCD NIH HHS [DC03583] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; Belliveau MJ, 1999, DEVELOPMENT, V126, P555; Brown NL, 2001, DEVELOPMENT, V128, P2497; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Dyer MA, 2003, NAT GENET, V34, P53, DOI 10.1038/ng1144; Federman SM, 2000, J BONE MINER RES, V15, pS463; Gamer LW, 1999, DEV BIOL, V208, P222, DOI 10.1006/dbio.1998.9191; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; Gonzalez-Hoyuela M, 2001, DEVELOPMENT, V128, P117; Hatakeyama J, 2001, DEVELOPMENT, V128, P1313; Kanekar S, 1997, NEURON, V19, P981, DOI 10.1016/S0896-6273(00)80391-8; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Liu W, 2000, DEV DYNAM, V217, P320, DOI 10.1002/(SICI)1097-0177(200003)217:3<320::AID-DVDY10>3.0.CO;2-F; Marquardt T, 2002, TRENDS NEUROSCI, V25, P32, DOI 10.1016/S0166-2236(00)02028-2; Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1; Morrow EM, 1999, DEVELOPMENT, V126, P23; Nakashima M, 1999, MECH DEVELOP, V80, P185, DOI 10.1016/S0925-4773(98)00205-6; Oh SP, 2002, GENE DEV, V16, P2749, DOI 10.1101/gad.1021802; Rapaport DH, 2001, J NEUROBIOL, V49, P129, DOI 10.1002/neu.1070; Rapaport DH, 2004, J COMP NEUROL, V474, P304, DOI 10.1002/cne.20134; REH TA, 1986, DEV BIOL, V114, P463, DOI 10.1016/0012-1606(86)90210-1; SPARROW JR, 1990, DEV BRAIN RES, V51, P69, DOI 10.1016/0165-3806(90)90259-2; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; Vetter ML, 2001, SEMIN CELL DEV BIOL, V12, P491, DOI 10.1006/scdb.2001.0273; WAID DK, 1995, NEURON, V14, P117, DOI 10.1016/0896-6273(95)90245-7; Waid DK, 1998, DEVELOPMENT, V125, P1059; WATANABE T, 1990, NEURON, V4, P461, DOI 10.1016/0896-6273(90)90058-N; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; Wu HH, 2003, NEURON, V37, P197, DOI 10.1016/S0896-6273(02)01172-8; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; Yang ZY, 2003, DEV BIOL, V264, P240, DOI 10.1016/j.ydbio.2003.08.005; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	32	168	184	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	2005	308	5730					1927	1930		10.1126/science.1110175	http://dx.doi.org/10.1126/science.1110175			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976303	Green Submitted			2022-12-28	WOS:000230120000045
J	Hankey, GJ				Hankey, GJ			Redefining risks after TIA and minor ischaemic stroke	LANCET			English	Editorial Material							SHORT-TERM PROGNOSIS; ATTACK		Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA, Australia; Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia	Royal Perth Hospital; University of Western Australia; University of Western Australia	Hankey, GJ (corresponding author), Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA, Australia.	gjhankey@cyllene.uwa.edu.au	Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Coull AJ, 2004, BMJ-BRIT MED J, V328, P326, DOI 10.1136/bmj.37991.635266.44; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; Eliasziw M, 2004, CAN MED ASSOC J, V170, P1105, DOI 10.1503/cmaj.1030460; HANKEY GJ, 1992, J NEUROL NEUROSUR PS, V55, P640, DOI 10.1136/jnnp.55.8.640; Hankey GJ, 1994, TRANSIENT ISCHAEMIC; Hill MD, 2004, NEUROLOGY, V62, P2015, DOI 10.1212/01.WNL.0000129482.70315.2F; Johnston SC, 2003, ANN NEUROL, V54, P439, DOI 10.1002/ana.10678; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; Kleindorfer D, 2005, STROKE, V36, P720, DOI 10.1161/01.STR.0000158917.59233.b7; Lovett JK, 2004, NEUROLOGY, V62, P569, DOI 10.1212/01.WNL.0000110311.09970.83; Rao SV, 2003, AM J CARDIOL, V91, P936, DOI 10.1016/S0002-9149(03)00107-3; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; Rothwell PM, 2004, LANCET, V363, P915, DOI 10.1016/S0140-6736(04)15785-1; Rothwell PM, 2005, NEUROLOGY, V64, P817, DOI 10.1212/01.WNL.0000152985.32732.EE; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P176; SANDERCOCK P, 2003, COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD00002; Vasan RS, 2005, ANN INTERN MED, V142, P393, DOI 10.7326/0003-4819-142-6-200503150-00005; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	20	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2065	2066		10.1016/S0140-6736(05)66713-X	http://dx.doi.org/10.1016/S0140-6736(05)66713-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964427				2022-12-28	WOS:000229858800004
J	Shenfield, F				Shenfield, F			Semantics and ethics of human embryonic stem-cell research	LANCET			English	Editorial Material									UCL Hosp, Reprod Med Unit, London WC1E 6AY, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Shenfield, F (corresponding author), UCL Hosp, Reprod Med Unit, London WC1E 6AY, England.	mfi@easynet.co.uk						*DEP HLTH, 2000, STEM CELL RES MED PR; *EUR COUNC EUR, 1996, CONV PROT HUM RIGHTS; *EUR GROUP ETH SCI, 2002, AD OP ETH ASP HUM CE; Shenfield F, 2002, HUM REPROD, V17, P1409; Shenfield F, 2001, HUM REPROD, V16, P1046; SHENFIELD F, 1995, HUM REPROD, V10, P253, DOI 10.1093/oxfordjournals.humrep.a135924; Shenfield F., 2002, ETHICAL DILEMMAS REP; WARNOCK M, 1984, REPORT COMMITTEE ENQ	8	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2071	2073		10.1016/S0140-6736(05)66555-5	http://dx.doi.org/10.1016/S0140-6736(05)66555-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	936LZ	15964431				2022-12-28	WOS:000229858800008
J	Trenberth, K				Trenberth, K			Uncertainty in hurricanes and global warming	SCIENCE			English	Editorial Material							TROPICAL CYCLONES; INTENSITY; PRECIPITATION; VARIABILITY; OSCILLATION		Natl Ctr Atmospher Res, Boulder, CO 80307 USA	National Center Atmospheric Research (NCAR) - USA	Trenberth, K (corresponding author), Natl Ctr Atmospher Res, POB 3000, Boulder, CO 80307 USA.	trenbert@ucar.edu	Trenberth, Kevin Edward/A-5683-2012	Trenberth, Kevin Edward/0000-0002-1445-1000				Chan JCL, 2004, J CLIMATE, V17, P4590, DOI 10.1175/3240.1; Chelliah M, 2004, J CLIMATE, V17, P1777, DOI 10.1175/1520-0442(2004)017<1777:TMAICV>2.0.CO;2; Delworth TL, 2000, CLIM DYNAM, V16, P661, DOI 10.1007/s003820000075; DeMott CA, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD003784; Durre I, 2002, J CLIMATE, V15, P1335, DOI 10.1175/1520-0442(2002)015<1335:EOTEOT>2.0.CO;2; Emanuel KA, 1999, NATURE, V401, P665, DOI 10.1038/44326; Gettelman A, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001082; Goldenberg SB, 2001, SCIENCE, V293, P474, DOI 10.1126/science.1060040; GRAY WM, 1984, MON WEATHER REV, V112, P1649, DOI 10.1175/1520-0493(1984)112<1649:ASHFPI>2.0.CO;2; Groisman PY, 2004, J HYDROMETEOROL, V5, P64, DOI 10.1175/1525-7541(2004)005<0064:CCOTHC>2.0.CO;2; Henderson-Sellers A, 1998, B AM METEOROL SOC, V79, P19, DOI 10.1175/1520-0477(1998)079<0019:TCAGCC>2.0.CO;2; Holland GJ, 1997, J ATMOS SCI, V54, P2519, DOI 10.1175/1520-0469(1997)054<2519:TMPIOT>2.0.CO;2; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; Knutson TR, 2004, J CLIMATE, V17, P3477, DOI [10.1175/1520-0442(2004)017<3477:IOCWOS>2.0.CO;2, 10.1175/1520-0442(2004)017&lt;3477:IOCWOS&gt;2.0.CO;2]; LEVINSON DH, 2005, B AM METEOROL SOC S, V86; Rayner NA, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002670; SCHLESINGER ME, 1994, NATURE, V367, P723, DOI 10.1038/367723a0; Tang BH, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021072; Trenberth KE, 2005, CLIM DYNAM, V24, P741, DOI 10.1007/s00382-005-0017-4; Trenberth KE, 2003, B AM METEOROL SOC, V84, P1205, DOI 10.1175/BAMS-84-9-1205	20	288	312	6	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1753	1754		10.1126/science.1112551	http://dx.doi.org/10.1126/science.1112551			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961661				2022-12-28	WOS:000229926800043
J	Marson, A; Jacoby, A; Johnson, A; Kim, L; Gamble, C; Chadwick, D				Marson, A; Jacoby, A; Johnson, A; Kim, L; Gamble, C; Chadwick, D		Med Res Council MESS Study Grp	Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial	LANCET			English	Article							1ST UNPROVOKED SEIZURE; TONIC-CLONIC SEIZURE; QUALITY-OF-LIFE; RECURRENCE; REMISSION; RISK; PROGNOSIS; RELAPSE; PEOPLE	Background The relative risks and benefits of starting or withholding antiepileptic drug treatment in patients with few or infrequent seizures are unclear. We sought to compare policies of immediate versus deferred treatment in such patients and to assess the effects of these policies on short-term recurrence and long-term outcomes. Methods We undertook an unmasked, multicentre, randomised study of immediate and deferred antiepileptic drug treatment in 1847 patients with single seizures and early epilepsy. Outcomes comprised time to first, second, and fifth seizures; time to 2-year remission; no seizures between years 1 and 3 and between years 3 and 5 after randomisation; and quality of life. Analysis was by intention to treat. Findings 404 patients invited to join the trial did not consent to randomisation; 722 were subsequently assigned immediate treatment with antiepileptic drugs and 721 were assigned deferred treatment. Immediate treatment increased time to first seizure (hazard ratio 1.4 [95% CI 1.2 to 1.7]), second seizure (1.3 [1.1 to 1.6]), and first tonic-clonic seizure (1.5 [1.2 to 1.81). It also reduced the time to achieve 2-year remission of seizures (p=0.023). At 5-years follow-up, 76% of patients in the immediate treatment group and 77% of those in the deferred treatment group were seizure free between 3 and 5 years after randomisation (difference -0.2% [95% CI -5.8% to 5.5%]). The two policies did not differ with respect to quality of life outcomes or serious complications. Interpretation Immediate antiepileptic drug treatment reduces the occurrence of seizures in the next 1-2 years, but does not affect long-term remission in individuals with single or infrequent seizures.	Univ Liverpool, Dept Neurol Sci, Walton Ctr, Div Neurosci, Liverpool L9 7J, Merseyside, England; Univ Liverpool, Div Publ Hlth, Liverpool L9 7J, Merseyside, England; Univ Liverpool, Ctr Med Stat, Liverpool L9 7J, Merseyside, England; MRC, Biostat Unit, Cambridge CB2 2BW, England	University of Liverpool; Walton Centre; University of Liverpool; University of Liverpool; MRC Biostatistics Unit	Chadwick, D (corresponding author), Univ Liverpool, Dept Neurol Sci, Walton Ctr, Div Neurosci, Lower Lane, Liverpool L9 7J, Merseyside, England.	d.w.chadwick@liv.ac.uk	Gambardella, Antonio/F-5295-2012; Gamble, Carrol/AAE-9895-2019; Marson, Anthony/AAW-9776-2020	Gambardella, Antonio/0000-0001-7384-3074; Gamble, Carrol/0000-0002-3021-1955; Marson, Anthony/0000-0002-6861-8806				Abetz L, 2000, EPILEPSIA, V41, P1119, DOI 10.1111/j.1528-1157.2000.tb00317.x; Altman D.G., 2000, STAT CONFIDENCE, Vsecond; ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; BAKER GA, 1993, EPILEPSY RES, V16, P65, DOI 10.1016/0920-1211(93)90041-5; Baker GA, 1997, EPILEPSIA, V38, P353, DOI 10.1111/j.1528-1157.1997.tb01128.x; Berg AT, 1997, J CLIN NEUROPHYSIOL, V14, P102, DOI 10.1097/00004691-199703000-00003; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; CAMFIELD P, 1989, NEUROLOGY, V39, P851, DOI 10.1212/WNL.39.6.851; CHADWICK D, 1991, LANCET, V337, P1175; CHANDRA B, 1992, CLIN NEUROL NEUROSUR, V94, pS613; Das CP, 2000, NEUROL INDIA, V48, P357; Gilad R, 1996, ARCH NEUROL-CHICAGO, V53, P1149, DOI 10.1001/archneur.1996.00550110089017; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; JACOBY A, 1994, SOC SCI MED, V38, P269, DOI 10.1016/0277-9536(94)90396-4; JACOBY A, 1992, EPILEPSIA, V33, P1123, DOI 10.1111/j.1528-1157.1992.tb01769.x; Musicco M, 1997, NEUROLOGY, V49, P991, DOI 10.1212/WNL.49.4.991; MUSICCO M, 1993, NEUROLOGY, V43, P478; PAURANIK A, 1997, EPILEPSIA S3, V38, P88; REYNOLDS EH, 1987, EPILEPSIA, V28, P97, DOI 10.1111/j.1528-1157.1987.tb03633.x; Scambler G., 1989, EPILEPSY; Shinnar S, 2000, ANN NEUROL, V48, P140, DOI 10.1002/1531-8249(200008)48:2<140::AID-ANA2>3.0.CO;2-Y; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; VICKREY BG, 1992, MED CARE, V30, P162	23	277	286	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2005	365	9476					2007	2013		10.1016/S0140-6736(05)66694-9	http://dx.doi.org/10.1016/S0140-6736(05)66694-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950714				2022-12-28	WOS:000229701400022
J	McIntosh, AM; Berkovic, SF				McIntosh, AM; Berkovic, SF			Treatment of new-onset epilepsy: seizures beget discussion	LANCET			English	Editorial Material							ANTIEPILEPTIC DRUG-TREATMENT; NATURAL-HISTORY		Univ Melbourne, Epilepsy Res Ctr, Heidelberg, Vic 3081, Australia; Univ Melbourne, Dept Med, Heidelberg, Vic 3081, Australia; Univ Melbourne, Sch Nursing, Melbourne, Vic, Australia; Austin Hlth, Dept Neurol, Melbourne, Vic, Australia	University of Melbourne; University of Melbourne; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health	McIntosh, AM (corresponding author), Univ Melbourne, Epilepsy Res Ctr, Heidelberg, Vic 3081, Australia.	s.berkovic@unimelb.edu.au	jiang, yu/HGU-0029-2022	Berkovic, Samuel/0000-0003-4580-841X; McIntosh, Anne/0000-0002-5020-260X				Berg AT, 1997, J CLIN NEUROPHYSIOL, V14, P102, DOI 10.1097/00004691-199703000-00003; Camfield P, 2002, EPILEPSIA, V43, P662, DOI 10.1046/j.1528-1157.2002.03102.x; FEKSI AT, 1991, LANCET, V337, P406, DOI 10.1016/0140-6736(91)91176-U; Gowers WR, 1881, EPILEPSY OTHER CHRON; HAUSER WA, 1998, EPILEPSY COMPREHENSI, P47; Haut SR, 2004, LANCET NEUROL, V3, P608, DOI 10.1016/S1474-4422(04)00881-6; Kwan P, 2004, J NEUROL NEUROSUR PS, V75, P1376, DOI 10.1136/jnnp.2004.045690; Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009; Morrell Frank, 1993, P126; Sutula TP, 2004, EPILEPSY RES, V60, P161, DOI 10.1016/j.eplepsyres.2004.07.001; VANDONSELAAR CA, 1997, BRIT MED J, V314, P391; WATTS AE, 1992, EPILEPSIA, V33, P464, DOI 10.1111/j.1528-1157.1992.tb01692.x	12	10	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2005	365	9476					1985	1986		10.1016/S0140-6736(05)66674-3	http://dx.doi.org/10.1016/S0140-6736(05)66674-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950700				2022-12-28	WOS:000229701400004
J	Ashikari, M; Sakakibara, H; Lin, SY; Yamamoto, T; Takashi, T; Nishimura, A; Angeles, ER; Qian, Q; Kitano, H; Matsuoka, M				Ashikari, M; Sakakibara, H; Lin, SY; Yamamoto, T; Takashi, T; Nishimura, A; Angeles, ER; Qian, Q; Kitano, H; Matsuoka, M			Cytokinin oxidase regulates rice grain production	SCIENCE			English	Article							QUANTITATIVE TRAIT LOCUS; ORYZA-SATIVA L.; GREEN-REVOLUTION; PHOTOPERIOD SENSITIVITY; DRAFT SEQUENCE; FLOWERING TIME; ARABIDOPSIS; MAIZE; GENES; YIELD	Most agriculturally important traits are regulated by genes known as quantitative trait loci (QTLs) derived from natural allelic variations. We here show that a QTL that increases grain productivity in rice, Gn1a, is a gene for cytokinin oxidase/ dehydrogenase (OsCKX2), an enzyme that degrades the phytohormone cytokinin. Reduced expression of OsCKX2 causes cytokinin accumulation in inflorescence meristems and increases the number of reproductive organs, resulting in enhanced grain yield. QTL pyramiding to combine loci for grain number and plant height in the same genetic background generated lines exhibiting both beneficial traits. These results provide a strategy for tailormade crop improvement.	Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan; RIKEN, Plant Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Honda Res Inst Japan Co Ltd, Chiba 2920818, Japan; China Natl Rice Res Inst, Hangzhou 310006, Peoples R China	Nagoya University; RIKEN; Honda Motor Company; Chinese Academy of Agricultural Sciences; China National Rice Research Institute, CAAS	Matsuoka, M (corresponding author), Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan.	makoto@agr.nagoya-u.ac.jp	qian, qian/AAH-8708-2021; Sakakibara, Hitoshi/A-6040-2010; Ding, Cheng-Qiang/B-6287-2011; Yamamoto, Toshio/AAX-7146-2020	Sakakibara, Hitoshi/0000-0001-5449-6492; Yamamoto, Toshio/0000-0002-5209-7735				ARMSTRONG D, 1994, CYTOKININ CHEM ACTIV, pCH11; ASHIKARI M, 2002, BREED SCI; Austin DF, 2000, CROP SCI, V40, P30, DOI 10.2135/cropsci2000.40130x; BERNIER G, 1993, PLANT CELL, V5, P1147, DOI 10.1105/tpc.5.10.1147; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; El-Assal SED, 2001, NAT GENET, V29, P435, DOI 10.1038/ng767; *FAO, STAT FOOD INS WORLD; Feng Q, 2002, NATURE, V420, P316, DOI 10.1038/nature01183; Frary A, 2000, SCIENCE, V289, P85, DOI 10.1126/science.289.5476.85; Fridman E, 2000, P NATL ACAD SCI USA, V97, P4718, DOI 10.1073/pnas.97.9.4718; Gale MD, 1998, P NATL ACAD SCI USA, V95, P1971, DOI 10.1073/pnas.95.5.1971; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Ho JC, 2002, THEOR APPL GENET, V105, P440, DOI 10.1007/s00122-002-0945-x; Khush G, 2003, NUTR REV, V61, pS114, DOI 10.1301/nr.2003.jun.S114-S116; Khush GS, 2001, P NUTR SOC, V60, P15, DOI 10.1079/PNS200075; Kojima S, 2002, PLANT CELL PHYSIOL, V43, P1096, DOI 10.1093/pcp/pcf156; Liu JP, 2002, P NATL ACAD SCI USA, V99, P13302, DOI 10.1073/pnas.162485999; MILLER CO, 1955, J AM CHEM SOC, V77, P1392, DOI 10.1021/ja01610a105; Mok DWS, 2001, ANNU REV PLANT PHYS, V52, P89, DOI 10.1146/annurev.arplant.52.1.89; MOK MC, 1994, CYTOKININ CHEM ACTIV, pCH12; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; Peng JR, 1999, NATURE, V400, P256, DOI 10.1038/22307; *RIC CHROM 10 SEQ, 2003, SCIENCE NEW YORK NY, V0300; Salse J, 2004, PLANT J, V38, P396, DOI 10.1111/j.1365-313X.2004.02058.x; Sasaki A, 2002, NATURE, V416, P701, DOI 10.1038/416701a; Sasaki T, 2005, PLANT CELL PHYSIOL, V46, P3, DOI 10.1093/pcp/pci503; Sasaki T, 2002, NATURE, V420, P312, DOI 10.1038/nature01184; Schmulling T, 2003, J PLANT RES, V116, P241, DOI 10.1007/s10265-003-0096-4; Spielmeyer W, 2002, P NATL ACAD SCI USA, V99, P9043, DOI 10.1073/pnas.132266399; Takahashi Y, 2001, P NATL ACAD SCI USA, V98, P7922, DOI 10.1073/pnas.111136798; *UN POP FUND, 2004, STAT WORLD POP; Veldboom LR, 1996, CROP SCI, V36, P1310, DOI 10.2135/cropsci1996.0011183X003600050040x; Werner T, 2003, PLANT CELL, V15, P2532, DOI 10.1105/tpc.014928; Werner T, 2001, P NATL ACAD SCI USA, V98, P10487, DOI 10.1073/pnas.171304098; Yano M, 2001, CURR OPIN PLANT BIOL, V4, P130, DOI 10.1016/S1369-5266(00)00148-5; Yano M, 2000, PLANT CELL, V12, P2473, DOI 10.1105/tpc.12.12.2473; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037	37	1151	1409	37	551	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 29	2005	309	5735					741	745		10.1126/science.1113373	http://dx.doi.org/10.1126/science.1113373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951NU	15976269				2022-12-28	WOS:000230938200041
J	Franssen, MTM; Korevaar, JC; Leschot, NJ; Bossuyt, PMM; Knegt, AC; Gerssen-Schoorl, KBJ; Wouters, CH; Hansson, KBM; Hochstenbach, R; Madan, K; van der Veen, F; Goddijn, M				Franssen, MTM; Korevaar, JC; Leschot, NJ; Bossuyt, PMM; Knegt, AC; Gerssen-Schoorl, KBJ; Wouters, CH; Hansson, KBM; Hochstenbach, R; Madan, K; van der Veen, F; Goddijn, M			Selective chromosome analysis in couples with two or more miscarriages: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECURRENT MISCARRIAGE; ABNORMALITIES	Objective To identify additional factors, such as maternal age or factors related to previous reproductive outcome or family history, and the corresponding probability of carrying a chromosome abnormality in couples with two or more miscarriages. Design Nested case-control study. Setting Six centres for clinical genetics in the Netherlands. Participants Couples referred for chromosome analysis after two or more miscarriages in 1992-2000; 279 carrier couples were marked as cases, and 428 non-carrier couples served as controls. Main outcome measures Independent factors influencing the probability of carrier status and the corresponding probability of carrier status. Results Four factors influencing the probability of carrier status could be identified: maternal age at second miscarriage, a history of three or more miscarriages, a history of two or more miscarriages in a brother or sister of either partner, and a history of two or more miscarriages in the parents of either partner. The calculated probability of carrier status in couples referred for chromosome analysis after two or more miscarriages varied between 0.5% and 10.2%. Conclusions The probability of carrier status in couples with two or more miscarriages is modified by additional factors. Selective chromosome analysis would result in a more appropriate referral policy, could decrease the annual number of chromosome analyses, and could therefore lower the costs.	Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynaecol, Ctr Reprod Med, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, VU Med Ctr, Dept Clin Genet, NL-1012 WX Amsterdam, Netherlands; Univ Groningen Hosp, Dept Clin Genet, Groningen, Netherlands; Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands; Leiden Univ, Med Ctr, Dept Clin Genet, Leiden, Netherlands; Univ Med Ctr Utrecht, Dept Clin Genet, Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Groningen; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; Utrecht University Medical Center	Franssen, MTM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynaecol, Ctr Reprod Med, POB 22660, NL-1100 DD Amsterdam, Netherlands.	maureen.franssen@planet.nl	Goddijn, Mariette/L-7849-2013; Bossuyt, Patrick M/AAR-1183-2021; Bossuyt, Patrick M./B-4557-2016	Bossuyt, Patrick M/0000-0003-4427-0128; Bossuyt, Patrick M./0000-0003-4427-0128; Goddijn, Mariette/0000-0001-9928-9673; Wouters, Carine/0000-0002-6426-8845				Andersen AMN, 2000, BRIT MED J, V320, P1708, DOI 10.1136/bmj.320.7251.1708; [Anonymous], 2002, INT J GYNECOL OBSTET, V78, P179; BOURROUILLOU G, 1986, HUM GENET, V74, P399, DOI 10.1007/BF00280493; CLIFFORD K, 1994, HUM REPROD, V9, P1328, DOI 10.1093/oxfordjournals.humrep.a138703; COWCHOCK FS, 1993, FERTIL STERIL, V59, P1011; de La Rochebrochard E, 2002, HUM REPROD, V17, P1649, DOI 10.1093/humrep/17.6.1649; DEBRAEKELEER M, 1990, HUM REPROD, V5, P519, DOI 10.1093/oxfordjournals.humrep.a137135; *DUTCH SOC OBST GY, 1999, 20 DUTCH SOC OBST GY; Fryns JP, 1998, EUR J OBSTET GYN R B, V81, P171, DOI 10.1016/S0301-2115(98)00185-7; Goddijn M, 2004, HUM REPROD, V19, P1013, DOI 10.1093/humrep/deh172; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; HASSOLD T, 1985, HUM GENET, V70, P11, DOI 10.1007/BF00389450; HOOK EB, 1989, ANN HUM GENET, V53, P237, DOI 10.1111/j.1469-1809.1989.tb01790.x; HOSMER DW, 1989, APPL LOGISTIC REGRES; *ISCN, 1995, ISCN 1995 REC INT ST; PORTNOI MF, 1988, OBSTET GYNECOL, V72, P31; *ROYAL COLL OBST G, 2003, 17 RCOG; SACHS ES, 1985, OBSTET GYNECOL, V65, P375; SMITH A, 1990, AUST NZ J OBSTET GYN, V30, P57, DOI 10.1111/j.1479-828X.1990.tb03197.x; Stephenson MD, 2002, HUM REPROD, V17, P446, DOI 10.1093/humrep/17.2.446; THARAPEL AT, 1985, BRIT J OBSTET GYNAEC, V92, P899, DOI 10.1111/j.1471-0528.1985.tb03069.x	21	76	82	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 16	2005	331	7509					137	139		10.1136/bmj.38498.669595.8F	http://dx.doi.org/10.1136/bmj.38498.669595.8F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947GV	15985440	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000230632300015
J	Mestan, KKL; Marks, JD; Hecox, K; Huo, D; Schreiber, MD				Mestan, KKL; Marks, JD; Hecox, K; Huo, D; Schreiber, MD			Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-BIRTH-WEIGHT; NEONATAL RESEARCH NETWORK; NATIONAL INSTITUTE; CHILD HEALTH; FUNCTIONAL OUTCOMES; CEREBRAL-PALSY; SYNTHASE; IMMUNOREACTIVITY; PREDICTION; AGE	Background: Chronic lung disease and severe intraventricular hemorrhage or periventricular leukomalacia in premature infants are associated with abnormal neurodevelopmental outcomes. In a previous randomized, controlled, single-center trial of premature infants with the respiratory distress syndrome, inhaled nitric oxide decreased the risk of death or chronic lung disease as well as severe intraventricular hemorrhage and periventricular leukomalacia. We hypothesized that infants treated with inhaled nitric oxide would also have improved neurodevelopmental outcomes. Methods: We conducted a prospective, longitudinal follow-up study of premature infants who had received inhaled nitric oxide or placebo to investigate neurodevelopmental outcomes at two years of corrected age. Neurologic examination, neurodevelopmental assessment, and anthropometric measurements were made by examiners who were unaware of the children's original treatment assignment. Results: A total of 138 children (82 percent of survivors) were evaluated. In the group given inhaled nitric oxide, 17 of 70 children (24 percent) had abnormal neurodevelopmental outcomes, defined as either disability (cerebral palsy, bilateral blindness, or bilateral hearing loss) or delay (no disability, but one score of less than 70 on the Bayley Scales of Infant Development II), as compared with 31 of 68 children (46 percent) in the placebo group (relative risk, 0.53; 95 percent confidence interval, 0.33 to 0.87; P=0.01). This effect persisted after adjustment for birth weight and sex, as well as for the presence or absence of chronic lung disease and severe intraventricular hemorrhage or periventricular leukomalacia. The improvement in neurodevelopmental outcome in the group given inhaled nitric oxide was primarily due to a 47 percent decrease in the risk of cognitive impairment (defined by a score of less than 70 on the Bayley Mental Developmental Index) (P=0.03). Conclusions: Premature infants treated with inhaled nitric oxide have improved neurodevelopmental outcomes at two years of age.	Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Schreiber, MD (corresponding author), Univ Chicago, Dept Pediat, MC 6060,5841 S Maryland Ave, Chicago, IL 60637 USA.	mschreiber@peds.bsd.uchicago.edu	Marks, Jeremy/W-2087-2019	Marks, Jeremy/0000-0002-2644-5257	NINDS NIH HHS [R01 NS038547] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038547] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bayley N, 1993, BAYLEY SCALES INFANT; BLAYMOREBIER J, 1994, ACTA PAEDIATR, V83, P1244, DOI 10.1111/j.1651-2227.1994.tb13005.x; Cheung PY, 1998, J PEDIATR-US, V133, P735, DOI 10.1016/S0022-3476(98)70142-8; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Dezoete JA, 2003, CHILD CARE HLTH DEV, V29, P367, DOI 10.1046/j.1365-2214.2003.00349.x; Doyle LW, 2001, ARCH DIS CHILD-FETAL, V85, pF159, DOI 10.1136/fn.85.3.F159; Gidday JM, 1999, J CEREBR BLOOD F MET, V19, P331, DOI 10.1097/00004647-199903000-00011; Guo, 2002, VITAL HLTH STAT, V11, DOI DOI 10.1016/J.BBRC.2015.06.114; Hack M, 2000, ARCH PEDIAT ADOL MED, V154, P725, DOI 10.1001/archpedi.154.7.725; Hack M, 1999, EARLY HUM DEV, V53, P193, DOI 10.1016/S0378-3782(98)00052-8; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Lemons JA, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.1.e1; Msall ME, 2000, CLIN PERINATOL, V27, P381, DOI 10.1016/S0095-5108(05)70027-0; O'Shea TM, 1998, PAEDIATR PERINAT EP, V12, P72; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Piecuch RE, 1997, PEDIATRICS, V100, P633, DOI 10.1542/peds.100.4.633; Pinto-Martin JA, 2001, PEDIATRICS, V108, P238; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; RUBIN RA, 1979, DEV PSYCHOL, V15, P225, DOI 10.1037/0012-1649.15.2.225; Sanchez-Islas E, 2004, NITRIC OXIDE-BIOL CH, V10, P141, DOI 10.1016/j.niox.2004.04.001; Schreiber MD, 2003, NEW ENGL J MED, V349, P2099, DOI 10.1056/NEJMoa031154; Soyguder Z, 2004, J CHEM NEUROANAT, V27, P3, DOI 10.1016/j.jchemneu.2003.08.004; Stevenson DK, 1998, AM J OBSTET GYNECOL, V179, P1632, DOI 10.1016/S0002-9378(98)70037-7; SWAIMAN KF, 1999, PEDIAT NEUROLOGY PRI, P314; Van Meurs KP, 2005, NEW ENGL J MED, V353, P13, DOI 10.1056/NEJMoa043927; Vohr BR, 2000, PEDIATRICS, V105, P1216, DOI 10.1542/peds.105.6.1216; Wang XD, 2004, P NATL ACAD SCI USA, V101, P11477, DOI 10.1073/pnas.0402201101; Yeh TF, 2004, NEW ENGL J MED, V350, P1304, DOI 10.1056/NEJMoa032089; Zhang YT, 2002, BRAIN RES BULL, V58, P385, DOI 10.1016/S0361-9230(02)00808-0; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	30	135	146	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2005	353	1					23	32		10.1056/NEJMoa043514	http://dx.doi.org/10.1056/NEJMoa043514			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942FC	16000353				2022-12-28	WOS:000230267300005
J	Stockinger, ZT				Stockinger, ZT			Death and life in Iraq	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												ztstockinger@mar.med.navy.mil						Hopson LR, 2003, J AM COLL SURGEONS, V196, P106, DOI 10.1016/S1072-7515(02)01668-X; Stockinger ZT, 2004, J AM COLL SURGEONS, V198, P227, DOI 10.1016/j.jamcollsurg.2003.10.012	2	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2005	294	1					17	18		10.1001/jama.294.1.17	http://dx.doi.org/10.1001/jama.294.1.17			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941JD	15998875				2022-12-28	WOS:000230210200001
J	Kamphuis, S; Kuis, W; de Jager, W; Teklenburg, G; Massa, M; Gordon, G; Boerhof, M; Rijkers, GT; Uiterwaal, CS; Otten, HG; Sette, A; Albani, S; Prakken, BJ				Kamphuis, S; Kuis, W; de Jager, W; Teklenburg, G; Massa, M; Gordon, G; Boerhof, M; Rijkers, GT; Uiterwaal, CS; Otten, HG; Sette, A; Albani, S; Prakken, BJ			Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis	LANCET			English	Article							HEAT-SHOCK PROTEINS; RHEUMATOID-ARTHRITIS; VACCINE DESIGN; HUMAN HSP60; INTERLEUKIN-10; AUTOIMMUNITY; RECOGNITION; REMISSION; TOOLS	Background juvenile idiopathic arthritis is a heterogeneous autoimmune disease characterised by chronic inflammation of one or more joints. In patients with this disease, T-cell reactivity to autologous heat-shock protein 60 (HSP60) is associated with a favourable prognosis. We sought to identify HSP60 T-cell epitopes to find potential targets for HSP60 immunotherapy and to assess whether immune responses to these epitopes contribute to the distinct clinical outcome of this disease. Methods We identified eight potential epitopes using a computer algorithm from both self and microbial HSP60 binding to many HLA-DR molecules. We analysed the pattern of T-cell responses induced by these HSP60 peptides in peripheral-blood mononuclear cells (PBMC) of 57 patients with juvenile idiopathic arthritis, 27 healthy controls, and 20 disease controls. We undertook in-vitro MHC binding studies with the identified peptides, and HLA class II typing of a subset of patients with juvenile idiopathic arthritis. Findings Five of the eight peptides identified yielded proliferative T-cell responses in 50-70% of PBMC from patients with juvenile idiopathic arthritis irrespective of MHC genotype, but not in PBMC from healthy or disease controls. Although PBMC from both patients with juvenile idiopathic arthritis and healthy controls produced interferon gamma in response to these peptides, only PBMC from patients with the disease produced interleukin 10. Interpretation The recorded T-cell-induction in juvenile idiopathic arthritis is tolerogenic. In patients with oligoarticular disease, the immune responses to the HSP60 epitopes identified could contribute to disease remission. Relevance to practice The broad recognition of these HSP60 epitopes in a population of patients with polymorphic MHC genotypes opens the way for HSP60-peptide immunotherapy, representing a novel treatment option to specifically modulate the immune system in patients with juvenile idiopathic arthritis.	Univ Med Ctr Utrecht, Dept Paediat Immunol, NL-3508 AB Utrecht, Netherlands; Univ Med Ctr Utrecht, IACOPO Inst Translat Med, NL-3508 AB Utrecht, Netherlands; Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 AB Utrecht, Netherlands; IRCCS San Matteo, Biotechnol Lab, Pavia, Italy; La Jolla Inst Allergy & Immunol, La Jolla, CA USA; Univ Calif San Diego, Dept Med & Paediat, San Diego, CA 92103 USA; Univ Calif San Diego, IACOPO Inst Translat Med, San Diego, CA 92103 USA; Androclus Therapeut, Milan, Italy	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; IRCCS Fondazione San Matteo; La Jolla Institute for Immunology; University of California System; University of California San Diego; University of California System; University of California San Diego	Prakken, BJ (corresponding author), Univ Med Ctr Utrecht, Dept Paediat Immunol, KC-03-063-0,POB 85090, NL-3508 AB Utrecht, Netherlands.	b.prakken@wkz.azu.nl	Massa, Margherita/K-4682-2016; Kamphuis, Sylvia/AAJ-8195-2020; Sette, Alessandro/AFO-8916-2022; Rijkers, Ger/AAW-6143-2020; Rijkers, Ger/R-7236-2019	Massa, Margherita/0000-0001-8037-0439; Rijkers, Ger/0000-0001-6948-6123; de Jager, Wilco/0000-0002-0014-0682				Abulafia-Lapid R, 1999, J AUTOIMMUN, V12, P121, DOI 10.1006/jaut.1998.0262; ALBANI S, 1995, NAT MED, V1, P448, DOI 10.1038/nm0595-448; Bason C, 2003, LANCET, V362, P1971, DOI 10.1016/S0140-6736(03)15016-7; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Cohen IR, 2004, J CLIN INVEST, V114, P1227, DOI 10.1172/JCI200422396; COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; de Kleer IM, 2003, ARTHRITIS RHEUM, V48, P2001, DOI 10.1002/art.11174; DEGRAEFFMEEDER ER, 1995, J CLIN INVEST, V95, P934, DOI 10.1172/JCI117801; DEGRAEFFMEEDER ER, 1991, LANCET, V337, P1368, DOI 10.1016/0140-6736(91)93057-G; Gaston JSH, 1997, AUTOIMMUNITY, V26, P33, DOI 10.3109/08916939709009548; Lillicrap MS, 2004, INT IMMUNOL, V16, P405, DOI 10.1093/intimm/dxh032; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nepom GT, 2002, ARTHRITIS RHEUM, V46, P5, DOI 10.1002/1529-0131(200201)46:1<5::AID-ART10063>3.0.CO;2-S; Petty RE, 2004, J RHEUMATOL, V31, P390; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Prakken ABJ, 1996, ARTHRITIS RHEUM-US, V39, P1826, DOI 10.1002/art.1780391108; Prakken B, 2000, NAT MED, V6, P1406, DOI 10.1038/82231; Prakken BJ, 2004, P NATL ACAD SCI USA, V101, P4228, DOI 10.1073/pnas.0400061101; Prakken BJ, 2003, SPRINGER SEMIN IMMUN, V25, P47, DOI 10.1007/s00281-003-0128-7; Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5; Sette A, 2000, SCIENCE, V290, P2074; Sette A, 2003, CURR OPIN IMMUNOL, V15, P461, DOI 10.1016/S0952-7915(03)00083-9; Southwood S, 1998, J IMMUNOL, V160, P3363; van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593; VANDERZEE R, 1995, PEPTIDES 1994, P841; vanRoon JAG, 1997, J CLIN INVEST, V100, P459, DOI 10.1172/JCI119553; Woo P, 1998, LANCET, V351, P969	28	130	140	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	2005	366	9479					50	56		10.1016/S0140-6736(05)66827-4	http://dx.doi.org/10.1016/S0140-6736(05)66827-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993233				2022-12-28	WOS:000230277600034
J	Rose, PW; Hamden, A; Brueggemann, AB; Perera, R; Sheikh, A; Crook, D; Mant, D				Rose, PW; Hamden, A; Brueggemann, AB; Perera, R; Sheikh, A; Crook, D; Mant, D			Chloramphenicol treatment for,acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial	LANCET			English	Article							EYE DISEASE	Background One in eight schoolchildren have an episode of acute infective conjunctivitis every year. Standard clinical practice is to prescribe a topical antibiotic, although the evidence to support this practice is scarce. We undertook a randomised double-blind trial to compare the effectiveness of chloramphenicol eye drops with placebo in children with infective conjunctivitis in primary care. Methods Our study included 326 children aged 6 months to 12 years with a clinical diagnosis of conjunctivitis who were recruited from 12 general medical practices in the UK. We assigned 163 children to receive chloramphenicol eye drops and 163 to receive placebo eye drops. Eye swabs were taken for bacterial and viral analysis. The primary outcome was clinical cure at day 7, which was assessed from diaries completed by parents. All children were followed up for 6 weeks to identify relapse. Survival statistics were used for comparison, and analysis was by intention to treat. Findings Nine children were lost to follow-up (one in chloramphenicol group; eight in placebo group). Clinical cure by day 7 occurred in 128 (83%) of 155 children with placebo compared with 140 (86%) of 162 with chloramphenicol (risk difference 3.8%, 95% CI-4.1% to 11.8%). Seven (4%) children with chloramphenicol and five (3%) with placebo had further conjunctivitis episodes within 6 weeks (1.2%, -2.9% to 5.3%). Adverse events were rare and evenly distributed between each group. Interpretation Most children presenting with acute infective conjunctivitis in primary care will get better by themselves and do not need treatment with an antibiotic.	Univ Oxford, Dept Primary Hlth Care, Oxford OX3 7LF, England; Univ Oxford, Acad Dept Microbiol & Infect Dis, Oxford OX3 7LF, England; Univ Edinburgh, Div Community Hlth Sci, GP Sect, Edinburgh, Midlothian, Scotland	University of Oxford; University of Oxford; University of Edinburgh	Rose, PW (corresponding author), Univ Oxford, Dept Primary Hlth Care, Oxford OX3 7LF, England.	peter.rose@dphpc.ox.ac.uk	Sheikh, Aziz/D-2818-2009; Mant, David CA/C-7763-2009	Sheikh, Aziz/0000-0001-7022-3056; Brueggemann, Angela/0000-0002-2329-1934; Perera, Rafael/0000-0003-2418-2091	Medical Research Council [G0000340] Funding Source: Medline; MRC [G0000340] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		DART JKG, 1986, BRIT MED J, V293, P1477, DOI 10.1136/bmj.293.6560.1477; DELMAR CB, 2004, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000023.PUB2; Department of Health, 2004, PRESCR COST AN ENGL; DOONA M, 1995, BRIT MED J, V310, P1217, DOI 10.1136/bmj.310.6989.1217; Everitt H, 2002, FAM PRACT, V19, P658, DOI 10.1093/fampra/19.6.658; GIGLIOTTI F, 1981, J PEDIATR-US, V98, P531, DOI 10.1016/S0022-3476(81)80754-8; GIGLIOTTI F, 1984, J PEDIATR-US, V104, P623; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; KETTENMEYER A, 1998, J CLIN RES, V1, P75; Lancaster T, 1998, BRIT MED J, V316, P667, DOI 10.1136/bmj.316.7132.667; MCCORMICK M, 1995, MORBIDITY STAT GEN P; MCDONNELL PJ, 1988, BRIT J OPHTHALMOL, V72, P733, DOI 10.1136/bjo.72.10.733; MONTERO J, 1998, J CLIN RES, V1, P29; Normann EK, 2002, ACTA OPHTHALMOL SCAN, V80, P183, DOI 10.1034/j.1600-0420.2002.800212.x; Papas EB, 2000, INVEST OPHTH VIS SCI, V41, P687; SHEIKH A, 1999, COCHRANE DATABASE SY, V4; Venekamp RP, 2015, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD000219.PUB4, 10.1002/14651858.CD000219.pub4]; WEISS A, 1993, J PEDIATR-US, V122, P10, DOI 10.1016/S0022-3476(05)83479-1	18	81	88	1	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	2005	366	9479					37	43		10.1016/S0140-6736(05)66709-8	http://dx.doi.org/10.1016/S0140-6736(05)66709-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993231				2022-12-28	WOS:000230277600032
J	Tokatlidis, K				Tokatlidis, K			A disulfide relay system in mitochondria	CELL			English	Editorial Material							INTERMEMBRANE SPACE; IMPORT; MIA40	In this issue of Cell, Mesecke et al. (2005) show that there is a disulfide relay system in the intermembrane space (IMS) of mitochondria that is comprised of the proteins Mia40 and Erv1. This disulfide relay system promotes the import and oxidative folding of proteins. Oxidized Mia40 traps newly imported proteins through mixed disulfide bridges. Subsequent isomerization of these disulfide bridges allows the imported protein to be folded in the IMS. The reduced Mia40 generated is then reoxidized by the sulfhydryl oxidase Erv1, promoting the next round of disulficle exchange. The new work clarifies the molecular function of Mia40 and reveals Mia40 to be the first physiological substrate for the FAD-linked Erv1.	Univ Crete, Vasilika Vouton, IMBB FORTH, GR-71110 Iraklion, Crete, Greece; Univ Crete, Dept Chem, GR-71110 Iraklion, Crete, Greece	University of Crete; University of Crete	Tokatlidis, K (corresponding author), Univ Crete, Vasilika Vouton, IMBB FORTH, GR-71110 Iraklion, Crete, Greece.			Tokatlidis, Kostas/0000-0001-6295-8183	MRC [G0000153] Funding Source: UKRI; Medical Research Council [G0000153] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Allen S, 2003, J BIOL CHEM, V278, P38505, DOI 10.1074/jbc.M306027200; Arnesano F, 2005, STRUCTURE, V13, P713, DOI 10.1016/j.str.2005.02.015; Chacinska A, 2004, EMBO J, V23, P3735, DOI 10.1038/sj.emboj.7600389; Curran SP, 2004, J BIOL CHEM, V279, P43744, DOI 10.1074/jbc.M404878200; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Lee JE, 2000, FEBS LETT, V477, P62, DOI 10.1016/S0014-5793(00)01767-1; Lu H, 2004, J BIOL CHEM, V279, P18952, DOI 10.1074/jbc.M313045200; Lu H, 2004, J BIOL CHEM, V279, P18959, DOI 10.1074/jbc.M313046200; Mesecke N, 2005, CELL, V121, P1059, DOI 10.1016/j.cell.2005.04.011; Naoe M, 2004, J BIOL CHEM, V279, P47815, DOI 10.1074/jbc.M410272200; Terziyska N, 2005, FEBS LETT, V579, P179, DOI 10.1016/j.febslet.2004.11.072	14	55	56	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	2005	121	7					965	967		10.1016/j.cell.2005.06.019	http://dx.doi.org/10.1016/j.cell.2005.06.019			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989945	Bronze			2022-12-28	WOS:000230448000002
J	Bryce, J; Black, RE; Walker, N; Bhutta, ZA; Lawn, JE; Steketee, RW				Bryce, J; Black, RE; Walker, N; Bhutta, ZA; Lawn, JE; Steketee, RW			Can the world afford to save the lives of 6 million children each year?	LANCET			English	Article							HEALTH; INTERVENTIONS; MORTALITY	Background In July, 2003, the Bellagio Study Group on Child Survival estimated that the lives of 6 million children could be saved each year if 23 proven interventions were universally available in the 42 countries responsible for 90% of child deaths in 2000. Here we assess the cost of delivering these interventions, and discuss whether the achievement of the Millennium Development Goal (MDG) for child survival falls within the financial capacities of donors and developing countries. Methods All child survival interventions shown to reduce mortality from the major causes of death in children younger than 5 years were incorporated into a delivery timetable comprised of 18 contacts between a child or mother and a health-care provider in the period from before birth until the child reaches 5 years. The running costs of delivering the interventions at universal coverage levels were calculated as the sum of unit costs for drugs and materials, delivery costs, and programme management and support costs, including supervision. We estimated the cost of providing interventions at coverage levels reported for 2000 and the additional costs of providing services at universal coverage levels. Findings US$5.1 billion in new resources is needed annually to save 6 million child lives in the 42 countries responsible for 90% of child deaths in 2000. This cost represents $1.23 per head in these countries, or an average cost per child life saved of $887. Sensitivity analyses for salary levels for community delivery agents, drug costs, and coverage rates for 2000 were used to develop uncertainty estimates around the US$ 5.1 billion annual price tag that range from about $3.1 billion to $8.0 billion. Interpretation Achieving the MDG for child survival is affordable for donors and developing countries. Scaling up health delivery is the challenge, and, along with the lack of funds, will be the limiting factor in reducing child mortality by two-thirds by 2015.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; UNICEF, Div Policy & Planning, New York, NY USA; Aga Khan Univ, Dept Paediat, Karachi, Pakistan; Save Children USA, Saving Newborn Lives, Westport, CT USA; Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; UNICEF; Aga Khan University; Save the Children; Centers for Disease Control & Prevention - USA	Black, RE (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.	rblack@jhsph.edu	Lawn, Joy/ABE-6382-2020	Lawn, Joy/0000-0002-4573-1443; Black, Robert/0000-0001-9926-7984				[Anonymous], STAT WORLDS VACC IMM; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; *EC RES SERV, USDA BRIEF ROOM TOB; Edejer T, 2003, MAKING CHOICES HLTH; *GAVI, 2004, GAVI HIB SUPPL SUBGR; *GLOB FUND, GLOB FUND ANN REP 20; Johns B, 2005, HEALTH POLICY PLANN, V20, P1, DOI 10.1093/heapol/czi001; Johns Benjamin, 2003, Cost Eff Resour Alloc, V1, P1, DOI 10.1186/1478-7547-1-1; *JOINT UN PROGR HI, 2004, FIN EXP RESP AIDS; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Montgomery M.R., 1998, DEATH BIRTH MORTALIT; Morris SS, 2004, LANCET, V364, P2030, DOI 10.1016/S0140-6736(04)17515-6; *POP DIV DEP EC SO, 2001, WORLD POP PROSP 2000; Sachs JD, 2001, MACR HLTH INV HLTH E; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; Snow RW, 2003, TRENDS PARASITOL, V19, P363, DOI 10.1016/S1471-4922(03)00168-5; Stein CE, 2003, J INFECT DIS, V187, pS8, DOI 10.1086/368114; *UNICEF WHO, 2000, GLOB WAT SUPPL SAN A; United Nations, 2001, REPORT SECRETARY GEN; VANDEMOORTELE J, MAKING SENSE MDG COS; Victora CG, 2004, LANCET, V364, P1541, DOI 10.1016/S0140-6736(04)17279-6; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0; WHO, 2000, INT MAN PREGN CHILD; *WHO UNICEF UNFPA, 2002, MAT MORT 2000; World Bank, 2004, WORLD DEV REP 2004 M, DOI [10.1596/0-8213-5468-x, DOI 10.1596/0-8213-5468-X]; World Health Organization, INT MAN CHILDH ILLN; World Health Organization, WORLD HLTH REP 2005	33	113	114	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	2005	365	9478					2193	2200		10.1016/S0140-6736(05)66777-3	http://dx.doi.org/10.1016/S0140-6736(05)66777-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978927				2022-12-28	WOS:000230034800029
J	Keymeulen, B; Vandemeulebroucke, E; Ziegler, AG; Mathieu, C; Kaufman, L; Hale, G; Gorus, F; Goldman, M; Walter, M; Candon, S; Schandene, L; Crenier, L; De Block, C; Seigneurin, JM; De Pauw, P; Pierard, D; Weets, I; Rebello, P; Bird, P; Berrie, E; Frewin, M; Waldmann, H; Bach, JF; Pipeleers, D; Chatenoud, L				Keymeulen, B; Vandemeulebroucke, E; Ziegler, AG; Mathieu, C; Kaufman, L; Hale, G; Gorus, F; Goldman, M; Walter, M; Candon, S; Schandene, L; Crenier, L; De Block, C; Seigneurin, JM; De Pauw, P; Pierard, D; Weets, I; Rebello, P; Bird, P; Berrie, E; Frewin, M; Waldmann, H; Bach, JF; Pipeleers, D; Chatenoud, L			Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-CD3 MONOCLONAL-ANTIBODY; CD3 ANTIBODY; SELF-TOLERANCE; PHASE-I; MODULATION; DIAGNOSIS; RESPONSES; MELLITUS; RELEASE; ASSAY	Background Type 1 diabetes mellitus is a T-cell-mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be prevented by treatment with CD3 monoclonal antibodies, as suggested by the results of a phase 1 study. To provide proof of this therapeutic principle at the metabolic level, we initiated a phase 2 placebo-controlled trial with a humanized antibody, an aglycosylated human IgG1 antibody directed against CD3 (ChAglyCD3). Methods In a multicenter study, 80 patients with new-onset type 1 diabetes were randomly assigned to receive placebo or ChAglyCD3 for six consecutive days. Patients were followed for 18 months, during which their daily insulin needs and residual beta-cell function were assessed according to glucose-clamp-induced C-peptide release before and after the administration of glucagon. Results At 6, 12, and 18 months, residual beta-cell function was better maintained with ChAglyCD3 than with placebo. The insulin dose increased in the placebo group but not in the ChAglyCD3 group. This effect of ChAglyCD3 was most pronounced among patients with initial residual beta-cell function at or above the 50th percentile of the 80 patients. In this subgroup, the mean insulin dose at 18 months was 0.22 IU per kilogram of body weight per day with ChAglyCD3, as compared with 0.61 IU per kilogram with placebo (P<0.001). In this subgroup, 12 of 16 patients who received ChAglyCD3 (75 percent) received minimal doses of insulin (lessthan/equal 0.25 IU per kilogram per day) as compared with none of the 21 patients who received placebo. Administration of ChAglyCD3 was associated with a moderate "flu-like'' syndrome and transient symptoms of Epstein-Barr viral mononucleosis. Conclusions Short-term treatment with CD3 antibody preserves residual beta-cell function for at least 18 months in patients with recent-onset type 1 diabetes.	Free Univ Brussels, Acad Hosp, B-1090 Brussels, Belgium; Free Univ Brussels, Diabet Res Ctr, Brussels, Belgium; Free Univ Brussels, Dept Biostat & Med Informat, Brussels, Belgium; Hosp Munchen Schwabing, Munich, Germany; Katholieke Univ Leuven, Dept Endocrinol, Louvain, Belgium; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Libre Bruxelles, Hop Erasme, Brussels, Belgium; Hop Necker Enfants Malad, IRNEM, INSERM, U580, Paris, France; Univ Antwerp Hosp, Dept Diabetol, Edegem, Belgium; Ctr Hosp Univ Michallon, Virol Lab, Grenoble, France	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; KU Leuven; University of Oxford; Universite Libre de Bruxelles; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Antwerp; CHU Grenoble Alpes	Keymeulen, B (corresponding author), Free Univ Brussels, JDRF Ctr Beta Cell Therapy, Med Campus,Laarbeeklaan 103, B-1090 Brussels, Belgium.	bart.keymeulen@az.vub.ac.be	waldmann, herman/W-8051-2019; waldmann, herman/F-7412-2011; Ziegler, Anette-Gabriele/M-4614-2014; mathieu, chantal/ABD-5505-2021; De+Block, Christophe/ABE-1600-2020	Ziegler, Anette-Gabriele/0000-0002-6290-5548; mathieu, chantal/0000-0002-4055-5233; Weets, Ilse/0000-0002-9007-5203; Gorus, Frans/0000-0002-9007-6177; Hale, Geoff/0000-0001-9473-423X; Crenier, Laurent/0000-0003-2326-4108; De Pauw, Pieter/0000-0002-6463-4585; Pierard, DEnis/0000-0002-7756-3691; Waldmann, Herman/0000-0001-7519-6720; Keymeulen, Bart/0000-0002-8671-4527; Pipeleers, Daniel/0000-0002-6440-2485				ABRAMOWICZ D, 1989, TRANSPLANTATION, V47, P606, DOI 10.1097/00007890-198904000-00008; ALEGRE ML, 1994, TRANSPLANTATION, V57, P1537; [Anonymous], 1988, Diabetes, V37, P1574; Bachelez H, 1998, J AUTOIMMUN, V11, P53, DOI 10.1006/jaut.1997.0175; Belghith M, 2003, NAT MED, V9, P1202, DOI 10.1038/nm924; BOLT S, 1993, EUR J IMMUNOL, V23, P403, DOI 10.1002/eji.1830230216; Brengel-Pesce K, 2002, J MED VIROL, V66, P360, DOI 10.1002/jmv.2153; Chatenoud L, 1997, J IMMUNOL, V158, P2947; CHATENOUD L, 1994, P NATL ACAD SCI USA, V91, P123, DOI 10.1073/pnas.91.1.123; CHATENOUD L, 1982, EUR J IMMUNOL, V12, P979, DOI 10.1002/eji.1830121116; CHATENOUD L, 1990, TRANSPLANTATION, V49, P697, DOI 10.1097/00007890-199004000-00009; Chatenoud L, 2003, NAT REV IMMUNOL, V3, P123, DOI 10.1038/nri1000; Decochez K, 2000, DIABETES CARE, V23, P838, DOI 10.2337/diacare.23.6.838; Decochez K, 2000, DIABETES CARE, V23, P1072, DOI 10.2337/diacare.23.8.1072; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; FEUTREN G, 1986, LANCET, V2, P119; Friend PJ, 1999, TRANSPLANTATION, V68, P1632, DOI 10.1097/00007890-199912150-00005; FRIER BM, 1977, DIABETES, V26, P369; Gerlo E, 1997, CLIN CHEM, V43, P2353; Greenbaum CJ, 2003, DIABETES, V52, P2643; Greenbaum CJ, 2003, DIABETES, V52, P1059, DOI 10.2337/diabetes.52.5.1059; Hale G, 2004, BLOOD, V104, P948, DOI 10.1182/blood-2004-02-0593; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Hislop AD, 2002, J EXP MED, V195, P893, DOI 10.1084/jem.20011692; Hislop AD, 2001, J IMMUNOL, V167, P2019, DOI 10.4049/jimmunol.167.4.2019; LIKE AA, 1979, SCIENCE, V206, P1421, DOI 10.1126/science.388619; Phillips J, 2001, CYTOTHERAPY, V3, P233, DOI 10.1080/146532401753174061; Rebello P, 2002, J IMMUNOL METHODS, V260, P285, DOI 10.1016/S0022-1759(01)00556-7; ROUTLEDGE EG, 1991, EUR J IMMUNOL, V21, P2717, DOI 10.1002/eji.1830211111; STILLER CR, 1984, SCIENCE, V223, P1362, DOI 10.1126/science.6367043; Van der Auwera BJ, 2002, HUM IMMUNOL, V63, P40, DOI 10.1016/S0198-8859(01)00362-7; Woodle ES, 1999, TRANSPLANTATION, V68, P608, DOI 10.1097/00007890-199909150-00003	32	814	875	1	52	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					2598	2608		10.1056/NEJMoa043980	http://dx.doi.org/10.1056/NEJMoa043980			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972866				2022-12-28	WOS:000229953700007
J	Peters, CJ				Peters, CJ			Marburg and ebola - Arming ourselves against the deadly filoviruses	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Texas, Med Branch, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston	Peters, CJ (corresponding author), Univ Texas, Med Branch, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77550 USA.								0	29	30	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					2571	2573		10.1056/NEJMp058109	http://dx.doi.org/10.1056/NEJMp058109			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972860	Bronze			2022-12-28	WOS:000229953700001
J	Zwierlein, MW; Abo-Shaeer, JR; Schirotzek, A; Schunck, CH; Ketterle, W				Zwierlein, MW; Abo-Shaeer, JR; Schirotzek, A; Schunck, CH; Ketterle, W			Vortices and superfluidity in a strongly interacting Fermi gas	NATURE			English	Article							BOSE-EINSTEIN CONDENSATE	Quantum degenerate Fermi gases provide a remarkable opportunity to study strongly interacting fermions. In contrast to other Fermi systems, such as superconductors, neutron stars or the quark-gluon plasma of the early Universe, these gases have low densities and their interactions can be precisely controlled over an enormous range. Previous experiments with Fermi gases have revealed condensation of fermion pairs. Although these and other studies were consistent with predictions assuming superfluidity, proof of superfluid behaviour has been elusive. Here we report observations of vortex lattices in a strongly interacting, rotating Fermi gas that provide definitive evidence for superfluidity. The interaction and therefore the pairing strength between two Li-6 fermions near a Feshbach resonance can be controlled by an external magnetic field. This allows us to explore the crossover from a Bose-Einstein condensate of molecules to a Bardeen-Cooper-Schrieffer superfluid of loosely bound pairs. The crossover is associated with a new form of superfluidity that may provide insights into high-transition-temperature superconductors.	MIT, Dept Phys, MIT HArvard Ctr Ultracold Atoms, Cambridge, MA 02139 USA; MIT, Elect Res Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Zwierlein, MW (corresponding author), MIT, Dept Phys, MIT HArvard Ctr Ultracold Atoms, Cambridge, MA 02139 USA.	zwierlei@mit.edu	Schunck, Christian H/A-3625-2010	Schunck, Christian H/0000-0002-7917-8180; /0000-0001-8120-8548				Abo-Shaeer JR, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.070409; Abo-Shaeer JR, 2001, SCIENCE, V292, P476, DOI 10.1126/science.1060182; Anglin JR, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.240401; Bartenstein M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.203201; Bartenstein M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.120401; Bartenstein M., 2004, PHYS REV LETT, V94; Bourdel T, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.050401; Bruun GM, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.063606; Bulgac A, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.190404; Carr LD, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.150404; Chin C, 2004, SCIENCE, V305, P1128, DOI 10.1126/science.1100818; Cozzini M, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.070401; Dieckmann K, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.203201; EAGLES DM, 1969, PHYS REV, V186, P456, DOI 10.1103/PhysRev.186.456; Greiner M, 2003, NATURE, V426, P537, DOI 10.1038/nature02199; Hadzibabic Z, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.160401; Haljan PC, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.210403; Hodby E, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.010405; Huang K., 1995, BOSE EINSTEIN CONDEN, P31; Jochim S, 2003, SCIENCE, V302, P2101, DOI 10.1126/science.1093280; Kinast J, 2005, SCIENCE, V307, P1296, DOI 10.1126/science.1109220; Kinast J, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.150402; Leggett A. J., 1980, Modern Trends in the Theory of Condensed Matter. Proceedings of the XVIth Karpacz Winter School of Theoretical Physics, P13; Madison KW, 2001, PHYS REV LETT, V86, P4443, DOI 10.1103/PhysRevLett.86.4443; Madison KW, 2000, PHYS REV LETT, V84, P806, DOI 10.1103/PhysRevLett.84.806; Madison KW, 2000, J MOD OPTIC, V47, P2715, DOI 10.1080/095003400750039645; Matthews MR, 1999, PHYS REV LETT, V83, P2498, DOI 10.1103/PhysRevLett.83.2498; NOZIERES P, 1985, J LOW TEMP PHYS, V59, P195, DOI 10.1007/BF00683774; O'Hara KM, 2002, SCIENCE, V298, P2179, DOI 10.1126/science.1079107; Onofrio R, 2000, PHYS REV LETT, V84, P810, DOI 10.1103/PhysRevLett.84.810; Pitaevskii L, 2002, SCIENCE, V298, P2144, DOI 10.1126/science.1080087; Raman C, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.210402; Regal CA, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.040403; Rodriguez M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.100402; Schecter DA, 1999, PHYS FLUIDS, V11, P905, DOI 10.1063/1.869961; TONINI G, 2005, FORMATION VORTEX LAT; Zwierlein MW, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.120403; Zwierlein MW, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.250401	39	810	823	2	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1047	1051		10.1038/nature03858	http://dx.doi.org/10.1038/nature03858			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973400	Green Submitted			2022-12-28	WOS:000229970400038
J	Santaguida, PL; Helfand, M; Raina, P				Santaguida, PL; Helfand, M; Raina, P			Challenges in systematic reviews that evaluate drug efficacy or effectiveness	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIALS; ALZHEIMER-DISEASE; NETWORK METAANALYSIS; HEALTH-POLICY; HEPATITIS-C; COMBINATION; PROGRESSION; DEMENTIA; VALIDITY; THERAPY	Increasingly, consumers, clinicians, regulatory bodies, and insurers are using systematic reviews of drug interventions to select treatments and set policies. Although a systematic review cannot provide all the information a clinician needs to make an informed choice for therapy, it can help decision makers distinguish what claims about effectiveness are based on evidence, identify critical information gaps, describe features of the evidence that limit applicability in practice, and address whether drug effectiveness differs for particular subgroups of patients. To improve the relevance and validity of reviews of drug therapies, reviewers need to delineate clinically important subgroups, specific aims of therapy, and most important outcomes. They may need to find unpublished trials, studies other than direct comparator (head-to-head) trials, and additional details of published trials from pharmaceutical manufacturers and regulatory agencies. In this paper, we address ways to formulate questions relevant to specific clinical therapeutic aims; discuss types of studies to include in drug efficacy and effectiveness reviews and how to find them; and describe ways to assess applicability of studies to actual practice.	McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada; Portland VA Med Ctr, Portland, OR USA; Oregon Hlth & Sci Univ, Evidence Based Pract Ctr, Portland, OR USA	McMaster University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Oregon Health & Science University	Raina, P (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, DTC Room 306,1280 Main St W, Hamilton, ON L8S 4L8, Canada.							Baker Stuart G, 2002, BMC Med Res Methodol, V2, P13, DOI 10.1186/1471-2288-2-13; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Bowler JV, 1997, ARCH NEUROL-CHICAGO, V54, P697, DOI 10.1001/archneur.1997.00550180021007; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Chou R, 2005, ANN INTERN MED, V142, P1090, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00009; Chou R, 2004, ANN INTERN MED, V140, P465, DOI 10.7326/0003-4819-140-6-200403160-00014; Cochrane Collaboration, 2003, COCHR REV HDB VERS 4; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; EDDY DM, 1990, MED DECIS MAKING, V10, P15, DOI 10.1177/0272989X9001000104; Falck-Ytter Y, 2002, ANN INTERN MED, V136, P288, DOI 10.7326/0003-4819-136-4-200202190-00008; Fox DM, 2005, HEALTH AFFAIR, V24, P114, DOI 10.1377/hlthaff.24.1.114; Frackiewicz Editya J., 2002, ETHNICITY DRUG DEV T; Helfand M., 2005, DRUG CLASS REV TRIPT; Huster WJ, 1998, STAT MED, V17, P1829; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Kalow W, 1998, PHARMACOGENETICS, V8, P283; Khan A, 2002, INT J NEUROPSYCHOPH, V5, P193, DOI 10.1017/S1461145702002912; Leber P, 1997, ALZ DIS ASSOC DIS, V11, pS10; Leber P, 1997, ALZ DIS ASSOC DIS, V11, pS37; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201; McDermott MP, 2002, CONTROL CLIN TRIALS, V23, P635, DOI 10.1016/S0197-2456(02)00238-6; MULROW CD, 1999, AHCPR PUBLICATION; Phillips Carl V, 2004, BMC Med Res Methodol, V4, P20, DOI 10.1186/1471-2288-4-20; Psaty BM, 2002, JAMA-J AM MED ASSOC, V287, P1680, DOI 10.1001/jama.287.13.1680; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; SANTAGUIDA PS, 2004, AHRQ PUBLICATION; Shekelle P, 2003, AHRQ PUBLICATION, V03-E023; Snow V, 2002, ANN INTERN MED, V137, P840, DOI 10.7326/0003-4819-137-10-200211190-00014; Snow V, 2000, ANN INTERN MED, V132, P738, DOI 10.7326/0003-4819-132-9-200005020-00010; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; SONG F, 2000, HEALTH TECHNOL ASSES, V4, P10; STERN RG, 1994, AM J PSYCHIAT, V151, P390; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; WEINSHILBOUM R, 2003, NEW ENGL J MED, P41; Whitehouse PJ, 1998, ALZ DIS ASSOC DIS, V12, P281, DOI 10.1097/00002093-199812000-00007; Yazdanpanah Y, 2004, BMJ-BRIT MED J, V328, P249, DOI 10.1136/bmj.37995.435787.A6	38	22	22	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1066	1072		10.7326/0003-4819-142-12_Part_2-200506211-00006	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938CN	15968031				2022-12-28	WOS:000229977600006
J	Brey, EM; Greisler, HP				Brey, EM; Greisler, HP			Telomerase expression in somatic cells	LANCET			English	Editorial Material									Loyola Univ, Med Ctr, Dept Surg, Maywood, IL 60153 USA; Hines VA Hosp, Dept Surg, Hines, IL USA; IIT, Dept Biomed Engn, Chicago, IL 60616 USA; Loyola Univ, Med Ctr, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Illinois Institute of Technology; Loyola University Chicago	Greisler, HP (corresponding author), Loyola Univ, Med Ctr, Dept Surg, Maywood, IL 60153 USA.	hgreisl@lumc.edu						Badylak SF, 2002, ANN NY ACAD SCI, V961, P319, DOI 10.1111/j.1749-6632.2002.tb03113.x; Brey EM, 2005, TISSUE ENG, V11, P567, DOI 10.1089/ten.2005.11.567; Cao P, 2000, J VASC SURG, V31, P19, DOI 10.1016/S0741-5214(00)70064-4; Matsubara J, 2001, J CARDIOVASC SURG, V42, P375; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Xue L, 2003, J VASC SURG, V37, P472, DOI 10.1067/mva.2003.88	6	5	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2068	2069		10.1016/S0140-6736(05)66715-3	http://dx.doi.org/10.1016/S0140-6736(05)66715-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964429				2022-12-28	WOS:000229858800006
J	Poh, M; Boyer, M; Solan, A; Dahl, SLM; Pedrotty, D; Banik, SSR; McKee, JA; Klinger, RY; Counter, CM; Niklason, LE				Poh, M; Boyer, M; Solan, A; Dahl, SLM; Pedrotty, D; Banik, SSR; McKee, JA; Klinger, RY; Counter, CM; Niklason, LE			Blood vessels engineered from human cells	LANCET			English	Article							IN-VITRO	Tissue engineering has made considerable progress in the past decade, but advances have stopped short of clinical application for most tissues. We postulated that an obstacle in engineering human tissues is the limited replicative capacity of adult somatic cells. To test this hypothesis, the effectiveness of telomerase expression to extend cellular lifespan was assessed in a model of human vascular tissue engineering. Telomerase expression in vascular cells isolated from elderly patients enabled the successful culture of engineered autologous blood vessels. Engineered vessels may one day provide a source of bypass conduit for patients with atherosclerotic disease.	Duke Univ, Med Ctr, Dept Anesthesia, Durham, NC 27708 USA; Duke Univ, Med Ctr, Dept Biomed Engn, Durham, NC 27708 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27708 USA; Univ Pittsburgh, Pittsburgh, PA USA	Duke University; Duke University; Duke University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Niklason, LE (corresponding author), Duke Univ, Med Ctr, Dept Anesthesia, CIEMAS Room 1395,100 Sci Dr, Durham, NC 27708 USA.	nikla001@mc.duke.edu		Boyer, Matthew/0000-0002-8970-2046; Counter, Christopher M/0000-0003-0748-3079	NCI NIH HHS [CA-82481] Funding Source: Medline; NHLBI NIH HHS [HL-63766, F32-HL-71407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082481] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063766, F32HL071407] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Counter CM, 2003, LANCET, V361, P1345, DOI 10.1016/S0140-6736(03)13042-5; Dahl SLM, 2003, CELL TRANSPLANT, V12, P659, DOI 10.3727/000000003108747136; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; McKee JA, 2003, EMBO REP, V4, P633, DOI 10.1038/sj.embor.embor847; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489	6	167	178	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2122	2124		10.1016/S0140-6736(05)66735-9	http://dx.doi.org/10.1016/S0140-6736(05)66735-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964449				2022-12-28	WOS:000229858800029
J	Sherwood, DR; Butler, JA; Kramer, JM; Sternberg, PW				Sherwood, DR; Butler, JA; Kramer, JM; Sternberg, PW			FOS-1 promotes basement-membrane removal during anchor-cell invasion in C. elegans	CELL			English	Article							CAENORHABDITIS-ELEGANS; EXTRACELLULAR-MATRIX; CADHERIN SUPERFAMILY; AMINO-ACID; CANCER; EXPRESSION; DROSOPHILA; GENES; JUN; PROTEINS	Cell invasion through basement membranes is crucial during morphogenesis and cancer metastasis. Here, we genetically dissect this process during anchor-cell invasion into the vulval epithelium in C. elegans. We have identified the fos transcription factor ortholog fos-1 as a critical regulator of basement-membrane removal. In fos-1 mutants, the gonadal anchor cell extends cellular processes normally toward vulval cells, but these processes fail to remove the basement membranes separating the gonad from the vulval epithelium. fos-1 is expressed in the anchor cell and controls invasion cell autonomously. We have identified ZMP-1, a membrane-type matrix metalloproteinase, CDH-3, a Fat-like protocadherin, and hemicentin, a fibulin family extracellular matrix protein, as transcriptional targets of FOS-1 that promote invasion. These results reveal a key genetic network that controls basement-membrane removal during cell invasion.	CALTECH, HHMI, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; Northwestern University	Sternberg, PW (corresponding author), CALTECH, HHMI, 1200 E Calif Blvd, Pasadena, CA 91125 USA.	pws@caltech.edu	Sherwood, David/ABG-4265-2020	Sherwood, David/0000-0002-4448-6917	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027211] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K01CA098316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079320, F32GM019977] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA098316-01, K01 CA098316] Funding Source: Medline; NICHD NIH HHS [HD27211] Funding Source: Medline; NIGMS NIH HHS [F32 GM019977, R01 GM079320] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Affolter M, 2003, DEV CELL, V4, P11, DOI 10.1016/S1534-5807(02)00410-0; Aoyagi K, 1998, CLIN CANCER RES, V4, P2153; Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; BRENNER S, 1974, GENETICS, V77, P71; Burdine RD, 1998, DEVELOPMENT, V125, P1083; Castillejo-Lopez C, 2004, J BIOL CHEM, V279, P24034, DOI 10.1074/jbc.M313878200; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Ciani L, 2003, MOL CELL BIOL, V23, P3575, DOI 10.1128/MCB.23.10.3575-3582.2003; Coghlan A, 2002, GENOME RES, V12, P857, DOI 10.1101/gr.172702; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; Doyle TG, 2000, P NATL ACAD SCI USA, V97, P7877, DOI 10.1073/pnas.97.14.7877; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ERNTAGE L, 2004, NEURON, V44, P795; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Hill E, 2001, J MOL BIOL, V305, P1011, DOI 10.1006/jmbi.2000.4361; Huang CC, 2003, DEVELOPMENT, V130, P3343, DOI 10.1242/dev.00481; Hwang BJ, 2004, DEVELOPMENT, V131, P143, DOI 10.1242/dev.00924; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kataki A, 2003, NEOPLASMA, V50, P26; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; Kirouac M, 2003, DEV BIOL, V257, P85, DOI 10.1016/S0012-1606(03)00032-0; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Moeller MJ, 2004, EMBO J, V23, P3769, DOI 10.1038/sj.emboj.7600380; Moghal N, 2003, EXP CELL RES, V284, P150, DOI 10.1016/S0014-4827(02)00097-6; Moitra J, 1997, BIOCHEMISTRY-US, V36, P12567, DOI 10.1021/bi971424h; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605; Pettitt J, 1996, DEVELOPMENT, V122, P4149; Plenefisch JD, 2000, DEVELOPMENT, V127, P1197; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schreiber M, 2000, DEVELOPMENT, V127, P4937; SEYDOUX G, 1993, DEV BIOL, V157, P423, DOI 10.1006/dbio.1993.1146; Sherwood DR, 2003, DEV CELL, V5, P21, DOI 10.1016/S1534-5807(03)00168-0; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Souid S, 2003, DEV DYNAM, V227, P150, DOI 10.1002/dvdy.10293; Starz-Gaiano M, 2004, CURR OPIN GENET DEV, V14, P86, DOI 10.1016/j.gde.2003.12.001; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STETLERSTEVENSO.WG, 2001, CANC BIOL, V11, P143; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; Vogel BE, 2001, DEVELOPMENT, V128, P883; VOLM M, 1993, J CANCER RES CLIN, V119, P507, DOI 10.1007/BF01686458; Wada K, 1998, GENE, V211, P57, DOI 10.1016/S0378-1119(98)00076-6; Yang CH, 2002, CELL, V108, P675, DOI 10.1016/S0092-8674(02)00658-X; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	57	143	155	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	2005	121	6					951	962		10.1016/j.cell.2005.03.031	http://dx.doi.org/10.1016/j.cell.2005.03.031			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960981	Bronze			2022-12-28	WOS:000230011200016
J	Camacho, J; Arenas, A				Camacho, J; Arenas, A			Food-web topology - Universal scaling in food-web structure?	NATURE			English	Editorial Material									Univ Autonoma Barcelona, Dept Fis, Bellaterra 08193, Spain; Univ Rovira & Virgili, Dept Informat Engn & Matemat, Tarragona 43007, Spain	Autonomous University of Barcelona; Universitat Rovira i Virgili	Camacho, J (corresponding author), Univ Autonoma Barcelona, Dept Fis, Bellaterra 08193, Spain.	juan.camacho@uab.es	Arenas, Alex/A-5216-2009; Camacho, Juan/I-7963-2014	Arenas, Alex/0000-0003-0937-0334; Camacho, Juan/0000-0002-8095-4167				Dunne JA, 2002, P NATL ACAD SCI USA, V99, P12917, DOI 10.1073/pnas.192407699; Garlaschelli D, 2003, NATURE, V423, P165, DOI 10.1038/nature01604; Link J, 2002, MAR ECOL PROG SER, V230, P1, DOI 10.3354/meps230001; Opitz S., 1996, INT CTR LIVING AQUAT, V43, P1; Yodzis P, 1998, J ANIM ECOL, V67, P635, DOI 10.1046/j.1365-2656.1998.00224.x	5	19	19	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 16	2005	435	7044					E3	E4		10.1038/nature03839	http://dx.doi.org/10.1038/nature03839			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959469				2022-12-28	WOS:000229799700035
J	Feagan, BG; Greenberg, GR; Wild, G; Fedorak, RN; Pare, P; McDonald, JWD; Dube, R; Cohen, A; Steinhart, AH; Landau, S; Aguzzi, RA; Fox, IH; Vandervoort, MK				Feagan, BG; Greenberg, GR; Wild, G; Fedorak, RN; Pare, P; McDonald, JWD; Dube, R; Cohen, A; Steinhart, AH; Landau, S; Aguzzi, RA; Fox, IH; Vandervoort, MK			Treatment of ulcerative colitis with a humanized antibody to the alpha(4)beta(7) integrin	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLAMMATORY-BOWEL-DISEASE; CELL-ADHESION MOLECULE-1; CROHNS-DISEASE; INTEGRIN ALPHA-4-BETA-7; CONTROLLED-TRIAL; THERAPY; INFLIXIMAB; MADCAM-1; NATALIZUMAB; EXPRESSION	BACKGROUND: Selective blockade of interactions between leukocytes and vascular endothelium in the gut is a promising strategy for the treatment of inflammatory bowel diseases. METHODS: We conducted a multicenter, double-blind, placebo-controlled trial of MLN02, a humanized antibody to the (alpha)(sub 4)(beta)(sub 7) integrin, in patients with active ulcerative colitis. We randomly assigned 181 patients to receive 0.5 mg of MLN02 per kilogram of body weight, 2.0 mg per kilogram, or an identical-appearing placebo intravenously on day 1 and day 29. Eligible patients also received concomitant mesalamine or no other treatment for colitis. Ulcerative colitis clinical scores and sigmoidoscopic assessments were evaluated six weeks after randomization. RESULTS: Clinical remission rates at week 6 were 33 percent, 32 percent, and 14 percent for the group receiving 0.5 mg of MLN02 per kilogram, the group receiving 2.0 mg per kilogram, and the placebo group, respectively (P=0.03). The corresponding proportions of patients who improved by at least 3 points on the ulcerative colitis clinical score were 66 percent, 53 percent, and 33 percent (P=0.002). Twenty-eight percent of patients receiving 0.5 mg per kilogram and 12 percent of those receiving 2.0 mg per kilogram had endoscopically evident remission, as compared with 8 percent of those receiving placebo (P=0.007). For the minority of patients in whom an MLN02 antibody titer greater than 1:125 developed, incomplete saturation of the (alpha)(sub 4)(beta)(sub 7) receptor on circulating lymphocytes was observed and no benefit of treatment was identifiable. CONCLUSIONS: In this short-term study, MLN02 was more effective than placebo for the induction of clinical and endoscopic remission in patients with active ulcerative colitis.	John P Robarts Res Inst, Robarts Clin Trials, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada; Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; Dynogen Pharmaceut, Waltham, MA USA; Millennium Pharmaceut Inc, Cambridge, MA USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; McGill University; University of Alberta; Laval University; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Feagan, BG (corresponding author), John P Robarts Res Inst, Robarts Clin Trials, 100 Perth Dr, London, ON N6A 5K8, Canada.	bfeagan@robarts.ca	Feagan, Brian G/M-4283-2015; Greenberg, Gordon/C-4620-2015; Feagan, Brian/G-3292-2011	Fedorak, Richard/0000-0002-7382-0080				Arihiro S, 2002, PATHOL INT, V52, P367, DOI 10.1046/j.1440-1827.2002.01365.x; Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; BARON JH, 1964, BRIT MED J, V1, P89, DOI 10.1136/bmj.1.5375.89; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Briskin M, 1997, AM J PATHOL, V151, P97; Clark M, 2000, IMMUNOL TODAY, V21, P397, DOI 10.1016/S0167-5699(00)01680-7; ERLE DJ, 1994, J IMMUNOL, V153, P517; Farrell RJ, 2003, GASTROENTEROLOGY, V124, P917, DOI 10.1053/gast.2003.50145; Faubion WA, 2001, GASTROENTEROLOGY, V121, P255, DOI 10.1053/gast.2001.26279; Feagan BG, 2000, GASTROENTEROLOGY, V118, pA874, DOI 10.1016/S0016-5085(00)85637-1; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; Gisbert JP, 2002, DIGEST DIS SCI, V47, P471, DOI 10.1023/A:1017987229718; Hesterberg PE, 1996, GASTROENTEROLOGY, V111, P1373, DOI 10.1053/gast.1996.v111.pm8898653; *INT FED PHARM MAN, 2003, MED DICT REG ACT MED; IRVINE EJ, 1994, GASTROENTEROLOGY, V106, P287, DOI 10.1016/0016-5085(94)90585-1; Jani N, 2002, GASTROENTEROL CLIN N, V31, P147, DOI 10.1016/S0889-8553(01)00010-3; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KRESS S, CLIN REV ABBOTT BIOL; Kugathasan S, 2002, AM J GASTROENTEROL, V97, P1408, DOI 10.1016/S0002-9270(02)04140-0; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Pharand C, 2002, PHARMACOTHERAPY, V22, P380, DOI 10.1592/phco.22.5.380.33196; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; RILEY SA, 1991, GUT, V32, P174, DOI 10.1136/gut.32.2.174; Ritter G, 2001, CANCER RES, V61, P6851; Rutgeerts P, 2004, GASTROENTEROLOGY, V126, P1593, DOI 10.1053/j.gastro.2004.02.070; Sandborn WJ, 2001, INFLAMM BOWEL DIS, V7, pS9, DOI 10.1002/ibd.3780070504; Sandborn WJ, 2003, ALIMENT PHARM THER, V17, P29, DOI 10.1046/j.1365-2036.2003.01408.x; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; Stein RB, 2000, DRUG SAFETY, V23, P429, DOI 10.2165/00002018-200023050-00006; SWINTON J, 1994, J THEOR BIOL, V169, P23, DOI 10.1006/jtbi.1994.1127; Van Assche G, 2002, INFLAMM BOWEL DIS, V8, P291, DOI 10.1097/00054725-200207000-00009; von Andrian UH, 2003, NEW ENGL J MED, V348, P68, DOI 10.1056/NEJMe020157; Yang YX, 2002, AM J GASTROENTEROL, V97, P803	33	521	551	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2005	352	24					2499	2507		10.1056/NEJMoa042982	http://dx.doi.org/10.1056/NEJMoa042982			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935RH	15958805				2022-12-28	WOS:000229798900005
J	Kessler, RC; Demler, O; Frank, RG; Olfson, M; Pincus, HA; Walters, EE; Wang, P; Wells, KB; Zaslavsky, AM				Kessler, RC; Demler, O; Frank, RG; Olfson, M; Pincus, HA; Walters, EE; Wang, P; Wells, KB; Zaslavsky, AM			Prevalence and treatment of mental disorders, 1990 to 2003	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNATIONAL DIAGNOSTIC INTERVIEW; DSM-IV DISORDERS; UNITED-STATES; COMPETING DEMANDS; COMORBIDITY; CARE; DEPRESSION; HEALTH; SEVERITY; LIFETIME	BACKGROUND: Although the 1990s saw enormous change in the mental health care system in the United States, little is known about changes in the prevalence or rate of treatment of mental disorders. \ METHODS: We examined trends in the prevalence and rate of treatment of mental disorders among people 18 to 54 years of age during roughly the past decade. Data from the National Comorbidity Survey (NCS) were obtained in 5388 face-to-face household interviews conducted between 1990 and 1992, and data from the NCS Replication were obtained in 4319 interviews conducted between 2001 and 2003. Anxiety disorders, mood disorders, and substance-abuse disorders that were present during the 12 months before the interview were diagnosed with the use of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV). Treatment for emotional disorders was categorized according to the sector of mental health services: psychiatry services, other mental health services, general medical services, human services, and complementary-alternative medical services. RESULTS: The prevalence of mental disorders did not change during the decade (29.4 percent between 1990 and 1992 and 30.5 percent between 2001 and 2003, P=0.52), but the rate of treatment increased. Among patients with a disorder, 20.3 percent received treatment between 1990 and 1992 and 32.9 percent received treatment between 2001 and 2003 (P<0.001). Overall, 12.2 percent of the population 18 to 54 years of age received treatment for emotional disorders between 1990 and 1992 and 20.1 percent between 2001 and 2003 (P<0.001). Only about half those who received treatment had disorders that met diagnostic criteria for a mental disorder. Significant increases in the rate of treatment (49.0 percent between 1990 and 1992 and 49.9 percent between 2001 and 2003) were limited to the sectors of general medical services (2.59 times as high in 2001 to 2003 as in 1990 to 1992), psychiatry services (2.17 times as high), and other mental health services (1.59 times as high) and were independent of the severity of the disorder and of the sociodemographic characteristics of the respondents. CONCLUSIONS: Despite an increase in the rate of treatment, most patients with a mental disorder did not receive treatment. Continued efforts are needed to obtain data on the effectiveness of treatment in order to increase the use of effective treatments.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; RAND, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA	Harvard University; Harvard Medical School; Columbia University; New York State Psychiatry Institute; Columbia University; RAND Corporation; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kessler, RC (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	kessler@hcp.med.harvard.edu	Young, Alexander/A-1523-2009; Olfson, Mark/AAA-8547-2021; Demler, Olga/AAE-8436-2019	Young, Alexander/0000-0002-9367-9213; Demler, Olga/0000-0003-3355-3210	FOGARTY INTERNATIONAL CENTER [R03TW006481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049098, R13MH066849, U13MH066849, R01MH046376, R01MH069864, R01MH052861, U01MH060220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA015799, R01DA016558] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW006481-01A1, R01-TW006481, R03 TW006481] Funding Source: Medline; NIDA NIH HHS [K05 DA015799, R01 DA016558-02, R01 DA016558] Funding Source: Medline; NIMH NIH HHS [R01 MH049098, R01-MH069864, R01 MH069864, R13 MH066849, R01 MH046376, R01 MH52861, U01-MH60220, R01 MH046376-11, MH46376, U01 MH060220-04, R13 MH066849-03, U01 MH060220, R13-MH066849, R01 MH069864-02, U13 MH066849] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BENDER E, 2002, PSYCH NEWS      0816, P2; Department of Health and Human Services, 1999, MENT HLTH REP SURG G; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; FRANK R, IN PRESS BETTER NOT; Institute of Medicine Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; JACOBS DG, 1995, HARVARD REV PSYCHIAT, V3, P156, DOI 10.3109/10673229509017181; Kessler R.C., 1998, INT J METH PSYCH RES, V7, P33, DOI [DOI 10.1002/MPR.33, 10.1016/j.jad.2006.08.018]; Kessler RC, 1999, AM J PSYCHIAT, V156, P115, DOI 10.1176/ajp.156.1.115; Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Kessler RC, 2004, INT J METH PSYCH RES, V13, P69, DOI 10.1002/mpr.167; Kessler RC, 2003, ARCH GEN PSYCHIAT, V60, P1117, DOI 10.1001/archpsyc.60.11.1117; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Klinkman MS, 1997, GEN HOSP PSYCHIAT, V19, P98, DOI 10.1016/S0163-8343(96)00145-4; Leon AC, 1997, INT J PSYCHIAT MED, V27, P93, DOI 10.2190/T8EM-C8YH-373N-1UWD; MANDERSCHEID RW, 2001, MENTAL HLTH US 2000, P135; Mechanic D, 2004, HEALTH AFFAIR, V23, P84, DOI 10.1377/hlthaff.23.4.84; Mechanic D, 2003, HEALTH AFFAIR, V22, P8, DOI 10.1377/hlthaff.22.5.8; Narrow WE, 2002, ARCH GEN PSYCHIAT, V59, P115, DOI 10.1001/archpsyc.59.2.115; *NAT I MENT HLTH, 2003, REAL MEN REAL DEPR P; Olfson M, 2002, JAMA-J AM MED ASSOC, V287, P203, DOI 10.1001/jama.287.2.203; Pincus HA, 2003, INT J METH PSYCH RES, V12, P54, DOI 10.1002/mpr.142; President's New Freedom Commission on Mental Health, 2003, ACH PROM TRANSF MENT; Regier DA, 1998, ARCH GEN PSYCHIAT, V55, P109, DOI 10.1001/archpsyc.55.2.109; Robins L.N., 1991, PSYCHIAT DISORDERS A; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; Rost K, 2002, MED CARE RES REV, V59, P231, DOI 10.1177/1077558702059003001; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; Sturm R, 1999, J BEHAV HEALTH SER R, V26, P360, DOI 10.1007/BF02287297; Wakefield JC, 2002, ARCH GEN PSYCHIAT, V59, P129, DOI 10.1001/archpsyc.59.2.129; Wang PS, 2000, J GEN INTERN MED, V15, P284, DOI 10.1046/j.1525-1497.2000.9908044.x; Wang PS, 2003, INT J METH PSYCH RES, V12, P22, DOI 10.1002/mpr.139; Williams JW, 1998, J GEN INTERN MED, V13, P137, DOI 10.1046/j.1525-1497.1998.00032.x; Wolter K. M., 1985, INTRO VARIANCE ESTIM	35	1229	1246	4	111	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2005	352	24					2515	2523		10.1056/NEJMsa043266	http://dx.doi.org/10.1056/NEJMsa043266			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	935RH	15958807	Green Accepted			2022-12-28	WOS:000229798900007
J	Smith, C				Smith, C			Getting down to details	NATURE			English	Article																			0	13	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 16	2005	435	7044					991	996		10.1038/435991a	http://dx.doi.org/10.1038/435991a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959523	Bronze			2022-12-28	WOS:000229799700056
J	Dalton, R				Dalton, R			California stem-cell institute fights legal challenges	NATURE			English	News Item								The Californian stem-cell institute, California Institute for Regenerative Medicine, fights legal challenges.										2005, NATURE, V434, P427	1	0	0	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 2	2005	435	7042					544	544						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15957195				2022-12-28	WOS:000229476200008
J	Green, J; Young, J; Forster, A; Mallinder, K; Bogle, S; Lowson, K; Small, N				Green, J; Young, J; Forster, A; Mallinder, K; Bogle, S; Lowson, K; Small, N			Effects of locality based community hospital care on independence in older people needing rehabilitation: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE; OXFORDSHIRE; SCALE; BEDS	Objective To determine the effects on independence in older people needing rehabilitation in a locality based community hospital compared with care on a ward for elderly people in a district general hospital. Design Randomised controlled trial. Setting Care in a community hospital and district general hospital in Bradford, England. Participants 220 patients needing rehabilitation after an acute illness that required hospital admission. Interventions Patients were randomly allocated to a locality based community hospital or to remain within a department for the care of elderly people in a district general hospital. Main outcome measures Primary outcomes were Nottingham extended activities of daily living scale and general health questionnaire 28 (carer). Secondary outcomes were activities of daily living (Barthel index), Nottingham health profile, hospital anxiety and depression scale, mortality, destination after discharge, satisfaction with services, carer strain index, and carer's satisfaction with services. Results The median length of stay was 15 days for both the community hospital and the district general hospital groups (interquartile range: community hospital 9-25 days; district general hospital 9-24 days). Independence at six months was greater in the community hospital group (adjusted mean difference 5.30, 95% confidence interval 0.64 to 9.96). Results for the secondary outcome measures, including care satisfaction and measures of carer burden, were similar for both groups. Conclusions Care in a locality based community hospital is associated with greater independence for older people than care in wards for elderly people in a district general hospital.	St Lukes Hosp, Dept Hlth Care Elderly, Bradford BD5 0NA, W Yorkshire, England; Aysgarth Stat, Beaconsfield HP9 2AS, England; Univ York, York Hlth Econ Consortium, York YO10 5NH, N Yorkshire, England; Univ Bradford, Sch Hlth Studies, Bradford BD5 0BB, W Yorkshire, England	University of York - UK; University of Bradford	Green, J (corresponding author), St Lukes Hosp, Dept Hlth Care Elderly, Bradford BD5 0NA, W Yorkshire, England.	becarrd.1@bradfordhospitals.nhs.uk		young, john/0000-0003-4085-9306; Forster, Anne/0000-0001-7466-4414				BAKER JE, 1986, J EPIDEMIOL COMMUN H, V40, P117, DOI 10.1136/jech.40.2.117; BROOK RH, 1992, JAMA-J AM MED ASSOC, V268, P1321, DOI 10.1001/jama.268.10.1321; Collin C, 1988, Int Disabil Stud, V10, P61; Cook PJ, 1998, AGE AGEING, V27, P357, DOI 10.1093/ageing/27.3.357; *DEP HLTH, 2001, INT CAR; *DEP HLTH, 2000, CM48181; Department of Health, 2001, NAT SERV FRAM OLD PE; Department of Health, 2000, CM4818 DEP HLTH; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Harwood RH, 2002, DISABIL REHABIL, V24, P371, DOI 10.1080/09638280110101541; Hine C, 1996, J ROY SOC MED, V89, P681, DOI 10.1177/014107689608901207; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; Hunt SM, 1986, MEASURING HLTH STATU; MAHONEY F I, 1965, Md State Med J, V14, P61; McCormack B, 1993, Qual Health Care, V2, P253, DOI 10.1136/qshc.2.4.253; Nouri F., 1987, CLIN REHABIL, V1, P301, DOI [DOI 10.1177/026921558700100409, 10.1177/026921558700100409]; POUND P, 1993, J EPIDEMIOL COMMUN H, V47, P500, DOI 10.1136/jech.47.6.500; POUND P, 1994, CLIN REHABIL, V8, P7, DOI DOI 10.1177/026921559400800102; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Shepperd S, 2001, COCHRANE DB SYST REV, V2, DOI [10.1002/14651858.CD000356, DOI 10.1002/14651858.CD000356]; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; Young J, 2005, HEALTH SOC CARE COMM, V13, P307, DOI 10.1111/j.1365-2524.2005.00555.x; Young J, 2001, AGE AGEING, V30, P7, DOI 10.1093/ageing/30.suppl_3.7; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	24	40	42	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	2005	331	7512					317	320		10.1136/bmj.38498.387569.8F	http://dx.doi.org/10.1136/bmj.38498.387569.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	955WZ	15994660	Bronze, Green Published			2022-12-28	WOS:000231259800013
J	Cardis, E; Vrijheid, M; Blettner, M; Gilbert, E; Hakama, M; Hill, C; Howe, G; Kaldor, J; Muirhead, CR; Schubauer-Berigan, M; Yoshimura, T				Cardis, E; Vrijheid, M; Blettner, M; Gilbert, E; Hakama, M; Hill, C; Howe, G; Kaldor, J; Muirhead, CR; Schubauer-Berigan, M; Yoshimura, T		Int Study Grp	Risk of cancer after low doses of ionising radiation - retrospective cohort study in 15 countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; EXPOSURE; SMOKING; ENERGY; RATES	Objectives To provide direct estimates of risk of cancer after protracted low doses of ionising radiation and to strengthen the scientific basis of radiation protection standards for environmental, occupational, and medical diagnostic exposures. Design Multinational retrospective cohort study of cancer mortality. Setting Cohorts of workers in the nuclear industry in 15 countries. Participants 407 391 workers individually monitored for external radiation with a total follow-up of 5.2 million person years. Main outcome measurements Estimates of excess relative risks per sievert (Sv) of radiation dose for mortality from cancers other than leukaemia and from leukaemia excluding chronic lymphocytic leukaemia, the main causes of death considered by radiation protection authorities. Results The excess relative risk for cancers other than leukaemia was 0.97 per Sv, 95% confidence interval 0.14 to 1.97. Analyses of causes of death related or unrelated to smoking indicate that, although confounding by smoking may be present, it is unlikely to explain all of this increased risk. The excess relative risk for leukaemia excluding chronic lymphocytic leukaemia was 1.93 per Sv (< 0 to 8.47). On the basis of these estimates, 1-2% of deaths from cancer among workers in this cohort may be attributable to radiation. Conclusions These estimates, from the largest study of nuclear workers ever conducted, are higher than, but statistically compatible with, the risk estimates used for current radiation protection standards. The results suggest that there is a small excess risk of cancer, even at the low doses and dose rates typically received by nuclear workers in this study.	Int Agcy Res Canc, Radiat Grp, F-69372 Lyon, France; Johannes Gutenberg Univ Mainz, Inst Med Biostat Epidemiol & Informat, D-6500 Mainz, Germany; NCI, Radiat Epidemiol Branch, Div Epidemiol & Genet, Bethesda, MD 20892 USA; Univ Tampere, FIN-33101 Tampere, Finland; Inst Gustave Roussy, Villejuif, France; Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA; Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Hlth Protect Agcy, Radiat Protect Div, Didcot, Oxon, England; NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Industrywide Studies Branch, Cincinnati, OH 45226 USA; Fukuoka Inst Hlth & Environm Sci, Fukuoka, Japan	World Health Organization; International Agency for Research on Cancer (IARC); Johannes Gutenberg University of Mainz; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); UNICANCER; Gustave Roussy; Columbia University; University of New South Wales Sydney; Kirby Institute; Health Protection Agency; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Cardis, E (corresponding author), Int Agcy Res Canc, Radiat Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	cardis@iarc.fr	Schubauer-Berigan, Mary/B-3149-2009; Gulis, Gabriel/E-4505-2013; THIERRY-CHEF, Isabelle/P-8324-2018; Cardis, Elisabeth/C-3904-2017; Schubauer-Berigan, Mary/ABC-7996-2020; Vrijheid, Martine/H-2702-2014; Kaldor, John M/D-4545-2011; Ahn, Yoon-Ok/J-5530-2012; TARDY, HELENE/AAE-6287-2019	Schubauer-Berigan, Mary/0000-0002-5175-924X; Gulis, Gabriel/0000-0002-8174-4591; THIERRY-CHEF, Isabelle/0000-0001-6304-2783; Cardis, Elisabeth/0000-0003-0999-6839; Vrijheid, Martine/0000-0002-7090-1758; Auvinen, Anssi/0000-0003-1125-4818; Muirhead, Colin/0000-0001-5394-1267; TARDY, HELENE/0000-0001-8351-9825; Pearce, Mark/0000-0002-0583-3779	ODCDC CDC HHS [U50/CCU011778] Funding Source: Medline	ODCDC CDC HHS		Auvinen A, 2002, J OCCUP ENVIRON MED, V44, P634, DOI 10.1097/00043764-200207000-00008; *BEIR, 1990, EFF POP EXP LOW LEV; Berrington de Gonzalez A, 2004, LANCET, V363, P345, DOI 10.1016/S0140-6736(04)15433-0; CARDIS E, 1995, RADIAT RES, V142, P117, DOI 10.2307/3579020; CARDIS E, 1994, LANCET, V344, P1039; CARDIS E, 1997, INT COLLABORATIVE ST, V3; CARDIS E, 1992, 92001 INT AG RES CAN; CARDIS E, 1997, 97002 INT AG RES CAN; CARPENTER L, 1989, Journal of Radiological Protection, V9, P286, DOI 10.1088/0952-4746/9/4/110; Fix JJ, 1997, RADIAT PROT DOSIM, V74, P39, DOI 10.1093/oxfordjournals.rpd.a032180; GRIBBIN MA, 1993, RADIAT RES, V133, P375, DOI 10.2307/3578225; ICRP, 1991, TRAINING COURSE SERI, V60; International Agency for Research on Cancer, 2004, IARC MON EV CARC RIS, V83; Lee DJ, 2004, J OCCUP ENVIRON MED, V46, P538, DOI 10.1097/01.jom.0000128152.01896.ae; Muirhead C. R., 1999, Journal of Radiological Protection, V19, P3, DOI 10.1088/0952-4746/19/1/002; Murata Motoi, 2002, J Epidemiol, V12, P310; PETERSEN GR, 1990, HEALTH PHYS, V58, P3, DOI 10.1097/00004032-199001000-00001; Pierce DA, 1996, RADIAT RES, V146, P1, DOI 10.2307/3579391; Preston DL, 2003, RADIAT RES, V160, P381, DOI 10.1667/RR3049; Thierry-Chef I, 2002, RADIAT PROT DOSIM, V102, P101, DOI 10.1093/oxfordjournals.rpd.a006078; Thierry-Chef I, 2001, RADIAT PROT DOSIM, V94, P215, DOI 10.1093/oxfordjournals.rpd.a006493; United Nations Scientific Committee on the Effects of Atomic Radiation, 2000, UNSCEAR 2000 REPORT	22	407	439	0	41	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 9	2005	331	7508					77	80B		10.1136/bmj.38499.599861.E0	http://dx.doi.org/10.1136/bmj.38499.599861.E0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	945XR	15987704	Green Published, Bronze			2022-12-28	WOS:000230536800013
J	Bloche, MG; Marks, JH				Bloche, MG; Marks, JH			Doctors and interrigators at Guantanamo Bay	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Georgetown Univ, Washington, DC 20057 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Matrix Chambers, London, England	Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bloche, MG (corresponding author), Georgetown Univ, Washington, DC 20057 USA.		Marks, Jonathan/A-9696-2009					*DEP ARM, 1992, FIELD MAN 34 52 INT; HUCK RA, 2002, COMMUNICATION   0806; Lewis Neil A, 2004, N Y Times Web, pA14; Physicians for Human Rights, 2005, BREAK THEM SYST US P; CHURCH REPORT UNCLAS	5	79	80	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2005	353	1					6	8		10.1056/NEJMp058145	http://dx.doi.org/10.1056/NEJMp058145			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942FC	15972858				2022-12-28	WOS:000230267300002
J	Lobo, RA				Lobo, RA			Current concepts - Potential options for preservation of fertility in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FOLLICLE-STIMULATING-HORMONE; FUNCTION FOLLOWING CHEMOTHERAPY; BONE-MARROW-TRANSPLANTATION; OVARIAN TISSUE-BANKING; CITRATE CHALLENGE TEST; LONG-TERM SURVIVORS; IN-VITRO; CLOMIPHENE CITRATE; CANCER-PATIENTS; HUMAN OOCYTES		Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA; New York Presbyterian Hosp, New York, NY USA	Columbia University; NewYork-Presbyterian Hospital	Lobo, RA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, 622 W 168th St, New York, NY 10032 USA.	ral35@columbia.edu						Al-Fozan H, 2004, FERTIL STERIL, V82, P1561, DOI 10.1016/j.fertnstert.2004.04.070; *AM SOC REPR MED P, 2004, FERTIL STERIL S1, V82, pS102; [Anonymous], 2004, FERTIL STERIL, V82, P993, DOI 10.1016/j.fertnstert.2004.07.925; ATAYA K, 1995, BIOL REPROD, V52, P365, DOI 10.1095/biolreprod52.2.365; Baird DT, 1999, ENDOCRINOLOGY, V140, P462, DOI 10.1210/en.140.1.462; Bath LE, 2004, HUM REPROD, V19, P2569, DOI 10.1093/humrep/deh472; Battaglia DE, 1996, HUM REPROD, V11, P2217; Bedaiwy MA, 2004, HUM REPROD, V19, P1242, DOI 10.1093/humrep/deh262; Benadiva CA, 1996, FERTIL STERIL, V66, P248, DOI 10.1016/S0015-0282(16)58448-9; Bisharah M, 2003, AM J OBSTET GYNECOL, V188, P367, DOI 10.1067/mob.2003.38; Blumenfeld Z, 1996, HUM REPROD, V11, P1620; Borini A, 2004, FERTIL STERIL, V82, P601, DOI 10.1016/j.fertnstert.2004.04.025; BYRNE J, 1992, AM J OBSTET GYNECOL, V166, P788, DOI 10.1016/0002-9378(92)91335-8; Candy CJ, 2000, HUM REPROD, V15, P1300, DOI 10.1093/humrep/15.6.1300; *CDCP, 2004, 2002 ASS REPR TECHN; Cha KY, 1998, HUM REPROD UPDATE, V4, P103, DOI 10.1093/humupd/4.2.103; Chang MY, 1998, FERTIL STERIL, V69, P505, DOI 10.1016/S0015-0282(97)00557-8; Chian RC, 2004, CURR OPIN OBSTET GYN, V16, P211, DOI 10.1097/00001703-200406000-00003; CLARK ST, 1995, J CLIN ONCOL, V13, P134, DOI 10.1200/JCO.1995.13.1.134; Critchley Hilary O D, 2002, Hum Fertil (Camb), V5, P61, DOI 10.1080/1464727022000198942; de Bruin JP, 2001, HUM REPROD, V16, P2014, DOI 10.1093/humrep/16.9.2014; de Vet A, 2002, FERTIL STERIL, V77, P357, DOI 10.1016/S0015-0282(01)02993-4; Donnez J, 2004, LANCET, V364, P1405, DOI 10.1016/S0140-6736(04)17222-X; Donnez J, 2004, LANCET, V364, P2020; Donovan PJ, 2003, CURR OPIN GENET DEV, V13, P463, DOI 10.1016/j.gde.2003.08.010; Erickson GF, 2000, MENOPAUSE BIOL PATHO, P13; Fabbri R, 2001, HUM REPROD, V16, P411, DOI 10.1093/humrep/16.3.411; FADDY MJ, 1992, HUM REPROD, V7, P1342, DOI 10.1093/oxfordjournals.humrep.a137570; GaltierDereure F, 1996, HUM REPROD, V11, P1393; GOOK DA, 1994, HUM REPROD, V9, P684, DOI 10.1093/oxfordjournals.humrep.a138572; GOSDEN RG, 1994, HUM REPROD, V9, P597, DOI 10.1093/oxfordjournals.humrep.a138556; GOUGEON A, 1994, BIOL REPROD, V50, P653, DOI 10.1095/biolreprod50.3.653; Hubner K, 2003, SCIENCE, V300, P1251, DOI 10.1126/science.1083452; Jain T, 2004, FERTIL STERIL, V82, P180, DOI 10.1016/j.fertnstert.2003.11.045; Johnson J, 2004, NATURE, V430, P1062, DOI 10.1038/nature02868; Kalantaridou SN, 1998, ENDOCRIN METAB CLIN, V27, P989, DOI 10.1016/S0889-8529(05)70051-7; Klein NA, 1996, J CLIN ENDOCR METAB, V81, P2742, DOI 10.1210/jc.81.7.2742; Klinkert ER, 2005, HUM REPROD, V20, P611, DOI 10.1093/humrep/deh663; Kuleshova L, 1999, HUM REPROD, V14, P3077, DOI 10.1093/humrep/14.12.3077; Larsen EC, 2003, HUM REPROD, V18, P417, DOI 10.1093/humrep/deg073; Larsen EC, 2003, J CLIN ENDOCR METAB, V88, P5307, DOI 10.1210/jc.2003-030352; Letur H, 2004, Gynecol Obstet Fertil, V32, P748, DOI 10.1016/S1297-9589(04)00204-8; Levy R, 2004, HUM REPROD UPDATE, V10, P241, DOI 10.1093/humupd/dmh016; Liu J, 2002, HUM REPROD, V17, P605, DOI 10.1093/humrep/17.3.605; Lobo RA, 2003, HUM REPROD, V18, P1762, DOI 10.1093/humrep/deg377; LUSHBAUGH CC, 1976, CANCER, V37, P1111, DOI 10.1002/1097-0142(197602)37:2+<1111::AID-CNCR2820370821>3.0.CO;2-E; Mackie EJ, 1996, MED PEDIATR ONCOL, V27, P74, DOI 10.1002/(SICI)1096-911X(199608)27:2<74::AID-MPO2>3.0.CO;2-Q; Martin JSB, 1996, FERTIL STERIL, V65, P1238, DOI 10.1016/S0015-0282(16)58347-2; Martinez-Madrid B, 2004, FERTIL STERIL, V82, P1390, DOI 10.1016/j.fertnstert.2004.06.036; Meirow D, 2000, MOL CELL ENDOCRINOL, V169, P123, DOI 10.1016/S0303-7207(00)00365-8; Morice P, 2000, FERTIL STERIL, V74, P743, DOI 10.1016/S0015-0282(00)01500-4; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; NAVOT D, 1987, LANCET, V2, P645; Nikolaou D, 2003, HUM REPROD, V18, P1137, DOI 10.1093/humrep/deg245; Oktay K, 2000, NEW ENGL J MED, V342, P1919, DOI 10.1056/NEJM200006223422516; Oktay K, 2004, LANCET, V363, P837, DOI 10.1016/S0140-6736(04)15728-0; Oktay K, 2001, JAMA-J AM MED ASSOC, V286, P1490, DOI 10.1001/jama.286.12.1490; Oktay K, 2001, CURR OPIN OBSTET GYN, V13, P263, DOI 10.1097/00001703-200106000-00003; Porcu E, 2000, MOL CELL ENDOCRINOL, V169, P33, DOI 10.1016/S0303-7207(00)00348-8; Quintans CJ, 2002, HUM REPROD, V17, P3149, DOI 10.1093/humrep/17.12.3149; Rebar RW., 2000, MENOPAUSE BIOL PATHO, P135; Revel A, 2004, FERTIL STERIL, V82, P1714, DOI 10.1016/j.fertnstert.2004.06.046; Revel A, 2004, HUM REPROD, V19, P14, DOI 10.1093/humrep/deh002; SCHILSKY RL, 1981, AM J MED, V71, P552, DOI 10.1016/0002-9343(81)90205-9; Schmidt KLT, 2004, REPROD BIOMED ONLINE, V8, P448, DOI 10.1016/S1472-6483(10)60929-7; SCHWARTZ D, 1982, NEW ENGL J MED, V306, P404, DOI 10.1056/NEJM198202183060706; SCOTT RT, 1989, FERTIL STERIL, V51, P651; SCOTT RT, 1993, OBSTET GYNECOL, V82, P539; SCOTT RT, 1995, HUM REPROD, V10, P1706, DOI 10.1093/oxfordjournals.humrep.a136159; Seifer DB, 1999, FERTIL STERIL, V72, P63, DOI 10.1016/S0015-0282(99)00193-4; Silber SJ, 2005, NEW ENGL J MED, V353, P58, DOI 10.1056/NEJMoa043157; Simpson JL, 2000, MENOPAUSE BIOL PATHO, P77; SINGH RP, 1966, ANAT REC, V155, P369, DOI 10.1002/ar.1091550309; TANBO T, 1992, FERTIL STERIL, V57, P819; Teinturier C, 1998, BONE MARROW TRANSPL, V22, P989, DOI 10.1038/sj.bmt.1701483; Thibaud E, 1998, BONE MARROW TRANSPL, V21, P287, DOI 10.1038/sj.bmt.1701075; van Asselt KM, 2004, FERTIL STERIL, V82, P1348, DOI 10.1016/j.fertnstert.2004.04.047; van Rooij IAJ, 2002, HUM REPROD, V17, P3065, DOI 10.1093/humrep/17.12.3065; vanNoord PAH, 1997, FERTIL STERIL, V68, P95, DOI 10.1016/S0015-0282(97)81482-3; WALLACE WHB, 1989, BRIT J RADIOL, V62, P995, DOI 10.1259/0007-1285-62-743-995; WOOD C, 1992, J ASSIST REPROD GEN, V9, P482, DOI 10.1007/BF01204055; Yoon TK, 2003, FERTIL STERIL, V79, P1323, DOI 10.1016/S0015-0282(03)00258-9	82	194	201	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2005	353	1					64	73		10.1056/NEJMra043475	http://dx.doi.org/10.1056/NEJMra043475			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942FC	16000356				2022-12-28	WOS:000230267300009
J	Limchawalit, K; Suchato, C				Limchawalit, K; Suchato, C			Images in clinical medicine: Tsunami sinusitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Samitivej Hosp, Bangkok 10110, Thailand		Limchawalit, K (corresponding author), Samitivej Hosp, Bangkok 10110, Thailand.								0	9	9	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					E23	E23		10.1056/NEJMicm050461	http://dx.doi.org/10.1056/NEJMicm050461			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972859				2022-12-28	WOS:000229953700011
J	Cohen, J; Schleifer, R; Tate, T				Cohen, J; Schleifer, R; Tate, T			AIDS in Uganda: the human-rights dimension	LANCET			English	Editorial Material									HIV AIDS & Human Rights Programme, New York, NY 10118 USA; Childrens Rights Div Human Rights Watch, New York, NY 10118 USA		Cohen, J (corresponding author), HIV AIDS & Human Rights Programme, New York, NY 10118 USA.	cohenj@hrw.org						ANGELO I, 2004, MONITOR         1129; Bruckner H, 2005, J ADOLESCENT HEALTH, V36, P271, DOI 10.1016/j.jadohealth.2005.01.005; COHEN J, 2005, HUMAN RIGHTS WAT MAR, P29; Hauser T., 2004, 42 AIAA AER SCI M EX, P1088; *HIV AIDS INT MOD, 2004, 4 PRES DIAL YOUNG LE, P19; *I MED COMM HIV PR, 2001, NO TIM LOS GETT MOR, P118; KARANJA L, 2003, HUMAN RIGHTS WAT AUG, P15; KEMPNER ME, 2001, SEXUALLY HLTH AM ABS; KIRBY D, 2001, EMERGING ANSWERS RES, P5; Manlove J., 2004, NOT YET PROGRAMS DEL; SCHLEIFER R, 2002, HUMAN RIGHTS WAT SEP, P19; *UG MIN ED SPORTS, 2004, IN PRESS PIASCY HDB, P22; *US HR COMM GOV RE, 2004, CONT FED FUND ABST O	13	14	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 18	2005	365	9477					2075	2076		10.1016/S0140-6736(05)66716-5	http://dx.doi.org/10.1016/S0140-6736(05)66716-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	936LZ	15964433				2022-12-28	WOS:000229858800010
J	Elwood, P; Morgan, G; Brown, G; Pickering, J; Baigent, C				Elwood, P; Morgan, G; Brown, G; Pickering, J; Baigent, C		Welsh Aspirin Grp	For and against - Aspirin for everyone older than 50?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-DOSE ASPIRIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PRIMARY PREVENTION; CARDIOVASCULAR-DISEASE; RANDOMIZED-TRIAL; SALICYLIC-ACID; EVENTS		Cardiff Univ, Llandough Hosp, Dept Epidemiol Stat & Publ Hlth, Welsh Aspirin Grp, Penarth CF64 2XW, S Glam, Wales; Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Radcliffe Infirm, Epidemiol Studies Unit, Oxford OX2 6HE, England	Cardiff University; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Elwood, P (corresponding author), Cardiff Univ, Llandough Hosp, Dept Epidemiol Stat & Publ Hlth, Welsh Aspirin Grp, Penarth CF64 2XW, S Glam, Wales.	pelwood@doctors.org.uk; colin.baigent@ctsu.ox.ac.uk						ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; [Anonymous], 1984, J Epidemiol Community Health, V38, P259; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Baron JA, 2003, PROG EXP TUMOR RES, V37, P1; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Department of Health, 2004, CHOOS HLTH MAK HLTH; Din FVN, 2004, BRIT J CANCER, V91, P381, DOI 10.1038/sj.bjc.6601913; Ebrahim S, 1997, BMJ-BRIT MED J, V314, P1666, DOI 10.1136/bmj.314.7095.1666; ELWOOD PC, 1974, BRIT MED J, V1, P436, DOI 10.1136/bmj.1.5905.436; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hayden M, 2002, ANN INTERN MED, V136, P161, DOI 10.7326/0003-4819-136-2-200201150-00016; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Hernandez-Diaz S, 2002, J CLIN EPIDEMIOL, V55, P157, DOI 10.1016/S0895-4356(01)00461-9; *HLTH PROM AUTH WA, 1985, 20 HLTH PROM AUTH WA; *KINGS FUND, 2004, PUBL ATT PUBL HLTH P; Meade TW, 1998, LANCET, V351, P233; Mur LAJ, 2000, PLANT J, V23, P609, DOI 10.1046/j.1365-313x.2000.00825.x; Nelson MR, 2003, DRUG AGING, V20, P897, DOI 10.2165/00002512-200320120-00004; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Sanmuganathan PS, 2001, HEART, V85, P265, DOI 10.1136/heart.85.3.265; Smith GD, 2004, INT J EPIDEMIOL, V33, P30, DOI 10.1093/ije/dyh132; Szekely CA, 2004, NEUROEPIDEMIOLOGY, V23, P159, DOI 10.1159/000078501; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Wood D, 2000, BRIT MED J, V320, P705, DOI 10.1136/bmj.320.7236.705	27	33	33	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 18	2005	330	7505					1440	1443		10.1136/bmj.330.7505.1440	http://dx.doi.org/10.1136/bmj.330.7505.1440			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938NP	15961818	Green Published			2022-12-28	WOS:000230010400022
J	Douglass, AD; Vale, RD				Douglass, AD; Vale, RD			Single-molecule microscopy reveals plasma membrane microdomains created by protein-protein networks that exclude or trap signaling molecules in T cells	CELL			English	Article							IMMUNOLOGICAL SYNAPSE FORMATION; GPI-ANCHORED PROTEINS; LIPID RAFTS; BACTERIAL CHEMOTAXIS; DYNAMIC RECRUITMENT; TYROSINE KINASES; LIVING CELLS; ACTIVATION; RECEPTOR; LAT	Membrane subdomains have been implicated in T cell signaling, although their properties and mechanisms of formation remain controversial. Here, we have used single-molecule and scanning confocal imaging to characterize the behavior of GFP-tagged signaling proteins in Jurkat T cells. We show that the coreceptor CD2, the adaptor protein LAT, and tyrosine kinase Lck cocluster in discrete microdomains in the plasma membrane of signaling T cells. These microdomains require protein-protein interactions mediated through phosphorylation of LAT and are not maintained by interactions with actin or lipid rafts. Using a two color imaging approach that allows tracking of single molecules relative to the CD2/LAT/Lck clusters, we demonstrate that these microdomains exclude and limit the free diffusion of molecules in the membrane but also can trap and immobilize specific proteins. Our data suggest that diffusional trapping through protein-protein interactions creates microdomains that concentrate or exclude cell surface proteins to facilitate T cell signaling.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94107 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94107 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vale, RD (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94107 USA.	vale@cmp.ucsf.edu			Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [R01 GM038499, R01 GM038499-16] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038499] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axelrod D, 2003, METHOD ENZYMOL, V361, P1; Bachmann MF, 1999, J EXP MED, V190, P1383, DOI 10.1084/jem.190.10.1383; Badour K, 2003, IMMUNITY, V18, P141, DOI 10.1016/S1074-7613(02)00516-2; Bierer B E, 1993, Semin Immunol, V5, P249, DOI 10.1006/smim.1993.1029; Bonello G, 2004, J CELL SCI, V117, P1009, DOI 10.1242/jcs.00968; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Calvert PD, 2001, NATURE, V411, P90, DOI 10.1038/35075083; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; Dietrich C, 2002, BIOPHYS J, V82, P274, DOI 10.1016/S0006-3495(02)75393-9; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Ehrlich LIR, 2002, IMMUNITY, V17, P809, DOI 10.1016/S1074-7613(02)00481-8; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; Gil D, 2002, CELL, V109, P901, DOI 10.1016/S0092-8674(02)00799-7; Glebov OO, 2004, NAT CELL BIOL, V6, P238, DOI 10.1038/ncb1103; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Green JM, 2000, J IMMUNOL, V164, P3591, DOI 10.4049/jimmunol.164.7.3591; Harder T, 2000, J CELL BIOL, V151, P199, DOI 10.1083/jcb.151.2.199; Hartgroves LC, 2003, J BIOL CHEM, V278, P20389, DOI 10.1074/jbc.M301212200; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Hermiston ML, 2002, J CLIN INVEST, V109, P9; Huppa JB, 2003, NAT IMMUNOL, V4, P749, DOI 10.1038/ni951; Ike H, 2003, CHEMPHYSCHEM, V4, P620, DOI 10.1002/cphc.200300670; Jacobelli J, 2004, NAT IMMUNOL, V5, P531, DOI 10.1038/ni1065; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Johnson KG, 2000, P NATL ACAD SCI USA, V97, P10138, DOI 10.1073/pnas.97.18.10138; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kenworthy AK, 2004, J CELL BIOL, V165, P735, DOI 10.1083/jcb.200312170; KILLEEN N, 1992, EMBO J, V11, P4329, DOI 10.1002/j.1460-2075.1992.tb05532.x; Klopfenstein DR, 2002, CELL, V109, P347, DOI 10.1016/S0092-8674(02)00708-0; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Lee SJE, 2002, TRENDS IMMUNOL, V23, P492, DOI 10.1016/S1471-4906(02)02285-8; Leupin O, 2000, CURR BIOL, V10, P277, DOI 10.1016/S0960-9822(00)00362-6; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; Lommerse PHM, 2004, BIOPHYS J, V86, P609, DOI 10.1016/S0006-3495(04)74139-9; Mello BA, 2004, BIOPHYS J, V87, P1578, DOI 10.1529/biophysj.104.042739; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nakada C, 2003, NAT CELL BIOL, V5, P626, DOI 10.1038/ncb1009; Qi SY, 2001, P NATL ACAD SCI USA, V98, P6548, DOI 10.1073/pnas.111536798; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Roose JP, 2003, PLOS BIOL, V1, P271, DOI 10.1371/journal.pbio.0000053; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Schutz GJ, 1997, BIOPHYS J, V73, P1073, DOI 10.1016/S0006-3495(97)78139-6; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Tanimura N, 2003, J CELL BIOL, V160, P125, DOI 10.1083/jcb.200207096; Trautmann A, 2003, CURR OPIN IMMUNOL, V15, P249, DOI 10.1016/S0952-7915(03)00040-2; TURING AM, 1990, B MATH BIOL, V52, P153, DOI 10.1007/BF02459572; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Weis RM, 2003, J BACTERIOL, V185, P3636, DOI 10.1128/JB.185.12.3636-3643.2003; Weiss M, 2004, TRENDS CELL BIOL, V14, P267, DOI 10.1016/j.tcb.2004.03.012; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yang HL, 2001, J BIOL CHEM, V276, P18775, DOI 10.1074/jbc.M009852200; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu MH, 2005, J IMMUNOL, V174, P31, DOI 10.4049/jimmunol.174.1.31	65	596	615	1	82	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 17	2005	121	6					937	950		10.1016/j.cell.2005.04.009	http://dx.doi.org/10.1016/j.cell.2005.04.009			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960980	Green Accepted, Bronze			2022-12-28	WOS:000230011200015
J	Kolfschoten, IGM; van Leeuwen, B; Berns, K; Mullenders, J; Beijersbergen, RL; Bernards, R; Voorhoeve, PM; Agami, R				Kolfschoten, IGM; van Leeuwen, B; Berns, K; Mullenders, J; Beijersbergen, RL; Bernards, R; Voorhoeve, PM; Agami, R			A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity	CELL			English	Article							TRANSCRIPTION FACTOR; HUMAN-CELLS; CANCER; EXPRESSION; MAINTENANCE; ACTIVATION; MECHANISMS; BINDING; P53	Activating mutations of RAS frequently occur in subsets of human cancers, indicating that RAS activation is important for tumorigenesis. However, a large proportion of these cancers still retain wild-type RAS alleles, suggesting that either the RAS pathway is activated in a distinct manner or another pathway is deregulated. To uncover novel tumor-suppressor genes, we screened an RNA-interference library for knockdown constructs that transform human primary cells in the absence of ectopically introduced oncogenic RAS. Here we report the identification of PITX1, whose inhibition induces the RAS pathway and tumorigenicity. Interestingly, we observed low expression of PITX1 in prostate and bladder tumors and in colon cancer cell lines containing wild-type RAS. Restoration of PITX1 in the colon cancer cells inhibited tumorigenicity in a wild-type RAS-dependent manner. Finally, we identified RASAL1, a RAS-GTPase-activating protein, as a transcription target through which PITX1 affects RAS function. Thus, PITX1 suppresses tumorigenicity by downregulating the RAS pathway through RASAL1.	Netherlands Canc Inst, Div Tumor Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Agami, R (corresponding author), Netherlands Canc Inst, Div Tumor Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.agami@nki.nl	agami, reuven/GOG-8289-2022; Mullenders, Jasper/J-2398-2015	Mullenders, Jasper/0000-0003-3737-6901; Agami, Reuven/0000-0002-2848-2473; Beijersbergen, Roderick/0000-0003-0116-4130; Bernards, Rene/0000-0001-8677-3423				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Arun D, 2004, CURR OPIN NEUROL, V17, P101, DOI 10.1097/00019052-200404000-00004; Barre B, 2005, J BIOL CHEM, V280, P15673, DOI 10.1074/jbc.M413203200; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; BOS JL, 1989, CANCER RES, V49, P4682; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harrisingh MC, 2004, CELL CYCLE, V3, P1255, DOI 10.4161/cc.3.10.1182; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Ohnishi S, 2003, BIOCHEM BIOPH RES CO, V308, P251, DOI 10.1016/S0006-291X(03)01356-1; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Repasky GA, 2004, TRENDS CELL BIOL, V14, P639, DOI 10.1016/j.tcb.2004.09.014; Rhim JS, 2001, RADIAT RES, V155, P128, DOI 10.1667/0033-7587(2001)155[0128:MAGMOP]2.0.CO;2; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Subramanian L, 2004, BIOCHEMISTRY-US, V43, P11175, DOI 10.1021/bi048848d; Vooijs M, 2002, CANCER RES, V62, P1862; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Walker SA, 2004, EMBO J, V23, P1749, DOI 10.1038/sj.emboj.7600197; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	31	230	247	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	2005	121	6					849	858		10.1016/j.cell.2005.04.017	http://dx.doi.org/10.1016/j.cell.2005.04.017			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960973	Green Published, Bronze			2022-12-28	WOS:000230011200008
J	Turvey, ST; Green, OR; Holdaway, RN				Turvey, ST; Green, OR; Holdaway, RN			Cortical growth marks reveal extended juvenile development in New Zealand moa	NATURE			English	Article							BONE MICROSTRUCTURE; PERIOSTEAL BONE; LIFE-HISTORY; EVOLUTION; AGE; EXTINCTION; SEQUENCES; DINOSAURS; RATES; BIRDS	Cyclical growth marks in cortical bone, deposited before attainment of adult body size, reflect osteogenetic changes caused by annual rhythms and are a general phenomenon in non-avian ectothermic and endothermic tetrapods(1). However, the growth periods of ornithurines (the theropod group including all modern birds) are usually apomorphically shortened to less than a year(2,3), so annual growth marks are almost unknown in this group(4-6). Here we show that cortical growth marks are frequent in long bones of New Zealand's moa (Aves: Dinornithiformes), a recently extinct ratite order. Moa showed the exaggerated K-selected life-history strategy formerly common in the New Zealand avifauna, and in some instances took almost a decade to attain skeletal maturity. This indicates that reproductive maturity in moa was extremely delayed relative to all extant birds. The two presently recognized moa families (Dinornithidae and Emeidae) also showed different postnatal growth rates, which were associated with their relative differences in body size. Both species of giant Dinornis moa attained their massive stature (up to 240 kg live mass) by accelerating their juvenile growth rate compared to the smaller emeid moa species, rather than by extending the skeletal growth period.	Univ Canterbury, Sch Biol Sci, Christchurch 8020, New Zealand; Zool Soc London, Inst Zool, London NW1 4RY, England; Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England; Palaecol Res Ltd, Christchurch 8004, New Zealand	University of Canterbury; Zoological Society of London; University of Oxford	Turvey, ST (corresponding author), Univ Canterbury, Sch Biol Sci, Private Bag 4800, Christchurch 8020, New Zealand.	samuel.turvey@ioz.ac.uk						Amprino R., 1947, ARCH BIOL SCI, V58, P315; Bennett P. M., 2002, OX ECOL EV; Broughton JM, 2002, IBIS, V144, P143, DOI 10.1046/j.0019-1019.2001.00004.x; Bunce M, 2003, NATURE, V425, P172, DOI 10.1038/nature01871; Castanet J, 2000, CR ACAD SCI III-VIE, V323, P543, DOI 10.1016/S0764-4469(00)00181-5; Castanet J, 1996, CR ACAD SCI III-VIE, V319, P301; Chinsamy A, 1998, J VERTEBR PALEONTOL, V18, P385, DOI 10.1080/02724634.1998.10011066; CHINSAMY A, 1995, SENCKENBERG, V181, P317; Chinsamy Anusuya, 2002, P421; Cooper A, 2001, NATURE, V409, P704, DOI 10.1038/35055536; CRACRAFT J, 1974, IBIS, V116, P494, DOI 10.1111/j.1474-919X.1974.tb07648.x; Davies S.J.J.F., 2002, RATITES TINAMOUS; de Margerie E, 2004, J EXP BIOL, V207, P869, DOI 10.1242/jeb.00841; de Ricqles A, 2001, NEW PERSPECTIVES ON THE ORIGIN AND EARLY EVOLUTION OF BIRDS, P411; Enlow D. H., 1957, Texas Journal of Science, V9, P186; Erickson GM, 2004, NATURE, V430, P772, DOI 10.1038/nature02699; HALL BK, 1993, BONE, V7; Holdaway RN, 2000, SCIENCE, V287, P2250, DOI 10.1126/science.287.5461.2250; Horner JR, 1999, PALEOBIOLOGY, V25, P295, DOI 10.1017/S0094837300021308; HOUDE P, 1987, AUK, V104, P125, DOI 10.2307/4087243; Huynen L, 2003, NATURE, V425, P175, DOI 10.1038/nature01838; Johnson CN, 2002, P ROY SOC B-BIOL SCI, V269, P2221, DOI 10.1098/rspb.2002.2130; KLOMP NI, 1992, IBIS, V134, P245, DOI 10.1111/j.1474-919X.1992.tb03806.x; Lydekker R., 1891, CATALOGUE FOSSIL BIR; Owens IPF, 2000, P NATL ACAD SCI USA, V97, P12144, DOI 10.1073/pnas.200223397; Padian K, 2004, J VERTEBR PALEONTOL, V24, P555, DOI 10.1671/0272-4634(2004)024[0555:GISDAP]2.0.CO;2; Padian K, 2001, NATURE, V412, P405, DOI 10.1038/35086500; Sander PM, 2004, ORG DIVERS EVOL, V4, P165, DOI 10.1016/j.ode.2003.12.002; Starck JM, 2002, J MORPHOL, V254, P232, DOI 10.1002/jmor.10029; WORTHY TH, 2002, LOST WORLD MOA	30	67	70	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					940	943		10.1038/nature03635	http://dx.doi.org/10.1038/nature03635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959513				2022-12-28	WOS:000229799700046
J	Robison, BH; Reisenbichler, KR; Sherlock, RE				Robison, BH; Reisenbichler, KR; Sherlock, RE			Giant larvacean houses: Rapid carbon transport to the deep sea floor	SCIENCE			English	Article							PARTICULATE ORGANIC-MATTER; BENTHIC BOUNDARY-LAYER; EASTERN NORTH PACIFIC; ABYSSAL NE PACIFIC; MONTEREY-BAY; CENTRAL CALIFORNIA; OCEAN; FOOD; FLUX; DISCREPANCY	An unresolved issue in ocean science is the discrepancy between the food requirements of the animals living on the deep sea floor and their food supply, as measured by sediment traps. A 10-year time-series study of the water column off Monterey Bay, California, revealed that the discarded mucus feeding structures of giant larvaceans carry a substantial portion of the upper ocean's productivity to the deep seabed. These abundant, rapidly sinking, carbon-rich vectors are not detected by conventional,sampling methods and thus have not been included in calculations of vertical nutrient flux or in oceanic carbon budgets.	Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA	Monterey Bay Aquarium Research Institute	Robison, BH (corresponding author), Monterey Bay Aquarium Res Inst, 7700 Sandholdt Rd, Moss Landing, CA 95039 USA.	robr@mbari.org						AGASSIZ A, 1888, 3 CRUISES US COAST G, V1; ALLDREDGE AL, 1976, LIMNOL OCEANOGR, V21, P14, DOI 10.4319/lo.1976.21.1.0014; ALLDREDGE AL, 1988, PROG OCEANOGR, V20, P41, DOI 10.1016/0079-6611(88)90053-5; ALLDREDGE AL, 1972, SCIENCE, V177, P885, DOI 10.1126/science.177.4052.885; Baldwin RJ, 1998, DEEP-SEA RES PT II, V45, P643, DOI 10.1016/S0967-0645(97)00097-0; BARHAM EG, 1979, SCIENCE, V205, P1129, DOI 10.1126/science.205.4411.1129; Beaulieu SE, 1998, DEEP-SEA RES PT II, V45, P781, DOI 10.1016/S0967-0645(98)00003-4; Berelson W., 2001, OCEANOGRAPHY, V14, P59, DOI DOI 10.5670/0CEAN0G.2001.07; BURD AB, 2002, EOS, V83, P573; Chavez FP, 2002, PROG OCEANOGR, V54, P205, DOI 10.1016/S0079-6611(02)00050-2; DAVOLL PJ, 1990, DEEP-SEA RES, V37, P285, DOI 10.1016/0198-0149(90)90128-I; DEIBEL D, 1986, MAR BIOL, V93, P429, DOI 10.1007/BF00401110; Druffel ERM, 1999, SCIENCE, V284, P1139, DOI 10.1126/science.284.5417.1139; FENAUX R, 1998, BIOL PELAGIC TUNICAT, pCH15; FRANCOIS R, 2001, OCEANOGRAPHY, V14, P65; GALT CP, 1979, FISH B-NOAA, V77, P514; HAMNER WM, 1992, DEEP-SEA RES, V39, P1299, DOI 10.1016/0198-0149(92)90070-A; Hopcroft RR, 1999, J PLANKTON RES, V21, P1923, DOI 10.1093/plankt/21.10.1923; Hunt James C., 1999, Plankton Biology and Ecology, V46, P75; MARTIN JH, 1987, DEEP-SEA RES, V34, P267, DOI 10.1016/0198-0149(87)90086-0; McGowan JA, 1998, SCIENCE, V281, P210, DOI 10.1126/science.281.5374.210; Pilskaln CH, 1996, J MAR RES, V54, P1149, DOI 10.1357/0022240963213772; Reimers CE, 1992, GLOBAL BIOGEOCHEM CY, V6, P199, DOI 10.1029/92GB00105; ROEMMICH D, 1995, SCIENCE, V267, P1324, DOI 10.1126/science.267.5202.1324; ROEMMICH D, 1995, SCIENCE, V268, P352, DOI 10.1126/science.268.5209.352-b; Silver MW, 1998, LIMNOL OCEANOGR, V43, P498, DOI 10.4319/lo.1998.43.3.0498; Smith KL, 1999, SCIENCE, V284, P1174, DOI 10.1126/science.284.5417.1174; Smith KL, 2002, DEEP-SEA RES PT I, V49, P971, DOI 10.1016/S0967-0637(02)00006-7; SMITH KL, 1994, LIMNOL OCEANOGR, V39, P1101, DOI 10.4319/lo.1994.39.5.1101; SMITH KL, 1987, LIMNOL OCEANOGR, V32, P201, DOI 10.4319/lo.1987.32.1.0201; Volkman JK, 2002, J OCEANOGR, V58, P265, DOI 10.1023/A:1015809708632	31	125	131	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1609	1611		10.1126/science.1109104	http://dx.doi.org/10.1126/science.1109104			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947183				2022-12-28	WOS:000229827000051
J	Bassett, SE; Milne, GA; Mitrovica, JX; Clark, PU				Bassett, SE; Milne, GA; Mitrovica, JX; Clark, PU			Ice sheet and solid earth influences on far-field sea-level histories	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; GLOBAL MELTWATER DISCHARGE; ISOSTATIC-ADJUSTMENT; HUON PENINSULA; VM2 MODEL; RECORD; PALEOTOPOGRAPHY; RECONSTRUCTIONS; VISCOSITY; EQUATION	Previous predictions of sea-level change subsequent to the last glacial maximum show significant, systematic discrepancies between observations at Tahiti, Huon Peninsula, and Sunda Shelf during Lateglacial time (similar to 14,000 to 9000 calibrated years before the present). We demonstrate that a model of glacial isostatic adjustment characterized by both a high-viscosity lower mantle (4 x 10(22) Pa s) and a large contribution from the Antarctic ice sheet to meltwater pulse IA (similar to 15-meters eustatic equivalent) resolves these discrepancies. This result supports arguments that an early and rapid Antarctic deglaciation contributed to a sequence of climatic events that ended the most recent glacial period of the current ice age.	Univ Durham, Dept Earth Sci, Durham DH1 3LE, England; Univ Toronto, Dept Phys, Toronto, ON M5S 1A7, Canada; Oregon State Univ, Dept Geosci, Corvallis, OR 97331 USA	Durham University; University of Toronto; Oregon State University	Milne, GA (corresponding author), Univ Durham, Dept Earth Sci, Durham DH1 3LE, England.	g.a.milne@durham.ac.uk						BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; Bard E, 1996, NATURE, V382, P241, DOI 10.1038/382241a0; CHAPPELL J, 1991, NATURE, V349, P147, DOI 10.1038/349147a0; Chappell J, 1996, EARTH PLANET SC LETT, V141, P227, DOI 10.1016/0012-821X(96)00062-3; Clark PU, 2002, SCIENCE, V295, P2438; Cutler KB, 2003, EARTH PLANET SC LETT, V206, P253, DOI 10.1016/S0012-821X(02)01107-X; Denton GH, 2002, QUATERNARY SCI REV, V21, P193, DOI 10.1016/S0277-3791(01)00090-7; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; EDWARDS RL, 1995, SCIENCE, V267, P536, DOI 10.1126/science.267.5197.536; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; FARRELL WE, 1976, GEOPHYS J ROY ASTR S, V46, P647, DOI 10.1111/j.1365-246X.1976.tb01252.x; Hanebuth T, 2000, SCIENCE, V288, P1033, DOI 10.1126/science.288.5468.1033; Huybrechts P, 2002, QUATERNARY SCI REV, V21, P203, DOI 10.1016/S0277-3791(01)00082-8; Kanfoush SL, 2000, SCIENCE, V288, P1815, DOI 10.1126/science.288.5472.1815; Kaufmann G, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000941; Lambeck K, 2002, QUATERNARY SCI REV, V21, P343, DOI 10.1016/S0277-3791(01)00071-3; Lambeck K, 2002, NATURE, V419, P199, DOI 10.1038/nature01089; Lambeck K, 2003, QUATERNARY SCI REV, V22, P309, DOI 10.1016/S0277-3791(02)00142-7; Lambeck K, 1998, GEOPHYS J INT, V135, P375, DOI 10.1046/j.1365-246X.1998.00643.x; Marshall SJ, 2002, QUATERNARY SCI REV, V21, P175, DOI 10.1016/S0277-3791(01)00089-0; Milne GA, 1999, GEOPHYS J INT, V139, P464, DOI 10.1046/j.1365-246x.1999.00971.x; Milne GA, 2002, QUATERNARY SCI REV, V21, P361, DOI 10.1016/S0277-3791(01)00108-1; Mitrovica JX, 2003, GEOPHYS J INT, V154, P253, DOI 10.1046/j.1365-246X.2003.01942.x; Mitrovica JX, 2003, QUATERNARY SCI REV, V22, P127, DOI 10.1016/S0277-3791(02)00225-1; Mitrovica JX, 1997, J GEOPHYS RES-SOL EA, V102, P2751, DOI 10.1029/96JB03175; Peltier WR, 2002, QUATERNARY SCI REV, V21, P377, DOI 10.1016/S0277-3791(01)00084-1; Peltier WR, 2004, ANNU REV EARTH PL SC, V32, P111, DOI 10.1146/annurev.earth.32.082503.144359; Peltier WR, 2002, J QUATERNARY SCI, V17, P491, DOI 10.1002/jqs.713; PELTIER WR, 1995, SCIENCE, V267, P536, DOI 10.1126/science.267.5197.536-a; Peltier WR, 1998, REV GEOPHYS, V36, P603, DOI 10.1029/98RG02638; PELTIER WR, 1994, SCIENCE, V265, P195, DOI 10.1126/science.265.5169.195; Peltier WR, 1998, GEOL SOC SPEC PUBL, V146, P1, DOI 10.1144/GSL.SP.1999.146.01.01; RADTKE U, 1988, QUATERNARY RES, V29, P197, DOI 10.1016/0033-5894(88)90030-0; Shennan I, 1999, J QUATERNARY SCI, V14, P715, DOI 10.1002/(SICI)1099-1417(199912)14:7<715::AID-JQS511>3.0.CO;2-G; TUSHINGHAM AM, 1991, J GEOPHYS RES-SOLID, V96, P4497, DOI 10.1029/90JB01583; Weaver AJ, 2003, SCIENCE, V299, P1709, DOI 10.1126/science.1081002; Yokoyama Y, 2000, NATURE, V406, P713, DOI 10.1038/35021035	37	126	133	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					925	928		10.1126/science.1111575	http://dx.doi.org/10.1126/science.1111575			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	15976270				2022-12-28	WOS:000231101400044
J	Pagani, M; Zachos, JC; Freeman, KH; Tipple, B; Bohaty, S				Pagani, M; Zachos, JC; Freeman, KH; Tipple, B; Bohaty, S			Marked decline in atmospheric carbon dioxide concentrations during the Paleogene	SCIENCE			English	Article							DRILLING PROJECT LEG-71; ISOTOPE FRACTIONATION; C-4 PHOTOSYNTHESIS; SOUTHWEST ATLANTIC; EMILIANIA-HUXLEYI; FALKLAND PLATEAU; MIDDLE EOCENE; CO2; EVOLUTION; OCEAN	The relation between the partial pressure of atmospheric carbon dioxide (pCO(2)) and Paleogene climate is poorly resolved. We used stable carbon isotopic values of di-unsaturated alkenones extracted from deep sea cores to reconstruct pCO(2) from the middle Eocene to the late Oligocene (similar to 45 to 25 million years ago). Our results demonstrate that pCO(2) ranged between 1000 to 1500 parts per million by volume in the middle to late Eocene, then decreased in several steps during the Oligocene, and reached modem levels by the latest Oligocene. The fall in pCO(2) likely allowed for a critical expansion of ice sheets on Antarctica and promoted conditions that forced the onset of terrestrial C-4 photosynthesis.	Yale Univ, Dept Geol & Geophys, New Haven, CT 06511 USA; Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA	Yale University; University of California System; University of California Santa Cruz; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Pagani, M (corresponding author), Yale Univ, Dept Geol & Geophys, 210 Whitney Ave, New Haven, CT 06511 USA.		Zachos, James C/A-7674-2008; Freeman, Katherine H/H-5140-2011; Pagani, Mark/B-3233-2008	Zachos, James C/0000-0001-8439-1886; Freeman, Katherine H/0000-0002-3350-7671; 				BACKMAN J, 1986, PALAEOGEOGR PALAEOCL, V57, P103, DOI 10.1016/0031-0182(86)90009-X; BASOV IA, 1983, INITIAL REP DEEP SEA, V71, P445; Berggren W. A., 1995, GEOCHRONOLOGY TIME S, P129, DOI DOI 10.2110/PEC.95.04.0129; Berner RA, 2001, AM J SCI, V301, P182, DOI 10.2475/ajs.301.2.182; Bidigare RR, 1999, GLOBAL BIOGEOCHEM CY, V13, P251, DOI 10.1029/1998GB900011; Bidigare RR, 1997, GLOBAL BIOGEOCHEM CY, V11, P279, DOI 10.1029/96GB03939; Bohaty SM, 2003, GEOLOGY, V31, P1017, DOI 10.1130/G19800.1; Browning JV, 1996, GEOLOGY, V24, P639, DOI 10.1130/0091-7613(1996)024<0639:GIOLTM>2.3.CO;2; Cerling TE, 1997, NATURE, V389, P153, DOI 10.1038/38229; CONTE MH, 1994, HAPTOPHYTE ALGAE, P351; Coxall HK, 2005, NATURE, V433, P53, DOI 10.1038/nature03135; DeConto RM, 2003, NATURE, V421, P245, DOI 10.1038/nature01290; Eek MK, 1999, DEEP-SEA RES PT II, V46, P2863, DOI 10.1016/S0967-0645(99)00086-7; EHLERINGER JR, 1991, TRENDS ECOL EVOL, V6, P95, DOI 10.1016/0169-5347(91)90183-X; Ennyu A, 2002, MAR MICROPALEONTOL, V46, P317, DOI 10.1016/S0377-8398(02)00079-8; EREZ J, 1983, GEOCHIM COSMOCHIM AC, V47, P1025, DOI 10.1016/0016-7037(83)90232-6; Fox DL, 2003, GEOLOGY, V31, P809, DOI 10.1130/G19580.1; FREEMAN KH, 2005, HIST ATMOSPHERIC CO2, P35, DOI DOI 10.1007/0-387-27048-5_3; Gaut BS, 1997, P NATL ACAD SCI USA, V94, P6809, DOI 10.1073/pnas.94.13.6809; HATCH MD, 1987, BIOCHIM BIOPHYS ACTA, V895, P81, DOI 10.1016/S0304-4173(87)80009-5; KELLOGG EA, 1999, C4 PLANT BIOL, P313; Laws EA, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2000GC000057; LECKIE RM, 1993, P OCEAN DRILLING PRO, V0130; MILLER K G, 1991, Palaios, V6, P17, DOI 10.2307/3514951; Miller KG, 1987, PALEOCEANOGRAPHY, V2, P1, DOI 10.1029/PA002i001p00001; MOOK WG, 1974, EARTH PLANET SC LETT, V22, P169, DOI 10.1016/0012-821X(74)90078-8; Pagani M, 1999, PALEOCEANOGRAPHY, V14, P273, DOI 10.1029/1999PA900006; Pagani M, 1999, SCIENCE, V285, P876, DOI 10.1126/science.285.5429.876; Pagani M, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2002PA000756; Pagani M, 2000, PALEOCEANOGRAPHY, V15, P486, DOI 10.1029/1999PA000484; PEARCY RW, 1984, PLANT CELL ENVIRON, V7, P1, DOI 10.1111/j.1365-3040.1984.tb01194.x; Pearson PN, 2000, NATURE, V406, P695, DOI 10.1038/35021000; Pearson PN, 2001, NATURE, V413, P481, DOI 10.1038/35097000; Popp BN, 1998, PALEOCEANOGRAPHY, V13, P35, DOI 10.1029/97PA02594; Popp BN, 1998, GEOCHIM COSMOCHIM AC, V62, P69, DOI 10.1016/S0016-7037(97)00333-5; Popp BN, 1999, RECONSTRUCTING OCEAN HISTORY, P381; PUJOL C, 1983, INITIAL REP DEEP SEA, V72, P623; RAYMO ME, 1991, GEOLOGY, V19, P344, DOI 10.1130/0091-7613(1991)019<0344:GESTCC>2.3.CO;2; Riebesell U, 2000, GEOCHIM COSMOCHIM AC, V64, P4179, DOI 10.1016/S0016-7037(00)00474-9; Robert C, 1997, GEOLOGY, V25, P587, DOI 10.1130/0091-7613(1997)025<0587:ACWCDE>2.3.CO;2; ROMANEK CS, 1992, GEOCHIM COSMOCHIM AC, V56, P419, DOI 10.1016/0016-7037(92)90142-6; Rost B, 2003, LIMNOL OCEANOGR, V48, P55, DOI 10.4319/lo.2003.48.1.0055; ROYER DL, 2001, NATURE, V292, P2310; Sage RF, 2004, NEW PHYTOL, V161, P341, DOI 10.1111/j.1469-8137.2004.00974.x; Schrag DP, 1999, CHEM GEOL, V161, P215, DOI 10.1016/S0009-2541(99)00088-1; Shackleton N.J., 1975, INITIAL REPORTS DEEP, V29, P743, DOI [DOI 10.2973/DSDP.PROC.29.117.1975, 10.2973/DSDP.PROC.29.117.1975]; SHACKLETON NJ, 1984, INITIAL REP DEEP SEA, V74, P599; Stott L.D., 1990, Proceedings of the Ocean Drilling Program Scientific Results, V113, P849, DOI 10.2973/odp.proc.sr.113.187.1990; VALENTINE PC, 1987, INITIAL REP DEEP SEA, V95, P359; WEI WC, 1989, MAR MICROPALEONTOL, V14, P119, DOI 10.1016/0377-8398(89)90034-0; Weiss R.F., 1974, MAR CHEM, V2, P203, DOI DOI 10.1016/0304-4203(74)90015-2; WISE SW, 1983, INITIAL REP DEEP SEA, V71, P481; Young John W., COMMUNICATION; YOUNGDAHL CK, 1990, INT J IMPACT ENG, V9, P71, DOI 10.1016/0734-743X(90)90023-O; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412; Zachos JC, 1996, PALEOCEANOGRAPHY, V11, P251, DOI 10.1029/96PA00571; Zachos JC, 1999, CHEM GEOL, V161, P165, DOI 10.1016/S0009-2541(99)00085-6; ZACHOS JC, 1994, PALEOCEANOGRAPHY, V9, P353, DOI 10.1029/93PA03266	58	642	679	8	220	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 22	2005	309	5734					600	603		10.1126/science.1110063	http://dx.doi.org/10.1126/science.1110063			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948SE	15961630				2022-12-28	WOS:000230735200045
J	Jellema, P; van der Windt, DAWM; van der Horst, HE; Twisk, JWR; Stalman, WAB; Bouter, LM				Jellema, P; van der Windt, DAWM; van der Horst, HE; Twisk, JWR; Stalman, WAB; Bouter, LM			Should treatment of (sub)acute low back pain be aimed at psychosocial prognostic factors? Cluster randomised clinical trial in general practice	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE	Objective To compare the effects of a minimal intervention strategy aimed at assessment and modification of psychosocial prognostic factors and usual care for treatment of (sub)acute low back pain in general practice. Design Cluster randomised clinical trial. Setting 60 general practitioners in 41 general practices. Participants 314 patients with non-specific low back pain of less than 12 weeks' duration, recruited by their general practitioner. Interventions In die minimal intervention strategy group the general practitioner explored the presence of psychosocial prognostic factors, discussed these factors, set specific goals for reactivation, and provided an educational booklet. The consultation took about 20 minutes. Usual care was not standardised. Main outcome measures Functional disability (Roland-Morris disability questionnaire), perceived recovery, and sick leave because of low back pain assessed at baseline and after 6, 13, 26, and 52 weeks. Results The dropout rate was 8% in the minimal intervention strategy group and 9% in the usual care group. Multilevel analyses showed no significant differences between the groups on any outcome measure during 12 months of follow-up in the whole group or in relevant subgroups (patients with high scores on psychosocial measures at baseline or a history of frequent or prolonged low back pain). Conclusion This study provides no evidence that (Dutch) general practitioners should adopt our new treatment strategy aimed at psychosocial prognostic factors in patients with (sub)acute low back pain. Further research should examine why our new strategy was not more effective than usual care.	Vrije Univ Amsterdam Med Ctr, Inst Res Extramural Med, Dept Gen Practice, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam Med Ctr, Dept Clin Epidemiol & Biostat, NL-1081 BT Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	van der Windt, DAWM (corresponding author), Vrije Univ Amsterdam Med Ctr, Inst Res Extramural Med, Dept Gen Practice, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	dawm.vanderwindt@vumc.nl		van der Windt, Danielle/0000-0002-7248-6703; Bouter, Lex/0000-0002-2659-5482				*AC ZIEK MAASTR, 2000, RUGH; Beurskens AJ, 1999, J MANIP PHYSIOL THER, V22, P144, DOI 10.1016/S0161-4754(99)70127-2; Bombardier C, 2001, J RHEUMATOL, V28, P431; Burton AK, 1999, SPINE, V24, P2484, DOI 10.1097/00007632-199912010-00010; Cherkin DC, 1996, SPINE, V21, P345, DOI 10.1097/00007632-199602010-00019; Cosby RH, 2003, FAM PRACT, V20, P77, DOI 10.1093/fampra/20.1.77; Faas A., 1996, HUIS WETEN, V39, P18; George SZ, 2003, SPINE, V28, P2551, DOI 10.1097/01.BRS.0000096677.84605.A2; Kendall NAS, 1997, GUIDE ASSESSING PSYC; Lundeberg T, 2001, J REHABIL MED, V33, P279; MAIN CJ, 2001, TOPICAL ISSUES PAIN, V3; Pengel LHM, 2003, BMJ-BRIT MED J, V327, P323, DOI 10.1136/bmj.327.7410.323; Picavet HSJ, 2003, PAIN, V102, P167, DOI 10.1016/S0304-3959(02)00372-X; Pincus Tamar, 2002, Spine (Phila Pa 1976), V27, pE109, DOI 10.1097/00007632-200203010-00017; Roberts L, 2002, SPINE, V27, P1821, DOI 10.1097/00007632-200209010-00002; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROSENSTIEL AK, 1983, PAIN, V17, P33, DOI 10.1016/0304-3959(83)90125-2; *ROYAL COLL GEN PR, 1996, BACK BOOK; Terluin B, 2004, WORK STRESS, V18, P187, DOI 10.1080/0267837042000297535; Thomas E, 1999, BRIT MED J, V318, P1662, DOI 10.1136/bmj.318.7199.1662; van der Heijden GJMG, 1999, ANN RHEUM DIS, V58, P530, DOI 10.1136/ard.58.9.530; van der Horst HE, 1998, PATIENT EDUC COUNS, V35, P149, DOI 10.1016/S0738-3991(98)00053-6; VANDERLINDEN MW, 2004, TWEEDE NATL STUDIE Z; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	25	107	110	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 9	2005	331	7508					84	87		10.1136/bmj.38495.686736.E0	http://dx.doi.org/10.1136/bmj.38495.686736.E0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	945XR	15967762	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000230536800015
J	Akhtar, S; Bradley, MJ; Quinton, DN; Burke, FD				Akhtar, S; Bradley, MJ; Quinton, DN; Burke, FD			Management and referral for trigger finger/thumb	BRITISH MEDICAL JOURNAL			English	Review							STENOSING TENOVAGINITIS; PERCUTANEOUS RELEASE; STEROID INJECTION; DIABETES-MELLITUS; A1 PULLEY; THUMB; FINGERS; CHILDREN; HAND; EFFICACY		Derbyshire Royal Infirm, Pulvertaft Hand Ctr, Derby DE1 2QY, England		Akhtar, S (corresponding author), 27 Belle Vue Ave, Leeds LS8 2NN, W Yorkshire, England.	sohailakhtar001@yahoo.co.uk						AMETEWEE K, 1983, HAND, V15, P103, DOI 10.1016/S0072-968X(83)80045-X; ANDERSON B, 1991, ARCH INTERN MED, V151, P153, DOI 10.1001/archinte.151.1.153; BAIN GI, 1995, J HAND SURG-AM, V20A, P781, DOI 10.1016/S0363-5023(05)80430-7; Benson LS, 1997, J HAND SURG-AM, V22A, P138, DOI 10.1016/S0363-5023(05)80194-7; BONNICI AV, 1988, J HAND SURG-BRIT EUR, V13B, P202, DOI 10.1016/0266-7681(88)90139-8; CHAMMAS M, 1995, J HAND SURG-AM, V20A, P109, DOI 10.1016/S0363-5023(05)80068-1; Cihantimur B, 1998, ACTA ORTHOP SCAND, V69, P167, DOI 10.3109/17453679809117620; CLARK DD, 1973, PLAST RECONSTR SURG, V51, P179, DOI 10.1097/00006534-197302000-00014; FAHEY JJ, 1954, J BONE JOINT SURG AM, V36-A, P1200, DOI 10.2106/00004623-195436060-00009; Gaffield JW, 2001, ANN PLAS SURG, V46, P352, DOI 10.1097/00000637-200103000-00037; GRIGGS SM, 1995, J HAND SURG-AM, V20A, P787, DOI 10.1016/S0363-5023(05)80432-0; HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P1720, DOI 10.2106/00004623-199411000-00018; KAMHIN M, 1983, HAND, V15, P218, DOI 10.1016/S0072-968X(83)80018-7; KOLINDSORENSEN V, 1970, ACTA ORTHOP SCAND, V41, P428, DOI 10.3109/17453677008991530; LAPIDUS PW, 1972, CLIN ORTHOP RELAT R, P87; LORTHIOIR J, 1958, J BONE JOINT SURG AM, V40, P793, DOI 10.2106/00004623-195840040-00003; Nemoto K, 1996, J HAND SURG-BRIT EUR, V21B, P416, DOI 10.1016/S0266-7681(05)80221-9; NEWPORT ML, 1990, J HAND SURG-AM, V15A, P748, DOI 10.1016/0363-5023(90)90149-L; Park BH, 2001, IEEE T PLASMA SCI, V29, P502, DOI 10.1109/27.928948; Patel MR, 1997, J HAND SURG-AM, V22A, P150, DOI 10.1016/S0363-5023(05)80196-0; PATEL MR, 1992, J HAND SURG-AM, V17A, P110, DOI 10.1016/0363-5023(92)90124-8; POPE DF, 1995, J HAND SURG-AM, V20A, P280, DOI 10.1016/S0363-5023(05)80026-7; Rodgers JA, 1998, ORTHOPEDICS, V21, P305; SAMPSON SP, 1991, J HAND SURG-AM, V16A, P714, DOI 10.1016/0363-5023(91)90200-U; SCHOFIELD CB, 1993, J HAND SURG-BRIT EUR, V18B, P247, DOI 10.1016/0266-7681(93)90120-5; SERADGE H, 1981, J HAND SURG-AM, V6, P54; Sherman PJ, 1996, J BONE JOINT SURG AM, V78A, P1753, DOI 10.2106/00004623-199611000-00019; Stahl S, 1997, J DIABETES COMPLICAT, V11, P287, DOI 10.1016/S1056-8727(96)00076-1; Strom L, 1977, J Med Soc N J, V74, P951; Tan AHC, 2002, J PEDIATR ORTHOP B, V11, P256, DOI 10.1097/00009957-200207000-00011; TARAS JS, 1995, J HAND SURG-AM, V20A, P276, DOI 10.1016/S0363-5023(05)80024-3; Taras JS, 1998, J HAND SURG-AM, V23A, P717, DOI 10.1016/S0363-5023(98)80060-9; THORPE AP, 1988, J HAND SURG-BRIT EUR, V13B, P199, DOI 10.1016/0266-7681(88)90138-6; Trezies AJH, 1998, J HAND SURG-BRIT EUR, V23B, P539, DOI 10.1016/S0266-7681(98)80142-3; Verdon ME, 1996, PRIMARY CARE, V23, P305, DOI 10.1016/S0095-4543(05)70278-5; Watanabe H, 2001, ARCH ORTHOP TRAUM SU, V121, P388, DOI 10.1007/s004020000249; Wilhelmi BJ, 2003, PLAST RECONSTR SURG, V112, P993, DOI 10.1097/01.PRS.0000076225.79854.F7; Wilhelmi BJ, 2001, PLAST RECONSTR SURG, V108, P908, DOI 10.1097/00006534-200109150-00014; YOSIPOVITCH G, 1990, J RHEUMATOL, V17, P951; YOUNG L, 1980, PLAST RECONSTR SURG, V65, P68, DOI 10.1097/00006534-198001000-00013	40	77	79	3	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 2	2005	331	7507					30	33		10.1136/bmj.331.7507.30	http://dx.doi.org/10.1136/bmj.331.7507.30			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947TD	15994689	Green Published			2022-12-28	WOS:000230668500019
J	Lavy, C				Lavy, C			Open letter to Tony Blair on publication of the report of the Commission for Africa	BRITISH MEDICAL JOURNAL			English	Article								As world leaders prepare to discuss Africa at the G8 summit, a British doctor working in Africa gives his perspective on the continent's health needs and points out some omissions in the recent report.	Coll Med, Dept Surg, Blantyre 3, Malawi	University of Malawi	Lavy, C (corresponding author), Coll Med, Dept Surg, Private Bag 360, Blantyre 3, Malawi.	lavy@malawi.net						*AD HOC COMM HLTH, 1996, INV RES DEV; *COMM AFR, 2005, OUR COMM INT; Heath I, 2005, BRIT MED J, V330, P954, DOI 10.1136/bmj.330.7497.954; Roberts I, 2005, BRIT MED J, V330, P972, DOI 10.1136/bmj.330.7497.972	4	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 2	2005	331	7507					46	47		10.1136/bmj.331.7507.46	http://dx.doi.org/10.1136/bmj.331.7507.46			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947TD	15994694	Green Published			2022-12-28	WOS:000230668500024
J	van der Meer, V; Neven, AK; van den Brock, P; Assendelft, WJ				van der Meer, V; Neven, AK; van den Brock, P; Assendelft, WJ			Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review	BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; ERYTHROCYTE SEDIMENTATION-RATE; HEALTH-CARE; CHILDREN; BACTERIAL; ETIOLOGY; MANAGEMENT; SYMPTOMS; ADULTS; COUNT	Objectives To evaluate the diagnostic accuracy of C reactive protein in detecting radiologically proved pneumonia and to evaluate how well it can discriminate between bacterial and viral infections of the lower respiratory tract. Data sources Medline and Embase (January 1966 to April 2004), with reference checking. Study selection We included articles comparing C reactive protein with a chest radiograph or with microbiological work-up as a reference test. Two authors independently assessed methodological items. Results None of the studies met all validity criteria. Six studies used an infiltrate on chest radiograph as reference test. Sensitivities ranged from 10% to 98%, specificities from 44% to 99%. For adults, the relation of C reactive protein with an infiltrate (in a subgroup analysis of five studies) showed an area under the curve of 0.80 (95% confidence interval 0.75 to 0.85). In 12 studies, the relation of C reactive protein with a bacterial actiology of infection of the lower respiratory tract was studied. Sensitivities ranged from 8% to 99%, specificities from 27% to 95%. These data were epidemiologically and statistically heterogeneous, so overall outcomes could not be calculated. Conclusion Testing for C reactive protein is neither sufficiently sensitive to rule out nor sufficiently specific to rule in an infiltrate on chest radiograph and bacterial actiology of lower respiratory tract infection. The methodological quality of the diagnostic studies is generally poor. The evidence does not consistently and sufficiently support a wide introduction of C reactive protein as a rapid test to guide antibiotics prescription.	Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gen Practice & Nursing Home Med, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van der Meer, V (corresponding author), Leiden Univ, Med Ctr, Dept Med Decis Making, Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.	V.van_der_Meer@lumc.nl	assendelft, willem/AAW-1854-2021; Assendelft, W.J.J./H-8008-2014	assendelft, willem/0000-0002-2966-3778; Assendelft, W.J.J./0000-0002-2966-3778				Almirall J, 2004, CHEST, V125, P1335, DOI 10.1378/chest.125.4.1335; BABU G, 1989, TROP GEOGR MED, V41, P309; CASTELL JV, 1990, HEPATOLOGY, V12, P1179, DOI 10.1002/hep.1840120517; Clyne B, 1999, J EMERG MED, V17, P1019, DOI 10.1016/S0736-4679(99)00135-3; *COCHR METH GROUP, 1996, REC METH; Flanders SA, 2004, AM J MED, V116, P529, DOI 10.1016/j.amjmed.2003.11.023; Heiskanen-Kosma T, 2000, SCAND J INFECT DIS, V32, P399, DOI 10.1080/003655400750044971; HJORTDAHL P, 1991, Scandinavian Journal of Primary Health Care, V9, P3, DOI 10.3109/02813439109026574; Holmes WF, 2001, BRIT J GEN PRACT, V51, P177; Hopstaken RM, 2003, BRIT J GEN PRACT, V53, P358; Johnson Heather L., 1999, Journal of Microbiology Immunology and Infection, V32, P73; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; KERTTULA Y, 1987, J INFECTION, V14, P21, DOI 10.1016/S0163-4453(87)90730-4; Koch H, 2004, ALCOHOL ALCOHOLISM, V39, P75, DOI 10.1093/alcalc/agh031; KORPPI M, 1993, SCAND J INFECT DIS, V25, P207, DOI 10.3109/00365549309008486; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; MELBYE H, 1992, Scandinavian Journal of Primary Health Care, V10, P234, DOI 10.3109/02813439209014067; Melbye H, 1988, Scand J Prim Health Care, V6, P111, DOI 10.3109/02813438809009300; MELBYE H, 1992, SCAND J INFECT DIS, V24, P647, DOI 10.3109/00365549209054652; MIDGETTE AS, 1993, MED DECIS MAKING, V13, P253, DOI 10.1177/0272989X9301300313; NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P484, DOI 10.1097/00006454-199506000-00004; Prat C, 2003, PEDIATR INFECT DIS J, V22, P963, DOI 10.1097/01.inf.0000095197.72976.4f; Raherison C, 2002, EUR RESPIR J, V19, P314, DOI 10.1183/09031936.02.00219102; Requejo Henry I. Z., 2003, Braz J Infect Dis, V7, P241, DOI 10.1590/S1413-86702003000400003; Virkki R, 2002, THORAX, V57, P438, DOI 10.1136/thorax.57.5.438; YOUNG B, 1991, PATHOLOGY, V23, P118, DOI 10.3109/00313029109060809	26	150	156	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 2	2005	331	7507					26	29		10.1136/bmj.38483.478183.EB	http://dx.doi.org/10.1136/bmj.38483.478183.EB			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947TD	15979984	Bronze, Green Published			2022-12-28	WOS:000230668500018
J	Ng, KL; Li, JD; Cheng, MY; Leslie, FM; Lee, AG; Zhou, QY				Ng, KL; Li, JD; Cheng, MY; Leslie, FM; Lee, AG; Zhou, QY			Dependence of olfactory bulb neurogenesis on prokineticin 2 signaling	SCIENCE			English	Article							NEURONAL MIGRATION; SUBVENTRICULAR ZONE; POSTNATAL NEUROGENESIS; DIRECTIONAL GUIDANCE; FOREBRAIN; PROTEIN; IDENTIFICATION; RECEPTORS; CELLS; RAT	Neurogenesis persists in the olfactory bulb (OB) of the adult mammalian brain. New interneurons are continually added to the OB from the subventricular zone (SVZ) via the rostral migratory stream (RMS). Here we show that secreted prokineticin 2 (PK2) functions as a chemoattractant for SVZ-derived neuronal progenitors. Within the OB, PK2 may also act as a detachment signal for chain-migrating progenitors arriving from the RMS. PK2 deficiency in mice leads to a marked reduction in OB size, loss of normal OB architecture, and the accumulation of neuronal progenitors in the RMS. These findings define an essential role for G protein-coupled PK2 signaling in postnatal and adult OB neurogenesis.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Zhou, QY (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.	qzhou@uci.edu		Cheng, Michelle/0000-0003-3241-5174; Li, Jia-Da/0000-0002-4236-3518				ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; BAYER SA, 1983, EXP BRAIN RES, V50, P329; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Betarbet R, 1996, INT J DEV NEUROSCI, V14, P921, DOI 10.1016/S0736-5748(96)00066-4; Bullock CM, 2004, MOL PHARMACOL, V65, P582, DOI 10.1124/mol.65.3.582; Cheng MY, 2002, NATURE, V417, P405, DOI 10.1038/417405a; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Hack I, 2002, NAT NEUROSCI, V5, P939, DOI 10.1038/nn923; Hu HY, 1996, NEURON, V16, P933, DOI 10.1016/S0896-6273(00)80116-6; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KISHI K, 1990, ARCH HISTOL CYTOL, V53, P219, DOI 10.1679/aohc.53.219; LeCouter J, 2003, P NATL ACAD SCI USA, V100, P2685, DOI 10.1073/pnas.0337667100; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Li J. P. H., UNPUB; Li M, 2001, MOL PHARMACOL, V59, P692, DOI 10.1124/mol.59.4.692; Lin DCH, 2002, J BIOL CHEM, V277, P19276, DOI 10.1074/jbc.M202139200; Liu GF, 2003, J NEUROSCI, V23, P6651; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Mollay C, 1999, EUR J PHARMACOL, V374, P189, DOI 10.1016/S0014-2999(99)00229-0; Negri L, 2002, BRIT J PHARMACOL, V137, P1147, DOI 10.1038/sj.bjp.0704995; Ng K., UNPUB; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Pencea V, 2001, EXP NEUROL, V172, P1, DOI 10.1006/exnr.2001.7768; Piao XH, 2004, SCIENCE, V303, P2033, DOI 10.1126/science.1092780; Saghatelyan A, 2004, NAT NEUROSCI, V7, P347, DOI 10.1038/nn1211; Soga T, 2002, BBA-GENE STRUCT EXPR, V1579, P173, DOI 10.1016/S0167-4781(02)00546-8; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; Ward M, 2003, J NEUROSCI, V23, P5170; Wichterle H, 1997, NEURON, V18, P779, DOI 10.1016/S0896-6273(00)80317-7; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Zhang HX, 2003, J CELL BIOL, V163, P1375, DOI 10.1083/jcb.200308040	34	232	252	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	2005	308	5730					1923	1927		10.1126/science.1112103	http://dx.doi.org/10.1126/science.1112103			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976302				2022-12-28	WOS:000230120000044
J	Avorn, J				Avorn, J			Torcetrapid and atorvastatin - Should marketing drive the research agenda?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ESTER TRANSFER PROTEIN; CHOLESTEROL; INHIBITOR		Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Avorn, J (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Avorn J, 2004, POWERFUL MED BENEFIT; Brousseau ME, 2005, ARTERIOSCL THROM VAS, V25, P1057, DOI 10.1161/01.ATV.0000161928.16334.dd; Brousseau ME, 2004, NEW ENGL J MED, V350, P1505, DOI 10.1056/NEJMoa031766; Davidson M, 2005, J AM COLL CARDIOL, V45, p394A; Fischer MA, 2004, JAMA-J AM MED ASSOC, V291, P1850, DOI 10.1001/jama.291.15.1850	5	23	24	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					2573	2576		10.1056/NEJMp058075	http://dx.doi.org/10.1056/NEJMp058075			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972861				2022-12-28	WOS:000229953700002
J	Winton, T; Livingston, R; Johnson, D; Rigas, J; Johnston, M; Butts, C; Cormier, Y; Goss, G; Inculet, R; Vallieres, E; Fry, W; Bethune, D; Ayoub, J; Ding, K; Seymour, L; Graham, B; Tsao, MS; Gandara, D; Kesler, K; Demmy, T; Shepherd, F				Winton, T; Livingston, R; Johnson, D; Rigas, J; Johnston, M; Butts, C; Cormier, Y; Goss, G; Inculet, R; Vallieres, E; Fry, W; Bethune, D; Ayoub, J; Ding, K; Seymour, L; Graham, B; Tsao, MS; Gandara, D; Kesler, K; Demmy, T; Shepherd, F		Natl Canc Inst Canada Clin Trials Grp; Natl Canc Inst US Intergroup JBR 10	Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RAS GENE-MUTATIONS; QUALITY-OF-LIFE; STAGE-II; ADJUVANT CHEMOTHERAPY; SURVIVAL; TRIAL; THERAPY	Background We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer. Methods We randomly assigned patients with completely resected stage IB or stage II non-small-cell lung cancer to vinorelbine plus cisplatin or to observation. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimen. Results A total of 482 patients underwent randomization to vinorelbine plus cisplatin (242 patients) or observation (240); 45 percent of the patients had pathological stage IB disease and 55 percent had stage II, and all had an Eastern Cooperative Oncology Group performance status score of 0 or 1. In both groups, the median age was 61 years, 65 percent were men, and 53 percent had adenocarcinomas. Chemotherapy caused neutropenia in 88 percent of patients (including grade 3 febrile neutropenia in 7 percent) and death from toxic effects in two patients (0.8 percent). Nonhematologic toxic effects of chemotherapy were fatigue (81 percent of patients), nausea (80 percent), anorexia (55 percent), vomiting (48 percent), neuropathy (48 percent), and constipation (47 percent), but severe (grade 3 or greater) toxic effects were uncommon (<10 percent). Overall survival was significantly prolonged in the chemotherapy group as compared with the observation group (94 vs. 73 months; hazard ratio for death, 0.69; P=0.04), as was relapse-free survival (not reached vs. 46.7 months; hazard ratio for recurrence, 0.60; P<0.001). Five-year survival rates were 69 percent and 54 percent, respectively (P=0.03). Conclusions Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.	Natl Canc Inst Canada Clin Trials Grp, Kingston, ON, Canada; SW Oncol Grp, San Antonio, TX USA; Eastern Cooperat Oncol Grp, Boston, MA USA; Canc & Leukemia Grp B, Chicago, IL USA	Queens University - Canada; Canadian Cancer Trials Group; Southwest Oncology Group	Winton, T (corresponding author), Univ Alberta Hosp, Walter Mackenzie Hlth Sci Ctr 2D2 09, 8440 112th St, Edmonton, AB T6G 2B7, Canada.	twinton@cha.ab.ca	Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; Vallieres, Eric/0000-0003-1732-2658	NATIONAL CANCER INSTITUTE [U10CA031946, U10CA004326] Funding Source: NIH RePORTER; NCI NIH HHS [CA31946, CA04326] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alam N, 2005, LUNG CANCER, V47, P385, DOI 10.1016/j.lungcan.2004.08.016; ALBERTI W, 1995, BRIT MED J, V311, P899; BEZIAK A, 2003, LUNG CANCER S4, V41, pS20; Bonomi P, 2000, J CLIN ONCOL, V18, P623, DOI 10.1200/JCO.2000.18.3.623; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; Bunn PA, 1998, CLIN CANCER RES, V4, P1087; Burdett S, 1998, LANCET, V352, P257; COX DR, 1972, J R STAT SOC B, V34, P187; Cullen M, 2003, THORAX, V58, P352, DOI 10.1136/thorax.58.4.352; Giaccone G, 1998, J CLIN ONCOL, V16, P2133, DOI 10.1200/JCO.1998.16.6.2133; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keller SM, 2000, NEW ENGL J MED, V343, P1217, DOI 10.1056/NEJM200010263431703; Keller SM, 2002, LUNG CANCER, V37, P303, DOI 10.1016/S0169-5002(02)00103-4; Kelly K, 2001, J CLIN ONCOL, V19, P3210, DOI 10.1200/JCO.2001.19.13.3210; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; LECHEVALIER T, 1994, J CLIN ONCOL, V12, P360, DOI 10.1200/JCO.1994.12.2.360; MITSUDOMI T, 1991, CANCER RES, V51, P4999; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Ponn RB, 2005, GEN THORACIC SURG, V6, P1548; ROILA F, 1992, LANCET, V340, P96; ROSELL R, 1993, ONCOGENE, V8, P2407; Scagliotti GV, 2003, JNCI-J NATL CANCER I, V95, P1453, DOI 10.1093/jnci/djg059; SHEPHERD FA, 2002, THORACIC SURG, P859; Socinski MA, 2003, CHEST, V123, p226S, DOI 10.1378/chest.123.1_suppl.226S; Soria JC, 2002, ANN ONCOL, V13, P1515, DOI 10.1093/annonc/mdf331; Strauss GM, 2004, J CLIN ONCOL, V22, P7019; SUGIO K, 1992, CANCER RES, V52, P2903; Tsao MS, 1997, CLIN CANCER RES, V3, P1807; TSIATIS AA, 1984, BIOMETRICS, V40, P797, DOI 10.2307/2530924; Waller D, 2004, EUR J CARDIO-THORAC, V26, P173, DOI 10.1016/j.ejcts.2004.03.041; Zojwalla NJ, 2004, J CLIN ONCOL, V22, p633S	33	1410	1481	2	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					2589	2597		10.1056/NEJMoa043623	http://dx.doi.org/10.1056/NEJMoa043623			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972865				2022-12-28	WOS:000229953700006
J	Fowler, VG; Miro, JM; Hoen, B; Cabell, CH; Abrutyn, E; Rubinstein, E; Corey, GR; Spelman, D; Bradley, SF; Barsic, B; Pappas, PA; Anstrom, KJ; Wray, D; Fortes, CQ; Anguera, I; Athan, E; Jones, P; van der Meer, JTM; Elliott, TSJ; Levine, DP; Bayer, AS				Fowler, VG; Miro, JM; Hoen, B; Cabell, CH; Abrutyn, E; Rubinstein, E; Corey, GR; Spelman, D; Bradley, SF; Barsic, B; Pappas, PA; Anstrom, KJ; Wray, D; Fortes, CQ; Anguera, I; Athan, E; Jones, P; van der Meer, JTM; Elliott, TSJ; Levine, DP; Bayer, AS		ICE Investigators	Staphylococcus aureus endocarditis - A consequence of medical progress	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMERICAN-HEART-ASSOCIATION; BLOOD-STREAM INFECTIONS; CLINICAL-FEATURES; BACTEREMIA; VANCOMYCIN; MANAGEMENT; DIAGNOSIS; THERAPY; SURVEILLANCE; GUIDELINES	Context The global significance of infective endocarditis (IE) caused by Staphylococcus aureus is unknown. Objectives To document the international emergence of health care-associated S aureus IE and methicillin-resistant S aureus (MRSA) IE and to evaluate regional variation in patients with S aureus IE. Design, Setting, and Participants Prospective observational cohort study set in 39 medical centers in 16 countries. Participants were a population of 1779 patients with definite IE as defined by Duke criteria who were enrolled in the International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to December 2003. Main Outcome Measure In-hospital mortality. Results S aureus was the most common pathogen among the 1779 cases of definite IE in the International Collaboration on Endocarditis Prospective-Cohort Study (558 patients, 31.4%). Health care-associated infection was the most common form of S aureus IE (218 patients, 39.1%), accounting for 25.9% (Australia/New Zealand) to 54.2% (Brazil) of cases. Most patients with health care-associated S aureus I E (131 patients, 60.1%) acquired the infection outside of the hospital. MRSA IE was more common in the United States (37.2%) and Brazil (37.5%) than in Europe/Middle East (23.7%) and Australia/ New Zealand (15.5%, P<.001). Persistent bacteremia was independently associated with MRSA IE (odds ratio, 6.2; 95% confidence interval, 2.9-13.2). Patients in the United States were most likely to be hemodialysis dependent, to have diabetes, to have a presumed intravascular device source, to receive vancomycin, to be infected with MRSA, and to have persistent bacteremia (P<.001 for all comparisons). Conclusions S aureus is the leading cause of IE in many regions of the world. Characteristics of patients with S aureus IE vary significantly by region. Further studies are required to determine the causes of regional variation.	Duke Univ, Med Ctr, Div Infect Dis, Durham, NC 27710 USA; Univ Barcelona, Hosp Clin, IDIBAPS, E-08007 Barcelona, Spain; Hop St Jacques, F-25030 Besancon, France; Drexel Univ, Coll Med, Philadelphia, PA 19104 USA; Tel Aviv Univ, Sch Med, IL-69978 Tel Aviv, Israel; Alfred Hosp, Melbourne, Vic, Australia; Univ Michigan, Ann Arbor, MI 48109 USA; Univ Zagreb, Univ Hosp Infect Dis, Zagreb, Croatia; Med Univ S Carolina, Charleston, SC 29425 USA; Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil; Hosp Sabadell, Sabadell, Spain; Geelong Hosp, Geelong, Vic, Australia; Prince Wales Hosp, Sydney, NSW, Australia; Univ Amsterdam, Acad Med Ctr, NL-1012 WX Amsterdam, Netherlands; Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England; Wayne State Univ, Detroit, MI USA; Harbor UCLA Med Ctr, Los Angeles, CA USA; LA Biomed Res Inst, Los Angeles, CA USA	Duke University; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universite de Franche-Comte; CHU Besancon; Drexel University; Tel Aviv University; Florey Institute of Neuroscience & Mental Health; University of Michigan System; University of Michigan; University of Zagreb; Medical University of South Carolina; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Geelong Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Birmingham; Wayne State University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Fowler, VG (corresponding author), Duke Univ, Med Ctr, Div Infect Dis, Box 3281, Durham, NC 27710 USA.	vance.fowler@duke.edu	Fowler, Vance/AAW-2017-2021	Querido Fortes, Claudio/0000-0002-9700-9743; Athan, Eugene/0000-0001-9838-6471; Gordon, David/0000-0003-3276-9685	NHLBI NIH HHS [HL-70861] Funding Source: Medline; NIAID NIH HHS [AI-059111, AI-39108] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL070861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039108, R01AI059111] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; BAYER AS, 1980, WESTERN J MED, V132, P294; Bonow RO, 1998, J AM COLL CARDIOL, V32, P1486, DOI 10.1016/S0735-1097(98)00454-9; Cabell CH, 2004, AM HEART J, V147, P582, DOI 10.1016/j.ahj.2003.06.005; Cabell CH, 2002, ARCH INTERN MED, V162, P90, DOI 10.1001/archinte.162.1.90; Cabell CH, 2002, INFECT DIS CLIN N AM, V16, P255, DOI 10.1016/S0891-5520(01)00007-1; CHAMBERS HF, 1983, MEDICINE, V62, P170, DOI 10.1097/00005792-198305000-00004; Darouiche RO, 2004, NEW ENGL J MED, V350, P1422, DOI 10.1056/NEJMra035415; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; EHNI WF, 1989, ARCH INTERN MED, V149, P533, DOI 10.1001/archinte.149.3.533; ESPERSEN F, 1986, ARCH INTERN MED, V146, P1118, DOI 10.1001/archinte.146.6.1118; FERNANDEZGUERRERO ML, 1995, CLIN INFECT DIS, V20, P16, DOI 10.1093/clinids/20.1.16; Figueiredo Luiz Tadeu M., 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P213, DOI 10.1590/S0036-46652001000400007; Fluit AC, 2000, CLIN INFECT DIS, V30, P454, DOI 10.1086/313710; Fowler VG, 1999, CLIN INFECT DIS, V28, P106; Friedman ND, 2002, ANN INTERN MED, V137, P791, DOI 10.7326/0003-4819-137-10-200211190-00007; Gouello JP, 2000, CRIT CARE MED, V28, P377, DOI 10.1097/00003246-200002000-00015; Hlatky MA, 2002, AM HEART J, V144, P397, DOI 10.1067/mhj.2002.125496; IANNINI PB, 1976, ANN INTERN MED, V84, P558, DOI 10.7326/0003-4819-84-5-558; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; LEVINE DP, 1991, ANN INTERN MED, V115, P674, DOI 10.7326/0003-4819-115-9-674; Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LOWES JA, 1980, LANCET, V1, P133, DOI 10.1016/S0140-6736(80)90614-5; MARKOWITZ N, 1992, ANN INTERN MED, V117, P390, DOI 10.7326/0003-4819-117-5-390; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; MORTARA LA, 1993, INFECT DIS CLIN N AM, V7, P53; MYLOTTE JM, 1987, REV INFECT DIS, V9, P891; Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976; NOLAN CM, 1976, AM J MED, V60, P495, DOI 10.1016/0002-9343(76)90715-4; PELLETIER LL, 1977, MEDICINE, V56, P287, DOI 10.1097/00005792-197707000-00002; Roder BL, 1999, ARCH INTERN MED, V159, P462, DOI 10.1001/archinte.159.5.462; SMALL PM, 1990, ANTIMICROB AGENTS CH, V34, P1227, DOI 10.1128/AAC.34.6.1227; TERPENNING MS, 1988, ARCH INTERN MED, V148, P1601, DOI 10.1001/archinte.148.7.1601; WATANAKUNAKORN C, 1994, ARCH INTERN MED, V154, P2330, DOI 10.1001/archinte.154.20.2330; Watanakunakorn C, 1999, CLIN INFECT DIS, V28, P115, DOI 10.1086/515077; Wisplinghoff H, 2004, CLIN INFECT DIS, V39, P309, DOI 10.1086/421946	37	774	808	0	45	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 22	2005	293	24					3012	3021		10.1001/jama.293.24.3012	http://dx.doi.org/10.1001/jama.293.24.3012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937SG	15972563	Bronze, Green Published			2022-12-28	WOS:000229945200016
J	Buyon, JP; Petri, MA; Kim, MY; Kalunian, KC; Grossman, J; Hahn, BH; Merrill, JT; Sammaritano, L; Lockshin, M; Alarcon, GS; Manzi, S; Belmont, HM; Askanase, AD; Sigler, L; Dooley, MA; Von Feldt, J; McCune, WJ; Friedman, A; Wachs, J; Cronin, M; Hearth-Holmes, M; Tan, M; Licciardi, F				Buyon, JP; Petri, MA; Kim, MY; Kalunian, KC; Grossman, J; Hahn, BH; Merrill, JT; Sammaritano, L; Lockshin, M; Alarcon, GS; Manzi, S; Belmont, HM; Askanase, AD; Sigler, L; Dooley, MA; Von Feldt, J; McCune, WJ; Friedman, A; Wachs, J; Cronin, M; Hearth-Holmes, M; Tan, M; Licciardi, F			The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; ORAL-CONTRACEPTIVE THERAPY; POSTMENOPAUSAL WOMEN; PLUS PROGESTIN; FOLLOW-UP; ACCELERATED ATHEROSCLEROSIS; PULMONARY-HYPERTENSION; CARDIOVASCULAR-DISEASE; RISK; SLE	Background: There is concern that exogenous female hormones may worsen disease activity in women with systemic lupus erythematosus (SLE). Objective: To evaluate the effect of hormone replacement therapy (HRT) on disease activity in postmenopausal women with SLE. Design: Randomized, double-blind, placebo-controlled nonin-feriority trial conducted from March 1996 to June 2002. Setting: 16 university-affiliated rheumatology clinics or practices in 11 U.S. states. Patients: 351 menopausal patients (mean age, 50 years) with inactive (81.5%) or stable-active (18.5%) SLE. Interventions: 12 months of treatment with active drug (0.625 mg of conjugated estrogen daily, plus 5 mg of medroxyprogesterone for 12 days per month) or placebo. The 12-month follow-up rate was 82% for the HRT group and 87% for the placebo group. Measurements: The primary end point was occurrence of a severe flare as defined by Safety of Estrogens in Lupus Erythem- atosus, National Assessment-Systemic Lupus Erythematosus Disease Activity Index composite. Results: Severe flare was rare in both treatment groups: The 12-month severe flare rate was 0.081 for the HRT group and 0.049 for the placebo group, yielding an estimated difference of 0.033 (P = 0.23). The upper limit of the 1-sided 95% Cl for the treatment difference was 0.078, within the prespecified margin of 9% for noninferiority. Mild to moderate flares were significantly increased in the HRT group: 1.14 flares/person-year for HRT and 0.86 flare/person-year for placebo (relative risk, 1.34; P = 0.01). The probability of any type of flare by 12 months was 0.64 for the HRT group and 0.51 for the placebo group (P = 0.01). In the HRT group, there were 1 death, 1 stroke, 2 cases of deep venous thrombosis, and 1 case of thrombosis in an arteriovenous graft; in the placebo group, 1 patient developed deep venous thrombosis. Limitations: Findings are not generalizable to women with high-titer anticardiolipin antibodies, lupus anticoagulant, or previous thrombosis. Conclusions: Adding a short course of HRT is associated with a small risk for increasing the natural flare rate of lupus. Most of these flares are mild to moderate. The benefits of HRT can be balanced against the risk for flare because HRT did not significantly increase the risk for severe flare compared with placebo.	NYU, Hosp Joint Dis, Sch Med, New York, NY 10003 USA; Johns Hopkins Univ, Baltimore, MD 21218 USA	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; Johns Hopkins University	Buyon, JP (corresponding author), NYU, Hosp Joint Dis, Sch Med, 550 1St Ave, New York, NY 10003 USA.	jill.buyon@nyumc.org	Kalunian, Kenneth/L-4471-2019; Kalunian, Kenneth/AAK-6424-2020	Kalunian, Kenneth/0000-0003-0261-3102; Licciardi, Frederick/0000-0002-2186-5981; Buyon, Jill/0000-0002-3852-7129; Belmont, Howard/0000-0003-3389-2976	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096, M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043727, U01AR042540, R55AR043727] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00052, M01 RR00096] Funding Source: Medline; NIAMS NIH HHS [AR 43727, U01 AR42540] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARCHER DF, 1994, OBSTET GYNECOL, V83, P686; ARDEN NK, 1994, LUPUS, V3, P11, DOI 10.1177/096120339400300104; Asanuma Y, 2003, NEW ENGL J MED, V349, P2407, DOI 10.1056/NEJMoa035611; Bagger YZ, 2004, BONE, V34, P728, DOI 10.1016/j.bone.2003.12.021; BARRETT C, 1986, BRIT J RHEUMATOL, V25, P300; Bastian Holly M., 1994, Arthritis and Rheumatism, V37, pS321; BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606; CASTELOBRANCO C, 1995, J REPROD MED, V40, P556; CHAPEL TA, 1971, AM J OBSTET GYNECOL, V110, P366, DOI 10.1016/0002-9378(71)90730-7; Esdaile JM, 2001, ARTHRITIS RHEUM, V44, P2331, DOI 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I; FURUKAWA F, 1991, Journal of Dermatology (Tokyo), V18, P56; GAROVICH M, 1980, ARTHRITIS RHEUM, V23, P1396, DOI 10.1002/art.1780231213; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grimaldi CM, 2002, J CLIN INVEST, V109, P1625, DOI 10.1172/JCI200214873; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; HADIDA M, 1968, B SOC FR DERMATO SYP, V74, P616; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JUNGERS P, 1982, ARTHRITIS RHEUM, V25, P618, DOI 10.1002/art.1780250603; Kreidstein S, 1997, J RHEUMATOL, V24, P2149; LAHITA RG, 1982, ARTHRITIS RHEUM, V25, P843, DOI 10.1002/art.1780250726; LAHITA RG, 1979, ARTHRITIS RHEUM, V22, P1195, DOI 10.1002/art.1780221106; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Manzi S, 1997, AM J EPIDEMIOL, V145, P408; MASI AT, 1978, ARTHRITIS RHEUM-US, V21, P480, DOI 10.1002/art.1780210413; Meier CR, 1998, J RHEUMATOL, V25, P1515; MILLER MH, 1987, ANN RHEUM DIS, V46, P159, DOI 10.1136/ard.46.2.159; Mok CC, 1998, SCAND J RHEUMATOL, V27, P342, DOI 10.1080/03009749850154357; Naftolin F, 2004, FERTIL STERIL, V81, P1498, DOI 10.1016/j.fertnstert.2004.02.095; Peeva E, 2004, BIOMED PHARMACOTHER, V58, P310, DOI 10.1016/j.biopha.2004.04.007; Petri M, 1999, LUPUS, V8, P685, DOI 10.1191/096120399680411281; Petri M, 2000, RHEUM DIS CLIN N AM, V26, P199, DOI 10.1016/S0889-857X(05)70135-6; Pimstone B., 1966, S AFR MED J, V4, P62; Ramsey-Goldman R, 1999, ARTHRITIS RHEUM, V42, P882, DOI 10.1002/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C; Roman MJ, 2003, NEW ENGL J MED, V349, P2399, DOI 10.1056/NEJMoa035471; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; ROUBINIAN J, 1979, ARTHRITIS RHEUM, V22, P1162; Sanchez-Guerrero J, 2001, ARTHRITIS RHEUM, V44, pS263; SANCHEZGUERRERO J, 1995, ANN INTERN MED, V122, P430, DOI 10.7326/0003-4819-122-6-199503150-00005; Selzer F, 2001, HYPERTENSION, V37, P1075, DOI 10.1161/01.HYP.37.4.1075; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TODD GRG, 1985, ANN RHEUM DIS, V44, P266, DOI 10.1136/ard.44.4.266; TRAVERS RL, 1978, J RHEUMATOL, V5, P448; Wang DR, 1996, MOL BIOL REP, V23, P205, DOI 10.1007/BF00351170; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084	46	418	429	1	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	1				953	962		10.7326/0003-4819-142-12_Part_1-200506210-00004	http://dx.doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937IN	15968009				2022-12-28	WOS:000229917900001
J	Crowther, CA; Hiller, JE; Moss, JR; McPhee, AJ; Jeffries, WS; Robinson, JS				Crowther, CA; Hiller, JE; Moss, JR; McPhee, AJ; Jeffries, WS; Robinson, JS		ACHOIS Trial Grp	Effect of treatment of gestational diabetes mellitus on pregnancy outcomes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNATIONAL WORKSHOP; BIRTH-WEIGHT; SHORT-FORM; HEALTH	BACKGROUND: We conducted a randomized clinical trial to determine whether treatment of women with gestational diabetes mellitus reduced the risk of perinatal complications. METHODS: We randomly assigned women between 24 and 34 weeks' gestation who had gestational diabetes to receive dietary advice, blood glucose monitoring, and insulin therapy as needed (the intervention group) or routine care. Primary outcomes included serious perinatal complications (defined as death, shoulder dystocia, bone fracture, and nerve palsy), admission to the neonatal nursery, jaundice requiring phototherapy, induction of labor, cesarean birth, and maternal anxiety, depression, and health status. RESULTS: The rate of serious perinatal complications was significantly lower among the infants of the 490 women in the intervention group than among the infants of the 510 women in the routine-care group (1 percent vs. 4 percent; relative risk adjusted for maternal age, race or ethnic group, and parity, 0.33; 95 percent confidence interval, 0.14 to 0.75; P=0.01).However, more infants of women in the intervention group were admitted to the neonatal nursery (71 percent vs. 61 percent; adjusted relative risk, 1.13; 95 percent confidence interval, 1.03 to 1.23; P=0.01).Women in the intervention group had a higher rate of induction of labor than the women in the routine-care group (39 percent vs. 29 percent; adjusted relative risk, 1.36; 95 percent confidence interval, 1.15 to 1.62; P<0.001), although the rates of cesarean delivery were similar (31 percent and 32 percent, respectively; adjusted relative risk, 0.97; 95 percent confidence interval, 0.81 to 1.16; P=0.73).At three months post partum, data on the women's mood and quality of life, available for 573 women, revealed lower rates of depression and higher scores, consistent with improved health status, in the intervention group. CONCLUSIONS: Treatment of gestational diabetes reduces serious perinatal morbidity and may also improve the woman's health-related quality of life.	Univ Adelaide, Dept Obstet & Gynaecol, Adelaide, SA 5001, Australia; Univ Adelaide, Dept Publ Hlth, Adelaide, SA 5001, Australia; Womens & Childrens Hosp, Dept Perinatal Med, Adelaide, SA, Australia; Lyell McEwin Hlth Serv, Dept Med, Adelaide, SA, Australia	University of Adelaide; University of Adelaide; Womens & Childrens Hospital Australia; Lyell McEwin Hospital	Crowther, CA (corresponding author), Univ Adelaide, Dept Obstet & Gynaecol, Adelaide, SA 5001, Australia.		Moss, John/B-2327-2010; Hiller, Janet E./A-5633-2008; Dodd, Jodie/Y-6849-2019; jing, jiang/C-3378-2008; Lawrence, Annemarie/I-4180-2013	Moss, John/0000-0003-4216-1761; Hiller, Janet E./0000-0002-8532-4033; Dodd, Jodie/0000-0002-6363-4874; Lawrence, Annemarie/0000-0002-8736-4741				*ACOG, 2001, ACOG PRACT B, V30; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; American Diabetes Association, 2002, AM DIABETES ASS DIAB, V25, ps94, DOI DOI 10.2337/DIACARE.25.2007.S94); [Anonymous], 1985, World Health Organ Tech Rep Ser, V727, P1; BEAULIEU MD, 1992, CAN MED ASSOC J, V147, P435; BLANK A, 1995, DIABETES CARE, V18, P127, DOI 10.2337/diacare.18.1.127; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; BRODY SC, 2003, SCREENING GESTATIONA; CHAN A, 1993, PREGNANCY OUTCOME S; Contreras M, 2002, INT J GYNECOL OBSTET, V78, P69; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Hochberg Y., 1987, MULTIPLE COMP PROCED; Hoffman L, 1998, MED J AUSTRALIA, V169, P93, DOI 10.5694/j.1326-5377.1998.tb140192.x; HUNTER JS, 1989, EFFECTIVE CARE PREGN, P403; Innes KE, 2002, JAMA-J AM MED ASSOC, V287, P2534, DOI 10.1001/jama.287.19.2534; INNES KE, 2002, JAMA-J AM MED ASSOC, V287, P3212; Kerbel D, 1997, J Med Screen, V4, P128; Landon M B, 2002, J Matern Fetal Neonatal Med, V11, P226, DOI 10.1080/713605514; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Metzger BE, 1998, DIABETES CARE, V21, pB161; *NICE, 2003, CG6 ANT CAR ROUT CAR; OSullivan J., 1989, CARBOHYD METABOL, P287; Petitt D J, 1985, Diabetes, V34 Suppl 2, P119; *PREV SERV TASK FO, 1996, GUID CLIN PREV SERV, P193; Rizzo TA, 1997, CHILD DEV, V68, P26, DOI 10.2307/1131922; Roberts CL, 1999, MED J AUSTRALIA, V170, P114, DOI 10.5694/j.1326-5377.1999.tb127678.x; Rumbold AR, 2002, AUST NZ J OBSTET GYN, V42, P131, DOI 10.1111/j.0004-8666.2002.00131.x; Rumbold AR, 2001, AUST NZ J OBSTET GYN, V41, P86, DOI 10.1111/j.1479-828X.2001.tb01301.x; Scott D A, 2002, Health Technol Assess, V6, P1; SCOTT DA, 2002, HEALTH TECHNOL ASSES, V6, P36; SILVERMAN BL, 1995, DIABETES CARE, V18, P611, DOI 10.2337/diacare.18.5.611; TUFFNELL DJ, 2003, COCHRANE DB SYST REV, V3; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	34	1761	1835	7	282	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2005	352	24					2477	2486		10.1056/NEJMoa042973	http://dx.doi.org/10.1056/NEJMoa042973			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935RH	15951574	Bronze, Green Published			2022-12-28	WOS:000229798900003
J	Li, WK; Kamtekar, S; Xiong, Y; Sarkis, GJ; Grindley, NDF; Steitz, TA				Li, WK; Kamtekar, S; Xiong, Y; Sarkis, GJ; Grindley, NDF; Steitz, TA			Structure of a synaptic gamma delta resolvase tetramer covalently linked to two cleaved DNAs	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; TN3 RESOLVASE; CRYSTAL-STRUCTURE; COMPLEX; ARCHITECTURE; MUTANTS; MODEL; SUBUNITS; IDENTIFY; INVITRO	The structure of a Synaptic intermediate of the site-specific recombinase gamma delta resolvase covalently linked through Ser(10) to two cleaved duplex DNAs has been determined at 3.4 angstrom resolution. This resolvase, activated for recombination by mutations, forms a tetramer whose structure is substantially changed from that of a presynaptic complex between dimeric resolvase and the cleavage site DNA. Because the two cleaved DNA duplexes that are to be recombined lie on opposite sides of the core tetramer, large movements of both protein and DNA are required to achieve strand exchange. The two dimers linked to the DNAs that are to be recombined are held together by a flat interface. This may allow a 180 degrees rotation of one dimer relative to the other in order to reposition the DNA duplexes for strand exchange.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.	eatherton@csb.yale.edu	Steitz, Thomas A./C-6559-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028470, R01GM057510, R01GM028470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57510, GM28470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold PH, 1999, EMBO J, V18, P1407, DOI 10.1093/emboj/18.5.1407; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen Y, 2003, ANNU REV BIOPH BIOM, V32, P135, DOI 10.1146/annurev.biophys.32.110601.141732; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; CRAIG NL, 2002, MOBILE DNA, V2; Dhar G, 2004, CELL, V119, P33, DOI 10.1016/j.cell.2004.09.010; Grindley NDF, 2002, MOBILE DNA, P272; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HATFULL GF, 1986, P NATL ACAD SCI USA, V83, P5429, DOI 10.1073/pnas.83.15.5429; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; Krebs WG, 2000, NUCLEIC ACIDS RES, V28, P1665, DOI 10.1093/nar/28.8.1665; Leschziner AE, 2003, MOL CELL, V12, P775, DOI 10.1016/S1097-2765(03)00351-4; McIlwraith MJ, 1997, J MOL BIOL, V266, P108, DOI 10.1006/jmbi.1996.0765; Murley LL, 1998, CELL, V95, P553, DOI 10.1016/S0092-8674(00)81622-0; Nollmann M, 2004, MOL CELL, V16, P127, DOI 10.1016/j.molcel.2004.09.027; REED RR, 1981, CELL, V25, P721, DOI 10.1016/0092-8674(81)90179-3; RICE PA, 1994, STRUCTURE, V2, P371, DOI 10.1016/S0969-2126(00)00039-3; RICE PA, 1994, EMBO J, V13, P1514, DOI 10.1002/j.1460-2075.1994.tb06413.x; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; Sarkis GJ, 2001, MOL CELL, V8, P623, DOI 10.1016/S1097-2765(01)00334-3; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1994, J MOL BIOL, V239, P25, DOI 10.1006/jmbi.1994.1348; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0	24	95	99	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	2005	309	5738					1210	1215		10.1126/science.1112064	http://dx.doi.org/10.1126/science.1112064			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	15994378				2022-12-28	WOS:000231395400037
J	Nallamothu, BK; Saint, M; Saint, S; Mukherjee, D				Nallamothu, BK; Saint, M; Saint, S; Mukherjee, D			Clinical problem-solving: Double jeopardy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CORONARY-ARTERY DISSECTION; ACUTE MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; PREGNANCY; CHEMOTHERAPY; PACLITAXEL; RADIATION; PATIENT		Ann Arbor Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Saddleback Hosp, Orange Coast Womens Med Grp, Laguna Hills, CA USA; Saddleback Hosp, Dept Obstet & Gynecol, Laguna Hills, CA USA; Univ Kentucky, Sch Med, Gill Heart Inst, Lexington, KY 40536 USA; Univ Kentucky, Sch Med, Dept Internal Med, Lexington, KY 40536 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Kentucky; University of Kentucky	Nallamothu, BK (corresponding author), B1F266 Univ Hosp, Ann Arbor, MI 48109 USA.	bnallamo@umich.edu	Saint, Sanjay/AAF-5126-2019; Mukherjee, Debabrata/AAG-1486-2019	Mukherjee, Debabrata/0000-0002-5131-3694	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K12RR017607] Funding Source: NIH RePORTER; AHRQ HHS [P20-HS11540] Funding Source: Medline; NCRR NIH HHS [K-12 RR017607-01] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Almeda FQ, 2004, CLIN CARDIOL, V27, P377, DOI 10.1002/clc.4960270702; [Anonymous], 2004, MATERNAL FETAL MED P; Balter S, 1999, CATHETER CARDIO INTE, V47, P229, DOI 10.1002/(SICI)1522-726X(199906)47:2<229::AID-CCD23>3.0.CO;2-W; BUYS EM, 1994, CATHETER CARDIO DIAG, V33, P157, DOI 10.1002/ccd.1810330216; Callans DJ, 2002, CIRCULATION, V105, P2704, DOI 10.1161/01.CIR.0000017824.52823.B2; Fattibene P, 1999, ACTA PAEDIATR, V88, P693; Gabbe SG, 2002, OBSTET NORMAL PROBLE; Klutstein MW, 1997, CATHETER CARDIO DIAG, V40, P372, DOI 10.1002/(SICI)1097-0304(199704)40:4<372::AID-CCD11>3.0.CO;2-P; Koul AK, 2001, CATHETER CARDIO INTE, V52, P88, DOI 10.1002/1522-726X(200101)52:1<88::AID-CCD1022>3.0.CO;2-P; MABIE WC, 1995, OBSTET GYN CLIN N AM, V22, P19; Mendez LE, 2003, OBSTET GYNECOL, V102, P1200, DOI 10.1016/S0029-7844(03)00698-7; Newby KH, 1998, CIRCULATION, V98, P2567, DOI 10.1161/01.CIR.98.23.2567; Roth A, 1996, ANN INTERN MED, V125, P751, DOI 10.7326/0003-4819-125-9-199611010-00009; Sood AK, 2001, GYNECOL ONCOL, V83, P599, DOI 10.1006/gyno.2001.6439; Volpi A, 1998, AM J CARDIOL, V82, P265, DOI 10.1016/S0002-9149(98)00336-1	15	20	20	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2005	353	1					75	80		10.1056/NEJMcps050117	http://dx.doi.org/10.1056/NEJMcps050117			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942FC	16000358				2022-12-28	WOS:000230267300012
J	Sullivan, R; Banfield, D; Bell, JF; Calvin, W; Fike, D; Golombek, M; Greeley, R; Grotzinger, J; Herkenhoff, K; Jerolmack, D; Malin, M; Ming, D; Soderblom, LA; Squyres, SW; Thompson, S; Watters, WA; Weitz, CM; Yen, A				Sullivan, R; Banfield, D; Bell, JF; Calvin, W; Fike, D; Golombek, M; Greeley, R; Grotzinger, J; Herkenhoff, K; Jerolmack, D; Malin, M; Ming, D; Soderblom, LA; Squyres, SW; Thompson, S; Watters, WA; Weitz, CM; Yen, A			Aeolian processes at the Mars Exploration Rover Meridiani Planum landing site	NATURE			English	Article							WIND STREAKS; DUST; EARTH; SPECTROMETER; OPPORTUNITY; TRANSPORT; SURFACES; VENUS; SOILS	The martian surface is a natural laboratory for testing our understanding of the physics of aeolian (wind-related) processes in an environment different from that of Earth. Martian surface markings and atmospheric opacity are time-variable, indicating that fine particles at the surface are mobilized regularly by wind(1-3). Regolith (unconsolidated surface material) at the Mars Exploration Rover Opportunity's landing site has been affected greatly by wind, which has created and reoriented bedforms, sorted grains, and eroded bedrock. Aeolian features here preserve a unique record of changing wind direction and wind strength. Here we present an in situ examination of a martian bright wind streak, which provides evidence consistent with a previously proposed formational model(4,5) for such features. We also show that a widely used criterion for distinguishing between aeolian saltation- and suspension-dominated grain behaviour is different on Mars, and that estimated wind friction speeds between 2 and 3 ms(-1), most recently from the northwest, are associated with recent global dust storms, providing ground truth for climate model predictions.	Cornell Univ, Ctr Radiophys & Space Res, Dept Astron, Ithaca, NY 14853 USA; Univ Nevada, Reno, NV 89557 USA; MIT, Cambridge, MA 02139 USA; Jet Prop Lab, Pasadena, CA 90119 USA; Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA; US Geol Survey, Flagstaff, AZ 86001 USA; Malin Space Sci Syst, San Diego, CA 92191 USA; NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; Planetary Sci Inst, Tucson, AZ 85719 USA	Cornell University; Nevada System of Higher Education (NSHE); University of Nevada Reno; Massachusetts Institute of Technology (MIT); National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Arizona State University; Arizona State University-Tempe; United States Department of the Interior; United States Geological Survey; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER	Sullivan, R (corresponding author), Cornell Univ, Ctr Radiophys & Space Res, Dept Astron, Ithaca, NY 14853 USA.	rjs33@cornell.edu	Sullivan, Robert/AAR-8193-2020; Fike, David A/D-3634-2011; Banfield, Don J/I-3523-2018	Fike, David A/0000-0003-2848-0328; Banfield, Don J/0000-0003-2664-0164				Arvidson RE, 2004, SCIENCE, V306, P1730, DOI 10.1126/science.1104211; ARVIDSON RE, 1974, ICARUS, V21, P12, DOI 10.1016/0019-1035(74)90086-4; BELL JF, 1990, J GEOPHYS RES-SOLID, V95, P14447, DOI 10.1029/JB095iB09p14447; Cantor BA, 2001, J GEOPHYS RES-PLANET, V106, P23653, DOI 10.1029/2000JE001310; EDGETT KS, 1991, J GEOPHYS RES-PLANET, V96, P22765, DOI 10.1029/91JE02412; GILLETTE DA, 1989, J GEOPHYS RES-ATMOS, V94, P12885, DOI 10.1029/JD094iD10p12885; GOOSSENS D, 1991, CATENA, V18, P379, DOI 10.1016/0341-8162(91)90033-T; GREELEY R, 1982, J GEOPHYS RES, V87, P9, DOI 10.1029/JB087iB12p10009; GREELEY R, 1974, SCIENCE, V183, P847, DOI 10.1126/science.183.4127.847; GREELEY R, 1985, WIND GEOLOGICAL PROC, P68; Greeley R., 2003, J GEOPHYS RES, V108; Greeley R., 1992, MARS, P730; Herkenhoff KE, 2004, SCIENCE, V306, P1727, DOI 10.1126/science.1105286; IVERSEN JD, 1982, SEDIMENTOLOGY, V29, P111, DOI 10.1111/j.1365-3091.1982.tb01713.x; IVERSEN JD, 1976, J ATMOS SCI, V33, P2425, DOI 10.1175/1520-0469(1976)033<2425:WDOEMA>2.0.CO;2; Klingelhofer G, 2004, SCIENCE, V306, P1740, DOI 10.1126/science.1104653; MARTIN LJ, 1993, J GEOPHYS RES-PLANET, V98, P3221, DOI 10.1029/92JE02937; NICKLING WG, 1995, SEDIMENTOLOGY, V42, P403, DOI 10.1111/j.1365-3091.1995.tb00381.x; Rieder R, 2004, SCIENCE, V306, P1746, DOI 10.1126/science.1104358; SAGAN C, 1975, ICARUS, V26, P209, DOI 10.1016/0019-1035(75)90080-9; SAGAN C, 1973, J GEOPHYS RES, V78, P4163, DOI 10.1029/JB078i020p04163; Soderblom LA, 2004, SCIENCE, V306, P1723, DOI 10.1126/science.1105127; THOMAS P, 1981, ICARUS, V45, P124, DOI 10.1016/0019-1035(81)90010-5; THOMAS P, 1984, ICARUS, V60, P161, DOI 10.1016/0019-1035(84)90145-3; TSOAR H, 1987, SEDIMENTOLOGY, V34, P139, DOI 10.1111/j.1365-3091.1987.tb00566.x; VEVERKA J, 1981, ICARUS, V45, P154, DOI 10.1016/0019-1035(81)90011-7; White BR, 1997, J GEOPHYS RES-PLANET, V102, P25629, DOI 10.1029/97JE01753	27	192	198	4	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 7	2005	436	7047					58	61		10.1038/nature03641	http://dx.doi.org/10.1038/nature03641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	942QJ	16001061				2022-12-28	WOS:000230296600038
J	Chen, DL; Kon, N; Li, MY; Zhang, WZ; Qin, J; Gu, W				Chen, DL; Kon, N; Li, MY; Zhang, WZ; Qin, J; Gu, W			ARF-BP1/mule is a critical mediator of the ARF tumor suppressor	CELL			English	Article							UBIQUITIN-PROTEIN LIGASE; RING-FINGER DOMAIN; CELL-CYCLE ARREST; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; NUCLEAR EXPORT; P53 PATHWAY; G(2) ARREST; DNA-DAMAGE; IN-VIVO	Although the importance of the ARF tumor suppressor in p53 regulation is well established, numerous studies indicate that ARF also suppresses cell growth in a p53/Mdm2-independent manner. To understand the mechanism of ARF-mediated tumor suppression we identified a ubiquitin ligase, ARF-BP1, as a key factor associated with ARF in vivo. ARF-BP1 harbors a signature HECT motif, and its ubiquitin ligase activity is inhibited by ARK Notably, inactivation of ARFBP1, but not Mdm2, suppresses the growth of p53 null cells in a manner reminiscent of ARF induction. Surprisingly, in p53 wild-type cells, ARF-BP1 directly binds and ubiquitinates p53, and inactivation of endogenous ARF-BP1 is crucial for ARF-mediated p53 stabilization. Thus, our study modifies the current view of ARF-mediated p53 activation and reveals that ARF-BP1 is a critical mediator of both the p53-independent and p53-dependent tumor suppressor functions of ARE As such, ARF-BP1 may serve as a potential target for therapeutic intervention in tumors regardless of p53 status.	Columbia Univ Coll Phys & Surg, Inst Canc Genet, Dept Pathol, New York, NY 10032 USA; Baylor Coll Med, Dept Biochem & Cell Biol, Houston, TX 77030 USA	Columbia University; Baylor College of Medicine	Gu, W (corresponding author), Columbia Univ Coll Phys & Surg, Inst Canc Genet, Dept Pathol, 1150 St Nicholas Ave, New York, NY 10032 USA.	wg8@columbia.edu						Aravind L, 2001, TRENDS BIOCHEM SCI, V26, P273, DOI 10.1016/S0968-0004(01)01787-X; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CUMMINS JM, 2004, NATURE, V428, P486, DOI [DOI 10.1038/NATURE02501, 10.1038/nature02501]; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GU J, 1994, MOL BRAIN RES, V24, P77, DOI 10.1016/0169-328X(94)90120-1; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuo ML, 2003, CANCER RES, V63, P1046; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUNA RMD, 1995, NATURE, V378, P203; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; McKeller RN, 2002, P NATL ACAD SCI USA, V99, P3848, DOI 10.1073/pnas.052484199; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Modestou M, 2001, CANCER RES, V61, P3145; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1999, J PATHOL, V187, P112; QUELLE DE, 1995, CELL, V83, P993; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	69	429	455	3	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	2005	121	7					1071	1083		10.1016/j.cell.2005.03.037	http://dx.doi.org/10.1016/j.cell.2005.03.037			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989956	Bronze			2022-12-28	WOS:000230448000013
J	Hassan, MHA				Hassan, MHA			Small things and big changes in the developing world	SCIENCE			English	Editorial Material									Acad Sci Dev World, TWAS, Trieste, Italy		Hassan, MHA (corresponding author), Acad Sci Dev World, TWAS, Trieste, Italy.	mhassan@twas.org						COURT E, 2004, NANOTECHNOL SOC  JAN; CURI R, 2004, BIOCHEMIST       AUG, P51; *EUR COMM, RES THEM 7 FRAM; *INTERACADEMY COUN, 2003, INV BETT FUT STRAT B; ISOUN TT, 2005, HARN SCI SOC INT S O; Kosto RN, 2004, SCIENTIST, V18, P10; MAHAJAN RL, 2005, PLEN LECT N S DIAL N; *MER I, 2005, GLOB DIAL NAN POOR O; Nemets A., 2004, CHINAS NANOTECH REVO; OBERDORSTER G, IN PRESS ENV HLTH PE; Royal Society and the Royal Academy of Engineering, 2004, NAN NAN OPP UNC; SALAMANCABUENTE.F, 2005, PLOS MED         APR; *UN DEV PROGR, 2004, UNDP HUM DEV REP 200; Wilsdon J, 2004, IEEE TECHNOL SOC MAG, V23, P16, DOI 10.1109/MTAS.2004.1371634; 2004, TWAS NEWSL, P23; 2005, ELECTRICNEWS NE 0505; 2005, ECONOMIST       0305, P9; 2005, SCIDEV NET      0512; 2005, ECONOMIST       0311, P9	19	76	80	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 1	2005	309	5731					65	66		10.1126/science.1111138	http://dx.doi.org/10.1126/science.1111138			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994516				2022-12-28	WOS:000230212800033
J	Pufall, MA; Lee, GM; Nelson, ML; Kang, HS; Velyvis, A; Kay, LE; McIntosh, LP; Graves, BJ				Pufall, MA; Lee, GM; Nelson, ML; Kang, HS; Velyvis, A; Kay, LE; McIntosh, LP; Graves, BJ			Variable control of Ets-1 DNA binding by multiple phosphates in an unstructured region	SCIENCE			English	Article							TRANSCRIPTION FACTOR NFAT1; ALLOSTERIC REGULATION; NMR-SPECTROSCOPY; PROTEIN; PHOSPHORYLATION; DOMAIN; AUTOINHIBITION; DYNAMICS; SITES; TRANSACTIVATION	Cell signaling that culminates in posttranslational modifications directs protein activity. Here we report how multiple Ca2+-dependent phosphorylation sites within the transcription activator Ets-1 act additively to produce graded DNA binding affinity. Nuclear magnetic resonance spectroscopic analyses show that phosphorylation shifts Ets-1 from a dynamic conformation poised to bind DNA to a well-folded inhibited state. These phosphates lie in an unstructured flexible region that functions as the allosteric effector of autoinhibition. Variable phosphorylation thus serves as a "rheostat" for cell signaling to fine-tune transcription at the level of DNA binding.	Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Michael Smith Lab, Vancouver, BC V6T 1Z3, Canada; Univ Toronto, Dept Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Chem, Toronto, ON M5S 1A8, Canada	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of British Columbia; University of British Columbia; University of British Columbia; University of Toronto; University of Toronto; University of Toronto	Graves, BJ (corresponding author), Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.	Barbara.Graves@hci.utah.edu		Kang, Hyun-Seo/0000-0003-4029-5096; Pufall, Miles/0000-0002-7022-6916	NATIONAL CANCER INSTITUTE [T32CA093247, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008537, R01GM038663] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA24014, T32-CA93247] Funding Source: Medline; NIGMS NIH HHS [R01 GM038663, R01 GM38663, GM08537] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Cowley DO, 2000, GENE DEV, V14, P366; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; Finerty PJ, 2005, BIOCHEMISTRY-US, V44, P694, DOI 10.1021/bi048641k; Garvie CW, 2002, J BIOL CHEM, V277, P45529, DOI 10.1074/jbc.M206327200; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Hudson BP, 2000, J MOL BIOL, V304, P355, DOI 10.1006/jmbi.2000.4207; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kalodimos CG, 2004, SCIENCE, V305, P386, DOI 10.1126/science.1097064; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; Kim C, 2005, SCIENCE, V307, P690, DOI 10.1126/science.1104607; Lee GM, 2005, J BIOL CHEM, V280, P7088, DOI 10.1074/jbc.M410722200; Liu H, 2002, MOL BIOL CELL, V13, P4497, DOI 10.1091/mbc.E02-03-0149; Mulder FAA, 2001, NAT STRUCT BIOL, V8, P932, DOI 10.1038/nsb1101-932; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Salazar C, 2003, J MOL BIOL, V327, P31, DOI 10.1016/S0022-2836(03)00085-8; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; Wang H, 2002, J BIOL CHEM, V277, P2225, DOI 10.1074/jbc.M109430200; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110	30	195	197	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					142	145		10.1126/science.1111915	http://dx.doi.org/10.1126/science.1111915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994560				2022-12-28	WOS:000230212800079
J	Sutton, RT; Hodson, DLR				Sutton, RT; Hodson, DLR			Atlantic Ocean forcing of North American and European summer climate	SCIENCE			English	Article							SAHEL RAINFALL; VARIABILITY; CIRCULATION; OSCILLATION; DROUGHT; SYSTEM; US	Recent extreme events such as the devastating 2003 European summer heat wave raise important questions about the possible causes of any underlying trends, or low-frequency variations, in regional climates. Here, we present new evidence that basin-scale changes in the Atlantic Ocean, probably related to the thermohaline circulation, have been an important driver of multidecadal variations in the summertime climate of both North America and western Europe. Our findings advance understanding of past climate changes and also have implications for decadal climate predictions.	Univ Reading, Dept Meteorol, Ctr Global Atmosph Modelling, Nat Environm Res Council,Ctr Atmosph Sci, Reading RG6 6BB, Berks, England	University of Reading	Sutton, RT (corresponding author), Univ Reading, Dept Meteorol, Ctr Global Atmosph Modelling, Nat Environm Res Council,Ctr Atmosph Sci, POB 243, Reading RG6 6BB, Berks, England.	r.sutton@reading.ac.uk	Hodson, Dan/A-5563-2012	Hodson, Dan/0000-0001-7159-6700; Sutton, Rowan/0000-0001-8345-8583				CASSOU C, IN PRESS J CLIM; COLLINS M, 2003, CLIVAR EXCHANGES, V8, P6; Delworth TL, 2000, CLIM DYNAM, V16, P661, DOI 10.1007/s003820000075; Dong BW, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015229; Enfield DB, 2001, GEOPHYS RES LETT, V28, P2077, DOI 10.1029/2000GL012745; FOLLAND C, 1991, J FORECASTING, V10, P21, DOI 10.1002/for.3980100104; FOLLAND CK, 1986, NATURE, V320, P602, DOI 10.1038/320602a0; Giannini A, 2003, SCIENCE, V302, P1027, DOI 10.1126/science.1089357; GILL AE, 1980, Q J ROY METEOR SOC, V106, P447, DOI 10.1002/qj.49710644905; Gray ST, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019932; Griffies SM, 1997, SCIENCE, V275, P181, DOI 10.1126/science.275.5297.181; Houghton J. T., 2001, CLIMATE CHANGE 2001; Hurrell J. C., 2002, CLIVAR EXCHANGES, V25, P52; HURRELL JW, COMMUNICATION; Kerr RA, 2000, SCIENCE, V288, P1984, DOI 10.1126/science.288.5473.1984; Koster RD, 2004, SCIENCE, V305, P1138, DOI 10.1126/science.1100217; Kushnir Y, 2002, J CLIMATE, V15, P2233, DOI 10.1175/1520-0442(2002)015<2233:AGRTES>2.0.CO;2; McCabe GJ, 2004, P NATL ACAD SCI USA, V101, P4136, DOI 10.1073/pnas.0306738101; Rayner NA, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002670; Rodwell MJ, 2003, ANN GEOPHYS-ITALY, V46, P47; SCHLESINGER ME, 1994, NATURE, V367, P723, DOI 10.1038/367723a0; Schubert SD, 2004, SCIENCE, V303, P1855, DOI 10.1126/science.1095048; Schubert SD, 2004, J CLIMATE, V17, P485, DOI [10.1175/1520-0442(2004)017<0485:COLDIT>2.0.CO;2, 10.1175/1520-0442(2004)017&lt;0485:COLDIT&gt;2.0.CO;2]; Stott PA, 2004, NATURE, V432, P610, DOI 10.1038/nature03089; ZHANG R, IN PRESS J CLIM	25	976	1002	7	176	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					115	118		10.1126/science.1109496	http://dx.doi.org/10.1126/science.1109496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994552				2022-12-28	WOS:000230212800070
J	Schulte-Pelkum, V; Monsalve, G; Sheehan, A; Pandey, MR; Sapkota, S; Bilham, R; Wu, F				Schulte-Pelkum, V; Monsalve, G; Sheehan, A; Pandey, MR; Sapkota, S; Bilham, R; Wu, F			Imaging the Indian subcontinent beneath the Himalaya	NATURE			English	Article							CRUSTAL STRUCTURE; PETROLOGICAL MODEL; GRAVITY-ANOMALIES; TIBET; CONSTRAINTS; SUPPORT; METAMORPHISM; EVOLUTION; PLATEAU; THRUST	The rocks of the Indian subcontinent are last seen south of the Ganges before they plunge beneath the Himalaya and the Tibetan plateau. They are next glimpsed in seismic reflection profiles deep beneath southern Tibet(1), yet the surface seen there has been modified by processes within the Himalaya that have consumed parts of the upper Indian crust and converted them into Himalayan rocks(2,3). The geometry of the partly dismantled Indian plate as it passes through the Himalayan process zone has hitherto eluded imaging. Here we report seismic images both of the decollement at the base of the Himalaya and of the Moho ( the boundary between crust and mantle) at the base of the Indian crust. A significant finding is that strong seismic anisotropy develops above the decollement in response to shear processes that are taken up as slip in great earthquakes at shallower depths. North of the Himalaya, the lower Indian crust is characterized by a high-velocity region consistent with the formation of eclogite, a high-density material whose presence affects the dynamics of the Tibetan plateau.	Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USA; Dept Mines & Geol, Kathmandu, Nepal; SUNY Binghamton, Binghamton, NY 13902 USA	University of Colorado System; University of Colorado Boulder; State University of New York (SUNY) System; State University of New York (SUNY) Binghamton	Schulte-Pelkum, V (corresponding author), Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USA.	vera.schulte-pelkum@colorado.edu	Sheehan, Anne F/B-3954-2014	Sheehan, Anne F/0000-0002-9629-1687; Bilham, Roger/0000-0002-5547-4102; Schulte-Pelkum, Vera/0000-0002-6057-5637; Monsalve, Gaspar/0000-0002-6029-3058				Avouac JP, 2003, ADV GEOPHYS, V46, P1, DOI 10.1016/S0065-2687(03)46001-9; Bilham R, 1997, NATURE, V386, P61, DOI 10.1038/386061a0; Bjornerud MG, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000527; Bollinger L, 2004, TECTONICS, V23, DOI 10.1029/2003TC001564; Bousquet R, 1997, TECTONOPHYSICS, V273, P105, DOI 10.1016/S0040-1951(96)00290-9; BRUNEL M, 1986, TECTONICS, V5, P247, DOI 10.1029/TC005i002p00247; Cattin R, 2001, GEOPHYS J INT, V147, P381, DOI 10.1046/j.0956-540x.2001.01541.x; Chen WP, 2004, SCIENCE, V304, P1949, DOI 10.1126/science.1097324; CHRISTENSEN NI, 1995, J GEOPHYS RES-SOL EA, V100, P9761, DOI 10.1029/95JB00259; Cotte N, 1999, GEOPHYS J INT, V138, P809, DOI 10.1046/j.1365-246x.1999.00927.x; Daniel CG, 2003, J METAMORPH GEOL, V21, P317, DOI 10.1046/j.1525-1314.2003.00445.x; DeCelles PG, 2001, TECTONICS, V20, P487, DOI 10.1029/2000TC001226; Dueker KG, 1998, J GEOPHYS RES-SOL EA, V103, P7153, DOI 10.1029/97JB03509; Frederiksen AW, 2000, GEOPHYS J INT, V141, P401, DOI 10.1046/j.1365-246x.2000.00090.x; Galve A, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015611; Henry P, 1997, TECTONOPHYSICS, V273, P31, DOI 10.1016/S0040-1951(96)00287-9; HIRN A, 1984, ANN GEOPHYS, V2, P123; Jackson JA, 2004, GEOLOGY, V32, P625, DOI 10.1130/G20397.1; Johnson MRW, 2002, EARTH-SCI REV, V59, P101, DOI 10.1016/S0012-8252(02)00071-5; Kind R, 2002, SCIENCE, V298, P1219, DOI 10.1126/science.1078115; Kumar MR, 2001, GEOPHYS RES LETT, V28, P1339, DOI 10.1029/2000GL012310; LEPICHON X, 1992, TECTONICS, V11, P1085, DOI 10.1029/92TC01566; LePichon X, 1997, TECTONOPHYSICS, V273, P57, DOI 10.1016/S0040-1951(96)00288-0; LYONCAEN H, 1985, TECTONICS, V4, P513, DOI 10.1029/TC004i006p00513; MOLNAR P, 1988, PHILOS T R SOC A, V326, P33, DOI 10.1098/rsta.1988.0080; MONSALVE G, 2003, EOS, V84; PANDEY MR, 1995, GEOPHYS RES LETT, V22, P751, DOI 10.1029/94GL02971; Sapin M, 1997, TECTONOPHYSICS, V273, P1; SCHELLING D, 1992, TECTONICS, V11, P925, DOI 10.1029/92TC00213; Zandt G, 2004, NATURE, V431, P41, DOI 10.1038/nature02847; Zhao LS, 1996, GEOPHYS J INT, V125, P355, DOI 10.1111/j.1365-246X.1996.tb00004.x; ZHAO WJ, 1993, NATURE, V366, P557, DOI 10.1038/366557a0	32	374	398	6	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1222	1225		10.1038/nature03678	http://dx.doi.org/10.1038/nature03678			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988523				2022-12-28	WOS:000230140500041
J	Lakhani, A; Coles, J; Eayres, D; Spence, C; Sanderson, C				Lakhani, A; Coles, J; Eayres, D; Spence, C; Sanderson, C			Creative use of existing clinical and health outcomes data to assess NHS performance in England: Part 2 - More challenging aspects of monitoring	BRITISH MEDICAL JOURNAL			English	Article								In the second of their two articles about using existing routine data to assess performance in the NHS, the authors make practical suggestions about using data for mental health care, potentially avoidable deaths, and forecasting coronary heart disease outcomes, and raise issues about assumptions and technical aspects for discussion.	London Sch Hyg & Trop Med, Natl Ctr Hlth Outcomes Dev, London WC1E 6AZ, England; CASPE Res, London W1G 0AN, England; Northgate Informat Solut, Hemel Hempstead HP2 7HU, England; London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Lakhani, A (corresponding author), London Sch Hyg & Trop Med, Natl Ctr Hlth Outcomes Dev, London WC1E 6AZ, England.	Azim.Lakhani@lshtm.ac.uk	Sanderson, Colin F/O-9877-2014	Sanderson, Colin/0000-0002-4838-6112				Atkinson A., 2004, ATKINSON REV INTERIM; Brenner H, 1996, CANCER-AM CANCER SOC, V78, P2004, DOI 10.1002/(SICI)1097-0142(19961101)78:9<2004::AID-CNCR23>3.0.CO;2-#; Charlton J R, 1984, Community Med, V6, P306; DAVIES R, 2004, POLICY ANAL CORONARY; Department of Health, 1999, NAT SERV FRAM MENT H; Department of Health, 2004, CHIEF EX REP NHS; Dixon J, 1998, J PUBLIC HEALTH MED, V20, P63, DOI 10.1093/oxfordjournals.pubmed.a024721; Keppel KG, 2004, 25 NAT CTR HLTH STAT; Lakhani A, 2005, BRIT MED J, V330, P1426, DOI 10.1136/bmj.330.7505.1426; LAKHANI A, 2000, HARNESSING OFFICIAL; LAKHANI A, 2003, COMPENDIUM CLIN HLTH; Nolte E. M. McKee, 2004, DOES HEALTHCARE SAVE; Office for National Statistics, NAT STAT 2001 AR CLA; RUDD A, 1999, HLTH OUTCOME INDICAT; Smith R, 2003, BRIT MED J, V327, P1239, DOI 10.1136/bmj.327.7426.1239	15	8	8	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 25	2005	330	7506					1486	1492		10.1136/bmj.330.7506.1486	http://dx.doi.org/10.1136/bmj.330.7506.1486			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942NR	15976423	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000230289600023
J	Chou, R; Helfand, M				Chou, R; Helfand, M			Challenges in systematic reviews that assess treatment harms	ANNALS OF INTERNAL MEDICINE			English	Review							ADVERSE DRUG-REACTIONS; SEROTONIN REUPTAKE INHIBITORS; RANDOMIZED CONTROLLED-TRIALS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONFLICT-OF-INTEREST; HEALTH-CARE; CAUSALITY ASSESSMENT; BALANCING BENEFITS; GASTROINTESTINAL TOXICITY; METHODOLOGICAL QUALITY	An evidence synthesis of a medical intervention should assess the balance of benefits and harms. Investigators performing systematic reviews of harms face challenges in finding data, rating the quality of harms reporting, and synthesizing and displaying data from different sources. Systematic reviews of harms often rely primarily on published clinical trials. Identifying important harms of treatment and quantifying the risk associated with them, however, often require a broader range of data sources, including unpublished trials, observational studies, and unpublished information on published trials submitted to the U.S. Food and Drug Administration. Each source of data has some potential for yielding important information. Criteria for judging the quality of harms assessment and reporting are still in their early stages of development. Investigators conducting systematic reviews of harms should consider empirically validating the criteria they use to judge the validity of studies reporting harms. Synthesizing harms data from different sources requires careful consideration of internal validity, applicability, and sources of heterogeneity. This article highlights examples of approaches to methodologic issues associated with performing systematic reviews of harms from 96 Evidence-based Practice Center evidence reports.	Oregon Hlth & Sci Univ, Oregon Evidence Based Pract Ctr, Portland, OR 97201 USA; Portland VA Med Ctr, Portland, OR USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center	Chou, R (corresponding author), Oregon Hlth & Sci Univ, Oregon Evidence Based Pract Ctr, 3181 SW Sam Jackson Pk Rd,Mail Code BICC, Portland, OR 97201 USA.	chour@ohsu.edu		Chou, Roger/0000-0001-9889-8610				[Anonymous], 2001, UND SYST REV RES EFF; Arnaiz JA, 2001, EUR J CLIN PHARMACOL, V57, P89, DOI 10.1007/s002280100265; Aronson JK, 2003, BRIT MED J, V326, P1346, DOI 10.1136/bmj.326.7403.1346; Aronson JK, 2002, FUND CLIN PHARMACOL, V16, P49, DOI 10.1046/j.1472-8206.2002.00066.x; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; BEGAUD B, 1994, BRIT J CLIN PHARMACO, V38, P401, DOI 10.1111/j.1365-2125.1994.tb04373.x; BENICHOU C, 1993, J CLIN EPIDEMIOL, V46, P1331, DOI 10.1016/0895-4356(93)90102-7; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Berlin JA, 1999, JAMA-J AM MED ASSOC, V281, P830, DOI 10.1001/jama.281.9.830; Black N, 1999, WORLD J SURG, V23, P789, DOI 10.1007/s002689900581; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Bond R, 2003, STROKE, V34, P2290, DOI 10.1161/01.STR.0000087785.01407.CC; Britton A, 1998, HLTH TECHNOLOGY ASSE, V2, P1; Brown NJ, 1996, CLIN PHARMACOL THER, V60, P8, DOI 10.1016/S0009-9236(96)90161-7; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Cuervo LG, 2003, BMJ-BRIT MED J, V327, P65, DOI 10.1136/bmj.327.7406.65; Cuervo LG, 2004, BMJ-BRIT MED J, V329, P1, DOI 10.1136/bmj.329.7456.1; Dalziel K, 2005, HEALTH TECHNOL ASSES, V9, P1; DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6; Derry S, 2001, BMC Med Res Methodol, V1, P7, DOI 10.1186/1471-2288-1-7; Dickersin K, 2002, INT J EPIDEMIOL, V31, P6, DOI 10.1093/ije/31.1.6; Dieppe P, 2004, BMJ-BRIT MED J, V329, P31, DOI 10.1136/bmj.329.7456.31; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Edwards JE, 1999, J PAIN SYMPTOM MANAG, V18, P427, DOI 10.1016/S0885-3924(99)00093-7; Egger M, 1998, BRIT MED J, V316, P140; Egger M, 2003, Health Technol Assess, V7, P1; Ernst E, 2001, BRIT MED J, V323, P546, DOI 10.1136/bmj.323.7312.546; Etminan M, 2004, PHARMACOTHERAPY, V24, P1105, DOI 10.1592/phco.24.13.1105.38083; Etminan M, 2004, PHARMACOTHERAPY, V24, P964, DOI 10.1592/phco.24.11.964.36143; Ettinger B, 1998, AM J MANAG CARE, V4, P1377; Farrington CP, 2004, VACCINE, V22, P2064, DOI 10.1016/j.vaccine.2004.01.017; *FDA CTR DRUG EV R, FDA PUBL HLTH ADV CR; Fergusson D, 2005, BMJ-BRIT MED J, V330, P396, DOI 10.1136/bmj.330.7488.396; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; Glasziou P, 2004, BMJ-BRIT MED J, V328, P39, DOI 10.1136/bmj.328.7430.39; GOUDAS L, 2001, AHRQ PUBLICATION; Gunnell D, 2005, BMJ-BRIT MED J, V330, P385, DOI 10.1136/bmj.330.7488.385; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Hrachovec JB, 2001, JAMA-J AM MED ASSOC, V286, P2398, DOI 10.1001/jama.286.19.2398; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V285, P437, DOI 10.1001/jama.285.4.437; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jefferson T, 2003, VACCINE, V21, P3954, DOI 10.1016/S0264-410X(03)00271-8; Jefferson T, 2003, VACCINE, V21, P2003, DOI 10.1016/S0264-410X(02)00770-3; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Kaufman DW, 2000, LANCET, V356, P1339, DOI 10.1016/S0140-6736(00)02826-9; Lasser KE, 2002, JAMA-J AM MED ASSOC, V287, P2215, DOI 10.1001/jama.287.17.2215; LAU J, 2002, AHRQ PUBLICATION; Lawlor DA, 2004, LANCET, V363, P1724, DOI 10.1016/S0140-6736(04)16260-0; Lawlor DA, 2003, J CLIN EPIDEMIOL, V56, P155; LEE S, 2005, STAT REV; Lindbloom EJ, 2004, MED CARE, V42, P45, DOI 10.1097/01.mlr.0000119397.65643.d4; Loke YK, 2004, BRIT J CLIN PHARMACO, V57, P616, DOI 10.1111/j.0306-5251.2003.02055.x; LOKE YK, 2004, INCLUDING ADVERSE EF; Lucena MA, 2001, HEPATOLOGY, V33, P123, DOI 10.1053/jhep.2001.20645; Mann RD, 1998, BRIT J CLIN PHARMACO, V46, P195, DOI 10.1046/j.1365-2125.1998.00774.x; Maria VAJ, 1997, HEPATOLOGY, V26, P664, DOI 10.1002/hep.510260319; Martin RCG, 2002, ANN SURG, V235, P803, DOI 10.1097/00000658-200206000-00007; Martinez C, 2005, BRIT MED J, V330, P389, DOI 10.1136/bmj.330.7488.389; McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0; McIntosh Heather M, 2004, BMC Med Res Methodol, V4, P19, DOI 10.1186/1471-2288-4-19; McPherson K, 2004, BRIT MED J, V328, P518, DOI 10.1136/bmj.328.7438.518; MEENAN RT, 2002, AHRQ PUBLICATION, V48; MICHEL DJ, 1986, AM J HOSP PHARM, V43, P1709, DOI 10.1093/ajhp/43.7.1709; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moore SW, 2003, SOUTH MED J, V96, P1244, DOI 10.1097/01.SMJ.0000102285.48482.C9; MULROW C, 2000, AHRQ PUBLICATION; MULROW CD, 1988, AHCPR PUBLICATION; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Ofman JJ, 2002, J RHEUMATOL, V29, P804; Papanikolaou PN, 2004, AM J MED, V117, P582, DOI 10.1016/j.amjmed.2004.04.026; Papanikolaou PN, 2004, AM J PSYCHIAT, V161, P1692, DOI 10.1176/appi.ajp.161.9.1692; Petticrew M, 2003, BMJ-BRIT MED J, V326, P756, DOI 10.1136/bmj.326.7392.756; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Psaty BM, 1999, J AM GERIATR SOC, V47, P749, DOI 10.1111/j.1532-5415.1999.tb01603.x; Psaty BM, 2004, JAMA-J AM MED ASSOC, V292, P2622, DOI 10.1001/jama.292.21.2622; Ray JG, 2002, ARCH INTERN MED, V162, P249, DOI 10.1001/archinte.162.3.249; Ray WA, 2003, NEW ENGL J MED, V349, P1592, DOI 10.1056/NEJMp038145; Rosendaal FR, 2001, CURR CONTR TRIALS C, V2, P109; Ross SD, 2001, ARCH INTERN MED, V161, P1041, DOI 10.1001/archinte.161.8.1041; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; Rothwell PM, 1996, STROKE, V27, P260, DOI 10.1161/01.STR.27.2.260; Santaguida PL, 2005, ANN INTERN MED, V142, P1066, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00006; Saunders LD, 2003, WESTERN J NURS RES, V25, P223, DOI 10.1177/0193945902250039; Schunemann HJ, 2003, CAN MED ASSOC J, V169, P677; SHEKELLE P, AHRQ PUBLICATION; Shepherd J, 2004, AM J CARDIOL, V94, P882, DOI 10.1016/j.amjcard.2004.06.049; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x; Smith L A, 2001, BMC Med Res Methodol, V1, P1, DOI 10.1186/1471-2288-1-1; Stricker BHC, 2004, BRIT MED J, V329, P44, DOI 10.1136/bmj.329.7456.44; Strom BL, 2004, JAMA-J AM MED ASSOC, V292, P2643, DOI 10.1001/jama.292.21.2643; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Thase ME, 2001, BRIT J PSYCHIAT, V178, P234, DOI 10.1192/bjp.178.3.234; Vandenbroucke JP, 2004, BRIT MED J, V329, P2, DOI 10.1136/bmj.329.7456.2; Vandenbroucke JP, 2004, LANCET, V363, P1728, DOI 10.1016/S0140-6736(04)16261-2; VENNING GR, 1983, BRIT MED J, V286, P458, DOI 10.1136/bmj.286.6363.458; VENNING GR, 1982, BMJ-BRIT MED J, V284, P249, DOI 10.1136/bmj.284.6311.249; Wald NJ, 2003, BRIT MED J, V327, P616, DOI 10.1136/bmj.327.7415.616; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; WEST S, 2002, 47 RES TRIANGL I U N; Whittington CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1; WITTER J, MED REV 1; Wood L, 2004, DRUG SAFETY, V27, P871, DOI 10.2165/00002018-200427120-00004; Wright JM, 2001, JAMA-J AM MED ASSOC, V286, P2398	109	103	104	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1090	1099		10.7326/0003-4819-142-12_Part_2-200506211-00009	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938CN	15968034				2022-12-28	WOS:000229977600009
J	Gafter-Gvili, A; Fraser, A; Paul, M; Leibovici, L				Gafter-Gvili, A; Fraser, A; Paul, M; Leibovici, L			Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients	ANNALS OF INTERNAL MEDICINE			English	Review							BONE-MARROW TRANSPLANTATION; ACUTE NONLYMPHOCYTIC LEUKEMIA; PLACEBO-CONTROLLED TRIAL; TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS; HOSPITALIZED GRANULOCYTOPENIC PATIENTS; ORAL ANTIMICROBIAL PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; GRAM-POSITIVE PROPHYLAXIS; ANTI-MICROBIAL MODULATION; DOUBLE-BLIND	Background: Bacterial infections are a major cause of illness and death in patients who are neutropenic after chemotherapy treatment for cancer. Trials have shown the efficacy of antibiotic prophylaxis in decreasing the incidence of bacterial infections but not in reducing mortality rates. Purpose: To evaluate whether antibiotic prophylaxis in neutropenic patients reduces mortality and incidence of infection and to assess related adverse events. Data Sources: The Cochrane Cancer Network register of trials (2004), The Cochrane Library (issue 4, 2004), EMBASE (19802004), MEDLINE (1966-2004), and references of identified studies. Study Selection: Randomized, controlled trials comparing antibiotic prophylaxis with placebo or no intervention or another antibiotic in afebrile neutropenic patients. Data Extraction: Two reviewers independently appraised the quality of trials and extracted data. Data Synthesis: Ninety-five trials performed between 1973 and 2004 met inclusion criteria. Fifty-two trials addressed quinolone prophylaxis. Antibiotic prophylaxis significantly decreased the risk for death when compared with placebo or no treatment (relative risk, 0.67 [95% Cl, 0.55 to 0.81]). All prophylactic antibiotics were associated with an increased risk for adverse events (relative risk, 1.69 [Cl, 1.14 to 2.50]). Fluoroquinolone prophylaxis reduced the risk for all-cause mortality (relative risk, 0.52 [Cl, 0.35 to 0.77]), as well as infection-related mortality, fever, clinically documented infections, and microbiologically documented infections. Fluoroquinolone prophylaxis increased the risk for harboring bacilli resistant to the specific drug after treatment and adverse events, but these results were not statistically significant (relative risks, 1.69 [Cl, 0.73 to 3.92]) and 1.30 [Cl, 0.61 to 2.761, respectively). Limitations: Most trials involved patients with hematologic cancer. Data on all-cause mortality were missing in 10 of 50 trials comparing prophylaxis with no prophylaxis. Effect estimates were larger in trials of unclear methodologic quality compared with trials of adequate methodologic quality. Conclusions: Antibiotic prophylaxis for neutropenic patients undergoing cytotoxic therapy reduces mortality. Mortality was substantially reduced when analysis was limited to fluoroquinolones. Antibiotic prophylaxis, preferably with a fluoroquinolone, should be considered for neutropenic patients.	Rabin Med Ctr, Petah Tiqwa, Israel; Tel Aviv Univ, IL-69978 Tel Aviv, Israel	Rabin Medical Center; Tel Aviv University	Leibovici, L (corresponding author), Rabin Med Ctr, Petah Tiqwa, Israel.	leibovic@post.tau.ac.il		Fraser, Abigail/0000-0002-7741-9470				ARCHIMBAUD E, 1991, EUR J CANCER, V27, P174, DOI 10.1016/0277-5379(91)90481-R; ARNING M, 1990, J ANTIMICROB CHEMOTH, V26, P137, DOI 10.1093/jac/26.suppl_D.137; ATTAL M, 1991, J CLIN ONCOL, V9, P865, DOI 10.1200/JCO.1991.9.5.865; BARTOLONI A, 1989, J CHEMOTHERAPY, V1, P91, DOI 10.1080/1120009X.1989.11738871; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BENDER JF, 1979, ANTIMICROB AGENTS CH, V15, P455, DOI 10.1128/AAC.15.3.455; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BOW EJ, 1988, AM J MED, V84, P847, DOI 10.1016/0002-9343(88)90062-9; Bow EJ, 1996, ANN INTERN MED, V125, P183, DOI 10.7326/0003-4819-125-3-199608010-00004; BOW EJ, 1984, AM J MED, V76, P223, DOI 10.1016/0002-9343(84)90777-0; BRODSKY AL, 1993, MEDICINA-BUENOS AIRE, V53, P401; BROUN ER, 1994, ANTIMICROB AGENTS CH, V38, P576, DOI 10.1128/AAC.38.3.576; Carlson JW, 1997, GYNECOL ONCOL, V65, P325, DOI 10.1006/gyno.1997.4630; CASALI A, 1988, CHEMIOTERAPIA, V7, P327; Castagnola E, 2003, PEDIATR INFECT DIS J, V22, P359; CRUCIANI M, 1989, INFECTION, V17, P65, DOI 10.1007/BF01646878; Cruciani M, 1996, CLIN INFECT DIS, V23, P795, DOI 10.1093/clinids/23.4.795; Cruciani M, 2003, J CLIN ONCOL, V21, P4127, DOI 10.1200/JCO.2003.01.234; DANTONIO D, 1994, J ANTIMICROB CHEMOTH, V33, P837, DOI 10.1093/jac/33.4.837; DANTONIO D, 1992, DRUG EXP CLIN RES, V18, P141; DANTONIO D, 1991, CURR THER RES CLIN E, V50, P304; DEJONGH CA, 1983, J CLIN ONCOL, V1, P302, DOI 10.1200/JCO.1983.1.5.302; DEKKER AW, 1981, ANN INTERN MED, V95, P555, DOI 10.7326/0003-4819-95-5-555; DEKKER AW, 1987, ANN INTERN MED, V106, P7, DOI 10.7326/0003-4819-106-1-7; DELFAVERO A, 1991, ANN INTERN MED, V115, P7, DOI 10.7326/0003-4819-115-1-7; DONNELLY JP, 1992, EUR J CANCER, V28A, P873; Engels EA, 1998, J CLIN ONCOL, V16, P1179, DOI 10.1200/JCO.1998.16.3.1179; ENNO A, 1978, LANCET, V2, P395; ESTEY E, 1984, ARCH INTERN MED, V144, P1562, DOI 10.1001/archinte.144.8.1562; FANCI R, 1993, J CHEMOTHERAPY, V5, P119; Ford CD, 1998, ANTIMICROB AGENTS CH, V42, P1402, DOI 10.1128/AAC.42.6.1402; GAFTERGVILI A, 2003, COCHRANE DATABASE SY; Gentry C, 2002, AM J INFECT CONTROL, V30, P411, DOI 10.1067/mic.2002.124937; GLUCKMAN E, 1988, PATHOL BIOL, V36, P902; GLUCKMAN E, 1991, CHEMOTHERAPY, V37, P33, DOI 10.1159/000238904; Gomez-Martin C, 2000, J CLIN ONCOL, V18, P2126, DOI 10.1200/JCO.2000.18.10.2126; GOORIN AM, 1985, PEDIATR INFECT DIS J, V4, P265, DOI 10.1097/00006454-198505000-00012; GUALTIERI RJ, 1983, AM J MED, V74, P934, DOI 10.1016/0002-9343(83)90785-4; GUIOT HFL, 1983, J INFECT DIS, V147, P615, DOI 10.1093/infdis/147.4.615; GUIOT HFL, 1992, ANN HEMATOL, V64, P260, DOI 10.1007/BF01695467; GURWITH MJ, 1979, AM J MED, V66, P248, DOI 10.1016/0002-9343(79)90539-4; HARGADON MT, 1981, ANTIMICROB AGENTS CH, V20, P620, DOI 10.1128/AAC.20.5.620; HAROUSSEAU JL, 1987, PRESSE MED, V16, P1737; HARTLAPP JH, 1987, DRUGS, V34, P131, DOI 10.2165/00003495-198700341-00028; HENRY SA, 1984, AM J MED, V77, P663, DOI 10.1016/0002-9343(84)90359-0; Hidalgo M, 1997, ANTIMICROB AGENTS CH, V41, P1175, DOI 10.1128/AAC.41.5.1175; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; Hughes WT, 2002, CLIN INFECT DIS, V34, P730, DOI 10.1086/339215; INOUE M, 1983, DRUG EXP CLIN RES, V9, P35; JANSEN J, 1994, AM J MED, V96, P335, DOI 10.1016/0002-9343(94)90063-9; JEHN U, 1981, KLIN WOCHENSCHR, V59, P1093, DOI 10.1007/BF01746196; KARP JE, 1987, ANN INTERN MED, V106, P1, DOI 10.7326/0003-4819-106-1-1; KAUFFMAN CA, 1983, AM J MED, V74, P599, DOI 10.1016/0002-9343(83)91017-3; KERN W, 1991, INFECTION, V19, P73, DOI 10.1007/BF01645571; KERN WV, 1994, ANTIMICROB AGENTS CH, V38, P465, DOI 10.1128/AAC.38.3.465; KERN WV, 1994, ANTIMICROB AGENTS CH, V38, P681, DOI 10.1128/AAC.38.4.681; KLASTERSKY J, 1974, PATHOL BIOL, V22, P5; KOVATCH AL, 1985, PEDIATRICS, V76, P754; KRAMER BS, 1984, CANCER, V53, P329, DOI 10.1002/1097-0142(19840115)53:2<329::AID-CNCR2820530226>3.0.CO;2-X; KURRLE E, 1986, INFECTION, V14, P226, DOI 10.1007/BF01644268; KURRLE E, 1983, KLIN WOCHENSCHR, V61, P691, DOI 10.1007/BF01487614; LAMYA T, 1993, ACTA HAEMATOL-BASEL, V90, P109, DOI 10.1159/000204389; LANGE AB, 1984, ARCH INSECT BIOCHEM, V1, P231, DOI 10.1002/arch.940010306; Lee Dong Gun, 2002, Korean J Intern Med, V17, P38; LEIBOVICI L, 1992, EUR J CLIN MICROBIOL, V11, P782, DOI 10.1007/BF01960876; LEVINE AS, 1973, NEW ENGL J MED, V288, P477, DOI 10.1056/NEJM197303082881001; LEW MA, 1995, J CLIN ONCOL, V13, P239, DOI 10.1200/JCO.1995.13.1.239; LEW MA, 1991, TRANSPLANTATION, V51, P630, DOI 10.1097/00007890-199103000-00017; LIANG RHS, 1990, ANTIMICROB AGENTS CH, V34, P215, DOI 10.1128/AAC.34.2.215; Lucas KG, 1996, CANCER, V77, P791, DOI 10.1002/(SICI)1097-0142(19960215)77:4<791::AID-CNCR27>3.3.CO;2-B; MAICHE AG, 1993, EUR J CANCER, V29A, P1403, DOI 10.1016/0959-8049(93)90011-4; MALARME M, 1981, EUR J CANCER CLIN ON, V17, P1315, DOI 10.1016/0014-2964(81)90014-1; MARTINO P, 1984, AM J MED SCI, V287, P7, DOI 10.1097/00000441-198405000-00002; MASCHMEYER G, 1988, INFECTION, V16, P98, DOI 10.1007/BF01644312; Mocikova K, 1992, Vnitr Lek, V38, P166; Moreau P, 1995, BONE MARROW TRANSPL, V15, pS129; Moriuchi Y, 1990, Rinsho Ketsueki, V31, P1664; Murase T, 1995, Kansenshogaku Zasshi, V69, P28; NEMET D, 1989, Bone Marrow Transplantation, V4, P105; Nenova I S, 2001, Folia Med (Plovdiv), V43, P40; OPPENHEIM BA, 1989, BRIT MED J, V299, P294, DOI 10.1136/bmj.299.6694.294; ORLANDI E, 1990, HAEMATOLOGICA, V75, P296; PETERSEN FB, 1986, INFECTION, V14, P115, DOI 10.1007/BF01643474; PIGNON B, 1990, NOUV REV FR HEMATOL, V32, P249; PIZZO PA, 1983, J PEDIATR-US, V102, P125, DOI 10.1016/S0022-3476(83)80310-2; Prentice HG, 2001, BRIT J HAEMATOL, V115, P46, DOI 10.1046/j.1365-2141.2001.03034.x; ROTSTEIN C, 1997, CURR ONCOL S2, V4, pS2; Sampi K, 1992, Gan To Kagaku Ryoho, V19, P823; SCHIMPFF SC, 1986, AM J MED, V80, P13; SCHIMPFF SC, 1975, ANN INTERN MED, V82, P351, DOI 10.7326/0003-4819-82-3-351; SCHROEDER M, 1992, ONKOLOGIE, V15, P476; SLEIJFER DT, 1980, EUR J CANCER, V16, P859, DOI 10.1016/0014-2964(80)90140-1; STARKE ID, 1982, LANCET, V1, P5; TALBOT GH, 1993, ANTIMICROB AGENTS CH, V37, P474, DOI 10.1128/AAC.37.3.474; TEINTURIER C, 1995, PEDIATR HEMAT ONCOL, V12, P73, DOI 10.3109/08880019509029531; Thomas X, 2000, PRESSE MED, V29, P1745; Tjan-Heijnen VCG, 2001, ANN ONCOL, V12, P1359, DOI 10.1023/A:1012545507920; TSUTANI H, 1992, INTERNAL MED, V31, P319, DOI 10.2169/internalmedicine.31.319; VANEYS J, 1987, CANCER, V59, P19; WADE JC, 1981, NEW ENGL J MED, V304, P1057, DOI 10.1056/NEJM198104303041801; WADE JC, 1983, J INFECT DIS, V147, P624, DOI 10.1093/infdis/147.4.624; WADE JC, 1994, CLIN APPROACH INFECT; WALSH TJ, 1994, BAILLIERE CLIN INF D, V1, P469; WARD TT, 1993, CLIN INFECT DIS, V17, P323, DOI 10.1093/clinids/17.3.323; WATSON JG, 1982, LANCET, V1, P6; WEISER B, 1981, ANN INTERN MED, V95, P436, DOI 10.7326/0003-4819-95-4-436; WINSTON DJ, 1990, AM J MED, V88, P36, DOI 10.1016/0002-9343(90)90125-W; WINSTON DJ, 1986, AM J MED, V80, P884, DOI 10.1016/0002-9343(86)90633-9; YAMADA T, 1993, INTERNAL MED, V32, P710, DOI 10.2169/internalmedicine.32.710; YATES JW, 1973, CANCER, V32, P1490, DOI 10.1002/1097-0142(197312)32:6<1490::AID-CNCR2820320628>3.0.CO;2-6; YOUNG LS, 1994, CLIN APPROACH INFECT; ZINNER S, 1984, J INFECT DIS, V150, P372; ZINNER SH, 1994, JAMA-J AM MED ASSOC, V272, P1183, DOI 10.1001/jama.1994.03520150051036	114	317	339	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	1				979	995		10.7326/0003-4819-142-12_Part_1-200506210-00008	http://dx.doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00008			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937IN	15968013				2022-12-28	WOS:000229917900005
J	Schartl, M; Hornung, U; Hissmann, K; Schauer, J; Fricke, H				Schartl, M; Hornung, U; Hissmann, K; Schauer, J; Fricke, H			Relatedness among east African coelacanths	NATURE			English	Editorial Material							LATIMERIA-CHALUMNAE; HOME		Univ Wurzburg, Biozentrum, D-97074 Wurzburg, Germany; Max Planck Inst Seewiesen, Arbeitsgrp Fricke, D-82327 Tutzing, Germany	University of Wurzburg; Max Planck Society	Schartl, M (corresponding author), Univ Wurzburg, Biozentrum, D-97074 Wurzburg, Germany.	hfricke@jago-sub.de		Schartl, Manfred/0000-0001-9882-5948				Cane MA, 2001, NATURE, V411, P157, DOI 10.1038/35075500; de Ruijter WPM, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013714; DURVILLE C, 2005, COELACANTH FISH CAUG; Fricke H, 2000, MAR BIOL, V136, P379, DOI 10.1007/s002270050697; FRICKE H, 1994, MAR BIOL, V120, P171, DOI 10.1007/BF00349676; Hissmann K, 2000, MAR BIOL, V136, P943, DOI 10.1007/s002270000294; Holder MT, 1999, P NATL ACAD SCI USA, V96, P12616, DOI 10.1073/pnas.96.22.12616; Keller LF, 2002, TRENDS ECOL EVOL, V17, P230, DOI 10.1016/S0169-5347(02)02489-8; SCHLIEWEN U, 1993, NATURE, V363, P405, DOI 10.1038/363405a0	9	13	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					901	901		10.1038/435901a	http://dx.doi.org/10.1038/435901a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959506	Bronze			2022-12-28	WOS:000229799700034
J	Piercy, J				Piercy, J			10-minute consultation - Bell's palsy	BRITISH MEDICAL JOURNAL			English	Article								A 32 year old man presents to you with sudden onset of weakness on the left side of his face. He also says that he is unable to close his left eye. He is otherwise well and last saw a doctor five years ago. He is anxious and thinks he has had a stroke.	Univ Warwick, Warwick Med Sch, Div Med Educ, Coventry CV4 7AL, W Midlands, England	University of Warwick	Piercy, J (corresponding author), Univ Warwick, Warwick Med Sch, Div Med Educ, Coventry CV4 7AL, W Midlands, England.	Joanna.piercy@warwick.ac.uk							0	20	21	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 11	2005	330	7504					1374	1374		10.1136/bmj.330.7504.1374	http://dx.doi.org/10.1136/bmj.330.7504.1374			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936FE	15947400	Green Published			2022-12-28	WOS:000229840100029
J	Alsayed, AM; Islam, MF; Zhang, J; Collings, PJ; Yodh, AG				Alsayed, AM; Islam, MF; Zhang, J; Collings, PJ; Yodh, AG			Premelting at defects within bulk colloidal crystals	SCIENCE			English	Article							DENSITY-FUNCTIONAL THEORY; MOLECULAR-DYNAMICS; SURFACE; SUSPENSIONS; INTERFACES; TRANSITION; SPHERES; MODEL	Premelting is the localized loss of crystalline order at surfaces and defects at temperatures below the bulk melting transition. It can be thought of as the nucleation of the melting process. Premelting has been observed at the surfaces of crystals but not within. We report observations of premelting at grain boundaries and dislocations within bulk colloidal crystals using real-time video microscopy. The crystals are equilibrium close-packed, three-dimensional colloidal structures made from thermally responsive microgel spheres. Particle tracking reveals increased disorder in crystalline regions bordering defects, the amount of which depends on the type of defect, distance from the defect, and particle volume fraction. Our observations suggest that interfacial free energy is the crucial parameter for premelting in colloidal and atomic-scale crystals.	Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA; Swarthmore Coll, Dept Phys & Astron, Swarthmore, PA 19081 USA	University of Pennsylvania; Swarthmore College	Yodh, AG (corresponding author), Univ Penn, Dept Phys & Astron, 209 S 33rd St, Philadelphia, PA 19104 USA.	yodh@physics.upenn.edu	Islam, Mohammad/B-7211-2011	Islam, Mohammad/0000-0001-9253-3709				Bongers J, 1996, J CHEM PHYS, V104, P1519, DOI 10.1063/1.470917; BROUGHTON JQ, 1986, PHYS REV LETT, V56, P2692, DOI 10.1103/PhysRevLett.56.2692; Burakovsky L, 2000, PHYS REV B, V61, P15011, DOI 10.1103/PhysRevB.61.15011; CAHN RW, 1986, NATURE, V323, P668, DOI 10.1038/323668a0; Cahn RW, 2001, NATURE, V413, P582, DOI 10.1038/35098169; CICCOTTI G, 1983, PHYS REV B, V27, P5576, DOI 10.1103/PhysRevB.27.5576; Crocker JC, 1996, J COLLOID INTERF SCI, V179, P298, DOI 10.1006/jcis.1996.0217; CURTIN WA, 1989, PHYS REV B, V39, P6775, DOI 10.1103/PhysRevB.39.6775; Dahmen U, 2004, PHILOS MAG, V84, P2651, DOI 10.1080/14786430410001671403; Dash JG, 1999, REV MOD PHYS, V71, P1737, DOI 10.1103/RevModPhys.71.1737; DASH JG, 1995, REP PROG PHYS, V58, P115, DOI 10.1088/0034-4885/58/1/003; Debord SB, 2003, J PHYS CHEM B, V107, P2927, DOI 10.1021/jp026783n; EDWARDS SF, 1979, PHILOS MAG A, V40, P257, DOI 10.1080/01418617908243102; FRENKEN JWM, 1985, PHYS REV LETT, V54, P134, DOI 10.1103/PhysRevLett.54.134; Hirth J. P., 1972, THEORY DISLOCATIONS; Lindemann F.A., 1910, PHYSICALISCHE Z, V5, P609; LIPOWSKY R, 1986, PHYS REV LETT, V57, P2876, DOI 10.1103/PhysRevLett.57.2876; LIPOWSKY R, 1989, PHYS REV LETT, V62, P913, DOI 10.1103/PhysRevLett.62.913; OHNESORGE R, 1994, PHYS REV E, V50, P4801, DOI 10.1103/PhysRevE.50.4801; Ohshima YN, 2001, J CHEM PHYS, V114, P8649, DOI 10.1063/1.1366640; PETTERSEN MS, 1989, PHYS REV B, V40, P4938, DOI 10.1103/PhysRevB.40.4938; PHILLPOT SR, 1989, PHYS REV B, V40, P2831, DOI 10.1103/PhysRevB.40.2831; PLUIS B, 1987, PHYS REV LETT, V59, P2678, DOI 10.1103/PhysRevLett.59.2678; PLUIS B, 1990, SURF SCI, V239, P282, DOI 10.1016/0039-6028(90)90231-V; Pronk S, 1999, J CHEM PHYS, V110, P4589, DOI 10.1063/1.478339; PUSEY PN, 1986, NATURE, V320, P340, DOI 10.1038/320340a0; PUSEY PN, 1989, PHYS REV LETT, V63, P2753, DOI 10.1103/PhysRevLett.63.2753; Schall P, 2004, SCIENCE, V305, P1944, DOI 10.1126/science.1102186; Stieger M, 2004, LANGMUIR, V20, P7283, DOI 10.1021/la049518x; van der Veen JF, 1999, SURF SCI, V433, P1, DOI 10.1016/S0039-6028(99)00084-9; Wu JZ, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.048304; Zhu JX, 1997, NATURE, V387, P883, DOI 10.1038/43141	33	393	397	6	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	2005	309	5738					1207	1210		10.1126/science.1112399	http://dx.doi.org/10.1126/science.1112399			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	15994377	Green Submitted			2022-12-28	WOS:000231395400036
J	Devereaux, PJ; Beattie, WS; Choi, PTL; Badner, NH; Guyatt, GH; Villar, JC; Cina, CS; Leslie, K; Jacka, MJ; Montori, VM; Bhandari, M; Avezum, A; Cavalcanti, AB; Giles, JW; Schricker, T; Yang, H; Jakobsen, CJ; Yusuf, S				Devereaux, PJ; Beattie, WS; Choi, PTL; Badner, NH; Guyatt, GH; Villar, JC; Cina, CS; Leslie, K; Jacka, MJ; Montori, VM; Bhandari, M; Avezum, A; Cavalcanti, AB; Giles, JW; Schricker, T; Yang, H; Jakobsen, CJ; Yusuf, S			How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HIGH-RISK PATIENTS; MYOCARDIAL-ISCHEMIA; HEART-RATE; HYPERTENSIVE PATIENTS; ADRENERGIC-BLOCKADE; TRACHEAL INTUBATION; CARDIAC EVENTS; BLOOD-PRESSURE; METOPROLOL; ESMOLOL	Objective To determine the effect of perioperative beta blocker treatment in patients having non-cardiac surgery. Design Systematic review and meta-analysis. Data sources Seven search strategies, including searching two bibliographic databases and hand searching seven medical journals. Study selection and outcomes We included randomised controlled trials that evaluated beta blocker treatment in patients having non-cardiac surgery. Perioperative outcomes within 30 days of surgery included total mortality, cardiovascular mortality, non-fatal myocardial infarction, non-fatal cardiac arrest, non-fatal stroke, congestive heart failure, hypotension needing treatment, bradycardia needing treatment, and bronchospasm. Results Twenty two trials that randomised a total of 2437 patients met the eligibility criteria. Perioperative beta blockers did not show any statistically significant beneficial effects on any of the individual outcomes and the only nominally statistically significant beneficial relative risk was 0.44 (95% confidence interval 0.20 to 0.97, 99% confidence interval 0.16 to 1.24) for the composite outcome of cardiovascular mortality, non-fatal myocardial infarction, and non-fatal cardiac arrest. Methods adapted from formal interim monitoring boundaries applied to cumulative meta-analysis showed that the evidence failed, by a considerable degree, to meet standards for forgoing additional studies. The individual safety outcomes in patients treated with perioperative beta blockers showed a relative risk for bradycardia needing treatment of 2.27 (95% CI 1.53 to 3.36, 99% CI 1.36 to 3.80) and a nominally statistically significant relative risk for hypotension needing treatment of 1.27 (95% CI 1.04 to 1.56, 99% CI 0.97 to 1.66). Conclusion The evidence that perioperative beta blockers reduce major cardiovascular events is encouraging but too unreliable to allow definitive conclusions to be drawn.	McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada; McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8S 4L8, Canada; Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; Univ British Columbia, Vancouver Coastal Hlth Res Inst, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Anesthesia, Vancouver, BC V5Z 1M9, Canada; Univ Western Ontario, Dept Anesthesiol, London, ON, Canada; Univ Western Ontario, Dept Perioperat Med, London, ON, Canada; Univ Autonoma Bucaramanga, Grp Cardiol Prevent, Bucaramanga, Colombia; Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; Univ Alberta, Dept Anesthesiol, Edmonton, AB, Canada; Univ Alberta, Dept Crit Care, Edmonton, AB, Canada; Mayo Clin, Coll Med, Dept Med, Rochester, MN USA; Dante Pazzanese Inst Cardiol, Sao Paulo, Brazil; Albert Einstein Hosp, Sao Paulo, Brazil; Univ Oxford, Nuffield Dept Anaesthet, Oxford OX1 2JD, England; McGill Univ, Dept Anesthesia, Montreal, PQ, Canada; Univ Ottawa, Dept Anesthesia, Ottawa, ON, Canada; Aarhus Univ Hosp, Dept Anaesthesia & Intens Care, DK-8000 Aarhus, Denmark	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; McMaster University; McMaster University; Population Health Research Institute; University of Toronto; University of British Columbia; Vancouver Coastal Health Research Institute; University of British Columbia; Western University (University of Western Ontario); Western University (University of Western Ontario); Royal Melbourne Hospital; University of Alberta; University of Alberta; Mayo Clinic; Instituto Dante Pazzanese de Cardiologia; Hospital Israelita Albert Einstein; University of Oxford; McGill University; University of Ottawa; Aarhus University	Devereaux, PJ (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	philipj@mcmaster.ca	Devereaux, PJ/AAF-2862-2019; Bhandari, Mohit/AAQ-1675-2021; Devereaux, PJ/AAY-1757-2021; Beattie, William Scott/A-4352-2008; Avezum, Alvaro AA/K-6137-2016; Villar Centeno, Juan Carlos/AAX-5401-2021; Avezum, Alvaro/AAP-7687-2020; Cavalcanti, Alexandre/K-5529-2013	Avezum, Alvaro AA/0000-0002-3073-6890; Devereaux, PJ/0000-0003-2935-637X; Leslie, Kate/0000-0001-8512-3517; Cavalcanti, Alexandre/0000-0003-2798-6263; Villar, Juan Carlos/0000-0002-7047-7299; Montori, Victor/0000-0003-0595-2898; Yusuf, Salim/0000-0003-4776-5601				[Anonymous], 1986, Lancet, V2, P57; Auerbach AD, 2002, JAMA-J AM MED ASSOC, V287, P1435, DOI 10.1001/jama.287.11.1435; Bayliff CD, 1999, ANN THORAC SURG, V67, P182, DOI 10.1016/S0003-4975(98)01226-0; Butterworth J, 2003, ANESTH ANALG, V97, P613, DOI 10.1213/01.ANE.0000082527.03681.BD; COLEMAN AJ, 1980, ANAESTHESIA, V35, P972, DOI 10.1111/j.1365-2044.1980.tb04995.x; CUCCHIARA RF, 1986, ANESTHESIOLOGY, V65, P528, DOI 10.1097/00000542-198611000-00016; DAVIES MJ, 1992, ANAESTH INTENS CARE, V20, P161, DOI 10.1177/0310057X9202000207; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Eagle KA, 2002, J AM COLL CARDIOL, V39, P542, DOI 10.1016/S0735-1097(01)01788-0; FLINN WR, 1984, J VASC SURG, V1, P888, DOI 10.1067/mva.1984.avs0010888; GIBSON BE, 1988, CLIN PHARMACOL THER, V44, P650, DOI 10.1038/clpt.1988.207; Grayburn PA, 2003, ANN INTERN MED, V138, P506, DOI 10.7326/0003-4819-138-6-200303180-00017; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hjalmarson A, 1999, LANCET, V353, P2001; Inada E, 1989, J Clin Anesth, V1, P207, DOI 10.1016/0952-8180(89)90043-3; Jacka MJ, 2004, ANESTH ANALG, V98, P269, DOI [10.1213/01.ANE.0000077688.55641.0a, 10.1213/01.ANE.0000077688.55641.0A]; Jakobsen CJ, 1997, ACTA ANAESTH SCAND, V41, P1324, DOI 10.1111/j.1399-6576.1997.tb04652.x; JAKOBSEN CJ, 1990, ANAESTHESIA, V45, P40, DOI 10.1111/j.1365-2044.1990.tb14502.x; JAKOBSEN CJ, 1986, BRIT J ANAESTH, V58, P261, DOI 10.1093/bja/58.3.261; Lechat P, 1999, LANCET, V353, P9; Lechat P, 1998, CIRCULATION, V98, P1184, DOI 10.1161/01.CIR.98.12.1184; Lee TH, 1999, NEW ENGL J MED, V341, P1838, DOI 10.1056/NEJM199912093412410; Leslie J B, 1989, J Clin Anesth, V1, P194, DOI 10.1016/0952-8180(89)90041-X; LIU PL, 1986, CAN ANAESTH SOC J, V33, P556, DOI 10.1007/BF03014260; MACKENZIE JW, 1989, BRIT MED J, V298, P363, DOI 10.1136/bmj.298.6670.363; MAGNUSSON J, 1986, BRIT J ANAESTH, V58, P251, DOI 10.1093/bja/58.3.251; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MCDANIEL MD, 1984, J VASC SURG, V1, P261, DOI 10.1067/mva.1984.avs0010261; MILLER DR, 1991, CAN J ANAESTH, V38, P849, DOI 10.1007/BF03036959; Miller DR, 1990, J CARDIOTHORAIC A S2, V4, P31; Palda VA, 1997, ANN INTERN MED, V127, P313, DOI 10.7326/0003-4819-127-4-199708150-00012; PARKER SD, 1995, CRIT CARE MED, V23, P1954, DOI 10.1097/00003246-199512000-00003; Pogue J, 1998, LANCET, V351, P47, DOI 10.1016/S0140-6736(97)08461-4; Pogue JM, 1997, CONTROL CLIN TRIALS, V18, P580, DOI 10.1016/S0197-2456(97)00051-2; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; Priebe HJ, 2004, BRIT J ANAESTH, V93, P9, DOI 10.1093/bja/aeh147; Raby KE, 1999, ANESTH ANALG, V88, P477, DOI 10.1097/00000539-199903000-00002; ROSENFELD BA, 1993, ANESTHESIOLOGY, V79, P435, DOI 10.1097/00000542-199309000-00005; Sametz W, 1999, EUR J CLIN INVEST, V29, P582; Schillinger M, 2002, INTENS CARE MED, V28, P740, DOI 10.1007/s00134-002-1299-1; Stevens RD, 2003, ANESTH ANALG, V97, P623, DOI 10.1213/01.ANE.0000074795.68061.16; STONE JG, 1988, ANESTHESIOLOGY, V68, P495, DOI 10.1097/00000542-198804000-00004; Swedberg K, 1998, Evid Based Cardiovasc Med, V2, P33, DOI 10.1016/S1361-2611(98)80029-8; Urban MK, 2000, ANESTH ANALG, V90, P1257, DOI 10.1097/00000539-200006000-00001; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005; WEISSMAN C, 1990, ANESTHESIOLOGY, V73, P308, DOI 10.1097/00000542-199008000-00020; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; YANG H, 2004, CAN J ANAESTH, V51, pA7; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Zaugg M, 1999, ANESTHESIOLOGY, V91, P1674, DOI 10.1097/00000542-199912000-00020	50	304	317	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	2005	331	7512					313	316B		10.1136/bmj.38503.623646.8F	http://dx.doi.org/10.1136/bmj.38503.623646.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955WZ	15996966	Green Published, Bronze			2022-12-28	WOS:000231259800012
J	Ethgen, M; Boutron, I; Baron, G; Giraudeau, B; Sibilia, J; Ravaud, P				Ethgen, M; Boutron, I; Baron, G; Giraudeau, B; Sibilia, J; Ravaud, P			Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; SPINAL MANIPULATION; SAFETY; QUALITY; ACUPUNCTURE; PAIN	Background: Reports of clinical trials usually emphasize benefits and give less attention to harms. Purpose: To compare the reporting of harm in trials of pharmacologic and nonpharmacologic treatment. Data Sources: MEDLINE and the Cochrane Central Register of Controlled Trials. Study Selection: Reports of randomized, controlled trials assessing treatment of rheumatic disease that were published between January 1999 and January 2005. Data Extraction: A standardized abstraction form was used to extract data. Data Synthesis: 193 articles were analyzed. After adjustment for medical area, sample size, funding source, and multicenter trials, data on harm were more often described in pharmacologic treatment reports than in nonpharmacologic treatment reports in reporting adverse events (odds ratio, 5.2 [95% CI, 2.1 to 12.91), reporting withdrawals due to adverse events (odds ratio, 4.6 [CI, 2.0 to 10.9]), reporting severity (odds ratio, 3.7 [CI, 1.5 to 9.1]), and allocating space for describing harm (odds ratio, 1.6 [CI, 1.2 to 2.31]). Limitations: Extrapolating results to trials in areas other than rheumatic disease is questionable. Conclusions: The lack of reporting harm in trials assessing nonpharmacologic treatment in rheumatic disease is an important barrier to evaluating the benefit-harm balance of nonpharmacologic treatments.	Grp Hosp Bichat Claude Bernard, Dept Epidemiol Biostat & Rech Clin, INSERM, U738, F-75877 Paris, France; Univ Paris 07, F-75221 Paris, France; Bretonneau Hosp, Tours, France; CHU Hautepierre, F-67098 Strasbourg, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHU Tours; CHU Strasbourg	Boutron, I (corresponding author), Grp Hosp Bichat Claude Bernard, Dept Epidemiol Biostat & Rech Clin, INSERM, U738, 46 Reu Henri Huchard, F-75877 Paris, France.	isabelle.boutron@bch.ap-hop-paris.fr	Giraudeau, Bruno/L-9003-2015; ravaud, philippe/C-1694-2009	Giraudeau, Bruno/0000-0003-3031-8258; Sibilia, Jean/0000-0002-1601-4795; Boutron, Isabelle/0000-0002-5263-6241; Ravaud, Philippe/0000-0001-8264-9206				Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Cherkin DC, 2003, ANN INTERN MED, V138, P898, DOI 10.7326/0003-4819-138-11-200306030-00011; Derry S, 2001, BMC Med Res Methodol, V1, P7, DOI 10.1186/1471-2288-1-7; Edwards JE, 1999, J PAIN SYMPTOM MANAG, V18, P427, DOI 10.1016/S0885-3924(99)00093-7; Ernst E, 2001, J PAIN SYMPTOM MANAG, V21, P238, DOI 10.1016/S0885-3924(00)00262-1; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; Ioannidis JPA, 1998, LANCET, V352, P1752, DOI 10.1016/S0140-6736(05)79825-1; IOANNIDISJP, 2001, JAMA-J AM MED ASSOC, V285, P437; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; LEE KP, 1995, NEUROLOGY, V45, P1213, DOI 10.1212/WNL.45.6.1213; Lee KP, 2002, JAMA-J AM MED ASSOC, V287, P2805, DOI 10.1001/jama.287.21.2805; Loke Y K, 2001, BMC Clin Pharmacol, V1, P3, DOI 10.1186/1472-6904-1-3; NORHEIM AJ, 1995, LANCET, V345, P1576, DOI 10.1016/S0140-6736(95)91127-8; Papanikolaou PN, 2004, AM J PSYCHIAT, V161, P1692, DOI 10.1176/appi.ajp.161.9.1692; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0	15	37	38	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 5	2005	143	1					20	25		10.7326/0003-4819-143-1-200507050-00006	http://dx.doi.org/10.7326/0003-4819-143-1-200507050-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941XB	15998751				2022-12-28	WOS:000230246400003
J	Diaconu, M; Kothe, U; Schlunzen, F; Fischer, N; Harms, JM; Tonevitsky, AG; Stark, H; Rodnina, MV; Wahl, MC				Diaconu, M; Kothe, U; Schlunzen, F; Fischer, N; Harms, JM; Tonevitsky, AG; Stark, H; Rodnina, MV; Wahl, MC			Structural basis for the function of the ribosomal L7/12 stalk in factor binding and GTPase activation	CELL			English	Article							ELONGATION-FACTOR TU; AMINOACYL-TRANSFER-RNA; PROTEIN L7/L12; CODON-RECOGNITION; SUBUNIT; SITE; VISUALIZATION; TRANSLOCATION; LOCALIZATION; TRANSLATION	The L7/12 stalk of the large subunit of bacterial ribosomes encompasses protein L10 and multiple copies of L7/12. We present crystal structures of Thermotoga maritima L10 in complex with three L7/12 N-terminaldomain dimers, refine the structure of an archaeal L10E N-terminal domain on the 50S subunit, and identify these elements in cryo-electron-microscopic reconstructions of Escherichia coli ribosomes. The mobile C-terminal helix alpha 8 of L10 carries three L7/12 dimers in T maritima and two in E. coli, in concordance with the different length of helix alpha 8 of L10 in these organisms. The stalk is organized into three elements (stalk base, L10 helix alpha 8-L7/12 N-terminaldomain complex, and L7/12 C-terminal domains) linked by flexible connections. Highly mobile L7/12 C-terminal domains promote recruitment of translation factors to the ribosome and stimulate GTP hydrolysis by the ribosome bound factors through stabilization of their active GTPase conformation.	Max Planck Inst Biophys Chem, Rontgenkristallog, D-37077 Gottingen, Germany; Max Planck Inst Biophys Chem, 3D Kryoelektr Mikroskopie, D-37077 Gottingen, Germany; Univ Witten Herdecke, Inst Phys Biochem, D-58448 Witten, Germany; DESY, Max Planck Arbeitsgrppen Strukt Mol Biol, D-22607 Hamburg, Germany; Moscow MV Lomonosov State Univ, Dept Biol, Moscow 119899, Russia	Max Planck Society; Max Planck Society; Witten Herdecke University; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society; Lomonosov Moscow State University	Wahl, MC (corresponding author), Max Planck Inst Biophys Chem, Rontgenkristallog, Fassberg 11, D-37077 Gottingen, Germany.	mwahl@gwdg.de	Schluenzen, Frank/P-9177-2019; Harms, Joerg/K-8786-2012; Tonevitsky, Alexander/R-5596-2019; Wahl, Markus C./D-6365-2017; Diaconu, Mihaela Stefania/C-3644-2012; Schluenzen, Frank/H-6274-2014; Rodnina, Marina V./AAD-4667-2019; Fischer, Niels/ABA-5342-2021; Kothe, Ute/K-5568-2019; Tonevitsky, Alexander G/F-8640-2014	Schluenzen, Frank/0000-0003-2849-0542; Harms, Joerg/0000-0002-9442-8264; Wahl, Markus C./0000-0002-2811-5307; Diaconu, Mihaela Stefania/0000-0002-1144-338X; Schluenzen, Frank/0000-0003-2849-0542; Rodnina, Marina V./0000-0003-0105-3879; Fischer, Niels/0000-0002-4609-4052; Kothe, Ute/0000-0002-2744-7334; Holger, Stark/0000-0002-6161-1118				Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BEAUCLERK AAD, 1984, J BIOL CHEM, V259, P6559; Blanchard SC, 2004, NAT STRUCT MOL BIOL, V11, P1008, DOI 10.1038/nsmb831; Bocharov EV, 2004, J BIOL CHEM, V279, P17697, DOI 10.1074/jbc.M313384200; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Dey D, 1998, J BIOL CHEM, V273, P1670, DOI 10.1074/jbc.273.3.1670; Gonzalo P, 2003, BIOL CELL, V95, P179, DOI 10.1016/S0248-4900(03)00034-0; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Klaholz BP, 2004, NATURE, V427, P862, DOI 10.1038/nature02332; Kothe U, 2004, J MOL BIOL, V336, P1011, DOI 10.1016/j.jmb.2003.12.080; LILJAS A, 1987, BIOCHIMIE, V69, P1043, DOI 10.1016/0300-9084(87)90004-6; Mohr D, 2000, EMBO J, V19, P3458, DOI 10.1093/emboj/19.13.3458; Mohr D, 2002, BIOCHEMISTRY-US, V41, P12520, DOI 10.1021/bi026301y; Montesano-Roditis L, 2001, J BIOL CHEM, V276, P14117, DOI 10.1074/jbc.M008430200; Mulder FAA, 2004, BIOCHEMISTRY-US, V43, P5930, DOI 10.1021/bi0495331; OLEINIKOV AV, 1993, J BIOL CHEM, V268, P917; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; Rodnina MV, 1996, J BIOL CHEM, V271, P646, DOI 10.1074/jbc.271.2.646; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; Savelsbergh A, 2000, J BIOL CHEM, V275, P890, DOI 10.1074/jbc.275.2.890; Savelsbergh A, 2003, MOL CELL, V11, P1517, DOI 10.1016/S1097-2765(03)00230-2; Stark H, 2002, NAT STRUCT BIOL, V9, P849, DOI 10.1038/nsb859; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; Valle M, 2003, NAT STRUCT BIOL, V10, P899, DOI 10.1038/nsb1003; Vetter IR, 1999, Q REV BIOPHYS, V32, P1, DOI 10.1017/S0033583599003480; Vila-Sanjurjo A, 2003, P NATL ACAD SCI USA, V100, P8682, DOI 10.1073/pnas.1133380100; Wahl MC, 2000, EMBO J, V19, P174, DOI 10.1093/emboj/19.2.174; Wahl MC, 2002, CURR PROTEIN PEPT SC, V3, P93, DOI 10.2174/1389203023380756; Wieden HJ, 2001, J MOL EVOL, V52, P129, DOI 10.1007/s002390010141; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	37	308	318	0	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	2005	121	7					991	1004		10.1016/j.cell.2005.04.015	http://dx.doi.org/10.1016/j.cell.2005.04.015			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989950	Green Published, Bronze			2022-12-28	WOS:000230448000007
J	Nudleman, E; Wall, D; Kaiser, D				Nudleman, E; Wall, D; Kaiser, D			Cell-to-cell transfer of bacterial outer membrane lipoproteins	SCIENCE			English	Article							MYXOCOCCUS-XANTHUS; GLIDING MOTILITY; IV PILI; MOVEMENT; MYXOBACTERIA; STIMULATION	Myxococcus xanthus cells can glide forward by retracting type IV pili. Tgl, an outer membrane lipoprotein, is necessary to assemble pili. Tgl(+) mutants can be transiently "stimulated" if brought into end-to-end contact with tgl(+) donor cells. By separating the stimulated recipient cells from donor cells, we found that Tgl protein was transferred from the donors to the rescued recipient cells. Mutants lacking CglB lipoprotein, which is part of a second gliding engine, could also be stimulated, and CglB protein was transferred from donor to recipient cells. The high transfer efficiency of Tgl and CglB proteins suggests that donor and recipient cells briefly fuse their outer membranes.	Stanford Univ, Dept Dev Biol, Sch Med, Beckman Ctr B300, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Sch Med, Beckman Ctr B300, Stanford, CA 94305 USA	Stanford University; Stanford University	Kaiser, D (corresponding author), Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	kaiser@cmgm.stanford.edu		Wall, Daniel/0000-0002-0273-1371	NIGMS NIH HHS [GM23441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023441, R01GM023441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Hardie KR, 1996, MOL MICROBIOL, V22, P967, DOI 10.1046/j.1365-2958.1996.01539.x; HODGKIN J, 1977, P NATL ACAD SCI USA, V74, P2938, DOI 10.1073/pnas.74.7.2938; HODGKIN J, 1979, MOL GEN GENET, V171, P177, DOI 10.1007/BF00270004; KAISER D, 1979, P NATL ACAD SCI USA, V76, P5952, DOI 10.1073/pnas.76.11.5952; Kaiser D, 2005, CURR OPIN MICROBIOL, V8, P216, DOI 10.1016/j.mib.2005.02.002; Kaiser D, 2003, NAT REV MICROBIOL, V1, P45, DOI 10.1038/nrmicro733; MACRAE TH, 1976, CAN J MICROBIOL, V22, P1589, DOI 10.1139/m76-234; McBride MJ, 2001, ANNU REV MICROBIOL, V55, P49, DOI 10.1146/annurev.micro.55.1.49; Merz AJ, 2000, NATURE, V407, P98, DOI 10.1038/35024105; Nouwen N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/pnas.96.14.8173; Nudleman E, 2004, J MOL MICROB BIOTECH, V7, P52, DOI 10.1159/000077869; NUDLEMAN E, UNPUB; Rodriguez AM, 1999, J BACTERIOL, V181, P4381, DOI 10.1128/JB.181.14.4381-4390.1999; Thanassi DG, 2002, J MOL MICROB BIOTECH, V4, P11; Wall D, 1998, J BACTERIOL, V180, P759, DOI 10.1128/JB.180.3.759-761.1998; Wall D, 1999, J BACTERIOL, V181, P24, DOI 10.1128/JB.181.1.24-33.1999; Wolgemuth C, 2002, CURR BIOL, V12, P369, DOI 10.1016/S0960-9822(02)00716-9; WU SS, 1995, MOL MICROBIOL, V18, P547, DOI 10.1111/j.1365-2958.1995.mmi_18030547.x	19	120	123	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					125	127		10.1126/science.1112440	http://dx.doi.org/10.1126/science.1112440			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994555				2022-12-28	WOS:000230212800073
J	Ninis, N; Phillips, C; Bailey, L; Pollock, JI; Nadel, S; Britto, J; Maconochie, I; Winrow, A; Coen, PG; Booy, R; Levin, M				Ninis, N; Phillips, C; Bailey, L; Pollock, JI; Nadel, S; Britto, J; Maconochie, I; Winrow, A; Coen, PG; Booy, R; Levin, M			The role of healthcare delivery in the outcome of meningococcal disease in children: case-control study of fatal and non-fatal cases	BRITISH MEDICAL JOURNAL			English	Article							SEPTICEMIA; MANAGEMENT	Objective To determine whether suboptimal management in hospital could contribute to poor outcome in children admitted with meningococcal disease. Design Case-control study of childhood deaths from meningococcal disease, comparing hospital care in fatal mid non-fatal cases. Setting National statistics and hospital records. Subjects All children under 17 years who died from meningococcal disease (cases) matched by age with three survivors (controls) from the same region of the country. Main outcome measures Predefined criteria defined optimal management. A panel of paediatricians blinded to the outcome assessed case records using a standardised form and scored patients for suboptimal management. Results We identified 143 cases and 355 controls. Departures from optimal (per protocol) management occurred more frequently in the fatal cases than in the survivors. Multivariate analysis identified three factors independently associated with an increased risk of death: failure to be looked after by a paediatrician, failure of sufficient supervision of junior staff, and failure of staff to administer adequate inotropes. Failure to recognise complications of the disease was a significant risk factor for death, although not independently of absence of paediatric care (P=0.002). The odds ratio for death was 8.7 (95% confidence interval 2.3 to 33) with two failures, increasing with multiple failures. Conclusions Suboptimal healthcare delivery significantly reduces the likelihood of survival in children with meningococcal disease. Improved training of medical and nursing staff, adherence to published protocols, and increased supervision by consultants may improve the outcome for these children and also those with other life threatening illnesses.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Paediat, Infect Dis Unit, London W2 1PG, England; Royal Coll Paediat & Child Hlth, Res Unit, London W1W 6DE, England; Univ W England, Fac Hlth & Social Care, Bristol BS16 1DD, Avon, England; St Marys Hosp, Paediat Intens Care Unit, London W2 1PG, England; St Marys Hosp, Paediat Accid & Emergency Dept, London W2 1PG, England; Kingston Hosp, Dept Paediat, Kingston upon Thames KT2 7QB, Surrey, England; Univ London, Queen Marys Sch Med & Dent, London E1 1BB, England	Imperial College London; University of West England; Imperial College London; Imperial College London; University of London; Queen Mary University London	Ninis, N (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Paediat, Infect Dis Unit, London W2 1PG, England.	ninisn@gosh.nhs.uk	Booy, Robert/D-4188-2011	Maconochie, Ian/0000-0001-6319-8550; Levin, Michael/0000-0003-2767-6919				*ADV LIF SUPP GROU, 2001, ADV PAED LIF SUPP MA; Booy R, 2001, ARCH DIS CHILD, V85, P386, DOI 10.1136/adc.85.5.386; HOSMER DW, 1989, APPL LOGISTIC REGRES; JONES D, 1995, MENINGOCOCCAL DIS, P147; Nadel S, 1998, J ACCID EMERG MED, V15, P298; NADEL S, 1995, MENINGOCOCCAL DIS, P207; *OFF NAT STAT, 2000, MORT STAT DH2, V26; Pathan N, 2000, J ROY COLL PHYS LOND, V34, P436; Pollard AJ, 1999, ARCH DIS CHILD, V80, P290, DOI 10.1136/adc.80.3.290; Ramsay M, 1997, Commun Dis Rep CDR Rev, V7, pR49; Stuart J M, 1997, Commun Dis Rep CDR Rev, V7, pR3; THOMSON APJ, 1991, CRIT CARE MED, V19, P26, DOI 10.1097/00003246-199101000-00010; Thorburn K, 2001, ARCH DIS CHILD, V85, P382, DOI 10.1136/adc.85.5.382; Thornhill J, 2000, BJU INT, V85, P382	14	112	120	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 25	2005	330	7506					1475	1478		10.1136/bmj.330.7506.1475	http://dx.doi.org/10.1136/bmj.330.7506.1475			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942NR	15976421	Green Published, Bronze			2022-12-28	WOS:000230289600017
J	Merke, DP; Bornstein, SR				Merke, DP; Bornstein, SR			Congenital adrenal hyperplasia	LANCET			English	Review							STEROID 21-HYDROXYLASE DEFICIENCY; FOR-PEDIATRIC-ENDOCRINOLOGY; POLYCYSTIC-OVARY-SYNDROME; HIGH-INTENSITY EXERCISE; GENDER-RELATED BEHAVIOR; GLUCOCORTICOID TREATMENT; HORMONE ANALOG; FINAL HEIGHT; ADRENOMEDULLARY FUNCTION; DEXAMETHASONE TREATMENT	Congenital adrenal hyperplasia (CAH) due to deficiency of 21-hydroxylase is a disorder of the adrenal cortex characterised by cortisol deficiency, with or without aldosterone deficiency, and androgen excess. Patients with the most severe form also have abnormalities of the adrenal medulla and epinephrine deficiency. The severe classic form occurs in one in 15 000 births worldwide, and the mild non-classic form is a common cause of hyperandrogenism. Neonatal screening for CAH and gene-specific prenatal diagnosis are now possible. Standard hormone replacement fails to achieve normal growth and development for many children with CAH, and adults can experience iatrogenic Cushing's syndrome, hyperandrogenism, infertility, or the development of the metabolic syndrome. This Seminar reviews the epidemiology, genetics, pathophysiology, diagnosis, and management of CAH, and provides an overview of clinical challenges and future therapies.	NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIH, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA; Univ Dresden, Dept Internal Med 3, Dresden, Germany	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; Technische Universitat Dresden	Merke, DP (corresponding author), NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bldg 10,Room 1-2740,10 Ctr Dr MSC 1932, Bethesda, MD 20892 USA.	dmerke@nih.gov						Alesci S, 2002, P NATL ACAD SCI USA, V99, P7484, DOI 10.1073/pnas.062170099; Allen DB, 1997, J PEDIATR-US, V130, P128, DOI 10.1016/S0022-3476(97)70321-4; Arlt W, 1999, NEW ENGL J MED, V341, P1013, DOI 10.1056/NEJM199909303411401; Arslanian SA, 2002, J CLIN ENDOCR METAB, V87, P1555, DOI 10.1210/jc.87.4.1555; Avila NA, 1999, AM J ROENTGENOL, V172, P1235, DOI 10.2214/ajr.172.5.10227495; AXELROD J, 1984, SCIENCE, V224, P452, DOI 10.1126/science.6143403; Azziz R, 2004, J CLIN ENDOCR METAB, V89, P453, DOI 10.1210/jc.2003-031122; AZZIZ R, 1994, J CLIN ENDOCR METAB, V78, P810, DOI 10.1210/jc.78.4.810; Azziz R, 1999, FERTIL STERIL, V72, P915, DOI 10.1016/S0015-0282(99)00383-0; BALDUCCI R, 1994, J CLIN ENDOCR METAB, V79, P582, DOI 10.1210/jc.79.2.582; BARNES RB, 1994, J CLIN ENDOCR METAB, V79, P1328, DOI 10.1210/jcem.79.5.7962325; Baumgartner-Parzer SM, 2002, CLIN ENDOCRINOL, V56, P811, DOI 10.1046/j.1365-2265.2002.01299.x; Beaujean D, 2003, EXP NEUROL, V184, P348, DOI 10.1016/j.expneurol.2003.07.007; Berenbaum S, 2002, HORM RES, V58, P188; Berenbaum S, 2002, J CLIN ENDOCR METAB, V87, P4048, DOI 10.1210/jc.2002-020611; BERENBAUM SA, 1995, DEV PSYCHOL, V31, P31, DOI 10.1037/0012-1649.31.1.31; Berenbaum SA, 1999, HORM BEHAV, V35, P102, DOI 10.1006/hbeh.1998.1503; Berenbaum SA, 1997, PSYCHONEUROENDOCRINO, V22, P505, DOI 10.1016/S0306-4530(97)00049-8; Berenbaum SA, 2004, J PEDIATR-US, V144, P741, DOI 10.1016/j.jpeds.2004.03.037; Berenbaum SA, 2003, J CLIN ENDOCR METAB, V88, P1102, DOI 10.1210/jc.2002-020782; Berenbaum SA, 2001, ENDOCRIN METAB CLIN, V30, P173, DOI 10.1016/S0889-8529(08)70025-2; BIRNBAUM MD, 1984, OBSTET GYNECOL, V63, P445; BLUM RW, 1995, J ADOLESCENT HEALTH, V17, P3, DOI 10.1016/1054-139X(95)00073-2; Blum RW, 2002, PEDIATRICS, V110, P1304; Bornstein SR, 1999, FASEB J, V13, P1185, DOI 10.1096/fasebj.13.10.1185; Bornstein SR, 1998, ENDOCRINOLOGY, V139, P1546, DOI 10.1210/en.139.4.1546; BROOK CGD, 1974, J PEDIATR-US, V85, P12, DOI 10.1016/S0022-3476(74)80277-5; Brown JW, 1998, STEROIDS, V63, P587, DOI 10.1016/S0039-128X(98)00068-3; Cabrera MS, 2001, J CLIN ENDOCR METAB, V86, P3070, DOI 10.1210/jc.86.7.3070; Charmandari E, 2004, J CLIN ENDOCR METAB, V89, P2228, DOI 10.1210/jc.2003-031322; Charmandari E, 2002, J CLIN ENDOCR METAB, V87, P3031, DOI 10.1210/jc.87.7.3031; Charmandari E, 2002, J CLIN ENDOCR METAB, V87, P2114, DOI 10.1210/jc.87.5.2114; Charmandari E, 2002, J CLIN ENDOCR METAB, V87, P3197, DOI 10.1210/jc.87.7.3197; Christiansen P, 2004, HORM RES, V61, P133, DOI 10.1159/000075588; CHROUSOS GP, 1982, HORM RES, V16, P193, DOI 10.1159/000179502; Cornean RE, 1998, ARCH DIS CHILD, V78, P261, DOI 10.1136/adc.78.3.261; Crouch NS, 2004, J PEDIATR ENDOCR MET, V17, P1591; CUTLER GB, 1990, NEW ENGL J MED, V323, P1806; Dacou-Voutetakis C, 1999, J CLIN ENDOCR METAB, V84, P1570, DOI 10.1210/jc.84.5.1570; DAVID M, 1994, ARCH PEDIATRIE, V1, P363; Deneux C, 2001, J CLIN ENDOCR METAB, V86, P207, DOI 10.1210/jc.86.1.207; DIMARTINONARDI J, 1986, ACTA ENDOCRINOL-COP, V113, P305; DITTMANN RW, 1990, PSYCHONEUROENDOCRINO, V15, P401, DOI 10.1016/0306-4530(90)90065-H; DONALDSON MDC, 1994, ARCH DIS CHILD, V70, P214, DOI 10.1136/adc.70.3.214; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; Eugster EA, 2001, J PEDIATR-US, V138, P26, DOI 10.1067/mpd.2001.110527; EVINGER MJ, 1992, CELL MOL NEUROBIOL, V12, P193, DOI 10.1007/BF00712926; FALLS JL, 1955, CANCER-AM CANCER SOC, V8, P143, DOI 10.1002/1097-0142(1955)8:1<143::AID-CNCR2820080120>3.0.CO;2-P; FEDERMAN DD, 1987, NEW ENGL J MED, V316, P209, DOI 10.1056/NEJM198701223160408; FELDMAN S, 1992, J CLIN ENDOCR METAB, V74, P635, DOI 10.1210/jc.74.3.635; Fitness J, 1999, J CLIN ENDOCR METAB, V84, P960, DOI 10.1210/jc.84.3.960; Forest MG, 1998, TRENDS ENDOCRIN MET, V9, P284, DOI 10.1016/S1043-2760(98)00067-8; Golden SH, 2004, AM J EPIDEMIOL, V160, P540, DOI 10.1093/aje/kwh250; GOTOH H, 1988, ENDOCRINOLOGY, V123, P1923, DOI 10.1210/endo-123-4-1923; Grumbach MM, 1998, PEDIATRICS, V102, P215; GRUMBACH MM, 1952, PEDIATRICS, V10, P397; Gruneiro-Papendieck L, 2001, HORM RES, V55, P271, DOI 10.1159/000050012; Hagenfeldt K, 2000, EUR J ENDOCRINOL, V143, P667, DOI 10.1530/eje.0.1430667; Hampson E, 1998, DEV NEUROPSYCHOL, V14, P299, DOI 10.1080/87565649809540713; HELLEDAY J, 1994, PSYCHONEUROENDOCRINO, V19, P343, DOI 10.1016/0306-4530(94)90015-9; HINDE FRJ, 1984, BRIT MED J, V289, P1603, DOI 10.1136/bmj.289.6458.1603; Hines M, 2004, J SEX RES, V41, P75, DOI 10.1080/00224490409552215; Hughes IA, 2004, GROWTH HORM IGF RES, V14, pS60, DOI 10.1016/j.ghir.2004.03.015; Huppert Jill, 2004, J Pediatr Adolesc Gynecol, V17, P103, DOI 10.1016/j.jpag.2004.01.005; Jaaskelainen J, 2000, ACTA OBSTET GYN SCAN, V79, P687, DOI 10.1034/j.1600-0412.2000.079008687.x; Jaaskelainen J, 1997, PEDIATR RES, V41, P30; Jaaskelainen J, 2000, ACTA PAEDIATR, V89, P183, DOI 10.1080/080352500750028807; Jaaskelainen J, 1997, J CLIN ENDOCR METAB, V82, P3293, DOI 10.1210/jc.82.10.3293; JARESCH S, 1992, J CLIN ENDOCR METAB, V74, P685, DOI 10.1210/jcem.74.3.1311000; Kalachanis I, 2002, ARCH ANDROLOGY, V48, P37, DOI 10.1080/014850102753385198; KAWAGUCHI H, 1992, AM J HUM GENET, V50, P766; KERRIGAN JR, 1993, J CLIN ENDOCR METAB, V76, P1505, DOI 10.1210/jc.76.6.1505; KIRKLAND RT, 1978, J CLIN ENDOCR METAB, V47, P1320, DOI 10.1210/jcem-47-6-1320; KLINGENSMITH GJ, 1977, J PEDIATR-US, V90, P996, DOI 10.1016/S0022-3476(77)80581-7; Knochenhauer ES, 1997, J CLIN ENDOCR METAB, V82, P479, DOI 10.1210/jc.82.2.479; Krone N, 2000, J CLIN ENDOCR METAB, V85, P1059, DOI 10.1210/jc.85.3.1059; Krone N, 2001, CLIN ENDOCRINOL, V55, P523, DOI 10.1046/j.1365-2265.2001.01359.x; Kruse B, 2004, EXP CLIN ENDOCR DIAB, V112, P343, DOI 10.1055/s-2004-821013; la Marca A, 1999, FERTIL STERIL, V72, P985, DOI 10.1016/S0015-0282(99)00407-0; LEBOVITZ RM, 1984, AM J DIS CHILD, V138, P571, DOI 10.1001/archpedi.1984.02140440055014; Leveroni CL, 1998, DEV NEUROPSYCHOL, V14, P321, DOI 10.1080/87565649809540714; LEVINE LS, 1981, J CLIN ENDOCR METAB, V53, P1193, DOI 10.1210/jcem-53-6-1193; LEVINE LS, 1978, NEW ENGL J MED, V299, P911, DOI 10.1056/NEJM197810262991702; LINDER BL, 1990, J PEDIATR-US, V117, P892, DOI 10.1016/S0022-3476(05)80128-3; Lo JC, 1999, J CLIN ENDOCR METAB, V84, P930, DOI 10.1210/jc.84.3.930; Lo JC, 2001, ENDOCRIN METAB CLIN, V30, P207, DOI 10.1016/S0889-8529(08)70027-6; MACKINNON J, 1977, ARCH DIS CHILD, V52, P591, DOI 10.1136/adc.52.7.591; Manoli I, 2002, CLIN ENDOCRINOL, V57, P669, DOI 10.1046/j.1365-2265.2002.01645.x; MARGOLIS G, 1974, AM J PATHOL, V75, P363; Merke DP, 2000, NEW ENGL J MED, V343, P1362, DOI 10.1056/NEJM200011093431903; Merke DP, 2003, J CLIN ENDOCR METAB, V88, P1760, DOI 10.1210/jc.2002-021730; Merke DP, 2000, J CLIN ENDOCR METAB, V85, P1114, DOI 10.1210/jc.85.3.1114; METZGER DL, 1993, J CLIN ENDOCR METAB, V77, P458, DOI 10.1210/jc.77.2.458; Meyer-Bahlburg HFL, 1999, J CLIN ENDOCR METAB, V84, P1844, DOI 10.1210/jc.84.6.1844; Meyer-Bahlburg HFL, 2004, ARCH SEX BEHAV, V33, P97, DOI 10.1023/B:ASEB.0000014324.25718.51; Moran C, 2003, SEMIN REPROD MED, V21, P295; Moran C, 2000, AM J OBSTET GYNECOL, V183, P1468, DOI 10.1067/mob.2000.108020; MULAIKAL RM, 1987, NEW ENGL J MED, V316, P178, DOI 10.1056/NEJM198701223160402; Murphy H, 2001, HUM REPROD, V16, P263, DOI 10.1093/humrep/16.2.263; Nass R, 1997, J CHILD NEUROL, V12, P181, DOI 10.1177/088307389701200306; New M I, 1988, Acta Paediatr Jpn, V30 Suppl, P79; NEW MI, 1993, ANN NY ACAD SCI, V687, P193; NEW MI, 1983, J CLIN ENDOCR METAB, V57, P320, DOI 10.1210/jcem-57-2-320; New MI, 2001, J CLIN ENDOCR METAB, V86, P5651, DOI 10.1210/jc.86.12.5651; Nordenstrom A, 1999, J CLIN ENDOCR METAB, V84, P1505, DOI 10.1210/jc.84.5.1505; PANG S, 1982, J CLIN ENDOCR METAB, V55, P413, DOI 10.1210/jcem-55-3-413; PANG S, 1988, PEDIATRICS, V81, P866; Pang S, 1993, SCREENING, V2, P105, DOI 10.1016/0925-6164(93)90024-D; PANG SY, 1992, J CLIN ENDOCR METAB, V75, P249, DOI 10.1210/jc.75.1.249; PESCOVITZ OH, 1984, J CLIN ENDOCR METAB, V58, P857, DOI 10.1210/jcem-58-5-857; PETER M, 1990, LANCET, V335, P1296, DOI 10.1016/0140-6736(90)91185-D; Pinto G, 2003, J CLIN ENDOCR METAB, V88, P2624, DOI 10.1210/jc.2002-021433; Premawardhana LDKE, 1997, CLIN ENDOCRINOL, V46, P327, DOI 10.1046/j.1365-2265.1997.1360962.x; Punthakee Z, 2003, J PEDIATR-US, V143, P402, DOI 10.1067/S0022-3476(03)00294-4; Quintos JBQ, 2001, J CLIN ENDOCR METAB, V86, P1511, DOI 10.1210/jc.86.4.1511; Raff H, 2004, TRENDS ENDOCRIN MET, V15, P351, DOI 10.1016/j.tem.2004.08.003; RASAT R, 1995, NEW ZEAL MED J, V108, P311; Reiner WG, 2004, NEW ENGL J MED, V350, P333, DOI 10.1056/NEJMoa022236; Reiner William G., 1999, Current Opinion in Pediatrics, V11, P363, DOI 10.1097/00008480-199908000-00016; Rivkees SA, 2000, PEDIATRICS, V106, P767, DOI 10.1542/peds.106.4.767; Russo G, 1998, NEW ENGL J MED, V339, P853, DOI 10.1056/NEJM199809173391220; Scaroni C, 2003, EXP CLIN ENDOCR DIAB, V111, P41, DOI 10.1055/s-2003-37499; Seckl JR, 1997, JAMA-J AM MED ASSOC, V277, P1077, DOI 10.1001/jama.277.13.1077; SINFORIANI E, 1994, PSYCHONEUROENDOCRINO, V19, P55, DOI 10.1016/0306-4530(94)90059-0; Soliman AT, 1997, METABOLISM, V46, P513, DOI 10.1016/S0026-0495(97)90186-4; SPEISER PW, 1985, AM J HUM GENET, V37, P650; SPEISER PW, 1992, J CLIN INVEST, V90, P584, DOI 10.1172/JCI115897; SPEISER PW, 1992, J CLIN ENDOCR METAB, V75, P1421, DOI 10.1210/jc.75.6.1421; STAUBER E, 1978, CAN J COMP MED, V42, P466; Stikkelbroeck NMML, 2003, OBSTET GYNECOL SURV, V58, P275; Stikkelbroeck NMML, 2003, J CLIN ENDOCR METAB, V88, P1036, DOI 10.1210/jc.2002-021074; Stikkelbroeck NMML, 2001, J CLIN ENDOCR METAB, V86, P5721, DOI 10.1210/jc.86.12.5721; Swerdlow AJ, 1998, J PEDIATR-US, V133, P516, DOI 10.1016/S0022-3476(98)70060-5; Tajima T, 1999, GENE THER, V6, P1898, DOI 10.1038/sj.gt.3301018; Tajima T, 1999, ENDOCRINOLOGY, V140, P3354, DOI 10.1210/en.140.7.3354; TAJIMA T, 1993, J CLIN ENDOCR METAB, V77, P86, DOI 10.1210/jc.77.1.86; Therrell BL, 1998, PEDIATRICS, V101, P583, DOI 10.1542/peds.101.4.583; Therrell BL, 2001, ENDOCRIN METAB CLIN, V30, P15, DOI 10.1016/S0889-8529(08)70017-3; TUSIELUNA MT, 1995, P NATL ACAD SCI USA, V92, P10796, DOI 10.1073/pnas.92.23.10796; URBAN MD, 1978, NEW ENGL J MED, V299, P1392, DOI 10.1056/NEJM197812212992505; Van Wyk JJ, 2003, J CLIN ENDOCR METAB, V88, P2993, DOI 10.1210/jc.2002-022026; Walker BR, 1997, J UROLOGY, V157, P1460, DOI 10.1016/S0022-5347(01)65023-7; Watson AR, 2000, PEDIATR NEPHROL, V14, P469, DOI 10.1007/s004670050794; Webster EL, 1996, ENDOCRINOLOGY, V137, P5747, DOI 10.1210/en.137.12.5747; Weintrob N, 1997, EUR J ENDOCRINOL, V136, P188, DOI 10.1530/eje.0.1360188; Weise M, 2004, J CLIN ENDOCR METAB, V89, P3679, DOI 10.1210/jc.2003-032051; Weise M, 2004, J CLIN ENDOCR METAB, V89, P591, DOI 10.1210/jc.2003-030634; WENZEL U, 1978, HELV PAEDIATR ACTA, V33, P11; WHITE PC, 1994, HUM MUTAT, V3, P373, DOI 10.1002/humu.1380030408; WILLI U, 1991, PEDIATR RADIOL, V21, P284, DOI 10.1007/BF02018626; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P2322, DOI 10.1210/jc.80.8.2322; WURTMAN RJ, 1972, PHARMACOL REV, V24, P411; YOUNG MC, 1991, ACTA PAEDIATR SCAND, V80, P120, DOI 10.1111/j.1651-2227.1991.tb11744.x; YOUNG MC, 1990, ARCH DIS CHILD, V65, P441, DOI 10.1136/adc.65.4.441	154	444	488	1	56	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2125	2136		10.1016/S0140-6736(05)66736-0	http://dx.doi.org/10.1016/S0140-6736(05)66736-0			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964450				2022-12-28	WOS:000229858800030
J	Kalo, P; Gleason, C; Edwards, A; Marsh, J; Mitra, RM; Hirsch, S; Jakab, J; Sims, S; Long, SR; Rogers, J; Kiss, GB; Downie, JA; Oldroyd, GED				Kalo, P; Gleason, C; Edwards, A; Marsh, J; Mitra, RM; Hirsch, S; Jakab, J; Sims, S; Long, SR; Rogers, J; Kiss, GB; Downie, JA; Oldroyd, GED			Nodulation signaling in legumes requires NSP2, a member of the GRAS family of transcriptional regulators	SCIENCE			English	Article							MEDICAGO-TRUNCATULA; CALCIUM SPIKING; NOD FACTORS; MUTANTS; IDENTIFICATION; TRANSDUCTION; SYMBIOSIS; GENE	Rhizobial bacteria enter a symbiotic interaction with legumes, activating diverse responses in roots through the lipochito oligosaccharide signaling molecule Nod factor. Here, we show that NSP2 from Medicago truncatula encodes a GRAS protein essential for Nod-factor signaling. NSP2 functions downstream of Nod-factor-induced calcium spiking and a calcium/calmodulin-dependent protein kinase. We show that NSP2-GFP expressed from a constitutive promoter is localized to the endoplasmic reticulum/nuclear envelope and relocalizes to the nucleus after Nod-factor elicitation. This work provides evidence that a GRAS protein transduces calcium signals in plants and provides a possible regulator of Nod-factor-inducible gene expression.	John Innes Ctr, Dept Dis & Stress Biol, Norwich NR4 7UH, Norfolk, England; John Innes Ctr, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; Agr Biotechnol Ctr, Inst Genet, H-2100 Godollo, Hungary; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Wellcome Trust Sanger Institute; Stanford University	Oldroyd, GED (corresponding author), John Innes Ctr, Dept Dis & Stress Biol, Norwich NR4 7UH, Norfolk, England.	giles.oldroyd@bbsrc.ac.uk	Oldroyd, Giles/ABD-8143-2021; Oldroyd, Giles/ABA-7501-2020; Downie, Allan/I-3487-2012; Kalo, Peter/A-3919-2012; Mitra, Raka/GQA-9960-2022	Oldroyd, Giles/0000-0002-5245-6355; Kalo, Peter/0000-0002-0404-8904; Downie, Allan/0000-0003-1011-4960; Gleason, Cynthia/0000-0001-8365-9131; Mitra, Raka/0000-0002-2798-2038				Ben Amor B, 2003, PLANT J, V34, P495, DOI 10.1046/j.1365-313X.2003.01743.x; Bolle C, 2004, PLANTA, V218, P683, DOI 10.1007/s00425-004-1203-z; Catoira R, 2000, PLANT CELL, V12, P1647, DOI 10.1105/tpc.12.9.1647; Ehrhardt DW, 1996, CELL, V85, P673, DOI 10.1016/S0092-8674(00)81234-9; Kalo P, 2004, MOL GENET GENOMICS, V272, P235, DOI 10.1007/s00438-004-1055-z; Levy J, 2004, SCIENCE, V303, P1361, DOI 10.1126/science.1093038; Long SR, 1996, PLANT CELL, V8, P1885, DOI 10.1105/tpc.8.10.1885; Mitra RM, 2004, P NATL ACAD SCI USA, V101, P10217, DOI 10.1073/pnas.0402186101; Mitra RM, 2004, P NATL ACAD SCI USA, V101, P4701, DOI 10.1073/pnas.0400595101; Oldroyd GED, 2004, NAT REV MOL CELL BIO, V5, P566, DOI 10.1038/nrm1424; Oldroyd GED, 2003, PLANT PHYSIOL, V131, P1027, DOI 10.1104/pp.102.010710; Smit P, 2005, SCIENCE, V308, P1789, DOI 10.1126/science.1111025; Wais RJ, 2000, P NATL ACAD SCI USA, V97, P13407, DOI 10.1073/pnas.230439797; Walker SA, 2000, P NATL ACAD SCI USA, V97, P13413, DOI 10.1073/pnas.230440097	14	400	429	2	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1786	1789		10.1126/science.1110951	http://dx.doi.org/10.1126/science.1110951			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961668				2022-12-28	WOS:000229926800054
J	Kowalewski, M; Hoffmeister, AP; Baumiller, TK; Bambach, RK				Kowalewski, M; Hoffmeister, AP; Baumiller, TK; Bambach, RK			Secondary evolutionary escalation between brachiopods and enemies of other prey	SCIENCE			English	Article							MESOZOIC MARINE REVOLUTION; DRILLING PREDATION; FOSSIL RECORD; COMPETITION; BEHAVIOR; MUSSELS; SNAILS	The fossil record of predation indicates that attacks on Paleozoic brachiopods were very rare, especially compared to those on post-Pateozoic mollusks, yet stratigraphically and geographically widespread. Drilling frequencies were very tow in the early Paleozoic (<<1%) and went up slightly in the mid-to-late Paleozoic. Present-day brachiopods revealed frequencies only slightly higher. The persistent rarity of drilling suggests that brachiopods were the secondary casualties of mistaken or opportunistic attacks by the enemies of other taxa. Such sporadic attacks became slightly more frequent as trophic systems escalated and predators diversified. Some evolutionarily persistent biotic interactions may be incidental rather than coevolutionary or escalatory in nature.	Virginia Polytech Inst & State Univ, Dept Geosci, Blacksburg, VA 24061 USA; Univ Michigan, Museum Paleontol, Ann Arbor, MI 48109 USA; Harvard Univ, Bot Museum, Cambridge, MA 02138 USA	Virginia Polytechnic Institute & State University; University of Michigan System; University of Michigan; Harvard University	Kowalewski, M (corresponding author), Virginia Polytech Inst & State Univ, Dept Geosci, Blacksburg, VA 24061 USA.	michalk@vt.edu	Kowalewski, Michal/B-4263-2008; Baumiller, Tomasz K/C-3596-2012	Kowalewski, Michal/0000-0002-8575-4711; Baumiller, Tomasz K/0000-0002-4506-9330				AUSICH WI, 1979, J PALEONTOL, V53, P335; Bambach RK, 1999, GEOBIOS-LYON, V32, P131, DOI 10.1016/S0016-6995(99)80025-4; Baumiller TK, 1999, PALAEOGEOGR PALAEOCL, V147, P283, DOI 10.1016/S0031-0182(98)00165-5; Baumiller TK, 2004, PALAEOGEOGR PALAEOCL, V214, P85, DOI 10.1016/j.palaeo.2004.07.023; Baumiller TK, 2004, SCIENCE, V305, P1453, DOI 10.1126/science.1101009; Brett Carlton E., 2002, Paleontological Society Papers, V8, P93; Brett CE, 2003, T GEOBIOL, V20, P401; CADEE GC, 1984, LETHAIA, V17, P289, DOI 10.1111/j.1502-3931.1984.tb00674.x; Delance JH, 2004, PALAEOGEOGR PALAEOCL, V208, P23, DOI 10.1016/j.palaeo.2004.02.025; Dietl GP, 2004, SCIENCE, V306, P2229, DOI 10.1126/science.1106182; Harper EM, 2003, PALAEOGEOGR PALAEOCL, V210, P185, DOI 10.1016/S0031-0182(03)00624-2; Harper EM, 1998, PALAIOS, V13, P352, DOI 10.2307/3515323; Harper EM, 2000, PALAEOGEOGR PALAEOCL, V158, P15, DOI 10.1016/S0031-0182(99)00164-9; Harper EM, 2003, POLAR BIOL, V26, P208, DOI 10.1007/s00300-002-0455; Hoffmeister AP, 2004, ACTA PALAEONTOL POL, V49, P443; Hoffmeister AP, 2003, LETHAIA, V36, P107, DOI 10.1080/00241160310000408; HUGHES RN, 1984, J EXP MAR BIOL ECOL, V77, P45, DOI 10.1016/0022-0981(84)90050-9; KELLEY PH, 1993, PALAIOS, V8, P358, DOI 10.2307/3515266; Kelley PH, 1996, GEOL SOC SP, P373, DOI 10.1144/GSL.SP.1996.001.01.27; Kowalewski M, 1998, GEOLOGY, V26, P1091, DOI 10.1130/0091-7613(1998)026<1091:AFRFOH>2.3.CO;2; LABARBERA M, 1981, PALEOBIOLOGY, V7, P510, DOI 10.1017/S0094837300025550; Leighton LR, 2003, PALAEOGEOGR PALAEOCL, V210, P221, DOI 10.1016/S0031-0182(03)00627-8; Nebelsick JH, 1999, PALAIOS, V14, P127, DOI 10.2307/3515369; Rilov G, 2002, MAR ENVIRON RES, V54, P85, DOI 10.1016/S0141-1136(02)00096-X; SIGNOR PW, 1984, PALEOBIOLOGY, V10, P229, DOI 10.1017/S0094837300008174; SMITH SA, 1985, SCIENCE, V230, P1033, DOI 10.1126/science.230.4729.1033; Steer MA, 2003, J EXP MAR BIOL ECOL, V290, P165, DOI 10.1016/S0022-0981(03)00076-5; THAYER CW, 1985, SCIENCE, V228, P1527, DOI 10.1126/science.228.4707.1527; Van Valen L., 1973, EVOL THEORY REV, V1, P1, DOI DOI 10.1038/344864A0; VERMEIJ G J, 1977, Paleobiology, V3, P245; Vermeij G.J., 1987, EVOLUTION ESCALATION; VERMEIJ GJ, 1981, SCIENCE, V214, P1024, DOI 10.1126/science.214.4524.1024; WALKER SE, 1993, PALAEONTOLOGY, V36, P735; WAREN A, 1994, VELIGER, V37, P141	34	70	72	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1774	1777		10.1126/science.1113408	http://dx.doi.org/10.1126/science.1113408			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961667				2022-12-28	WOS:000229926800051
J	Somesh, BP; Reid, J; Liu, WF; Sogaard, TMM; Erdjument-Bromage, H; Tempst, P; Svejstrup, JQ				Somesh, BP; Reid, J; Liu, WF; Sogaard, TMM; Erdjument-Bromage, H; Tempst, P; Svejstrup, JQ			Multiple mechanisms confining RNA polymerase II ubiquitylation to polymerases undergoing transcriptional arrest	CELL			English	Article							TERMINAL REPEAT DOMAIN; LARGE SUBUNIT; STRUCTURAL BASIS; DNA-REPAIR; PROTEIN; UBIQUITIN; ELONGATION; COMPLEX; KINASE; GENE	In order to study mechanisms and regulation of RNA polymerase II (RNAPII) ubiquitylation and degradation, highly purified factors were used to reconstitute RNAPII ubiquitylation in vitro. We show that arrested RNAPII elongation complexes are the preferred substrates for ubiquitylation. Accordingly, not only DNA-damage-dependent but also DNA-damage-independent transcriptional arrest results in RNAPII ubiquitylation in vivo. Def1, known to be required for damage-induced degradation of RNAPII, stimulates ubiquitylation of RNAPII only in an elongation complex. Ubiquitylation of RNAPII is dependent on its C-terminal repeat domain (CTD). Moreover, CTD phosphorylation at serine 5, a hallmark of the initiating polymerase, but not at serine 2, a hallmark of the elongating polymerase, completely inhibits ubiqultylation. In agreement with this, ubiquitylated RNAPII is hypophosphorylated at serine 5 in vivo, and mutation of the serine 5 phosphatase SSU72 inhibits RNAPII degradation. These results identify several mechanisms that confine ubiquitylation of RNAPII to the forms of the enzyme that arrest during elongation.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Cancer Research UK; Memorial Sloan Kettering Cancer Center	Svejstrup, JQ (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, Blanche Lane, S Mimms EN6 3LD, Herts, England.	j.svejstrup@cancer.org.uk		Svejstrup, Jesper/0000-0003-4964-6147; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Sogaard, Teit Max Moscote/0000-0001-6224-4818; Tempst, Paul/0000-0002-6680-3987				Arndt KM, 2003, TRENDS GENET, V19, P543, DOI 10.1016/j.tig.2003.08.008; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Jones JC, 2004, J BIOL CHEM, V279, P24957, DOI 10.1074/jbc.M402218200; Kireeva ML, 2000, J BIOL CHEM, V275, P6530, DOI 10.1074/jbc.275.9.6530; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Krishnamurthy S, 2004, MOL CELL, V14, P387, DOI 10.1016/S1097-2765(04)00235-7; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; Luo ZH, 2001, MUTAT RES-DNA REPAIR, V486, P259, DOI 10.1016/S0921-8777(01)00097-0; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Reid J, 2004, J BIOL CHEM, V279, P29875, DOI 10.1074/jbc.C400185200; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHERMAN F, 1991, P3; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Svejstrup JQ, 2004, BBA-GENE STRUCT EXPR, V1677, P64, DOI 10.1016/j.bbaexp.2003.10.012; Svejstrup JQ, 2003, J CELL SCI, V116, P447, DOI 10.1242/jcs.00271; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Woudstra EC, 2002, NATURE, V415, P929, DOI 10.1038/415929a	43	177	185	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	2005	121	6					913	923		10.1016/j.cell.2005.04.010	http://dx.doi.org/10.1016/j.cell.2005.04.010			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960978	Bronze			2022-12-28	WOS:000230011200013
J	Barthelmes, L; Davidson, LA; Gaffney, C; Gateley, CA				Barthelmes, L; Davidson, LA; Gaffney, C; Gateley, CA			Pregnancy and breast cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PREMENOPAUSAL WOMEN; YOUNG-WOMEN; TAMOXIFEN; CYCLOPHOSPHAMIDE; SURVIVAL; PROGNOSIS; CHEMOTHERAPY; RADIOTHERAPY; POPULATION; CARCINOMA	Breast cancer is rare in young women, with an increase in incidence in the fourth and fifth decades. A trend is to defer childbearing to later in life. ne issues of pregnancy and breast cancer are of importance as some women discover their breast cancer while pregnant and some may not have completed their family at the time of treatment. We discuss the case of a woman whose breast cancer was diagnosed during pregnancy. We review the choices she was faced with at the time of diagnosis and after treatment.	Royal Gwent Hosp, Dept Surg, Breast Unit, Newport NP20 2UB, Gwent, Wales; Velindre Hosp, Cardiff CF14 2TL, Wales	Royal Gwent Hospital; Velindre Hospital	Barthelmes, L (corresponding author), Royal Gwent Hosp, Dept Surg, Breast Unit, Newport NP20 2UB, Gwent, Wales.	barthelmes@tinyonline.co.uk						ABE O, 1995, NEW ENGL J MED, V333, P1444; Anderson BO, 1996, ANN SURG ONCOL, V3, P204, DOI 10.1007/BF02305802; Andreadis C, 2004, GYNECOL ONCOL, V95, P252, DOI 10.1016/j.ygyno.2004.06.037; [Anonymous], 1992, Lancet, V339, P1; Barthelmes L, 2004, BREAST, V13, P446, DOI 10.1016/j.breast.2004.08.007; Bladstrom Anna, 2003, Clin Breast Cancer, V4, P280, DOI 10.3816/CBC.2003.n.033; Blakely LJ, 2004, CANCER-AM CANCER SOC, V100, P465, DOI 10.1002/cncr.11929; BLATT J, 1980, AM J MED, V69, P828, DOI 10.1016/S0002-9343(80)80007-6; Bonnier P, 1997, INT J CANCER, V72, P720, DOI 10.1002/(SICI)1097-0215(19970904)72:5<720::AID-IJC3>3.0.CO;2-U; Boostanfar R, 2001, FERTIL STERIL, V75, P1024, DOI 10.1016/S0015-0282(01)01749-6; Buzdar A U, 1982, Breast Cancer Res Treat, V2, P163, DOI 10.1007/BF01806452; Clark R M, 1989, Clin Oncol (R Coll Radiol), V1, P11, DOI 10.1016/S0936-6555(89)80004-4; CLARK S, 1993, LANCET, V342, P168, DOI 10.1016/0140-6736(93)91361-O; Clarke M, 1998, LANCET, V351, P1451; CULLINS SL, 1994, JAMA-J AM MED ASSOC, V271, P1905, DOI 10.1001/jama.1994.03510480029019; CUNHA GR, 1987, HUM PATHOL, V18, P1132, DOI 10.1016/S0046-8177(87)80381-7; Daling JR, 2002, CANCER EPIDEM BIOMAR, V11, P235; DEEMARSKY LJ, 1981, BREAST, V7, P17; DONEGAN WL, 1995, CANC BREAST, P732; DOW KH, 1994, J NATL CANC I MONOGR, V16, P131; Enns GM, 1999, AM J MED GENET, V86, P237, DOI 10.1002/(SICI)1096-8628(19990917)86:3<237::AID-AJMG8>3.0.CO;2-V; Ezzat A, 1996, Clin Oncol (R Coll Radiol), V8, P367, DOI 10.1016/S0936-6555(96)80081-1; Gelber S, 2001, J CLIN ONCOL, V19, P1671, DOI 10.1200/JCO.2001.19.6.1671; GREENBERG LH, 1964, JAMA-J AM MED ASSOC, V188, P423; GUINEE VF, 1994, LANCET, V343, P1587; He CH, 2002, CONTRACEPTION, V66, P221, DOI 10.1016/S0010-7824(02)00359-1; Ibrahim EM, 2000, MED ONCOL, V17, P293, DOI 10.1007/BF02782194; Isaacs RJ, 2001, GYNECOL ONCOL, V80, P405, DOI 10.1006/gyno.2000.6080; ISHIDA T, 1992, JPN J CANCER RES, V83, P1143, DOI 10.1111/j.1349-7006.1992.tb02737.x; KING RM, 1985, SURG GYNECOL OBSTET, V160, P228; KIRSHON B, 1988, OBSTET GYNECOL, V72, P462; KOIZUMI K, 1986, FERTIL STERIL, V46, P312; Kroman N, 1997, LANCET, V350, P319, DOI 10.1016/S0140-6736(97)03052-3; Kroman N, 1997, BRIT MED J, V315, P851, DOI 10.1136/bmj.315.7112.851; Lethaby AE, 1996, INT J CANCER, V67, P751, DOI 10.1002/(SICI)1097-0215(19960917)67:6<751::AID-IJC1>3.0.CO;2-Q; Malamos NA, 1996, ONCOLOGY, V53, P471; Merkel DE, 1996, SEMIN SURG ONCOL, V12, P370, DOI 10.1002/(SICI)1098-2388(199609/10)12:5<370::AID-SSU13>3.0.CO;2-T; MURRAY CL, 1984, JAMA-J AM MED ASSOC, V252, P2607, DOI 10.1001/jama.252.18.2607; MURRAY EU, 1997, S AFR MED J, V88, P155; Nettleton J, 1996, OBSTET GYNECOL, V87, P414, DOI 10.1016/0029-7844(95)00470-X; NUGENT P, 1985, ARCH SURG-CHICAGO, V120, P1221; Oksuzoglu B, 2002, EUR J OBSTET GYN R B, V104, P79, DOI 10.1016/S0301-2115(01)00552-8; Olson SH, 1998, EPIDEMIOLOGY, V9, P669, DOI 10.1097/00001648-199811000-00019; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Paladini D, 2004, BIRTH DEFECTS RES A, V70, P99, DOI 10.1002/bdra.10147; PETREK JA, 1991, CANCER-AM CANCER SOC, V67, P869, DOI 10.1002/1097-0142(19910215)67:4<869::AID-CNCR2820670402>3.0.CO;2-Q; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402; Reed W, 2003, VIRCHOWS ARCH, V443, P44, DOI 10.1007/s00428-003-0817-z; SANKILA R, 1994, AM J OBSTET GYNECOL, V170, P818, DOI 10.1016/S0002-9378(94)70290-X; SAUNDERS CM, 2001, BREAST CANC NEW HORI, P316; Tewari K, 1997, LANCET, V350, P183, DOI 10.1016/S0140-6736(97)24029-8; TOLEDO TM, 1971, ANN INTERN MED, V74, P87, DOI 10.7326/0003-4819-74-1-87; Vaux KK, 2003, BIRTH DEFECTS RES A, V67, P403, DOI 10.1002/bdra.10060; Velentgas P, 1999, CANCER, V85, P2424, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2424::AID-CNCR17>3.0.CO;2-4; VONSCHOULTZ E, 1995, J CLIN ONCOL, V13, P430, DOI 10.1200/JCO.1995.13.2.430; WILLEMSE PHB, 1990, GYNECOL ONCOL, V36, P281, DOI 10.1016/0090-8258(90)90188-Q; ZEMLICKIS D, 1992, AM J OBSTET GYNECOL, V166, P781, DOI 10.1016/0002-9378(92)91334-7; ZEMLICKIS D, 1993, TERATOGEN CARCIN MUT, V13, P139, DOI 10.1002/tcm.1770130304	58	24	26	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 11	2005	330	7504					1375	1378D		10.1136/bmj.330.7504.1375	http://dx.doi.org/10.1136/bmj.330.7504.1375			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936FE	15947401	Green Published			2022-12-28	WOS:000229840100030
J	Blanford, S; Chan, BHK; Jenkins, N; Sim, D; Turner, RJ; Read, AF; Thomas, MB				Blanford, S; Chan, BHK; Jenkins, N; Sim, D; Turner, RJ; Read, AF; Thomas, MB			Fungal pathogen reduces potential for malaria transmission	SCIENCE			English	Article							METARHIZIUM-FLAVOVIRIDE; ENTOMOPATHOGENIC FUNGUS; BIOLOGICAL-CONTROL; MYCOINSECTICIDE; INSECTICIDES; LOCUSTS	Using a rodent malaria model, we found that exposure to surfaces treated with fungal entornopathogens following an infectious blood meal reduced the number of mosquitoes able to transmit malaria by a factor of about 80. Fungal infection, achieved through contact with both solid surfaces and netting for durations well within the typical post-feed resting periods, was sufficient to cause >90% mortality. Daily mortality rates escalated dramatically around the time of sporozoite maturation, and infected mosquitoes showed reduced propensity to blood feed. Residual sprays of fungal biopesticides might replace or supplement chemical insecticides for malaria control, particularly in areas of high insecticide resistance.	Univ London Imperial Coll Sci Technol & Med, Div Biol, Wye TN25 5AH, Kent, England; Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Wye TN25 5AH, Kent, England; Univ Edinburgh, Inst Evolut, Sch Biol Sci, Ashworth Labs, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Edinburgh, Inst Immunol, Sch Biol Sci, Ashworth Labs, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Edinburgh, Inst Infect Res, Sch Biol Sci, Ashworth Labs, Edinburgh EH9 3JT, Midlothian, Scotland; Univ London Imperial Coll Sci Technol & Med, CABI Biosci, Dept Agr Sci, Wye TN25 5AH, Kent, England	Imperial College London; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Edinburgh; University of Edinburgh; University of Edinburgh; Imperial College London	Thomas, MB (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Biol, Wye Campus, Wye TN25 5AH, Kent, England.	m.thomas@imperial.ac.uk		Chan, Brian/0000-0002-9451-4621	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATEMAN RP, 1993, ANN APPL BIOL, V122, P145, DOI 10.1111/j.1744-7348.1993.tb04022.x; Brooke BD, 2001, B ENTOMOL RES, V91, P265, DOI 10.1079/BER2001108; Carucci D, 2004, NATURE, V430, P944, DOI 10.1038/430944a; Charlwood JD, 1997, AFR ENTOMOL, V5, P93; GELFAND H. M., 1955, TRANS ROY SOC TROP MED AND HYG, V49, P508, DOI 10.1016/0035-9203(55)90023-7; GILLIES MT, 1954, B ENTOMOL RES, V45, P375, DOI 10.1017/S000748530002719X; Greenwood B, 2004, NATURE, V430, P926, DOI 10.1038/430926a; Hargreaves K, 2000, MED VET ENTOMOL, V14, P181, DOI 10.1046/j.1365-2915.2000.00234.x; Hemingway J, 2004, NATURE, V430, P936, DOI 10.1038/430936a; Hemingway J, 2004, SCIENCE, V303, P1984, DOI 10.1126/science.1096548; LACEY LA, 1986, ANNU REV ENTOMOL, V31, P265, DOI 10.1146/annurev.en.31.010186.001405; Lomer CJ, 2001, ANNU REV ENTOMOL, V46, P667, DOI 10.1146/annurev.ento.46.1.667; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; Osta MA, 2004, SCIENCE, V303, P2030, DOI 10.1126/science.1091789; Rishikesh N., 1988, P1227; Scholte EJ, 2004, J INSECT SCI, V4, DOI 10.1093/jis/4.1.19; Scholte EJ, 2005, SCIENCE, V308, P1641, DOI 10.1126/science.1108639; Scholte EJ, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-29; SCHOLTE EJ, IN PRESS J INVERTEBR; Scholte Ernst-Jan, 2003, Proceedings of the Section Experimental and Applied Entomology of the Netherlands Entomological Society (N.E.V.), V14, P25; StLeger RJ, 1996, P NATL ACAD SCI USA, V93, P6349, DOI 10.1073/pnas.93.13.6349; Thomas MB, 1998, ENTOMOL EXP APPL, V87, P93, DOI 10.1023/A:1003298103716; Thomas MB, 1997, PESTIC SCI, V49, P47, DOI 10.1002/(SICI)1096-9063(199701)49:1&lt;47::AID-PS471&gt;3.0.CO;2-O; THOMAS MB, 2004, BIOCONTROL NEWS INFO, V25, pN47; Zaim M, 2002, TRENDS PARASITOL, V18, P161, DOI 10.1016/S1471-4922(01)02220-6	25	247	262	6	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1638	1641		10.1126/science.1108423	http://dx.doi.org/10.1126/science.1108423			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947189				2022-12-28	WOS:000229827000060
J	Todorov, A; Mandisodza, AN; Goren, A; Hall, CC				Todorov, A; Mandisodza, AN; Goren, A; Hall, CC			Inferences of competence from faces predict election outcomes	SCIENCE			English	Article							PERSON PERCEPTION; BEHAVIOR	We show that inferences of competence based solely on facial appearance predicted the outcomes of U.S. congressional elections better than chance (e.g., 68.8% of the Senate races in 2004) and also were linearly related to the margin of victory. These inferences were specific to competence and occurred within a 1-second exposure to the faces of the candidates. The findings suggest that rapid, unreflective trait inferences can contribute to voting choices, which are widely assumed to be based primarily on rational and, deliberative considerations.	Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA; Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08544 USA	Princeton University; Princeton University	Todorov, A (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.	atodorov@princeton.edu						Ambady N, 2000, ADV EXP SOC PSYCHOL, V32, P201, DOI 10.1016/S0065-2601(00)80006-4; Bartels LM, 2000, AM J POLIT SCI, V44, P35, DOI 10.2307/2669291; BUDESHEIM TL, 1994, PERS SOC PSYCHOL B, V20, P339, DOI 10.1177/0146167294204001; Chen S, 1999, DUAL-PROCESS THEORIES IN SOCIAL PSYCHOLOGY, P73; COVER AD, 1977, AM J POLIT SCI, V21, P523, DOI 10.2307/2110580; DARWIN F, 1950, C DARWINS AUTOBIOGRA, P36; GILBERT D T, 1989, P189; Gosling SD, 2003, J RES PERS, V37, P504, DOI 10.1016/S0092-6566(03)00046-1; Hassin R, 2000, J PERS SOC PSYCHOL, V78, P837, DOI 10.1037/0022-3514.78.5.837; Haxby JV, 2000, TRENDS COGN SCI, V4, P223, DOI 10.1016/S1364-6613(00)01482-0; Kahneman D, 2003, AM PSYCHOL, V58, P697, DOI 10.1037/0003-066X.58.9.697; Keating CF, 1999, POLIT PSYCHOL, V20, P593, DOI 10.1111/0162-895X.00158; Kelley CM, 1998, ACTA PSYCHOL, V98, P127, DOI 10.1016/S0001-6918(97)00039-5; KELLEY HH, 1950, J PERS, V18, P431, DOI 10.1111/j.1467-6494.1950.tb01260.x; KINDER DR, 1980, POLITICAL BEHAV, V0002; MARTIN DS, 1978, AUST J PSYCHOL, V30, P255, DOI 10.1080/00049537808256378; Montepare JM, 1998, ADV EXP SOC PSYCHOL, V30, P93, DOI 10.1016/S0065-2601(08)60383-4; Mueller U, 1996, SOC FORCES, V74, P823, DOI 10.2307/2580383; QUATTRONE GA, 1988, AM POLIT SCI REV, V82, P719, DOI 10.2307/1962487; Todorov A, 2003, J EXP SOC PSYCHOL, V39, P549, DOI 10.1016/S0022-1031(03)00059-3; Winston JS, 2002, NAT NEUROSCI, V5, P277, DOI 10.1038/nn816; Zaller JohnR., 1992, NATURE ORIGINS MASS; Zebrowitz LA, 2002, PERS SOC PSYCHOL B, V28, P238, DOI 10.1177/0146167202282009; ZEBROWITZ LA, 1999, READING FACES WINDOW	24	841	847	4	196	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1623	1626		10.1126/science.1110589	http://dx.doi.org/10.1126/science.1110589			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	936BH	15947187				2022-12-28	WOS:000229827000056
J	Berken, A; Thomas, C; Wittinghofer, A				Berken, A; Thomas, C; Wittinghofer, A			A new family of RhoGEFs activates the Rop molecular switch in plants	NATURE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SALMONELLA-TYPHIMURIUM; GTPASE; DOMAIN; RAS; FLUORESCENCE; SUPERFAMILY; INHIBITOR; GUANOSINE; REGION	In plants, the small GTP-binding proteins called Rops work as signalling switches that control growth, development and plant responses to various environmental stimuli(1-3). Rop proteins ( Rho of plants, Rac-like and AtRac in Arabidopsis thaliana) belong to the Rho family of Ras-related GTP-binding proteins that turn on signalling pathways by switching from a GDP-bound inactive to a GTP-bound active conformation(4,5). Activation depends on guanine nucleotide exchange factors ( GEFs) that catalyse the otherwise slow GDP dissociation for subsequent GTP binding(6). Although numerous RhoGEFs exist in animals and yeasts(7), no Rop-specific GEFs have yet been identified in plants and so Rop activation has remained elusive(1-3,8). Here we describe a new family of RhoGEF proteins that are exclusive to plants. We define a unique domain within these RopGEFs, termed PRONE (plant-specific Rop nucleotide exchanger), which is exclusively active towards members of the Rop subfamily. It increases nucleotide dissociation from Rop more than a thousand-fold and forms a tight complex with nucleotide-free Rop. RopGEFs may represent the missing link in signal transduction from receptor kinases to Rops and their identification has implications for the evolution of the Rho molecular switch.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Max Planck Society	Berken, A (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	antje.berken@mpi-dortmund.mpg.de		Thomas, Christoph/0000-0001-7441-1089				Baldauf SL, 2003, SCIENCE, V300, P1703, DOI 10.1126/science.1085544; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Cool RH, 1999, MOL CELL BIOL, V19, P6297; Fan HY, 1997, PLANT J, V12, P999, DOI 10.1046/j.1365-313X.1997.12050999.x; Haeusler LC, 2003, FEBS LETT, V555, P556, DOI 10.1016/S0014-5793(03)01351-6; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; HARPER JW, 1993, CELL, V75, P805; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; Kaothien P, 2005, PLANT J, V42, P492, DOI 10.1111/j.1365-313X.2005.02388.x; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; Qiu JL, 2002, PLANT CELL, V14, P101, DOI 10.1105/tpc.010346; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; ROSS MD, 1980, CLIN ONCOL, V6, P167; Rudolph MG, 1999, J BIOL CHEM, V274, P30501, DOI 10.1074/jbc.274.43.30501; Schmidt G, 1996, ONCOGENE, V12, P87; Valster AH, 2000, TRENDS CELL BIOL, V10, P141, DOI 10.1016/S0962-8924(00)01728-1; Vernoud V, 2003, PLANT PHYSIOL, V131, P1191, DOI 10.1104/pp.013052; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yang ZB, 2002, PLANT CELL, V14, pS375, DOI 10.1105/tpc.001065; Zheng ZL, 2000, PLANT MOL BIOL, V44, P1, DOI 10.1023/A:1006402628948	30	193	224	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1176	1180		10.1038/nature03883	http://dx.doi.org/10.1038/nature03883			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	15980860				2022-12-28	WOS:000231416600050
J	Hafting, T; Fyhn, M; Molden, S; Moser, MB; Moser, EI				Hafting, T; Fyhn, M; Molden, S; Moser, MB; Moser, EI			Microstructure of a spatial map in the entorhinal cortex	NATURE			English	Article							HEAD-DIRECTION CELLS; HIPPOCAMPAL ENSEMBLE CODE; PATH-INTEGRATION; PLACE CELLS; FUNCTIONAL-ORGANIZATION; NEURONS; RAT; MEMORY; CA3; INFORMATION	The ability to find one's way depends on neural algorithms that integrate information about place, distance and direction, but the implementation of these operations in cortical microcircuits is poorly understood. Here we show that the dorsocaudal medial entorhinal cortex ( dMEC) contains a directionally oriented, topographically organized neural map of the spatial environment. Its key unit is the 'grid cell', which is activated whenever the animal's position coincides with any vertex of a regular grid of equilateral triangles spanning the surface of the environment. Grids of neighbouring cells share a common orientation and spacing, but their vertex locations ( their phases) differ. The spacing and size of individual fields increase from dorsal to ventral dMEC. The map is anchored to external landmarks, but persists in their absence, suggesting that grid cells may be part of a generalized, path-integration-based map of the spatial environment.	Norwegian Univ Sci & Technol, Ctr Biol Memory, N-7489 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Moser, EI (corresponding author), Norwegian Univ Sci & Technol, Ctr Biol Memory, N-7489 Trondheim, Norway.	edvard.moser@ntnu.no		Hafting, Torkel/0000-0002-0928-3487				[Anonymous], 1998, NEURAL NETWORKS BRAI; Biegler R, 2000, ANIM LEARN BEHAV, V28, P257, DOI 10.3758/BF03200260; Bostock E, 1991, Hippocampus, V1, P193, DOI 10.1002/hipo.450010207; Dhillon A, 2000, NEUROSCIENCE, V99, P413, DOI 10.1016/S0306-4522(00)00225-6; Egorov AV, 2002, NATURE, V420, P173, DOI 10.1038/nature01171; Etienne AS, 2004, HIPPOCAMPUS, V14, P180, DOI 10.1002/hipo.10173; Frank LM, 2000, NEURON, V27, P169, DOI 10.1016/S0896-6273(00)00018-0; Fyhn M, 2004, SCIENCE, V305, P1258, DOI 10.1126/science.1099901; Fyhn M, 2002, NEURON, V35, P555, DOI 10.1016/S0896-6273(02)00784-5; GALLISTER CR, 1990, ORG LEARNING; GERMROTH P, 1991, J COMP NEUROL, V305, P215, DOI 10.1002/cne.903050205; GOODRIDGE JP, 1995, BEHAV NEUROSCI, V109, P49, DOI 10.1037/0735-7044.109.1.49; Gothard KM, 1996, J NEUROSCI, V16, P8027; Iijima T, 1996, SCIENCE, V272, P1176, DOI 10.1126/science.272.5265.1176; IKEDA J, 1989, BRAIN RES, V505, P176, DOI 10.1016/0006-8993(89)90134-0; Jeffery KJ, 1997, EXP BRAIN RES, V117, P131, DOI 10.1007/s002210050206; KNIERIM JJ, 1995, J NEUROSCI, V15, P1648, DOI 10.1523/JNEUROSCI.15-03-01648.1995; Lee I, 2004, NATURE, V430, P456, DOI 10.1038/nature02739; Leutgeb S, 2004, SCIENCE, V305, P1295, DOI 10.1126/science.1100265; LINGENHOHL K, 1991, EXP BRAIN RES, V84, P57; Lorincz A, 2000, ANN NY ACAD SCI, V911, P83; MARKUS EJ, 1995, J NEUROSCI, V15, P7079; McNaughton BL, 1996, J EXP BIOL, V199, P173; MITTELSTAEDT ML, 1980, NATURWISSENSCHAFTEN, V67, P566, DOI 10.1007/BF00450672; Mountcastle VB, 1997, BRAIN, V120, P701, DOI 10.1093/brain/120.4.701; MULLER RU, 1987, J NEUROSCI, V7, P1951; Nadel L., 1991, Hippocampus, V1, P221, DOI 10.1002/hipo.450010302; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKeefe J, 1996, NATURE, V381, P425, DOI 10.1038/381425a0; OKEEFE J, 1978, EXP BRAIN RES, V31, P573; Parron C, 2004, EXP BRAIN RES, V159, P349, DOI 10.1007/s00221-004-1960-8; QUIRK GJ, 1992, J NEUROSCI, V12, P1945; Redish A. D., 1999, COGNITIVE MAP PLACE, DOI DOI 10.1038/nature14445; Redish AD, 1997, HIPPOCAMPUS, V7, P15; Rockland KS, 2004, EXP BRAIN RES, V158, P265, DOI 10.1007/s00221-004-2024-9; Samsonovich A, 1997, J NEUROSCI, V17, P5900; SARGOLINI F, 2004, SOC NEUR ABSTR, V30; SHARP PE, 1995, J NEUROSCI, V15, P173; Sharp PE, 1999, HIPPOCAMPUS, V9, P432, DOI 10.1002/(SICI)1098-1063(1999)9:4<432::AID-HIPO9>3.3.CO;2-G; Skaggs W E, 1995, Adv Neural Inf Process Syst, V7, P173; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Steffenach HA, 2005, NEURON, V45, P301, DOI 10.1016/j.neuron.2004.12.044; Taube JS, 1998, PROG NEUROBIOL, V55, P225, DOI 10.1016/S0301-0082(98)00004-5; TAUBE JS, 1990, J NEUROSCI, V10, P436; vanHaeften T, 1997, J NEUROSCI, V17, P862; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; Witter M. P., 2004, RAT NERVOUS SYSTEM, V3rd, P637; WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9; Wood ER, 2000, NEURON, V27, P623, DOI 10.1016/S0896-6273(00)00071-4	50	2151	2235	23	522	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					801	806		10.1038/nature03721	http://dx.doi.org/10.1038/nature03721			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	15965463				2022-12-28	WOS:000231116500035
J	Assefi, NP; Sherman, KJ; Jacobsen, C; Goldberg, J; Smith, WR; Buchwald, D				Assefi, NP; Sherman, KJ; Jacobsen, C; Goldberg, J; Smith, WR; Buchwald, D			A Randomized clinical trial of acupuncture compared with sham acupuncture in Fibromyalgia	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC-FATIGUE-SYNDROME; GENERAL-POPULATION; PAIN; ELECTROACUPUNCTURE	Background: Fibromyalgia is a common chronic pain condition for which patients frequently use acupuncture. Objective: To determine whether acupuncture relieves pain in fibromyalgia. Design: Randomized, sham-controlled trial in which participants, data collection staff, and data analysts were blinded to treatment group. Setting: Private acupuncture offices in the greater Seattle, Washington, metropolitan area. Patients: 100 adults with fibromyalgia. Intervention: Twice-weekly treatment for 12 weeks with an acupuncture program that was specifically designed to treat fibromyalgia, or 1 of 3 sham acupuncture treatments: acupuncture for an unrelated condition, needle insertion at nonacupoint locations, or noninsertive simulated acupuncture. Measurements: The primary outcome was subjective pain as measured by a 10-cm visual analogue scale ranging from 0 (no pain) to 10 (worst pain ever). Measurements were obtained at baseline; 1, 4, 8, and 12 weeks of treatment; and 3 and 6 months after completion of treatment. Participant blinding and adverse effects were ascertained by self-report. The primary outcomes were evaluated by pooling the 3 sham-control groups and comparing them with the group that received acupuncture to treat fibromyalgia. Results: The mean subjective pain rating among patients who received acupuncture for fibromyalgia did not differ from that in the pooled sham acupuncture group (mean between-group difference, 0.5 cm [95% CI, -0.3 cm to 1.2 cm]). Participant blinding was adequate throughout the trial, and no serious adverse effects were noted. Limitations: A prescription of acupuncture at fixed points may differ from acupuncture administered in clinical settings, in which therapy is individualized and often combined with herbal supplementation and other adjunctive measures. A usual-care comparison group was not studied. Conclusion: Acupuncture was no better than sham acupuncture at relieving pain in fibromyalgia.	Univ Washington, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; Group Health Cooperative	Buchwald, D (corresponding author), Box 359780,1730 Minor Ave,Suite 1760, Seattle, WA 98101 USA.		Muler, Clemma/O-5595-2019	Muller, Clemma/0000-0001-5379-8747	NCCIH NIH HHS [R01AT00003] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000003] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Bombardier CH, 1996, MED CARE, V34, P924, DOI 10.1097/00005650-199609000-00005; Buchwald D, 1996, AM J MED, V101, P364, DOI 10.1016/S0002-9343(96)00234-3; CHEN XH, 1992, EUR J PHARMACOL, V211, P203; Cho ZH, 2002, J ALTERN COMPLEM MED, V8, P399, DOI 10.1089/107555302760253577; CHOU J, 1984, J PHARMACOL EXP THER, V230, P349; Crofford L J, 2001, Curr Rheumatol Rep, V3, P147, DOI 10.1007/s11926-001-0010-9; DELUZE C, 1992, BRIT MED J, V305, P1249, DOI 10.1136/bmj.305.6864.1249; Dimmock S, 1996, CLIN RHEUMATOL, V15, P478, DOI 10.1007/BF02229645; Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8; Goddard G, 2002, J OROFAC PAIN, V16, P71; Komaroff AL, 1996, AM J MED, V101, P281, DOI 10.1016/S0002-9343(96)00174-X; Le Bars D, 1992, Patol Fiziol Eksp Ter, P55; Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4; Lewith G T, 1996, J Altern Complement Med, V2, P79, DOI 10.1089/acm.1996.2.79; NOSEWORTHY JH, 1994, NEUROLOGY, V44, P16, DOI 10.1212/WNL.44.1.16; Park J, 1999, ACUPUNCT MED, V17, P110, DOI DOI 10.1136/AIM.17.2.110; PioroBoisset M, 1996, ARTHRIT CARE RES, V9, P13, DOI 10.1002/art.1790090105; Sherman KJ, 2002, J ALTERN COMPLEM MED, V8, P11, DOI 10.1089/107555302753507140; Shlay JC, 1998, JAMA-J AM MED ASSOC, V280, P1590, DOI 10.1001/jama.280.18.1590; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; STUX G, 2001, CLIN ACUPUNCTURE; Twisk JWR, 2003, APPL LONGITUDINAL DA; VINCENT C, 1995, J ROY SOC MED, V88, P199; WARE JE, 1994, SHORT FORM 36 PHYS M; WARE JE, 2000, SHORT FORM 36 HLTH S; WOLFE F, 1995, ARTHRITIS RHEUM-US, V38, P19, DOI 10.1002/art.1780380104; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; XINNONG C, 1999, CHINESE ACUPUNCTURE	28	146	168	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 5	2005	143	1					10	19		10.7326/0003-4819-143-1-200507050-00005	http://dx.doi.org/10.7326/0003-4819-143-1-200507050-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941XB	15998750				2022-12-28	WOS:000230246400002
J	Timimi, S				Timimi, S			Effect of globalisation on children's mental health	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Globalisation is resulting in inappropriate domination of the Western view of mental health as well as of economic approaches. Western child psychiatrists have much to learn from child rearing practices in other countries.	Lincolnshire Partnership NHS Trust, Sleaford NG34 8QA, Lincs, England		Timimi, S (corresponding author), Lincolnshire Partnership NHS Trust, Sleaford NG34 8QA, Lincs, England.	sfimitni@talk2l.com						[Anonymous], 1995, PSYCHOSOCIAL DISORDE; Boyden J., 1997, CONSTRUCTING RECONST, P190; Fernea Elizabeth Warnock, 1995, CHILDREN MUSLIM MIDD; GOONATILAKE S, 1998, MINING CUVILIZATIONA; HACKETT L, 1994, BRIT J SOC WORK, V24, P191; HAMILTON A, 1980, NATURE NURTURE ABORI; Hamilton C., 2003, GROWTH FETISH; KAKAR S, 1994, INNER WORLD INDIAN C; LeVine R.A., 1994, CHILD CARE CULTURE L; McMunn AM, 2001, SOC SCI MED, V53, P423, DOI 10.1016/S0277-9536(00)00346-4; MOSS JR, 1996, GROWIN CRITICAL ALTE; OBEYESEKERE G, 1977, Culture Medicine and Psychiatry, V1, P155, DOI 10.1007/BF00114848; Organisation of African Unity, 1990, AFR CHART RIGHTS WEL; Prout A, 1997, CONSTRUCTING RECONST, P7; RICHARDS B, 1989, FREE ASS, V16, P31; Stephens S, 1995, PRIN ST CULT POW HIS, P3; SUVANNATHAT C, 1985, HDB ASIAN CHILD DEV; Timimi S., 2005, NAUGHTY BOYS ANTISOC; Timimi S., 2002, PATHOLOGICAL CHILD P; United Nations General Assembly, 1989, AD CONV RIGHTS CHILD; WHO, 2002, MENT HLTH GLOB ACT P; Wong ICK, 2004, ARCH DIS CHILD, V89, P1131, DOI 10.1136/adc.2004.050468	22	32	33	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	2005	331	7507					37	39		10.1136/bmj.331.7507.37	http://dx.doi.org/10.1136/bmj.331.7507.37			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	947TD	15994691	Green Published			2022-12-28	WOS:000230668500021
J	Balagadde, FK; You, LC; Hansen, CL; Arnold, FH; Quake, SR				Balagadde, FK; You, LC; Hansen, CL; Arnold, FH; Quake, SR			Long-term monitoring of bacteria undergoing programmed population control in a microchemostat	SCIENCE			English	Article							MICROBIOREACTOR; GROWTH	Using an active approach to preventing biofilm formation, we implemented a microfluidic bioreactor that enables long-term culture and monitoring of extremely small populations of bacteria with single-cell resolution. We used this device to observe the dynamics of Escherichia coli carrying a synthetic "population control" circuit that regulates cell density through a feedback mechanism based on quorum sensing. The microfluidic bioreactor enabled long-term monitoring of unnatural behavior programmed by the synthetic circuit, which included sustained oscillations in cell density and associated morphological changes, over hundreds of hours.	CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Quake, SR (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.	quake@stanford.edu		Arnold, Frances H./0000-0002-4027-364X				Atkinson MR, 2003, CELL, V113, P597, DOI 10.1016/S0092-8674(03)00346-5; COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431; DYKHUIZEN DE, 1990, ANNU REV ECOL SYST, V21, P373, DOI 10.1146/annurev.ecolsys.21.1.373; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; FOX MS, 1955, J GEN PHYSIOL, V39, P267, DOI 10.1085/jgp.39.2.267; Kim JW, 1998, J KOREAN PHYS SOC, V33, pS462; Kostov Y, 2001, BIOTECHNOL BIOENG, V72, P346, DOI 10.1002/1097-0290(20010205)72:3<346::AID-BIT12>3.0.CO;2-X; LARSEN DH, 1964, J BACTERIOL, V88, P1380, DOI 10.1128/JB.88.5.1380-1387.1964; Maharbiz MM, 2004, BIOTECHNOL BIOENG, V85, P376, DOI 10.1002/bit.10835; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; MONOD J, 1950, ANN I PASTEUR PARIS, V79, P390; NOVICK A, 1955, ANNU REV MICROBIOL, V9, P97, DOI 10.1146/annurev.mi.09.100155.000525; NOVICK A, 1950, SCIENCE, V112, P715, DOI 10.1126/science.112.2920.715; TOPIWALA HH, 1971, BIOTECHNOL BIOENG, V13, P919, DOI 10.1002/bit.260130614; You LC, 2004, NATURE, V428, P868, DOI 10.1038/nature02491; Zanzotto A, 2004, BIOTECHNOL BIOENG, V87, P243, DOI 10.1002/bit.20140	17	441	463	6	233	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					137	140		10.1126/science.1109173	http://dx.doi.org/10.1126/science.1109173			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994559				2022-12-28	WOS:000230212800077
J	Petrides, M; Cadoret, GV; Mackey, S				Petrides, M; Cadoret, GV; Mackey, S			Orofacial somatomotor responses in the macaque monkey homologue of Broca's area	NATURE			English	Article							VENTROLATERAL PREFRONTAL CORTEX; FRONTAL EYE FIELDS; PREMOTOR CORTEX; MNEMONIC RETRIEVAL; GREAT APES; LANGUAGE; REGION; VARIABILITY; ACTIVATION; MOVEMENTS	In the ventrolateral frontal lobe of the human brain there is a distinct entity, cytoarchitectonic area 44 ( Broca's area), which is crucial in speech production(1-4). There has been controversy(5,6) over whether monkeys possess an area comparable to human area 44. We have addressed this question in the macaque monkey by combining quantitative architectonic analysis of the cortical areas within the ventrolateral frontal region with electrophysiological recording of neuron activity and electrical intracortical microstimulation. Here we show that, immediately in front of the ventral part of the agranular premotor cortical area 6, there is a distinct cortical area that is architectonically comparable to human area 44 and that this monkey area 44 is involved with the orofacial musculature. We suggest that area 44 might have evolved originally as an area exercising high-level control over orofacial actions, including those related to communicative acts, and that, in the human brain, area 44 eventually also came to control certain aspects of the speech act.	McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	McGill University	Petrides, M (corresponding author), McGill Univ, Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	petrides@ego.psych.mcgill.ca	Galantucci, Bruno/E-5770-2010					Amunts K, 1999, J COMP NEUROL, V412, P319, DOI 10.1002/(SICI)1096-9861(19990920)412:2<319::AID-CNE10>3.0.CO;2-7; Amunts K, 2004, NEUROIMAGE, V22, P42, DOI 10.1016/j.neuroimage.2003.12.031; Brodmann K, 1909, VERGLEICHENDE LOKALI; BRUCE CJ, 1985, J NEUROPHYSIOL, V54, P714, DOI 10.1152/jn.1985.54.3.714; Cadoret G, 2001, EUR J NEUROSCI, V14, P1164, DOI 10.1046/j.0953-816x.2001.01737.x; CADORET G, 2004, SOC NEUROSCI PROG, V324, P3; Cantalupo C, 2001, NATURE, V414, P505, DOI 10.1038/35107134; Duffau H, 2003, NEUROIMAGE, V20, P1903, DOI 10.1016/S1053-8119(03)00203-9; Ferrari PF, 2003, EUR J NEUROSCI, V17, P1703, DOI 10.1046/j.1460-9568.2003.02601.x; HOOVER JE, 1993, SCIENCE, V259, P819, DOI 10.1126/science.7679223; HUERTA MF, 1987, J COMP NEUROL, V271, P473; Hurford JR, 2004, VIENNA S THEOR BIOL, P297; LYNCH JC, 1994, EXP BRAIN RES, V100, P181; MATELLI M, 1986, J COMP NEUROL, V251, P281, DOI 10.1002/cne.902510302; Matelli M., 2004, HUMAN NERVOUS SYSTEM, P973, DOI [10.1016/B978-012547626-3/50027-2, DOI 10.1016/B978-012547626-3/50027-2]; MOHR JP, 1976, STUDIES NEUROLINGUIS, P201; OJEMANN G, 1989, J NEUROSURG, V71, P316, DOI 10.3171/jns.1989.71.3.0316; Penfield W., 1959, SPEECH BRAIN MECH; Petrides M, 2002, NEUROBIOL LEARN MEM, V78, P528, DOI 10.1006/nlme.2002.4107; PETRIDES M, 1995, P NATL ACAD SCI USA, V92, P5803, DOI 10.1073/pnas.92.13.5803; Poeppel D, 2004, COGNITION, V92, P1, DOI 10.1016/j.cognition.2003.11.001; Rasmussen T., 1975, CEREBRAL LOCALIZATIO, P238, DOI DOI 10.1007/978-3-642-66204-1.J9; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0; Schleicher A, 2000, J CHEM NEUROANAT, V20, P31, DOI 10.1016/S0891-0618(00)00076-4; Sherwood CC, 2003, ANAT REC PART A, V271A, P276, DOI 10.1002/ar.a.10046; STANTON GB, 1989, J COMP NEUROL, V282, P415, DOI 10.1002/cne.902820308; TIAN JR, 1995, J NEUROPHYSIOL, V74, P2204, DOI 10.1152/jn.1995.74.5.2204; Tian JR, 1996, J NEUROPHYSIOL, V76, P2740, DOI 10.1152/jn.1996.76.4.2740; Tokuno H, 1997, J COMP NEUROL, V389, P34, DOI 10.1002/(SICI)1096-9861(19971208)389:1<34::AID-CNE3>3.0.CO;2-F	30	254	261	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 30	2005	435	7046					1235	1238		10.1038/nature03628	http://dx.doi.org/10.1038/nature03628			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988526				2022-12-28	WOS:000230140500044
J	Stoller, JK; Aboussouan, LS				Stoller, JK; Aboussouan, LS			alpha 1-antitrypsin deficiency	LANCET			English	Review							ALPHA-1 ANTITRYPSIN DEFICIENCY; MEDIATE INCREASED SECRETION; VOLUME-REDUCTION SURGERY; PI-TYPE-Z; ALPHA(1)-ANTITRYPSIN DEFICIENCY; AUGMENTATION THERAPY; ALPHA1-ANTITRYPSIN DEFICIENCY; REPLACEMENT THERAPY; PULMONARY-EMPHYSEMA; COST-EFFECTIVENESS	alpha 1-antitrypsin deficiency is a genetic disorder that affects about one in 2000-5000 individuals. It is clinically characterised by liver disease and early-onset emphysema. Although alpha 1 antitrypsin is mainly produced in the liver, its main function is to protect the lung against proteolytic damage from neutrophil elastase. The most frequent mutation that causes severe alpha 1-antitrypsin deficiency arises in the SERPINA1 gene and gives rise to the Zallele. This mutation reduces concentrations in serum of alpha 1 antitrypsin by retaining polymerised molecules within hepatocytes: an amount below the serum protective threshold of 11 mu mol/L increases risk for emphysema. In addition to the usual treatments for emphysema, infusion of purified alpha 1 antitrypsin from pooled human plasma represents a specific treatment and raises the concentrations in serum and epithelial-lining fluid above the protective threshold. Evidence suggests that this approach is safe, slows the decline of lung function, could reduce infection rates, and might enhance survival. However, uncertainty about the cost-effectiveness of this expensive treatment remains.	Cleveland Clin Fdn, Dept Pulm Allergy & Crit Care Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stoller, JK (corresponding author), Cleveland Clin Fdn, Dept Pulm Allergy & Crit Care Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stollej@ccf.org	Aboussouan, Loutfi/O-2317-2019	Aboussouan, Loutfi/0000-0003-2716-0904				Abboud R T, 2001, Can Respir J, V8, P81; Aldonyte R, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-11; Alkins SA, 2000, CHEST, V117, P875, DOI 10.1378/chest.117.3.875; Amer Thoracic Soc European Respir, 2003, AM J RESP CRIT CARE, V168, P818, DOI 10.1164/rccm.168.7.818; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P814; Barker AF, 1997, CHEST, V112, P607, DOI 10.1378/chest.112.3.607; BEATTY K, 1980, J BIOL CHEM, V255, P3931; Bofinger A, 2000, J HUM HYPERTENS, V14, P91, DOI 10.1038/sj.jhh.1000935; BRANTLY M, 1996, ALPHA 1 ANTITRYPSIN, P45; BRANTLY ML, 1988, AM REV RESPIR DIS, V138, P327, DOI 10.1164/ajrccm/138.2.327; Burrows JAJ, 2000, P NATL ACAD SCI USA, V97, P1796, DOI 10.1073/pnas.97.4.1796; Cantin AM, 2002, AM J RESP CELL MOL, V27, P659, DOI 10.1165/rcmb.4866; Carrell Robin W, 2004, COPD, V1, P71, DOI 10.1081/COPD-120028703; Chng WJ, 2001, BRIT J DERMATOL, V144, P1282, DOI 10.1046/j.1365-2133.2001.04260.x; Chowdhury MMU, 2002, BRIT J DERMATOL, V147, P1258, DOI 10.1046/j.1365-2133.2002.05095.x; Cuvelier A, 2000, CHEST, V117, P415, DOI 10.1378/chest.117.2.415; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Dawkins PA, 2003, THORAX, V58, P1020, DOI 10.1136/thorax.58.12.1020; de Serres FJ, 2002, CHEST, V122, P1818, DOI 10.1378/chest.122.5.1818; de Serres FJ, 2003, CLIN GENET, V64, P382, DOI 10.1034/j.1399-0004.2003.00143.x; DeMeo DL, 2004, THORAX, V59, P259, DOI 10.1136/thx.2003.006502; Devlin GL, 2002, J MOL BIOL, V324, P859, DOI 10.1016/S0022-2836(02)01088-4; Dirksen A, 1999, AM J RESP CRIT CARE, V160, P1468, DOI 10.1164/ajrccm.160.5.9901055; EDMONDS BK, 1991, PEDIATR DERMATOL, V8, P296, DOI 10.1111/j.1525-1470.1991.tb00937.x; Elliott PR, 1998, AM J RESP CELL MOL, V18, P670, DOI 10.1165/ajrcmb.18.5.3065; Elzouki AN, 1996, QJM-MON J ASSOC PHYS, V89, P877, DOI 10.1093/qjmed/89.11.877; Elzouki AN, 1999, INFLAMM BOWEL DIS, V5, P246, DOI 10.1097/00054725-199911000-00002; Elzouki AN, 1999, EUR J VASC ENDOVASC, V17, P149, DOI 10.1053/ejvs.1998.0740; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; Eriksson S, 1996, CHEST, V110, pS237, DOI 10.1378/chest.110.6_Supplement.237S; ERIKSSON S, 1987, ACTA MED SCAND, V221, P461; ESNAULT VLM, 1993, KIDNEY INT, V43, P1329, DOI 10.1038/ki.1993.186; Fallat RJ, 1996, ALPHA 1 ANTITRYPSIN, P259; Fishman A, 2003, NEW ENGL J MED, V348, P2059; Flotte TR, 2004, HUM GENE THER, V15, P93; GADEK JE, 1983, METABOLIC BASIS INHE, P1450; Gildea TR, 2003, AM J RESP CRIT CARE, V167, P1387, DOI 10.1164/rccm.200209-1035OC; GISHEN P, 1982, CLIN RADIOL, V33, P371, DOI 10.1016/S0009-9260(82)80297-3; Gottlieb DJ, 2000, AM J RESP CRIT CARE, V162, P2069, DOI 10.1164/ajrccm.162.6.2002032; HAY JW, 1991, AM J PUBLIC HEALTH, V81, P427, DOI 10.2105/AJPH.81.4.427; HUBBARD RC, 1988, JAMA-J AM MED ASSOC, V260, P1259, DOI 10.1001/jama.260.9.1259; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; HUSSAIN M, 1991, J INHERIT METAB DIS, V14, P497, DOI 10.1007/BF01797920; Hutchison DC, 1987, PULMONARY EMPHYSEMA; Janciauskiene S, 2004, BIOCHEM BIOPH RES CO, V321, P592, DOI 10.1016/j.bbrc.2004.06.123; JANOFF A, 1985, AM REV RESPIR DIS, V132, P417; JANUS ED, 1985, LANCET, V1, P152; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; LARSSON C, 1978, ACTA MED SCAND, V204, P345, DOI 10.1111/j.0954-6820.1978.tb08452.x; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LETHBRIDGECEJKU M, 2002, VITAL HLTH STAT, V10; LIEBERMAN J, 1986, CHEST, V89, P370, DOI 10.1378/chest.89.3.370; Lieberman J, 2000, CHEST, V118, P1480, DOI 10.1378/chest.118.5.1480; Loche F, 1999, EUR J DERMATOL, V9, P565; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Lomas DA, 2002, J CLIN INVEST, V110, P1585, DOI 10.1172/JCI200216782; Luisetti M, 2004, THORAX, V59, P164, DOI 10.1136/thorax.2003.006494; Mahadeva R, 2002, THORAX, V57, P908, DOI 10.1136/thorax.57.10.908; Marcus NY, 2000, J BIOL CHEM, V275, P1987, DOI 10.1074/jbc.275.3.1987; McBean J, 2003, CUTIS, V71, P205; McElvaney NG, 1997, CHEST, V111, P394, DOI 10.1378/chest.111.2.394; Mendes ES, 2004, AM J RESP CRIT CARE, V169, P1131, DOI 10.1164/rccm.200311-1544OC; Montanelli A, 2002, NEPHRON, V90, P114, DOI 10.1159/000046325; Mulgrew AT, 2004, CHEST, V125, P1952, DOI 10.1378/chest.125.5.1952; OBRIEN ML, 1978, J PEDIATR-US, V92, P1006, DOI 10.1016/S0022-3476(78)80388-6; OGUSHI F, 1987, J CLIN INVEST, V80, P1366, DOI 10.1172/JCI113214; ORiordan K, 1997, TRANSPLANTATION, V63, P480, DOI 10.1097/00007890-199702150-00028; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; Parfrey H, 2004, AM J RESP CELL MOL, V31, P133, DOI 10.1165/rcmb.2003-0276OC; Parmar JS, 2002, AM J RESP CELL MOL, V26, P723, DOI 10.1165/ajrcmb.26.6.4739; Parr DG, 2004, AM J RESP CRIT CARE, V170, P1172, DOI 10.1164/rccm.200406-761OC; Piitulainen E, 1999, EUR RESPIR J, V13, P247, DOI 10.1183/09031936.99.13224799; PINTO AR, 1993, CLIN EXP DERMATOL, V18, P154, DOI 10.1111/j.1365-2230.1993.tb01000.x; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RABASSA AA, 1995, DIGEST DIS SCI, V40, P1997, DOI 10.1007/BF02208669; ROMERO FP, 1986, J CLIN GASTROENTEROL, V8, P559, DOI 10.1097/00004836-198610000-00014; SCHLUCHTER MD, 1994, CHEST, V106, P1223; SEERSHOLM N, 1994, EUR RESPIR J, V7, P1985; SEERSHOLM N, 1995, AM J RESP CRIT CARE, V152, P1922, DOI 10.1164/ajrccm.152.6.8520756; Seersholm N, 1997, EUR RESPIR J, V10, P2260, DOI 10.1183/09031936.97.10102260; Shapiro SD, 2002, BIOCHEM SOC T, V30, P98, DOI 10.1042/BST0300098; Sifers RN, 2003, SCIENCE, V299, P1330, DOI 10.1126/science.1082718; SILVERMAN EK, 1989, AM REV RESPIR DIS, V140, P961, DOI 10.1164/ajrccm/140.4.961; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; SPENCE WC, 1993, BIOCHEM MED METAB B, V50, P233, DOI 10.1006/bmmb.1993.1065; Spencer LT, 2004, AM J PHYSIOL-LUNG C, V286, pL514, DOI 10.1152/ajplung.00099.2003; Stecenko AA, 2003, GENE THER, V10, P95, DOI 10.1038/sj.gt.3301947; Stockley RA, 2002, AM J RESP CRIT CARE, V165, P1494, DOI 10.1164/rccm.2109013; Stoller JK, 2002, NEW ENGL J MED, V346, P988, DOI 10.1056/NEJMcp012477; Stoller JK, 2003, CHEST, V123, P1425, DOI 10.1378/chest.123.5.1425; Stoller JK, 2002, CHEST, V122, P66, DOI 10.1378/chest.122.1.66; STOLLER JK, 1994, CLEV CLIN J MED, V61, P461, DOI 10.3949/ccjm.61.6.461; STOLLER JK, IN PRESS CHEST; STONE PJ, 1995, RESPIRATION, V62, P76; Strauss MB., 1968, FAMILIAR MED QUOTATI FAMILIAR MED QUOTATI; Sun ZF, 2004, LANCET ONCOL, V5, P182, DOI 10.1016/S1470-2045(04)01414-7; Sutherland ER, 2004, NEW ENGL J MED, V350, P2689, DOI 10.1056/NEJMra030415; SVEGER T, 1976, NEW ENGL J MED, V294, P1316, DOI 10.1056/NEJM197606102942404; TOBIN MJ, 1983, BRIT J DIS CHEST, V77, P14, DOI 10.1016/S0007-0971(83)80054-0; Tomashefski JF, 2004, HUM PATHOL, V35, P1452, DOI 10.1016/j.humpath.2004.08.013; Turino GM, 1996, AM J RESP CRIT CARE, V154, P1718, DOI 10.1164/ajrccm.154.6.8970361; Tutic M, 2004, J THORAC CARDIOV SUR, V128, P408, DOI 10.1016/j.jtcvs.2004.03.040; US Census Bureau, 2002, 2000 CENS POP HOUS S; Vreim CE, 1998, AM J RESP CRIT CARE, V158, P49; WARTER J, 1972, Annales de Medecine Interne, V123, P877; Wencker M, 2001, CHEST, V119, P737, DOI 10.1378/chest.119.3.737; Wencker M, 1998, EUR RESPIR J, V11, P428, DOI 10.1183/09031936.98.11020428; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704; WU MC, 1988, J CLIN EPIDEMIOL, V41, P1157, DOI 10.1016/0895-4356(88)90019-4; Wu SS, 2002, PEDIATR DEVEL PATHOL, V5, P293, DOI 10.1007/s10024-001-0202-3; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Zhou A, 2004, J MOL BIOL, V342, P931, DOI 10.1016/j.jmb.2004.07.078	114	419	451	2	76	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	2005	365	9478					2225	2236		10.1016/S0140-6736(05)66781-5	http://dx.doi.org/10.1016/S0140-6736(05)66781-5			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978931				2022-12-28	WOS:000230034800033
J	Bell, T; Ager, D; Song, JI; Newman, JA; Thompson, IP; Lilley, AK; van der Gast, CJ				Bell, T; Ager, D; Song, JI; Newman, JA; Thompson, IP; Lilley, AK; van der Gast, CJ			Larger islands house more bacterial taxa	SCIENCE			English	Article							DISPERSAL		NERC, Ctr Ecol & Hydrol, Environm Biotechnol Sect, Oxford OX1 3SR, England; NERC, Ctr Ecol & Hydrol, Mol Microbial Ecol Sect, Oxford OX1 3SR, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Univ Oxford, Dept Engn Sci, Oxford OX1 3PJ, England	UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Oxford; University of Oxford	van der Gast, CJ (corresponding author), NERC, Ctr Ecol & Hydrol, Environm Biotechnol Sect, Mansfield Rd, Oxford OX1 3SR, England.	cjvdg@ceh.ac.uk	van der Gast, Christopher/G-1153-2011; Newman, Jonathan/A-5932-2008	van der Gast, Christopher/0000-0003-1101-4048; Newman, Jonathan/0000-0003-3155-4084; Bell, Thomas/0000-0002-2615-3932; Song, Ji-Inn/0000-0002-0180-6423				Azovsky AI, 2002, ECOGRAPHY, V25, P273, DOI 10.1034/j.1600-0587.2002.250303.x; Finlay BJ, 2002, SCIENCE, V296, P1061, DOI 10.1126/science.1070710; Finlay BJ, 1999, NATURE, V400, P828, DOI 10.1038/23616; Green JL, 2004, NATURE, V432, P747, DOI 10.1038/nature03034; Horner-Devine MC, 2004, NATURE, V432, P750, DOI 10.1038/nature03073; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002	6	184	208	5	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	2005	308	5730					1884	1884		10.1126/science.1111318	http://dx.doi.org/10.1126/science.1111318			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976296				2022-12-28	WOS:000230120000031
J	Selker, T				Selker, T			Voting technology - Election auditing is an end-to-end procedure	SCIENCE			English	Editorial Material									MIT, CalTech MIT Voting Technol Project, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Selker, T (corresponding author), MIT, CalTech MIT Voting Technol Project, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	selker@media.mit.edu						ALVAREZ RM, 2001, VOTING WHAT WAS WHAT; Ambler S., 2002, AGILE MODELING EFFEC; BERARD B., 2001, SYSTEMS SOFTWARE VER; COHEN S, 2005, 28 CALTECH MIT; Fischer E. A, 2003, RL32139 C RES SERV L; HELLER D, 2004, C REP NAT AM EL PROC; KIMBALL D, SUMMARY TABLES VOTIN; LIBURD SD, 2004, THESIS MIT; MECURI R, 2002, IEEE SPECTRUM, V39, P10; Popov P, 2003, IEEE T SOFTWARE ENG, V29, P345, DOI 10.1109/TSE.2003.1191798; SALTMAN RG, 1989, SPEC PUBL NBS; *SECR STATE CAL, 2004, CAL PAR MON PROGR RE; Selker T, 2004, SCI AM, V291, P90, DOI 10.1038/scientificamerican1004-90; SELKER T, 2004, CALTECH MIT VOT TECH; SELKER T, 2005, USER EXPERIENCE, V4, P1; SINNOTT R, 2004, 1 IR COMM EL VOT, P153; SLED SM, 2004, 6R CALTECH MIT; STEWART C, 2004, ADDENDUM VOTING MACH; STEWART C, 2005, RESIDUAL VOTE 2004 E; TEICH AH, 2003, TECHNOLOGY FUTURE; Williams BJ, 2004, COMMUN ACM, V47, P39, DOI 10.1145/1022594.1022620; 2004, CALTECH MIT VOT TECH; 2004, ELECT INCIDENT REPOR	24	3	3	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	2005	308	5730					1873	1874		10.1126/science.1109901	http://dx.doi.org/10.1126/science.1109901			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	940BZ	15976291				2022-12-28	WOS:000230120000026
J	Templeton, CN; Greene, E; Davis, K				Templeton, CN; Greene, E; Davis, K			Allometry of alarm calls: Black-capped chickadees encode information about predator size	SCIENCE			English	Article							MOBBING CALLS; EVOLUTION; URGENCY	Many animals produce alarm signals when they detect a potential predator, but we still know little about the information contained in these signals. Using presentations of 15 species of live predators, we show that acoustic features of the mobbing calls of black-capped chickadees (Poecile atricapilla) vary with the size of the predator. Companion playback experiments revealed that chickadees detect this information and that the intensity of mobbing behavior is related to the size and threat of the potential predator. This study demonstrates ani unsuspected level of complexity and sophistication in avian alarm calls.	Univ Montana, Div Biol Sci, Missoula, MT 59812 USA; Univ Montana, Div Biol Sci, Florence, MT 59833 USA; Raptors Rockies, Florence, MT 59833 USA	University of Montana System; University of Montana; University of Montana System; University of Montana	Templeton, CN (corresponding author), Univ Montana, Div Biol Sci, Missoula, MT 59812 USA.	ctemple2@u.washington.edu	Templeton, Christopher/AAY-4832-2021	Templeton, Christopher/0000-0001-8701-3186				Baker MC, 2002, WILSON BULL, V114, P510, DOI 10.1676/0043-5643(2002)114[0510:MCOBCC]2.0.CO;2; Blumstein Daniel T., 2002, Evolution of Communication, V3, P135, DOI 10.1075/eoc.3.2.03blu; Blumstein DT, 1999, BEHAVIOUR, V136, P731, DOI 10.1163/156853999501540; Bradbury Jack W., 1998, pi; Cheney D. L., 1990, MONKEYS SEE WORLD IN; Dial KP, 2003, AUK, V120, P941, DOI 10.1642/0004-8038(2003)120[0941:EOALCO]2.0.CO;2; EVANS CS, 1993, ANIM BEHAV, V46, P23, DOI 10.1006/anbe.1993.1158; Evans CS, 1997, PERSP ETHOL, V12, P99; FICKEN MS, 1977, AUK, V94, P156; FICKEN MS, 1978, AUK, V95, P34, DOI 10.2307/4085493; Foresman K.R., 2001, WILD MAMMALS MONTANA; Greene E, 1998, ANIM BEHAV, V55, P511, DOI 10.1006/anbe.1997.0620; Hauser, 1996, EVOL COMMUN; HOWLAND HC, 1974, J THEOR BIOL, V47, P333, DOI 10.1016/0022-5193(74)90202-1; Hurd CR, 1996, BEHAV ECOL SOCIOBIOL, V38, P287, DOI 10.1007/s002650050244; Johnsgard P. A., 1990, HAWKS EAGLES FALCONS; Johnsgard P. A., 2002, N AM OWLS BIOL NATUR; Le Roux A, 2001, BEHAVIOUR, V138, P757, DOI 10.1163/156853901752233398; MACEDONIA JM, 1993, ETHOLOGY, V93, P177, DOI 10.1111/j.1439-0310.1993.tb00988.x; Manser MB, 2002, TRENDS COGN SCI, V6, P55, DOI 10.1016/S1364-6613(00)01840-4; MARLER P, 1955, NATURE, V176, P6, DOI 10.1038/176006a0; Mennill DJ, 2002, SCIENCE, V296, P873, DOI 10.1126/science.296.5569.873; NOWICKI S, 1983, BEHAV ECOL SOCIOBIOL, V12, P317, DOI 10.1007/BF00302899; Seyfarth RM, 2003, ANNU REV PSYCHOL, V54, P145, DOI 10.1146/annurev.psych.54.101601.145121; SEYFARTH RM, 1980, ANIM BEHAV, V28, P1070, DOI 10.1016/S0003-3472(80)80097-2; SHERMAN PW, 1977, SCIENCE, V197, P1246, DOI 10.1126/science.197.4310.1246; Sibley David Allen, 2000, SIBLEY GUIDE BIRDS; Smith S.M., 1991, BLACK CAPPED CHICKAD	28	436	444	10	223	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	2005	308	5730					1934	1937		10.1126/science.1108841	http://dx.doi.org/10.1126/science.1108841			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976305				2022-12-28	WOS:000230120000047
J	Matchar, DB; Westermann-Clark, EV; McCrory, DC; Patwardhan, M; Samsa, G; Kulasingam, S; Myers, E; Sarria-Santamera, A; Lee, A; Gray, R; Liu, K				Matchar, DB; Westermann-Clark, EV; McCrory, DC; Patwardhan, M; Samsa, G; Kulasingam, S; Myers, E; Sarria-Santamera, A; Lee, A; Gray, R; Liu, K			Dissemination of Evidence-Based Practice Center reports	ANNALS OF INTERNAL MEDICINE			English	Article							MODEL	The Evidence-based Practice Center (EPC) program within the Agency for Healthcare Research and Quality (AHRQ) provides detailed evidence reports for partner organizations that they can translate into activities that improve patient care. A review of these dissemination activities provides a rich opportunity to understand how to create more successful linkages between best evidence and best practice. On the basis of interviews with EPC directors, AHRQ staff, and representatives of public and private users of EPC reports, we summarize the variety of efforts to disseminate the work of the EPCs. We also identify a case example of a successful dissemination of an EPC report. Experience to date reinforces the importance of creating close ties between researchers and the policymakers, clinicians, and other decision makers who use EPC evidence reports; developing a conceptual framework to guide the process; and establishing the resource foundation for the entire effort.	Duke Univ, Ctr Clin Hlth Policy Res, Durham, NC 27705 USA	Duke University	Matchar, DB (corresponding author), Duke Univ, Ctr Clin Hlth Policy Res, 2200 W Main St,Suite 220, Durham, NC 27705 USA.	david.matchar@duke.edu	Matchar, David/M-3951-2019; Sarria-Santamera, Antonio/AAE-1556-2019	Sarria-Santamera, Antonio/0000-0001-5734-7468; Kulasingam, Shalini/0000-0002-0932-9166; Matchar, David/0000-0003-3020-2108; McCrory, Douglas/0000-0003-2093-0611				ACOG, 2002, INT J GYNECOL OBSTET, V76, P95; *AHRQ, AHRQ PUBL; *AHRQ, 2003, AHRQ PUBL; [Anonymous], 2001, OBSTET GYNECOL, V98, P177; [Anonymous], ATTENTION DEFICIT HY; [Anonymous], 1998, NIH CONSENS STATEMEN, V16, P1; Banta H D, 1990, Int J Technol Assess Health Care, V6, P115; Bartunek Jean, 2003, J Health Serv Res Policy, V8 Suppl 2, P62, DOI 10.1258/135581903322405199; CARNEY N, 1999, AHCPR PUBLICATION; Denis Jean-Louis, 2003, J Health Serv Res Policy, V8 Suppl 2, P1, DOI 10.1258/135581903322405108; Dewilde S, 2004, MED DECIS MAKING, V24, P486, DOI 10.1177/0272989X04268953; Ferlie Ewan, 2003, J Health Serv Res Policy, V8 Suppl 2, P51, DOI 10.1258/135581903322405171; *FLOR HOSP ASS, PAT SAF TOOL KIT; FRENK J, 1992, SOC SCI MED, V35, P1397, DOI 10.1016/0277-9536(92)90043-P; Goering Paula, 2003, J Health Serv Res Policy, V8 Suppl 2, P14, DOI 10.1258/135581903322405126; GOLDENBIDDLE K, 2003, J HLTH SERV RES P S2, V83, P20; Hartmann KE, 2002, SCREENING CERVICAL C; Innvaer Simon, 2002, J Health Serv Res Policy, V7, P239, DOI 10.1258/135581902320432778; JADAD AR, 1999, AHRQ PUBLICATION; Lieberthal AS, 2004, PEDIATRICS, V113, P1451, DOI 10.1542/peds.113.5.1451; MATCHAR DB, 2001, 7 AG HEALTHC RES QUA; MCCRORY D, EVIDENCE REPORT APPR; MCCRORY DC, 1999, AHRQ PUBLICATION; MULROW C, 2000, AHRQ PUBLICATION; Myers ER, 2000, OBSTET GYNECOL, V96, P645, DOI 10.1016/S0029-7844(00)00979-0; Myers ER, 2000, AM J EPIDEMIOL, V151, P1158, DOI 10.1093/oxfordjournals.aje.a010166; *REN PHYS ASS, 2002, REN PHYS ASS APPR PR; Sawaya GF, 2003, NEW ENGL J MED, V349, P1501, DOI 10.1056/NEJMoa035419; Shekelle P, 2003, AHRQ PUBLICATION, V03-E023; SHOJANIA K, 2001, AHRQ PUBLICATION; SPURLOCK B, 2003, CONVERGENCE HLTH CON; *SSM HLTH CAR, SSMHC ENH ITS PAT SA; Stern P. C., 1996, UNDERSTANDING RISK I; US Preventive Service Task Force, SCREEN CERV CANC; Walshe K, 2001, MILBANK Q, V79, P429, DOI 10.1111/1468-0009.00214; Walter Isabel, 2003, J Health Serv Res Policy, V8 Suppl 2, P58; WEISS R, MED PROPOSES COVER P; P 2 ANN CAN RES TRAN; P C KNOW TRANSF 26 2; 2002, REQUEST PROPOSALS; 2002 CAN HLTH SERV R	41	10	10	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1120	1125		10.7326/0003-4819-142-12_Part_2-200506211-00012	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938CN	15968037				2022-12-28	WOS:000229977600012
J	Westbrook, TF; Martin, ES; Schlabach, MR; Leng, YM; Liang, AC; Feng, B; Zhao, JJ; Roberts, TM; Mandel, G; Hannon, GJ; DePinho, RA; Chin, L; Elledge, SJ				Westbrook, TF; Martin, ES; Schlabach, MR; Leng, YM; Liang, AC; Feng, B; Zhao, JJ; Roberts, TM; Mandel, G; Hannon, GJ; DePinho, RA; Chin, L; Elledge, SJ			A genetic screen for candidate tumor suppressors identifies REST	CELL			English	Article							MAMMARY EPITHELIAL-CELLS; TGF-BETA; HUMAN CANCER; TRANSFORMATION; RAS; EXPRESSION; PATHWAY; ADENOCARCINOMA; PROLIFERATION; REQUIREMENTS	Tumorigenesis is a multistep process characterized by a myriad of genetic and epigenetic alterations. Identifying the causal perturbations that confer malignant transformation is a central goal in cancer biology. Here we report an RNAi-based genetic screen for genes that suppress transformation of human mammary epithelial cells. We identified genes previously implicated in proliferative control and epithelial cell function including two established tumor suppressors, TGFBR2 and PTEN. In addition, we uncovered a previously unrecognized tumor suppressor role for REST/ NRSF, a transcriptional repressor of neuronal gene expression. Array-CGH analysis identified REST as a frequent target of deletion in colorectal cancer. Furthermore, we detect a frameshift mutation of the REST gene in colorectal cancer cells that encodes a dominantly acting truncation capable of transforming epithelial cells. Cells lacking REST exhibit increased PI(3)K signaling and are dependent upon this pathway for their transformed phenotype. These results implicate REST as a human tumor suppressor and provide a novel approach to identifying candidate genes that suppress the development of human cancer.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet,Partners Ctr Genet & Genom, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA; SUNY Stony Brook, Howard Hughes Med Inst, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA; Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Partners Healthcare System; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cold Spring Harbor Laboratory	Elledge, SJ (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet,Partners Ctr Genet & Genom, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	selledge@genetics.med.harvard.edu	Hannon, Gregory/AAB-3568-2019	DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [R01CA93947, 5T32CA09361, U01 CA084313, 5 P50 CA090381-03, 5 P01 CA89021-04, R01CA99041] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA089021, T32CA009361, P50CA090381, R01CA099041, U01CA084313, R01CA093947] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre AJ, 2004, P NATL ACAD SCI USA, V101, P9067, DOI 10.1073/pnas.0402932101; Albert ML, 2004, NAT REV CANCER, V4, P36, DOI 10.1038/nrc1255; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bachoo RM, 2004, P NATL ACAD SCI USA, V101, P8384, DOI 10.1073/pnas.0402140101; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; Neumann SB, 2004, MOL BRAIN RES, V120, P173, DOI 10.1016/j.molbrainres.2003.10.021; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhao JJ, 2004, TRENDS MOL MED, V10, P344, DOI 10.1016/j.molmed.2004.05.005	45	396	416	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	2005	121	6					837	848		10.1016/j.cell.2005.03.033	http://dx.doi.org/10.1016/j.cell.2005.03.033			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960972	Bronze			2022-12-28	WOS:000230011200007
J	Charo, RA				Charo, RA			The celestial fire of conscience - Refusing to deliver medical care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Wisconsin, Sch Law, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Charo, RA (corresponding author), Univ Wisconsin, Sch Law, Madison, WI 53706 USA.			Charo, Robin Alta/0000-0003-3710-1043					0	87	89	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2005	352	24					2471	2473		10.1056/NEJMp058112	http://dx.doi.org/10.1056/NEJMp058112			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935RH	15958802				2022-12-28	WOS:000229798900001
J	Wang, HW; Nogales, E				Wang, HW; Nogales, E			Nucleotide-dependent bending flexibility of tubulin regulates microtubule assembly	NATURE			English	Article							SLOWLY HYDROLYZABLE ANALOG; ALPHA-BETA-TUBULIN; CRYOELECTRON MICROSCOPY; STRUCTURAL-CHANGES; GTP HYDROLYSIS; DYNAMICS; ENDS; INFORMATION; COLCHICINE; RESOLUTION	The atomic structure of tubulin in a polymerized, straight protofilament is clearly distinct from that in a curved conformation bound to a cellular depolymerizer. The nucleotide contents are identical, and in both cases the conformation of the GTP-containing, intra-dimer interface is indistinguishable from the GDP-containing, inter-dimer contact. Here we present two structures corresponding to the start and end points in the microtubule polymerization and hydrolysis cycles that illustrate the consequences of nucleotide state on longitudinal and lateral assembly. In the absence of depolymerizers, GDP-bound tubulin shows distinctive intra-dimer and inter-dimer interactions and thus distinguishes the GTP and GDP interfaces. A cold-stable tubulin polymer with the non-hydrolysable GTP analogue GMPCPP, containing semi-conserved lateral interactions, supports a model in which the straightening of longitudinal interfaces happens sequentially, starting with a conformational change after GTP binding that straightens the dimer enough for the formation of lateral contacts into a non-tubular intermediate. Closure into a microtubule does not require GTP hydrolysis.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Nogales, E (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.	enogales@lbl.gov			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM051487] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM051487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREU JM, 1991, BIOCHEMISTRY-US, V30, P3777, DOI 10.1021/bi00229a027; CAPLOW M, 1994, J CELL BIOL, V127, P779, DOI 10.1083/jcb.127.3.779; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Heald R, 2002, J CELL SCI, V115, P3; HOWARD WD, 1986, BIOCHEMISTRY-US, V25, P8292, DOI 10.1021/bi00373a025; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; Janosi IM, 1998, EUR BIOPHYS J BIOPHY, V27, P501, DOI 10.1007/s002490050160; Jordan M. A., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P1, DOI 10.2174/1568011023354290; Li HL, 2002, STRUCTURE, V10, P1317, DOI 10.1016/S0969-2126(02)00827-4; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; Muller-Reichert T, 1998, P NATL ACAD SCI USA, V95, P3661, DOI 10.1073/pnas.95.7.3661; Nicholson WV, 1999, CELL BIOCHEM BIOPHYS, V31, P175, DOI 10.1007/BF02738171; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393; Tran PT, 1997, J STRUCT BIOL, V118, P107, DOI 10.1006/jsbi.1997.3844; Wang HW, 2005, J STRUCT BIOL, V149, P65, DOI 10.1016/j.jsb.2004.08.006	20	232	238	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					911	915		10.1038/nature03606	http://dx.doi.org/10.1038/nature03606			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959508	Green Accepted			2022-12-28	WOS:000229799700038
J	Hsu, CC; Kao, WHL; Coresh, J; Pankow, JS; Marsh-Manzi, J; Boerwinkle, E; Bray, MS				Hsu, CC; Kao, WHL; Coresh, J; Pankow, JS; Marsh-Manzi, J; Boerwinkle, E; Bray, MS			Apolipoprotein E and progression of chronic kidney disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIABETIC-NEPHROPATHY; ATHEROSCLEROSIS RISK; RENAL-FUNCTION; E POLYMORPHISM; ALZHEIMERS-DISEASE; APOE POLYMORPHISM; SERUM CREATININE; ALLELE; TYPE-1; LIPOPROTEINS	Context Apolipoprotein E (APOE) genetic variation has been implicated in diabetic nephropathy with the epsilon 2 allele increasing and the epsilon 4 allele decreasing risk. APOE allelic associations with chronic kidney disease beyond diabetic nephropathy are unknown, with no studies reported in high-risk African American populations. Objective To quantify the risk of chronic kidney disease progression associated with APOE in a population-based study including white, African American, diabetic, and nondiabetic individuals. Design, Setting, and Participants Prospective follow-up (through January 1, 2003) of Atherosclerosis Risk in Communities (ARIC) study participants, including 3859 African American and 10 661 white adults aged 45 to 64 years without severe renal dysfunction at baseline in 1987-1989, sampled from 4 US communities. Main Outcome Measures Incident chronic kidney disease progression, defined as hospitalization or death with kidney disease or increase in serum creatinine level of 0.4 mg/dL (35 mu mol/L) or more above baseline, examined by APOE genotypes and alleles. Results During median follow-up of 14 years, chronic kidney disease progression developed in 1060 individuals (incidence per 1000 person-years: 5.5 overall; 8.8 in African Americans and 4.4 in whites). Adjusting for major chronic kidney disease risk factors, F-2 moderately increased and epsilon 4 decreased risk of disease progression (likelihood ratio test, P=.03). Further adjustment for low- and high-density lipoprotein cholesterol and triglycerides did not attenuate relative risks (RRs) (epsilon 2: 1.08 [95% CI, 0.93-1.25] and epsilon 4: 0.85 [95% CI, 0.75-0.95] compared with epsilon 3; likelihood ratio test, P = .008). epsilon 4 decreased risk of end-stage renal disease (RR, 0.60 [95% CI, 0.43-0.84]). epsilon 2 was associated with a decline in renal function (RR, 1.25 [95% CI, 1.02-1.53]), though not with events, such as hospitalizations or end-stage renal disease. Risks were similar stratified by race, sex, diabetes, and hypertension (all P values for interaction >.05). Excess risk of chronic kidney disease in African Americans was not explained by APOE alleles. Conclusions APOE variation predicts chronic kidney disease progression, independent of diabetes, race, lipid, and nonlipid risk factors. Our study suggests that nonlipid-mediated pathways, such as cellular mechanisms of kidney remodeling, may be involved in the association of APOE alleles and progression of chronic kidney disease.	Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Dept Epidemiol, Baltimore, MD 21205 USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA; Univ Texas, Houston Hlth Sci Ctr, Ctr Human Genet, Houston, TX 77004 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; University of Texas Health Science Center Houston	Coresh, J (corresponding author), Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Dept Epidemiol, 2024 E Monument St,Suite 2-600, Baltimore, MD 21205 USA.	coresh@jhu.edu		Pankow, James/0000-0001-7076-483X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055021, N01HC055015, N01HC055016, N01HC055018, N01HC055019, N01HC055020, N01HC055022] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007024, R01HL073366] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL73366, 5T32HL007024, N01-HC-55015, N01-HC-55022, N01-HC-55021, N01-HC-55020, N01-HC-55016, N01-HC-55019, N01-HC-55018] Funding Source: Medline; ODCDC CDC HHS [UR6/CCU617218] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); ODCDC CDC HHS		Araki S, 2000, DIABETES, V49, P2190, DOI 10.2337/diabetes.49.12.2190; Araki SI, 2003, DIABETES CARE, V26, P2416, DOI 10.2337/diacare.26.8.2416; Boize R, 1998, NEPHROL DIAL TRANSPL, V13, P72, DOI 10.1093/ndt/13.1.72; Chen GP, 2001, J BIOL CHEM, V276, P49142, DOI 10.1074/jbc.M104879200; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DIAMOND JR, 1991, KIDNEY INT, V39, pS29; ECKFELDT JH, 1994, ARCH PATHOL LAB MED, V118, P496; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Eto M, 1995, CLIN GENET, V48, P288; Eto M, 2002, AM J KIDNEY DIS, V40, P243, DOI 10.1053/ajkd.2002.34502; Evans DA, 2003, ARCH NEUROL-CHICAGO, V60, P185, DOI 10.1001/archneur.60.2.185; Freedman BI, 2000, CURR OPIN NEPHROL HY, V9, P273, DOI 10.1097/00041552-200005000-00011; Fried LF, 2001, KIDNEY INT, V59, P260, DOI 10.1046/j.1523-1755.2001.00487.x; Ha SK, 1999, NEPHROL DIAL TRANSPL, V14, P2144, DOI 10.1093/ndt/14.9.2144; Hadjadj S, 2000, NEPHROL DIAL TRANSPL, V15, P1971, DOI 10.1093/ndt/15.12.1971; Hsieh MC, 2002, J NEPHROL, V15, P368; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Kimura H, 1998, AM J KIDNEY DIS, V31, P666, DOI 10.1053/ajkd.1998.v31.pm9531184; Krop JS, 1999, ARCH INTERN MED, V159, P1777, DOI 10.1001/archinte.159.15.1777; Liberopoulos E, 2004, AM J KIDNEY DIS, V43, P223, DOI 10.1053/j.ajkd.2003.10.013; Liberopoulos EN, 2004, AM J KIDNEY DIS, V44, P300, DOI 10.1053/j.ajkd.2004.04.035; Liberopoulos EN, 2004, NEPHROL DIAL TRANSPL, V19, P2006, DOI 10.1093/ndt/gfh349; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Morrison AC, 2002, GENET EPIDEMIOL, V22, P233, DOI 10.1002/gepi.0191; Muntner P, 2000, KIDNEY INT, V58, P293, DOI 10.1046/j.1523-1755.2000.00165.x; *NAT HEART LUNG BL, 1987, ARIC MAN OP; Nishida Y, 1997, AM J KIDNEY DIS, V29, P919, DOI 10.1016/S0272-6386(97)90467-4; Oda H, 1999, KIDNEY INT, V56, pS25, DOI 10.1046/j.1523-1755.1999.07107.x; Onuma T, 1996, J AM SOC NEPHROL, V7, P1075; PERRONE RD, 1992, CLIN CHEM, V38, P1933; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883; Shcherbak N S, 2001, BMC Med Genet, V2, P8, DOI 10.1186/1471-2350-2-8; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; Tarnow L, 2000, NEPHROL DIAL TRANSPL, V15, P625, DOI 10.1093/ndt/15.5.625; Werle E, 1998, DIABETES CARE, V21, P994, DOI 10.2337/diacare.21.6.994; WILSON PWF, 1994, JAMA-J AM MED ASSOC, V272, P1666, DOI 10.1001/jama.272.21.1666; Yorioka N, 1999, NEPHRON, V83, P246, DOI 10.1159/000045517; Zeleny M, 2002, BIOCHEMISTRY-US, V41, P11820, DOI 10.1021/bi026202k	41	77	80	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	2005	293	23					2892	2899		10.1001/jama.293.23.2892	http://dx.doi.org/10.1001/jama.293.23.2892			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935MD	15956634	Bronze			2022-12-28	WOS:000229785500024
J	Hudson, M; Richard, H; Pilote, L				Hudson, M; Richard, H; Pilote, L			Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; CARDIOVASCULAR THROMBOTIC EVENTS; ACUTE MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; GASTROINTESTINAL TOXICITY; COX-2 INHIBITORS; CLINICAL-TRIALS; RISK; OSTEOARTHRITIS; NAPROXEN	Objectives To compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib. Design Population based retrospective cohort study. Setting Databases of hospital discharge summaries and prescription drug claims in Quebec. Participants 2256 patients aged 66 or more prescribed celecoxib, rofecoxib, or a NSAID after an index admission for congestive heart failure between April 2000 and March 2002. Main outcome measures Time to all cause death and recurrent congestive heart failure, combined and separately. Results The risk of death and recurrent congestive heart failure combined was higher in patients prescribed NSAIDs or rofexocib than in those prescribed celecoxib (hazard ratio 1.26, 95% confidence interval 1.00 to 1.57 and 1.27, 1.09 to 1.49, respectively). The findings were similar when the outcomes were assessed separately. In pairwise analysis, the risks of death and recurrent congestive heart failure, combined and separate, were similar between patients prescribed NSAIDs and rofecoxib. Conclusions Celecoxib seems safer than rofecoxib and NSAIDs in elderly patients with congestive heart failure. Differences were found among cyclo-oxygenase-2 inhibitors.	McGill Univ, Div Clin Epidemiol, Res Inst, Ctr Hlth, Montreal, PQ H3G 1A4, Canada	McGill University	Pilote, L (corresponding author), McGill Univ, Div Clin Epidemiol, Res Inst, Ctr Hlth, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	louise.pilote@mcgill.ca		Pilote, Louise/0000-0002-6159-0628				Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Brater DC, 2001, AM J NEPHROL, V21, P1, DOI 10.1159/000046212; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Feenstra J, 2002, ARCH INTERN MED, V162, P265, DOI 10.1001/archinte.162.3.265; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; Gertz BJ, 2002, CURR MED RES OPIN, V18, P82, DOI 10.1185/030079902125000354; Goff DC, 2000, ARCH INTERN MED, V160, P197, DOI 10.1001/archinte.160.2.197; Graham DJ, 2005, LANCET, V365, P475, DOI 10.1016/S0140-6736(05)17864-7; Jassal DS, 2003, CIRCULATION, V108, P665; JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003-4819-121-4-199408150-00011; Jong P, 2002, ARCH INTERN MED, V162, P1689, DOI 10.1001/archinte.162.15.1689; Jong P, 2003, CIRCULATION, V108, P184, DOI 10.1161/01.CIR.0000080290.39027.48; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; Ko D, 2002, AM HEART J, V143, P475, DOI 10.1067/mhj.2002.121270; Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078; Lee DS, 2003, JAMA-J AM MED ASSOC, V290, P2581, DOI 10.1001/jama.290.19.2581; Lipsky, 2000, J RHEUMATOL, V27, P1338; Mamdani M, 2003, ARCH INTERN MED, V163, P481, DOI 10.1001/archinte.163.4.481; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; *NIH NEWS, 2004, US NONST ANT DRUGS S; Page J, 2000, ARCH INTERN MED, V160, P777, DOI 10.1001/archinte.160.6.777; Perazella MA, 2001, AM J MED, V111, P64, DOI 10.1016/S0002-9343(01)00757-4; Pilote L, 2000, CAN MED ASSOC J, V163, P31; Pitkala KH, 2002, AM J MED, V112, P424, DOI 10.1016/S0002-9343(01)01107-X; POPE JE, 1993, ARCH INTERN MED, V153, P477, DOI 10.1001/archinte.153.4.477; Rahme E, 2002, ARTHRIT RHEUM-ARTHR, V47, P595, DOI 10.1002/art.10796; RALUNE E, 2002, ARCH INTERN MED, V162, P1111; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; Ray WA, 2002, LANCET, V359, P118, DOI 10.1016/S0140-6736(02)07370-1; Reicin AS, 2002, AM J CARDIOL, V89, P204, DOI 10.1016/S0002-9149(01)02201-9; Rodriguez LAG, 2003, EPIDEMIOLOGY, V14, P240; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Solomon DH, 2002, ARCH INTERN MED, V162, P1099, DOI 10.1001/archinte.162.10.1099; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; Tannenbaum H, 2000, Can J Clin Pharmacol, V7 Suppl A, p4A; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; Watson DJ, 2002, ARCH INTERN MED, V162, P1105, DOI 10.1001/archinte.162.10.1105; Whelton A, 2002, AM J CARDIOL, V90, P959, DOI 10.1016/S0002-9149(02)02661-9; White WB, 2002, AM J CARDIOL, V89, P425, DOI 10.1016/S0002-9149(01)02265-2; Wolfe F, 2004, J RHEUMATOL, V31, P1143; Wong SCY, 1998, CIRCULATION, V98, P100, DOI 10.1161/01.CIR.98.2.100; Zhang ZB, 2003, CIRC RES, V92, P1153, DOI 10.1161/01.RES.0000071749.22027.45; Zhao SZ, 2002, AM J MANAG CARE, V8, pS414; Zhao SZ, 2001, CLIN THER, V23, P1478, DOI 10.1016/S0149-2918(01)80121-1; 2001, FDA ARTHR ADV COMM F	49	98	103	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 11	2005	330	7504					1370	1373		10.1136/bmj.330.7504.1370	http://dx.doi.org/10.1136/bmj.330.7504.1370			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936FE	15947399	Green Published			2022-12-28	WOS:000229840100028
J	Schwab, JM; Failli, V; Chedotal, A				Schwab, JM; Failli, V; Chedotal, A			Injury-related dynamic myelin/oligodendrocyte axon-outgrowth inhibition in the central nervous system	LANCET			English	Review							GROWTH CONE; FUNCTIONAL RECOVERY; PROTEIN-SYNTHESIS; MYELIN; NOGO; REGENERATION; RAT; INVOLVEMENT; EXPRESSION; RECEPTOR	Context By contrast with the glial scar, myelin was considered a constitutive static inhibitory barrier unreactive to lesions in the central nervous system (CNS). However, recent results suggest considerable add-on inhibition of myelin as a result of CNS injury. Furthermore, catastrophic events cause morphological and biochemical changes in the axon itself This results in the accumulation of cytoskeleton components and intraaxonal transported proteins paralleled by extensive membrane remodelling at the axonal tip (a process called axotomy) which might modify the axonal response to its inhibitory environment. Starting point Ji-Eun Kim and colleagues recently reported an axonal subpopulation with a different capacity to respond to myelin inhibitors (Neuron 2004; 44: 439-51). Axonal specificity but also evidence for injury reactivity summarised here challenges our understanding of axon-growth inhibition in the injured CNS. This might be due to (i) qualitative and quantitative enrichment of the periaxonal environment by myelin/oligodendrocytes, (ii) increased axonal sensitivity to its inhibitory environment, and (iii) axons and lesion-induced, altered axonal signalling. Where next? Postlesional reactive inhibition of myelin or the oligodendrocyte necessitates the development of novel screening approaches and therapeutic agents to promote axonal regeneration. Moreover, we need to improve our understanding of the pathophysiology of the lesion to find more efficient experimental strategies to restore neurological function.	Univ Paris 06, CNRS, UMR 7102, Equipe Dev Neuronal, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Schwab, JM (corresponding author), Harvard Univ, Sch Med, Ctr Expt Therapeut, Brigham & Womens Hosp, Boston, MA 02115 USA.	jschwab@zeus.bwh.harvard.edu	Chedotal, Alain/F-2750-2017	Chedotal, Alain/0000-0001-7577-3794; Schwab, Jan/0000-0001-6784-4919				Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; Bandtlow CE, 1997, EUR J NEUROSCI, V9, P2743, DOI 10.1111/j.1460-9568.1997.tb01703.x; Bartholdi D, 1998, GLIA, V23, P278, DOI 10.1002/(SICI)1098-1136(199807)23:3<278::AID-GLIA10>3.0.CO;2-Q; Brittis PA, 2002, CELL, V110, P223, DOI 10.1016/S0092-8674(02)00813-9; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; de la Houssaye BA, 1999, J NEUROSCI, V19, P10843, DOI 10.1523/JNEUROSCI.19-24-10843.1999; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Grimpe B, 2002, PROG BRAIN RES, V137, P333; Huber AB, 2002, J NEUROSCI, V22, P3553; Josephson A, 2003, CELL TISSUE RES, V311, P333, DOI 10.1007/s00441-002-0695-8; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Mandolesi G, 2004, FASEB J, V18, P1934, DOI 10.1096/fj.04-1805fje; Mikule K, 2003, J BIOL CHEM, V278, P21168, DOI 10.1074/jbc.M211828200; Mingorance A, 2004, MOL CELL NEUROSCI, V26, P34, DOI 10.1016/j.mcn.2004.01.001; Moreau-Fauvarque C, 2003, J NEUROSCI, V23, P9229; Pasterkamp RJ, 2001, BRAIN RES REV, V35, P36, DOI 10.1016/S0165-0173(00)00050-3; Schwab ME, 2002, PROG BRAIN RES, V137, P351; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; SOTELO C, 1971, LAB INVEST, V25, P653; Tang S, 2001, MOL CELL NEUROSCI, V18, P259, DOI 10.1006/mcne.2001.1020; Tom VJ, 2004, J NEUROSCI, V24, P6531, DOI 10.1523/JNEUROSCI.0994-04.2004; Zhou CM, 2003, BIOCHEM BIOPH RES CO, V309, P368, DOI 10.1016/j.bbrc.2003.08.006	24	16	19	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2005	365	9476					2055	2057		10.1016/S0140-6736(05)66699-8	http://dx.doi.org/10.1016/S0140-6736(05)66699-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950719				2022-12-28	WOS:000229701400027
J	Khamsi, R				Khamsi, R			Deadly combinations	NATURE			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2005	435	7041					406	406						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15952256				2022-12-28	WOS:000229337800016
J	Boyet, M; Carlson, RW				Boyet, M; Carlson, RW			Nd-142 evidence for early (> 4.53 Ga) global differentiation of the silicate Earth	SCIENCE			English	Article							ND ISOTOPIC EVOLUTION; EARLY ARCHEAN ROCKS; ANGRA-DOS-REIS; CONTINENTAL-CRUST; RAPID ACCRETION; DEPLETED MANTLE; LU-HF; SYSTEMATICS; CHONDRITES; AGE	New high-precision samarium-neodymium isotopic data for chondritic meteorites show that their Nd-142/Nd-144 ratio is 20 parts per million lower than that of most terrestrial rocks. This difference indicates that most (70 to 95%) of Earth's mantle is compositionally similar to the incompatible element-depleted source of mid-ocean ridge basalts, possibly as a result of a global differentiation 4.53 billion years ago (Ga), within 30 million years of Earth's formation. The complementary enriched reservoir has never been sampled and is probably located at the base of the mantle. These data influence models of Earth's compositional structure and require revision of the timing of global differentiation on Earth's Moon and Mars.	Carnegie Inst Sci, Dept Terr Magnetism, Washington, DC 20015 USA	Carnegie Institution for Science	Boyet, M (corresponding author), Carnegie Inst Sci, Dept Terr Magnetism, 5241 Broad Branch Rd NW, Washington, DC 20015 USA.	boyet@dtm.ciw.edu						Albarede F, 2002, PHILOS T R SOC A, V360, P2569, DOI 10.1098/rsta.2002.1081; ALIBERT C, 1994, GEOCHIM COSMOCHIM AC, V58, P2921, DOI 10.1016/0016-7037(94)90125-2; ALLEGRE CJ, 1983, EARTH PLANET SC LETT, V66, P191, DOI 10.1016/0012-821X(83)90136-X; ALLEGRE CJ, 1983, NATURE, V303, P762, DOI 10.1038/303762a0; Amelin Y, 2004, EARTH PLANET SC LETT, V223, P267, DOI 10.1016/j.epsl.2004.04.025; Amelin Y, 2002, SCIENCE, V297, P1678, DOI 10.1126/science.1073950; Andreasen R, 2004, GEOCHIM COSMOCHIM AC, V68, pA747; Bennett V. C., 2003, TREATISE GEOCHEMISTR, P493, DOI [10.1016/B0-08-043751-6/02013-2, DOI 10.1016/B0-08-043751-6/02013-2]; BENNETT VC, 1993, EARTH PLANET SC LETT, V119, P299, DOI 10.1016/0012-821X(93)90140-5; BENNETT VC, 1992, T AM GEOPHYS UNION, V73, P621; BlichertToft J, 1997, EARTH PLANET SC LETT, V148, P243, DOI 10.1016/S0012-821X(97)00040-X; Borg L, 1999, GEOCHIM COSMOCHIM AC, V63, P2679, DOI 10.1016/S0016-7037(99)00130-1; Boyet M, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021873; Boyet M, 2003, EARTH PLANET SC LETT, V214, P427, DOI 10.1016/S0012-821X(03)00423-0; BOYET M, 2004, EOS, V85; Buffett BA, 2003, SCIENCE, V299, P1675, DOI 10.1126/science.1081518; Canup RM, 2004, ICARUS, V168, P433, DOI 10.1016/j.icarus.2003.09.028; CARLSON RW, 1988, EARTH PLANET SC LETT, V90, P119, DOI 10.1016/0012-821X(88)90095-7; Caro G, 2003, NATURE, V423, P428, DOI 10.1038/nature01668; Corgne A, 2005, GEOCHIM COSMOCHIM AC, V69, P485, DOI 10.1016/j.gca.2004.06.041; FOLEY CN, IN PRESS GEOCHIM COS; GALER SJG, 1992, T AM GEOPHYS UNION, V73, P622; Gruau G, 1996, CHEM GEOL, V133, P225, DOI 10.1016/S0009-2541(96)00092-7; HARPER CL, 1992, NATURE, V360, P728, DOI 10.1038/360728a0; HARPER CL, 1995, SCIENCE, V267, P213, DOI 10.1126/science.7809625; HOFMANN AW, 1988, EARTH PLANET SC LETT, V90, P297, DOI 10.1016/0012-821X(88)90132-X; JACOBSEN SB, 1980, EARTH PLANET SC LETT, V50, P139, DOI 10.1016/0012-821X(80)90125-9; JACOBSEN SB, 1984, EARTH PLANET SC LETT, V67, P137, DOI 10.1016/0012-821X(84)90109-2; JACOBSEN SB, 1979, J GEOPHYS RES, V84, P7411, DOI 10.1029/JB084iB13p07411; JACOBSEN SB, 1988, J GEOPHYS RES-SOLID, V93, P338, DOI 10.1029/JB093iB01p00338; JAHN BM, 1987, PRECAMBRIAN RES, V34, P311, DOI 10.1016/0301-9268(87)90006-4; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; Kleine T, 2002, NATURE, V418, P952, DOI 10.1038/nature00982; LUGMAIR GW, 1992, GEOCHIM COSMOCHIM AC, V56, P1673, DOI 10.1016/0016-7037(92)90234-A; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; NYQUIST LE, 1995, GEOCHIM COSMOCHIM AC, V59, P2817, DOI 10.1016/0016-7037(95)00175-Y; NYQUIST LE, 1994, METEORITICS, V29, P872, DOI 10.1111/j.1945-5100.1994.tb01102.x; Parmentier EM, 2002, EARTH PLANET SC LETT, V201, P473, DOI 10.1016/S0012-821X(02)00726-4; Patchett PJ, 2004, EARTH PLANET SC LETT, V222, P29, DOI 10.1016/j.epsl.2004.02.030; PRINZHOFER A, 1992, GEOCHIM COSMOCHIM AC, V56, P797, DOI 10.1016/0016-7037(92)90099-5; Regelous M, 1996, GEOCHIM COSMOCHIM AC, V60, P3513, DOI 10.1016/0016-7037(96)00203-7; Rudnick R.L., 2004, TREATISE GEOCHEMISTR, P1, DOI DOI 10.1016/B0-08-043751-6/03016-4; Salters VJM, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2003GC000597; Samuel H, 2003, EARTH PLANET SC LETT, V207, P39, DOI 10.1016/S0012-821X(02)01125-1; Sharma M, 2004, PRECAMBRIAN RES, V135, P315, DOI 10.1016/j.precamres.2004.09.003; Sharma M, 1996, GEOCHIM COSMOCHIM AC, V60, P2037, DOI 10.1016/0016-7037(96)00082-8; Snyder G. A., 2000, ORIGIN EARTH MOON, p361 395; STEWART BW, 1994, GEOCHIM COSMOCHIM AC, V58, P3487, DOI 10.1016/0016-7037(94)90100-7; Tolstikhin I, 2005, PHYS EARTH PLANET IN, V148, P109, DOI 10.1016/j.pepi.2004.05.011; van Keken PE, 2002, ANNU REV EARTH PL SC, V30, P493, DOI 10.1146/annurev.earth.30.091201.141236; Vervoort JD, 1999, GEOCHIM COSMOCHIM AC, V63, P533, DOI 10.1016/S0016-7037(98)00274-9; WARREN PH, 1979, REV GEOPHYS, V17, P73, DOI 10.1029/RG017i001p00073; Wilde SA, 2001, NATURE, V409, P175, DOI 10.1038/35051550	53	494	504	3	137	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 22	2005	309	5734					576	581		10.1126/science.1113634	http://dx.doi.org/10.1126/science.1113634			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948SE	15961629				2022-12-28	WOS:000230735200038
J	Choe, J; Kelker, MS; Wilson, IA				Choe, J; Kelker, MS; Wilson, IA			Crystal structure of human Toll-like receptor 3 (TLR3) ectodomain	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; LEUCINE-RICH REPEAT; GLYCOPROTEIN IB-ALPHA; NF-KAPPA-B; RIBONUCLEASE INHIBITOR; CUTTING EDGE; PROTEIN; RECOGNITION; DOMAIN; ACTIVATION	Toll-like receptors (TLRs) play key roles in activating immune responses during infection. The human TLR3 ectodomain structure at 2.1 angstroms reveals a large horseshoe-shaped solenoid assembled from 23 leucine-rich repeats (LRRs). Asparagines conserved in the 24-residue LRR motif contribute extensive hydrogen-bonding networks for solenoid stabilization. TLR3 is largely masked by carbohydrate, but one face is glycosylation-free, which suggests its potential role in ligand binding and oligomerization. Highly conserved surface residues and a TLR3-specific LRR insertion form a homodimer interface in the crystal, whereas two patches of positively charged residues and a second insertion would provide an appropriate binding site for double-stranded RNA.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Wilson, IA (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wilson@scripps.edu			NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI042266, R01AI042266] Funding Source: NIH RePORTER; NCI NIH HHS [CA-58896] Funding Source: Medline; NIAID NIH HHS [T32 AI077606, AI-42266, R01 AI042266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; Beutler B, 2004, MOL IMMUNOL, V40, P845, DOI 10.1016/j.molimm.2003.10.005; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Enkhbayar P, 2004, PROTEINS, V54, P394, DOI 10.1002/prot.10605; Evdokimov AG, 2001, J MOL BIOL, V312, P807, DOI 10.1006/jmbi.2001.4973; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; He XLL, 2003, NEURON, V38, P177, DOI 10.1016/S0896-6273(03)00232-0; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Kim JI, 2005, J BIOL CHEM, V280, P11347, DOI 10.1074/jbc.M414607200; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Lee HK, 2004, J BIOL CHEM, V279, P10564, DOI 10.1074/jbc.M311564200; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Sarkar SN, 2003, J BIOL CHEM, V278, P4393, DOI 10.1074/jbc.C200655200; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; Sen GC, 2005, CYTOKINE GROWTH F R, V16, P1, DOI 10.1016/j.cytogfr.2005.01.006; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Tian B, 2004, NAT REV MOL CELL BIO, V5, P1013, DOI 10.1038/nrm1528; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; Ulevitch RJ, 2004, NAT REV IMMUNOL, V4, P512, DOI 10.1038/nri1396; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Zuany-Amorim C, 2002, NAT REV DRUG DISCOV, V1, P797, DOI 10.1038/nrd914	43	454	506	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 22	2005	309	5734					581	585		10.1126/science.1115253	http://dx.doi.org/10.1126/science.1115253			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948SE	15961631				2022-12-28	WOS:000230735200039
J	Kuehn, BM				Kuehn, BM			Evidence-based guidelines needed for osteoporosis screening and treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item							POSTMENOPAUSAL WOMEN; FRACTURE OUTCOMES; RISK-ASSESSMENT	Despite the prevalence of osteopenia and osteoporosis in the aging female population in the USA, women are not always routinely advised to have osteoporosisscreening. Ethel S. Siris, MD, president-elect of the National Osteoporosis Foundation (NOF), and leader of the National Osteoporosis Risk Assessment (NORA) project, would like to see osteoporosis screening, including bone mineral density measurements or a risk assessment, become part of the standard care for older women. The WHO, in association with NOF and the International Osteoporosis Foundation, is developing evidence-based treatment and intervention guidelines, including a risk assessment algorithm, to address the problem.										Miller PD, 2004, ARCH INTERN MED, V164, P1113, DOI 10.1001/archinte.164.10.1113; Siris ES, 2004, J BONE MINER RES, V19, P1215, DOI 10.1359/JBMR.040508; Siris ES, 2001, JAMA-J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815	3	1	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2005	294	1					34	34		10.1001/jama.294.1.34	http://dx.doi.org/10.1001/jama.294.1.34			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941JD	15998880				2022-12-28	WOS:000230210200006
J	Bodenheimer, T; Fernandez, A				Bodenheimer, T; Fernandez, A			High and rising health care costs. Part 4: Can costs be controlled while preserving quality?	ANNALS OF INTERNAL MEDICINE			English	Article							DISEASE MANAGEMENT PROGRAMS; HEART-FAILURE; PREVENTABLE HOSPITALIZATIONS; REGIONAL-VARIATIONS; MEDICAL OUTCOMES; SELF-MANAGEMENT; UNITED-STATES; INTERVENTION; EXPENDITURES; PHYSICIANS	Several interrelated strategies involving physician leadership and participation have been proposed to contain health care costs while preserving or improving quality. These include programs targeting the 10% of the population that incurs 70% of health care expenditures, disease management programs to prevent costly complications of chronic conditions, efforts to reduce medical errors, the strengthening of primary care practice, decision support tools to avoid inappropriate services, and improved diffusion of technology assessment. An example of a cost-reducing, quality-enhancing program is post-hospital nurse monitoring and intervention for patients at high risk for repeated hospitalization for congestive heart failure. Disease management programs that target groups with a chronic condition rather than focusing efforts on high-utilizing individuals may be effective in improving quality but may not reduce costs. Error reduction has great potential to improve quality while reducing costs, although the probable cost reduction is a small portion of national health care expenditures. Access to primary care has been shown to correlate with reduced hospital use while preserving quality. Inappropriate care and overuse of new technologies can be reduced through shared decision-making between well-informed physicians and patients. Physicians have a central role to play in fostering these quality-enhancing strategies that can help to slow the growth of health care expenditures.	Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Family & Community Med, Bldg 80-83,1001 Potrero Ave, San Francisco, CA 94110 USA.	tbodenheimer@medsch.ucsf.edu						Anderson G, 2002, CHRONIC CONDITIONS M; Axene DV, 1997, ANAL MED UNNECESSARY; Backus L, 2002, MED CARE, V40, P315, DOI 10.1097/00005650-200204000-00007; BAIKER K, 2004, WEB EXCLUSIVE   0407; Banta D, 2003, HEALTH POLICY, V63, P121, DOI 10.1016/S0168-8510(02)00059-3; Basu J, 2004, HEALTH SERV RES, V39, P489, DOI 10.1111/j.1475-6773.2004.00241.x; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Berk ML, 2001, HEALTH AFFAIR, V20, P9, DOI 10.1377/hlthaff.20.2.9; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Bodenheimer T, 2005, ANN INTERN MED, V142, P996, DOI 10.7326/0003-4819-142-12_Part_1-200506210-00009; Bodenheimer T, 2005, ANN INTERN MED, V142, P932, DOI 10.7326/0003-4819-142-11-200506070-00012; Bodenheimer T, 2005, ANN INTERN MED, V142, P847, DOI 10.7326/0003-4819-142-10-200505170-00010; Bodenheimer T, 1999, NEW ENGL J MED, V340, P1202, DOI 10.1056/NEJM199904153401511; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; Cohen JW, 2003, HEALTH AFFAIR, V22, P129, DOI 10.1377/hlthaff.22.2.129; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Crosson FJ, 2004, HEALTH AFFAIR, V23, P76, DOI 10.1377/hlthaff.23.6.76; DeBusk RF, 2004, ANN INTERN MED, V141, P606, DOI 10.7326/0003-4819-141-8-200410190-00008; Deyo RA, 2004, NEW ENGL J MED, V350, P722, DOI 10.1056/NEJMsb031771; Deyo RA, 2002, ANNU REV PUBL HEALTH, V23, P23, DOI 10.1146/annurev.publhealth.23.092101.134534; Dove HG, 2003, AM J MANAG CARE, V9, P381; Emanuel EJ, 2003, ANN INTERN MED, V138, P639, DOI 10.7326/0003-4819-138-8-200304150-00011; Fetterolf Donald, 2004, Dis Manag, V7, P5, DOI 10.1089/109350704322918961; Fireman B, 2004, HEALTH AFFAIR, V23, P63, DOI 10.1377/hlthaff.23.6.63; Fischer MA, 2004, JAMA-J AM MED ASSOC, V291, P1850, DOI 10.1001/jama.291.15.1850; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fisher ES, 2003, NEW ENGL J MED, V349, P1665, DOI 10.1056/NEJMe038149; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; Heisler M, 2002, J GEN INTERN MED, V17, P243, DOI 10.1046/j.1525-1497.2002.10905.x; Institute of Medicine, 2001, CROSSING QUALITY CHA; Jiang HJ, 2003, DIABETES CARE, V26, P1421, DOI 10.2337/diacare.26.5.1421; LEAPE LL, 1992, ANNU REV PUBL HEALTH, V13, P363, DOI 10.1146/annurev.pu.13.050192.002051; Leatherman S, 2003, HEALTH AFFAIR, V22, P17, DOI 10.1377/hlthaff.22.2.17; LIEBERMAN SM, 1980, NEW ENGL J MED, V302, P996; Lubitz J, 2003, NEW ENGL J MED, V349, P1048, DOI 10.1056/NEJMsa020614; McAlister FA, 2001, AM J MED, V110, P378, DOI 10.1016/S0002-9343(00)00743-9; *MED PAYM ADV COMM, 2003, VAR INN MED; Naylor CD, 1998, NEW ENGL J MED, V338, P1918, DOI 10.1056/NEJM199806253382612; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; O'Brien M K, 1992, Med Care Rev, V49, P435, DOI 10.1177/002570879204900403; O'Connor AM, 2004, HLTH AFF        1007; PARCHMAN ML, 1994, J FAM PRACTICE, V39, P123; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Rich MW, 2001, AM J MED, V110, P410, DOI 10.1016/S0002-9343(01)00632-5; Schneider EC, 2001, ANN INTERN MED, V135, P328, DOI 10.7326/0003-4819-135-5-200109040-00009; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; Shekelle PG, 2001, NEW ENGL J MED, V344, P677, DOI 10.1056/NEJM200103013440912; STARFIELD B, 1998, PRIMARY CARE; THORPE KE, 2004, WEB EXCLUSIVE   0825; Villagra VG, 2004, HEALTH AFFAIR, V23, P255, DOI 10.1377/hlthaff.23.4.255; Wagner EH, 2004, ANN INTERN MED, V141, P644, DOI 10.7326/0003-4819-141-8-200410190-00015; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269; Zhan CL, 2004, HEALTH SERV RES, V39, P345, DOI 10.1111/j.1475-6773.2004.00231.x; Zhan CL, 2003, JAMA-J AM MED ASSOC, V290, P1868, DOI 10.1001/jama.290.14.1868; 2003, LOS ANGELES TIM 0122, pB1; 2004, MED ERRORS SCOP EPRO	62	104	106	1	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 5	2005	143	1					26	31		10.7326/0003-4819-143-1-200507050-00007	http://dx.doi.org/10.7326/0003-4819-143-1-200507050-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941XB	15998752				2022-12-28	WOS:000230246400004
J	Leaman, D; Chen, PY; Fak, J; Yalcin, A; Pearce, M; Unnerstall, U; Marks, DS; Sander, C; Tuschl, T; Gaul, U				Leaman, D; Chen, PY; Fak, J; Yalcin, A; Pearce, M; Unnerstall, U; Marks, DS; Sander, C; Tuschl, T; Gaul, U			Antisense-mediated depletion reveals essential and specific functions of microRNAs in Drosophila development	CELL			English	Article							PROGRAMMED CELL-DEATH; C-ELEGANS; COMPUTATIONAL IDENTIFICATION; CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; ENCODES; MELANOGASTER; ACTIVATION; STRIPES; TARGET	MicroRNAs are small noncoding RNAs that control gene function posttranscriptionally through mRNA degradation or translational inhibition. Much has been learned about the processing and mechanism of action of microRNAs, but little is known about their biological function. Here, we demonstrate that injection of 2'O-methyl antisense oligoribonucleotides into early Drosophila embryos leads to specific and efficient depletion of microRNAs and thus permits systematic loss-of-function analysis in vivo. Twenty-five of the forty-six embryonically expressed microRNAs show readily discernible defects; pleiotropy is moderate and family members display similar yet distinct phenotypes. Processes under microRNA regulation include cellularization and patterning in the blastoderm, morphogenesis, and cell survival. The largest microRNA family in Drosophila (miR-2/6/11/13/308) is required for suppressing embryonic apoptosis; this is achieved by differential posttranscriptional repression of the proapoptotic factors hid, grim, reaper, and sickle. Our findings demonstrate that microRNAs act as specific and essential regulators in a wide range of developmental processes.	Rockefeller Univ, Lab Dev Neurogenet, New York, NY 10021 USA; Rockefeller Univ, Lab RNA Mol Biol, New York, NY 10021 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA	Rockefeller University; Rockefeller University; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center	Gaul, U (corresponding author), Rockefeller Univ, Lab Dev Neurogenet, 1230 York Ave, New York, NY 10021 USA.	gaul@mail.rockefeller.edu	Yalcin, Abdullah/AAG-4175-2019; Sander, Chris/H-1452-2011	Yalcin, Abdullah/0000-0001-8604-4749; Sander, Chris/0000-0001-6059-6270				Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bergmann A, 2002, DEV CELL, V2, P159, DOI 10.1016/S1534-5807(02)00116-8; Boutla A, 2003, NUCLEIC ACIDS RES, V31, P4973, DOI 10.1093/nar/gkg707; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; CARROLL SB, 1990, CELL, V60, P9, DOI 10.1016/0092-8674(90)90711-M; Chang S, 2004, NATURE, V430, P785, DOI 10.1038/nature02752; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen XM, 2004, SCIENCE, V303, P2022, DOI 10.1126/science.1088060; Christich A, 2002, CURR BIOL, V12, P137, DOI 10.1016/S0960-9822(01)00658-3; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Enright AJ, 2004, GENOME BIOL, V5; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Griffiths-Jones S, 2003, NUCLEIC ACIDS RES, V31, P439, DOI 10.1093/nar/gkg006; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; Hipfner DR, 2002, GENETICS, V161, P1527; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Jacinto A, 2002, DEV CELL, V3, P9, DOI 10.1016/S1534-5807(02)00208-3; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 2004, EMBO REP, V5, P762, DOI 10.1038/sj.embor.7400207; Lai EC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-115; Lai EC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r42; Lecuit T, 2002, TRAFFIC, V3, P92, DOI 10.1034/j.1600-0854.2002.030202.x; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lin SY, 2003, DEV CELL, V4, P639, DOI 10.1016/S1534-5807(03)00124-2; Mazumdar A, 2002, BIOESSAYS, V24, P1012, DOI 10.1002/bies.10184; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Nambu PA, 1996, DEVELOPMENT, V122, P3467; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; Pick L, 1998, DEV GENET, V23, P1; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rajewsky N, 2004, DEV BIOL, V267, P529, DOI 10.1016/j.ydbio.2003.12.003; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; RiveraPomar R, 1996, TRENDS GENET, V12, P478, DOI 10.1016/0168-9525(96)10044-5; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Schock F, 2002, ANNU REV CELL DEV BI, V18, P463, DOI 10.1146/annurev.cellbio.18.022602.131838; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Tittel JN, 2000, GENOME BIOL, V1, pS3; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Welte MA, 1998, CELL, V92, P547, DOI 10.1016/S0092-8674(00)80947-2; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zhang S, 2002, CELL, V108, P45, DOI 10.1016/S0092-8674(01)00630-4	52	256	289	1	30	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	2005	121	7					1097	1108		10.1016/j.cell.2005.04.016	http://dx.doi.org/10.1016/j.cell.2005.04.016			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989958	Bronze, Green Published			2022-12-28	WOS:000230448000015
J	Vidanes, GM; Bonilla, CY; Toczyski, DP				Vidanes, GM; Bonilla, CY; Toczyski, DP			Complicated tails: Histone modifications and the DNA damage response	CELL			English	Review							DOUBLE-STRAND BREAKS; GAMMA-H2AX FOCI; REPAIR; RECRUITMENT; H2A; PHOSPHORYLATION; SITES; METHYLATION; ACETYLATION; BINDING	In recent years, several ATP-dependent chromatin-remodeling complexes and covalent histone modifications have been implicated in the response to double-stranded DNA breaks (DSBs). When a DSB occurs, cells must identify the DSB, activate the DNA damage checkpoint, and repair the break. Chromatin modification appears to be important but not essential for each of these processes, yet its precise mechanistic roles are only beginning to come into focus. Here, we discuss the role of chromatin in signaling by the DNA damage checkpoint pathway.	Univ Calif San Francisco, Canc Res Inst, Dept Biochem & Biophys, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	Toczyski, DP (corresponding author), Univ Calif San Francisco, Canc Res Inst, Dept Biochem & Biophys, Box 0128, San Francisco, CA 94115 USA.	toczyski@cc.ucsf.edu						Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Ehrenhofer-Murray AE, 2004, EUR J BIOCHEM, V271, P2335, DOI 10.1111/j.1432-1033.2004.04162.x; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Kamakaka RT, 2005, GENE DEV, V19, P295, DOI 10.1101/gad.1272805; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Nakamura TM, 2004, MOL CELL BIOL, V24, P6215, DOI 10.1128/MCB.24.14.6215-6230.2004; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Strom L, 2004, MOL CELL, V16, P1003, DOI 10.1016/j.molcel.2004.11.026; Unal E, 2004, MOL CELL, V16, P991, DOI 10.1016/j.molcel.2004.11.027; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200	19	120	126	0	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 1	2005	121	7					973	976		10.1016/j.cell.2005.06.013	http://dx.doi.org/10.1016/j.cell.2005.06.013			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989948	Bronze			2022-12-28	WOS:000230448000005
J	Michor, F; Hughes, TP; Iwasa, Y; Branford, S; Shah, NP; Sawyers, CL; Nowak, MA				Michor, F; Hughes, TP; Iwasa, Y; Branford, S; Shah, NP; Sawyers, CL; Nowak, MA			Dynamics of chronic myeloid leukaemia	NATURE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; COMPLETE CYTOGENETIC REMISSION; TIME QUANTITATIVE PCR; IMATINIB MESYLATE; BLAST CRISIS; ABL GENE; HEMATOPOIETIC PROGENITORS; CLINICAL RESISTANCE; TYROSINE KINASE; CHRONIC PHASE	The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for molecularly targeted therapy of cancer(1-4), but at least two critical questions remain. Can imatinib eradicate leukaemic stem cells? What are the dynamics of relapse due to imatinib resistance, which is caused by mutations in the ABL kinase domain? The precise understanding of how imatinib exerts its therapeutic effect in CML and the ability to measure disease burden by quantitative polymerase chain reaction provide an opportunity to develop a mathematical approach. We find that a four-compartment model, based on the known biology of haematopoietic differentiation(5), can explain the kinetics of the molecular response to imatinib in a 169-patient data set. Successful therapy leads to a biphasic exponential decline of leukaemic cells. The first slope of 0.05 per day represents the turnover rate of differentiated leukaemic cells, while the second slope of 0.008 per day represents the turnover rate of leukaemic progenitors. The model suggests that imatinib is a potent inhibitor of the production of differentiated leukaemic cells, but does not deplete leukaemic stem cells. We calculate the probability of developing imatinib resistance mutations and estimate the time until detection of resistance. Our model provides the first quantitative insights into the in vivo kinetics of a human cancer.	Harvard Univ, Dept Math, Dept Organism & Evolutionary Biol, Program Evolutionary Dynam, Cambridge, MA 02138 USA; Inst Med & Vet Sci, Adelaide, SA 5000, Australia; Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Dept Med & Mol Pharmacol,Dept Urol,Mol Biol Inst, Los Angeles, CA 90095 USA	Harvard University; Institute Medical & Veterinary Science Australia; Kyushu University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Michor, F (corresponding author), Harvard Univ, Dept Math, Dept Organism & Evolutionary Biol, Program Evolutionary Dynam, Cambridge, MA 02138 USA.	michor@fas.harvard.edu	Hughes, Tim/AAO-9975-2021; Branford, Susan/X-7733-2019; Nowak, Martin A/A-6977-2008; Sawyers, Charles/G-5327-2016; Iwasa, Yoh/G-5368-2010	Iwasa, Yoh/0000-0003-0691-1852; Branford, Susan/0000-0002-5095-7981				BEDI A, 1993, BLOOD, V81, P2898; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Branford S, 2003, BLOOD, V102, P276, DOI 10.1182/blood-2002-09-2896; Branford S, 2004, BLOOD, V104, P2926, DOI 10.1182/blood-2004-03-1134; Branford S, 1999, BRIT J HAEMATOL, V107, P587; Branford S, 2003, BLOOD, V102, p414A; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; Chu S, 2005, BLOOD, V105, P2093, DOI 10.1182/blood-2004-03-1114; Cortes J, 2004, BLOOD, V104, P2204, DOI 10.1182/blood-2004-04-1335; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Higashi T, 2004, AM J HEMATOL, V76, P275, DOI 10.1002/ajh.20096; Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Holyoake TL, 2002, LEUKEMIA, V16, P549, DOI 10.1038/sj.leu.2402444; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Mahon FX, 2003, BLOOD, V101, P2368, DOI 10.1182/blood.V101.6.2368; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; Roche-Lestienne C, 2003, NEW ENGL J MED, V348, P2265, DOI 10.1056/NEJMc035089; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810	27	610	628	0	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1267	1270		10.1038/nature03669	http://dx.doi.org/10.1038/nature03669			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988530				2022-12-28	WOS:000230140500050
J	Rubin, EM; Raptopoulos, VD				Rubin, EM; Raptopoulos, VD			The virtual apple core of a colonic carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Crozer Chester Med Ctr, Upland, PA 19013 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Rubin, EM (corresponding author), Crozer Chester Med Ctr, Upland, PA 19013 USA.								0	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					2733	2733		10.1056/NEJMicm040235	http://dx.doi.org/10.1056/NEJMicm040235			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	940HH	15987922				2022-12-28	WOS:000230133800010
J	Ryan, DP; Fernandez-del Castillo, C; Willett, CG; Brugge, WR; Sahani, D; Brachtel, EF; Sahani, D				Ryan, DP; Fernandez-del Castillo, C; Willett, CG; Brugge, WR; Sahani, D; Brachtel, EF; Sahani, D			A 58-year-old man with locally advanced pancreatic cancer - Ductal adenocarcinoma of the pancreas, with residual microscopic tumor after chemoradiation therapy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESECTED ADENOCARCINOMA; ADJUVANT IRRADIATION; CHEMOTHERAPY; CARCINOMA; TRIAL; PHASE; PANCREATICODUODENECTOMY; DIAGNOSIS; MORTALITY; SURVIVAL		Massachusetts Gen Hosp, Dept Hematol & Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Div Gastroenterol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Duke University	Ryan, DP (corresponding author), Massachusetts Gen Hosp, Dept Hematol & Oncol, Boston, MA 02114 USA.		Castillo, Carlos Fenandez-del/AAO-2602-2020					[Anonymous], 1987, Cancer, V59, P2006; BAKKEVOLD KE, 1992, SCAND J GASTROENTERO, V27, P317, DOI 10.3109/00365529209000081; Balcom JH, 2001, ARCH SURG-CHICAGO, V136, P391, DOI 10.1001/archsurg.136.4.391; Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205; Centeno BA, 1999, FINE NEEDLE ASPIRATION BIOPSY OF THE PANCREAS, P109; CRIST DW, 1987, ANN SURG, V206, P358, DOI 10.1097/00000658-198709000-00014; EVANS DB, 1992, ARCH SURG-CHICAGO, V127, P1335; FOO ML, 1993, INT J RADIAT ONCOL, V26, P483, DOI 10.1016/0360-3016(93)90967-Z; HEYWOOD G, 1998, BIOSCIENCE, V3, pE175; Hoffman JP, 1998, J CLIN ONCOL, V16, P317, DOI 10.1200/JCO.1998.16.1.317; Ichikawa T, 1997, RADIOLOGY, V202, P655, DOI 10.1148/radiology.202.3.9051012; Jimenez RE, 2000, ARCH SURG-CHICAGO, V135, P409, DOI 10.1001/archsurg.135.4.409; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; KLOPPEL G, 2000, WHO CLASSIFICATION T, V2, P221; Lu DSK, 1997, AM J ROENTGENOL, V168, P1439, DOI 10.2214/ajr.168.6.9168704; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2001, ANN SURG, V234, P758, DOI 10.1097/00000658-200112000-00007; PERMERT J, 1991, INT J PANCREATOL, V9, P113; ROSCH T, 1992, GASTROENTEROLOGY, V102, P188; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; Spitz FR, 1997, J CLIN ONCOL, V15, P928, DOI 10.1200/JCO.1997.15.3.928; TEPPER JE, 1986, INT J RADIAT ONCOL, V12, P667, DOI 10.1016/0360-3016(86)90078-7; Vargas R, 2004, AM J ROENTGENOL, V182, P419, DOI 10.2214/ajr.182.2.1820419; WESTERDAHL J, 1993, HEPATO-GASTROENTEROL, V40, P384; WHITTINGTON R, 1991, INT J RADIAT ONCOL, V21, P1137, DOI 10.1016/0360-3016(91)90268-9; WILLETT CG, 1993, ANN SURG, V217, P144, DOI 10.1097/00000658-199302000-00008	26	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					2734	2741		10.1056/NEJMcpc059014	http://dx.doi.org/10.1056/NEJMcpc059014			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	940HH	15987923				2022-12-28	WOS:000230133800012
J	Diepstra, A; Niens, M; Vellenga, E; van Imhoff, GW; Nolte, IM; Schaapveld, M; van der Steege, G; van den Berg, A; Kibbelaar, RE; te Meerman, GJ; Poppema, S				Diepstra, A; Niens, M; Vellenga, E; van Imhoff, GW; Nolte, IM; Schaapveld, M; van der Steege, G; van den Berg, A; Kibbelaar, RE; te Meerman, GJ; Poppema, S			Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma	LANCET			English	Article							REED-STERNBERG CELLS; MAJOR HISTOCOMPATIBILITY COMPLEX; DISEASE; GENE; SUSCEPTIBILITY; POLYMORPHISM; POPULATION; EXPRESSION; PATTERNS; SUGGESTS	Background Associations of Hodgkin's lymphoma with HLA have been reported for many years. In 20-40% of patients with this disorder, Epstein-Barr virus (EBV) is present in the neoplastic cells. Because presentation of EBV antigenic peptides can elicit vigorous immune responses, we investigated associations of the HLA region with EBV-positive and EBV-negative Hodgkin's lymphoma. Methods In a retrospective, population-based study, patients with Hodgkin's lymphoma were reclassified according to the WHO classification, and EBV status was assessed by in-situ hybridisation of EBV-encoded small RNAs. Germline DNA was isolated from 200 patients diagnosed between 1987 and 2000 and from their first-degree relatives. Genotyping was done with 33 microsatellite markers spanning the entire HLA region and two single-nucleotide polymorphisms in the genes for tumour necrosis factor alpha and beta. Classic association analysis and the haplotype sharing statistic were used to compare patients with controls. Findings Classic association analysis (but not the haplotype sharing statistic) showed an association of consecutive markers D6S265 and D6S510 (p=0.0002 and 0.0003), located in the HLA class I region, with EBV-positive lymphomas. The haplotype sharing statistic (but not classic association analysis) showed a significant difference in mean haplotype sharing between patients and controls surrounding marker D6S273 (p=0.00003), located in HLA class III. Interpretation Areas within the HLA class I and class III regions are associated with susceptibility to Hodgkin's lymphoma, the association with class I being specific for EBV-positive disease. This finding strongly suggests that antigenic presentation of EBV-derived peptides is involved in the pathogenesis of EBV-involved Hodgkin's lymphoma. Relevance to practice Polymorphisms in the HLA region could explain ethnic variation in the incidence of Hodgkin's lymphoma. The association of EBV-positive Hodgkin's lymphoma with HLA class I suggests that this polymorphism might affect the proper presentation of EBV antigens to cytotoxic T lymphocytes.	Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands; Univ Med Ctr Groningen, Dept Med Genet, Groningen, Netherlands; Univ Med Ctr Groningen, Dept Haematol, Groningen, Netherlands; Univ Med Ctr Groningen, Dept Med Biol, Groningen, Netherlands; Univ Groningen, Groningen, Netherlands; Comprehens Canc Ctr N Netherlands, Groningen, Netherlands; Lab Publ Hlth Friesland, Dept Pathol, Leeuwarden, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen	Diepstra, A (corresponding author), Univ Med Ctr Groningen, Dept Pathol & Lab Med, Hanzepl 1,POB 30-001, NL-9700 RB Groningen, Netherlands.	a.diepstra@path.umcg.nl	Schaapveld, Michael/ABC-9714-2020; van den Berg, Anke/H-1718-2011; Poppema, Sibrand/D-1204-2012	van den Berg, Anke/0000-0002-8894-2638; Schaapveld, Michael/0000-0003-4390-7182; Diepstra, Arjan/0000-0001-9239-1050				Ahmad T, 2003, HUM MOL GENET, V12, P647, DOI 10.1093/hmg/ddg066; Beck J, 2001, SOURCE-NOTE HIST ART, V21, P1; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; Boon M, 2001, NEUROGENETICS, V3, P221; Brinkman B M, 1995, J Inflamm, V46, P32; de Jong MM, 2003, HUM MOL GENET, V12, P2311, DOI 10.1093/hmg/ddg245; Ferraris AM, 1997, ANN HEMATOL, V74, P131, DOI 10.1007/s002770050270; Glaser SL, 2002, LEUKEMIA RES, V26, P261, DOI 10.1016/S0145-2126(01)00126-6; Glaser SL, 1996, BAILLIERE CLIN HAEM, V9, P401, DOI 10.1016/S0950-3536(96)80018-7; Harty LC, 2002, BLOOD, V99, P690, DOI 10.1182/blood.V99.2.690; HORS J, 1983, IMMUNOL REV, V70, P167, DOI 10.1111/j.1600-065X.1983.tb00714.x; KLITZ W, 1994, AM J HUM GENET, V54, P497; Leen A, 2001, J VIROL, V75, P8649, DOI 10.1128/JVI.75.18.8649-8659.2001; Levinson DF, 2001, AM J MED GENET, V105, P65, DOI 10.1002/1096-8628(20010108)105:1<65::AID-AJMG1064>3.3.CO;2-S; LEWONTIN RC, 1964, GENETICS, V49, P49; Libura J, 2002, ANTICANCER RES, V22, P921; MACK TM, 1995, NEW ENGL J MED, V332, P413, DOI 10.1056/NEJM199502163320701; Maggio EM, 2001, INT J CANCER, V94, P60, DOI 10.1002/ijc.1438; Mainou-Fowler T, 2000, LEUKEMIA LYMPHOMA, V38, P547, DOI 10.3109/10428190009059274; Meij P, 2002, INT J CANCER, V99, P93, DOI 10.1002/ijc.10309; MESSER G, 1991, J EXP MED, V173, P209, DOI 10.1084/jem.173.1.209; Oudejans JJ, 1996, BLOOD, V87, P3844, DOI 10.1182/blood.V87.9.3844.bloodjournal8793844; OZA AM, 1994, CANCER RES, V54, P5101; Poppema S, 2000, SEMIN CANCER BIOL, V10, P345, DOI 10.1006/scbi.2000.0327; Schwering I, 2003, BLOOD, V101, P1505, DOI 10.1182/blood-2002-03-0839; Skinnider BF, 2002, BLOOD, V99, P4283, DOI 10.1182/blood-2002-01-0099; STEIN HJ, 2001, PROGNOSTIC FACTORS C, P237; Taylor GM, 1999, BRIT J CANCER, V80, P1405, DOI 10.1038/sj.bjc.6690536; Taylor GM, 1996, LEUKEMIA, V10, P854; Wihlborg C, 1999, BRIT J HAEMATOL, V104, P346, DOI 10.1046/j.1365-2141.1999.01176.x	30	115	118	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 25	2005	365	9478					2216	2224		10.1016/S0140-6736(05)66780-3	http://dx.doi.org/10.1016/S0140-6736(05)66780-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978930				2022-12-28	WOS:000230034800032
J	Corwin, EI; Jaeger, HM; Nagel, SR				Corwin, EI; Jaeger, HM; Nagel, SR			Structural signature of jamming in granular media	NATURE			English	Article							DISTRIBUTIONS; FLUCTUATIONS; FORCES	Glasses are rigid, but flow when the temperature is increased. Similarly, granular materials are rigid, but become unjammed and flow if sufficient shear stress is applied. The rigid and flowing phases are strikingly different, yet measurements reveal that the structures of glass and liquid are virtually indistinguishable(1,2). It is therefore natural to ask whether there is a structural signature of the jammed granular state that distinguishes it from its flowing counterpart. Here we find evidence for such a signature, by measuring the contact-force distribution between particles during shearing. Because the forces are sensitive to minute variations in particle position, the distribution of forces can serve as a microscope with which to observe correlations in the positions of nearest neighbours. We find a qualitative change in the force distribution at the onset of jamming. If, as has been proposed(3-9), the jamming and glass transitions are related, our observation of a structural signature associated with jamming hints at the existence of a similar structural difference at the glass transition presumably too subtle for conventional scattering techniques to uncover. Our measurements also provide a determination of a granular temperature that is the counterpart in granular systems to the glass-transition temperature in liquids.	Univ Chicago, James Franck Inst, Dept Phys, Chicago, IL 60637 USA	University of Chicago	Corwin, EI (corresponding author), Univ Chicago, James Franck Inst, Dept Phys, 5640 S Ellis Ave, Chicago, IL 60637 USA.	ecorwin@uchicago.edu						Baxter GW, 1997, POWDERS & GRAINS 97, P345; Blair DL, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.041304; Brujic J, 2003, PHYSICA A, V327, P201, DOI 10.1016/S0378-4371(03)00477-1; Conway SL, 2004, NATURE, V431, P433, DOI 10.1038/nature02901; Edwards SF, 2003, GRANUL MATTER, V4, P147, DOI 10.1007/s10035-002-0117-3; Ferguson A, 2004, EUROPHYS LETT, V66, P277, DOI 10.1209/epl/i2003-10190-3; FRICK B, 1995, SCIENCE, V267, P1939, DOI 10.1126/science.267.5206.1939; Howell D, 1999, PHYS REV LETT, V82, P5241, DOI 10.1103/PhysRevLett.82.5241; Howell D, 1997, POWDERS & GRAINS 97, P337; LACEVIC N, 2004, DYNAMICAL HETEROGENE; Landau L. D., 1986, THEORY ELASTICITY; Landry JW, 2003, B AM PHYS SOC, V48, P153; Leheny RL, 1996, J CHEM PHYS, V105, P7783, DOI 10.1063/1.472561; Liu A., 2001, JAMMING RHEOLOGY CON; Liu AJ, 1998, NATURE, V396, P21, DOI 10.1038/23819; LIU CH, 1995, SCIENCE, V269, P513, DOI 10.1126/science.269.5223.513; Longhi E, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.045501; Lovoll G, 1999, PHYS REV E, V60, P5872, DOI 10.1103/PhysRevE.60.5872; Makse HA, 2000, PHYS REV LETT, V84, P4160, DOI 10.1103/PhysRevLett.84.4160; Mueth DM, 1998, PHYS REV E, V57, P3164, DOI 10.1103/PhysRevE.57.3164; Nicodemi M, 2004, UNIFYING CONCEPTS IN GRANULAR MEDIA AND GLASSES, P47, DOI 10.1016/B978-044451607-7/50005-4; O'Hern CS, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.011306; O'Hern CS, 2001, PHYS REV LETT, V86, P111, DOI 10.1103/PhysRevLett.86.111; Ono IK, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.095703; Radjai F, 1999, CHAOS, V9, P544, DOI 10.1063/1.166428; Silbert LE, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.061303; Silbert LE, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.051307; Snoeijer JH, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.054302; Trappe V, 2001, NATURE, V411, P772, DOI 10.1038/35081021	29	244	250	3	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1075	1078		10.1038/nature03698	http://dx.doi.org/10.1038/nature03698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973404				2022-12-28	WOS:000229970400043
J	Gozlan, RE; St-Hilaire, S; Feist, SW; Martin, P; Kent, ML				Gozlan, RE; St-Hilaire, S; Feist, SW; Martin, P; Kent, ML			Biodiversity - Disease threat to European fish	NATURE			English	Editorial Material							SPHAEROTHECUM-DESTRUENS; INVASIONS; VIRUS		Winfrith Technol Ctr, Ctr Ecol & Hydrol, Dorchester DT2 8ZD, Dorset, England; Idaho State Univ, Dept Biol Sci, Pocatello, ID 83209 USA; CEFAS Weymouth Lab, Weymouth DT4 8UB, Dorset, England; Oregon State Univ, Dept Microbiol, Ctr Fish Dis Res, Corvallis, OR 97331 USA	UK Centre for Ecology & Hydrology (UKCEH); Idaho; Idaho State University; Centre for Environment Fisheries & Aquaculture Science; Oregon State University	Gozlan, RE (corresponding author), Winfrith Technol Ctr, Ctr Ecol & Hydrol, Dorchester DT2 8ZD, Dorset, England.	reg@ceh.ac.uk	St-HIlaire, Sophie/GSI-8705-2022; Gozlan, Rodolphe/B-3973-2009					Arkush KD, 2003, J EUKARYOT MICROBIOL, V50, P430, DOI 10.1111/j.1550-7408.2003.tb00269.x; Gilad O, 2002, DIS AQUAT ORGAN, V48, P101, DOI 10.3354/dao048101; GIURCA R, 1971, ROMANIEI B CERC PISC, V30, P99; Gozlan RE, 2002, J FISH BIOL, V61, P298, DOI 10.1006/jfbi.2002.2042; LELEK A, 1987, FRESHWATER FISHES EU; LODGE DM, 1993, TRENDS ECOL EVOL, V8, P133, DOI 10.1016/0169-5347(93)90025-K; Mendonca HL, 2004, DIS AQUAT ORGAN, V61, P187, DOI 10.3354/dao061187; St-Hilaire S, 2001, DIS AQUAT ORGAN, V46, P173, DOI 10.3354/dao046173; Vander Zanden MJ, 1999, NATURE, V401, P464, DOI 10.1038/46762; Wolfram-Wais A, 1999, HYDROBIOLOGIA, V408, P123, DOI 10.1023/A:1017014130103	10	227	255	2	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1046	1046		10.1038/4351046a	http://dx.doi.org/10.1038/4351046a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973399				2022-12-28	WOS:000229970400034
J	Wang, SP; Niu, HS; Cui, XY; Jiang, S; Li, YH; Xiao, XM; Wang, JZ; Wang, GJ; Huang, DH; Qi, QH; Yang, ZG				Wang, SP; Niu, HS; Cui, XY; Jiang, S; Li, YH; Xiao, XM; Wang, JZ; Wang, GJ; Huang, DH; Qi, QH; Yang, ZG			Plant communities - Ecosystem stability in inner Mongolia	NATURE			English	Editorial Material							LEYMUS-CHINENSE STEPPE; XILIN RIVER BASIN; ABOVEGROUND BIOMASS; ECOLOGY; DIVERSITY; CHINA		Chinese Acad Sci, Inst Bot, Beijing 100093, Peoples R China; Chinese Acad Sci, NW Inst Plateau Biol, Xining 810008, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing 100049, Peoples R China; Univ New Hampshire, Inst Study Earth Oceans & Space, Durham, NH 03824 USA	Chinese Academy of Sciences; Institute of Botany, CAS; Chinese Academy of Sciences; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; University System Of New Hampshire; University of New Hampshire	Wang, SP (corresponding author), Chinese Acad Sci, Inst Bot, Beijing 100093, Peoples R China.		Wu, Jianguo/G-6267-2010; Li, Frank Yonghong/AAN-3093-2020	Wu, Jianguo/0000-0002-1182-3024; Li, Frank Yonghong/0000-0002-5137-8017				Bai YF, 2004, NATURE, V431, P181, DOI 10.1038/nature02850; Chen Z., 2000, TYPICAL STEPPE ECOSY; Doak DF, 1998, AM NAT, V151, P264, DOI 10.1086/286117; Huston MA, 2002, BIODIVERSITY AND ECOSYSTEM FUNCTIONING: SYNTHESIS AND PERSPECTIVES, P47; MCNAUGHTON SJ, 1985, ECOL MONOGR, V55, P259, DOI 10.2307/1942578; MCNAUGHTON SJ, 1977, AM NAT, V111, P515, DOI 10.1086/283181; Tilman D, 1996, ECOLOGY, V77, P350, DOI 10.2307/2265614; Xiao XM, 1996, VEGETATIO, V123, P1, DOI 10.1007/BF00044884; XIAO XM, 1995, J ARID ENVIRON, V31, P283, DOI 10.1016/S0140-1963(05)80033-3	9	11	16	7	98	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 23	2005	435	7045					E5	E6		10.1038/nature03862	http://dx.doi.org/10.1038/nature03862			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973359				2022-12-28	WOS:000229970400035
J	Jackson, CM				Jackson, CM			Glassmaking in Bronze-Age Egypt	SCIENCE			English	Editorial Material							AMARNA		Univ Sheffield, Dept Archaeol, Sheffield S1 4ET, S Yorkshire, England	University of Sheffield	Jackson, CM (corresponding author), Univ Sheffield, Dept Archaeol, Sheffield S1 4ET, S Yorkshire, England.	c.m.jackson@sheffield.ac.uk		Jackson, Caroline/0000-0002-7379-7466				BASS GF, 1987, NATIONAL GEOGRAPHIC, V172, P692; Brill RH, 1999, CHEM ANAL EARLY GLAS, V1; Brill Robert H., 1999, CHEM ANAL EARLY GLAS, V2; Jackson CM, 1998, J GLASS STUD, V40, P11; Lilyquist C., 1993, STUDIES EARLY EGYPTI; NICHOLSON PT, 1995, J GLASS STUD, V37, P11; Nicholson PT, 1997, J EGYPT ARCHAEOL, V83, P143, DOI 10.2307/3822462; PETRIE WMF, 1894, TELL AMARNA; Rehren T, 2005, SCIENCE, V308, P1756, DOI 10.1126/science.1110466; Rehren T, 2000, J GLASS STUD, V42, P13; Tite MS, 2003, ARCHAEOMETRY, V45, P285, DOI 10.1111/1475-4754.00109	11	12	13	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 17	2005	308	5729					1750	1752		10.1126/science.1112553	http://dx.doi.org/10.1126/science.1112553			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961659				2022-12-28	WOS:000229926800041
J	Greenwood, RC; Franchi, IA; Jambon, A; Buchanan, PC				Greenwood, RC; Franchi, IA; Jambon, A; Buchanan, PC			Widespread magma oceans on asteroidal bodies in the early Solar System	NATURE			English	Article							CORE FORMATION; ISOTOPE SYSTEMATICS; OXYGEN-ISOTOPE; PARENT BODY; EARTH; EUCRITES; VESTA; MARS; CHONDRITES; METEORITES	Immediately following the formation of the Solar System, small planetary bodies accreted(1), some of which melted to produce igneous rocks(2,3). Over a longer timescale (15-33 Myr), the inner planets grew by incorporation of these smaller objects(4,5) through collisions. Processes operating on such asteroids strongly influenced the final composition of these planets(4), including Earth(5). Currently there is little agreement about the nature of asteroidal igneous activity: proposals range from small-scale melting, to near total fusion and the formation of deep magma oceans(2). Here we report a study of oxygen isotopes in two basaltic meteorite suites, the HEDs (howardites, eucrites and diogenites, which are thought to sample the asteroid 4 Vesta(6)) and the angrites (from an unidentified asteroidal source). Our results demonstrate that these meteorite suites formed during early, global-scale melting (>= 50 per cent) events. We show that magma oceans were present on all the differentiated Solar System bodies so far sampled. Magma oceans produced compositionally layered planetesimals; the modification of such bodies before incorporation into larger objects can explain some anomalous planetary features, such as Earth's high Mg/Si ratio.	Open Univ, PSSRI, Milton Keynes MK7 6AA, Bucks, England; Univ Paris 06, CNRS, UMR 7047, Lab MAGIE, F-75252 Paris, France; Rhodes Univ, Dept Geol, ZA-6140 Grahamstown, South Africa	Open University - UK; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Rhodes University	Greenwood, RC (corresponding author), Open Univ, PSSRI, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.	r.c.greenwood@open.ac.uk		Buchanan, Paul/0000-0003-1648-6079; Greenwood, Richard/0000-0002-5544-8027				Agnor C, 2004, ASTROPHYS J, V613, pL157, DOI 10.1086/425158; Amelin Y, 2002, SCIENCE, V297, P1678, DOI 10.1126/science.1073950; Boesenberg JS, 1997, GEOCHIM COSMOCHIM AC, V61, P3205, DOI 10.1016/S0016-7037(97)00150-6; BUCHANAN PC, 1993, METEORITICS, V28, P659, DOI 10.1111/j.1945-5100.1993.tb00637.x; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; Drake MJ, 2002, NATURE, V416, P39, DOI 10.1038/416039a; Drake MJ, 2001, METEORIT PLANET SCI, V36, P501, DOI 10.1111/j.1945-5100.2001.tb01892.x; Glavin DP, 2004, METEORIT PLANET SCI, V39, P693, DOI 10.1111/j.1945-5100.2004.tb00112.x; Guan YB, 2001, METEORIT PLANET SCI, V36, P1039, DOI 10.1111/j.1945-5100.2001.tb01943.x; Halliday AN, 2004, NATURE, V427, P505, DOI 10.1038/nature02275; JUREWICZ AJG, 1993, GEOCHIM COSMOCHIM AC, V57, P2123, DOI 10.1016/0016-7037(93)90098-H; Kleine T, 2004, GEOCHIM COSMOCHIM AC, V68, P2935, DOI 10.1016/j.gca.2004.01.009; Lugmair GW, 2001, METEORIT PLANET SCI, V36, P1017, DOI 10.1111/j.1945-5100.2001.tb01941.x; Mason B., 1962, METEORITES; McCoy TJ, 1997, GEOCHIM COSMOCHIM AC, V61, P639, DOI 10.1016/S0016-7037(96)00365-1; METZLER K, 1995, PLANET SPACE SCI, V43, P499, DOI 10.1016/0032-0633(94)00219-H; Miller MF, 1999, RAPID COMMUN MASS SP, V13, P1211, DOI 10.1002/(SICI)1097-0231(19990715)13:13<1211::AID-RCM576>3.3.CO;2-D; Mittlefehldt D. W., 1998, PLANETARY MAT; Mittlefehldt DW, 2003, GEOCHIM COSMOCHIM AC, V67, P1911, DOI 10.1016/S0016-7037(02)01411-4; Nolan MC, 2001, ICARUS, V153, P1, DOI 10.1006/icar.2001.6660; Nyquist LE, 2003, EARTH PLANET SC LETT, V214, P11, DOI 10.1016/S0012-821X(03)00371-6; REDDY KPR, 1980, J GEOPHYS RES, V85, P322, DOI 10.1029/JB085iB01p00322; Righter K, 1997, METEORIT PLANET SCI, V32, P929, DOI 10.1111/j.1945-5100.1997.tb01582.x; Rubie DC, 2004, NATURE, V429, P58, DOI 10.1038/nature02473; STOLPER E, 1977, GEOCHIM COSMOCHIM AC, V41, P587, DOI 10.1016/0016-7037(77)90300-3; TAYLOR GJ, 1992, J GEOPHYS RES, V97, P717; Telesco CM, 2005, NATURE, V433, P133, DOI 10.1038/nature03255; Valley JW, 2001, REV MINERAL GEOCHEM, V43, P365, DOI 10.2138/gsrmg.43.1.365; Wiechert UH, 2004, EARTH PLANET SC LETT, V221, P373, DOI 10.1016/S0012-821X(04)00090-1	30	244	247	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 16	2005	435	7044					916	918		10.1038/nature03612	http://dx.doi.org/10.1038/nature03612			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959509				2022-12-28	WOS:000229799700039
J	Camidge, R; Walker, A; Oliver, JJ; Nussey, F; Maxwell, S; Jodrell, D; Webb, DJ				Camidge, R; Walker, A; Oliver, JJ; Nussey, F; Maxwell, S; Jodrell, D; Webb, DJ			Prognosis without treatment as a modifier in health economic assessments	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL EXCELLENCE; NATIONAL INSTITUTE; COST-EFFECTIVENESS; RATIONING DEBATE; DECISION-MAKING; CARE; AGE; PERSPECTIVE; RESOURCES; SERVICES	Explicit rationing-decisions not to fund certain treatments-has become a fact of life in many healthcare systems.(1-4) Health economic assessments often underpin rationing decisions, although it remains unclear whether society's values are well reflected by the utilitarian approach of maximising the units of health attainable from available resources.(5-6) Health economic assessments are used to determine the additional cost per unit of health gain for different treatment options. Cost effectiveness analysis is the most common method of assessment(7-8) and, for life shortening conditions, primarily focuses on the additional cost per life year gained. We propose that prognosis without treatment is an important contextual modifier of life years gained in evaluating treatments for life shortening conditions. We present initial data supporting this hypothesis and describe resource allocation strategies that use this information.	Western Gen Hosp, Clin Pharmacol Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland; Western Gen Hosp, Edinburgh Canc Ctr, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Glasgow; University of Edinburgh	Camidge, R (corresponding author), Western Gen Hosp, Clin Pharmacol Unit, Edinburgh EH4 2XU, Midlothian, Scotland.	drcamidge@talk21.com	Camidge, David Ross/AAG-9144-2019					Coast J, 2004, BRIT MED J, V329, P1233, DOI 10.1136/bmj.329.7476.1233; Evans JG, 1997, BRIT MED J, V314, P822, DOI 10.1136/bmj.314.7083.822; Ham C, 1997, HEALTH POLICY, V42, P49, DOI 10.1016/S0168-8510(97)00054-7; Landman WA, 1999, J MED ETHICS, V25, P224, DOI 10.1136/jme.25.3.224; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; Maynard A, 2004, BMJ-BRIT MED J, V329, P227, DOI 10.1136/bmj.329.7459.227; Oliver A, 2002, LANCET, V359, P1771, DOI 10.1016/S0140-6736(02)08664-6; Rawlins MD, 2004, BRIT MED J, V329, P224, DOI 10.1136/bmj.329.7459.224; SKITKA LJ, 1992, J EXP SOC PSYCHOL, V28, P491, DOI 10.1016/0022-1031(92)90043-J; SMITH TJ, 1993, JNCI-J NATL CANCER I, V85, P1460, DOI 10.1093/jnci/85.18.1460; Spencer A, 2003, SOC SCI MED, V57, P1697, DOI 10.1016/S0277-9536(02)00554-3; Taylor RS, 2004, EVALUATING PHARM HLT, P67; Ubel PA, 1996, NEW ENGL J MED, V334, P1174, DOI 10.1056/NEJM199605023341807; Williams A, 1997, BRIT MED J, V314, P820, DOI 10.1136/bmj.314.7083.820; YELLEN SB, 1994, J NATL CANCER I, V86, P1766, DOI 10.1093/jnci/86.23.1766	15	11	11	1	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 11	2005	330	7504					1382	1384		10.1136/bmj.330.7504.1382	http://dx.doi.org/10.1136/bmj.330.7504.1382			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	936FE	15947403	Green Published			2022-12-28	WOS:000229840100032
J	Thompson, IM; Ankerst, DP; Chi, C; Lucia, MS; Goodman, PJ; Crowley, JJ; Parnes, HL; Coltman, CA				Thompson, IM; Ankerst, DP; Chi, C; Lucia, MS; Goodman, PJ; Crowley, JJ; Parnes, HL; Coltman, CA			Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER MORTALITY; TRENDS; SURVEILLANCE; VERIFICATION; PREVALENCE; SURVIVAL; DISEASE; IMPACT	Context Three fourths of US men older than 50 years have been screened with prostate-specific antigen (PSA) for prostate cancer. Objective To estimate the receiver operating characteristic (ROC) curve for PSA. Design, Setting, and Participants Calculation of PSA ROC curves in the placebo group of the Prostate Cancer Prevention Trial, a randomized, prospective study conducted from 1993 to 2003 at 221 US centers. Participants were 18 882 healthy men aged 55 years or older without prostate cancer and with PSA levels less than or equal to 3.0 ng/mL and normal digital rectal examination results, followed up for 7 years with annual PSA measurement and digital rectal examination. If PSA level exceeded 4.0 ng/mL or rectal examination result was abnormal, a prostate biopsy was recommended. After 7 years of study participation, an end-of-study prostate biopsy was recommended in all cancer-free men. Main Outcome Measures Operating characteristics of PSA for prostate cancer detection, including sensitivity, specificity, and ROC curve. Results Of 8575 men in the placebo group with at least 1 PSA measurement and digital rectal examination in the same year, 5587 (65.2%) had had at least 1 biopsy; of these, 1225 (21.9%) were diagnosed with prostate cancer. Of 1213 cancers with Gleason grade recorded, 250 (20.6%) were Gleason grade 7 or greater and 57 (4.7%) were Gleason grade 8 or greater. The areas under the ROC curve (AUC) for PSA to discriminate any prostate cancer vs no cancer, Gleason grade 7 or greater cancer vs no or lower-grade cancer, and Gleason grade 8 or greater cancer vs no or lower-grade cancer were 0.678 (95% confidence interval [CI], 0.666-0.689), 0.782 (95% Cl, 0.748-0.816), and 0.827 (95% Cl, 0.761-0.893), respectively (all P values <.001 for AUC vs 50%). For detecting any prostate cancer, PSA cutoff values of 1.1, 2.1, 3.1, and 4.1 ng/mL yielded sensitivities of 83.4%, 52.6%, 32.2%, and 20.5%, and specificities of 38.9%, 72.5%, 86.7%, and 93.8%, respectively. Age-stratified analyses showed slightly better performance of PSA in men younger than 70 years vs those 70 years or older with AUC values of 0.699 (SD, 0.013) vs 0.663 (SD, 0.013) (P=.03). Conclusion There is no cutpoint of PSA with simultaneous high sensitivity and high specificity for monitoring healthy men for prostate cancer, but rather a continuum of prostate cancer risk at all values of PSA.	SW Oncol Grp, Operat Off, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Dept Urol, San Antonio, TX USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Colorado, Denver, CO 80202 USA; Canc Res & Biostat, Seattle, WA USA; NCI, NIH, Bethesda, MD 20892 USA	Southwest Oncology Group; University of Texas System; University of Texas Health San Antonio; Fred Hutchinson Cancer Center; University of Colorado System; University of Colorado Denver; Cancer Research & Biostatistics; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thompson, IM (corresponding author), SW Oncol Grp, Operat Off, 14980 Omicron Dr, San Antonio, TX 78245 USA.	thompsoni@uthscsa.edu		Ankerst, Donna/0000-0003-4229-2462	NATIONAL CANCER INSTITUTE [U10CA035178, U10CA045808, U01CA086402, U10CA037429] Funding Source: NIH RePORTER; NCI NIH HHS [CA 35178, CA 86402, CA 45808, CA 37429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American Cancer Society, 2004, CANC FACTS FIG 2004; Antenor JAV, 2004, J UROLOGY, V172, P90, DOI 10.1097/01.ju.0000132133.10470.bb; BEGG CB, 1983, BIOMETRICS, V39, P207, DOI 10.2307/2530820; Brawley OW, 2004, UROL ONCOL-SEMIN ORI, V22, P353, DOI 10.1016/j.urolonc.2004.04.014; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; Clegg LX, 2002, ARCH INTERN MED, V162, P1985, DOI 10.1001/archinte.162.17.1985; Etzioni R, 1998, AM J EPIDEMIOL, V148, P775; Etzioni R, 1999, J NATL CANCER I, V91, P1033, DOI 10.1093/jnci/91.12.1033; Feuer EJ, 2002, CANCER-AM CANCER SOC, V95, P870, DOI 10.1002/cncr.10726; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; GELFAND AE, 1990, J AM STAT ASSOC, V85, P398, DOI 10.2307/2289776; Krumholtz JS, 2002, UROLOGY, V60, P469, DOI 10.1016/S0090-4295(02)01875-7; Lu-Yao G, 2002, BMJ-BRIT MED J, V325, P740, DOI 10.1136/bmj.325.7367.740; LuYao GL, 1996, J NATL CANCER I, V88, P166, DOI 10.1093/jnci/88.3-4.166; Oliver S, 2000, LANCET, V355, P1788, DOI 10.1016/S0140-6736(00)02269-8; Oliver SE, 2001, INT J CANCER, V92, P893, DOI 10.1002/ijc.1260; Pepe MS, 2001, J NATL CANCER I, V93, P1054, DOI 10.1093/jnci/93.14.1054; PROROK PC, 1999, CANC SCREENING THEOR, P29; Punglia RS, 2003, NEW ENGL J MED, V349, P335, DOI 10.1056/NEJMoa021659; Quinn M, 2002, BJU INT, V90, P162, DOI 10.1046/j.1464-410X.2002.2822.x; Sirovich BE, 2003, JAMA-J AM MED ASSOC, V289, P1414, DOI 10.1001/jama.289.11.1414; Thompson IM, 2004, NEW ENGL J MED, V350, P2239, DOI 10.1056/NEJMoa031918; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Weir HK, 2003, JNCI-J NATL CANCER I, V95, P1276, DOI 10.1093/jnci/djg040	24	489	517	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2005	294	1					66	70		10.1001/jama.294.1.66	http://dx.doi.org/10.1001/jama.294.1.66			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941JD	15998892				2022-12-28	WOS:000230210200026
J	Stephens, C; Nettleton, C; Porter, J; Willis, R; Clark, S				Stephens, C; Nettleton, C; Porter, J; Willis, R; Clark, S			Indigenous peoples' health - why are they behind everyone, everywhere?	LANCET			English	Editorial Material							INTELLECTUAL PROPERTY-RIGHTS; DIVERSITY; DISEASE		Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Hlth Unltd, London, England; The Lancet, London, England	University of London; London School of Hygiene & Tropical Medicine	Stephens, C (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	carolyn.stephens@lshtm.ac.uk		Willis, Ruth/0000-0001-9570-7436				Basu S K, 1994, Health Millions, V2, P12; Bourne Richard, 2003, INVISIBLE LIVES UNDE; BRISTOW F, 2003, HLTH WELLBEING INDIG; Condon JR, 2003, CANCER CAUSE CONTROL, V14, P109, DOI 10.1023/A:1023064400004; Escobar A L, 2001, Cad Saude Publica, V17, P285, DOI 10.1590/S0102-311X2001000200004; Hall G, 2005, INDIGENOUS PEOPLES P; Hetzel DMS, 2001, MED J AUSTRALIA, V174, P21, DOI 10.5694/j.1326-5377.2001.tb143140.x; Hsu H J, 1990, Pneumologie, V44 Suppl 1, P453; Janes CR, 1999, SOC SCI MED, V48, P1803, DOI 10.1016/S0277-9536(99)00082-9; JORALEMON D, 1982, J ANTHROPOL RES, V38, P108, DOI 10.1086/jar.38.1.3629951; Kestler Edgar E., 1995, World Health Statistics Quarterly, V48, P28; King SR, 1996, J ETHNOPHARMACOL, V51, P45, DOI 10.1016/0378-8741(95)01349-0; Maybury-Lewis D., 1997, CULTURAL SURVIVAL ST; Merson J, 2000, OSIRIS, V15, P282, DOI 10.1086/649331; MOLBECH A, 2001, INDIGENOUS WORLD; Sunday J, 2001, SOC SCI MED, V52, P635, DOI 10.1016/S0277-9536(00)00166-0; Ten Fingers K, 2005, CAN J PUBLIC HEALTH, V96, pS60, DOI 10.1007/BF03405319; *UNCHR, 2004, REP SECR GEN PREL RE; *UNICEF, 2004, ENS RIGHTS IND CHILD; Vinding Diane, 2005, INDIGENOUS WORLD 200; Willis R., 2004, C HELD LOND SCH HYG	21	139	139	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 2	2005	366	9479					10	13		10.1016/S0140-6736(05)66801-8	http://dx.doi.org/10.1016/S0140-6736(05)66801-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	942JB	15993213				2022-12-28	WOS:000230277600008
J	Kiel, MJ; Yilmaz, OH; Iwashita, T; Yilmaz, OH; Terhorst, C; Morrison, SJ				Kiel, MJ; Yilmaz, OH; Iwashita, T; Yilmaz, OH; Terhorst, C; Morrison, SJ			SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells	CELL			English	Article							DEFINITIVE HEMATOPOIESIS; VASCULAR NICHE; SELF-RENEWAL; IN-VITRO; T-CELL; EXPRESSION; PROLIFERATION; MICE; DIFFERENTIATION; IDENTIFICATION	To improve our ability to identify hematopoletic stem cells (HSCs) and their localization in vivo, we compared the gene expression profiles of highly purified HSCs and non-self-renewing multipotent hematopoletic progenitors (MPPs). Cell surface receptors of the SLAM family, including CD150, CD244, and CD48, were differentially expressed among functionally distinct progenitors. HSCs were highly purified as CD150(+)CD244(-)CD48(-) cells while MPPs were CD244(+) CD150(-)CD48(-) and most restricted progenitors were CD48(+)CD244(+)CD150(-). The primitiveness of hematopoietic progenitors could thus be predicted based on the combination of SLAM family members they expressed. This is the first family of receptors whose combinatorial expression precisely distinguishes stem and progenitor cells. The ability to purify HSCs based on a simple combination of SLAM receptors allowed us to identify HSCs in tissue sections. Many HSCs were associated with sinusoidal endothelium in spleen and bone marrow, though some HSCs were associated with endosteum. HSCs thus occupy multiple niches, including sinusoldal endothelium in diverse tissues.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Immunol, Boston, MA 02215 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Morrison, SJ (corresponding author), Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.	seanjm@umich.edu	Morrison, Sean/ABD-5326-2021	Morrison, Sean/0000-0003-1587-8329	NCI NIH HHS [CA46592] Funding Source: Medline; NIAMS NIH HHS [1 P30 AR48310] Funding Source: Medline; NICHD NIH HHS [R21 HD40760] Funding Source: Medline; NIDDK NIH HHS [DK58771] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD040760] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048310] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Avecilla ST, 2004, NAT MED, V10, P64, DOI 10.1038/nm973; Benveniste P, 2003, NAT IMMUNOL, V4, P708, DOI 10.1038/ni940; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Cardier JE, 1997, HEPATOLOGY, V26, P165; Chen CZ, 2003, IMMUNITY, V19, P525, DOI 10.1016/S1074-7613(03)00265-6; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; deHaan G, 1997, BLOOD, V89, P1543, DOI 10.1182/blood.V89.5.1543.1543_1543_1550; Dong XZ, 2001, CELL, V106, P619, DOI 10.1016/S0092-8674(01)00483-4; Easterday MC, 2003, DEV BIOL, V264, P309, DOI 10.1016/j.ydbio.2003.09.003; Engel P, 2003, NAT REV IMMUNOL, V3, P813, DOI 10.1038/nri1202; Evsikov AV, 2003, SCIENCE, V302; Ferkowicz MJ, 2003, DEVELOPMENT, V130, P4393, DOI 10.1242/dev.00632; Fortunel NO, 2003, SCIENCE, V302, P393; Hackney JA, 2002, P NATL ACAD SCI USA, V99, P13061, DOI 10.1073/pnas.192124499; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Howie D, 2002, BLOOD, V100, P2899, DOI 10.1182/blood-2002-02-0445; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Iwashita T, 2003, SCIENCE, V301, P972, DOI 10.1126/science.1085649; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Kubo H, 2003, GENE DEV, V17, P322, DOI 10.1101/gad.1071203; LATERVEER L, 1995, BLOOD, V85, P2269, DOI 10.1182/blood.V85.8.2269.bloodjournal8582269; Lemischka IR, 1997, STEM CELLS, V15, P63, DOI 10.1002/stem.5530150810; Li WM, 2004, EXP HEMATOL, V32, P1226, DOI 10.1016/j.exphem.2004.09.001; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Matsuzaki Y, 2004, IMMUNITY, V20, P87, DOI 10.1016/S1074-7613(03)00354-6; MICE JAX, 1997, HDB GENETICALLY STAN, P148; Mikkola HKA, 2003, BLOOD, V101, P508, DOI 10.1182/blood-2002-06-1699; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrison SJ, 1997, P NATL ACAD SCI USA, V94, P1908, DOI 10.1073/pnas.94.5.1908; MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302, DOI 10.1073/pnas.92.22.10302; Nakorn TN, 2003, P NATL ACAD SCI USA, V100, P205, DOI 10.1073/pnas.262655099; North TE, 2002, IMMUNITY, V16, P661, DOI 10.1016/S1074-7613(02)00296-0; Oberlin E, 2002, DEVELOPMENT, V129, P4147; Ohneda O, 1998, BLOOD, V92, P908; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; PHILLIPS DR, 1988, BLOOD, V71, P831; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Sidorenko SP, 2003, NAT IMMUNOL, V4, P19, DOI 10.1038/ni0103-19; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; SPANGRUDE GJ, 1992, BLOOD, V80, P1957; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1993, BLOOD, V82, P3327; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Takano H, 2004, J EXP MED, V199, P295, DOI 10.1084/jem.20030929; Taniguchi H, 1996, NAT MED, V2, P198, DOI 10.1038/nm0296-198; Uchida N, 2003, EXP HEMATOL, V31, P1338, DOI 10.1016/j.exphem.2003.09.001; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood-2003-11-4011; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang NH, 2004, J EXP MED, V199, P1255, DOI 10.1084/jem.20031835; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	61	2280	2393	5	156	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	2005	121	7					1109	1121		10.1016/j.cell.2005.05.026	http://dx.doi.org/10.1016/j.cell.2005.05.026			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989959	Bronze			2022-12-28	WOS:000230448000016
J	Lauer, P; Rinaudo, CD; Soriani, M; Margarit, I; Maione, D; Rosini, R; Taddei, AR; Mora, M; Rappuoli, R; Grandi, G; Telford, JL				Lauer, P; Rinaudo, CD; Soriani, M; Margarit, I; Maione, D; Rosini, R; Taddei, AR; Mora, M; Rappuoli, R; Grandi, G; Telford, JL			Genome analysis reveals pili in group B Streptococcus	SCIENCE			English	Article									Chiron Srl, I-53100 Siena, Italy; Univ Tuscia, Ctr Interdipartimentale Microscopia Elettron, Viterbo, Italy	Novartis; Tuscia University	Telford, JL (corresponding author), Chiron Srl, Via Fiorentina 1, I-53100 Siena, Italy.	john_telford@chiron.com	Telford, John Laird/ABG-8144-2020	Grandi, Guido/0000-0001-9724-2185; SORIANI, Marco/0000-0002-9752-5844	NIAID NIH HHS [U01-AI060693-01] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		LAUER P, UNPUB; Maione D, 2005, SCIENCE, V309, P148, DOI 10.1126/science.1109869; Merz AJ, 2000, ANNU REV CELL DEV BI, V16, P423, DOI 10.1146/annurev.cellbio.16.1.423; Paterson GK, 2004, TRENDS MICROBIOL, V12, P89, DOI 10.1016/j.tim.2003.12.007; Schuchat A, 1998, CLIN MICROBIOL REV, V11, P497, DOI 10.1128/CMR.11.3.497; Tettelin H, 2002, P NATL ACAD SCI USA, V99, P12391, DOI 10.1073/pnas.182380799; Ton-That H, 2003, MOL MICROBIOL, V50, P1429, DOI 10.1046/j.1365-2958.2003.03782.x; Ton-That H, 2004, TRENDS MICROBIOL, V12, P228, DOI 10.1016/j.tim.2004.03.004	8	243	258	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					105	105		10.1126/science.1111563	http://dx.doi.org/10.1126/science.1111563			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994549				2022-12-28	WOS:000230212800066
J	Levey, DJ; Bolker, BM; Tewksbury, JJ; Sargent, S; Haddad, NM				Levey, DJ; Bolker, BM; Tewksbury, JJ; Sargent, S; Haddad, NM			Effects of landscape corridors on seed dispersal by birds	SCIENCE			English	Article							INDIVIDUAL BEHAVIOR; POPULATION-DYNAMICS; MOVEMENT CORRIDORS; HABITAT; CONSERVATION; MODELS	Habitat fragmentation threatens biodiversity by disrupting dispersal. The mechanisms and consequences of this disruption are controversial, primarily because most organisms are difficult to track. We examined the effect of habitat corridors on long-distance dispersal of seeds by birds, and tested whether small-scale (< 20 meters) movements of birds could be scaled up to predict dispersal of seeds across hundreds of meters in eight experimentally fragmented landscapes. A simulation model accurately predicted the observed pattern of seed rain and revealed that corridors functioned through edge-following behavior of birds. Our study shows how models based on easily observed behaviors can be scaled up to predict landscape-level processes.	Univ Florida, Dept Zool, Gainesville, FL 32611 USA; N Carolina State Univ, Dept Zool, Raleigh, NC 27695 USA; Allegheny Coll, Dept Biol, Meadville, PA 16335 USA	State University System of Florida; University of Florida; University of North Carolina; North Carolina State University; Allegheny College	Levey, DJ (corresponding author), Univ Florida, Dept Zool, POB 118525, Gainesville, FL 32611 USA.	dlevey@zoo.ufl.edu		Bolker, Benjamin/0000-0002-2127-0443				Anderson GS, 1997, LANDSCAPE ECOL, V12, P261, DOI 10.1023/A:1007933623979; Beier P, 1998, CONSERV BIOL, V12, P1241, DOI 10.1046/j.1523-1739.1998.98036.x; Calabrese JM, 2004, FRONT ECOL ENVIRON, V2, P529, DOI 10.1890/1540-9295(2004)002[0529:ACGTCM]2.0.CO;2; Cantrell RS, 1999, THEOR POPUL BIOL, V55, P189, DOI 10.1006/tpbi.1998.1397; Fagan WE, 1999, AM NAT, V153, P165, DOI 10.1086/303162; FIEDLER PL, 1998, CONSERVATION BIOL CO; Gaggiotti O.E., 2004, ECOLOGY GENETICS EVO; Haddad NM, 1999, AM NAT, V153, P215, DOI 10.1086/303163; Haddad NM, 1999, ECOL APPL, V9, P623, DOI 10.1890/1051-0761(1999)009[0623:AETOCE]2.0.CO;2; Harrison S, 1999, ECOGRAPHY, V22, P225, DOI 10.1111/j.1600-0587.1999.tb00496.x; Levey DJ, 2000, ECOLOGY, V81, P267, DOI 10.1890/0012-9658(2000)081[0267:ASMFTV]2.0.CO;2; Lima SL, 1996, TRENDS ECOL EVOL, V11, P131, DOI 10.1016/0169-5347(96)81094-9; Machtans CS, 1996, CONSERV BIOL, V10, P1366, DOI 10.1046/j.1523-1739.1996.10051366.x; MANN CC, 1995, SCIENCE, V270, P1428, DOI 10.1126/science.270.5241.1428; Morales JM, 2004, ECOLOGY, V85, P2436, DOI 10.1890/03-0269; Nathan R, 2003, OIKOS, V103, P261, DOI 10.1034/j.1600-0706.2003.12146.x; Ovaskainen O, 2004, ECOLOGY, V85, P242, DOI 10.1890/02-0706; Revilla E, 2004, AM NAT, V164, pE130, DOI 10.1086/424767; Ricketts TH, 2001, AM NAT, V158, P87, DOI 10.1086/320863; Rosenberg DK, 1997, BIOSCIENCE, V47, P677, DOI 10.2307/1313208; Schultz CB, 2001, ECOLOGY, V82, P1879, DOI 10.1890/0012-9658(2001)082[1879:EMDBIA]2.0.CO;2; SIMBERLOFF D, 1992, CONSERV BIOL, V6, P493, DOI 10.1046/j.1523-1739.1992.06040493.x; Tewksbury JJ, 2002, P NATL ACAD SCI USA, V99, P12923, DOI 10.1073/pnas.202242699; Tischendorf L, 2000, LANDSCAPE ECOL, V15, P633, DOI 10.1023/A:1008177324187; Turchin Peter, 1998; Wiegand T, 1999, AM NAT, V154, P605, DOI 10.1086/303272; WILLSON MF, 1993, VEGETATIO, V108, P261	27	245	255	1	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					146	148		10.1126/science.1111479	http://dx.doi.org/10.1126/science.1111479			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994561				2022-12-28	WOS:000230212800080
J	Zhong, Q; Gao, WH; Du, FH; Wang, XD				Zhong, Q; Gao, WH; Du, FH; Wang, XD			Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis	CELL			English	Article							BCL-2 FAMILY; PROTEIN UBIQUITINATION; CELL-DIFFERENTIATION; SURVIVAL FACTOR; UBA DOMAIN; SEQUENCE; CLEAVAGE; DEATH; BINDING; MEMBER	The elimination of Mcl-1, an anti-apoptotic Bcl-2 family member, is an early and required step for DNA damage-induced apoptosis. The degradation of Mcl-1 can be blocked by proteasome inhibitors, suggesting a role for the ubiquitin proteasome pathway in apoptosis. Here, we demonstrate that Mcl-1 is ubiquinated at five lysines. Biochemical fractionation of cell extracts allowed us to identify a 482 kDa HECT-domain-containing ubiquitin ligase named Mule (Mcl-1 ubiquitin ligase E3) that is both required and sufficient for the polyubiquitination of Mcl-1. Mule also contains a region similar to the Bcl-2 homology region 3 (BH3) domain that allows Mule to specifically interact with Mcl-1. Elimination of Mule expression by RNA interference stabilizes Mcl-1 protein, resulting in an attenuation of the apoptosis induced by DNA-damage agents. Thus, Mule is a unique BH3-containing E3 ubiquitin ligase apical to Bcl-2 family proteins during DNA damage induced apoptosis.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wang, XD (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	xwang@biochem.swmed.edu	Zhong, Qing/GLT-4858-2022	Zhong, Qing/0000-0001-6979-955X; Wang, Xiaodong/0000-0001-9885-356X	NIGMS NIH HHS [GMR01-57158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057158] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2001, TRENDS BIOCHEM SCI, V26, P273, DOI 10.1016/S0968-0004(01)01787-X; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GU J, 1994, MOL BRAIN RES, V24, P77, DOI 10.1016/0169-328X(94)90120-1; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Nencioni A, 2005, BLOOD, V105, P3255, DOI 10.1182/blood-2004-10-3984; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Piret JP, 2005, J BIOL CHEM, V280, P9336, DOI 10.1074/jbc.M411858200; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Rinkenberger JL, 2000, GENE DEV, V14, P23; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Varshavsky A, 2000, Harvey Lect, V96, P93; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	40	656	671	6	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	2005	121	7					1085	1095		10.1016/j.cell.2005.06.009	http://dx.doi.org/10.1016/j.cell.2005.06.009			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989957	Bronze			2022-12-28	WOS:000230448000014
J	Snead, OC; Gibson, KM				Snead, OC; Gibson, KM			Drug therapy - gamma-hydroxybutyric acid	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GABA(B) RECEPTOR AGONISTS; RAT-BRAIN; AMINOBUTYRIC-ACID; ABSENCE SEIZURES; BINDING-SITES; G-PROTEIN; GHB; BUTYROLACTONE; WITHDRAWAL; MODEL		Hosp Sick Children, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Hosp Sick Children, Brain & Behav Res Program, Toronto, ON M5G 1X8, Canada; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Oregon Health & Science University	Snead, OC (corresponding author), Hosp Sick Children, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	csnead@sickkids.ca			NINDS NIH HHS [NS40270] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040270] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON HB, 2004, MED TOXICOL, P135; Antoniou T, 2002, ANN PHARMACOTHER, V36, P1598, DOI 10.1345/aph.1A447; Barbaccia ML, 2002, NEUROPHARMACOLOGY, V42, P782, DOI 10.1016/S0028-3908(02)00026-6; Bernasconi R, 1999, TRENDS PHARMACOL SCI, V20, P135, DOI 10.1016/S0165-6147(99)01341-3; Bettler B, 2004, PHYSIOL REV, V84, P835, DOI 10.1152/physrev.00036.2003; Bismuth C, 1997, J TOXICOL-CLIN TOXIC, V35, P595, DOI 10.3109/15563659709001238; Brenneisen R, 2004, J ANAL TOXICOL, V28, P625, DOI 10.1093/jat/28.8.625; Camacho A, 2004, AM J ADDICTION, V13, P120, DOI 10.1080/10550490490436019; Cami J, 2003, NEW ENGL J MED, V349, P975, DOI 10.1056/NEJMra023160; Carai MAM, 2002, LIFE SCI, V70, P3059, DOI 10.1016/S0024-3205(02)01553-9; Carai MAM, 2002, EUR J PHARMACOL, V441, P157, DOI 10.1016/S0014-2999(02)01502-9; Castelli MP, 2003, J NEUROCHEM, V87, P722, DOI 10.1046/j.1471-4159.2003.02037.x; CHAMBLISS KL, 1992, INT J BIOCHEM, V24, P1493, DOI 10.1016/0020-711X(92)90077-E; Chin RL, 1998, ANN EMERG MED, V31, P716, DOI 10.1016/S0196-0644(98)70230-6; Couper FJ, 2004, J ANAL TOXICOL, V28, P481, DOI 10.1093/jat/28.6.481; Cousins MS, 2002, DRUG ALCOHOL DEPEN, V65, P209, DOI 10.1016/S0376-8716(01)00163-6; Crunelli V, 2002, GAMMA-HYDROXYBUTYRATE: MOLECULAR, FUNCTIONAL, AND CLINICAL ASPECTS, P75, DOI 10.4324/9780203300992_chapter_5; Cruz HG, 2004, NAT NEUROSCI, V7, P153, DOI 10.1038/nn1181; DEAN W, GHB DEMONIZATION P S; DOHERTY JD, 1978, J PHARMACOL EXP THER, V207, P130; Dyer JE, 2001, ANN EMERG MED, V37, P147, DOI 10.1067/mem.2001.112985; DYER JE, 2004, POISONING DRUG OVERD, P63; DYER JE, 2004, MED TOXICOL, P1097; Elliott SP, 2004, THER DRUG MONIT, V26, P432, DOI 10.1097/00007691-200408000-00014; ElSohly MA, 1999, J ANAL TOXICOL, V23, P141, DOI 10.1093/jat/23.3.141; Erhardt S, 1998, N-S ARCH PHARMACOL, V357, P611, DOI 10.1007/PL00005215; Fattore L, 2001, NEUROREPORT, V12, P2243, DOI 10.1097/00001756-200107200-00039; Ferraro L, 2001, J NEUROCHEM, V78, P929, DOI 10.1046/j.1471-4159.2001.00530.x; Freese TE, 2002, J SUBST ABUSE TREAT, V23, P151, DOI 10.1016/S0740-5472(02)00267-2; Froestl W, 2004, BIOCHEM PHARMACOL, V68, P1479, DOI 10.1016/j.bcp.2004.07.030; Fuller DE, 2003, PHARMACOTHERAPY, V23, P1205, DOI 10.1592/phco.23.10.1205.32756; GARDNER EL, 1993, SEMIN NEUROSCI, V5, P359, DOI 10.1016/S1044-5765(05)80044-2; Gervasi N, 2003, J NEUROSCI, V23, P11469; Gobaille S, 2002, LIFE SCI, V70, P2101, DOI 10.1016/S0024-3205(01)01526-0; Guney O, 2004, J CLIN NEUROSCI, V11, P517, DOI 10.1016/j.jocn.2003.10.019; Harrington RD, 1999, ARCH INTERN MED, V159, P2221, DOI 10.1001/archinte.159.18.2221; HECHLER V, 1985, NEUROCHEM RES, V10, P387, DOI 10.1007/BF00964607; HECHLER V, 2003, J PHARMACOL EXP THER, V281, P753; HEDNER J, 1980, J NEURAL TRANSM, V49, P179, DOI 10.1007/BF01245223; Hicks AR, 2004, J CARDIOVASC PHARM, V44, P631, DOI 10.1097/00005344-200412000-00002; Hogema BM, 2001, NAT GENET, V29, P212, DOI 10.1038/ng727; Howard SG, 2002, GAMMA-HYDROXYBUTYRATE: MOLECULAR, FUNCTIONAL, AND CLINICAL ASPECTS, P111, DOI 10.4324/9780203300992_chapter_6; Hu RQ, 2000, NEUROPHARMACOLOGY, V39, P427, DOI 10.1016/S0028-3908(99)00152-5; HUNTER AS, 1971, BRIT J ANAESTH, V43, P620, DOI 10.1093/bja/43.6.620; Kam PCA, 1998, ANAESTHESIA, V53, P1195, DOI 10.1046/j.1365-2044.1998.00603.x; Kaupmann K, 2003, EUR J NEUROSCI, V18, P2722, DOI 10.1111/j.1460-9568.2003.03013.x; KUSCHINSKY W, 1985, J CEREBR BLOOD F MET, V5, P58, DOI 10.1038/jcbfm.1985.8; LABORIT H, 1964, INT J NEUROPHARMACOL, V3, P433; Li J, 1998, ANN EMERG MED, V31, P729, DOI 10.1016/S0196-0644(98)70232-X; Lingenhoehl K, 1999, NEUROPHARMACOLOGY, V38, P1667, DOI 10.1016/S0028-3908(99)00131-8; Madden TE, 1998, J PHARMACOL EXP THER, V287, P261; MAITRE M, 1983, J NEUROCHEM, V41, P287, DOI 10.1111/j.1471-4159.1983.tb11843.x; Maitre M, 1997, PROG NEUROBIOL, V51, P337, DOI 10.1016/S0301-0082(96)00064-0; Maldonado R, 2003, J NEURAL TRANSM-SUPP, P1; Mathivet P, 1997, EUR J PHARMACOL, V321, P67, DOI 10.1016/S0014-2999(96)00916-8; McDaniel CH, 2001, J PSYCHOACTIVE DRUGS, V33, P143, DOI 10.1080/02791072.2001.10400479; McDonough M, 2004, DRUG ALCOHOL DEPEN, V75, P3, DOI 10.1016/j.drugalcdep.2004.01.012; Meyer S, 2003, KLIN PADIATR, V215, P69, DOI 10.1055/s-2003-38500; Miotto K, 2001, AM J ADDICTION, V10, P232; Miro O, 2002, J TOXICOL-CLIN TOXIC, V40, P129, DOI 10.1081/CLT-120004400; Mokhlesi B, 2004, INTENS CARE MED, V30, P1526, DOI 10.1007/s00134-004-2229-1; Morris-Kukoski Cynthia L, 2004, Toxicol Rev, V23, P33, DOI 10.2165/00139709-200423010-00004; Muller C, 2002, J NEUROCHEM, V80, P899, DOI 10.1046/j.0022-3042.2002.00780.x; Okun MS, 2001, J PHARM PHARM SCI, V4, P167; Ottani A, 2004, EUR J PHARMACOL, V485, P183, DOI 10.1016/j.ejphar.2003.11.072; Owens DF, 2002, NAT REV NEUROSCI, V3, P715, DOI 10.1038/nrn919; Poldrugo F, 1999, ALCOHOL ALCOHOLISM, V34, P15, DOI 10.1093/alcalc/34.1.15; POLDRUGO F, 1985, ALCOHOL CLIN EXP RES, V9, P493, DOI 10.1111/j.1530-0277.1985.tb05589.x; POLDRUGO F, 1986, ALCOHOL, V3, P367, DOI 10.1016/0741-8329(86)90055-8; Queva S, 2003, BRIT J PHARMACOL, V140, P315, DOI 10.1038/sj.bjp.0705447; Raess BU, 2002, GAMMA-HYDROXYBUTYRATE: MOLECULAR, FUNCTIONAL, AND CLINICAL ASPECTS, P188, DOI 10.4324/9780203300992_chapter_11; Ren XH, 2003, J BIOL CHEM, V278, P42006, DOI 10.1074/jbc.M304238200; ROTH R. H., 1966, INT J NEUROPHARMACOL, V5, P421; ROTH RH, 1967, BIOCHEM PHARMACOL, V16, P596, DOI 10.1016/0006-2952(67)90110-4; RUBIN BA, 1947, YALE J BIOL MED, V19, P1017; Schwartz RH, 2000, SOUTH MED J, V93, P558; SETHY VH, 1976, N-S ARCH PHARMACOL, V295, P9, DOI 10.1007/BF00509765; Sircar R, 2004, PHARMACOL BIOCHEM BE, V79, P701, DOI 10.1016/j.pbb.2004.09.022; Sivilotti MLA, 2001, ANN EMERG MED, V38, P660, DOI 10.1067/mem.2001.119454; Slaughter L, 2000, J REPROD MED, V45, P425; Smith KM, 2002, AM J HEALTH-SYST PH, V59, P1067, DOI 10.1093/ajhp/59.11.1067; SNEAD OC, 1989, BIOCHEM PHARMACOL, V38, P4375, DOI 10.1016/0006-2952(89)90645-X; Snead OC, 2000, J NEUROCHEM, V75, P1986, DOI 10.1046/j.1471-4159.2000.0751986.x; SNEAD OC, 1991, NEUROPHARMACOLOGY, V30, P161, DOI 10.1016/0028-3908(91)90199-L; Snead OC, 2002, GAMMA-HYDROXYBUTYRATE: MOLECULAR, FUNCTIONAL, AND CLINICAL ASPECTS, P132, DOI 10.4324/9780203300992_chapter_8; SNEAD OC, 1993, NEUROPHARMACOLOGY, V32, P401, DOI 10.1016/0028-3908(93)90163-W; Sporer KA, 2003, ANN EMERG MED, V42, P3, DOI 10.1067/mem.2003.253; Szabo ST, 2004, BIOL PSYCHIAT, V55, P934, DOI 10.1016/j.biopsych.2003.12.013; Tarabar Asim F, 2004, Toxicol Rev, V23, P45, DOI 10.2165/00139709-200423010-00005; Teter CJ, 2001, PHARMACOTHERAPY, V21, P1486, DOI 10.1592/phco.21.20.1486.34472; Traub SJ, 2002, J TOXICOL-CLIN TOXIC, V40, P781, DOI 10.1081/CLT-120015839; Tunnicliff G, 1997, J TOXICOL-CLIN TOXIC, V35, P581, DOI 10.3109/15563659709001236; Van Sassenbroeck DK, 2003, EUR J EMERG MED, V10, P302, DOI 10.1097/00063110-200312000-00012; VanCauter E, 1997, J CLIN INVEST, V100, P745, DOI 10.1172/JCI119587; Varela M, 2004, EMERG MED J, V21, P255, DOI 10.1136/emj.2002.002402; Vickers M D, 1969, Int Anesthesiol Clin, V7, P75, DOI 10.1097/00004311-196900710-00007; Weir E, 2000, CAN MED ASSOC J, V162, P1843; Whiting PJ, 2003, CURR OPIN DRUG DISC, V6, P648; Wong C Guin Ting, 2004, Toxicol Rev, V23, P3, DOI 10.2165/00139709-200423010-00002; WONG CGT, 2003, GHB INCREASES CELL S; Wu Y, 2004, NEUROPHARMACOLOGY, V47, P1146, DOI 10.1016/j.neuropharm.2004.08.019; Yosunkaya A, 2004, J TRAUMA, V56, P585, DOI 10.1097/01.TA.0000058119.60074.25; Zvosec DL, 2001, NEW ENGL J MED, V344, P87, DOI 10.1056/NEJM200101113440202	103	189	200	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					2721	2732		10.1056/NEJMra044047	http://dx.doi.org/10.1056/NEJMra044047			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	940HH	15987921				2022-12-28	WOS:000230133800009
J	van Zanten, SV				van Zanten, SV			Upper gastrointestinal alarms: the 2-week rule	LANCET			English	Editorial Material							DYSPEPSIA; ENDOSCOPY; SYMPTOMS		Queen Elizabeth II Hlth Sci Ctr, Halifax, NS B3H 2Y9, Canada	Queen Elizabeth II Health Sciences Centre	van Zanten, SV (corresponding author), Queen Elizabeth II Hlth Sci Ctr, Victoria Gen Hosp Site, Halifax, NS B3H 2Y9, Canada.	Zanten@dal.ca						Axon ATR, 1997, GASTROENTEROLOGY, V112, P1376, DOI 10.1016/S0016-5085(97)70153-7; Department of Health, 2001, GUID COMM CANC SERV; Fransen GAJ, 2004, ALIMENT PHARM THERAP, V20, P1045, DOI 10.1111/j.1365-2036.2004.02251.x; Jacobson BC, 2003, AM J GASTROENTEROL, V98, P51, DOI 10.1111/j.1572-0241.2003.07186.x; Kapoor N, 2005, GUT, V54, P40, DOI 10.1136/gut.2004.039438; *NAT GUID RES DEV, 2004, DYSP MAN AD PRIM CAR; RYDER SD, 1994, BRIT MED J, V308, P827, DOI 10.1136/bmj.308.6932.827; *SIGN, 2003, CLIN LAUNCH SIGN DYS; Talley NJ, 1998, GASTROENTEROLOGY, V114, P582, DOI 10.1016/S0016-5085(98)70542-6; Vakil NB, 2004, CLIN GASTROENTEROL H, V2, P665, DOI 10.1016/S1542-3565(04)00289-7; van Zanten SJOV, 1999, AM J GASTROENTEROL, V94, P9; van Zanten SJOV, 2000, CAN MED ASSOC J, V162, pS3	12	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	2005	365	9478					2163	2164		10.1016/S0140-6736(05)66757-8	http://dx.doi.org/10.1016/S0140-6736(05)66757-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978912				2022-12-28	WOS:000230034800010
J	Kmita, M; Tarchini, B; Zakany, J; Logan, M; Tabin, CJ; Duboule, D				Kmita, M; Tarchini, B; Zakany, J; Logan, M; Tabin, CJ; Duboule, D			Early developmental arrest of mammalian limbs lacking HoxA/HoxD gene function	NATURE			English	Article							SONIC-HEDGEHOG; MICE LACKING; HOX GENES; AXIAL SKELETON; FORELIMB; ANTAGONISM; EVOLUTION; OUTGROWTH; DELETION; HOXD-11	Vertebrate HoxA and HoxD cluster genes are required for proper limb development(1-3). However, early lethality, compensation and redundancy have made a full assessment of their function difficult(3-5). Here we describe mice that are lacking all Hoxa and Hoxd functions in their forelimbs. We show that such limbs are arrested early in their developmental patterning and display severe truncations of distal elements, partly owing to the absence of Sonic hedgehog expression. These results indicate that the evolutionary recruitment of Hox gene function into growing appendages might have been crucial in implementing hedgehog signalling, subsequently leading to the distal extension of tetrapod appendages. Accordingly, these mutant limbs may be reminiscent of an ancestral trunk extension, related to that proposed for arthropods(6).	Univ Geneva, Dept Zool & Anim Biol, CH-1211 Geneva, Switzerland; Univ Geneva, Natl Res Ctr Frontiers Genet, CH-1211 Geneva, Switzerland; Natl Inst Med Res, Div Dev Biol, London NW7 1AA, England; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	University of Geneva; University of Geneva; MRC National Institute for Medical Research; Harvard University; Harvard Medical School	Duboule, D (corresponding author), Univ Geneva, Dept Zool & Anim Biol, Sci 3,Quai Ernest Ansermet 30, CH-1211 Geneva, Switzerland.	denis.duboule@zoo.unige.ch	kmita, marie/AAU-9620-2020	Kmita, Marie/0000-0003-4021-0478; duboule, denis/0000-0001-9961-2960; Tarchini, Basile/0000-0003-2708-6273	Medical Research Council [MC_U117560477] Funding Source: Medline; NICHD NIH HHS [R37 HD032443] Funding Source: Medline; MRC [MC_U117560477] Funding Source: UKRI; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD032443] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Capdevila J, 1999, MOL CELL, V4, P839, DOI 10.1016/S1097-2765(00)80393-7; Chiang C, 2001, DEV BIOL, V236, P421, DOI 10.1006/dbio.2001.0346; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; Dupe V, 1997, DEVELOPMENT, V124, P399; Favier B, 1996, DEVELOPMENT, V122, P449; FromentalRamain C, 1996, DEVELOPMENT, V122, P461; FromentalRamain C, 1996, DEVELOPMENT, V122, P2997; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; Harfe BD, 2004, CELL, V118, P517, DOI 10.1016/j.cell.2004.07.024; Knezevic V, 1997, DEVELOPMENT, V124, P4523; Kraus P, 2001, MECH DEVELOP, V100, P45, DOI 10.1016/S0925-4773(00)00492-5; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; Litingtung Y, 2002, NATURE, V418, P979, DOI 10.1038/nature01033; Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092; Medina-Martinez O, 2000, DEV BIOL, V222, P71, DOI 10.1006/dbio.2000.9683; Mercader N, 1999, NATURE, V402, P425, DOI 10.1038/46580; Rallis C, 2003, DEVELOPMENT, V130, P2741, DOI 10.1242/dev.00473; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Ros MA, 2003, DEVELOPMENT, V130, P527, DOI 10.1242/dev.00245; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; Snodgrass RE, 1935, PRINCIPLES INSECT MO; Sordino P, 1996, TRENDS ECOL EVOL, V11, P114, DOI 10.1016/0169-5347(96)81089-5; Spitz F, 2001, GENE DEV, V15, P2209, DOI 10.1101/gad.205701; Suemori H, 2000, DEV BIOL, V220, P333, DOI 10.1006/dbio.2000.9651; TABIN C, 1993, NATURE, V361, P692, DOI 10.1038/361692a0; van den Akker E, 2001, DEVELOPMENT, V128, P1911; Wellik DM, 2003, SCIENCE, V301, P363, DOI 10.1126/science.1085672; Welscher PT, 2002, SCIENCE, V298, P827, DOI 10.1126/science.1075620; Zakany J, 2004, SCIENCE, V304, P1669, DOI 10.1126/science.1096049	29	194	199	3	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1113	1116		10.1038/nature03648	http://dx.doi.org/10.1038/nature03648			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973411				2022-12-28	WOS:000229970400052
J	Hartling, L; McAlister, FA; Rowe, BH; Ezekowitz, J; Friesen, C; Klassen, TP				Hartling, L; McAlister, FA; Rowe, BH; Ezekowitz, J; Friesen, C; Klassen, TP			Challenges in systematic reviews of therapeutic devices and procedures	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CLINICAL-TRIALS; MAMMARY-ARTERY LIGATION; CAROTID-ENDARTERECTOMY; PUBLICATION BIAS; PHARMACEUTICAL-INDUSTRY; SURGICAL MORTALITY; PEDIATRIC-SURGERY; UNPUBLISHED DATA; UNITED-STATES; HEALTH-CARE	The authors discuss 3 challenges in conducting and interpreting any systematic review that are particularly relevant for systematic reviews of therapeutic devices or surgical procedures: 1) inclusion or exclusion of grey literature, 2) the role of nonrandomized studies, and 3) issues in applying the results to clinical care that are unique to the surgical and therapeutic device literature. The authors also discuss empirical evidence related to these topics and illustrate how reviewers in the Agency for Healthcare Research and Quality's Evidence-based Practice Center program have dealt with these challenges in developing evidence reports for decision makers and clinicians about therapeutic devices or surgical procedures.	Univ Alberta, Walter Mackenzie Hlth Sci Ctr, Edmonton, AB T6G 2R7, Canada	University of Alberta	McAlister, FA (corresponding author), Univ Alberta, Walter Mackenzie Hlth Sci Ctr, 8440 112 St, Edmonton, AB T6G 2R7, Canada.	Finlay.McAlister@ualberta.ca	McAlister, Finlay/C-4151-2013; Ezekowitz, Justin A/C-4579-2013	McAlister, Finlay/0000-0001-7435-3341; Ezekowitz, Justin A/0000-0002-2724-4086; Friesen, Carol/0000-0001-6437-9126; Klassen, Terry/0000-0002-5309-7091				ALBERANI V, 1990, B MED LIBR ASSOC, V78, P358; Albin RL, 2002, J MED ETHICS, V28, P324, DOI 10.1136/jme.28.5.322; Alderson P, COCHRANE REV HDB 4 2; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; *AM MED ASS, 2002, EV BAS MED WORK GROU; AUDIGE L, 4 S SYST REV PUSH BO; BADER J, 2001, AHRQ PUBLICATION; Baraldini V, 1998, PEDIATR SURG INT, V13, P331, DOI 10.1007/s003830050332; BEAVERS KL, 2001, LIVER TRANSPLANTATIO; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Berger RL, 2001, ANN THORAC SURG, V72, P649, DOI 10.1016/S0003-4975(01)02636-4; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Black N, 1996, BRIT MED J, V312, P1215; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Britton A, 1998, HLTH TECHNOLOGY ASSE, V2, P1; Bruce J, 2001, Health Technol Assess, V5, P1; Burdett S, 2003, INT J TECHNOL ASSESS, V19, P129, DOI 10.1017/S0266462303000126; CHAPELL R, 2003, AHRQ PUBLICATION; Chassin MR, 1998, NEW ENGL J MED, V339, P1468, DOI 10.1056/NEJM199811123392010; COATES VH, 2002, AHRQ PUBLICATION; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; COSMI B, 2000, 8 ANN COCHR C OCT 20; Deeks J J, 2003, Health Technol Assess, V7, piii; Deeks JJ, 1998, ANN ONCOL, V9, P703, DOI 10.1023/A:1008335706631; Dimick JB, 2001, ARCH SURG-CHICAGO, V136, P796, DOI 10.1001/archsurg.136.7.796; DIMOND EG, 1960, AM J CARDIOL, V5, P483, DOI 10.1016/0002-9149(60)90105-3; Edwards JE, 1999, J PAIN SYMPTOM MANAG, V18, P427, DOI 10.1016/S0885-3924(99)00093-7; Egger M, 1998, BRIT MED J, V316, P140; Egger M, 2003, Health Technol Assess, V7, P1; Egger M, 2002, INT J EPIDEMIOL, V31, P1, DOI 10.1093/ije/31.1.1; Ernst E, 2001, BRIT MED J, V323, P546, DOI 10.1136/bmj.323.7312.546; FERRITER N, 2002, 10 COCHR C 31 JUL 3; FLAMM CR, 2002, AHRQ PUBLICATION; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Furukawa TA, 2002, INT J EPIDEMIOL, V31, P72, DOI 10.1093/ije/31.1.72; Gelijns AC, 1989, TECHNOLOGICAL INNOVA; GOTZSCHE PC, SEARCHING NON RANDOM; GOUDAS L, 2001, AHRQ PUBLICATION; GRADY D, 2003, AHRQ PUBLICATION; Greenland S, 1998, DRUG SAFETY, V18, P297, DOI 10.2165/00002018-199818040-00005; Gross CP, 2000, JAMA-J AM MED ASSOC, V284, P2886, DOI 10.1001/jama.284.22.2886; GUISE JM, 2003, AHRQ PUBLICATION; Haig A, 2003, MED TEACH, V25, P352, DOI 10.1080/0142159031000136815; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Hardin WD, 1999, J PEDIATR SURG, V34, P908, DOI 10.1016/S0022-3468(99)90396-2; Hayashi K, 1996, CONTROL CLIN TRIALS, V17, P99, DOI 10.1016/S0197-2456(96)80001-8; HOPEWELL S, 11 COCHR C EV HLTH C; Hopewell S., 2004, GREY LIT METAANALYSE; Horng S, 2003, CRIT CARE MED, V31, pS126, DOI 10.1097/01.CCM.0000054906.49187.67; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; Ioannidis JPA, 2002, DRUG SAFETY, V25, P77, DOI 10.2165/00002018-200225020-00002; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V285, P437, DOI 10.1001/jama.285.4.437; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Ioannidis JPA, 1998, LANCET, V352, P1752, DOI 10.1016/S0140-6736(05)79825-1; JADAD A, AHRQ PUBLICATION; Jampel HD, 2003, AHRQ PUBLICATION; Kane RL, 2003, AHRQ PUBLICATION; Kunz R, 1998, BRIT MED J, V317, P1185, DOI 10.1136/bmj.317.7167.1185; LATHAM NK, 2002, 4 S SYST REV PUSH BO; LAU J, 2002, AHRQ PUBLICATION; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; LEVINE C, AHRQ PUBLICATION; LEVINE CB, 2003, AHRQ PUBLICATION; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; LIPSEY MW, 1993, AM PSYCHOL, V48, P1181, DOI 10.1037/0003-066X.48.12.1181; Loke Y K, 2001, BMC Clin Pharmacol, V1, P3, DOI 10.1186/1472-6904-1-3; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; MacLean CH, 2003, J CLIN EPIDEMIOL, V56, P44, DOI 10.1016/S0895-4356(02)00520-6; MACLEHOSE HG, 2003, 9 COCHR C EV HLTH CA; MacLehose R R, 2000, Health Technol Assess, V4, P1; Mallet S, 2002, 4 S SYST REV PUSH BO; MARINOVICH L, 2004, 12 COCHR C 2 6 OCT 2; McAlister FA, 2004, ANN INTERN MED, V141, P381, DOI 10.7326/0003-4819-141-5-200409070-00101; McAlister FA, 2003, ANN INTERN MED, V138, P938, DOI 10.7326/0003-4819-138-11-200306030-00016; McAlister FA, 2002, INT J EPIDEMIOL, V31, P76, DOI 10.1093/ije/31.1.76; McAlister FA, 2000, JAMA-J AM MED ASSOC, V283, P2829, DOI 10.1001/jama.283.21.2829; MCALISTER FA, AHRQ PUBLICATION; McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0; MCCRORY DC, 2001, AHRQ PUBLICATION; MCCRORY DC, 2000, AHRQ PUBLICATION; McCulloch P, 2002, BRIT MED J, V324, P1448, DOI 10.1136/bmj.324.7351.1448; McDonagh MS, 2003, AHRQ PUBLICATION, V03-E050; MEENAN RT, 2002, AHRQ PUBLICATION; Moher D., 1999, HEALTH TECHNOL ASSES, V3, pi, DOI [DOI 10.3310/HTA3120, 10.3310/hta3120]; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; MYERS ER, 2002, AHRQ PUBLICATION; Myers ER, AHRQ PUBLICATION; Newhouse JP, 1998, ANNU REV PUBL HEALTH, V19, P17, DOI 10.1146/annurev.publhealth.19.1.17; OLSON O, COLLECTING DATA; Pablos-Mendez A, 1998, JAMA-J AM MED ASSOC, V279, P222, DOI 10.1001/jama.279.3.222; Price D, 2004, VACCINE, V22, P2080, DOI 10.1016/j.vaccine.2004.01.009; PRICE D, 2002, 4 S SYST REV PUSH BO; Radford MJ, 2001, JAMA-J AM MED ASSOC, V286, P1228, DOI 10.1001/jama.286.10.1228; Ramsay C R, 2001, Health Technol Assess, V5, P1; RAMSEY SD, 1998, AM J MANAG CARE, V4; Ray JG, 2002, ARCH INTERN MED, V162, P249, DOI 10.1001/archinte.162.3.249; Robert G, 1999, Health Technol Assess, V3, P1; ROSENZWEIG P, 1993, CLIN PHARMACOL THER, V54, P578, DOI 10.1038/clpt.1993.190; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; Russell EM, 2003, BRIT J SURG, V90, P527, DOI 10.1002/bjs.4126; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SACKETT DL, 1998, SPINE, V23, P1885; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; Santaguida PL, 2005, ANN INTERN MED, V142, P1066, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00006; SCHERER RW, 2000, COCHRANE DATABASE ME, P4; Schmid CH, 1998, STAT MED, V17, P1923, DOI 10.1002/(SICI)1097-0258(19980915)17:17<1923::AID-SIM874>3.0.CO;2-6; SEIDENFELD J, 1999, AHCPR PUBLICATION; SHEKELLE PG, 2004, AHRQ PUBLICATION; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SOLOMON MJ, 1993, DIS COLON RECTUM, V36, P43, DOI 10.1007/BF02050300; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; STEWART L, 2000, 8 ANN COCHR C OCT 20; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Tu JV, 1998, NEW ENGL J MED, V339, P1441, DOI 10.1056/NEJM199811123392006; *US FDA, DEV ADV; VELMAHOS GC, 2000, AHRQ PUBLICATION; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WAN PAL, 2000, 8 ANN C COLL OCT 200; WEINTRAUB WH, 1987, J PEDIATR SURG, V22, P11, DOI 10.1016/S0022-3468(87)80005-2; Wennberg DE, 1998, JAMA-J AM MED ASSOC, V279, P1278, DOI 10.1001/jama.279.16.1278; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; [No title captured]	126	49	51	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1100	1111		10.7326/0003-4819-142-12_Part_2-200506211-00010	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	938CN	15968035				2022-12-28	WOS:000229977600010
J	Pignone, M; Saha, S; Hoerger, T; Lohr, KN; Teutsch, S; Mandelblatt, J				Pignone, M; Saha, S; Hoerger, T; Lohr, KN; Teutsch, S; Mandelblatt, J			Challenges in systematic reviews of economic analyses	ANNALS OF INTERNAL MEDICINE			English	Article							SERVICES-TASK-FORCE; COST-EFFECTIVENESS ANALYSES; COLORECTAL-CANCER; PREVENTIVE-SERVICES; AVERAGE-RISK; GUIDELINES; QUALITY; HEALTH; RECOMMENDATIONS; UTILITY	Economic analyses can provide valuable information for health care decision makers. Systematic reviews of economic analyses can integrate information from multiple studies and provide important insights by systematically examining how differences between models lead to different results. We use our experience in developing and implementing systematic reviews of economic analyses for the U.S. Preventive Services Task Force, particularly our systematic review of the cost-effectiveness of colorectal cancer screening, to illustrate key methodologic challenges and suggest a framework for other researchers in this area.	Univ N Carolina, Chapel Hill, NC 27515 USA; Portland VA Med Ctr, Portland, OR USA; Oregon Hlth & Sci Univ, Portland, OR USA; RTI Univ N Carolina, Evidence Based Practice Ctr, Res Triangle Pk, NC USA; Merck & Co Inc, West Point, PA USA; Georgetown Univ, Ctr Med, Washington, DC 20057 USA; Lombardi Comprehens Canc Ctr, Washington, DC USA	University of North Carolina; University of North Carolina Chapel Hill; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Oregon Health & Science University; Research Triangle Institute; Merck & Company; Georgetown University	Pignone, M (corresponding author), Univ N Carolina Hosp, Dept Med, Div Gen Internal Med, 5039 Old Clin Bldg, Chapel Hill, NC 27599 USA.	Pignone@med.unc.edu		Hoerger, Thomas/0000-0003-4154-7806; Pignone, Michael/0000-0002-6657-7342; Lohr, Kathleen/0000-0002-3825-0713; Saha, Shampa/0000-0002-8305-3495	NATIONAL CANCER INSTITUTE [U01CA088283, K05CA096940] Funding Source: NIH RePORTER; NCI NIH HHS [U01CA88283A, K05CA96940] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benade MM, 2002, STROKE, V33, P629, DOI 10.1161/hs0202.102880; Briggs AH, 2002, MED DECIS MAKING, V22, P290, DOI 10.1177/027298902400448867; BROWN ML, 1993, BREAST CANCER RES TR, V25, P113, DOI 10.1007/BF00662136; Carande-Kulis VG, 2000, AM J PREV MED, V18, P75, DOI 10.1016/S0749-3797(99)00120-8; Chiou CF, 2003, MED CARE, V41, P32, DOI 10.1097/00005650-200301000-00007; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Frazier AL, 2000, JAMA-J AM MED ASSOC, V284, P1954, DOI 10.1001/jama.284.15.1954; Gerard K, 2000, INT J TECHNOL ASSESS, V16, P100, DOI 10.1017/S0266462300016196; Gold MR, 1996, COST EFFECTIVENESS H; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; *I MED, 2005, COST EFF MOD OUTC IN; Jefferson T, 2002, JAMA-J AM MED ASSOC, V287, P2809, DOI 10.1001/jama.287.21.2809; Khandker RK, 2000, INT J TECHNOL ASSESS, V16, P799, DOI 10.1017/S0266462300102077; Loeve F, 2000, J NATL CANCER I, V92, P557, DOI 10.1093/jnci/92.7.557; MUGFORD M, 2001, USING SYSTEMATIC REV; Ness RM, 2000, AM J GASTROENTEROL, V95, P1800; Neumann PJ, 2000, ANN INTERN MED, V132, P964, DOI 10.7326/0003-4819-132-12-200006200-00007; Ofman Joshua J, 2003, J Manag Care Pharm, V9, P53; Pignone M, 2002, ANN INTERN MED, V137, P132, DOI 10.7326/0003-4819-137-2-200207160-00015; Pignone M, 2002, ANN INTERN MED, V137, P96, DOI 10.7326/0003-4819-137-2-200207160-00007; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Siegel JE, 1997, PHARMACOECONOMICS, V11, P159, DOI 10.2165/00019053-199711020-00005; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; Sonnenberg A, 2000, ANN INTERN MED, V133, P573, DOI 10.7326/0003-4819-133-8-200010170-00007; Vijan S, 2001, AM J MED, V111, P593, DOI 10.1016/S0002-9343(01)00977-9; Wagner JL, 1997, CANCER METAST REV, V16, P281, DOI 10.1023/A:1005800227359	26	65	66	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1073	1079		10.7326/0003-4819-142-12_Part_2-200506211-00007	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	938CN	15968032				2022-12-28	WOS:000229977600007
J	Tzeng, DZ; Fein, J; Boe, N; Chan, A				Tzeng, DZ; Fein, J; Boe, N; Chan, A			A pregnant woman with headaches, seizures, and hypertension	LANCET			English	Editorial Material							MOYAMOYA-DISEASE		Univ Calif Davis, Med Ctr, Div Pulm & Crit Care Med, Sacramento, CA 95817 USA; Univ Calif Davis, Med Ctr, Dept Internal Med, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis	Tzeng, DZ (corresponding author), Univ Calif Davis, Med Ctr, Div Pulm & Crit Care Med, Sacramento, CA 95817 USA.	david.tzeng@ucdmc.ucdavis.edu						AMINHANJANI S, 1993, AM J OBSTET GYNECOL, V169, P395, DOI 10.1016/0002-9378(93)90095-Z; Chiu D, 1998, STROKE, V29, P1347, DOI 10.1161/01.STR.29.7.1347; Fukui M, 2000, NEUROPATHOLOGY, V20, pS61, DOI 10.1046/j.1440-1789.2000.00300.x; Yamada T, 1999, OBSTET GYNECOL, V94, P822, DOI 10.1016/S0029-7844(99)00361-0; Yilmaz EY, 2001, ARCH NEUROL-CHICAGO, V58, P1274, DOI 10.1001/archneur.58.8.1274	5	3	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 18	2005	365	9477					2150	2150		10.1016/S0140-6736(05)66742-6	http://dx.doi.org/10.1016/S0140-6736(05)66742-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964456				2022-12-28	WOS:000229858800036
J	Lochhead, PA; Sibbet, G; Morrice, N; Cleghon, V				Lochhead, PA; Sibbet, G; Morrice, N; Cleghon, V			Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs	CELL			English	Article							GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN-KINASE; DUAL-SPECIFICITY; TYROSINE-PHOSPHORYLATION; DOWN-SYNDROME; CATALYTIC SUBUNIT; REGULATED KINASE; FAMILY; CELLS; INHIBITORS	Autophosphorylation of a critical residue in the activation loop of several protein kinases is an essential maturation event required for full enzyme activity. However, the molecular mechanism by which this happens is unknown. We addressed this question for two dual-specificity tyrosine-phosphorylation-regulated protein kinases (DYRKs), as they autophosphorylate their activation loop on an essential tyrosine but phosphorylate their substrates on serine and threonine. Here we demonstrate that autophosphorylation of the critical activation-loop tyrosine is intramolecular and mediated by the nascent kinase passing through a transitory intermediate form. This DYRK intermediate differs in residue and substrate specificity, as well as sensitivity to small-molecule inhibitors, compared with its mature counterpart. The intermediate's characteristics are lost upon completion of translation, making the critical tyrosine autophosphorylation a "one-off" inceptive event. This mechanism is likely to be shared with other kinases.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Dundee, MRC, Prot Phosphorylat Unit, Sch Life Sci, Dundee DD1 5EH, Scotland	Beatson Institute; University of Dundee	Lochhead, PA (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	p.lochhead@beatson.gla.ac.uk; v.cleghon@beatson.gla.ac.uk						Abe MK, 2001, J BIOL CHEM, V276, P21272, DOI 10.1074/jbc.M100026200; Abe MK, 1999, MOL CELL BIOL, V19, P1301; Bahler J, 1998, GENE DEV, V12, P1356, DOI 10.1101/gad.12.9.1356; Bahler J, 2001, EMBO J, V20, P1064, DOI 10.1093/emboj/20.5.1064; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Campbell LE, 2002, FEBS LETT, V510, P31, DOI 10.1016/S0014-5793(01)03221-5; Cauthron RD, 1998, MOL CELL BIOL, V18, P1416, DOI 10.1128/MCB.18.3.1416; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; de Wit NJW, 2002, MELANOMA RES, V12, P57, DOI 10.1097/00008390-200202000-00009; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; Fotaki V, 2002, MOL CELL BIOL, V22, P6636, DOI 10.1128/MCB.22.18.6636-6647.2002; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Guimera J, 1999, GENOMICS, V57, P407, DOI 10.1006/geno.1999.5775; Hammerle B, 2003, J NEURAL TRANSM-SUPP, P129; Hammerle B, 2003, EUR J NEUROSCI, V17, P2277, DOI 10.1046/j.1460-9568.2003.02665.x; Hammerle B, 2002, DEV BIOL, V246, P259, DOI 10.1006/dbio.2002.0675; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kentrup H, 1996, J BIOL CHEM, V271, P3488; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; Lee K, 2000, CANCER RES, V60, P3631; Lochhead PA, 2003, BIOCHEM J, V374, P381, DOI 10.1042/BJ20030500; Miller CT, 2003, CANCER RES, V63, P4136; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; Moore MJ, 2002, J BIOL CHEM, V277, P47878, DOI 10.1074/jbc.M204970200; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Pang KM, 2004, DEV BIOL, V265, P127, DOI 10.1016/j.ydbio.2003.09.024; Pellettieri J, 2003, DEV CELL, V5, P451, DOI 10.1016/S1534-5807(03)00231-4; Quintin S, 2003, EMBO REP, V4, P1175, DOI 10.1038/sj.embor.7400029; Sarno S, 2003, BIOCHEM J, V374, P639, DOI 10.1042/BJ20030674; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P313, DOI 10.1016/S0079-6107(98)00059-5; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; SZYSZKA R, 1995, BIOCHEM BIOPH RES CO, V208, P418, DOI 10.1006/bbrc.1995.1354; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; Villerbu N, 2002, INT J CANCER, V97, P761, DOI 10.1002/ijc.10125; Way G, 2002, MOL BIOL CELL, V13, P3344, DOI 10.1091/mbc.E01-10-0094; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	44	216	219	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	2005	121	6					925	936		10.1016/j.cell.2005.03.034	http://dx.doi.org/10.1016/j.cell.2005.03.034			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960979	Bronze			2022-12-28	WOS:000230011200014
J	Gales, NJ; Kasuya, T; Clapham, PJ; Brownell, RL				Gales, NJ; Kasuya, T; Clapham, PJ; Brownell, RL			Japan's whaling plan under scrutiny	NATURE			English	Editorial Material									Australian Antarctic Div, Kingston, Tas 7050, Australia; Teikyo Univ Sci & Technol, Yamanashi 4090193, Japan; Natl Marine Mammal Lab, Alaska Fisheries Sci Ctr, Seattle, WA 98115 USA; SW Fisheries Sci Ctr, Pacific Grove, CA 93950 USA	Australian Antarctic Division; National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA	Gales, NJ (corresponding author), Australian Antarctic Div, Channel Highway, Kingston, Tas 7050, Australia.							Brownell RL, 2000, SCIENCE, V290, P1696; DELAMARE W, 1990, NATURE, V345, P771, DOI 10.1038/345771a0; NAGASAKI F, 1990, NATURE, V344, P189, DOI 10.1038/344189a0; Normile D, 2000, SCIENCE, V289, P2264, DOI 10.1126/science.289.5488.2264	4	45	45	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 16	2005	435	7044					883	884		10.1038/435883a	http://dx.doi.org/10.1038/435883a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959491	Green Submitted			2022-12-28	WOS:000229799700020
J	Hippisley-Cox, J; Coupland, C				Hippisley-Cox, J; Coupland, C			Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; CROSS-SECTIONAL SURVEY; RHEUMATOID-ARTHRITIS; GASTROINTESTINAL TOXICITY; CARDIOVASCULAR EVENTS; NAPROXEN; ROFECOXIB; BENEFITS; OUTCOMES	Aims To determine the comparative risk of myocardial infarction in patients taking cyclo-oxygenase-2 and other non-steroidal anti-inflammatory drugs (NSAIDs) in primary care between 2000 and 2004; to determine these risks in patients with and without pre-existing coronary heart disease and in those taking and not taking aspirin. Design Nested case-control study. Setting 367 general practices contributing to the UK QRESEARCH database and spread throughout every strategic health authority and health board in England, Wales, and Scotland. Subjects 9218 cases with a first ever diagnosis of myocardial infarction during the four year study period; 86 349 controls matched for age, calendar year, sex, and practice. Outcome measures Unadjusted and adjusted odds ratios with 95% confidence intervals for myocardial infarction associated with rofecoxib, celecoxib, naproxen, ibuprofen, diclofenac, and other selective and non-selective NSAIDS. Odds ratios were adjusted for smoking status, comorbidity, deprivation, and use of statins, aspirin, and antidepressants. Results A significantly increased risk of myocardial infarction was associated with current use of rofecoxib (adjusted odds ratio 1.32, 95% confidence interval 1.09 to 1.61) compared with no use within the previous three years; with current use of diclofenac (1.55, 1.39 to 1.72); and with current use of ibuprofen (1.24, 1.11 to 1.39). Increased risks were associated with the other selective NSAIDs, with naproxen, and with non-selective NSAIDs; these risks were significant at < 0.05 rather than < 0.01 for current use but significant at < 0.01 in the tests for trend. No significant interactions occurred between any of the NSAIDs and either aspirin or coronary heart disease. Conclusion These results suggest an increased risk of myocardial infarction associated with current use of rofecoxib, diclofenac, and ibuprofen despite adjustment for many potential confounders. No evidence was found to support a reduction in risk of myocardial infarction associated with current use of naproxen. This is an observational study and may be subject to residual confounding that cannot be fully corrected for. However, enough concerns may exist to warrant a reconsideration of the cardiovascular safety of all NSAIDs.			Hippisley-Cox, J (corresponding author), Inst 13th Floor,Tower Bldg,Univ Pk, Nottingham NG2 7RD, England.	Julia.hippisley-cox@nottingham.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Coupland, Carol/0000-0002-2327-3306				Blower AL, 1997, ALIMENT PHARM THERAP, V11, P283, DOI 10.1046/j.1365-2036.1997.d01-604.x; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Department of Health, 2000, NAT SERV FRAM COR AR; Dieppe P, 2004, BMJ-BRIT MED J, V329, P31, DOI 10.1136/bmj.329.7456.31; Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140-6736(04)16894-3; Hammersley V, 2002, BRIT J GEN PRACT, V52, P463; Hippisley-Cox J, 2001, BRIT MED J, V323, P666, DOI 10.1136/bmj.323.7314.666; Hippisley-Cox J, 2004, LANCET, V364, P423, DOI 10.1016/S0140-6736(04)16765-2; Hippisley-Cox J, 2004, HLTH INFORMATICS J, V10, P91, DOI 10.1177/1460458204042230; HIPPISLEYCOX J, 1998, BMJ-BRIT MED J, V317, P1450; HIPPISLEYCOX J, 2004, J INFORMATICS PRIMAR, V12, P49; Jick H, 1997, EPIDEMIOLOGY, V8, P446, DOI 10.1097/00001648-199707000-00017; Jones R, 2002, BMJ-BRIT MED J, V325, P607, DOI 10.1136/bmj.325.7365.607; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; Juni P, 2002, BRIT MED J, V324, P1287, DOI 10.1136/bmj.324.7349.1287; MacDonald TM, 2003, GUT, V52, P1265, DOI 10.1136/gut.52.9.1265; Mamdani M, 2003, ARCH INTERN MED, V163, P481, DOI 10.1001/archinte.163.4.481; McMahon AD, 2003, PHARMACOEPIDEM DR S, V12, P551, DOI 10.1002/pds.883; Meier CR, 1998, LANCET, V351, P1467, DOI 10.1016/S0140-6736(97)11084-4; *NAT I CLIN EXC, 2001, 27 NICE; *OFF NAT STAT, 1998, KEY HLTH STAT GEN PR, P192; PEDERSEN TR, 1994, LANCET, V344, P1383; Ray WA, 2002, LANCET, V359, P118, DOI 10.1016/S0140-6736(02)07370-1; Rothman K., 1998, MODERN EPIDEMIOLOGY; Schlienger RG, 2002, BRIT J CLIN PHARMACO, V54, P327, DOI 10.1046/j.1365-2125.2002.01637.x; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Solomon DH, 2002, ARCH INTERN MED, V162, P1099, DOI 10.1001/archinte.162.10.1099; Topol EJ, 2004, LANCET, V364, P639, DOI 10.1016/S0140-6736(04)16906-7; TOWNSEND P, 1987, J SOC POLICY, V16, P125, DOI 10.1017/S0047279400020341; Vandenbroucke JP, 2004, BRIT MED J, V329, P2, DOI 10.1136/bmj.329.7456.2; Watson DJ, 2002, ARCH INTERN MED, V162, P1105, DOI 10.1001/archinte.162.10.1105; Wright JM, 2002, CAN MED ASSOC J, V167, P1131	32	391	406	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 11	2005	330	7504					1366	1369		10.1136/bmj.330.7504.1366	http://dx.doi.org/10.1136/bmj.330.7504.1366			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936FE	15947398	Green Published			2022-12-28	WOS:000229840100021
J	Lovas, K; Husebye, ES				Lovas, K; Husebye, ES			Addison's disease	LANCET			English	Editorial Material							SUBJECTIVE HEALTH-STATUS; ADRENAL INSUFFICIENCY; DEHYDROEPIANDROSTERONE REPLACEMENT; TRIAL; WOMEN		Haukeland Univ Hosp, Inst Med, Div Endocrinol, N-5021 Bergen, Norway; Univ Bergen, Bergen, Norway	University of Bergen; Haukeland University Hospital; University of Bergen	Lovas, K (corresponding author), Haukeland Univ Hosp, Inst Med, Div Endocrinol, N-5021 Bergen, Norway.	kristian.lovas@helse-bergen.no						Addison T., 1849, LOND MED GAZETTE, V43, P517; Addison T., 1855, CONSTITUTIONAL LOCAL; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Arlt W, 2003, LANCET, V361, P1881, DOI 10.1016/S0140-6736(03)13492-7; Arlt W, 1999, NEW ENGL J MED, V341, P1013, DOI 10.1056/NEJM199909303411401; Blomhoff A, 2004, J CLIN ENDOCR METAB, V89, P3474, DOI 10.1210/jc.2003-031854; CIRILLO VJ, 1985, J HIST MED ALL SCI, V40, P214, DOI 10.1093/jhmas/40.2.214; Eisenbarth GS, 2004, NEW ENGL J MED, V350, P2068, DOI 10.1056/NEJMra030158; GRANER JL, 1985, CAN MED ASSOC J, V133, P855; Graner JL, 1985, CMAJ, V133, P880; Hunt PJ, 2000, J CLIN ENDOCR METAB, V85, P4650, DOI 10.1210/jc.85.12.4650; Johannsson G, 2002, J CLIN ENDOCR METAB, V87, P2046, DOI 10.1210/jc.87.5.2046; Lovas K, 2003, J CLIN ENDOCR METAB, V88, P1112, DOI 10.1210/jc.2002-020769; Lovas K, 2002, CLIN ENDOCRINOL, V56, P581, DOI 10.1046/j.1365-2265.2002.01466.x; Lyons AS, 1978, MED ILLUSTRATED HIST; MACKINNON J, 1969, GUYS HOSP REP, V83, P366; NIEMAN LK, 2003, UPTODATE; WINQVIST O, 1992, LANCET, V339, P1559, DOI 10.1016/0140-6736(92)91829-W	18	27	30	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 11	2005	365	9476					2058	2061		10.1016/S0140-6736(05)66700-1	http://dx.doi.org/10.1016/S0140-6736(05)66700-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950720				2022-12-28	WOS:000229701400028
J	Yen, AS; Gellert, R; Schroder, C; Morris, RV; Bell, JF; Knudson, AT; Clark, BC; Ming, DW; Crisp, JA; Arvidson, RE; Blaney, D; Bruckner, J; Christensen, PR; DesMarais, DJ; de Souza, PA; Economou, TE; Ghosh, A; Hahn, BC; Herkenhoff, KE; Haskin, LA; Hurowitz, JA; Joliff, BL; Johnson, JR; Klingelhofer, G; Madsen, MB; McLennan, SM; McSween, HY; Richter, L; Rieder, R; Rodionov, D; Soderblom, L; Squyres, SW; Tosca, NJ; Wang, A; Wyatt, M; Zipfel, J				Yen, AS; Gellert, R; Schroder, C; Morris, RV; Bell, JF; Knudson, AT; Clark, BC; Ming, DW; Crisp, JA; Arvidson, RE; Blaney, D; Bruckner, J; Christensen, PR; DesMarais, DJ; de Souza, PA; Economou, TE; Ghosh, A; Hahn, BC; Herkenhoff, KE; Haskin, LA; Hurowitz, JA; Joliff, BL; Johnson, JR; Klingelhofer, G; Madsen, MB; McLennan, SM; McSween, HY; Richter, L; Rieder, R; Rodionov, D; Soderblom, L; Squyres, SW; Tosca, NJ; Wang, A; Wyatt, M; Zipfel, J			An integrated view of the chemistry and mineralogy of martian soils	NATURE			English	Article							THERMAL EMISSION SPECTROMETER; X-RAY SPECTROMETER; MINI-TES EXPERIMENT; GUSEV CRATER; MERIDIANI-PLANUM; MARS PATHFINDER; SPIRIT ROVER; CHEMICAL-COMPOSITION; OPPORTUNITY ROVER; MOSSBAUER SPECTROMETER	The mineralogical and elemental compositions of the martian soil are indicators of chemical and physical weathering processes. Using data from the Mars Exploration Rovers, we show that bright dust deposits on opposite sides of the planet are part of a global unit and not dominated by the composition of local rocks. Dark soil deposits at both sites have similar basaltic mineralogies, and could reflect either a global component or the general similarity in the compositions of the rocks from which they were derived. Increased levels of bromine are consistent with mobilization of soluble salts by thin films of liquid water, but the presence of olivine in analysed soil samples indicates that the extent of aqueous alteration of soils has been limited. Nickel abundances are enhanced at the immediate surface and indicate that the upper few millimetres of soil could contain up to one per cent meteoritic material.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Max Planck Inst Chem, D-55128 Mainz, Germany; Johannes Gutenberg Univ Mainz, D-55128 Mainz, Germany; NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA; Lockheed Martin Corp, Littleton, CO 80127 USA; Washington Univ, St Louis, MO 63130 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Co Vale Rio Doce, BR-29030900 Rio De Janeiro, Brazil; Univ Chicago, Enrico Fermi Inst, Chicago, IL 60637 USA; Univ Tennessee, Dept Earth & Planetary Sci, Knoxville, TN 37996 USA; SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA; US Geol Survey, Flagstaff, AZ 86001 USA; Univ Copenhagen, Niels Bohr Inst, DS-2100 Copenhagen, Denmark; DLR, Inst Raumsimulat, D-51170 Cologne, Germany	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Max Planck Society; Johannes Gutenberg University of Mainz; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; Cornell University; Arizona State University; Arizona State University-Tempe; Lockheed Martin; Washington University (WUSTL); National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Chicago; University of Tennessee System; University of Tennessee Knoxville; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; United States Department of the Interior; United States Geological Survey; University of Copenhagen; Niels Bohr Institute; Helmholtz Association; German Aerospace Centre (DLR)	Yen, AS (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	Albert.Yen@jpl.nasa.gov	de Souza, Paulo A/B-8961-2008; Johnson, Jeffrey R/F-3972-2015; Madsen, Morten Bo/D-2082-2011; Hurowitz, Joel A/A-8862-2008; Schröder, Christian/B-3870-2009; Crisp, Joy/H-8287-2016; Blaney, Diana/M-1756-2019; de Souza, Paulo/W-2993-2019; de Souza, Paulo/P-7294-2019	de Souza, Paulo A/0000-0002-0091-8925; Johnson, Jeffrey R/0000-0002-5586-4901; Madsen, Morten Bo/0000-0001-8909-5111; Schröder, Christian/0000-0002-7935-6039; Crisp, Joy/0000-0002-3202-4416; Blaney, Diana/0000-0002-4267-7939; de Souza, Paulo/0000-0002-0091-8925; Tosca, Nicholas/0000-0003-4415-4231; McLennan, Scott/0000-0003-4259-7178				ADAMS JB, 1969, J GEOPHYS RES, V74, P4851, DOI 10.1029/JB074i020p04851; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; Arvidson RE, 2004, SCIENCE, V305, P821, DOI 10.1126/science.1099922; Bandfield JL, 2000, SCIENCE, V287, P1626, DOI 10.1126/science.287.5458.1626; Bandfield JL, 2003, ICARUS, V161, P47, DOI 10.1016/S0019-1035(02)00025-8; Bell JF, 2004, SCIENCE, V306, P1703, DOI 10.1126/science.1105245; Bell JF, 2004, SCIENCE, V305, P800, DOI 10.1126/science.1100175; Bell JF, 2000, J GEOPHYS RES-PLANET, V105, P1721, DOI 10.1029/1999JE001060; BELL JF, 2003, J GEOPHYS RES-PLANET, V108, DOI DOI 10.1029/2003JE002070; Bertelsen P, 2004, SCIENCE, V305, P827, DOI 10.1126/science.1100112; Binder A. B., 1977, Journal of Geophysical Research, V82, P4439, DOI 10.1029/JS082i028p04439; Bishop JL, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001581; Bruckner J, 2003, J GEOPHYS RES-PLANET, V108, DOI [10.1029/2003JE002060, 10.1029/2003JE002150]; Christensen PR, 2000, J GEOPHYS RES-PLANET, V105, P9609, DOI 10.1029/1999JE001127; Christensen PR, 2000, J GEOPHYS RES-PLANET, V105, P9623, DOI 10.1029/1999JE001093; Christensen PR, 2004, SCIENCE, V305, P837, DOI 10.1126/science.1100564; Christensen PR, 2004, SCIENCE, V306, P1733, DOI 10.1126/science.1104909; Christensen PR, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002117; Clark B. C.  III, 1977, Journal of Geophysical Research, V82, P4577, DOI 10.1029/JS082i028p04577; CLARK BC, 1982, J GEOPHYS RES, V87, P59, DOI 10.1029/JB087iB12p10059; CLARK BC, 1979, J GEOPHYS RES, V84, P8395, DOI 10.1029/JB084iB14p08395; FLYNN GJ, 1990, J GEOPHYS RES-SOLID, V95, P14497, DOI 10.1029/JB095iB09p14497; FOLEY CN, 2003, J GEOPHYS RES, V108, DOI DOI 10.1029/2003JE002019; GANAPATHY R, 1970, P APOLLO 11 LUNAR SC, V2, P1117; Gellert R, 2004, SCIENCE, V305, P829, DOI 10.1126/science.1099913; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; Gorevan SP, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002061; Hamilton VE, 2001, J GEOPHYS RES-PLANET, V106, P14733, DOI 10.1029/2000JE001353; Herkenhoff KE, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002076; Huck F. O., 1977, Journal of Geophysical Research, V82, P4401, DOI 10.1029/JS082i028p04401; Klingelhofer G, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002138; Klingelhofer G, 2004, SCIENCE, V306, P1740, DOI 10.1126/science.1104653; Lane MD, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021231; Madsen MB, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE002029; McLennan SM, 2000, GEOPHYS RES LETT, V27, P1335, DOI 10.1029/1999GL008432; McSween HY, 2004, SCIENCE, V305, P842, DOI 10.1126/science.3050842; Morris RV, 2004, SCIENCE, V305, P833, DOI 10.1126/science.1100020; Morris RV, 2000, J GEOPHYS RES-PLANET, V105, P1757, DOI 10.1029/1999JE001059; Mutch T. A., 1977, Journal of Geophysical Research, V82, P4452, DOI 10.1029/JS082i028p04452; Rieder R., 2003, Journal of Geophysical Research, V108, pROV7, DOI 10.1029/2003JE002150; Rieder R, 2004, SCIENCE, V306, P1746, DOI 10.1126/science.1104358; Rieder R, 1997, J GEOPHYS RES-PLANET, V102, P4027, DOI 10.1029/96JE03918; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; Soderblom LA, 2004, SCIENCE, V306, P1723, DOI 10.1126/science.1105127; Squyres SW, 2004, SCIENCE, V305, P794, DOI 10.1126/science.3050794; Squyres SW, 2004, SCIENCE, V306, P1698, DOI 10.1126/science.1106171; YEN AS, 2001, LUNAR PLANET SCI C, V32, P1766	47	282	283	3	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 7	2005	436	7047					49	54		10.1038/nature03637	http://dx.doi.org/10.1038/nature03637			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	942QJ	16001059				2022-12-28	WOS:000230296600036
J	Morris, CR; Kato, GJ; Poljakovic, M; Wang, XD; Blackwelder, WC; Sachdev, V; Hazen, SL; Vichinsky, EP; Morris, SM; Gladwin, MT				Morris, CR; Kato, GJ; Poljakovic, M; Wang, XD; Blackwelder, WC; Sachdev, V; Hazen, SL; Vichinsky, EP; Morris, SM; Gladwin, MT			Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NITRIC-OXIDE SYNTHASE; ARGINASE ACTIVITY; P-SELECTIN; AIRWAY HYPERRESPONSIVENESS; ADHESION MOLECULES; ENDOTHELIAL-CELLS; AMINO-ACID; ANEMIA; ERYTHROCYTES; EXPRESSION	Context Sickle cell disease is characterized by a state of nitric oxide resistance and limited bioavailability of L-arginine, the substrate for nitric oxide synthesis. We hypothesized that increased arginase activity and dysregulated arginine metabolism contribute to endothelial dysfunction, pulmonary hypertension, and patient outcomes. Objective To explore the role of arginase in sickle cell disease pathogenesis, pulmonary hypertension, and mortality. Design Plasma amino acid levels, plasma and erythrocyte arginase activities, and pulmonary hypertension status as measured by Doppler echocardiogram were prospectively obtained in outpatients with sickle cell disease. Patients were followed,up for survival up to 49 months. Setting Urban tertiary care center and community clinics in the United States between February 2001 and March 2005. Participants Two hundred twenty-eight patients with sickle cell disease, aged 18 to 74 years, and 36 control participants. Main Outcome Measures Plasma amino acid levels, plasma and erythrocyte arginase activities, diagnosis of pulmonary hypertension, and mortality. Results Plasma arginase activity was significantly elevated in patients with sickle cell disease, with highest activity found in patients with secondary pulmonary hypertension. Arginase activity correlated with the arginine-ornithine ratio, and lower ratios were associated with greater severity of pulmonary hypertension and with mortality in this population (risk ratio, 2.5; 95% confidence interval [CI] 1.2-5.2; P=.006). Global arginine bioavailability, characterized by the ratio of arginine to ornithine plus citrulline, was also strongly associated with mortality (risk ratio, 3.6; 95% Cl, 1.5-8.3; P<.001). Increased plasma arginase activity was correlated with increased intravascular hemolytic rate and, to a lesser extent, with markers of inflammation and soluble adhesion molecule levels. Conclusions These data support a novel mechanism of disease in which hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase, which limits arginine bioavailability, and release of erythrocyte hemoglobin, which scavenges nitric oxide. The ratios of arginine to ornithine and arginine to ornithine plus citrulline are independently associated with pulmonary hypertension and increased mortality in patients with sickle cell disease.	Childrens Hosp & Res Ctr Oakland, Dept Emergency Med, Oakland, CA 94609 USA; Childrens Hosp & Res Ctr Oakland, Dept Hematol Oncol, Oakland, CA 94609 USA; NHLBI, Vasc Therapeut Sect, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA; NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA; NIH, Echocardiog Lab, Bethesda, MD 20892 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Dept Cardiovasc Med, Cleveland, OH 44195 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Morris, SM (corresponding author), Childrens Hosp & Res Ctr Oakland, Dept Emergency Med, 747 52nd St, Oakland, CA 94609 USA.	claudiamorris@comcast.net	Hazen, Stanley L/ABD-5845-2021; Kato, Gregory J/I-7615-2014; Morris, Sidney M/I-3440-2015; Vichinsky, Elliott P/F-8541-2011	Kato, Gregory J/0000-0003-4465-3217; Vichinsky, Elliott P/0000-0002-0500-9579	Intramural NIH HHS [Z01 CL001174-07, ZIA HL006012-01, Z99 HL999999] Funding Source: Medline; NCRR NIH HHS [M01-RR01271, M01 RR001271] Funding Source: Medline; NHLBI NIH HHS [P01 HL076491, K23 HL004386, HL-04386-05] Funding Source: Medline; NIGMS NIH HHS [R01 GM057384, R01 GM57384] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004386, P01HL076491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057384] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL001174] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CLINICAL CENTER		AESSOPOS A, 1995, CHEST, V107, P50, DOI 10.1378/chest.107.1.50; [Anonymous], 2000, NITRIC OXIDE BIOL PA; Archer SL, 1998, AM J RESP CRIT CARE, V158, P1061, DOI 10.1164/ajrccm.158.4.9802113; Aslan M, 2001, P NATL ACAD SCI USA, V98, P15215, DOI 10.1073/pnas.221292098; AZIZI E, 1970, CLIN CHIM ACTA, V28, P391, DOI 10.1016/0009-8981(70)90063-X; Bank N, 1996, KIDNEY INT, V50, P184, DOI 10.1038/ki.1996.301; BELFIORE F, 1964, Riforma Med, V78, P1052; Boucher JL, 1999, CELL MOL LIFE SCI, V55, P1015, DOI 10.1007/s000180050352; Castro O, 2003, BLOOD, V101, P1257, DOI 10.1182/blood-2002-03-0948; Chou R, 2001, AM J HEMATOL, V67, P197, DOI 10.1002/ajh.1107; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Closs E, 2000, NITRIC OXIDE BIOL PA, P225; Closs EI, 2002, CURR OPIN NEPHROL HY, V11, P99, DOI 10.1097/00041552-200201000-00015; Cooper CJ, 1996, CIRCULATION, V93, P266, DOI 10.1161/01.CIR.93.2.266; DiasDaMotta PM, 1996, BRIT J HAEMATOL, V93, P333, DOI 10.1046/j.1365-2141.1996.4951036.x; Diwan BA, 2002, TOXICOL PATHOL, V30, P254, DOI 10.1080/019262302753559597; Embury SH, 2004, BLOOD, V104, P3378, DOI 10.1182/blood-2004-02-0713; ENWONWU C O, 1989, Medical Science Research, V17, P997; FEATHERSTON WR, 1973, AM J PHYSIOL, V224, P127, DOI 10.1152/ajplegacy.1973.224.1.127; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056/NEJMoa035477; Gladwin MT, 2003, CIRCULATION, V107, P271, DOI 10.1161/01.CIR.0000044943.12533.A8; Grunfeld C, 1996, NUTRITION, V12, pS24; Hebbel RP, 2004, MICROCIRCULATION, V11, P129, DOI 10.1080/10739680490278402; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HELLER PG, 1992, CHEST, V102, P642, DOI 10.1378/chest.102.2.642; Hosmer D. W., 1999, APPL SURVIVAL ANAL; Jison ML, 2004, BLOOD, V104, P270, DOI 10.1182/blood-2003-08-2760; Jison ML, 2003, AM J RESP CRIT CARE, V168, P3, DOI 10.1164/rccm.2304002; JUBELIRER SJ, 1991, ARCH INTERN MED, V151, P1221, DOI 10.1001/archinte.151.6.1221; Kaneko FT, 1998, AM J RESP CRIT CARE, V158, P917, DOI 10.1164/ajrccm.158.3.9802066; Kaul DK, 2004, J CLIN INVEST, V114, P1136, DOI 10.1172/JCI200421633; Kaul DK, 2000, AM J PHYSIOL-HEART C, V278, pH1799, DOI 10.1152/ajpheart.2000.278.6.H1799; Kim PS, 2002, MOL GENET METAB, V76, P100, DOI 10.1016/S1096-7192(02)00034-3; Komai M, 2003, BRIT J PHARMACOL, V138, P912, DOI 10.1038/sj.bjp.0705105; Koumbourlis AC, 2001, J PEDIATR-US, V138, P188, DOI 10.1067/mpd.2001.111824; Labrune P, 1999, EUR J PEDIATR, V158, P734, DOI 10.1007/s004310051190; Leong MA, 1997, J PEDIATR-US, V131, P278, DOI 10.1016/S0022-3476(97)70166-5; Maggi FM, 2004, J CLIN ENDOCR METAB, V89, P2946, DOI 10.1210/jc.2003-031977; Mansoor MA, 2004, CLIN BIOCHEM, V37, P408, DOI 10.1016/j.clinbiochem.2004.01.003; Marchesi S, 2003, J CLIN PHARM THER, V28, P419, DOI 10.1046/j.0269-4727.2003.00512.x; Matsui NM, 2001, BLOOD, V98, P1955, DOI 10.1182/blood.V98.6.1955; MEHTA S, 1995, CIRCULATION, V92, P1539, DOI 10.1161/01.CIR.92.6.1539; Meurs H, 2003, TRENDS PHARMACOL SCI, V24, P450, DOI 10.1016/S0165-6147(03)00227-X; Meurs H, 2002, BRIT J PHARMACOL, V136, P391, DOI 10.1038/sj.bjp.0704725; Mori M, 2000, BIOCHEM BIOPH RES CO, V275, P715, DOI 10.1006/bbrc.2000.3169; Morris CR, 2000, BRIT J HAEMATOL, V111, P498, DOI 10.1046/j.1365-2141.2000.02403.x; Morris CR, 2003, AM J RESP CRIT CARE, V168, P63, DOI 10.1164/rccm.200208-967OC; Morris CR, 2004, BLOOD, V104, p463A, DOI 10.1182/blood.V104.11.1666.1666; Morris CR, 2004, AM J RESP CRIT CARE, V170, P148, DOI 10.1164/rccm.200309-1304OC; Morris CR, 2003, J PEDIAT HEMATOL ONC, V25, P629, DOI 10.1097/00043426-200308000-00008; Morris CR, 2000, J PEDIAT HEMATOL ONC, V22, P515, DOI 10.1097/00043426-200011000-00009; Morris SM, 2002, ANNU REV NUTR, V22, P87, DOI 10.1146/annurev.nutr.22.110801.140547; Morris SM, 1998, AM J PHYSIOL-ENDOC M, V275, pE740, DOI 10.1152/ajpendo.1998.275.5.E740; Pathare Anil, 2003, Hematology, V8, P329; Raghupathy R, 2000, ACTA HAEMATOL-BASEL, V103, P197, DOI 10.1159/000041049; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Reiter CD, 2003, CURR OPIN HEMATOL, V10, P99, DOI 10.1097/00062752-200303000-00001; REYNOLDS J, 1957, J LAB CLIN MED, V50, P78; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Schnog JJB, 2004, ANN HEMATOL, V83, P371, DOI 10.1007/s00277-004-0856-9; Shores J, 2003, J NATL MED ASSOC, V95, P813; Solovey A, 1997, NEW ENGL J MED, V337, P1584, DOI 10.1056/NEJM199711273372203; Solovey A, 1998, J CLIN INVEST, V101, P1899, DOI 10.1172/JCI1932; STUARD ID, 1972, NEW ENGL J MED, V287, P869, DOI 10.1056/NEJM197210262871710; SUTTON LL, 1994, AM J CARDIOL, V74, P626, DOI 10.1016/0002-9149(94)90760-9; VanderJagt DJ, 1997, J TROP PEDIATRICS, V43, P220, DOI 10.1093/tropej/43.4.220; VERRESEN D, 1991, EUR RESPIR J, V4, P629; Wang XD, 2004, P NATL ACAD SCI USA, V101, P11477, DOI 10.1073/pnas.0402201101; Waugh WH, 1999, NUTR RES, V19, P501, DOI 10.1016/S0271-5317(99)00017-2; Wood K, 2004, MICROCIRCULATION, V11, P377, DOI 10.1080/10739680490437559; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Xu WL, 2004, FASEB J, V18, P1746, DOI 10.1096/fj.04-2317fje; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912; [No title captured]	75	492	517	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2005	294	1					81	90		10.1001/jama.294.1.81	http://dx.doi.org/10.1001/jama.294.1.81			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941JD	15998894	Bronze, Green Accepted, Green Submitted			2022-12-28	WOS:000230210200028
J	Dubos, F; Leclerc, F				Dubos, F; Leclerc, F			Infants refusing to walk	LANCET			English	Editorial Material									Hop Jeanne de Flandre, F-59037 Lille, France	Universite de Lille - ISITE; CHU Lille	Leclerc, F (corresponding author), Hop Jeanne de Flandre, F-59037 Lille, France.	fleclerc@chru-lille.fr	Dubos, Francois/AGD-5638-2022	dubos, francois/0000-0003-2151-1638					0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	2005	366	9479					93	93		10.1016/S0140-6736(05)66831-6	http://dx.doi.org/10.1016/S0140-6736(05)66831-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993238				2022-12-28	WOS:000230277600039
J	Summerskill, W				Summerskill, W			Literature searches: look before you leap	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Summerskill, W (corresponding author), The Lancet, London NW1 7BY, England.							BRICE A, 2004, CILIP UPDATE    0811; Dawes Martin, 2005, BMC Med Educ, V5, P1; GRAY M, 2003, E CONSULTATION VIGNE; Haynes RB, 2005, BMJ-BRIT MED J, V330, P1179, DOI 10.1136/bmj.38446.498542.8F; Henderson J, 2005, CAN MED ASSOC J, V172, P1549, DOI 10.1503/cmaj.050404; Holst R, 2005, J MED LIBR ASSOC, V93, P45; *NAT CTR BIOT INF, 2005, CLIN QUER US RES MET; *NAT LIB MED, 2005, NUMB MEDLINE SEARCH; RAFTERY J, 2005, HLTH TECHNOL ASSESS, V9; Sigouin C, 2002, JAMA-J AM MED ASSOC, V287, P2867, DOI 10.1001/jama.287.21.2867; Wagner KC, 2004, J MED LIBR ASSOC, V92, P14	11	7	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	2005	366	9479					13	14		10.1016/S0140-6736(05)66802-X	http://dx.doi.org/10.1016/S0140-6736(05)66802-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993214				2022-12-28	WOS:000230277600009
J	Heathman, S; Haire, RG; Le Bihan, T; Lindbaum, A; Idiri, M; Normile, P; Li, S; Ahuja, R; Johansson, B; Lander, GH				Heathman, S; Haire, RG; Le Bihan, T; Lindbaum, A; Idiri, M; Normile, P; Li, S; Ahuja, R; Johansson, B; Lander, GH			A high-pressure structure in curium linked to magnetism	SCIENCE			English	Article							X-RAY-DIFFRACTION; CRYSTAL-STRUCTURES; TRANSITION-METALS; 5F ELECTRONS; SYSTEMS	Curium ties at the center of the actinide series and has a half-filled shell. with seven 5f electrons spatially residing inside its radon core. As a function of pressure, curium exhibits five different crystallographic phases up to 100 gigapascals, of which all but one are also found in the preceding element, americium. We describe here a structure in curium, Cm III, with monoctinic symmetry, space group C2/c, found at intermediate pressures (between 37 and 56 gigapascals). Ab initio electronic structure calculations agree with the observed sequence of structures and establish that it is the spin polarization of curium's 5f electrons that stabilizes Cm Ill. The results reveal that curium is one of a few elements that has a lattice structure stabilized by magnetism.	Commiss European Communities, Joint Res Ctr, Inst Transuranium Elements, D-76125 Karlsruhe, Germany; Royal Inst Technol, Dept Mat Sci & Engn, SE-10044 Stockholm, Sweden; Univ Uppsala, Dept Phys, S-75121 Uppsala, Sweden; Vienna Univ Technol, Inst Solid State Phys, A-1040 Vienna, Austria; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Oak Ridge Natl Lab, Div Chem Sci, Oak Ridge, TN 37831 USA	European Commission Joint Research Centre; EC JRC Institute for Transuranium Elements (ITU); Royal Institute of Technology; Uppsala University; Technische Universitat Wien; European Synchrotron Radiation Facility (ESRF); United States Department of Energy (DOE); Oak Ridge National Laboratory	Heathman, S (corresponding author), Commiss European Communities, Joint Res Ctr, Inst Transuranium Elements, Postfach 2340, D-76125 Karlsruhe, Germany.	heathman@itu.fzk.de	Normile, Peter S/I-2320-2015; LE BIHAN, Tristan/I-5063-2013	Normile, Peter S/0000-0002-8851-9899; Ahuja, Rajeev/0000-0003-1231-9994; Lindbaum, Andreas/0000-0003-4624-8848				ANDERSEN OK, 1977, PHYSICA B & C, V86, P249, DOI 10.1016/0378-4363(77)90303-5; BENEDICT U, 1985, J PHYS F MET PHYS, V15, pL29, DOI 10.1088/0305-4608/15/2/002; BIRCH F, 1947, PHYS REV, V71, P809, DOI 10.1103/PhysRev.71.809; Brooks M. S. S., 1984, Handbook on the physics and chemistry of the actinides. Vol.1, P153; Cooper N.G., 2000, CHALLENGES PLUTONIUM, VI; Haire RG, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.134101; HAIRE RG, 1985, J LESS-COMMON MET, V109, P71, DOI 10.1016/0022-5088(85)90108-0; Heathman S, 2000, PHYS REV LETT, V85, P2961, DOI 10.1103/PhysRevLett.85.2961; Heathman S, 1998, J ALLOY COMPD, V271, P342, DOI 10.1016/S0925-8388(98)00085-1; Huray PG, 1987, HDB PHYSICS CHEM ACT, V5, P311; ITIE JP, 1985, JJ PHYS F, V15, P213; Le Bihan T, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.134102; Lindbaum A, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.214101; Lindbaum A, 2003, J PHYS-CONDENS MAT, V15, pS2297, DOI 10.1088/0953-8984/15/28/371; Penicaud M, 2002, J PHYS-CONDENS MAT, V14, P3575, DOI 10.1088/0953-8984/14/13/315; PRICE DL, 1989, PHYS REV B, V39, P4945, DOI 10.1103/PhysRevB.39.4945; SODERLIND P, 1995, NATURE, V374, P524, DOI 10.1038/374524a0; SODERLIND P, 1994, PHYS REV B, V50, P5918, DOI 10.1103/PhysRevB.50.5918; VINET P, 1987, J GEOPHYS RES-SOLID, V92, P9319, DOI 10.1029/JB092iB09p09319; WILLS JM, 1987, PHYS REV B, V36, P3809, DOI 10.1103/PhysRevB.36.3809	20	104	104	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 1	2005	309	5731					110	113		10.1126/science.1112453	http://dx.doi.org/10.1126/science.1112453			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994550				2022-12-28	WOS:000230212800068
J	Fournier, D; Estoup, A; Orivel, J; Foucaud, J; Jourdan, H; Le Breton, J; Keller, L				Fournier, D; Estoup, A; Orivel, J; Foucaud, J; Jourdan, H; Le Breton, J; Keller, L			Clonal reproduction by males and females in the little fire ant	NATURE			English	Article							SEX; PARTHENOGENESIS; EVOLUTION	Sexual reproduction can lead to major conflicts between sexes and within genomes(1-4). Here we report an extreme case of such conflicts in the little fire ant Wasmannia auropunctata. We found that sterile workers are produced by normal sexual reproduction, whereas daughter queens are invariably clonally produced. Because males usually develop from unfertilized maternal eggs in ants and other haplodiploid species, they normally achieve direct fitness only through diploid female offspring. Hence, although the clonal production of queens increases the queen's relatedness to reproductive daughters, it potentially reduces male reproductive success to zero. In an apparent response to this conflict between sexes, genetic analyses reveal that males reproduce clonally, most likely by eliminating the maternal half of the genome in diploid eggs. As a result, all sons have nuclear genomes identical to those of their father. The obligate clonal production of males and queens from individuals of the same sex effectively results in a complete separation of the male and female gene pools. These findings show that the haplodiploid sex-determination system provides grounds for the evolution of extraordinary genetic systems and new types of sexual conflict.	INRA, Ctr Biol & Gest Populat, F-34988 Montferrier Sur Lez, France; Univ Toulouse 3, Lab Evolut & Divers Biol, CNRS, UMR 5174, F-31062 Toulouse, France; IRD, Lab Zool Appl, Noumea 98948, New Caledonia; Univ Ryukyus, Lab Subtrop Zool, Okinawa 9030213, Japan; Univ Lausanne, Dept Ecol & Evolut, CH-1015 Lausanne, Switzerland	INRAE; Institut de Recherche pour le Developpement (IRD); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Ecole Nationale Formation Agronomique (ENSFEA); Institut de Recherche pour le Developpement (IRD); University of the Ryukyus; University of Lausanne	Fournier, D (corresponding author), Univ Libre Bruxelles, CP 160-12,50 Ave FD Roosevelt, B-1050 Brussels, Belgium.	denis.fournier@ulb.ac.be; estoup@ensam.inra.fr	Fournier, Denis/EZX-2474-2022; Jourdan, Herve/D-1452-2011; keller, laurent/AAI-7175-2020; Orivel, Jerome/C-4034-2011	Fournier, Denis/0000-0003-4094-0390; Jourdan, Herve/0000-0002-3756-4008; Orivel, Jerome/0000-0002-5636-3228; Foucaud, Julien/0000-0003-2272-3149; keller, laurent/0000-0002-5046-9953				Arnqvist G, 2002, NATURE, V415, P787, DOI 10.1038/415787a; Baudry E, 2004, GENETICS, V167, P243, DOI 10.1534/genetics.167.1.243; Cahan SH, 2003, NATURE, V424, P306, DOI 10.1038/nature01744; Chapuisat M, 1998, MOL ECOL, V7, P1097, DOI 10.1046/j.1365-294x.1998.00422.x; Cole BJ, 1999, SCIENCE, V285, P891, DOI 10.1126/science.285.5429.891; COOK JM, 1995, TRENDS ECOL EVOL, V10, P281, DOI 10.1016/0169-5347(95)90011-X; CROZIER RH, 1985, BEHAV ECOL SOCIOBIOL, V18, P105, DOI 10.1007/BF00299039; EBERHARD WG, 1980, Q REV BIOL, V55, P231, DOI 10.1086/411855; Fournier D, 2005, MOL ECOL NOTES, V5, P239, DOI 10.1111/j.1471-8286.2005.00889.x; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; Holldobler B., 1990, pi; HURST LD, 1992, P ROY SOC B-BIOL SCI, V248, P135, DOI 10.1098/rspb.1992.0053; KOENIGER N, 1989, APIDOLOGIE, V20, P391, DOI 10.1051/apido:19890503; Normark BB, 2003, ANNU REV ENTOMOL, V48, P397, DOI 10.1146/annurev.ento.48.091801.112703; NUR U, 1988, SCIENCE, V240, P512, DOI 10.1126/science.3358129; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Parker JD, 2004, TRENDS ECOL EVOL, V19, P83, DOI 10.1016/j.tree.2003.10.001; Pearcy M, 2004, SCIENCE, V306, P1780, DOI 10.1126/science.1105453; Pomiankowski A, 1999, MG BEH ECOL, P121; RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; SHERMAN PW, 1988, AM NAT, V131, P602, DOI 10.1086/284809; Simon JC, 2003, BIOL J LINN SOC, V79, P151, DOI 10.1046/j.1095-8312.2003.00175.x; Swanson WJ, 2001, P NATL ACAD SCI USA, V98, P2509, DOI 10.1073/pnas.051605998; Torres JA, 2001, SOCIOBIOLOGY, V37, P601; Ulloa-Chacon P., 1988, Actes des Colloques Insectes Sociaux, V4, P177; WERREN JH, 1987, NATURE, V327, P75, DOI 10.1038/327075a0	27	203	211	1	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1230	1234		10.1038/nature03705	http://dx.doi.org/10.1038/nature03705			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988525	Green Published			2022-12-28	WOS:000230140500043
J	Gu, KY; Yang, B; Tian, DS; Wu, LF; Wang, DJ; Sreekala, C; Yang, F; Chu, ZQ; Wang, GL; White, FF; Yin, ZC				Gu, KY; Yang, B; Tian, DS; Wu, LF; Wang, DJ; Sreekala, C; Yang, F; Chu, ZQ; Wang, GL; White, FF; Yin, ZC			R gene expression induced by a type-III effector triggers disease resistance in rice	NATURE			English	Article							BACTERIAL-BLIGHT-RESISTANCE; XANTHOMONAS-ORYZAE PV; TRANSCRIPTIONAL ACTIVATION; PROTEIN; AVRBS3; IDENTIFICATION; CAMPESTRIS; ENCODES; AVRRPT2; RIN4	Disease resistance (R) genes in plants encode products that specifically recognise incompatible pathogens and trigger a cascade of events leading to disease resistance in the host plant(1). R-gene specificity is dictated by both host R genes and cognate avirulence (avr) genes in pathogens(2,3). However, the basis of gene-for-gene specificity is not well understood. Here, we report the cloning of the R gene Xa27 from rice and the cognate avr gene avrXa27 from Xanthomonas oryzae pv. oryzae. Resistant and susceptible alleles of Xa27 encode identical proteins. However, expression of only the resistant allele occurs when a rice plant is challenged by bacteria harbouring avrXa27, whose product is a nuclear localized type-III effector. Induction of Xa27 occurs only in the immediate vicinity of infected tissue, whereas ectopic expression of Xa27 resulted in resistance to otherwise compatible strains of the pathogen. Thus Xa27 specificity towards incompatible pathogens involves the differential expression of the R gene in the presence of the AvrXa27 effector.	Natl Univ Singapore, Temasek Life Sci Lab, Singapore 117604, Singapore; Kansas State Univ, Dept Plant Pathol, Manhattan, KS 66506 USA; Natl Univ Singapore, Inst Mol Agrobiol, Singapore 117604, Singapore	National University of Singapore; Kansas State University; National University of Singapore	Yin, ZC (corresponding author), Natl Univ Singapore, Temasek Life Sci Lab, 1 Res Link, Singapore 117604, Singapore.	yinzc@tll.org.sg	Yang, Bing/D-3628-2019	Yang, Bing/0000-0002-2293-3384; YANG, Fan/0000-0002-9664-3953; ?, ??/0000-0002-3982-9858; Wang, Guo-Liang/0000-0001-8877-3064; Chellamma, Sreekala/0000-0002-4615-6719				Belkhadir Y, 2004, CURR OPIN PLANT BIOL, V7, P391, DOI 10.1016/j.pbi.2004.05.009; Belkhadir Y, 2004, PLANT CELL, V16, P2822, DOI 10.1105/tpc.104.024117; Bing Y, 2004, MOL PLANT MICROBE IN, V17, P1192, DOI 10.1094/MPMI.2004.17.11.1192; BONAS U, 1989, MOL GEN GENET, V218, P127, DOI 10.1007/BF00330575; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Greenberg JT, 2003, CURR OPIN MICROBIOL, V6, P20, DOI 10.1016/S1369-5274(02)00004-8; Gu K, 2004, THEOR APPL GENET, V108, P800, DOI 10.1007/s00122-003-1491-x; HERBERS K, 1992, NATURE, V356, P172, DOI 10.1038/356172a0; HOPKINS CM, 1992, MOL PLANT MICROBE IN, V5, P451, DOI 10.1094/MPMI-5-451; Iyer AS, 2004, MOL PLANT MICROBE IN, V17, P1348, DOI 10.1094/MPMI.2004.17.12.1348; KAUFFMAN HE, 1973, PLANT DIS REP, V57, P537; Levy M, 2004, PLANT PHYSIOL, V135, P2392, DOI 10.1104/pp.104.044859; Lim MTS, 2004, PLANT J, V40, P790, DOI 10.1111/j.1365-313X.2004.02251.x; Marois E, 2002, MOL PLANT MICROBE IN, V15, P637, DOI 10.1094/MPMI.2002.15.7.637; Martin GB, 2003, ANNU REV PLANT BIOL, V54, P23, DOI 10.1146/annurev.arplant.54.031902.135035; Radwan O, 2005, J EXP BOT, V56, P567, DOI 10.1093/jxb/eri030; Schornack S, 2004, PLANT J, V37, P46, DOI 10.1046/j.1365-313X.2003.01937.x; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; Stebbins CE, 2001, NATURE, V412, P701, DOI 10.1038/35089000; Sun XL, 2004, PLANT J, V37, P517, DOI 10.1046/j.1365-313X.2003.01976.x; SWARUP S, 1991, PHYTOPATHOLOGY, V81, P802, DOI 10.1094/Phyto-81-802; Szurek B, 2001, PLANT J, V26, P523, DOI 10.1046/j.0960-7412.2001.01046.x; WANG GL, 1995, PLANT J, V7, P525, DOI 10.1046/j.1365-313X.1995.7030525.x; White SD, 1998, ADVANCES IN VETERINARY DERMATOLOGY, VOL 3, P291; Wu AJ, 2004, PLANT CELL, V16, P2809, DOI 10.1105/tpc.104.024141; Yang B, 2000, P NATL ACAD SCI USA, V97, P9807, DOI 10.1073/pnas.170286897; Yin Z, 2000, THEOR APPL GENET, V100, P461, DOI 10.1007/s001220050060; Yoshimura S, 1998, P NATL ACAD SCI USA, V95, P1663, DOI 10.1073/pnas.95.4.1663; Zhu WG, 1998, MOL PLANT MICROBE IN, V11, P824, DOI 10.1094/MPMI.1998.11.8.824	29	406	533	5	120	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1122	1125		10.1038/nature03630	http://dx.doi.org/10.1038/nature03630			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973413				2022-12-28	WOS:000229970400054
J	Warrick, DR; Tobalske, BW; Powers, DR				Warrick, DR; Tobalske, BW; Powers, DR			Aerodynamics of the hovering hummingbird	NATURE			English	Article							VORTEX WAKE; FLIGHT; HAWKMOTH; MECHANICS; KINEMATICS; FORCES; WINGS	Despite profound musculoskeletal differences, hummingbirds (Trochilidae) are widely thought to employ aerodynamic mechanisms similar to those used by insects. The kinematic symmetry of the hummingbird upstroke and downstroke(1-3) has led to the assumption that these halves of the wingbeat cycle contribute equally to weight support during hovering, as exhibited by insects of similar size(4). This assumption has been applied, either explicitly or implicitly, in widely used aerodynamic models(1,5-7) and in a variety of empirical tests(8,9). Here we provide measurements of the wake of hovering rufous hummingbirds (Selasphorus rufus) obtained with digital particle image velocimetry that show force asymmetry: hummingbirds produce 75% of their weight support during the downstroke and only 25% during the upstroke. Some of this asymmetry is probably due to inversion of their cambered wings during upstroke. The wake of hummingbird wings also reveals evidence of leading-edge vortices created during the downstroke, indicating that they may operate at Reynolds numbers sufficiently low to exploit a key mechanism typical of insect hovering(10,11). Hummingbird hovering approaches that of insects, yet remains distinct because of effects resulting from an inherently dissimilar-avian-body plan.	Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA; Univ Portland, Dept Biol, Portland, OR 97203 USA; George Fox Univ, Dept Biol, Newberg, OR 97132 USA	Oregon State University; University of Portland	Warrick, DR (corresponding author), Oregon State Univ, Dept Zool, 3029 Cordley Hall, Corvallis, OR 97331 USA.	warrickd@science.oregonstate.edu	Powers, Donald/A-1704-2009	Powers, Donald/0000-0003-1126-7141				Altshuler DL, 2004, J ZOOL, V264, P327, DOI 10.1017/s0952836904005813; Combes SA, 2003, J EXP BIOL, V206, P2999, DOI 10.1242/jeb.00502; Dickinson MH, 1999, SCIENCE, V284, P1954, DOI 10.1126/science.284.5422.1954; Dudley R., 2000, BIOMECHANICS INSECT; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P79, DOI 10.1098/rstb.1984.0052; GREENEWALT CRAWFORD H., 1960, PROC AMER PHIL SOC, V104, P605; Hedrick TL, 2002, J EXP BIOL, V205, P1389; Norberg U., 1990, VERTEBRATE FLIGHT ME; Raffel M., 2000, PARTICLE IMAGE VELOC; RAYNER JMV, 1979, J FLUID MECH, V91, P697, DOI 10.1017/S0022112079000410; Spedding GR, 2003, J EXP BIOL, V206, P2313, DOI 10.1242/jeb.00423; Spedding GR, 2003, EXP FLUIDS, V34, P291, DOI 10.1007/S00348-002-0559-8; Stolpe M., 1939, Journal fuer Ornithologie, V87, P136, DOI 10.1007/BF01950821; Tobalske BW, 2003, J AVIAN BIOL, V34, P177, DOI 10.1034/j.1600-048X.2003.03006.x; Tobalske BW, 2004, J EXP BIOL, V207, P1345, DOI 10.1242/jeb.00889; Tytell ED, 2003, PHILOS T R SOC B, V358, P1559, DOI 10.1098/rstb.2003.1355; Usherwood JR, 2002, J EXP BIOL, V205, P1547; VandenBerg C, 1997, PHILOS T ROY SOC B, V352, P329, DOI 10.1098/rstb.1997.0024; WEISFOGH T, 1972, J EXP BIOL, V56, P79; WELLS DJ, 1993, J EXP BIOL, V178, P39; Willmott AP, 1997, PHILOS T ROY SOC B, V352, P303, DOI 10.1098/rstb.1997.0022; Willmott AP, 1997, J EXP BIOL, V200, P2705; Willmott AP, 1997, J EXP BIOL, V200, P2723; WOOTTON RJ, 1995, P ROY SOC B-BIOL SCI, V262, P181, DOI 10.1098/rspb.1995.0194	24	223	226	3	101	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1094	1097		10.1038/nature03647	http://dx.doi.org/10.1038/nature03647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973407	Green Submitted			2022-12-28	WOS:000229970400048
J	Bodenheimer, T				Bodenheimer, T			High and rising health care costs. Part 3: The role of health care providers	ANNALS OF INTERNAL MEDICINE			English	Article							DEFENSIVE-MEDICINE; PLAN PERFORMANCE; MEDICARE; SERVICES; QUALITY; VOLUME	one commonly held explanation for high and rising health care costs in the United States points to the market power of health care providers. This third article of a 4-part series examines how the prices and quantities of health care services interact to influence health care expenditures. The article also reviews cost-containment strategies that are designed to reduce prices and quantities of services. One major difference between the costs of care in the United States and those in other developed nations is the price per unit of care physician fees, payments per hospital day, and pharmaceutical prices. Greater quantities of high-priced innovative technologies in the United States also contribute to higher expenditures in the United States compared with other nations. During the 1990s, payers were partially successful in slowing cost growth by reducing the prices of physician and hospital payments, but more recently, hospitals increased their market power by consolidation and could demand higher prices. Quantities and costs of services for Medicare beneficiaries vary markedly among geographic regions, with research showing an association between health care costs and the supply of hospital beds and specialist physicians. These findings suggest that limiting the supply of resources may reduce the quantity, and thereby the costs, of health services. Shifting the financial risk of health care costs from insurers to providers, as has been done with the Medicare diagnosis-related-group payment and capitation reimbursement, can also be effective in containing costs.	Univ Calif San Francisco, Dept Family & Community Med, San Francisco Gen Hosp, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), Univ Calif San Francisco, Dept Family & Community Med, San Francisco Gen Hosp, Bldg 80-83, San Francisco, CA 94110 USA.	tbodenheimer@medsch.ucsf.edu						Aaron H., 1991, SERIOUS UNSTABLE CON; Anderson RE, 1999, ARCH INTERN MED, V159, P2399, DOI 10.1001/archinte.159.20.2399; ANGELL M, 2004, TRUTH DRUG COMPANIES, P196; Ashton CM, 2003, NEW ENGL J MED, V349, P1637, DOI 10.1056/NEJMsa003299; Bodenheimer T, 2005, ANN INTERN MED, V142, P932, DOI 10.7326/0003-4819-142-11-200506070-00012; Bodenheimer T, 2005, ANN INTERN MED, V142, P847, DOI 10.7326/0003-4819-142-10-200505170-00010; BODENHEIMER T, 2005, UNDERSTANDING HLTH P, P69; CHRISTENSEN S, 1992, HEALTH SERV RES, V27, P65; Chulis G S, 1991, Med Care Rev, V48, P167, DOI 10.1177/002570879104800203; Danzon P. M., 2003, PRICES AVAILABILITY; DAVIS K, 1990, HLTH CARE COST CONTA; Devers KJ, 2003, HEALTH SERV RES, V38, P419, DOI 10.1111/1475-6773.00123; DIPPE SE, 1989, WESTERN J MED, V151, P93; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fisher ES, 2003, NEW ENGL J MED, V349, P1665, DOI 10.1056/NEJMe038149; Fisher LS, 2000, HEALTH SERV RES, V34, P1351; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; FUCHS VR, 1978, J HUM RESOUR, V13, P35, DOI 10.2307/145247; GELIJNS A, 1994, HEALTH AFFAIR, V13, P28, DOI 10.1377/hlthaff.13.3.28; GINSBURG PB, 2003, CAN HOSP PHYS SHIFT; GRUMBACH K, 1990, HEALTH AFFAIR, V9, P120, DOI 10.1377/hlthaff.9.4.120; Kessler D, 1996, Q J ECON, V111, P353, DOI 10.2307/2946682; Levit K, 2004, HEALTH AFFAIR, V23, P147, DOI 10.1377/hlthaff.23.1.147; LIGHT DW, 1994, NEW ENGL J MED, V330, P498, DOI 10.1056/NEJM199402173300711; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; *MED PAYM ADV COMM, 2003, VAR INN MED; Melnick G, 1999, HEALTH AFFAIR, V18, P167, DOI 10.1377/hlthaff.18.3.167; Miller RH, 1997, HEALTH AFFAIR, V16, P7, DOI 10.1377/hlthaff.16.5.7; Miller RH, 2002, HEALTH AFFAIR, V21, P63, DOI 10.1377/hlthaff.21.4.63; *OFF TECHN ASS US, 1999, J HLTH EC, V18, P491; *ORG EC COOP DEV, 2004, HLTH DAT; *ORG EC COOP DEV, 2003, DIS COMP HLTH SYST; Phelps CE, 2010, HEALTH ECON; Reinhardt UE, 2004, HEALTH AFFAIR, V23, P10, DOI 10.1377/hlthaff.23.3.10; Reinhardt UE, 2002, HEALTH AFFAIR, V21, P169, DOI 10.1377/hlthaff.21.3.169; RICE TH, 1996, CHANGING US HLTH CAR, P81; Scott W.R., 1987, GROUP THEORY, V2; SKINNER J, 2003, HLTH AFFAIRS; STARFIELD B, 1998, PRIMARY CARE; Starr P, 1982, SOCIAL TRANSFORMATIO; Wennberg JE, 1999, DARTMOUTH ATLAS HLTH; Wholey DR, 1997, HEALTH AFFAIR, V16, P75, DOI 10.1377/hlthaff.16.6.75; Wickizer T M, 1990, Med Care Rev, V47, P327, DOI 10.1177/107755879004700303; Yip WC, 1998, J HEALTH ECON, V17, P675, DOI 10.1016/S0167-6296(98)00024-1; 1995, EFFECTS MANAGED CARE	45	59	59	2	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	1				996	1002		10.7326/0003-4819-142-12_Part_1-200506210-00009	http://dx.doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	937IN	15968014				2022-12-28	WOS:000229917900006
J	Ricaurte, GA; McCann, UD				Ricaurte, GA; McCann, UD			Recognition and management of complications of new recreational drug use	LANCET			English	Review							(ECSTASY)-INDUCED SEROTONIN NEUROTOXICITY; GAMMA-HYDROXYBUTYRATE; MDMA ECSTASY; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; CLUB DRUGS; KETAMINE; ABUSE; BUTYROLACTONE; FLUNITRAZEPAM; WITHDRAWAL	Use of illicit drugs in clubs and large dance parties (so-called raves) is a burgeoning cultural trend. Such recreational drug use is associated with several medical complications, both acute and longlasting. Although few, if any, of the drugs currently used in recreational venues are truly new, their patterns and context of use have changed (a great deal in some instances). For some of these substances, this cultural repackaging of the drug experience has resulted in various medical disorders that have previously gone undocumented. This review aims to help treating physicians recognise and manage complications associated with the use of new drugs in clubs, including methylenedioxymethamfetamine, ephedrine, gamma-hydroxybutyrate; gamma-butyrolactone, 1,4-butanediol, flunitrazepam, ketamine, and nitrites. We also alert researchers to specific toxic effects of club-drugs on which more basic information is needed.	Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Neurol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Psychiat, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Ricaurte, GA (corresponding author), Johns Hopkins Med Inst, Dept Neurol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	Ricaurte@jhmi.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009487, R01DA005707, R29DA005707, R01DA010217, R01DA013790] Funding Source: NIH RePORTER; NIDA NIH HHS [DA5707, DA13790, DA10217, DA00206, DA09487] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Andriamampandry C, 2003, FASEB J, V17, P1691, DOI 10.1096/fj.02-0846fje; Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; Catalano MC, 2001, PSYCHOSOMATICS, V42, P83, DOI 10.1176/appi.psy.42.1.83; Curran HV, 2000, ADDICTION, V95, P575, DOI 10.1046/j.1360-0443.2000.9545759.x; de la Torre R, 2000, BRIT J CLIN PHARMACO, V49, P104, DOI 10.1046/j.1365-2125.2000.00121.x; Diehl JL, 2000, ANN MED INTERNE, V151, pA44; Doyon S, 2001, CURR OPIN PEDIATR, V13, P170, DOI 10.1097/00008480-200104000-00015; Druid H, 2001, FORENSIC SCI INT, V122, P136, DOI 10.1016/S0379-0738(01)00481-9; Dyer JE, 2001, ANN EMERG MED, V37, P147, DOI 10.1067/mem.2001.112985; *EMCDDA, STAT DRUGS PROBL EUR; FARRE M, 2001, DRUG ALCOHOL DEPEN S, V63, pS46; Galloway GP, 1997, ADDICTION, V92, P89, DOI 10.1111/j.1360-0443.1997.tb03640.x; Giannini A J, 2000, Am J Ther, V7, P389; Graeme KA, 2000, EMERG MED CLIN N AM, V18, P625, DOI 10.1016/S0733-8627(05)70150-4; GREEN AR, 1995, PSYCHOPHARMACOLOGY, V119, P247, DOI 10.1007/BF02246288; Green SM, 2000, ACAD EMERG MED, V7, P278, DOI 10.1111/j.1553-2712.2000.tb01076.x; Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502; Hartung TK, 2002, QJM-INT J MED, V95, P431, DOI 10.1093/qjmed/95.7.431; Henry JA, 1998, LANCET, V351, P1784, DOI 10.1016/S0140-6736(05)78744-4; HENRY JA, 1992, LANCET, V340, P384, DOI 10.1016/0140-6736(92)91469-O; Jansen KLR, 2001, J PSYCHOACTIVE DRUGS, V33, P151, DOI 10.1080/02791072.2001.10400480; Johnston L D., 2003, MONITORING FUTURE NA, VII; Johnston L. D., 2003, MONITORING FUTURE NA, V1; Jones AL, 1999, ALIMENT PHARM THER, V13, P129; Kalant H, 2001, CAN MED ASSOC J, V165, P917; Koesters SC, 2002, PEDIATR CLIN N AM, V49, P415, DOI 10.1016/S0031-3955(01)00012-8; Kraner JC, 2001, J ANAL TOXICOL, V25, P645, DOI 10.1093/jat/25.7.645; Mallick A, 1997, J ACCID EMERG MED, V14, P336; McCann UD, 2000, NEUROPSYCHOBIOLOGY, V42, P11, DOI 10.1159/000026665; Miotto K, 2001, AM J ADDICTION, V10, P232; NEWELL GR, 1985, AM J MED, V78, P811, DOI 10.1016/0002-9343(85)90288-8; Nicholson KL, 2001, DRUG ALCOHOL DEPEN, V63, P1, DOI 10.1016/S0376-8716(00)00191-5; OCONNOR B, 1994, BRIT J HOSP MED, V52, P507; OLNEY JW, 1995, NEUROPSYCHOPHARMACOL, V13, P335, DOI 10.1038/sj.npp.1380292; Pal HR, 2002, ANAESTH INTENS CARE, V30, P382, DOI 10.1177/0310057X0203000323; Reneman L, 2001, LANCET, V358, P1864, DOI 10.1016/S0140-6736(01)06888-X; Ricaurte GA, 2000, NEUROPSYCHOBIOLOGY, V42, P5, DOI 10.1159/000026664; RICAURTE GA, 1995, NEUROLOGY GEN MED, P631; Ricaurte George A., 2003, Science (Washington D C), V301, P1479; Romanelli F, 2004, PHARMACOTHERAPY, V24, P69, DOI 10.1592/phco.24.1.69.34801; Ropero-Miller JD, 1998, CLIN LAB MED, V18, P727; Samenuk D, 2002, MAYO CLIN PROC, V77, P12, DOI 10.4065/77.1.12; Schneir AB, 2001, J EMERG MED, V21, P31, DOI 10.1016/S0736-4679(01)00324-9; Shannon M, 2000, PEDIATR EMERG CARE, V16, P377, DOI 10.1097/00006565-200010000-00022; Shannon M, 2000, PEDIATR EMERG CARE, V16, P435, DOI 10.1097/00006565-200012000-00017; Simmons MM, 1998, ANN PHARMACOTHER, V32, P117, DOI 10.1345/aph.17027; Sivilotti MLA, 2001, ANN EMERG MED, V38, P660, DOI 10.1067/mem.2001.119454; Smith KM, 2002, AM J HEALTH-SYST PH, V59, P1067, DOI 10.1093/ajhp/59.11.1067; Traub SJ, 2002, J URBAN HEALTH, V79, P549, DOI 10.1093/jurban/79.4.549; Verbaten MN, 2003, HUM PSYCHOPHARM CLIN, V18, P281, DOI 10.1002/hup.482; Weinbroum AA, 1997, DRUG SAFETY, V17, P181, DOI 10.2165/00002018-199717030-00004; Weiner AL, 2000, J EMERG MED, V18, P447, DOI 10.1016/S0736-4679(00)00162-1; Williams A, 1997, NEPHROL DIAL TRANSPL, V12, P361, DOI 10.1093/ndt/12.2.361; Woods JH, 1997, J CLIN PSYCHOPHARM, V17, pS1, DOI 10.1097/00004714-199706001-00001; WRIGHT HH, 1988, SOUTHERN MED J, V81, P565, DOI 10.1097/00007611-198805000-00005; Zvosec DL, 2001, NEW ENGL J MED, V344, P87, DOI 10.1056/NEJM200101113440202	56	97	98	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2137	2145		10.1016/S0140-6736(05)66737-2	http://dx.doi.org/10.1016/S0140-6736(05)66737-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	936LZ	15964451				2022-12-28	WOS:000229858800031
J	Montell, DJ				Montell, DJ			Anchors away! Fos fosters anchor-cell invasion	CELL			English	Editorial Material							C-FOS; PROGRESSION; JUN	Invasion of cells through breakdown of the basement membrane is a crucial step during development and cancer metastasis. In this issue of Cell, Sherwood et al., (2005) describe a simple and genetically tractable cellular assay in the worm for elucidating the molecular processes that underlie cell invasion in vivo. They demonstrate that the transcription factor Fos is required for cell invasion and identify three of its downstream target genes (encoding a matrix metalloproteinase, hemicentin, and a fat-like protocadherin).	Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Montell, DJ (corresponding author), Johns Hopkins Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.							Aoyagi K, 1998, CLIN CANCER RES, V4, P2153; Bischof P, 2001, Early Pregnancy, V5, P30; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sherwood DR, 2005, CELL, V121, P951, DOI 10.1016/j.cell.2005.03.031; Sherwood DR, 2003, DEV CELL, V5, P21, DOI 10.1016/S1534-5807(03)00168-0; VOLM M, 1993, J CANCER RES CLIN, V119, P507, DOI 10.1007/BF01686458	8	8	12	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 17	2005	121	6					816	817		10.1016/j.cell.2005.06.003	http://dx.doi.org/10.1016/j.cell.2005.06.003			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960969	Bronze			2022-12-28	WOS:000230011200004
J	Smit, P; Raedts, J; Portyanko, V; Debelle, F; Gough, C; Bisseling, T; Geurts, R				Smit, P; Raedts, J; Portyanko, V; Debelle, F; Gough, C; Bisseling, T; Geurts, R			NSP1 of the GRAS protein family is essential for rhizobial Nod factor-induced transcription	SCIENCE			English	Article							RECEPTOR KINASE GENE; MEDICAGO-TRUNCATULA; BACTERIAL; FUNGAL; IDENTIFICATION; TRANSDUCTION; SYMBIOSIS; MUTANTS; CALCIUM	Rhizobial Nod factors induce in their legume hosts the expression of many genes and set in motion developmental processes leading to root nodule formation. Here we report the identification of the Medicago GRAS-type protein Nodulation signaling pathway 1 (NSP1), which is essential for all known Nod factor-induced changes in gene expression. NSP1 is constitutively expressed, and so it acts as a primary transcriptional regulator mediating all known Nod factor-induced transcriptional responses, and therefore, we named it a Nod factor response factor.	Univ Wageningen & Res Ctr, Dept Plant Sci, Mol Biol Lab, NL-6703 HA Wageningen, Netherlands; Univ Minnesota, Dept Plant Biol, St Paul, MN 55108 USA; INRA, CNRS, Lab Interact Plantes Microorganismes, F-31326 Castanet Tolosan, France	Wageningen University & Research; University of Minnesota System; University of Minnesota Twin Cities; INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS)	Bisseling, T (corresponding author), Univ Wageningen & Res Ctr, Dept Plant Sci, Mol Biol Lab, NL-6703 HA Wageningen, Netherlands.	ton.bisseling@wur.nl	Bisseling, Ton/A-2421-2013					Ane JM, 2004, SCIENCE, V303, P1364, DOI 10.1126/science.1092986; Bolle C, 2004, PLANTA, V218, P683, DOI 10.1007/s00425-004-1203-z; Borisov AY, 2003, PLANT PHYSIOL, V131, P1009, DOI 10.1104/pp.102.016071; Catoira R, 2000, PLANT CELL, V12, P1647, DOI 10.1105/tpc.12.9.1647; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; Imaizumi-Anraku H, 2005, NATURE, V433, P527, DOI 10.1038/nature03237; Kalo P, 2005, SCIENCE, V308, P1786, DOI 10.1126/science.1110951; Levy J, 2004, SCIENCE, V303, P1361, DOI 10.1126/science.1093038; Limpens E, 2003, SCIENCE, V302, P630, DOI 10.1126/science.1090074; Madsen EB, 2003, NATURE, V425, P637, DOI 10.1038/nature02045; Mitra RM, 2004, P NATL ACAD SCI USA, V101, P10217, DOI 10.1073/pnas.0402186101; Mitra RM, 2004, P NATL ACAD SCI USA, V101, P4701, DOI 10.1073/pnas.0400595101; Oldroyd GED, 2004, NAT REV MOL CELL BIO, V5, P566, DOI 10.1038/nrm1424; Oldroyd GED, 2003, PLANT PHYSIOL, V131, P1027, DOI 10.1104/pp.102.010710; Pysh LD, 1999, PLANT J, V18, P111, DOI 10.1046/j.1365-313X.1999.00431.x; Radutoiu S, 2003, NATURE, V425, P585, DOI 10.1038/nature02039; Schauser L, 1999, NATURE, V402, P191, DOI 10.1038/46058; Stracke S, 2002, NATURE, V417, P959, DOI 10.1038/nature00841; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; Wais RJ, 2000, P NATL ACAD SCI USA, V97, P13407, DOI 10.1073/pnas.230439797	20	418	449	4	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1789	1791		10.1126/science.1111025	http://dx.doi.org/10.1126/science.1111025			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961669				2022-12-28	WOS:000229926800055
J	Fossum, A; Carlsson, M				Fossum, A; Carlsson, M			High-frequency acoustic waves are not sufficient to heat the solar chromosphere	NATURE			English	Article							EXCITATION; OSCILLATIONS; CONVECTION; FLUXES; MODELS; STARS	One of the main unanswered questions in solar physics is why the Sun's outer atmosphere is hotter than its surface. Theory predicts abundant production of high-frequency (10-50 mHz) acoustic waves in subsurface layers of the Sun(1), and such waves are believed by many to constitute the dominant heating mechanism of the chromosphere (the lower part of the outer solar atmosphere) in non-magnetic regions(2-4). Such high-frequency waves are difficult to detect because of high-frequency disturbances in Earth's atmosphere (seeing) and other factors. Here we report the detection of high-frequency waves, and we use numerical simulations to show that the acoustic energy flux of these waves is too low, by a factor of at least ten, to balance the radiative losses in the solar chromosphere. Acoustic waves therefore cannot constitute the dominant heating mechanism of the solar chromosphere.	Univ Oslo, Inst Theoret Astrophys, N-0315 Oslo, Norway	University of Oslo	Fossum, A (corresponding author), Univ Oslo, Inst Theoret Astrophys, PB 1029 Blindern, N-0315 Oslo, Norway.	astrid.fossum@astro.uio.no						ALMEIDA JS, IN PRESS ASTRON ASTR; CARLSSON M, 1995, ASTROPHYS J, V440, pL29, DOI 10.1086/187753; Carlsson M, 1997, ASTROPHYS J, V481, P500, DOI 10.1086/304043; Carlsson M, 2002, ASTROPHYS J, V572, P626, DOI 10.1086/340293; CARLSSON M, 2002, IAU C, V188, P293; DORFI EA, 1987, J COMPUT PHYS, V69, P175, DOI 10.1016/0021-9991(87)90161-6; Fawzy D, 2002, ASTRON ASTROPHYS, V386, P971, DOI 10.1051/0004-6361:20020256; FOSSUM A, IN PRESS ASTROPHYS J; GOLDREICH P, 1994, ASTROPHYS J, V424, P466, DOI 10.1086/173904; Gustafsson B., 1973, UPPSALA ASTRON OBS A, V5, P1; Handy BN, 1999, SOL PHYS, V187, P229, DOI 10.1023/A:1005166902804; Krijger JM, 2001, ASTRON ASTROPHYS, V379, P1052, DOI 10.1051/0004-6361:20011320; Kurucz R. L., 1995, ATOMIC LINE DATA; MUSIELAK ZE, 1994, ASTROPHYS J, V423, P474, DOI 10.1086/173825; Stein RF, 2001, ASTROPHYS J, V546, P585, DOI 10.1086/318218; TOBISKA WK, 1991, J ATMOS TERR PHYS, V53, P1005, DOI 10.1016/0021-9169(91)90046-A; Ulmschneider P, 1996, ASTRON ASTROPHYS, V315, P212; Ulmschneider P., 1990, ASTRON SOC PACIFIC C, V9, P3; VANREGEMORTER H, 1962, ASTROPHYS J, V136, P906, DOI 10.1086/147445; VERNAZZA JE, 1981, ASTROPHYS J SUPPL S, V45, P635, DOI 10.1086/190731	20	113	114	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					919	921		10.1038/nature03695	http://dx.doi.org/10.1038/nature03695			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959510				2022-12-28	WOS:000229799700040
J	Chanoine, JP; Hampl, S; Jensen, C; Boldrin, M; Hauptman, J				Chanoine, JP; Hampl, S; Jensen, C; Boldrin, M; Hauptman, J			Effect of orlistat on weight and body composition in obese adolescents - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILY-BASED TREATMENT; QUALITY-OF-LIFE; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; LIPASE INHIBITOR; DOUBLE-BLIND; US CHILDREN; FOLLOW-UP; OVERWEIGHT; MANAGEMENT	Context The prevalence of overweight and obesity in children and adolescents is increasing rapidly. In this population, behavioral therapy alone has had limited success in providing meaningful, sustained weight reduction, and pharmacological treatment has not been extensively studied. Objective To determine the efficacy and safety of orlistat in weight management of adolescents. Design, Setting, and Patients Multicenter, 54-week (August 2000-October 2002), randomized, double-blind study of 539 obese adolescents (aged 12-16 years; body mass index [BMI] >= 2 units above the 95th percentile) at 32 centers in the United States and Canada. Interventions A 120-mg dose of orlistat (n=357) or placebo (n=182) 3 times daily for 1 year, plus a mildly hypocaloric diet (30% fat calories), exercise, and behavioral therapy. Main Outcome Measures Change in BMI; secondary measures included changes in waist and hip circumference, weight loss, lipid measurements, and glucose and insulin responses to oral glucose challenge. Results There was a decrease in BMI in both treatment groups up to week 12, thereafter stabilizing with orlistat but increasing beyond baseline with placebo. At the end of the study, BMI had decreased by 0.55 with orlistat but increased by 0.31 with placebo (P=.001). Compared with 15.7% of the placebo group, 26.5% of participants taking orlistat had a 5% or higher decrease in BMI (P=.005); 4.5% and 13.3%, respectively, had a 10% or higher decrease in BMI (P=.002). At study end, weight had increased 0.53 kg with orlistat and 3.14 kg with placebo (P<.001). Dual-energy x-ray absorptiometry showed that this difference was explained by changes in fat mass. Waist circumference decreased in the orlistat group but increased in the placebo group (-1.33 cm vs +0.12 cm; P<.05). Generally mild to moderate gastrointestinal tract adverse events occurred in 9% to 50% of the orlistat group and in 1% to 13% of the placebo group. Conclusions In combination with diet, exercise, and behavioral modification, orlistat statistically significantly improved weight management in obese adolescents compared with placebo. The use of orlistat for 1 year in this adolescent population did not raise major safety issues although gastrointestinal adverse events were more common in the orlistat group.	British Columbia Childrens Hosp, Endocrinol & Diabet Unit, Vancouver, BC V6H 3V4, Canada; Hoffmann La Roche Inc, Nutley, NJ 07110 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Childrens Mercy Hosp & Clin, Kansas City, MO USA	BC Childrens Hospital; University of British Columbia; Roche Holding; Baylor College of Medicine; Children's Mercy Hospital	Chanoine, JP (corresponding author), British Columbia Childrens Hosp, Endocrinol & Diabet Unit, K4-212,4480 Oak St, Vancouver, BC V6H 3V4, Canada.	jchanoine@cw.bc.ca	Chanoine, Jean-Pierre/K-5026-2019	Chanoine, Jean-Pierre/0000-0002-5167-2064				Barlow SE, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e29; Berkowitz RI, 2003, JAMA-J AM MED ASSOC, V289, P1805, DOI 10.1001/jama.289.14.1805; Broom I, 2002, INT J CLIN PRACT, V56, P494; Curran MP, 2004, DRUGS, V64, P2845, DOI 10.2165/00003495-200464240-00010; Davidson MH, 1999, JAMA-J AM MED ASSOC, V281, P235, DOI 10.1001/jama.281.3.235; EPSTEIN LH, 1994, HEALTH PSYCHOL, V13, P373, DOI 10.1037/0278-6133.13.5.373; EPSTEIN LH, 1990, JAMA-J AM MED ASSOC, V264, P2519, DOI 10.1001/jama.264.19.2519; Epstein LH, 2001, PEDIATR CLIN N AM, V48, P981, DOI 10.1016/S0031-3955(05)70352-7; Goodman E, 2004, J PEDIATR-US, V145, P445, DOI 10.1016/j.jpeds.2004.04.059; Goran MI, 2003, J CLIN ENDOCR METAB, V88, P1417, DOI 10.1210/jc.2002-021442; Guerciolini R, 1997, INT J OBESITY, V21, pS12; Hollander PA, 1998, DIABETES CARE, V21, P1288, DOI 10.2337/diacare.21.8.1288; Jeffery RW, 2004, AM J MANAG CARE, V10, P378; Krempf M, 2003, INT J OBESITY, V27, P591, DOI 10.1038/sj.ijo.0802281; Lobstein T., 2004, OBES REV S1, V5, P4, DOI [https://doi.org/10.1111/j.1467-789X.2004.00133.x, DOI 10.1111/J.1467-789X.2004.00133.X]; McCann UD, 1997, JAMA-J AM MED ASSOC, V278, P666, DOI 10.1001/jama.278.8.666; McDuffie JR, 2002, OBES RES, V10, P642, DOI 10.1038/oby.2002.87; Muls E, 2001, INT J OBESITY, V25, P1713, DOI 10.1038/sj.ijo.0801814; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; Must A, 1996, AM J CLIN NUTR, V63, P445, DOI 10.1093/ajcn/63.3.445; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Porter JA, 2004, AM J MANAG CARE, V10, P369; Rosner B, 1998, J PEDIATR-US, V132, P211, DOI 10.1016/S0022-3476(98)70434-2; Schwimmer JB, 2003, JAMA-J AM MED ASSOC, V289, P1813, DOI 10.1001/jama.289.14.1813; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; SUMERBELL CD, 2003, COCHRANE DB SYST REV, P1872; Talley NJ, 2004, AM J GASTROENTEROL, V99, P1807, DOI 10.1111/j.1572-0241.2004.30388.x; THOMASDOBERSEN DA, 1993, J AM DIET ASSOC, V93, P535, DOI 10.1016/0002-8223(93)91812-5; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155; WABITSCH M, 1995, J CLIN ENDOCR METAB, V80, P3469, DOI 10.1210/jc.80.12.3469; WADDEN TA, 2000, WEIGHT REDUCTION PRI; Waldhausen JHT, 1999, AM J SURG, V177, P364, DOI 10.1016/S0002-9610(99)00063-X; Weiss R, 2004, NEW ENGL J MED, V350, P2362, DOI 10.1056/NEJMoa031049; Wesdorp I, 2000, J PEDIATR GASTR NUTR, V31, P411, DOI 10.1097/00005176-200010000-00015; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; Williams J, 2005, JAMA-J AM MED ASSOC, V293, P70, DOI 10.1001/jama.293.1.70; Wirth A, 2005, DIABETES OBES METAB, V7, P21, DOI 10.1111/j.1463-1326.2004.00428.x; World Health Organization, 1985, REP JOINT FAO WHO UN; Zhi JG, 1999, J CLIN PHARMACOL, V39, P41, DOI 10.1177/00912709922007543; ZHI JG, 1995, J CLIN PHARMACOL, V35, P1103, DOI 10.1002/j.1552-4604.1995.tb04034.x	40	334	345	0	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	2005	293	23					2873	2883		10.1001/jama.293.23.2873	http://dx.doi.org/10.1001/jama.293.23.2873			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935MD	15956632	Bronze			2022-12-28	WOS:000229785500022
J	Sigurdson, AJ; Ronckers, CM; Mertens, AC; Stovall, M; Smith, SA; Liu, Y; Berkow, RL; Hammond, S; Neglia, JP; Meadows, AT; Sklar, CA; Robison, LL; Inskip, PD				Sigurdson, AJ; Ronckers, CM; Mertens, AC; Stovall, M; Smith, SA; Liu, Y; Berkow, RL; Hammond, S; Neglia, JP; Meadows, AT; Sklar, CA; Robison, LL; Inskip, PD			Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study	LANCET			English	Article							2ND MALIGNANT NEOPLASMS; BONE-MARROW-TRANSPLANTATION; HODGKINS-DISEASE; EPIDEMIOLOGIC EVIDENCE; THERAPEUTIC RADIATION; RISK; RADIOTHERAPY; NEUROBLASTOMA; IRRADIATION; LEUKEMIA	Background Survivors of malignant disease in childhood who have had radiotherapy to the head, neck, or upper thorax have an increased risk of subsequent primary thyroid cancer, but the magnitude of risk over the therapeutic dose range has not been well established. We aimed to quantify the long-term risk of thyroid cancer after radiotherapy and chemotherapy. Methods In a nested case-control study, 69 cases with pathologically confirmed thyroid cancer and 265 matched controls without thyroid cancer were identified from 14 054 5-year survivors of cancer during childhood from the Childhood Cancer Survivor Study cohort. Childhood cancers were diagnosed between 1970 and 1986 with cohort follow-up to 2000. Findings Risk of thyroid cancer increased with radiation doses up to 20-29 Gy (odds ratio 9.8 [95% Cl 3.2-34.8]). At doses greater than 30 Gy, a fall in the dose-response relation was seen. Both the increased and decreased risks were more pronounced in those diagnosed with a first primary malignant disease before age 10 years than in those older than 10 years. Furthermore, the fall in risk remained when those diagnosed with Hodgkin's lymphoma were excluded. Chemotherapy for the first cancer was not associated with thyroid-cancer risk, and it did not modify the effect of radiotherapy. 29 (42%) cases had a first diagnosis of Hodgkin's lymphoma compared with 49 (19%) controls. 11 (42%) of those who had Hodgkin's lymphoma had subsequent thyroid cancers smaller than 1 cm compared with six (17%) of those who had other types of childhood cancer (p=0.07). Interpretation The reduction in radiation dose-response for risk of thyroid cancer after childhood exposure to thyroid doses higher than 30 Gy is consistent with a cell-killing effect. Standard long-term follow-up of patients who have had Hodgkin's lymphoma for detection of thyroid cancer should also be undertaken for survivors of any cancer during childhood who received radiotherapy to the thorax or head and neck region.	NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; Univ Texas, MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA; Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98104 USA; Univ Alabama Birmingham, Birmingham, AL USA; Childrens Hosp, Dept Lab Med & Pathol, Columbus, OH 43205 USA; Ohio State Univ, Coll Med, Columbus, OH 43210 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; UTMD Anderson Cancer Center; Fred Hutchinson Cancer Center; University of Alabama System; University of Alabama Birmingham; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Memorial Sloan Kettering Cancer Center	Sigurdson, AJ (corresponding author), NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, 6120 Execut Blvd,EPS 7092,MSC 7238, Bethesda, MD 20892 USA.	sigurdsa@mail.nih.gov	Ronckers, Cecile/GWN-0737-2022; Robison, Leslie/N-8122-2018	Ronckers, Cecile M./0000-0003-3524-4657; Neglia, Joseph/0000-0002-5525-0598	NATIONAL CANCER INSTITUTE [U24CA055727, U01CA055727] Funding Source: NIH RePORTER; NCI NIH HHS [U24 CA055727, CA 55727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 2003, CANCER-AM CANCER SOC, V97, P2397, DOI 10.1002/cncr.11362; BARNES ND, 1988, HORM RES, V30, P84, DOI 10.1159/000181034; Bhatia S, 2002, NAT REV CANCER, V2, P124, DOI 10.1038/nrc722; Black P, 1998, MED PEDIATR ONCOL, V31, P91, DOI 10.1002/(SICI)1096-911X(199808)31:2<91::AID-MPO8>3.0.CO;2-U; BOICE JD, 1987, J NATL CANCER I, V79, P1295; BOULAD F, 1995, BONE MARROW TRANSPL, V15, P71; DANGIO GJ, 1976, CANCER, V37, P1177, DOI 10.1002/1097-0142(197602)37:2+<1177::AID-CNCR2820370829>3.0.CO;2-3; Davis S, 2004, RADIAT RES, V162, P241, DOI 10.1667/RR3233; de Vathaire F, 1999, BRIT J CANCER, V79, P1884, DOI 10.1038/sj.bjc.6690300; de Vathaire F, 1999, ARCH INTERN MED, V159, P2713, DOI 10.1001/archinte.159.22.2713; DEVATHAIRE F, 1988, LANCET, V2, P455; DEVATHAIRE F, 1992, BRIT J CANCER, V65, P425, DOI 10.1038/bjc.1992.87; Eden K, 2001, MED PEDIATR ONCOL, V36, P583, DOI 10.1002/mpo.1134; Garwicz S, 2000, INT J CANCER, V88, P672, DOI 10.1002/1097-0215(20001115)88:4<672::AID-IJC24>3.0.CO;2-N; Gilbert ES, 2003, RADIAT RES, V159, P161, DOI 10.1667/0033-7587(2003)159[0161:LCATFH]2.0.CO;2; Gold DG, 2003, CANCER-AM CANCER SOC, V97, P2588, DOI 10.1002/cncr.11356; Goldin LR, 2004, CANCER-AM CANCER SOC, V100, P1902, DOI 10.1002/cncr.20189; Gray L. H., 1965, CELLULAR RAD BIOL, P7; HALL EJ, 2000, RADIOBIOLOGY RADIOLO, P144; HANCOCK SL, 1991, NEW ENGL J MED, V325, P599, DOI 10.1056/NEJM199108293250902; HAWKINS MM, 1988, LANCET, V2, P804; Inskip PD, 2001, MED PEDIATR ONCOL, V36, P568, DOI 10.1002/mpo.1132; Inskip PD, 1999, MULTIPLE PRIMARY CANCERS, P91; LAND CE, 1981, MEASUREMENT RISKS, V21, P71; LITTLEY MD, 1990, BAILLIERE CLIN ENDOC, V4, P147, DOI 10.1016/S0950-351X(05)80321-0; Metayer C, 2000, J CLIN ONCOL, V18, P2435, DOI 10.1200/JCO.2000.18.12.2435; Michel G, 1997, J CLIN ONCOL, V15, P2238, DOI 10.1200/JCO.1997.15.6.2238; Moppett J, 2001, EUR J RADIOL, V38, P234, DOI 10.1016/S0720-048X(01)00342-4; Neglia JP, 2001, J NATL CANCER I, V93, P618, DOI 10.1093/jnci/93.8.618; Oeffinger KC, 2003, AM FAM PHYSICIAN, V68, P1016; *PHIL MED SYST, RAD ONC SYST; PRESTON DL, 2003, EPICURE 2 10 PECAN; RIES LAG, 1996, CANC EPIDEMIOLOGY PR, P168; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; Ron E, 1996, CANC EPIDEMIOLOGY PR, P1000; Rubino C, 2003, INT J CANCER, V107, P791, DOI 10.1002/ijc.11455; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; Sklar C, 2000, J CLIN ENDOCR METAB, V85, P3227, DOI 10.1210/jc.85.9.3227; SKLAR CA, 1995, INT J RADIAT ONCOL, V31, P1113, DOI 10.1016/0360-3016(94)00427-M; STOVALL M, 1995, MED PHYS, V22, P63, DOI 10.1118/1.597525; STOVALL M, 1989, MED PHYS, V16, P726, DOI 10.1118/1.596331; TRAVIS LB, 2003, JAMA-J AM MED ASSOC, V290, P165; TUCKER MA, 1991, CANCER RES, V51, P2885; *U MINN CANC CTR, CHILDH CANC SURV STU; *UN SCI COMM EFF A, 2000, 2000 REP GEN ASS ANN; van Santen HM, 2003, J CLIN ENDOCR METAB, V88, P3657, DOI 10.1210/jc.2003-030209; WILLIAMS ED, 1993, HISTOPATHOLOGY, V23, P387, DOI 10.1111/j.1365-2559.1993.tb01227.x; 1983, BR J RADIOL S, V17, P1	49	264	275	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2005	365	9476					2014	2023		10.1016/S0140-6736(05)66695-0	http://dx.doi.org/10.1016/S0140-6736(05)66695-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950715				2022-12-28	WOS:000229701400023
J	Magill, A; Panosian, C				Magill, A; Panosian, C			Making antibacterial agents available in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Walter Reed Army Inst Res, Silver Spring, MD 20910 USA; Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Magill, A (corresponding author), Walter Reed Army Inst Res, Silver Spring, MD 20910 USA.							Institute of Medicine (US) Committee on the Economics of Antimalarial Drugs, 2004, SAVING LIVES BUYING; Wallace MR, 1996, AM J MED, V100, P49, DOI 10.1016/S0002-9343(96)90011-X; ZAKIN S, 2005, LOS ANGELES TIM 0612, pM1; 2000, MMWR MORB MORTAL WKL, V49, P1138	4	7	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 28	2005	353	4					335	337		10.1056/NEJMp058167	http://dx.doi.org/10.1056/NEJMp058167			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	949JW	16000347				2022-12-28	WOS:000230782800004
J	Chou, R; Smits, AK; Huffman, LH; Fu, RW; Korthuis, PT				Chou, R; Smits, AK; Huffman, LH; Fu, RW; Korthuis, PT			Prenatal screening for HIV: A review of the evidence for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; PERSISTENT MITOCHONDRIAL DYSFUNCTION; STANDARD ANTIRETROVIRAL THERAPY; MATERNAL-INFANT TRANSMISSION; REDUCE VERTICAL TRANSMISSION; BREAST-FED CHILDREN; NEW-YORK-STATE; PREGNANT-WOMEN; PERINATAL TRANSMISSION	Background: Each year in the United States, 6000 to 7000 women with HIV give birth. The management and outcomes of prenatal HIV infection have changed substantially since the U.S. Preventive Services Task Force issued recommendations in 1996. Purpose: To synthesize current evidence on risks and benefits of prenatal screening for HIV infection. Data Sources: MEDLINE, the Cochrane Library, reference lists, and experts. Study Selection: Studies of screening, risk factor assessment, accuracy of testing, follow-up testing, and efficacy of interventions. Data Extraction: Data on settings, patients, interventions, and outcomes were abstracted for included studies; quality was graded according to criteria developed by the Task Force. Data Synthesis: No published studies directly link prenatal screening for HIV with clinical outcomes. In developed countries, the rate of mother-to-child transmission from untreated HIV-infected women is 14% to 25%. Targeted screening based on risk factors would miss a substantial proportion of infected women. "Opt-out" testing policies appear to increase uptake rates. Standard HIV testing is highly (> 99%) sensitive and specific, and initial studies of rapid HIV tests found that both types of testing had similar accuracy. Rapid testing can facilitate timely interventions in persons testing positive. Recommended interventions (combination antiretroviral regimens, elective cesarean section in selected patients, and avoidance of breastfeeding) are associated with transmission rates of 1% to 2% and appear acceptable to pregnant women. Limitations: Long-term safety data for antiretroviral agents are not yet available. Data are insufficient to accurately estimate the benefits of screening on long-term maternal disease progression or other clinical outcomes, such as horizontal transmission. Conclusions: Identification and treatment of asymptomatic HIV infection in pregnant women can greatly decrease mother-to-child transmission rates.	Oregon Hlth & Sci Univ, Portland, OR 97239 USA; Oregon Evidence Based Practice Ctr, Portland, OR 97239 USA	Oregon Health & Science University	Chou, R (corresponding author), Oregon Hlth & Sci Univ, Mail Code BICC,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	chour@ohsu.edu		Chou, Roger/0000-0001-9889-8610; Korthuis, Philip/0000-0001-5556-3597	PHS HHS [290-02-0024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alimenti A, 2003, PEDIATR INFECT DIS J, V22, P782, DOI 10.1097/01.inf.0000086400.93257.74; Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; [Anonymous], 1999, Hum Reprod, V14, P242; BARBACCI MB, 1990, SEX TRANSM DIS, V17, P122, DOI 10.1097/00007435-199007000-00002; Bardeguez AD, 2003, JAIDS-J ACQ IMM DEF, V32, P170, DOI 10.1097/00126334-200302010-00009; Barret B, 2003, AIDS, V17, P1769, DOI 10.1097/00002030-200308150-00006; Bedimo AL, 1998, SOC SCI MED, V46, P171, DOI 10.1016/S0277-9536(97)00157-3; Bhore AV, 2003, INT J STD AIDS, V14, P37, DOI 10.1258/095646203321043246; Blair JM, 2004, OBSTET GYNECOL, V103, P663, DOI 10.1097/01.AOG.0000117083.33239.b5; Blanche S, 1999, LANCET, V354, P1084, DOI 10.1016/S0140-6736(99)07219-0; BROCKLEHURST P, 2002, COCHRANE DATABASE SY; Bulterys M, 2000, J ACQ IMMUN DEF SYND, V25, P261, DOI 10.1097/00126334-200011010-00009; Bulterys M, 2004, JAMA-J AM MED ASSOC, V292, P219, DOI 10.1001/jama.292.2.219; Bulterys M, 2000, ANN NY ACAD SCI, V918, P212; BULTERYS M, 2005, ADV PREVENTION MOTHE; CELUM CL, 1994, ARCH INTERN MED, V154, P1129, DOI 10.1001/archinte.154.10.1129; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1013; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P380; Chalermchockcharoenkit Amphan, 2002, J Med Assoc Thai, V85, P703; Chou R, SCREENING HUMAN IMMU; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; Coutsoudis A, 2004, J INFECT DIS, V189, P2154, DOI 10.1086/420834; *CTR DIS CONTR PRE, 2003, HIV AIDS SURV REP, V15; *CTR DIS CONTR PRE, 2004, RAP HIV ANT TEST LAB; *CTR DIS CONTR PRE, 2003, AIDS CAS DEATHS PERS; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; Cunningham CK, 2002, J INFECT DIS, V186, P181, DOI 10.1086/341300; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; de Martino M, 2002, ARCH PEDIAT ADOL MED, V156, P915, DOI 10.1001/archpedi.156.9.915; Divi RL, 2004, AIDS, V18, P1013, DOI 10.1097/00002030-200404300-00009; Dominguez K, 2000, ANN NY ACAD SCI, V918, P236; Dominguez KL, 2003, JAIDS-J ACQ IMM DEF, V33, P232, DOI 10.1097/00126334-200306010-00019; Doran TI, 2000, ARCH FAM MED, V9, P924, DOI 10.1001/archfami.9.9.924; Dorenbaum A, 2002, JAMA-J AM MED ASSOC, V288, P189, DOI 10.1001/jama.288.2.189; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Eastman PS, 1998, J INFECT DIS, V177, P557, DOI 10.1086/514228; Edwards S G, 2001, HIV Med, V2, P89, DOI 10.1046/j.1468-1293.2001.00059.x; ELLERBROCK TV, 1992, NEW ENGL J MED, V327, P1704, DOI 10.1056/NEJM199212103272402; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; FEHRS LJ, 1988, LANCET, V2, P379; FEHRS LJ, 1991, AM J PUBLIC HEALTH, V81, P619, DOI 10.2105/AJPH.81.5.619; Fiscus SA, 2002, PEDIATR INFECT DIS J, V21, P664, DOI 10.1097/00006454-200207000-00012; Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602; Giaquinto C, 2005, CLIN INFECT DIS, V40, P458, DOI 10.1086/427287; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; Green L, 2000, HOSP MED, V61, P311, DOI 10.12968/hosp.2000.61.5.1328; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Hanson IC, 1999, J ACQ IMMUN DEF SYND, V20, P463, DOI 10.1097/00042560-199904150-00008; HAWKEN J, 1994, BRIT J OBSTET GYNAEC, V101, P960, DOI 10.1111/j.1471-0528.1994.tb13040.x; Hitti J, 2004, JAIDS-J ACQ IMM DEF, V36, P772, DOI 10.1097/00126334-200407010-00002; Ioannidis JPA, 2001, J INFECT DIS, V183, P539, DOI 10.1086/318530; Irwin KL, 1996, AIDS, V10, P1707, DOI 10.1097/00002030-199612000-00016; Jackson JB, 2003, LANCET, V362, P859, DOI 10.1016/S0140-6736(03)14341-3; Jayaraman GC, 2003, CAN MED ASSOC J, V168, P679; John G C, 2001, East Afr Med J, V78, P75; Joo E, 2000, AM J PUBLIC HEALTH, V90, P273, DOI 10.2105/AJPH.90.2.273; Jourdain G, 2004, NEW ENGL J MED, V351, P229, DOI 10.1056/NEJMoa041305; Kaplan Jonathan E, 2002, MMWR Recomm Rep, V51, P1; Kleinman S, 1998, JAMA-J AM MED ASSOC, V280, P1080, DOI 10.1001/jama.280.12.1080; Koblavi-Deme S, 2001, J CLIN MICROBIOL, V39, P1808, DOI 10.1128/JCM.39.5.1808-1812.2001; Koenig LJ, 2002, AM J PUBLIC HEALTH, V92, P367, DOI 10.2105/AJPH.92.3.367; Lallemant M, 2000, NEW ENGL J MED, V343, P982, DOI 10.1056/NEJM200010053431401; Lallemant M, 2004, NEW ENGL J MED, V351, P217, DOI 10.1056/NEJMoa033500; LANDESMAN S, 1987, JAMA-J AM MED ASSOC, V258, P2701, DOI 10.1001/jama.258.19.2701; Lansky A, 2001, AM J PUBLIC HEALTH, V91, P1291, DOI 10.2105/AJPH.91.8.1291; Lee L M, 2001, J Am Med Womens Assoc (1972), V56, P94; LESTER P, 1995, J ACQ IMMUN DEF SYND, V10, P341; LEWIS R, 1995, AM J OBSTET GYNECOL, V173, P1329, DOI 10.1016/0002-9378(95)91381-5; Lien TX, 2000, AM J TROP MED HYG, V62, P301, DOI 10.4269/ajtmh.2000.62.301; Lindegren ML, 2000, ANN NY ACAD SCI, V918, P222; Lindegren ML, 1999, JAMA-J AM MED ASSOC, V282, P531, DOI 10.1001/jama.282.6.531; LINDSAY MK, 1991, OBSTET GYNECOL, V78, P678; LINDSAY MK, 1995, OBSTET GYNECOL, V85, P675, DOI 10.1016/0029-7844(95)00018-M; LINDSAY MK, 1989, OBSTET GYNECOL, V74, P289; LYONS F, 2003, 2 IAS C HIV PATH TRE; Malonza IA, 2003, AIDS, V17, P113, DOI 10.1097/00002030-200301030-00015; Mandelbrot L, 1996, AM J OBSTET GYNECOL, V175, P661; Mandelbrot L, 2001, JAMA-J AM MED ASSOC, V285, P2083, DOI 10.1001/jama.285.16.2083; Marcollet A, 2002, AM J OBSTET GYNECOL, V186, P784, DOI 10.1067/mob.2002.122251; Mashu A, 1997, AIDS, V11, P932; Massad LS, 2004, AIDS, V18, P281, DOI 10.1097/00002030-200401230-00018; Mercey D, 1996, BRIT J OBSTET GYNAEC, V103, P1129, DOI 10.1111/j.1471-0528.1996.tb09596.x; Minkoff H, 2003, AM J OBSTET GYNECOL, V189, P552, DOI 10.1067/S0002-9378(03)00467-8; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; Mofenson Lynne M, 2003, Semin Pediatr Infect Dis, V14, P295, DOI 10.1053/j.spid.2003.09.003; Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898; Morris AB, 2000, J ACQ IMMUN DEF SYND, V25, P306, DOI 10.1097/00126334-200012010-00003; Morris L, 2003, AIDS, V17, P1698, DOI 10.1097/00002030-200307250-00017; MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506; Nakchbandi IA, 1998, ANN INTERN MED, V128, P760, DOI 10.7326/0003-4819-128-9-199805010-00010; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Nduati R, 2000, ADV EXP MED BIOL, V478, P201; Newell ML, 2003, JAIDS-J ACQ IMM DEF, V32, P380, DOI 10.1097/00126334-200304010-00006; O'Connell RJ, 2003, J CLIN MICROBIOL, V41, P2153, DOI 10.1128/JCM.41.5.2153-2155.2003; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; Peterman TA, 1996, J ACQ IMMUN DEF SYND, V12, P69, DOI 10.1097/00042560-199605010-00010; Poirier MC, 2003, JAIDS-J ACQ IMM DEF, V33, P175, DOI 10.1097/00126334-200306010-00010; Pulver WP, 2004, ARCH PEDIAT ADOL MED, V158, P443, DOI 10.1001/archpedi.158.5.443; Ramalingam S, 2002, J CLIN MICROBIOL, V40, P1553, DOI 10.1128/JCM.40.4.1553-1554.2002; Read JS, 2001, J ACQ IMMUN DEF SYND, V26, P236, DOI 10.1097/00126334-200103010-00005; Reynolds SJ, 2002, INT J STD AIDS, V13, P171, DOI 10.1258/0956462021924857; Rodriguez EJ, 2001, AM J OBSTET GYNECOL, V184, P1108, DOI 10.1067/mob.2001.115179; Royce RA, 2001, AM J PUBLIC HEALTH, V91, P727, DOI 10.2105/AJPH.91.5.727; Saba J, 2002, LANCET, V359, P1178; Samson L, 1998, CAN MED ASSOC J, V158, P1449; Sansom SL, 2003, OBSTET GYNECOL, V102, P782, DOI 10.1016/S0029-7844(03)00624-0; SCOTT GB, 1995, PEDIATRICS, V95, P303; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P3567, DOI 10.1001/jama.261.24.3567; SEMPRINI AE, 1995, AIDS, V9, P913, DOI 10.1097/00002030-199508000-00013; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Shapiro DE, 1999, OBSTET GYNECOL, V94, P897, DOI 10.1016/S0029-7844(99)00451-2; SHEON AR, 1994, PUBLIC HEALTH REP, V109, P694; Simpson W M, 1999, Health Technol Assess, V3, P1; Sperling RS, 1998, AIDS, V12, P1805, DOI 10.1097/00002030-199814000-00012; STOTO MA, 1999, REDUCING ODDS PREVEN; Stringer EM, 2001, OBSTET GYNECOL, V98, P1104, DOI 10.1016/S0029-7844(01)01631-3; Taha TE, 2004, JAMA-J AM MED ASSOC, V292, P202, DOI 10.1001/jama.292.2.202; Taha TE, 2003, LANCET, V362, P1171, DOI 10.1016/S0140-6736(03)14538-2; Taylor GP, 2001, DRUG SAFETY, V24, P683, DOI 10.2165/00002018-200124090-00004; TEMMERMAN M, 1990, AIDS Care, V2, P247, DOI 10.1080/09540129008257737; Thorne C, 2001, AIDS, V15, P761, DOI 10.1097/00002030-200104130-00012; Tuomala RE, 2002, NEW ENGL J MED, V346, P1863, DOI 10.1056/NEJMoa991159; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; *USDHHS, 2005, PUBL HLTH SERV TASK; *USDHHS, 2002, RED OBST BARR OFF HI; Wade NA, 2004, JAIDS-J ACQ IMM DEF, V36, P1075, DOI 10.1097/00126334-200408150-00011; Watts DH, 2004, AM J OBSTET GYNECOL, V190, P506, DOI 10.1016/j.ajog.2003.07.018; Watts DH, 2003, JAIDS-J ACQ IMM DEF, V33, P585, DOI 10.1097/00126334-200308150-00006; Watts DH, 2000, AM J OBSTET GYNECOL, V183, P100, DOI 10.1067/mob.2000.105423; Webber MP, 2001, AM J PERINAT, V18, P49, DOI 10.1055/s-2001-12941; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; Wortley Pascale M., 2001, Morbidity and Mortality Weekly Report, V50, P17; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911; 1999, PEDIATRICS, V104, P128; 1998, MMWR MORB MORTAL WKL, V47, P211; 2004, MMWR MORB MORTAL WKL, V52, P1245; 1999, INT J GYNAECOL OBSTE, V66, P305; 2002, MMWR MORB MORTAL WKL, V51, P93; 1989, JAMA-J AM MED ASSOC, V262, P3395	140	52	57	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 5	2005	143	1					38	54		10.7326/0003-4819-143-1-200507050-00009	http://dx.doi.org/10.7326/0003-4819-143-1-200507050-00009			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	941XB	15998754				2022-12-28	WOS:000230246400006
J	Rothstein, MA				Rothstein, MA			Genetic justice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Louisville, Sch Med, Inst Bioeth Hlth Policy & Law, Louisville, KY 40292 USA	University of Louisville	Rothstein, MA (corresponding author), Univ Louisville, Sch Med, Inst Bioeth Hlth Policy & Law, Louisville, KY 40292 USA.							[Anonymous], INNOCENCE PROJECT; BIEBER FR, 2003, BOSTON GLOBE    0412; Gross Samuel R., 2012, EXONERATIONS US 1989; ROTHSTEIN MA, 2001, BROOK L REV, V67, P127	4	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					2667	2668		10.1056/NEJMp058021	http://dx.doi.org/10.1056/NEJMp058021			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	940HH	15987913				2022-12-28	WOS:000230133800001
J	Rahim, SA; Sahlas, DJ; Shadowitz, S				Rahim, SA; Sahlas, DJ; Shadowitz, S			Blinded by pressure and pain	LANCET			English	Editorial Material							GLAUCOMA		Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Neurol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Rahim, SA (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	sherali.rahim@utoronto.ca						AMINLARI A, 1993, GRAEF ARCH CLIN EXP, V231, P12, DOI 10.1007/BF01681694; GEANON JD, 1995, ARCH OPHTHALMOL-CHIC, V113, P1231, DOI 10.1001/archopht.1995.01100100019012; Khaw PT, 2004, BRIT MED J, V328, P97, DOI 10.1136/bmj.328.7431.97; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Tripathi RC, 2003, DRUG SAFETY, V26, P749, DOI 10.2165/00002018-200326110-00002	5	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 25	2005	365	9478					2244	2244		10.1016/S0140-6736(05)66785-2	http://dx.doi.org/10.1016/S0140-6736(05)66785-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978935				2022-12-28	WOS:000230034800037
J	Falkovich, G; Weinberg, A; Denissenko, P; Lukaschuk, S				Falkovich, G; Weinberg, A; Denissenko, P; Lukaschuk, S			Floater clustering in a standing wave	NATURE			English	Editorial Material									Weizmann Inst Sci, Dept Complex Syst, IL-76100 Rehovot, Israel; Univ Hull, Fluid Dynam Lab, Kingston Upon Hull HU6 7RX, N Humberside, England	Weizmann Institute of Science; University of Hull	Falkovich, G (corresponding author), Weizmann Inst Sci, Dept Complex Syst, IL-76100 Rehovot, Israel.		FALKOVICH, GREGORY/K-1561-2012; Denissenko, Petr/T-2700-2018; Lukaschuk, Sergei/A-4473-2014	FALKOVICH, GREGORY/0000-0002-0570-7895; Denissenko, Petr/0000-0002-9631-5810; Lukaschuk, Sergei/0000-0002-1541-1086				Chladni EFF, 1787, ENTDECKUNGEN THEORIE; Faraday M., 1831, PHILOS T R SOC LONDO, VA52, P299, DOI [DOI 10.1098/RSTL.1831.0018, 10.1098/rstl.1831.0018]; Faraday M., 1831, PHILOS T R SOC LONDO, V121, P319, DOI [10.1098/rstl.1831.0018, DOI 10.1098/RSTL.1831.0018]; King LV., 1934, P R SOC LOND A, V147, P212, DOI [10.1098/rspa.1934.0215, DOI 10.1098/RSPA.1934.0215]; Rayleigh Lord, 1883, PHIL T R SOC LOND, V175, P1, DOI DOI 10.1098/RSTL.1884.0002; Thomas B, 1998, PHYS REV LETT, V81, P574, DOI 10.1103/PhysRevLett.81.574; WALLER MD, 1961, CHLADNI FIGURES STUD	7	50	51	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 23	2005	435	7045					1045	1046		10.1038/4351045a	http://dx.doi.org/10.1038/4351045a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973398				2022-12-28	WOS:000229970400033
J	Josephsen, G				Josephsen, G			Images in clinical medicine: Mixed cryoglobulinemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Josephsen, G (corresponding author), Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					2627	2627		10.1056/NEJMicm030887	http://dx.doi.org/10.1056/NEJMicm030887			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972869				2022-12-28	WOS:000229953700010
J	Kawaoka, Y				Kawaoka, Y			Clinical implications of basic research: How ebola virus infects cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Tokyo, Int Res Ctr Infect Dis, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Virol, Tokyo, Japan; Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA	University of Tokyo; University of Tokyo; University of Wisconsin System; University of Wisconsin Madison	Kawaoka, Y (corresponding author), Univ Tokyo, Int Res Ctr Infect Dis, Tokyo, Japan.							CHANDRAN K, IN PRESS SCIENCE; DOMS RW, 1985, J BIOL CHEM, V260, P2973; Geisbert TW, 2003, LANCET, V362, P1953, DOI 10.1016/S0140-6736(03)15012-X; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; Sullivan NJ, 2003, NATURE, V424, P681, DOI 10.1038/nature01876	5	16	21	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					2645	2646		10.1056/NEJMcibr051754	http://dx.doi.org/10.1056/NEJMcibr051754			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972874				2022-12-28	WOS:000229953700016
J	Eisenberg, E; McNicol, ED; Carr, DB				Eisenberg, E; McNicol, ED; Carr, DB			Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin - Systematic review and meta-analysis of randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RECEPTOR ANTAGONIST KETAMINE; CONTROLLED-RELEASE OXYCODONE; CONTROLLED CROSSOVER TRIAL; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; POSTHERPETIC NEURALGIA; MORPHINE RESPONSIVENESS; INTRAVENOUS LIDOCAINE; DIABETIC-NEUROPATHY; IV MORPHINE	Context In the United States, an estimated 2 million persons have neuropathic pain that is often resistant to therapy. The use of opioids for neuropathic pain remains controversial, in part because studies have been small, have yielded equivocal results, and. have not established the long-term risk-benefit ratio of this treatment. Objective To assess the efficacy and safety of opioid agonists for the treatment of neuropathic pain based on published randomized controlled trials (RCTs). Data Sources We searched MEDLINE (1966 to December 2004) and the Cochrane Central Register of Controlled Trials (fourth quarter, 2004) for articles in any language, along with reference lists of reviews and retrieved articles, using a combination of 9 search terms for RCTs with 32 terms for opioids and 15 terms for neuropathic pain. Study Selection Trials were included in which opioid agonists were given to treat central or peripheral neuropathic pain of any etiology, pain was assessed using validated instruments, and adverse events were reported. Studies in which drugs other than opioid agonists were combined with opioids or opioids were administered epidurally or intrathecally were excluded. Data Extraction Data were extracted by 2 independent investigators and included demographic variables, diagnoses, interventions, efficacy, and adverse effects. Data Synthesis Twenty-two articles met inclusion criteria and were classified as short-term (less than 24 hours; n = 14) or intermediate-term (median = 28 days; range = 8-56 days; n=8) trials. The short-term trials had contradictory results. In contrast, all 8 intermediate-term trials demonstrated opioid efficacy for spontaneous neuropathic pain. A fixed-effects model meta-analysis of 6 intermediate-term studies showed mean post-treatment visual analog scale scores of pain intensity after opioids to be 14 units lower on a scale from 0 to 100 than after placebo (95% confidence interval [CI], -18 to -10; P<.001). According to number needed to harm (NNH), the most common adverse event was nausea (NNH, 3.6; 95% Cl, 2.9-4.8), followed by constipation (NNH, 4.6; 95% Cl, 3.4-7.1), drowsiness (NNH, 5.3; 95% Cl, 3.7-8.3), vomiting (NNH, 6.2; 95% Cl, 4.6-11.1), and dizziness (NNH, 6.7; 95% Cl, 4.8-10.0). Conclusions Short-term studies provide only equivocal evidence regarding the efficacy of opioids in reducing the intensity of neuropathic pain. Intermediate-term studies demonstrate significant efficacy of opioids over placebo for neuropathic pain, which is likely to be clinically important. Reported adverse events of opioids are common but not life-threatening. Further RCTs are needed to establish their long-term efficacy, safety (including addiction potential), and effects on quality of life.	Rambam Med Ctr, Pain Relief Unit, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Haifa Pain Res Grp, Haifa, Israel; Tufts New England Med Ctr, Dept Anesthesia, Boston, MA USA; Tufts New England Med Ctr, Dept Pharm, Boston, MA USA; Tufts New England Med Ctr, Div Clin Care Res, Boston, MA USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Tufts Medical Center; Tufts Medical Center; Tufts Medical Center; Tufts University	Eisenberg, E (corresponding author), Rambam Med Ctr, Pain Relief Unit, POB 9602, IL-31096 Haifa, Israel.	e_eisenberg@rambam.health.gov.il						AMER S, 1988, PAIN, V33, P11; Attal N, 2002, NEUROLOGY, V58, P554, DOI 10.1212/WNL.58.4.554; Attal N, 2004, NEUROLOGY, V62, P218, DOI 10.1212/01.WNL.0000103237.62009.77; Backonja M, 1998, JAMA-J AM MED ASSOC, V280, P1831, DOI 10.1001/jama.280.21.1831; Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411; Benedetti F, 1998, PAIN, V74, P205, DOI 10.1016/S0304-3959(97)00172-3; Canavero S, 2003, NEW ENGL J MED, V348, P2688; Carr Daniel B, 2004, J Natl Cancer Inst Monogr, P23; Carver A, 2001, Curr Neurol Neurosci Rep, V1, P97, DOI 10.1007/s11910-001-0001-2; Cepeda MS, 2003, PAIN, V105, P151, DOI 10.1016/S0304-3959(03)00176-3; CLARKE M, 2003, ANAL PRESENTING RESU; Cohen SP, 2004, ANESTH ANALG, V99, P1753, DOI 10.1213/01.ANE.0000136953.11583.7B; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; Dellemijn P, 1999, PAIN, V80, P453, DOI 10.1016/S0304-3959(98)00256-5; Dellemijn PLI, 1997, LANCET, V349, P753, DOI 10.1016/S0140-6736(96)09024-1; Duhmke R. M., 2004, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003726; Dunbar SA, 1996, J PAIN SYMPTOM MANAG, V11, P163, DOI 10.1016/0885-3924(95)00165-4; EIDE PK, 1994, PAIN, V58, P347, DOI 10.1016/0304-3959(94)90129-5; EIDE PK, 1995, NEUROSURGERY, V37, P1080, DOI 10.1227/00006123-199512000-00007; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Foley KM, 2003, NEW ENGL J MED, V348, P1279, DOI 10.1056/NEJMe030014; Galer BS, 1996, J PAIN SYMPTOM MANAG, V12, P161, DOI 10.1016/0885-3924(96)00126-1; Gimbel JS, 2003, NEUROLOGY, V60, P927, DOI 10.1212/01.WNL.0000057720.36503.2C; Harke H, 2001, ANESTH ANALG, V92, P488, DOI 10.1213/00000539-200102000-00039; Huse E, 2001, PAIN, V90, P47, DOI 10.1016/S0304-3959(00)00385-7; JADAD AR, 1992, LANCET, V339, P1367, DOI 10.1016/0140-6736(92)91194-D; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jorum E, 2003, PAIN, V101, P229, DOI 10.1016/S0304-3959(02)00122-7; Kalman S, 2002, EUR J PAIN-LONDON, V6, P69, DOI 10.1053/eujp.2001.0307; KUPERS RC, 1991, PAIN, V47, P5, DOI 10.1016/0304-3959(91)90004-H; Leung A, 2001, PAIN, V91, P177, DOI 10.1016/S0304-3959(00)00433-4; Maier C, 2002, PAIN, V97, P223, DOI 10.1016/S0304-3959(02)00020-9; Mailis A, 2003, COCHRANE DATABASESYS, V2; MAX MB, 1988, CLIN PHARMACOL THER, V43, P363, DOI 10.1038/clpt.1988.44; MAX MB, 1995, CLIN NEUROPHARMACOL, V18, P360, DOI 10.1097/00002826-199508000-00008; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; McNicol E, 2004, J CLIN ONCOL, V22, P1975, DOI 10.1200/JCO.2004.10.524; McQuay HJ, 1997, ACTA ANAESTH SCAND, V41, P175, DOI 10.1111/j.1399-6576.1997.tb04634.x; Morley JS, 2003, PALLIATIVE MED, V17, P576, DOI 10.1191/0269216303pm815oa; Nicholson BD, 2004, NEUROLOGY, V62, pS30, DOI 10.1212/WNL.62.5_suppl_2.S30; Rabben T, 1999, J PHARMACOL EXP THER, V289, P1060; Raja SN, 2002, NEUROLOGY, V59, P1015, DOI 10.1212/WNL.59.7.1015; Rowbotham MC, 2003, NEW ENGL J MED, V348, P1223, DOI 10.1056/NEJMoa021420; ROWBOTHAM MC, 1991, NEUROLOGY, V41, P1024, DOI 10.1212/WNL.41.7.1024; Sindrup SH, 1999, PAIN, V83, P389, DOI 10.1016/S0304-3959(99)00154-2; Stanton-Hicks Michael D, 2002, Pain Pract, V2, P1, DOI 10.1046/j.1533-2500.2002.02009.x; Sullivan M, 2005, J PAIN, V6, P2, DOI 10.1016/j.jpain.2004.10.006; Watson CPN, 2003, PAIN, V105, P71, DOI 10.1016/S0304-3959(03)00160-X; Watson CPN, 1998, NEUROLOGY, V50, P1837; WITTICK H, 2005, PAIN MANAGEMENT EVID; Wu CL, 2002, ANESTHESIOLOGY, V96, P841, DOI 10.1097/00000542-200204000-00010; Yarnitsky D, 1998, PAIN FORUM, V7, P241, DOI 10.1016/S1082-3174(98)80011-1	53	272	287	1	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 22	2005	293	24					3043	3052		10.1001/jama.293.24.3043	http://dx.doi.org/10.1001/jama.293.24.3043			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937SG	15972567				2022-12-28	WOS:000229945200020
J	Fine, DM				Fine, DM			Pharmacological therapy of lupus nephritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYCOPHENOLATE-MOFETIL; PULSE CYCLOPHOSPHAMIDE; OVARIAN-FUNCTION; CONTROLLED-TRIAL; RENAL INVOLVEMENT; ERYTHEMATOSUS; BIOPSY; METHYLPREDNISOLONE; PRESERVATION; EFFICACY	Kidney involvement is common in systemic lupus erythematosus, occurring in up to 60% of affected adults during the course of their disease. Diffuse proliferative lupus nephritis (World Health Organization class IV), the most ominous variant, has traditionally been treated with cyclophosphamide and glucocorticolds. With cyclophosphamide, women of childbearing potential must weigh the risks of sustained amenorrhea, infertility, increased susceptibility to infection, bone marrow suppression, hemorrhagic cystitis, and malignancy against the benefits of better disease control compared with glucocorticoids alone. Because of the host of adverse effects associated with cyclophosphamide, alternative approaches to the treatment of lupus nephritis are desirable. A 31-year-old woman developed class IV lupus nephritis in the postpartum period. Seeking to preserve fertility and avoid other known toxicities of cyclophosphamide, she chose to undergo therapy with mycophenolate mofetil. In the treatment of severe lupus nephritis, mycophenolate mofetil has emerged as an alternative to cyclophosphamide, offering a major advance in the therapy of lupus nephritis.	Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA	Johns Hopkins University	Fine, DM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, 1830 E Monument St,Suite 416, Baltimore, MD 21205 USA.	dfine1@jhmi.edu						Allison AC, 2000, IMMUNOPHARMACOLOGY, V47, P85, DOI 10.1016/S0162-3109(00)00188-0; Appel G, 2003, J AM SOC NEPHROL, V14, p38A; APPEL GB, 1987, AM J MED, V83, P877, DOI 10.1016/0002-9343(87)90645-0; AUSTIN HA, 1994, KIDNEY INT, V45, P544, DOI 10.1038/ki.1994.70; AUSTIN HA, 1983, AM J MED, V75, P382, DOI 10.1016/0002-9343(83)90338-8; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; Barr RG, 2003, NEPHROL DIAL TRANSPL, V18, P2039, DOI 10.1093/ndt/gfg345; Blaheta RA, 1999, TRANSPLANT P, V31, P1250, DOI 10.1016/S0041-1345(98)01984-8; Blumenfeld Z, 2000, LUPUS, V9, P401, DOI 10.1191/096120300678828596; Blumenfeld Z, 2001, J SOC GYNECOL INVEST, V8, pS60, DOI 10.1016/S1071-5576(00)00112-X; BORENSTEIN DG, 1978, ANN INTERN MED, V89, P619, DOI 10.7326/0003-4819-89-5-619; BOUMPAS DT, 1993, ANN INTERN MED, V119, P366, DOI 10.7326/0003-4819-119-5-199309010-00003; BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N; Briggs WA, 1998, AM J KIDNEY DIS, V31, P213, DOI 10.1053/ajkd.1998.v31.pm9469489; Cameron JS, 1999, J AM SOC NEPHROL, V10, P413; Chan TM, 2000, NEW ENGL J MED, V343, P1156, DOI 10.1056/NEJM200010193431604; Contreras G, 2004, NEW ENGL J MED, V350, P971, DOI 10.1056/NEJMoa031855; Contreras G, 2002, CLIN NEPHROL, V57, P95; DONADIO JV, 1978, NEW ENGL J MED, V299, P1151, DOI 10.1056/NEJM197811232992102; Dooley MA, 1999, J AM SOC NEPHROL, V10, P833; Dooley MA, 1997, KIDNEY INT, V51, P1188, DOI 10.1038/ki.1997.162; Dooley MA, 2000, ARTHRITIS RHEUM, V43, P2858; ESDAILE JM, 1994, J RHEUMATOL, V21, P2046; Fraenkel L, 2002, ARTHRIT RHEUM-ARTHR, V47, P421, DOI 10.1002/art.10534; Gelber AC, 2004, NEW ENGL J MED, V350, P2518; GLADMAN DD, 1989, Q J MED, V73, P1125; Gourley MF, 1996, ANN INTERN MED, V125, P549, DOI 10.7326/0003-4819-125-7-199610010-00003; Grande JP, 1998, LUPUS, V7, P611, DOI 10.1191/096120398678920730; GRINYO J, 1995, LANCET, V345, P1321; Halloran P, 1997, TRANSPLANTATION, V63, P39, DOI 10.1097/00007890-199701150-00008; HELLMANN DB, 1987, MEDICINE, V66, P341, DOI 10.1097/00005792-198709000-00002; Huong DLT, 1999, MEDICINE, V78, P148; Illei GG, 2001, ANN INTERN MED, V135, P248, DOI 10.7326/0003-4819-135-4-200108210-00009; KASHGARIAN M, 1994, KIDNEY INT, V45, P928, DOI 10.1038/ki.1994.123; MARTIN JN, 1991, AM J OBSTET GYNECOL, V164, P1500, DOI 10.1016/0002-9378(91)91429-Z; MCCUNE J, 2001, ARTHRITIS RHEUM S, V42, P2006; Meng C, 1999, Curr Opin Rheumatol, V11, P348, DOI 10.1097/00002281-199909000-00004; Mittal L, 2005, CURR OPIN NEPHROL HY, V14, P1; Moder KG, 1999, MAYO CLIN PROC, V74, P275, DOI 10.4065/74.3.275; Mok CC, 1998, ARTHRITIS RHEUM, V41, P831; Mok CC, 2003, ANN RHEUM DIS, V62, P799, DOI 10.1136/ard.62.9.799; Moroni G, 1999, AM J KIDNEY DIS, V34, P530, DOI 10.1016/S0272-6386(99)70082-X; Moroni G, 2002, AM J KIDNEY DIS, V40, P713, DOI 10.1053/ajkd.2002.35678; Neylan JF, 1997, TRANSPLANTATION, V64, P1277, DOI 10.1097/00007890-199711150-00008; NOSSENT HC, 1990, ARTHRITIS RHEUM, V33, P970, DOI 10.1002/art.1780330708; NOSSENT JC, 1991, RHEUMATOL INT, V11, P77; Nzerue CM, 2002, KIDNEY INT, V62, P733, DOI 10.1046/j.1523-1755.2002.00500.x; Petri M, 2004, LUPUS, V13, P688, DOI 10.1191/0961203303lu2006oa; Petri M, 2004, LUPUS, V13, P366, DOI 10.1191/0961203303lu1028oa; RAHMAN FZ, 2004, OBSTET GYNECOL SURV, V59, P754; RASKIN RJ, 1983, SOUTHERN MED J, V76, P258; *ROCH LAB, 1995, MYC MOF CELLC PROD I; ROSE BD, TREATMENT LUPUS NEPH; Slater CA, 1999, LUPUS, V8, P3, DOI 10.1191/096120399678847335; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; STEINBERG AD, 1991, ARTHRITIS RHEUM-US, V34, P945, DOI 10.1002/art.1780340803; Weening JJ, 2004, KIDNEY INT, V65, P521, DOI 10.1111/j.1523-1755.2004.00443.x	57	25	29	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 22	2005	293	24					3053	3060		10.1001/jama.293.24.3053	http://dx.doi.org/10.1001/jama.293.24.3053			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937SG	15972568				2022-12-28	WOS:000229945200021
J	Martinez, FJ; Safrin, S; Weycker, D; Starko, KM; Bradford, WZ; King, TE; Flaherty, KR; Schwartz, DA; Noble, PW; Raghu, G; Brown, KK				Martinez, FJ; Safrin, S; Weycker, D; Starko, KM; Bradford, WZ; King, TE; Flaherty, KR; Schwartz, DA; Noble, PW; Raghu, G; Brown, KK		IPF Study Grp	The clinical course of patients with idiopathic pulmonary fibrosis	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE EXACERBATION; DYSPNEA; DETERIORATION; PHASE	Background: Prospective data defining the clinical course in idiopathic pulmonary fibrosis (IPF) are sparse. Objective: To analyze the clinical course of patients with mild to moderate IPF. Design: Analysis of data from the placebo group of a randomized, controlled trial evaluating interferon-gamma 1b. Setting: Academic and community medical centers. Patients: 168 patients in the placebo group of a trial evaluating interferon-gamma 1b. Measurements: measures of physiology and dyspnea assessed at 12-week intervals; hospitalizations; and the pace of deterioration and cause of death over a median period of 76 weeks. Results: Physiologic variables changed minimally during the study. However, 23% of patients required hospitalization for a respiratory disorder and 21% died. Idiopathic pulmonary fibrosis was the primary cause of death in 89% of patients who died, and an apparent acute clinical deterioration preceded death in 47% of these patients. Limitations: The instrument used to define the pace of deterioration and cause of death was applied retrospectively. Conclusions: Recognition of the common occurrence of acute fatal deterioration in patients with mild to moderate IPF has important implications for monitoring patients and supports early referral for lung transplantation.	Univ Michigan, Ann Arbor, MI 48109 USA; InterMune Inc, Brisbane, CA USA; Policy Anal Inc, Brookline, MA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Duke Univ, Sch Med, Durham, NC 27706 USA; Yale Univ, New Haven, CT 06520 USA; Univ Washington, Seattle, WA 98195 USA; Natl Jewish Med & Res Ctr, Denver, CO USA	University of Michigan System; University of Michigan; Policy Analysis Inc; University of California System; University of California San Francisco; Duke University; Yale University; University of Washington; University of Washington Seattle; National Jewish Health	Martinez, FJ (corresponding author), Univ Michigan, Ann Arbor, MI 48109 USA.	fmartine@med.umich.edu	Brown, Kevin/ABF-2544-2020		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101947] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akira M, 1997, THORAX, V52, P333, DOI 10.1136/thx.52.4.333; Akira M, 1997, AM J ROENTGENOL, V168, P79, DOI 10.2214/ajr.168.1.8976924; *AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00; Ambrosini V, 2003, EUR RESPIR J, V22, P821, DOI 10.1183/09031936.03.00022703; American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, AM J RESP CRIT CARE, V165, P277, DOI [DOI 10.1164/AJRCCM.165.2.ATS01, 10.1164/ajrccm.165.2.ats01]; Eakin EG, 1998, CHEST, V113, P619, DOI 10.1378/chest.113.3.619; Gong MN, 2002, NEW ENGL J MED, V347, P2149, DOI 10.1056/NEJMcpc020028; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; KONDOH Y, 1993, CHEST, V103, P1808, DOI 10.1378/chest.103.6.1808; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; PANOS RJ, 1990, AM J MED, V88, P396, DOI 10.1016/0002-9343(90)90495-Y; Raghu G, 2004, NEW ENGL J MED, V350, P125, DOI 10.1056/NEJMoa030511; SCHWARTZ DA, 1994, AM J RESP CRIT CARE, V149, P444, DOI 10.1164/ajrccm.149.2.8306043; *UN NETW ORG SHAR, 2005, GUID CALC LUNG ALL S	14	449	468	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	1				963	967		10.7326/0003-4819-142-12_Part_1-200506210-00005	http://dx.doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937IN	15968010				2022-12-28	WOS:000229917900002
J	Johnson, KC; Daviss, BA				Johnson, KC; Daviss, BA			Outcomes of planned home births with certified professional midwives: large prospective study in North America	BRITISH MEDICAL JOURNAL			English	Article							OF-HOSPITAL BIRTHS; NEONATAL-MORTALITY; WASHINGTON-STATE; PREGNANCIES; MIDWIFERY; DELIVERY; SAFETY; VALIDATION; CAROLINA; WOMEN	Objective To evaluate the safety of home births in North America involving direct entry midwives, in jurisdictions where the practice is not well integrated into the healthcare system. Design Prospective cohort study. Setting All home births involving certified professional midwives across the United States (98% of cohort) and Canada, 2000. Participants All 5418 women expecting to deliver in 2000 using midwives with a common certification, who planned to deliver at home when labour began. Main outcome measures Intrapartum and neonatal mortality, perinatal transfer to hospital care, medical intervention during labour, breast feeding, and maternal satisfaction. Results 655 (12.1%) of women who intended to deliver at home when labour began were transferred to hospital. Medical intervention rates included epidural (4.7%), episiotomy (2.11%), forceps (1.0%), vacuum extraction (0.6%), and caesarean section (3.7%); substantially lower than for low risk US women having hospital births. The intrapartum and neonatal mortality among women considered at low risk at start of labour, excluding deaths concerning life threatening congenital anomalies, was 1.7 deaths per 1000 planned home births, similar to risks in other studies of low risk home and hospital births in North America. No mothers died. No discrepancies were found for perinatal outcomes independently validated. Conclusions Planned home birth for low risk women in North America using certified professional midwives was associated with lower rates of medical intervention but similar intrapartum and neonatal mortality to that of low risk hospital births in the United States.	Publ Hlth Agcy Canada, Ctr Chron Dis Prevent & Control, Surveillance & Risk Assessment Div, Ottawa, ON K1A 0K9, Canada; Int Federat Gynecol & Obstet, Safe Motherhood Newborn Initiat, Ottawa, ON, Canada	Public Health Agency of Canada	Johnson, KC (corresponding author), Publ Hlth Agcy Canada, Ctr Chron Dis Prevent & Control, Surveillance & Risk Assessment Div, PL 6702A, Ottawa, ON K1A 0K9, Canada.	ken_lcdc_johnson@phac-aspc.gc.ca	Daviss, Betty-Anne/AAW-8668-2021					ACKERMANNLIEBRICH, 1996, BRIT MED J, V313, P1313; AckermannLiebrich U, 1996, BRIT MED J, V313, P1313; ADAMS JL, 1983, WOMEN HEALTH, V8, P25, DOI 10.1300/J013v08n01_04; *AM COLL OBST GYN, 2001, MON AM COLL OBST GYN; AMATO JC, 1977, OBSTET GYNECOL, V50, P269; American Public Health Association, 2002, AM J PUBLIC HEALTH, V92, P453; Anderson RE, 1999, J NURSE-MIDWIFERY, V44, P30, DOI 10.1016/S0091-2182(98)00072-X; Anderson RE, 1995, J NURSE-MIDWIFERY, V40, P483, DOI 10.1016/0091-2182(95)00051-8; Barron SL, 1996, BRIT MED J, V313, P1306; Bastian H, 1998, BRIT MED J, V317, P384; BASTIAN H, 1999, BRIT MED J, V318, P605; BUESCHER PA, 1993, AM J PUBLIC HEALTH, V83, P1163, DOI 10.2105/AJPH.83.8.1163; BURNETT CA, 1980, JAMA-J AM MED ASSOC, V244, P2741, DOI 10.1001/jama.244.24.2741; CAMPBELL R, 1994, BORN DEBUTE EVIDENCE; CAMPBELL R, 1994, BORN DEBATE EVIDENCE; *COLL PHYS SURG ON, 2001, HOM BIRTH POL RESC; College of Physicians and Surgeons of Ontario, 2001, REP COUNC HOM BIRTH; DECLERCQ ER, 2002, MONOGRAPH MATERNITY; Dowswell T, 1996, BRIT MED J, V312, P753; DURAND AM, 1992, AM J PUBLIC HEALTH, V82, P450, DOI 10.2105/AJPH.82.3.450; EDEN RD, 1987, OBSTET GYNECOL, V69, P296; HINDS MW, 1985, JAMA-J AM MED ASSOC, V253, P1578, DOI 10.1001/jama.253.11.1578; Janssen PA, 2002, CAN MED ASSOC J, V166, P315; JANSSEN PA, 1994, BIRTH-ISS PERINAT C, V21, P141, DOI 10.1111/j.1523-536X.1994.tb00513.x; Johnson KC, 2003, OBSTET GYNECOL, V101, P198, DOI 10.1097/00006250-200301000-00043; Jun HW, 2002, J CERAM PROCESS RES, V3, P15; LEVENO KJ, 1986, NEW ENGL J MED, V315, P615, DOI 10.1056/NEJM198609043151004; Macfarlane A, 2000, BRIT MED J, V320, P798; Martin JA, 2002, NATL VITAL STAT REPO, V50; MEHL LE, 1977, J REPROD MED, V19, P281; Murphy PA, 1998, OBSTET GYNECOL, V92, P461, DOI 10.1016/S0029-7844(98)00182-3; NEURA RR, 1978, NEW ENGL J MED, V299, P324; Olsen O, 1997, BIRTH-ISS PERINAT C, V24, P4, DOI 10.1111/j.1523-536X.1997.tb00330.x; OLSEN O, 1997, BIRTH-ISS PERINAT C, V24, P1; Pang JWY, 2002, OBSTET GYNECOL, V100, P253, DOI 10.1016/S0029-7844(02)02074-4; Perkins Barbara Bridgman, 2004, MEDICAL DELIVERY BUS; PIPER JM, 1993, AM J EPIDEMIOL, V137, P758, DOI 10.1093/oxfordjournals.aje.a116736; ROOKS JP, 1989, NEW ENGL J MED, V321, P1894; ROOKS JP, 1997, MIDWIFERY CHILDBIRTH, P345; SCHLENZKA P, 1999, THESIS STANFORD U CA; SCHRAMM WF, 1987, AM J PUBLIC HEALTH, V77, P930, DOI 10.2105/AJPH.77.8.930; Society of Obstetricians and Gynaecologists of Canada, 2003, J OBSTET GYNAECOLOGY, V25, P5; Springer NP, 1996, BRIT MED J, V313, P1276; SULLIVAN DA, 1983, AM J PUBLIC HEALTH, V73, P641, DOI 10.2105/AJPH.73.6.641; TYSON H, 1991, BIRTH-ISS PERINAT C, V18, P14, DOI 10.1111/j.1523-536X.1991.tb00047.x; Wiegers TA, 1996, BRIT MED J, V313, P1309; WOOLBRIGHT LA, 1995, PUBLIC HEALTH REP, V110, P59	47	167	168	0	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 18	2005	330	7505					1416	1419		10.1136/bmj.330.7505.1416	http://dx.doi.org/10.1136/bmj.330.7505.1416			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938NP	15961814	Green Published, Bronze			2022-12-28	WOS:000230010400015
J	Lee, CS; Friedman, JR; Fulmer, JT; Kaestner, KH				Lee, CS; Friedman, JR; Fulmer, JT; Kaestner, KH			The initiation of liver development is dependent on Foxa transcription factors	NATURE			English	Article							GUT ENDODERM; GLUCOSE-HOMEOSTASIS; GENE; DIFFERENTIATION; CHROMATIN; HNF3; ORGANOGENESIS; NUCLEOSOME; EXPRESSION; HNF-3-BETA	The specification of the vertebrate liver is thought to occur in a two-step process, beginning with the establishment of competence within the foregut endoderm for responding to organ-specific signals, followed by the induction of liver-specific genes. On the basis of expression and in vitro studies, it has been proposed that the Foxa transcription factors establish competence by opening compacted chromatin structures within liver-specific target genes(1). Here we show that Foxa1 and Foxa2 (forkhead box proteins A1 and A2) are required in concert for hepatic specification in mouse. In embryos deficient for both genes in the foregut endoderm, no liver bud is evident and expression of the hepato-blast marker alpha-fetoprotein (Afp) is lost. Furthermore, Foxa1/Foxa2-deficient endoderm cultured in the presence of exogenous fibroblast growth factor 2 (FGF2) fails to initiate expression of the liver markers albumin and transthyretin. Thus, Foxa1 and Foxa2 are required for the establishment of competence within the foregut endoderm and the onset of hepatogenesis.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Kaestner, KH (corresponding author), Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.	kaestner@mail.med.upenn.edu	Friedman, Joshua/Q-9367-2019	Friedman, Joshua/0000-0001-9382-8429				ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Barbera JPM, 2000, DEVELOPMENT, V127, P2433; Bort R, 2004, DEVELOPMENT, V131, P797, DOI 10.1242/dev.00965; Bossard P, 2000, DEVELOPMENT, V127, P4915; Bossard P, 1998, DEVELOPMENT, V125, P4909; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; Clotman F, 2002, DEVELOPMENT, V129, P1819; Coffinier C, 2002, DEVELOPMENT, V129, P1829; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; Deutsch G, 2001, DEVELOPMENT, V128, P871; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Holmqvist PH, 2005, EXP CELL RES, V304, P593, DOI 10.1016/j.yexcr.2004.12.002; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Kaestner KH, 2000, TRENDS ENDOCRIN MET, V11, P281, DOI 10.1016/S1043-2760(00)00271-X; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Keng VW, 2000, BIOCHEM BIOPH RES CO, V276, P1155, DOI 10.1006/bbrc.2000.3548; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Lee CS, 2005, DEV BIOL, V278, P484, DOI 10.1016/j.ydbio.2004.10.012; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Shen W, 2001, J BIOL CHEM, V276, P42812, DOI 10.1074/jbc.M106344200; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Wilkinson DG, 1992, SITU HYBRIDIZATION P; Zaret KS, 2002, NAT REV GENET, V3, P499, DOI 10.1038/nrg837	27	415	434	2	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					944	947		10.1038/nature03649	http://dx.doi.org/10.1038/nature03649			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959514				2022-12-28	WOS:000229799700047
J	Schomig, A; Mehilli, J; Antoniucci, D; Ndrepepa, G; Markwardt, C; Di Pede, F; Nekolla, SG; Schlotterbeck, K; Schuhlen, H; Pache, J; Seyfarth, M; Martinoff, S; Benzer, W; Schmitt, C; Dirschinger, J; Schwaiger, M; Kastrati, A				Schomig, A; Mehilli, J; Antoniucci, D; Ndrepepa, G; Markwardt, C; Di Pede, F; Nekolla, SG; Schlotterbeck, K; Schuhlen, H; Pache, J; Seyfarth, M; Martinoff, S; Benzer, W; Schmitt, C; Dirschinger, J; Schwaiger, M; Kastrati, A		BRAVE2 Trial Investigators	Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR FUNCTION; THROMBOLYTIC THERAPY; CORONARY-ARTERY; IMMEDIATE ANGIOPLASTY; NATIONAL REGISTRY; PLUS ABCIXIMAB; SALVAGE; OCCLUSION; TIME; HIBERNATION	Context No specifically designed studies have addressed the role of primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction (STEMI) presenting more than 12 hours after symptom onset. Current guidelines do not recommend reperfusion treatment in these patients. Objective To assess whether an immediate invasive treatment strategy is associated with a reduction of infarct size in patients with acute STEMI, presenting between 12 and 48 hours after symptom onset, vs a conventional conservative strategy. Design, Setting, and Patients International, multicenter, open-label, randomized controlled trial conducted from May 23, 2001, to December 15, 2004, of 365 patients aged 18 to 80 years without persistent symptoms admitted with the diagnosis of acute STEMI between 12 and 48 hours after symptom onset. Interventions Random assignment to either an invasive strategy (n=182) based predominantly on coronary stenting with abciximab or a conventional conservative treatment strategy (n=183). Main Outcome Measures The primary end point was final left ventricular infarct size according to single-photon emission computed tomography study with technetium Tc99m sestamibi performed between 5 and 10 days after randomization in 347 patients (95.1%). Secondary end points included composite of death, recurrent MI, or stroke at 30 days. Results The final left ventricular infarct size was significantly smaller in patients assigned to the invasive group (median, 8.0%; interquartile range [IQR], 2.0%-15.8%) vs those assigned to the conservative group (median, 13.0%; IQR, 3.0%-27.0%; P<.001). The mean difference in final left ventricular infarct size between the invasive and conservative groups was -6.8% (95% confidence interval [CI], -10.2% to -3.5%). The secondary end points of death, recurrent MI, or stroke at 30 days occurred in 8 patients in the invasive group (4.4%) and 12 patients in the conservative group (6.6%) (relative risk, 0.67; 95% CI, 0.27-1.62; P = .37). Conclusion An invasive strategy based on coronary stenting with adjunctive use of abciximab reduces infarct size in patients with acute STEMI without persistent symptoms presenting 12 to 48 hours after symptom onset.	Tech Univ Munich, Deutsch Herzzentrum, D-80636 Munich, Germany; Tech Univ Munich, Klin Rechts Isar, Med Klin 1, D-80636 Munich, Germany; Tech Univ Munich, Klin & Poliklin Nukl Med Rechts Isar, D-80636 Munich, Germany; Azienda Osped Careggi, Florence, Italy; Osped Umberto 1, Venice, Italy; Klinikum Traunstein, Traunstein, Germany; Landeskrakenhaus, Feldkirch, Austria	German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; University of Florence; Azienda Ospedaliero Universitaria Careggi; ULSS 3 Serenissima	Schomig, A (corresponding author), Tech Univ Munich, Deutsch Herzzentrum, Lazarettstr 36, D-80636 Munich, Germany.	aschoemig@dhm.mhn.de	Nekolla, Stephan G/L-1857-2013; Mehilli, Julinda/F-2629-2016; , Kastrati/Y-2389-2019	Nekolla, Stephan G/0000-0002-8817-1482; schwaiger, markus/0000-0002-2305-7144; Schuhlen, Helmut/0000-0001-8630-4264				Abbate A, 2002, CIRCULATION, V106, P1051, DOI 10.1161/01.CIR.0000030936.97158.C4; Antman Elliott M., 2004, J Am Coll Cardiol, V44, pE1, DOI 10.1016/j.jacc.2004.07.014; Antoniucci D, 2003, J AM COLL CARDIOL, V42, P1879, DOI 10.1016/j.jacc.2003.07.017; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; CLEMENTS IP, 1993, CIRCULATION, V88, P1527, DOI 10.1161/01.CIR.88.4.1527; Cohen M, 2003, J AM COLL CARDIOL, V42, P1348, DOI 10.1016/S0735-1097(03)01040-4; Cohen M, 2003, CIRCULATION, V108, P14, DOI 10.1161/01.CIR.0000086952.14979.32; DZAVIK V, 1994, AM J CARDIOL, V73, P856, DOI 10.1016/0002-9149(94)90809-5; Eagle KA, 2002, LANCET, V359, P373, DOI 10.1016/S0140-6736(02)07595-5; Elad Y, 2002, J AM COLL CARDIOL, V39, P826, DOI 10.1016/S0735-1097(01)01817-4; ELLIS SG, 1989, J AM COLL CARDIOL, V13, P1122, DOI 10.1016/0735-1097(89)90272-6; French JK, 1996, BMJ-BRIT MED J, V312, P1637, DOI 10.1136/bmj.312.7047.1637; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; Gibbons RJ, 2000, CIRCULATION, V101, P101, DOI 10.1161/01.CIR.101.1.101; Gibbons RJ, 2005, J NUCL CARDIOL, V12, P12, DOI 10.1016/j.nuclcard.2004.10.002; Gibler WB, 2002, ANN EMERG MED, V39, P123, DOI 10.1067/mem.2002.121402; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HAMPTON J, 1993, LANCET, V342, P759; Heusch G, 2005, AM J PHYSIOL-HEART C, V288, pH984, DOI 10.1152/ajpheart.01109.2004; Horie H, 1998, CIRCULATION, V98, P2377, DOI 10.1161/01.CIR.98.22.2377; Kastrati A, 2004, J AM COLL CARDIOL, V43, P734, DOI 10.1016/j.jacc.2003.07.054; Kastrati A, 2004, JAMA-J AM MED ASSOC, V291, P947, DOI 10.1001/jama.291.8.947; Kastrati A, 2002, LANCET, V359, P920, DOI 10.1016/S0140-6736(02)08022-4; Kimura A, 1998, JPN CIRC J, V62, P294, DOI 10.1253/jcj.62.294; Kloner RA, 1998, CIRCULATION, V97, P1042, DOI 10.1161/01.CIR.97.11.1042; McCullough PA, 1998, J AM COLL CARDIOL, V32, P596, DOI 10.1016/S0735-1097(98)00284-8; Milavetz JJ, 1998, J AM COLL CARDIOL, V31, P1246, DOI 10.1016/S0735-1097(98)00088-6; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Neumann FJ, 1998, CIRCULATION, V98, P2695, DOI 10.1161/01.CIR.98.24.2695; Newby LK, 1996, J AM COLL CARDIOL, V27, P1646; PAOLASSO E, 1993, LANCET, V342, P767; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; RENTROP KP, 1989, J AM COLL CARDIOL, V14, P58, DOI 10.1016/0735-1097(89)90054-5; RENTROP KP, 1985, J AM COLL CARDIOL, V5, P587; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; SABIA PJ, 1992, NEW ENGL J MED, V327, P1825, DOI 10.1056/NEJM199212243272601; Sawyer DB, 2002, CIRCULATION, V105, P1517, DOI 10.1161/01.CIR.0000014689.12415.89; Schomig A, 2000, NEW ENGL J MED, V343, P385, DOI 10.1056/NEJM200008103430602; Schomig A, 2003, CIRCULATION, V108, P1084, DOI 10.1161/01.CIR.0000086346.32856.9C; SCHULZ R, 1993, CIRCULATION, V88, P684, DOI 10.1161/01.CIR.88.2.684; Sheifer SE, 2000, CIRCULATION, V102, P1651, DOI 10.1161/01.CIR.102.14.1651; Steg PG, 2004, EUR HEART J, V25, P2187, DOI 10.1016/j.ehj.2004.10.019; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; *TIMI, DEF US TIMI TRIALS; YUSUF S, 1981, BRIT HEART J, V45, P271; Zahn R, 2001, J Invasive Cardiol, V13, P367; Zijistra F, 2002, EUR HEART J, V23, P550, DOI 10.1053/euhj.2001.2901	49	205	225	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	2005	293	23					2865	2872		10.1001/jama.293.23.2865	http://dx.doi.org/10.1001/jama.293.23.2865			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935MD	15956631	Bronze			2022-12-28	WOS:000229785500021
J	Hammock, EAD; Young, LJ				Hammock, EAD; Young, LJ			Microsatellite instability generates diversity in brain and sociobehavioral traits	SCIENCE			English	Article							PAIR-BOND FORMATION; PRAIRIE VOLES; MICROTUS-OCHROGASTER; SOCIAL RECOGNITION; ARGININE-VASOPRESSIN; PARTNER PREFERENCE; OLFACTORY-BULB; MATING SYSTEM; RECEPTOR; PATTERNS	Repetitive microsatellites mutate at relatively high rates and may contribute to the rapid evolution of species-typical traits. We show that individual alleles of a repetitive polymorphic microsatellite in the 5' region of the prairie vole vasopressin 1a receptor (avpr1a) gene modify gene expression in vitro. In vivo, we observe that this regulatory polymorphism predicts both individual differences in receptor distribution patterns and socio-behavioral traits. These data suggest that individual differences in gene expression patterns may be conferred via polymorphic microsatellites in the cis-regulatory regions of genes and may contribute to normal variation in behavioral traits.	Emory Univ, Yerkes Natl Primate Res Ctr, Ctr Behav Neurosci, Dept Psychiat & Behav Sci, Atlanta, GA 30329 USA	Emory University	Young, LJ (corresponding author), Emory Univ, Yerkes Natl Primate Res Ctr, Ctr Behav Neurosci, Dept Psychiat & Behav Sci, Atlanta, GA 30329 USA.	Edunn2@emory.edu; Lyoun03@emory.edu	Hammock, Elizabeth/G-1897-2011; Young, Larry/HGE-5031-2022		NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH056897, K02MH064692, R01MH056897, F31MH067397] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00165] Funding Source: Medline; NIMH NIH HHS [MH64692, MH67397, MH56897] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bielsky IF, 2004, PEPTIDES, V25, P1565, DOI 10.1016/j.peptides.2004.05.019; Bielsky IF, 2004, NEUROPSYCHOPHARMACOL, V29, P483, DOI 10.1038/sj.npp.1300360; DEWAAL FBM, 1988, BEHAVIOUR, V106, P183, DOI 10.1163/156853988X00269; Dluzen DE, 1998, PEPTIDES, V19, P999, DOI 10.1016/S0196-9781(98)00047-3; ENGELMANN M, 1994, PHYSIOL BEHAV, V55, P145, DOI 10.1016/0031-9384(94)90022-1; Fondon JW, 2004, P NATL ACAD SCI USA, V101, P18058, DOI 10.1073/pnas.0408118101; Francis D, 1999, SCIENCE, V286, P1155, DOI 10.1126/science.286.5442.1155; *GENBANK, NW114825 GENBANK; *GENBANK, AF208541 GENBANK; GETZ LL, 1981, BEHAV ECOL SOCIOBIOL, V8, P189, DOI 10.1007/BF00299829; Gompel N, 2005, NATURE, V433, P481, DOI 10.1038/nature03235; HAMMOCK E, IN PRESS GENES BRAIN; Hammock EAD, 2004, MOL BIOL EVOL, V21, P1057, DOI 10.1093/molbev/msh104; Hammock EAD, 2002, EUR J NEUROSCI, V16, P399, DOI 10.1046/j.1460-9568.2002.02083.x; INSEL TR, 1994, J NEUROSCI, V14, P5381; JANNETT FJ, 1982, J MAMMAL, V63, P495, DOI 10.2307/1380450; Kashi Y, 1997, TRENDS GENET, V13, P74, DOI 10.1016/S0168-9525(97)01008-1; Kim SJ, 2002, MOL PSYCHIATR, V7, P503, DOI 10.1038/sj.mp.4001125; KING DG, 1994, SCIENCE, V263, P595, DOI 10.1126/science.263.5147.595-b; KIRKPATRICK B, 1994, PHYSIOL BEHAV, V55, P885, DOI 10.1016/0031-9384(94)90075-2; Kirschner M, 1998, P NATL ACAD SCI USA, V95, P8420, DOI 10.1073/pnas.95.15.8420; Li YC, 2004, MOL BIOL EVOL, V21, P991, DOI 10.1093/molbev/msh073; Lim MM, 2004, NATURE, V429, P754, DOI 10.1038/nature02539; Lim MM, 2004, NEUROSCIENCE, V125, P35, DOI 10.1016/j.neuroscience.2003.12.008; Liu Y, 2001, BEHAV NEUROSCI, V115, P910, DOI 10.1037//0735-7044.115.4.910; Phelps SM, 2003, J COMP NEUROL, V466, P564, DOI 10.1002/cne.10902; Pitkow LJ, 2001, J NEUROSCI, V21, P7392, DOI 10.1523/JNEUROSCI.21-18-07392.2001; Roberts RL, 1998, ANIM BEHAV, V55, P1131, DOI 10.1006/anbe.1997.0659; SHAPIRO LE, 1990, J COMP PSYCHOL, V104, P268, DOI 10.1037/0735-7036.104.3.268; Thibonnier M, 2000, J MOL CELL CARDIOL, V32, P557, DOI 10.1006/jmcc.2000.1108; THOMAS JA, 1979, BEHAV ECOL SOCIOBIOL, V5, P171, DOI 10.1007/BF00293304; WANG ZX, 1994, P NATL ACAD SCI USA, V91, P400, DOI 10.1073/pnas.91.1.400; Wassink TH, 2004, MOL PSYCHIATR, V9, P968, DOI 10.1038/sj.mp.4001503; WILLIAMS JR, 1992, PHYSIOL BEHAV, V52, P635, DOI 10.1016/0031-9384(92)90390-N; Wray GA, 2003, MOL BIOL EVOL, V20, P1377, DOI 10.1093/molbev/msg140; Young LJ, 1999, NATURE, V400, P766, DOI 10.1038/23475; Young LJ, 1997, BEHAV NEUROSCI, V111, P599, DOI 10.1037/0735-7044.111.3.599; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	38	385	396	1	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1630	1634		10.1126/science.1111427	http://dx.doi.org/10.1126/science.1111427			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947188				2022-12-28	WOS:000229827000058
J	Golombek, MP; Arvidson, RE; Bell, JF; Christensen, PR; Crisp, JA; Crumpler, LS; Ehlmann, BL; Fergason, RL; Grant, JA; Greeley, R; Haldemann, AFC; Kass, DM; Parker, TJ; Schofield, JT; Squyres, SW; Zurek, RW				Golombek, MP; Arvidson, RE; Bell, JF; Christensen, PR; Crisp, JA; Crumpler, LS; Ehlmann, BL; Fergason, RL; Grant, JA; Greeley, R; Haldemann, AFC; Kass, DM; Parker, TJ; Schofield, JT; Squyres, SW; Zurek, RW			Assessment of Mars Exploration Rover landing site predictions	NATURE			English	Article							THERMAL EMISSION SPECTROMETER; GUSEV CRATER; MERIDIANI-PLANUM; SPIRIT ROVER; MICROSCOPIC IMAGER; LOCALIZATION; OPPORTUNITY; SELECTION; DEPOSITS; SURFACE	Comprehensive analyses of remote sensing data during the three-year effort to select the Mars Exploration Rover landing sites at Gusev crater and at Meridiani Planum correctly predicted the atmospheric density profile during entry and descent and the safe and trafficable surfaces explored by the two rovers. The Gusev crater site was correctly predicted to be a low-relief surface that was less rocky than the Viking landing sites but comparably dusty. A dark, low-albedo, flat plain composed of basaltic sand and haematite with very few rocks was expected and found at Meridiani Planum. These results argue that future efforts to select safe landing sites based on existing and acquired remote sensing data will be successful. In contrast, geological interpretations of the sites based on remote sensing data were less certain and less successful, which emphasizes the inherent ambiguities in understanding surface geology from remotely sensed data and the uncertainty in predicting exactly what materials will be available for study at a landing site.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Washington Univ, St Louis, MO 63130 USA; Cornell Univ, Ithaca, NY 14853 USA; Arizona State Univ, Tempe, AZ 85287 USA; New Mexico Museum Nat Hist & Sci, Albuquerque, NM 87104 USA; Univ Oxford, Oxford OX1 3PG, England; Smithsonian Inst, Washington, DC 20560 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Washington University (WUSTL); Cornell University; Arizona State University; Arizona State University-Tempe; University of Oxford; Smithsonian Institution	Golombek, MP (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	mgolombek@jpl.nasa.gov	Haldemann, Albert F C/I-9224-2012; Crisp, Joy/H-8287-2016	Haldemann, Albert F C/0000-0003-3741-8841; Crisp, Joy/0000-0002-3202-4416				Anderson FS, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002125; Arvidson RE, 2004, SCIENCE, V306, P1730, DOI 10.1126/science.1104211; Arvidson RE, 2004, SCIENCE, V305, P821, DOI 10.1126/science.1099922; Arvidson RE, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001982; Bell JF, 2004, SCIENCE, V306, P1703, DOI 10.1126/science.1105245; Bell JF, 2004, SCIENCE, V305, P800, DOI 10.1126/science.1100175; Cabrol NA, 1998, ICARUS, V132, P362, DOI 10.1006/icar.1998.5903; CASTANO R, 2004, P 2004 IEEE AER C BI; Christensen, 1992, MARS, P686; Christensen PR, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2003JE002233; Christensen PR, 2004, SCIENCE, V305, P837, DOI 10.1126/science.1100564; CHRISTENSEN PR, 1986, ICARUS, V68, P217, DOI 10.1016/0019-1035(86)90020-5; Christensen PR, 2003, SCIENCE, V300, P2056, DOI 10.1126/science.1080885; Crisp JA, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE002038; EVANS JV, 1968, RADAR ASTRONOMY, P620; FERGASON RL, 2003, LUNAR PLANET SCI, V24; Golombek MP, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002074; Golombek MP, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE002035; Golombek MP, 1997, J GEOPHYS RES-PLANET, V102, P3967, DOI 10.1029/96JE03318; Grant JA, 2004, SCIENCE, V305, P807, DOI 10.1126/science.1099849; HAGFORS T, 1964, J GEOPHYS RES, V69, P3779, DOI 10.1029/JZ069i018p03779; Herkenhoff KE, 2004, SCIENCE, V306, P1727, DOI 10.1126/science.1105286; Herkenhoff KE, 2004, SCIENCE, V305, P824, DOI 10.1126/science.1100015; Kass DM, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002065; Kieffer H. H., 1977, Journal of Geophysical Research, V82, P4249, DOI 10.1029/JS082i028p04249; Kirk RL, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002131; LARSEN KW, 2004, LUNAR PLANET SCI, V35; Magalhaes JA, 1999, J GEOPHYS RES-PLANET, V104, P8943, DOI 10.1029/1998JE900041; Mellon MT, 2000, ICARUS, V148, P437, DOI 10.1006/icar.2000.6503; MOERSCH JE, 2005, LUNAR PLANET SCI, V36; Moore HJ, 1999, J GEOPHYS RES-PLANET, V104, P8729, DOI 10.1029/1998JE900005; Presley MA, 1997, J GEOPHYS RES-PLANET, V102, P6551, DOI 10.1029/96JE03303; Ruff SW, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001580; Shepard MK, 2001, J GEOPHYS RES-PLANET, V106, P32777, DOI 10.1029/2000JE001429; Smith DE, 2001, J GEOPHYS RES-PLANET, V106, P23689, DOI 10.1029/2000JE001364; Smith MD, 2004, ICARUS, V167, P148, DOI 10.1016/j.icarus.2003.09.010; Squyres SW, 2004, SCIENCE, V305, P794, DOI 10.1126/science.3050794; Squyres SW, 2004, SCIENCE, V306, P1709, DOI 10.1126/science.1104559	38	77	80	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 7	2005	436	7047					44	48		10.1038/nature03600	http://dx.doi.org/10.1038/nature03600			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	942QJ	16001058	Green Submitted			2022-12-28	WOS:000230296600035
J	Twelves, C; Wong, A; Nowacki, MP; Abt, M; Burris, H; Carrato, A; Cassidy, J; Cervantes, A; Fagerberg, J; Georgoulias, V; Husseini, F; Jodrell, D; Koralewski, P; Kroning, H; Maroun, J; Marschner, N; McKendrick, J; Pawlicki, M; Rosso, R; Schuller, J; Seitz, JF; Stabuc, B; Tujakowski, J; Van Hazel, G; Zaluski, J; Scheithauer, W				Twelves, C; Wong, A; Nowacki, MP; Abt, M; Burris, H; Carrato, A; Cassidy, J; Cervantes, A; Fagerberg, J; Georgoulias, V; Husseini, F; Jodrell, D; Koralewski, P; Kroning, H; Maroun, J; Marschner, N; McKendrick, J; Pawlicki, M; Rosso, R; Schuller, J; Seitz, JF; Stabuc, B; Tujakowski, J; Van Hazel, G; Zaluski, J; Scheithauer, W			Capecitabine as adjuvant treatment for stage III colon cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							5-FLUOROURACIL PLUS LEUCOVORIN; COLORECTAL-CANCER; ORAL CAPECITABINE; FOLINIC ACID; FLUOROURACIL; TRIAL; CHEMOTHERAPY; THERAPY; CARCINOMA; EFFICACY	BACKGROUND: Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting. METHODS: We randomly assigned a total of 1987 patients with resected stage III colon cancer to receive either oral capecitabine (1004 patients) or bolus fluorouracil plus leucovorin (Mayo Clinic regimen; 983 patients) over a period of 24 weeks. The primary efficacy end point was at least equivalence in disease-free survival; the primary safety end point was the incidence of grade 3 or 4 toxic effects due to fluoropyrimidines. RESULTS: Disease-free survival in the capecitabine group was at least equivalent to that in the fluorouracil-plus-leucovorin group (in the intention-to-treat analysis, P<0.001 for the comparison of the upper limit of the hazard ratio with the noninferiority margin of 1.20). Capecitabine improved relapse-free survival (hazard ratio, 0.86; 95 percent confidence interval, 0.74 to 0.99; P=0.04) and was associated with significantly fewer adverse events than fluorouracil plus leucovorin (P<0.001). CONCLUSIONS: Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.	Univ Leeds, Leeds, W Yorkshire, England; Bradford NHS Hosp Trust, Leeds, W Yorkshire, England; Univ Glasgow, Dept Med Oncol, Canc Res UK, Glasgow, Lanark, Scotland; Tom Baker Canc Clin, Calgary, AB, Canada; Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland; Inst Oncol, Warsaw, Poland; Hoffmann La Roche AG, Basel, Switzerland; Sarah Cannon Canc Ctr, Nashville, TN USA; Hosp Gen Elche, Alicante, Spain; Univ Aberdeen, Dept Med & Therapeut, Aberdeen, Scotland; Hosp Clin, Valencia, Spain; Univ Hosp Crete, Iraklion, Greece; Hop Louis Pasteur, Colmar, France; Univ Edinburgh, Edinburgh, Midlothian, Scotland; Rydgier Mem Hosp, Krakow, Poland; Stad Klinikum Magdeburg, Magdeburg, Germany; Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada; Outpatient Canc Ctr, Freiburg, Germany; Box Hill Hosp, Melbourne, Vic, Australia; Inst Canc Res, Krakow, Poland; Inst Nazl Ric Canc, Genoa, Italy; Krankenanstalt Rudolfstiftung Wien, Vienna, Austria; Hop Enfants La Timone, Marseille, France; Klin Ctr Ljubljana, Ljubljana, Slovenia; Reg Ctr Oncol, Bydgoszcz, Poland; Mt Hosp, Perth Oncol, Perth, Australia; Great Poland Canc Ctr, Poznan, Poland; Univ Kliniken Wien, Allgemeines Krankenhaus, Vienna, Austria	University of Leeds; Beatson Institute; Cancer Research UK; University of Glasgow; Tom Baker Cancer Clinic; University of Calgary; Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; Roche Holding; Sarah Cannon Research Institute; University of Aberdeen; University of Crete; University of Edinburgh; University of Ottawa; Ottawa Hospital Research Institute; Box Hill Hospital; University of Genoa; IRCCS AOU San Martino IST; Rudolfstiftung Hospital; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Wielkopolskie Centrum Onkologii	Twelves, C (corresponding author), Univ Bradford, Tom Connors Canc Res Ctr, Richmond Rd, Bradford BD7 1DP, W Yorkshire, England.	c.twelves@bradford.ac.uk	; Cervantes, Andres/J-8713-2013	CARRATO, ALFREDO/0000-0001-7749-8140; Cervantes, Andres/0000-0003-3806-3691				Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Andre T, 2003, J CLIN ONCOL, V21, P2896, DOI 10.1200/JCO.2003.10.065; Arkenau HT, 2003, ANN ONCOL, V14, P395, DOI 10.1093/annonc/mdg100; Ayanian JZ, 2003, J CLIN ONCOL, V21, P1293, DOI 10.1200/JCO.2003.06.178; Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063; Borner MM, 2002, EUR J CANCER, V38, P349, DOI 10.1016/S0959-8049(01)00371-9; Cassidy J, 2002, ANN ONCOL, V13, P566, DOI 10.1093/annonc/mdf089; Diaz-Rubio E, 2004, PROG P AM SOC CLIN O, V23, P304; Du XL, 2003, ANN INTERN MED, V139, P873; Du XLL, 2003, ANN INTERN MED, V138, P90, DOI 10.7326/0003-4819-138-2-200301210-00009; Edwards BK, 2002, CANCER-AM CANCER SOC, V94, P2766, DOI 10.1002/cncr.10593; Grothey A, 2002, MED KLIN, V97, P270, DOI 10.1007/s00063-002-1153-9; Haller DG, 1998, P AN M AM SOC CLIN, V17, p256a; Hensley Alford S, 2003, P AN M AM SOC CLIN, V22, P748; LABIANCA R, 1995, LANCET, V345, P939; Liu G, 1997, J CLIN ONCOL, V15, P110, DOI 10.1200/JCO.1997.15.1.110; Miwa M, 1998, EUR J CANCER, V34, P1274, DOI 10.1016/S0959-8049(98)00058-6; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; POPLIN E, 2000, P AN M AM SOC CLIN, V19, pA240; Porschen R, 2001, J CLIN ONCOL, V19, P1787, DOI 10.1200/JCO.2001.19.6.1787; Saini A, 2003, BRIT J CANCER, V88, P1859, DOI 10.1038/sj.bjc.6600995; Sargent DJ, 2004, P AN M AM SOC CLIN, V23, P246; Scheithauer W, 2003, ANN ONCOL, V14, P1735, DOI 10.1093/annonc/mdg500; Schuller J, 2000, CANCER CHEMOTH PHARM, V45, P291, DOI 10.1007/s002800050043; Stewart BW, 2003, WORLD CANC REPORT, P198; Twelves C, 2001, EUR J CANCER, V37, P597, DOI 10.1016/S0959-8049(00)00444-5; Van Cutsem E, 2002, EUR J CANCER, V38, P1429, DOI 10.1016/S0959-8049(02)00122-3; Van Cutsem E, 2004, BRIT J CANCER, V90, P1190, DOI 10.1038/sj.bjc.6601676; Wolmark N, 1999, J CLIN ONCOL, V17, P3553, DOI 10.1200/JCO.1999.17.11.3553	30	923	965	2	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					2696	2704		10.1056/NEJMoa043116	http://dx.doi.org/10.1056/NEJMoa043116			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	940HH	15987918	Bronze			2022-12-28	WOS:000230133800006
J	Alvarez, VM				Alvarez, VM			Guiltless resignation	LANCET			English	Editorial Material									Makati Med Ctr, Makati 1229, Philippines	Makati Medical Center	Alvarez, VM (corresponding author), Makati Med Ctr, 2 Amorsolo St, Makati 1229, Philippines.	docvical@yahoo.com							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	2005	365	9478					2240	2242		10.1016/S0140-6736(05)66783-9	http://dx.doi.org/10.1016/S0140-6736(05)66783-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978933				2022-12-28	WOS:000230034800035
J	Johnson, N; Barlow, D; Lethaby, A; Tavender, E; Curr, L; Garry, R				Johnson, N; Barlow, D; Lethaby, A; Tavender, E; Curr, L; Garry, R			Methods of hysterectomy: systematic review and meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ASSISTED VAGINAL HYSTERECTOMY; TOTAL ABDOMINAL HYSTERECTOMY; TOTAL LAPAROSCOPIC HYSTERECTOMY; ENLARGED UTERI; CLINICAL-TRIAL; MULTICENTER; LAVH	Objective To evaluate the most appropriate surgical method of hysterectomy (abdominal, vaginal, or laparoscopic) for women with benign disease. Design Systematic review and meta-analysis. Data sources Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials, Medline, Embase, and Biological Abstracts. Selection of studies Only randomised controlled trials were selected; participants had to have benign gynaecological disease; interventions had to comprise at least one hysterectomy method compared with another; and trials had to report primary outcomes (time taken to return to normal activities, intraoperative visceral injury, and major long term complications) or secondary outcomes (operating time, other immediate complications of surgery, short term complications, and duration of hospital stay). Results 27 trials (total of 3643 participants) were included. Return to normal activities was quicker after vaginal than after abdominal hysterectomy (weighted mean difference 9.5 (95% confidence interval 6.4 to 12.6) days) and after laparoscopic than after abdominal hysterectomy (difference 13.6 (11.8 to 15.4)) days, but was not significantly different for laparoscopic versus vaginal hysterectomy (difference -1.1 (-4.2 to 2.1) days). There were more urinary tract injuries with laparoscopic than with abdominal hysterectomy (odds ratio 2.61 (95% confidence interval 1.22 to 5.60)), but no other intraoperative visceral injuries showed a significant difference between surgical approaches. Data were notably absent for many important long term patient outcome measures, where the analyses were underpowered to detect important differences, or they were simply not reported in trials. Conclusions Significantly speedier return to normal activities and other improved secondary outcomes (shorter duration of hospital stay and fewer unspecified infections or febrile episodes) suggest that vaginal hysterectomy is preferable to abdominal hysterectomy where possible. Where vaginal hysterectomy is not possible, laparoscopic hysterectomy is preferable to abdominal hysterectomy, although it brings a higher chance of bladder or ureter injury.	Univ Auckland, Auckland Hosp, Natl Womens Dept Obstet & Gynaecol, Auckland, New Zealand; John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England; Univ Manchester, Cochrane Oral Hlth Grp, Manchester M13 9PL, Lancs, England; Univ Western Australia, Dept Obstet & Gynaecol, Perth, WA 6009, Australia	Auckland City Hospital; University of Auckland; University of Oxford; University of Manchester; University of Western Australia	Johnson, N (corresponding author), Univ Auckland, Auckland Hosp, Natl Womens Dept Obstet & Gynaecol, Auckland, New Zealand.	njohnson@auckland.ac.nz		Tavender, Emma/0000-0002-7230-712X				Apoola A., 1998, Journal of Obstetrics and Gynaecology (Abingdon), V18, P375; Benassi L, 2002, AM J OBSTET GYNECOL, V187, P1561, DOI 10.1067/mob.2002.127596; Chapron C, 1999, HUM REPROD, V14, P2464, DOI 10.1093/humrep/14.10.2464; Cucinella G, 2000, 16 FIGO WORLD C WASH, P45; Darai E, 2001, OBSTET GYNECOL, V97, P712, DOI 10.1016/S0029-7844(01)01194-2; DAVIES A, 1998, BR J OBSTET GYNAECOL; Ellstrom M, 1998, ACTA OBSTET GYN SCAN, V77, P923, DOI 10.1034/j.1600-0412.1998.770909.x; Ellstrom MA, 2003, ACTA OBSTET GYN SCAN, V82, P871, DOI 10.1034/j.1600-0412.2003.00216.x; Falcone T, 1999, AM J OBSTET GYNECOL, V180, P955, DOI 10.1016/S0002-9378(99)70667-8; Farquhar CM, 2002, OBSTET GYNECOL, V99, P229, DOI 10.1016/S0029-7844(01)01723-9; Ferrari MM, 2000, BRIT J OBSTET GYNAEC, V107, P620, DOI 10.1111/j.1471-0528.2000.tb13303.x; Garry R, 2004, BRIT MED J, V328, P129, DOI 10.1136/bmj.37984.623889.F6; Garry R, 1998, GYNAECOL ENDOSC, V7, P225, DOI 10.1046/j.1365-2508.1998.00217.x; Garry R, 1994, GYNAECOL ENDOSC, V3, P1; Hahlin M, 1994, Lakartidningen, V91, P220; Harkki-Siren P, 2000, ACTA OBSTET GYN SCAN, V79, P866, DOI 10.1034/j.1600-0412.2000.079010866.x; HarkkiSiren P, 1997, AM J OBSTET GYNECOL, V176, P118, DOI 10.1016/S0002-9378(97)80023-3; Holub Z, 2000, EUR J OBSTET GYN R B, V90, P31, DOI 10.1016/S0301-2115(99)00221-3; HOWARD FM, 1993, J GYNECOL SURG, V9, P83, DOI 10.1089/gyn.1993.9.83; Hwang JL, 2002, ACTA OBSTET GYN SCAN, V81, P1132, DOI 10.1034/j.1600-0412.2002.811206.x; Johnson N, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003677.pub2, 10.1002/14651858.CD003718.pub2]; Kunz G, 1996, GEBURTSH FRAUENHEILK, V56, P453, DOI 10.1055/s-2007-1022286; Langebrekke A, 1996, ACTA OBSTET GYN SCAN, V75, P404, DOI 10.3109/00016349609033340; Long CY, 2002, GYNECOL OBSTET INVES, V53, P214, DOI 10.1159/000064567; Lumsden MA, 2000, BRIT J OBSTET GYNAEC, V107, P1386, DOI 10.1111/j.1471-0528.2000.tb11653.x; Marana R, 1999, AM J OBSTET GYNECOL, V180, P270, DOI 10.1016/S0002-9378(99)70199-7; Miskry T, 2003, ACTA OBSTET GYN SCAN, V82, P351, DOI 10.1034/j.1600-0412.2003.00115.x; Moller C, 2001, EUR J OBSTET GYN R B, V98, P18, DOI 10.1016/S0301-2115(01)00342-6; NEZHAT F, 1992, J REPROD MED, V37, P247; Olsson JH, 1996, BRIT J OBSTET GYNAEC, V103, P345, DOI 10.1111/j.1471-0528.1996.tb09740.x; OSCARSON U, 2003, INT J OBSTET GYNECOL, V2, P42; Ottosen C, 2000, BRIT J OBSTET GYNAEC, V107, P1380; Pabuccu R, 1996, HUMAN REPROD, V11, P235; PARK NH, 2003, INT J OBSTET GYNECOL, V2, P79; Perino A, 1999, HUM REPROD, V14, P2996, DOI 10.1093/humrep/14.12.2996; Petrucco OM, 1999, 9 ANN SCI M AUSTR GY, P75; Phillips, 1995, GYNAECOL ENDOSC, V4, P77; PHIPPS JH, 1993, BRIT J OBSTET GYNAEC, V100, P698, DOI 10.1111/j.1471-0528.1993.tb14246.x; RAJU KS, 1994, BRIT J OBSTET GYNAEC, V101, P1068, DOI 10.1111/j.1471-0528.1994.tb13583.x; Reich H, 2003, REV GYNAECOLOGICAL P, V3, P32, DOI DOI 10.1016/S1471-7697(03)00008-X; Ribeiro SC, 2003, INT J GYNECOL OBSTET, V83, P37, DOI 10.1016/S0020-7292(03)00271-6; RICHARDSON RE, 1995, LANCET, V345, P36, DOI 10.1016/S0140-6736(95)91158-8; Schutz K, 2002, SURG ENDOSC, V16, P121, DOI 10.1007/s00464-001-0049-8; Seracchioli R, 2002, J AM ASSOC GYN LAP, V9, P333, DOI 10.1016/S1074-3804(05)60413-6; Soriano D, 2001, ACTA OBSTET GYN SCAN, V80, P337, DOI 10.1034/j.1600-0412.2001.080004337.x; SUMMITT RL, 1992, OBSTET GYNECOL, V80, P895; Summitt RL, 1998, OBSTET GYNECOL, V92, P321, DOI 10.1016/S0029-7844(98)00229-4; Tsai EM, 2003, GYNECOL OBSTET INVES, V55, P105, DOI 10.1159/000070182; Yuen PM, 1998, AM J OBSTET GYNECOL, V179, P1, DOI 10.1016/S0002-9378(98)70243-1	49	278	304	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 25	2005	330	7506					1478	1481		10.1136/bmj.330.7506.1478	http://dx.doi.org/10.1136/bmj.330.7506.1478			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942NR	15976422	Green Published, Bronze			2022-12-28	WOS:000230289600018
J	Kinra, S; Lewendon, G; Nelder, R; Herriott, N; Mohan, R; Hort, M; Harrison, S; Murray, V				Kinra, S; Lewendon, G; Nelder, R; Herriott, N; Mohan, R; Hort, M; Harrison, S; Murray, V			Evacuation decisions in a chemical air pollution incident: cross sectional survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To compare the health outcomes in sheltered and evacuated populations after a chemical incident in a plastics factory. Design Cross sectional survey. Setting Urban area in southwest England. Participants 1750 residents from the area exposed to the chemical smoke, of which 472 were evacuated and the remaining 1278 were advised to shelter indoors. Main outcome measure Number of adverse health symptoms. A case was defined by the presence of four or more symptoms. Main results 1096 residents (63%; 299 evacuated, 797 sheltered) provided data for analyses. The mean symptom score and proportion of cases were higher in evacuated people than in the sheltered population (evacuated: symptom score 1.9, cases 19.7% (n=59); sheltered: symptom score 1.0, cases 9.5% (n=76); P<0.001 for both). The difference between the two groups attenuated markedly at the end of two weeks from the start of the incident. The two main modifiable risk factors for the odds of becoming a case were evacuation (odds ratio 2.5, 95% confidence interval 1.7 to 3.8) and direct exposure to smoke for more than two hours on the first day of the incident (2.0, 1.7 to 2.3). The distance of residence from the factory or level of exposure before intervention (first six hours) had little effect on the odds of a person becoming a case. Conclusions Sheltering may have been a better protective action than evacuation in this chemical incident, which is consistent with the prevailing expert view. Although this study has limitations, it is based oil a real event. Evacuations carry their own risks and resource implications; increased awareness may help to reduce unnecessary evacuations in the future.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Plymouth Teaching Primary Care Trust, Publ Hlth Dev Unit, Plymouth PL1 2AD, Devon, England; Guys & St Thomas Hosp Trust, Hlth Protect Agcy, Chem Hazards Unit, London SE14 5ER, England; SW Peninsula Hlth Protect Unit, Devon Team, Dartington TQ9 6JE, England	University of Bristol; University of Plymouth; Guy's & St Thomas' NHS Foundation Trust; Health Protection Agency	Kinra, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	Sanjay.Kinra@bristol.ac.uk						Bauer U, 1998, PUBLIC HEALTH REP, V113, P62; BAXTER PJ, 1995, OCCUP ENVIRON MED, V52, P694, DOI 10.1136/oem.52.10.694; BOFFETTA P, 1993, SCAND J WORK ENV HEA, V19, P67; DAYAL HH, 1994, J EPIDEMIOL COMMUN H, V48, P560, DOI 10.1136/jech.48.6.560; ESSERY G, 1994, SAFETY HLTH PRACTITI, V12, P22; ESSERY GL, 1991, J LOSS PREVENT PROC, V4, P44, DOI 10.1016/0950-4230(91)80006-G; Fiedler N, 1999, ENVIRON HEALTH PERSP, V107, P343, DOI 10.2307/3434537; GRAY J, 1981, J HAZARD MATER, V4, P357, DOI 10.1016/0304-3894(81)87006-9; JONES A, 2004, UK MET OFFICES NEXT, V3; JONES A, 2004, IN PRESS UK MET OFFI, V3; KIZER KW, 1984, J OCCUP ENVIRON MED, V26, P33, DOI 10.1097/00043764-198401000-00008; MORRIS RD, 1997, HUMAN HLTH EFFECTS S; *NAT TRANSP, 1983, RAILR ACC REP DER IL; *NAT TRANSP SAF BO, 1983, RAILR ACC REP DER IL; *NHS EX, 2000, DEL REL BIOL CHEM AG; PURDY G, 1985, ASSESSMENT CONTROL M; REGGIANI G, 1978, ARCH TOXICOL, V40, P161, DOI 10.1007/BF00364649; SORENSEN JH, 1987, J HAZARD MATER, V14, P247, DOI 10.1016/0304-3894(87)87017-6; Williams FLR, 2002, OCCUP ENVIRON MED, V59, P2, DOI 10.1136/oem.59.1.2	19	13	13	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 25	2005	330	7506					1471	1474		10.1136/bmj.330.7506.1471	http://dx.doi.org/10.1136/bmj.330.7506.1471			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942NR	15976419	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000230289600015
J	Tripati, A; Elderfield, H				Tripati, A; Elderfield, H			Deep-sea temperature and circulation changes at the Paleocene-Eocene thermal maximum	SCIENCE			English	Article							ISOTOPE EXCURSION; METHANE HYDRATE; WATER-VAPOR; DISSOCIATION; MG/CA; END	A rapid increase in greenhouse gas levels is thought to have fueled global warming at the Paleocene-Eocene Thermal Maximum (PETM). Foraminiferal magnesium/calcium ratios indicate that bottom waters warmed by 4 degrees to 5 degrees C, similar to tropical and subtropical surface ocean waters, implying no amplification of warming in high-latitude regions of deep-water formation under ice-free conditions. Intermediate waters warmed before the carbon isotope excursion, in association with downwelling in the North Pacific and reduced Southern Ocean convection, supporting changing circulation as the trigger for methane hydrate release. A switch to deep convection in the North Pacific at the PETM onset could have amplified and sustained warming.	Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England	University of Cambridge	Tripati, A (corresponding author), Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England.	atri02@esc.cam.ac.uk	Tripati, Aradhna/C-9419-2011	Tripati, Aradhna/0000-0002-1695-1754	Natural Environment Research Council [NE/C510583/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Beerling DJ, 2000, PALAEOGEOGR PALAEOCL, V161, P395, DOI 10.1016/S0031-0182(00)00095-X; BICE KL, 2002, PALEOCEANOGRAPHY, V17, P9; Bowen GJ, 2004, NATURE, V432, P495, DOI 10.1038/nature03115; Broecker W.S., 1982, TRACERS SEA; CORFIELD RM, 1992, TERRA NOVA, V4, P443, DOI 10.1111/j.1365-3121.1992.tb00579.x; Dickens GR, 1997, GEOLOGY, V25, P259, DOI 10.1130/0091-7613(1997)025<0259:ABOGIT>2.3.CO;2; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; Inamdar AK, 1998, J GEOPHYS RES-ATMOS, V103, P32177, DOI 10.1029/1998JD900007; KENNETT JP, 1991, NATURE, V353, P225, DOI 10.1038/353225a0; Knox RWO, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P91; KOCH PL, 1992, NATURE, V358, P319, DOI 10.1038/358319a0; Lear CH, 2002, GEOCHIM COSMOCHIM AC, V66, P3375, DOI 10.1016/S0016-7037(02)00941-9; Lear CH, 2000, SCIENCE, V287, P269, DOI 10.1126/science.287.5451.269; MANABE S, 1967, J ATMOS SCI, V24, P241, DOI 10.1175/1520-0469(1967)024<0241:TEOTAW>2.0.CO;2; Miller KG, 1987, PALEOCEANOGRAPHY, V2, P1, DOI 10.1029/PA002i001p00001; Pak DK, 1992, PALEOCEANOGRAPHY, V7, P405, DOI 10.1029/92PA01234; Ravizza G, 2001, PALEOCEANOGRAPHY, V16, P155, DOI 10.1029/2000PA000541; Renssen H, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2003PA000968; RIND D, 1991, NATURE, V349, P500, DOI 10.1038/349500a0; ROBERT C, 1994, GEOLOGY, V22, P211, DOI 10.1130/0091-7613(1994)022<0211:ASHEAT>2.3.CO;2; Schmidt GA, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000757; *SHIPB SCI PART, 2005, 302 ECORD SHIPB SCI; Stoll HM, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000875; Thomas DJ, 2003, EARTH PLANET SC LETT, V209, P309, DOI 10.1016/S0012-821X(03)00096-7; Thomas DJ, 2002, GEOLOGY, V30, P1067, DOI 10.1130/0091-7613(2002)030<1067:WTFFTF>2.0.CO;2; THOMAS E, 1996, CORRELATION EARLY PA, V0101; Tripati AK, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2003GC000631; WILKINSON BH, 1989, AM J SCI, V289, P1158, DOI 10.2475/ajs.289.10.1158; Zachos JC, 2003, SCIENCE, V302, P1551, DOI 10.1126/science.1090110	29	175	179	3	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	2005	308	5730					1894	1898		10.1126/science.1109202	http://dx.doi.org/10.1126/science.1109202			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976299				2022-12-28	WOS:000230120000036
J	Quiroga, RQ; Reddy, L; Kreiman, G; Koch, C; Fried, I				Quiroga, RQ; Reddy, L; Kreiman, G; Koch, C; Fried, I			Invariant visual representation by single neurons in the human brain	NATURE			English	Article							MEDIAL TEMPORAL-LOBE; INFEROTEMPORAL CORTEX; OBJECT RECOGNITION; MONKEY; FACES; MEMORY; HIPPOCAMPUS; POTENTIALS; AMYGDALA; CORTICES	It takes a fraction of a second to recognize a person or an object even when seen under strikingly different conditions. How such a robust, high-level representation is achieved by neurons in the human brain is still unclear(1-6). In monkeys, neurons in the upper stages of the ventral visual pathway respond to complex images such as faces and objects and show some degree of invariance to metric properties such as the stimulus size, position and viewing angle(2,4,7-12). We have previously shown that neurons in the human medial temporal lobe (MTL) fire selectively to images of faces, animals, objects or scenes(13,14). Here we report on a remarkable subset of MTL neurons that are selectively activated by strikingly different pictures of given individuals, landmarks or objects and in some cases even by letter strings with their names. These results suggest an invariant, sparse and explicit code, which might be important in the transformation of complex visual percepts into long-term and more abstract memories.	CALTECH, Pasadena, CA 91125 USA; Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90095 USA; MIT, Cambridge, MA 02142 USA; Tel Aviv Univ, Tel Aviv Med Ctr, Funct Neurosurg Unit, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	California Institute of Technology; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Massachusetts Institute of Technology (MIT); Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Quiroga, RQ (corresponding author), Univ Leicester, Dept Engn, Leicester LE1 7RH, Leics, England.	rodri@vis.caltech.edu	Reddy, Leila/C-2181-2009	Koch, Christof/0000-0001-6482-8067				Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; Ekstrom AD, 2003, NATURE, V425, P184, DOI 10.1038/nature01964; Fried I, 1997, NEURON, V18, P753, DOI 10.1016/S0896-6273(00)80315-3; GROSS CG, 1969, SCIENCE, V166, P1303, DOI 10.1126/science.166.3910.1303; Halgren E, 1998, ELECTROEN CLIN NEURO, V106, P156, DOI 10.1016/S0013-4694(97)00119-3; Hampson RE, 2004, P NATL ACAD SCI USA, V101, P3184, DOI 10.1073/pnas.0400162101; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Koch Christof, 2004, QUEST CONSCIOUSNESS; Konorski J., 1967, INTEGRATIVE ACTIVITY; Kreiman G, 2000, NAT NEUROSCI, V3, P946, DOI 10.1038/78868; LOGOTHETIS NK, 1995, CURR BIOL, V5, P552, DOI 10.1016/S0960-9822(95)00108-4; Logothetis NK, 1996, ANNU REV NEUROSCI, V19, P577, DOI 10.1146/annurev.ne.19.030196.003045; LOGOTHETIS NK, 1995, CEREB CORTEX, V3, P270; Macmillan N. A., 1991, DETECTION THEORY USE; MCCARTHY G, 1989, J NEUROSCI, V9, P4253; MISHASHITA Y, 1988, NATURE, V335, P817; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; Quiroga RQ, 2004, NEURAL COMPUT, V16, P1661, DOI 10.1162/089976604774201631; Riesenhuber M, 2002, CURR OPIN NEUROBIOL, V12, P162, DOI 10.1016/S0959-4388(02)00304-5; Saleem KS, 1996, J NEUROSCI, V16, P4757; SCHWARTZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P5776, DOI 10.1073/pnas.80.18.5776; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Suzuki WA, 1996, SEMIN NEUROSCI, V8, P3, DOI 10.1006/smns.1996.0002; Tanaka K, 1996, ANNU REV NEUROSCI, V19, P109, DOI 10.1146/annurev.ne.19.030196.000545; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577	30	1017	1035	12	211	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1102	1107		10.1038/nature03687	http://dx.doi.org/10.1038/nature03687			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973409				2022-12-28	WOS:000229970400050
J	Norris, SL; Atkins, D				Norris, SL; Atkins, D			Challenges in using nonrandomized studies in systematic reviews of treatment interventions	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED-TRIALS; CLINICAL-TRIALS; QUALITY	Randomized, controlled trials (RCTs) are firmly established as the standard for determining which medical treatments are effective. in some areas of health care, however, among them surgery, public health, and the organization of health care delivery, most evidence addressing the effectiveness of clinical or policy interventions rests on nonrandomized studies. We examine the use of study designs other than RCTs in Evidence-based Practice Center reports addressing questions of the effectiveness of treatment interventions. These reports offer the opportunity to examine the approaches used and the challenges faced by reviewers when nonrandomized studies are included and their quality assessed. We then offer recommendations for using these studies in systematic reviews of treatment interventions.	Ctr Outcomes & Evidence, Agcy Healthcare Res & Qual, Rockville, MD 20850 USA	Agency for Healthcare Research & Quality	Norris, SL (corresponding author), Ctr Outcomes & Evidence, Agcy Healthcare Res & Qual, Room 6325,540 Gaither Rd, Rockville, MD 20850 USA.	snorris@ahrq.gov						AMMERMANN A, 2001, AHRQ PUBLICATION; ARONSON N, 2001, AHRQ PUBLICATION; Atkins D, 2005, ANN INTERN MED, V142, P1035, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00002; BADER J, 2001, AHRQ PUBLICATION; BALK E, 2004, AHRQ PUBLICATION; BERKMAN ND, 2000, AHRQ PUBL; CHAPELL R, 2003, AHRQ PUBLICATION; Chou R, 2005, ANN INTERN MED, V142, P1090, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00009; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; COULTER ID, 2001, AHRQ PUBLICATION; Deeks J J, 2003, Health Technol Assess, V7, piii; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; FLAMM CR, 2002, AHRQ PUBLICATION; GEBO K, 2002, AHRQ PUBLICATION; GOUDAS L, 2001, AHRQ PUBLICATION; GUISE JM, 2003, AHRQ PUBLICATION; HARDY M, 2001, AHRQ PUBLICATION; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HOLTZMANN J, 2004, AHRQ PUBLICATION; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Kane RL, 2003, AHRQ PUBLICATION; LAWRENCE V, 2000, AHRQ PUBLICATION; MacLean CH, 2004, AHRQ PUBLICATION, V04-E012-2; MCDONAGH M, AHRQ PUBLICATION; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; PIPER M, 2004, AHRQ PUBLICATION; Pocock SJ., 2013, CLIN TRIALS PRACTICA; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shekelle P, 2003, AHRQ PUBLICATION, V03-E023; SHEKELLE PG, 2004, AHRQ PUBLICATION; Tatsioni A, 2005, ANN INTERN MED, V142, P1048, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00004; Zaza S, 2001, AM J PREV MED, V21, P23, DOI 10.1016/S0749-3797(01)00379-8; 1979, CAN MED ASS J, V121, P1193	36	74	81	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1112	1119		10.7326/0003-4819-142-12_Part_2-200506211-00011	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938CN	15968036				2022-12-28	WOS:000229977600011
J	Burgess, IF; Brown, CM; Lee, PN				Burgess, IF; Brown, CM; Lee, PN			Treatment of head louse infestation with 4% dimeticone lotion: randomised controlled equivalence trial	BRITISH MEDICAL JOURNAL			English	Article							LICE; RESISTANCE; PERMETHRIN; MALATHION	Objective To evaluate the efficacy and safety of 4% dimeticone lotion for treatment of head louse infestation. Design Randomised controlled equivalence trial. Setting Community, with home visits. Participants 214 young people aged 4 to 18 years and 39 adults with active head louse infestation. Interventions Two applications seven days apart of either 4.0% dimeticone lotion, applied for eight hours or overnight, or 0.5% phenothrin liquid, applied for 12 hours or overnight. Outcome measures Cure of infestation (no evidence of head lice after second treatment) or reinfestation after cure. Results Cure or reinfestation after cure occurred in 89 of 127 (70%) participants treated with dimeticone and 94 of 125 (75%) treated with phenothrin (difference - 5%, 95% confidence interval - 16% to 6%). Per protocol analysis showed that 84 of 121 (69%) participants were cured with dimeticone and 90 of 116 (78%) were cured with phenothrin. Irritant reactions occurred significantly less with dimeticone (3/127,2%) than with phenothrin (11/125,9%; difference - 6%, - 12% to - I No). Per protocol this was 3 of 121 (3%) participants treated with dimeticone mid 10 of 116 (9%) treated with phenothrin (difference - 6%, - 12% to - 0.3%). Conclusion Dimeticone lotion cures head louse infestation. Dimeticone seems less irritant than existing treatments and has a physical action on lice that should not be affected by resistance to neurotoxic insecticides.	Insect Res & Dev, Royston SG8 6QZ, Yorks, England; PN Lee Stat & Comp, Surrey SM2 5DA, England	PN Lee Statistics & Computing Ltd	Burgess, IF (corresponding author), Insect Res & Dev, Royston SG8 6QZ, Yorks, England.	IFBurgessian@insectresearch.com	Burgess, Ian/N-2977-2013	Burgess, Ian/0000-0003-0747-3938; Lee, Peter/0000-0002-8244-1904				Bingham P, 2000, PUBLIC HEALTH, V114, P265, DOI 10.1016/S0033-3506(00)00342-5; BURGESS IF, 1995, BRIT MED J, V311, P752, DOI 10.1136/bmj.311.7007.752; BURGESS IF, 1999, DERMATOPHARMACOLOGY, P157; DODD CS, 2003, COCHRANE LIB; Downs AMR, 1999, PARASITOL TODAY, V15, P1, DOI 10.1016/S0169-4758(98)01361-1; Downs AMR, 1999, BRIT J DERMATOL, V141, P508, DOI 10.1046/j.1365-2133.1999.03046.x; HILL N, 2005, IN PRESS BMJ; Ibarra J, 2000, LANCET, V356, P2007, DOI 10.1016/S0140-6736(05)72974-3; IBARRA J, 1992, PROF CARE MOTHER CHI, V2, P241; Meinking TL, 2002, J PEDIATR-US, V141, P665, DOI 10.1067/mpd.2002.129031; Mumcuoglu KY, 2001, PEDIATR DERMATOL, V18, P9, DOI 10.1046/j.1525-1470.2001.018001009.x; Plastow L, 2001, J CLIN NURS, V10, P775, DOI 10.1046/j.1365-2702.2001.00541.x; Roberts RJ, 2000, LANCET, V356, P540, DOI 10.1016/S0140-6736(00)02578-2	13	70	77	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 18	2005	330	7505					1423	1425		10.1136/bmj.38497.506481.8F	http://dx.doi.org/10.1136/bmj.38497.506481.8F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938NP	15951310	Green Published, Bronze			2022-12-28	WOS:000230010400018
J	Hillman, K; Chen, J; Cretikos, M; Bellomo, R; Brown, D; Doig, G; Finfer, S; Flabouris, A				Hillman, K; Chen, J; Cretikos, M; Bellomo, R; Brown, D; Doig, G; Finfer, S; Flabouris, A		MERIT Study Investigators	Introduction of the medical emergency team (MET) system: a cluster-randomised controlled trial	LANCET			English	Article							INTENSIVE-CARE ADMISSIONS; HOSPITALIZED-PATIENTS; CARDIAC ARRESTS; ADVERSE EVENTS; TRAUMA CARE; ANTECEDENTS; MORTALITY; QUALITY; DEATHS	Background Patients with cardiac arrests or who die in general wards have often received delayed or inadequate care. We investigated whether the medical emergency team (MET) system could reduce the incidence of cardiac arrests, unplanned admissions to intensive care units (ICU), and deaths. Methods We randomised 23 hospitals in Australia to continue functioning as usual (n=11) or to introduce a MET system (n=12). The primary outcome was the composite of cardiac arrest, unexpected death, or unplanned ICU admission during the 6-month study period after MET activation. Analysis was by intention to treat. Findings Introduction of the MET increased the overall calling incidence for an emergency team (3.1 vs 8.7 per 1000 admissions, p=0.0001). The MET was called to 30% of patients who fulfilled the calling criteria and who were subsequently admitted to the ICU. During the study, we recorded similar incidence of the composite primary outcome in the control and MET hospitals (5.86 vs 5.31 per 1000 admissions, p=0.640), as well as of the individual secondary outcomes (cardiac arrests, 1.64 vs 1.31, p=0.736; unplanned ICU admissions, 4.68 vs 4.19, p=0.599; and unexpected deaths, 1.18 vs 1.06, p=0.752). A reduction in the rate of cardiac arrests (p=0.003) and unexpected deaths (p=0.01) was seen from baseline to the study period for both groups combined. Interpretation The MET system greatly increases emergency team calling, but does not substantially affect the incidence of cardiac arrest, unplanned ICU admissions, or unexpected death.	Univ New S Wales, Liverpool Hosp, Div Crit Care, Sydney, NSW 1871, Australia	Liverpool Hospital; University of New South Wales Sydney	Hillman, K (corresponding author), Univ New S Wales, Liverpool Hosp, Div Crit Care, Locked Bag 7103, Sydney, NSW 1871, Australia.	K.Hillman@unsw.edu.au	Chen, Jack/AAR-7346-2020; Hillman, Ken/P-6539-2015; Flabouris, Arthas/L-1347-2019; Flabouris, Arthas/AAF-9477-2019	Hillman, Ken/0000-0001-8241-0166; Flabouris, Arthas/0000-0002-1535-9441; Chen, Jack/0000-0003-4693-5234; Doig, Gordon/0000-0003-2141-7000; Finfer, Simon/0000-0002-2785-5864; Bellomo, Rinaldo/0000-0002-1650-8939				*APN BUS INF GROUP, 2001, AUSTR HOSP HLTH SERV; Bellomo R, 2003, MED J AUSTRALIA, V179, P283, DOI 10.5694/j.1326-5377.2003.tb05548.x; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Bristow PJ, 2000, MED J AUSTRALIA, V173, P236, DOI 10.5694/j.1326-5377.2000.tb125627.x; Buist MD, 2002, BRIT MED J, V324, P387, DOI 10.1136/bmj.324.7334.387; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Campbell MK, 2000, FAM PRACT, V17, P192, DOI 10.1093/fampra/17.2.192; DeVita MA, 2004, QUAL SAF HEALTH CARE, V13, P251, DOI 10.1136/qshc.2003.006585; Goldhill DR, 1999, ANAESTHESIA, V54, P529, DOI 10.1046/j.1365-2044.1999.00837.x; Hillman KM, 2001, INTERN MED J, V31, P343, DOI 10.1046/j.1445-5994.2001.00077.x; Hox J.J., 2017, MULTILEVEL ANAL TECH, V3rd ed., P1, DOI [10.4324/9781315650982, DOI 10.4324/9781315650982]; Johnston J., 1997, ECONOMETRIC METHODS; Kause J, 2004, RESUSCITATION, V62, P275, DOI 10.1016/j.resuscitation.2004.05.016; Kerridge RK, 2003, MED J AUSTRALIA, V179, P313, DOI 10.5694/j.1326-5377.2003.tb05556.x; Kerry SM, 1998, BRIT MED J, V316, P549, DOI 10.1136/bmj.316.7130.549; Kish L, 1995, J OFF STAT, V11, P55, DOI 10.4135/9780857020116.n132; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Lecky F, 2000, LANCET, V355, P1771, DOI 10.1016/S0140-6736(00)02264-9; LEE A, 1995, ANAESTH INTENS CARE, V23, P183, DOI 10.1177/0310057X9502300210; McQuillan P, 1998, BMJ-BRIT MED J, V316, P1853; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; *STAT CORP, 2003, STAT STAT SOFTW REL; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x	24	920	943	0	41	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 18	2005	365	9477					2091	2097						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964445				2022-12-28	WOS:000229858800025
J	Dou, YL; Milne, TA; Tackett, AJ; Smith, ER; Fukuda, A; Wysocka, J; Allis, CD; Chait, BT; Hess, JL; Roeder, RG				Dou, YL; Milne, TA; Tackett, AJ; Smith, ER; Fukuda, A; Wysocka, J; Allis, CD; Chait, BT; Hess, JL; Roeder, RG			Physical association and coordinate function of the H3K4 methyltransferase MLL1 and the H4K16 acetyltransferase MOF	CELL			English	Article							HISTONE H4 ACETYLATION; CHROMATIN IN-VITRO; DOSAGE COMPENSATION; MASS-SPECTROMETRY; GENE-EXPRESSION; METHYLATION; COMPLEX; DROSOPHILA; TRANSCRIPTION; TRITHORAX	A stable complex containing MILL1 and MOF has been immunoaffinity purified from a human cell line that stably expresses an epitope-tagged WDR5 subunit. Stable interactions between MILL1 and MOF were confirmed by reciprocal immunoprecipitation, cosedimentation, and cotransfection analyses, and interaction sites were mapped to MLL1 C-terminal and MOF zinc finger domains. The purified complex has a robust MILL1-mediated histone methyltransferase activity that can effect mono-, di-, and trimethylation of H3 K4 and a MOF-mediated histone acetyltransferase activity that is specific for H4 K16. Importantly, both activities are required for optimal transcription activation on a chromatin template in vitro and on an endogenous MLL1 target gene, Hox a9, in vivo. These results indicate an activator-based mechanism for joint MILLI1 and MOF recruitment and targeted methylation and acetylation and provide a molecular explanation for the closely correlated distribution of H3 K4 methylation and H4 K16 acetylation on active genes.	Rockefeller Univ, Lab Biochem & Mol Biol, New York, NY 10021 USA; Rockefeller Univ, Lab Chromatin Biol, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Rockefeller University; Rockefeller University; Rockefeller University; University of Pennsylvania	Roeder, RG (corresponding author), Rockefeller Univ, Lab Biochem & Mol Biol, New York, NY 10021 USA.	roeder@mail.rockefeller.edu	Milne, Tom/E-1872-2016	Milne, Tom/0000-0002-0413-4271				Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; An WJ, 2004, METHOD ENZYMOL, V377, P460; Beisel C, 2002, NATURE, V419, P857, DOI 10.1038/nature01126; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Corona DFV, 2002, EMBO REP, V3, P242, DOI 10.1093/embo-reports/kvf056; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Fujimoto S, 1998, GENE, V209, P77, DOI 10.1016/S0378-1119(98)00014-6; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Krutchinsky AN, 2000, J AM SOC MASS SPECTR, V11, P493, DOI 10.1016/S1044-0305(00)00114-8; Krutchinsky AN, 2001, ANAL CHEM, V73, P5066, DOI 10.1021/ac010682o; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Luger K, 1999, METHOD ENZYMOL, V304, P3; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Morales V, 2004, EMBO J, V23, P2258, DOI 10.1038/sj.emboj.7600235; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Neal KC, 2000, BBA-GENE STRUCT EXPR, V1490, P170, DOI 10.1016/S0167-4781(99)00211-0; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Owen-Hughes T, 1999, METH MOL B, V119, P319; Petruk S, 2001, SCIENCE, V294, P1331, DOI 10.1126/science.1065683; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Smith CM, 2003, ANAL BIOCHEM, V316, P23, DOI 10.1016/S0003-2697(03)00032-0; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Smith ER, 2001, J BIOL CHEM, V276, P31483, DOI 10.1074/jbc.C100351200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; VAQUERO A, 2002, SCI AGING KNOWLEDGE, pRE4; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zhang KL, 2004, PROTEOMICS, V4, P3765, DOI 10.1002/pmic.200400819; Zhang KL, 2002, MOL CELL PROTEOMICS, V1, P500, DOI 10.1074/mcp.M200031-MCP200	51	507	549	1	55	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	2005	121	6					873	885		10.1016/j.cell.2005.04.031	http://dx.doi.org/10.1016/j.cell.2005.04.031			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960975	Bronze			2022-12-28	WOS:000230011200010
J	Abrams, J				Abrams, J			Chronic stable angina	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY-DISEASE; ENHANCED EXTERNAL COUNTERPULSATION; ASSOCIATION TASK-FORCE; BETA-BLOCKER THERAPY; C-REACTIVE PROTEIN; MYOCARDIAL-INFARCTION; NITRATE TOLERANCE; AMERICAN-COLLEGE; CARDIOVASCULAR EVENTS; HEART-DISEASE		Univ New Mexico, Dept Internal Med, Div Cardiol, Albuquerque, NM 87131 USA	University of New Mexico	Abrams, J (corresponding author), Univ New Mexico, Dept Internal Med, Div Cardiol, Albuquerque, NM 87131 USA.	jabrams@salud.unm.edu	Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				Al Suwaidi J, 2004, AM HEART J, V147, P815, DOI 10.1016/j.ahj.2003.11.025; Allen KB, 1999, NEW ENGL J MED, V341, P1029, DOI 10.1056/NEJM199909303411403; ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, 2002, JAMA-J AM MED ASSOC, V288, P2981; Arora RR, 1999, J AM COLL CARDIOL, V33, P1833, DOI 10.1016/S0735-1097(99)00140-0; BELL MR, 1995, J AM COLL CARDIOL, V25, P1650, DOI 10.1016/0735-1097(95)00044-5; Bello N, 2004, PROG CARDIOVASC DIS, V46, P287, DOI 10.1016/j.pcad.2003.08.001; Berger PB, 2004, CIRCULATION, V109, P1079, DOI 10.1161/01.CIR.0000121313.22131.41; Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Bridges CR, 2004, ANN THORAC SURG, V77, P1494, DOI 10.1016/j.athoracsur.2004.01.007; Bucher HC, 2000, BMJ-BRIT MED J, V321, P73, DOI 10.1136/bmj.321.7253.73; Bugiardini R, 2005, JAMA-J AM MED ASSOC, V293, P477, DOI 10.1001/jama.293.4.477; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Chaitman BR, 2004, J AM COLL CARDIOL, V43, P1375, DOI 10.1016/j.jacc.2003.11.045; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; Eagle Kim A, 2004, Circulation, V110, P1168, DOI 10.1161/01.CIR.0000138790.14877.7D; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Fox KM, 2003, LANCET, V362, P782; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; GAGE JE, 1986, CIRCULATION, V73, P865, DOI 10.1161/01.CIR.73.5.865; Gibbons RJ, 2003, CIRCULATION, V107, P149, DOI 10.1161/01.CIR.0000047041.66447.29; Gielen S, 2001, CIRCULATION, V103, pE1; Gori T, 2002, CIRCULATION, V106, P2404, DOI 10.1161/01.CIR.0000036742.52907.91; Gori T, 2002, CIRCULATION, V106, P2510, DOI 10.1161/01.CIR.0000036743.07406.53; Greenland P, 2003, NEW ENGL J MED, V349, P465, DOI 10.1056/NEJMcp023197; Greenland P, 2002, INT J EPIDEMIOL, V31, P1129, DOI 10.1093/ije/31.6.1129; Grundy Scott M, 2004, J Am Coll Cardiol, V44, P720, DOI 10.1016/j.jacc.2004.07.001; Halcox JPJ, 2002, CIRCULATION, V106, P653, DOI 10.1161/01.CIR.0000025404.78001.D8; Hambrecht R, 2004, CIRCULATION, V109, P1371, DOI 10.1161/01.CIR.0000121360.31954.1F; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; Heidenreich PA, 1999, JAMA-J AM MED ASSOC, V281, P1927, DOI 10.1001/jama.281.20.1927; Henderson RA, 2003, J AM COLL CARDIOL, V42, P1161, DOI 10.1016/S0735-1097(03)00951-3; Hoffman SN, 2003, J AM COLL CARDIOL, V41, P1293, DOI 10.1016/S0735-1097(03)00157-8; Hueb W, 2004, J AM COLL CARDIOL, V43, P1743, DOI 10.1016/j.jacc.2003.08.065; Kernis SJ, 2004, J AM COLL CARDIOL, V43, P1773, DOI 10.1016/j.jacc.2003.09.071; Klocke FJ, 2003, CIRCULATION, V108, P1404, DOI 10.1161/01.CIR.0000080946.42225.4D; Ko DT, 2002, JAMA-J AM MED ASSOC, V288, P351, DOI 10.1001/jama.288.3.351; Kragelund C, 2005, NEW ENGL J MED, V352, P666, DOI 10.1056/NEJMoa042330; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Lee TH, 2001, NEW ENGL J MED, V344, P1840, DOI 10.1056/NEJM200106143442406; Marzilli M, 2003, CORONARY ARTERY DIS, V14, P171, DOI 10.1097/00019501-200304000-00010; Merz CNB, 2001, AM J MANAG CARE, V7, P959; Michaels AD, 2004, AM J CARDIOL, V93, P461, DOI 10.1016/j.amjcard.2003.10.044; MUNZEL T, 1995, J CLIN INVEST, V95, P187, DOI 10.1172/JCI117637; Nissen SE, 2005, NEW ENGL J MED, V352, P29, DOI 10.1056/NEJMoa042000; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; PEDERSEN TR, 1994, LANCET, V344, P1383; PEPINE CJ, 1994, AM J CARDIOL, V74, P226, DOI 10.1016/0002-9149(94)90361-1; Reis SE, 2001, AM HEART J, V141, P735, DOI 10.1067/mhj.2001.114198; Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378; Rihal CS, 2003, CIRCULATION, V108, P2439, DOI 10.1161/01.CIR.0000094405.21583.7C; Sangareddi V, 2004, CORONARY ARTERY DIS, V15, P111, DOI 10.1097/00019501-200403000-00007; Schoenhagen P, 2000, CIRCULATION, V101, P598, DOI 10.1161/01.CIR.101.6.598; Shah PK, 2003, J AM COLL CARDIOL, V41, p15S, DOI 10.1016/S0735-1097(02)02834-6; Snow V, 2004, ANN INTERN MED, V141, P57, DOI 10.7326/0003-4819-141-1-200407060-00015; Thadani U, 1999, CURR OPIN CARDIOL, V14, P349, DOI 10.1097/00001573-199907000-00011; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Turnbull F, 2003, LANCET, V362, P1527; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zouridakis E, 2004, CIRCULATION, V110, P1747, DOI 10.1161/01.CIR.0000142664.18739.92	61	160	167	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2005	352	24					2524	2533		10.1056/NEJMcp042317	http://dx.doi.org/10.1056/NEJMcp042317			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935RH	15958808				2022-12-28	WOS:000229798900008
J	Liu, J; Xiao, H; Lei, F; Zhu, Q; Qin, K; Zhang, XW; Zhang, XL; Zhao, D; Wang, G; Feng, Y; Ma, J; Liu, W; Wang, J; Gao, GF				Liu, J; Xiao, H; Lei, F; Zhu, Q; Qin, K; Zhang, XW; Zhang, XL; Zhao, D; Wang, G; Feng, Y; Ma, J; Liu, W; Wang, J; Gao, GF			Highly pathogenic H5N1 influenza virus infection in migratory birds	SCIENCE			English	Article									China Agr Univ, Coll Vet Med, Beijing 100094, Peoples R China; Chinese Acad Sci, Inst Microbiol, Beijing 100080, Peoples R China; Chinese Acad Sci, Inst Zool, Beijing 100101, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing, Peoples R China; Acad Mil Med Sci, Inst Microbiol & Epidemiol, Beijing 100071, Peoples R China; Chinese Acad Sci, Beijing Genom Inst, Beijing 101300, Peoples R China	China Agricultural University; Chinese Academy of Sciences; Institute of Microbiology, CAS; Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Academy of Military Medical Sciences - China; Beijing Genomics Institute (BGI); Chinese Academy of Sciences	Liu, J (corresponding author), China Agr Univ, Coll Vet Med, Beijing 100094, Peoples R China.	jhl@cau.edu.cn; gaof@im.ac.cn	Feng, Youjun/E-5670-2010; Feng, Youjun/E-8386-2010; Gao, George Fu/ABD-5229-2021					Chen H, 2004, P NATL ACAD SCI USA, V101, P10452, DOI 10.1073/pnas.0403212101; Cheng TX, 1979, FAUNA SINICA AVES; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350	6	553	684	3	358	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	2005	309	5738					1206	1206		10.1126/science.1115273	http://dx.doi.org/10.1126/science.1115273			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	957TE	16000410				2022-12-28	WOS:000231395400035
J	Perry, ACF				Perry, ACF			Progress in human somatic-cell nuclear transfer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EMBRYONIC STEM-CELLS		RIKEN, Ctr Dev Biol, Lab Mammalian Mol Embryol, Kobe, Hyogo, Japan	RIKEN	Perry, ACF (corresponding author), RIKEN, Ctr Dev Biol, Lab Mammalian Mol Embryol, Kobe, Hyogo, Japan.			Perry, Tony/0000-0003-3136-5355				Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; HWANG WS, IN PRESS SCIENCE; Perrier AL, 2004, P NATL ACAD SCI USA, V101, P12543, DOI 10.1073/pnas.0404700101; Tabar V, 2005, NAT BIOTECHNOL, V23, P601, DOI 10.1038/nbt1088	5	8	8	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2005	353	1					87	88		10.1056/NEJMcibr052068	http://dx.doi.org/10.1056/NEJMcibr052068			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942FC	16000361				2022-12-28	WOS:000230267300015
J	Davis, SR; Davison, SL; Donath, S; Bell, RJ				Davis, SR; Davison, SL; Donath, S; Bell, RJ			Circulating androgen levels and self-reported sexual function in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERUM TESTOSTERONE; BREAST-CANCER; HORMONES; DEHYDROEPIANDROSTERONE; ESTROGENS; THERAPY; PROFILE; RISK	Context It has been proposed that low sexual desire and sexual dysfunction are associated with low blood testosterone levels in women. However, evidence to support this is lacking. Objective To determine whether women with low self-reported sexual desire and sexual satisfaction are more likely to have low serum androgen levels than women without self-reported low sexual desire and sexual satisfaction. Design, Setting, and Participants A community-based, cross-sectional study of 1423 women aged 18 to 75 years, who were randomly recruited via the electoral roll in Victoria, Australia, from April 2002 to August 2003. Women were excluded from the analysis if they took psychiatric medication, had abnormal thyroid function, documented polycystic ovarian syndrome, or were younger than 45 years and using oral contraception. Main Outcome Measures Domain scores of the Profile of Female Sexual Function (PFSF) and serum levels of total and free testosterone, androstenedione, and dehydroepiandrosterone sulfate. Results A total of 1021 individuals were included in the final analysis. No clinically significant relationships between having a low score for any PFSF domain and having a low serum total or free testosterone or androstenedione level was demonstrated. A low domain score for sexual responsiveness for women aged 45 years or older was associated with higher odds of having a serum dehydroepiandrosterone sulfate level below the 10th percentile for this age group (odds ratio [OR], 3.90; 95% confidence interval [CI], 1.54-9.81 ; P = .004). For women aged 18 to 44 years, having a low domain score for sexual desire (OR, 3.86; 95% Cl, 1.27-11.67; P=.02), sexual arousal (OR, 6.39; 95% Cl, 2.30-17.73; P<.001), and sexual responsiveness (OR, 6.59; 95% Cl, 2.37-18.34; P<.001) was associated with having a dehydroepiandrosterone sulfate level below the 10th percentile. Conclusions No single androgen level is predictive of low female sexual function, and the majority of women with low dehydroepiandrosterone sulfate levels did not have low sexual function.	Alfred Hosp, Monash Med Sch, Dept Med, Womens Hlth Program, Prahran, Vic, Australia; Jean Hailes Fdn, Clayton, Vic, Australia; Monash Univ, Dept Biochem, Clayton, Vic 3168, Australia; Univ Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Monash University; Murdoch Children's Research Institute; University of Melbourne; University of Melbourne	Davis, SR (corresponding author), Monash Univ, Alfred Hosp, Cent & Eastern Clin Sch, Womens Hlth Program, Commercial Rd, Prahran, Vic 3181, Australia.	susan.davis@med.monash.edu.au	Davis, Susan R/A-3111-2009; Bell, Robin J/H-6750-2014; Davis, Susan D/GZL-2361-2022	Davis, Susan R/0000-0002-2955-0415; Bell, Robin J/0000-0003-1935-7627; Donath, Susan/0000-0003-2489-3977				Agarwal VR, 1997, J CLIN ENDOCR METAB, V82, P70, DOI 10.1210/jc.82.1.70; Bachmann G, 2002, FERTIL STERIL, V77, P660, DOI 10.1016/S0015-0282(02)02969-2; BEJIN A, 1994, SEXUAL BEHAV AIDS, P163; Burger HG, 2000, J CLIN ENDOCR METAB, V85, P2832, DOI 10.1210/jc.85.8.2832; Burger HG, 2002, FERTIL STERIL, V77, pS3; Cameron DR, 2004, FERTIL STERIL, V82, P273, DOI 10.1016/j.fertnstert.2003.11.062; Chen C, 2003, CANCER EPIDEM BIOMAR, V12, P1410; DAVIS SR, 1995, MATURITAS, V21, P227, DOI 10.1016/0378-5122(94)00898-H; DAVISON S, IN PRESS J CLIN ENDO; Dennerstein L, 1997, MATURITAS, V26, P83, DOI 10.1016/S0378-5122(96)01093-6; Derogatis L, 2004, J SEX MARITAL THER, V30, P25, DOI 10.1080/00926230490247183; GOEBELSMANN U, 1974, AM J OBSTET GYNECOL, V119, P445, DOI 10.1016/0002-9378(74)90199-9; Goldstat R, 2003, MENOPAUSE, V10, P390, DOI 10.1097/01.GME.0000060256.03945.20; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; KONTULA O, 1995, ENHANCEMENT SEX LIFE; Labrie F, 2003, ENDOCR REV, V24, P152, DOI 10.1210/er.2001-0031; Labrie F, 1998, STEROIDS, V63, P322, DOI 10.1016/S0039-128X(98)00007-5; Labrie F, 1997, J CLIN ENDOCR METAB, V82, P2403, DOI 10.1210/jc.82.8.2403; LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A; Lamar CA, 2003, CANCER EPIDEM BIOMAR, V12, P380; Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537; McHorney CA, 2004, MENOPAUSE, V11, P474, DOI 10.1097/01.GME.0000109316.11228.77; Miller KK, 2004, J CLIN ENDOCR METAB, V89, P525, DOI 10.1210/jc.2003-030680; NATHORSTBOOS J, 1992, GYNECOL OBSTET INVES, V34, P97, DOI 10.1159/000292735; SHERWIN BB, 1987, PSYCHOSOM MED, V49, P397, DOI 10.1097/00006842-198707000-00009; Shifren JL, 2000, NEW ENGL J MED, V343, P682, DOI 10.1056/NEJM200009073431002; Sinha-Hikim I, 1998, J CLIN ENDOCR METAB, V83, P1312, DOI 10.1210/jc.83.4.1312; SODERGARD R, 1982, J STEROID BIOCHEM, V16, P801, DOI 10.1016/0022-4731(82)90038-3; ZUMOFF B, 1995, J CLIN ENDOCR METAB, V80, P1429, DOI 10.1210/jc.80.4.1429	29	346	359	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2005	294	1					91	96		10.1001/jama.294.1.91	http://dx.doi.org/10.1001/jama.294.1.91			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941JD	15998895				2022-12-28	WOS:000230210200029
J	Keulers, BJ; Roumen, RHM; Keulers, MJ; Vandermeeren, L; Bekke, JPH				Keulers, BJ; Roumen, RHM; Keulers, MJ; Vandermeeren, L; Bekke, JPH			Bilateral groin pain from a rotten molar	LANCET			English	Editorial Material							PYOMYOSITIS		Maxima Med Ctr, NL-5500 MB Veldhoven, Netherlands; Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands	Maxima Medical Center; Jeroen Bosch Ziekenhuis	Keulers, BJ (corresponding author), Maxima Med Ctr, Run 4600,POB 7777, NL-5500 MB Veldhoven, Netherlands.	bram_keulers@yahoo.com						Andrews S K, 1998, J Am Board Fam Pract, V11, P291; BACK SA, 1990, REV INFECT DIS, V12, P784; DUDLER J, 1994, BRIT J RHEUMATOL, V33, P988; Ross JJ, 2003, MEDICINE, V82, P340, DOI 10.1097/01.md.0000091180.93122.1c; Soler R, 2000, EUR J RADIOL, V35, P59, DOI 10.1016/S0720-048X(99)00108-4	5	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 2	2005	366	9479					94	94		10.1016/S0140-6736(05)66832-8	http://dx.doi.org/10.1016/S0140-6736(05)66832-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993239				2022-12-28	WOS:000230277600040
J	Lehman, TJA				Lehman, TJA			Juvenile idiopathic arthritis and HSP60 vaccination: selective down-regulation?	LANCET			English	Editorial Material							T-CELL VACCINATION; TREGS		Cornell Univ, Weill Med Coll, Hosp Special Surg, Div Pediat Rheumatol, New York, NY 10021 USA	Cornell University	Lehman, TJA (corresponding author), Cornell Univ, Weill Med Coll, Hosp Special Surg, Div Pediat Rheumatol, New York, NY 10021 USA.	goldscout@aol.com						Bot A, 2004, Minerva Med, V95, P105; Cohen IR, 2004, J CLIN INVEST, V114, P1227, DOI 10.1172/JCI200422396; Kamphuis S, 2005, LANCET, V366, P50, DOI 10.1016/S0140-6736(05)66827-4; Prakken ABJ, 1996, ARTHRITIS RHEUM-US, V39, P1826, DOI 10.1002/art.1780391108; Van der AA A, 2003, CLIN EXP IMMUNOL, V131, P155, DOI 10.1046/j.1365-2249.2003.02019.x; Walsh PT, 2004, J CLIN INVEST, V114, P1398, DOI 10.1172/JCI200423238	6	4	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	2005	366	9479					9	10		10.1016/S0140-6736(05)66800-6	http://dx.doi.org/10.1016/S0140-6736(05)66800-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993212				2022-12-28	WOS:000230277600007
J	Hinnerwisch, J; Fenton, WA; Furtak, KJ; Farr, GW; Horwich, AL				Hinnerwisch, J; Fenton, WA; Furtak, KJ; Farr, GW; Horwich, AL			Loops in the central channel of ClpA chaperone mediate protein binding, unfolding, and translocation	CELL			English	Article							SPECIFICITY-ENHANCING FACTOR; MOLECULAR CHAPERONE; SUBSTRATE RECOGNITION; CRYSTAL-STRUCTURE; HSP100 CHAPERONE; DEGRADATION; PROTEASES; ATPASE; PORE	The cylindrical Hsp100 chaperone CipA mediates ATP-dependent unfolding of substrate proteins bearing "tag" sequences, such as the 11-residue ssrA sequence appended to proteins translationally stalled at ribosomes. Unfolding is coupled to translocation through a central channel into the associating protease, ClpP. To explore the topology and mechanism of ClpA action, we carried out chemical crosslinking and functional studies. Whereas a tag from RepA protein crosslinked proximally to the flexible N domains, the ssrA sequence in GFP-ssrA crosslinked distally in the channel to a segment of the distal ATPase domain (D2). Single substitutions placed in this D2 loop, and also in two apparently cooperating proximal (D1) loops, abolished binding of ssrA substrates and unfolded proteins lacking tags and blocked unfolding of GFP-RepA. Additionally, a substitution adjoining the D2 loop allowed binding of ssrA proteins but impaired their translocation. This loop, as in homologous nucleic-acid translocases, may bind substrates proximally and, coupled with ATP hydrolysis, translocate them distally, exerting mechanical force that mediates unfolding.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Yale University; Howard Hughes Medical Institute; Yale University; Scripps Research Institute	Horwich, AL (corresponding author), Yale Univ, Sch Med, Dept Genet, 295 Congress Ave, New Haven, CT 06510 USA.	horwich@csb.yale.edu						DeLaBarre B, 2005, J MOL BIOL, V347, P437, DOI 10.1016/j.jmb.2005.01.060; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Flynn JM, 2001, P NATL ACAD SCI USA, V98, P10584, DOI 10.1073/pnas.191375298; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 2002, P NATL ACAD SCI USA, V99, P11037, DOI 10.1073/pnas.172378899; Hoskins JR, 2002, ADV PROTEIN CHEM, V59, P413; Hoskins JR, 2000, J BIOL CHEM, V275, P35361, DOI 10.1074/jbc.M006288200; HUANG GS, 1995, P NATL ACAD SCI USA, V92, P6878, DOI 10.1073/pnas.92.15.6878; Ishikawa T, 2004, J STRUCT BIOL, V146, P180, DOI 10.1016/j.jsb.2003.11.018; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; Levchenko I, 2003, MOL CELL, V12, P365, DOI 10.1016/j.molcel.2003.08.014; Mancini EJ, 2004, CELL, V118, P743, DOI 10.1016/j.cell.2004.09.007; Piszczek G, 2005, J BIOL CHEM, V280, P12221, DOI 10.1074/jbc.M411733200; Reid BG, 2001, P NATL ACAD SCI USA, V98, P3768, DOI 10.1073/pnas.071043698; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; Siddiqui SM, 2004, GENE DEV, V18, P369, DOI 10.1101/gad.1170304; SINGH SK, 1994, J BIOL CHEM, V269, P29537; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Song HK, 2003, MOL CELL, V12, P75, DOI 10.1016/S1097-2765(03)00271-5; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a	33	190	190	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	2005	121	7					1029	1041		10.1016/j.cell.2005.04.012	http://dx.doi.org/10.1016/j.cell.2005.04.012			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989953	Bronze			2022-12-28	WOS:000230448000010
J	Camacho, A; Lee, JKW; Hensen, BJ; Braun, J				Camacho, A; Lee, JKW; Hensen, BJ; Braun, J			Short-lived orogenic cycles and the eclogitization of cold crust by spasmodic hot fluids	NATURE			English	Article							U-PB GEOCHRONOLOGY; BERGEN ARCS; HIGH-PRESSURE; MUSGRAVE BLOCK; SHEAR ZONES; DEEP CRUST; CALEDONIDES; METAMORPHISM; DEFORMATION; SUBDUCTION	Collision tectonics and the associated transformation of continental crust to high-pressure rocks ( eclogites) are generally well-understood processes, but important contradictions remain between tectonothermal models and petrological-isotopic data obtained from such rocks. Here we use 40Ar - 39Ar data coupled with a thermal model to constrain the time-integrated duration of an orogenic cycle ( the burial and exhumation of a particular segment of the crust) to be less than 13 Myr. We also determine the total duration of associated metamorphic events to be similar to 20 kyr, and of individual heat pulses experienced by the rocks to be as short as 10 years. Such short timescales are indicative of rapid tectonic processes associated with catastrophic deformation events ( earthquakes). Such events triggered transient heat advection by hot fluid along deformation ( shear) zones, which cut relatively cool and dry subducted crust. In contrast to current thermal models that assume thermal equilibrium and invoke high ambient temperatures in the thickened crust, our non-steady-state cold-crust model satisfactorily explains several otherwise contradictory geological observations.	Queens Univ, Kingston, ON K7L 3N6, Canada; Univ New S Wales, Sch Biol Earth & Environm Sci, Sydney, NSW 2052, Australia; Univ Rennes 1, CNRS, UMR 6118, Geosci Rennes, F-35042 Rennes, France	Queens University - Canada; University of New South Wales Sydney; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Rennes	Lee, JKW (corresponding author), Queens Univ, Kingston, ON K7L 3N6, Canada.	lee@geol.queensu.ca		Braun, Jean/0000-0002-7341-6344				ANDERSEN TB, 1991, TERRA NOVA, V3, P303, DOI 10.1111/j.1365-3121.1991.tb00148.x; AUSTRHEIM H, 1985, CHEM GEOL, V50, P267, DOI 10.1016/0009-2541(85)90124-X; Austrheim H, 1996, EARTH PLANET SC LETT, V139, P223, DOI 10.1016/0012-821X(95)00232-2; AUSTRHEIM H, 1994, SCIENCE, V265, P82, DOI 10.1126/science.265.5168.82; Bingen B, 2004, CONTRIB MINERAL PETR, V147, P671, DOI 10.1007/s00410-004-0585-z; Bingen B, 2001, GEOL SOC AM BULL, V113, P640, DOI 10.1130/0016-7606(2001)113<0640:ZUPGIT>2.0.CO;2; Bjornerud M, 2002, J STRUCT GEOL, V24, P1537, DOI 10.1016/S0191-8141(01)00148-1; Bjornerud MG, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000527; Boundy TM, 1997, LITHOS, V39, P159, DOI 10.1016/S0024-4937(96)00026-6; BOUNDY TM, 1992, J METAMORPH GEOL, V10, P127, DOI 10.1111/j.1525-1314.1992.tb00075.x; Boundy TM, 1997, EARTH PLANET SC LETT, V148, P223, DOI 10.1016/S0012-821X(97)00036-8; Braun J, 2003, COMPUT GEOSCI-UK, V29, P787, DOI 10.1016/S0098-3004(03)00052-9; Camacho A, 2000, TECTONICS, V19, P978, DOI 10.1029/1999TC001151; Camacho A, 2001, J STRUCT GEOL, V23, P1007, DOI 10.1016/S0191-8141(00)00172-3; CAMACHO A, 1998, THESIS AUSTR NATL U; CHOPIN C, 1987, PHILOS T R SOC A, V321, P183, DOI 10.1098/rsta.1987.0010; Cocks LRM, 2002, J GEOL SOC LONDON, V159, P631, DOI 10.1144/0016-764901-118; Dewey JF, 2003, J GEOL SOC LONDON, V160, P219, DOI 10.1144/0016-764902-085; DEWEY JF, 1993, GEOL SOC SPEC PUBL, V76, P325; ERAMBERT M, 1993, CONTRIB MINERAL PETR, V115, P204, DOI 10.1007/BF00321220; FOLAND KA, 1979, GEOCHIM COSMOCHIM AC, V43, P793, DOI 10.1016/0016-7037(79)90219-9; GEE DG, 1975, AM J SCI, VA275, P468; GILETTI BJ, 1974, GEOCHEMICAL TRANSPOR, P107; Glodny J, 2002, GEOCHIM COSMOCHIM AC, V66, pA280; HARRISON TM, 1981, CONTRIB MINERAL PETR, V78, P324; Hynes A, 1996, EARTH PLANET SC LETT, V140, P13, DOI 10.1016/0012-821X(96)00047-7; Jamtveit B, 2000, NATURE, V408, P75, DOI 10.1038/35040537; JAMTVEIT B, 1990, CONTRIB MINERAL PETR, V104, P184, DOI 10.1007/BF00306442; KELLEY SP, 1994, GEOCHIM COSMOCHIM AC, V58, P3519, DOI 10.1016/0016-7037(94)90103-1; KOONS PO, 1987, J PETROL, V28, P679, DOI 10.1093/petrology/28.4.679; Krabbendam M, 1998, GEOL SOC SPEC PUBL, V135, P159, DOI 10.1144/GSL.SP.1998.135.01.11; Kuhn A, 2000, LITHOS, V51, P305, DOI 10.1016/S0024-4937(99)00067-5; LEE JKW, 1995, CONTRIB MINERAL PETR, V120, P60, DOI 10.1007/s004100050058; Leech ML, 2001, EARTH PLANET SC LETT, V185, P149, DOI 10.1016/S0012-821X(00)00374-5; MATTEY D, 1994, J METAMORPH GEOL, V12, P311, DOI 10.1111/j.1525-1314.1994.tb00025.x; McDougall I., 1999, GEOCHRONOLOGY THERMO; Perchuk AL, 2002, PETROLOGY+, V10, P99; Philippot P, 2000, INT GEOL REV, V42, P312, DOI 10.1080/00206810009465085; Roberts D, 2003, TECTONOPHYSICS, V365, P283, DOI 10.1016/S0040-1951(03)00026-X; Seipold U, 1998, TECTONOPHYSICS, V291, P173, DOI 10.1016/S0040-1951(98)00038-9; Seipold U, 1998, TECTONOPHYSICS, V291, P161, DOI 10.1016/S0040-1951(98)00037-7; Torsvik TH, 1996, EARTH-SCI REV, V40, P229, DOI 10.1016/0012-8252(96)00008-6; Wain AL, 2001, J METAMORPH GEOL, V19, P607; WAYTE GJ, 1989, CONTRIB MINERAL PETR, V101, P426, DOI 10.1007/BF00372216	44	92	94	2	33	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1191	1196		10.1038/nature03643	http://dx.doi.org/10.1038/nature03643			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988516				2022-12-28	WOS:000230140500034
J	Hunte, C; Screpanti, E; Venturi, M; Rimon, A; Padan, E; Michel, H				Hunte, C; Screpanti, E; Venturi, M; Rimon, A; Padan, E; Michel, H			Structure of a Na+/H+ antiporter and insights into mechanism of action and regulation by pH	NATURE			English	Article							DEPENDENT CONFORMATIONAL-CHANGE; ESCHERICHIA-COLI; GLYCEROL-3-PHOSPHATE TRANSPORTER; PLASMA-MEMBRANE; NHAA; PROTEIN; PROTON; ARABIDOPSIS; EXCHANGER; ANGSTROM	The control by Na+/ H+ antiporters of sodium/proton concentration and cell volume is crucial for the viability of all cells. Adaptation to high salinity and/or extreme pH in plants and bacteria or in human heart muscles requires the action of Na+/H+ antiporters. Their activity is tightly controlled by pH. Here we present the crystal structure of pH-downregulated NhaA, the main antiporter of Escherichia coli and many enterobacteria. A negatively charged ion funnel opens to the cytoplasm and ends in the middle of the membrane at the putative ion-binding site. There, a unique assembly of two pairs of short helices connected by crossed, extended chains creates a balanced electrostatic environment. We propose that the binding of charged substrates causes an electric imbalance, inducing movements, that permit a rapid alternating-access mechanism. This ion-exchange machinery is regulated by a conformational change elicited by a pH signal perceived at the entry to the cytoplasmic funnel.	Max Planck Inst Biophys, Dept Mol Membrane Biol, D-60438 Frankfurt, Germany; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Max Planck Society; Hebrew University of Jerusalem	Hunte, C (corresponding author), Max Planck Inst Biophys, Dept Mol Membrane Biol, Max von Laue Str 3, D-60438 Frankfurt, Germany.	carola.hunte@mpibp-frankfurt.mpg.de; etana@vms.huji.ac.il; hartmut.michel@mpibp-frankfurt.mpg.de	Hunte, Carola/E-4071-2015	Hunte, Carola/0000-0002-0826-3986				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Apse MP, 2003, PLANT J, V36, P229, DOI 10.1046/j.1365-313X.2003.01871.x; Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; Auer M, 2001, BIOCHEMISTRY-US, V40, P6628, DOI 10.1021/bi010138+; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Engelhardt S, 2002, CIRC RES, V90, P814, DOI 10.1161/01.RES.0000014966.97486.C0; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Galili L, 2004, J BIOL CHEM, V279, P23104, DOI 10.1074/jbc.M400288200; Galili L, 2002, BIOCHEMISTRY-US, V41, P609, DOI 10.1021/bi011655v; Gerchman Y, 1999, J BIOL CHEM, V274, P24617, DOI 10.1074/jbc.274.35.24617; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Harding MM, 2004, ACTA CRYSTALLOGR D, V60, P849, DOI 10.1107/S0907444904004081; Hase CC, 1999, P NATL ACAD SCI USA, V96, P3183, DOI 10.1073/pnas.96.6.3183; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; INOUE H, 1995, FEBS LETT, V363, P264, DOI 10.1016/0014-5793(95)00331-3; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; Jin J, 2002, J BACTERIOL, V184, P4722, DOI 10.1128/JB.184.17.4722-4732.2002; Khademi S, 2004, SCIENCE, V305, P1587, DOI 10.1126/science.1101952; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KLINGENBERG M, 1985, ADP ATP CARRIER MITO; Krulwich TA, 2001, BBA-BIOENERGETICS, V1505, P158, DOI 10.1016/S0005-2728(00)00285-1; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Myers ML, 2003, SODIUM-HYDROGEN EXCHANGER: FROM MOLECULE TO ITS ROLE IN DISEASE, P279; Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3; Padan E, 2004, BBA-BIOENERGETICS, V1658, P2, DOI 10.1016/j.bbabio.2004.04.018; Padan E, 2001, BBA-BIOENERGETICS, V1505, P144, DOI 10.1016/S0005-2728(00)00284-X; Palsdottir H, 2004, BBA-BIOMEMBRANES, V1666, P2, DOI 10.1016/j.bbamem.2004.06.012; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Qiu QS, 2003, PLANT PHYSIOL, V132, P1041, DOI 10.1104/pp.102.010421; Rimon A, 2002, BIOCHEMISTRY-US, V41, P14897, DOI 10.1021/bi0261342; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; Tzubery T, 2004, J BIOL CHEM, V279, P3265, DOI 10.1074/jbc.M309021200; Venturi M, 2000, J BIOL CHEM, V275, P4734, DOI 10.1074/jbc.275.7.4734; VIITANEN P, 1984, P NATL ACAD SCI-BIOL, V81, P1629, DOI 10.1073/pnas.81.6.1629; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wakabayashi S, 2003, SODIUM-HYDROGEN EXCHANGER: FROM MOLECULE TO ITS ROLE IN DISEASE, P35; Wakabayashi S, 2003, J BIOL CHEM, V278, P43580, DOI 10.1074/jbc.M306690200; West IC, 1997, BBA-REV BIOMEMBRANES, V1331, P213, DOI 10.1016/S0304-4157(97)00007-5; WEST IC, 1974, BIOCHEM J, V144, P87, DOI 10.1042/bj1440087; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; ZILBERSTEIN D, 1982, J BIOL CHEM, V257, P3687	50	523	528	4	115	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1197	1202		10.1038/nature03692	http://dx.doi.org/10.1038/nature03692			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988517				2022-12-28	WOS:000230140500035
J	Lavados, PM; Sacks, C; Prina, L; Escobar, A; Tossi, C; Araya, F; Feuerhake, W; Galvez, M; Salinas, R; Alvarez, G				Lavados, PM; Sacks, C; Prina, L; Escobar, A; Tossi, C; Araya, F; Feuerhake, W; Galvez, M; Salinas, R; Alvarez, G			Incidence, 30-day case-fatality rate, and prognosis of stroke in Iquique, Chile: a 2-year community-based prospective study (PISCIS project)	LANCET			English	Article							ACUTE CEREBROVASCULAR-DISEASE; TRANSIENT ISCHEMIC ATTACKS; RISK-FACTORS; INTRACEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; ETHNIC-DIFFERENCES; SUBTYPES; OXFORDSHIRE; EPIDEMIOLOGY; POPULATION	Background The epidemiology of stroke in Latin-American populations and variation of subtypes between communities are unclear. Our aim was to ascertain prospectively the incidence of first-ever stroke in the predominantly Hispanic-Mestizo population of Iquique, a city in the northern desert region of Chile. Methods We prospectively identified all possible cases of stroke and transient ischaemic attacks between July 1, 2000, and June 30, 2002, from several overlapping sources. Patients were rapidly assessed by two field neurologists. Standard definitions for incident cases, stroke, transient ischaemic attack, pathological type, and infarction subtype were used. All cases identified were adjudicated by at least two stroke neurologists and followed up at 6 months. Incidence rates of first-ever strokes were calculated from the population of Iquique (214 526) according to the national census of 2002. Findings Of 380 cases of stroke identified, 292 were incident. CT scans were done in 267 (91%) patients and the mean time to scan was 2.2 days. The hospital admission rate was 71% (207/292). The overall age-adjusted incidence rate of first-ever stroke was 140.1 per 100 000 (95% CI 124.0-156.2). The incidence rates per 100 000 according to pathological type were: infarcts 87.3, intracerebral haemorrhage 27.6, and subarachnoid haemorrhage 6.2. The 30-day and 6-month case-fatality rates were 23.3% and 33.0%, respectively. Interpretation Our results show incidence rates of stroke similar to those reported in other community studies. Although the proportion of intracerebral haemorrhages was higher than reported in previous studies, the overall incidence was not, which could indicate a slightly lower incidence of ischaemic strokes in this population than in other countries. The prognosis was similar to that found in other population-based studies.	Clin Alemana Santiago, Dept Med, Serv Neurol, Programa Enfermedades Cerebrovasc, Santiago, Chile; Serv Salud Metropolitano Oriente, Inst Neurocirugia, Unidad Neurointens, Santiago, Chile; Univ Chile, Dept Ciencias Neurol, Santiago, Chile; Univ Valparaiso, Dept Med, Unidad Neurol, Valparaiso, Chile; Hosp Reg Iquique, Med Serv, Unidad Neurol, Iquique, Chile; Hosp Salvador, Serv Salud Metropolitano Oriente, Serv Neurol, Santiago, Chile; Serv Salud Metropolitano Oriente, Inst Neurocirugia Invest Cerebr Alfonso Asenjo, Serv Neuroradiol, Santiago, Chile; Inst Salud Publ Chile, Santiago, Chile	Clinica Alemana; Universidad de Chile; Universidad de Valparaiso; Universidad de Chile	Lavados, PM (corresponding author), Clin Alemana Santiago, Dept Med, Serv Neurol, Programa Enfermedades Cerebrovasc, Santiago, Chile.	pablolavados@yahoo.com	Lavados, Pablo M/E-9918-2016	Lavados, Pablo M/0000-0002-9118-9093				AHMAD OB, 2002, AGE STANDARDISATION; AHO K, 1980, B WORLD HEALTH ORGAN, V58, P113; Alvarez G, 1997, REV MED CHILE, V125, P561; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Bonita R, 1997, STROKE, V28, P758, DOI 10.1161/01.STR.28.4.758; BONITA R, 1993, LANCET, V342, P1470, DOI 10.1016/0140-6736(93)92938-P; Bruno A, 1996, NEUROLOGY, V47, P405, DOI 10.1212/WNL.47.2.405; Bustos P, 2003, REV MED CHILE, V131, P973; Carolei A, 1997, STROKE, V28, P2500, DOI 10.1161/01.STR.28.12.2500; Coull AJ, 2004, STROKE, V35, P2041, DOI 10.1161/01.STR.0000137605.48864.2f; DELBRUTTO OH, 1993, STROKE, V24, P1833, DOI 10.1161/01.STR.24.12.1833; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; Diaz V, 2003, NEUROEPIDEMIOLOGY, V22, P339, DOI 10.1159/000072923; Ellekjaer H, 1997, STROKE, V28, P2180, DOI 10.1161/01.STR.28.11.2180; Feigin VL, 2004, STROKE, V35, P2045; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; FEIGIN VL, 1995, MAYO CLIN PROC, V70, P847; Frey JL, 1998, STROKE, V29, P29, DOI 10.1161/01.STR.29.1.29; Fustinoni O, 2000, STROKE, V31, P1013, DOI 10.1161/01.STR.31.5.1013; Goldstein LB, 2001, STROKE, V32, P280, DOI 10.1161/01.STR.32.1.280; Hajat C, 2001, STROKE, V32, P37, DOI 10.1161/01.STR.32.1.37; Hankey GJ, 1994, TRANSIENT ISCHAEMIC; HOPPE A, 2004, P 5 WORLD STROK C JU, P199; Hsu RT, 1999, INT J EPIDEMIOL, V28, P853, DOI 10.1093/ije/28.5.853; *INE, 2004, RES CENS 2002; *INE, 2003, CHIL AN EST VIT 2000; Keir SL, 2002, J NEUROL, V249, P1226, DOI 10.1007/s00415-002-0816-z; KEYFITZ N, 1966, HUM BIOL, V38, P309; Kolominsky-Rabas PL, 1998, STROKE, V29, P2501, DOI 10.1161/01.STR.29.12.2501; LAURIA G, 1995, STROKE, V26, P1787, DOI 10.1161/01.STR.26.10.1787; Lavados P, 2000, STROKE, V31, P2789; Lee JW, 2003, LANCET, V362, P2083, DOI 10.1016/S0140-6736(03)15107-0; MEDINA E, 1992, REV MED CHILE, V120, P702; *MIN SAL CHIL, 2003, BAS DAT EGR HOSP DEP; Nogales-Gaete J, 2000, REV MED CHILE, V128, P1227; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445; SACKS C, 1999, P 54 ANN M CHIL SOC, P25; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; Saposnik G, 2003, STROKE, V34, P2103, DOI 10.1161/01.STR.0000088063.74250.DB; Saposnik G, 2000, STROKE, V31, P2385, DOI 10.1161/01.STR.31.10.2385; Sarti C, 2000, STROKE, V31, P1588, DOI 10.1161/01.STR.31.7.1588; Schulz UGR, 2003, STROKE, V34, P2050, DOI 10.1161/01.STR.0000079818.08343.8C; Smadja D, 2001, STROKE, V32, P2741, DOI 10.1161/hs1201.099385; Stewart JA, 1999, BRIT MED J, V318, P967, DOI 10.1136/bmj.318.7189.967; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; Sudlow CLM, 1996, STROKE, V27, P550, DOI 10.1161/01.STR.27.3.550; TAPIA J, 1992, REV MED CHILE, V120, P1414; Thrift AG, 2001, STROKE, V32, P1732, DOI 10.1161/01.STR.32.8.1732; URAKAMI K, 1987, STROKE, V18, P396, DOI 10.1161/01.STR.18.2.396; Vemmos KN, 2000, J NEUROL NEUROSUR PS, V69, P595, DOI 10.1136/jnnp.69.5.595; Vemmos KN, 1999, STROKE, V30, P363, DOI 10.1161/01.STR.30.2.363; Wardlaw JM, 2003, J NEUROL NEUROSUR PS, V74, P77, DOI 10.1136/jnnp.74.1.77; Warlow CP, 1998, LANCET, V352, pSIII1; WARLOW CP, 2001, STROKE PRACTICAL GUI, P416; Wein TH, 1999, STROKE, V30, P1501, DOI 10.1161/01.STR.30.8.1501; Wolfe CDA, 2002, J NEUROL NEUROSUR PS, V72, P211, DOI 10.1136/jnnp.72.2.211	60	184	196	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	2005	365	9478					2206	2215		10.1016/S0140-6736(05)66779-7	http://dx.doi.org/10.1016/S0140-6736(05)66779-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978929				2022-12-28	WOS:000230034800031
J	Hohmann, AG; Suplita, RL; Bolton, NM; Neely, MH; Fegley, D; Mangieri, R; Krey, JF; Walker, JM; Holmes, PV; Crystal, JD; Duranti, A; Tontini, A; Mor, M; Tarzia, G; Piomelli, D				Hohmann, AG; Suplita, RL; Bolton, NM; Neely, MH; Fegley, D; Mangieri, R; Krey, JF; Walker, JM; Holmes, PV; Crystal, JD; Duranti, A; Tontini, A; Mor, M; Tarzia, G; Piomelli, D			An endocannabinoid mechanism for stress-induced analgesia	NATURE			English	Article							STIMULUS-EVOKED ACTIVITY; DORSAL-HORN; NEURONS; BRAIN; SUPPRESSION; INHIBITORS; RECEPTORS; LIPASE; ESTERS; FORMS	Acute stress suppresses pain by activating brain pathways that engage opioid or non-opioid mechanisms. Here we show that an opioid-independent form of this phenomenon, termed stress-induced analgesia(1), is mediated by the release of endogenous marijuana-like (cannabinoid) compounds in the brain. Blockade of cannabinoid CB1 receptors in the periaqueductal grey matter of the midbrain prevents non-opioid stress-induced analgesia. In this region, stress elicits the rapid formation of two endogenous cannabinoids, the lipids 2-arachidonoylglycerol(2) (2-AG) and anandamide(3). A newly developed inhibitor of the 2-AG-deactivating enzyme, monoacylglycerol lipase(4,5), selectively increases 2-AG concentrations and, when injected into the periaqueductal grey matter, enhances stress-induced analgesia in a CB1-dependent manner. Inhibitors of the anandamide-deactivating enzyme fatty-acid amide hydrolase(6), which selectively elevate anandamide concentrations, exert similar effects. Our results indicate that the coordinated release of 2-AG and anandamide in the periaqueductal grey matter might mediate opioid-independent stress-induced analgesia. These studies also identify monoacylglycerol lipase as a previously unrecognized therapeutic target.	Univ Georgia, Dept Psychol, Neurosci & Behav Program, Athens, GA 30602 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Drug Discovery, Irvine, CA 92697 USA; Brown Univ, Dept Psychol, Schrier Res Lab, Providence, RI 02912 USA; Brown Univ, Dept Neurosci, Schrier Res Lab, Providence, RI 02912 USA; Univ Urbino Carlo Bo, Inst Med Chem, I-61029 Urbino, Italy; Univ Parma, Dept Pharmaceut, I-43100 Parma, Italy	University System of Georgia; University of Georgia; University of California System; University of California Irvine; University of California System; University of California Irvine; Brown University; Brown University; University of Urbino; University of Parma	Hohmann, AG (corresponding author), Univ Georgia, Dept Psychol, Neurosci & Behav Program, Athens, GA 30602 USA.	ahohmann@uga.edu; piomelli@uci.edu	Mor, Marco/D-2394-2009; Mangieri, Regina/N-1602-2019	Mor, Marco/0000-0003-0199-1849; Mangieri, Regina/0000-0002-4499-6183				AKIL H, 1986, ANN NY ACAD SCI, V467, P140, DOI 10.1111/j.1749-6632.1986.tb14625.x; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; CANNON JT, 1982, BRAIN RES, V243, P315, DOI 10.1016/0006-8993(82)90255-4; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Dinh TP, 2004, MOL PHARMACOL, V66, P1260, DOI 10.1124/mol.104.002071; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HOHMANN AG, 1995, LIFE SCI, V56, P2111, DOI 10.1016/0024-3205(95)00196-D; Hohmann AG, 1999, J NEUROPHYSIOL, V81, P575, DOI 10.1152/jn.1999.81.2.575; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Kozak KR, 2004, CURR PHARM DESIGN, V10, P659, DOI 10.2174/1381612043453081; LEWIS JW, 1980, SCIENCE, V208, P623, DOI 10.1126/science.7367889; Martin WJ, 1996, J NEUROSCI, V16, P6601; MARTIN WJ, 1995, LIFE SCI, V56, P2103, DOI 10.1016/0024-3205(95)00195-C; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Meng ID, 1998, NATURE, V395, P381, DOI 10.1038/26481; Mor M, 2004, J MED CHEM, V47, P4998, DOI 10.1021/jm031140x; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Tarzia G, 2003, J MED CHEM, V46, P2352, DOI 10.1021/jm021119g; TERMAN GW, 1986, BRAIN RES, V368, P101, DOI 10.1016/0006-8993(86)91046-2; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Valverde O, 2000, EUR J NEUROSCI, V12, P533, DOI 10.1046/j.1460-9568.2000.00929.x; Vaughan CW, 2000, MOL PHARMACOL, V57, P288; Walker JM, 2005, HANDB EXP PHARMACOL, V168, P509; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	30	559	591	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1108	1112		10.1038/nature03658	http://dx.doi.org/10.1038/nature03658			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973410	Green Published			2022-12-28	WOS:000229970400051
J	Tleyjeh, IM; Steckelberg, JM; Murad, HS; Anavekar, NS; Ghomrawi, HMK; Mirzoyev, Z; Moustafa, SE; Hoskin, TL; Mandrekar, JN; Wilson, WR; Baddour, LM				Tleyjeh, IM; Steckelberg, JM; Murad, HS; Anavekar, NS; Ghomrawi, HMK; Mirzoyev, Z; Moustafa, SE; Hoskin, TL; Mandrekar, JN; Wilson, WR; Baddour, LM			Temporal trends in infective endocarditis - A population-based study in Olmsted County, Minnesota	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	54th Annual Scientific Session of the American-College-of-Cardiology	MAR 06-09, 2005	Orlando, FL	Amer Coll Cardiol			PATIENT CHARACTERISTICS; EPIDEMIOLOGY; DIAGNOSIS; MORTALITY; SPECTRUM; CRITERIA; DENMARK; ADULTS	Context Limited data exist regarding population-based epidemiologic changes in incidence of infective endocarditis (IE). Objective To evaluate temporal trends in the incidence and clinical characteristics of I E. Design, Setting, and Patients Population-based survey using the resources of the Rochester Epidemiology Project of Olmsted County, Minnesota. One hundred seven IE episodes occurred in 102 Olmsted County residents between 1970 and 2000. The modified Duke criteria were used to validate the diagnosis of definite or possible IE. Main Outcome Measures Incidence of IE, proportion of patients with underlying heart disease, and causative microorganisms and clinical characteristics. Results Age- and sex-adjusted incidence of, IE ranged from 5.0 to 7.0 cases per 100000 person-years during the study period and did not change significantly over time (P=.42 for trend). Infective endocarditis caused by viridans group streptococci was the most common organism-specific subgroup, with an annual adjusted incidence of 1.7 to 3.5 cases per 100000; in comparison, IE due to Staphylococcus aureus had an annual adjusted incidence of 1.0 to 2.2 cases per 100000. No time trend was detected for either pathogen group (P=.63 and P=.66, respectively). An increasing temporal trend was observed in the proportions of prosthetic valve IE cases (P=.09). Among people with underlying heart disease, there was an increasing temporal trend in mitral valve prolapse (P=.04) and a decreasing trend in rheumatic heart disease (P=.08). However, the absolute numbers were small. There was no time trend in rates of valve surgery or 6-month mortality during the study period (P=.97 and P=.59, respectively). Conclusions In this community-based temporal trend study, we found no substantial change in the incidence of IE over the past 3 decades. Viridans group streptococci continue to outnumber S aureus as the most common causative organisms of IE in this population.	Mayo Clin, Mayo Clin Coll Med, Dept Med, Rochester, MN USA; Mayo Clin, Mayo Clin Coll Med, Div Infect Dis, Rochester, MN USA; Mayo Clin, Mayo Clin Coll Med, Dept Physiol & Biomed Engn, Rochester, MN USA; Mayo Clin, Mayo Clin Coll Med, Div Biostat, Rochester, MN USA; Univ Illinois, Michael Reese Hosp, Dept Med, Chicago, IL USA; Univ Minnesota, Div Hlth Serv Res & Policy, Minneapolis, MN USA; Univ Ottawa, Inst Heart, Div Cardiol, Ottawa, ON, Canada	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Michael Reese Hospital & Medical Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Ottawa; University of Ottawa Heart Institute	Tleyjeh, IM (corresponding author), 200 1st St SW, Rochester, MN 55905 USA.	tleyjeh.imad@mayo.edu		Ghomrawi, Hassan/0000-0003-1291-5278; Tleyjeh, Imad/0000-0002-5551-0353	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59205] Funding Source: Medline; NIAMS NIH HHS [AR30582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAYLISS R, 1986, J ROY COLL PHYS LOND, V20, P15; Benn M, 1997, J INTERN MED, V242, P15, DOI 10.1046/j.1365-2796.1997.00153.x; BERLIN JA, 1995, AM J CARDIOL, V76, P933, DOI 10.1016/S0002-9149(99)80264-1; Cabell CH, 2002, ARCH INTERN MED, V162, P90, DOI 10.1001/archinte.162.1.90; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; Fonager K, 2003, SCAND J INFECT DIS, V35, P27, DOI 10.1080/0036554021000026993; GRIFFIN MR, 1985, JAMA-J AM MED ASSOC, V254, P1199, DOI 10.1001/jama.254.9.1199; Hoen B, 2002, JAMA-J AM MED ASSOC, V288, P75, DOI 10.1001/jama.288.1.75; HOGEVIK H, 1995, MEDICINE, V74, P324, DOI 10.1097/00005792-199511000-00003; KING JW, 1988, AM J MED SCI, V295, P517, DOI 10.1097/00000441-198806000-00005; Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753; MCKINSEY DS, 1987, AM J MED, V82, P681, DOI 10.1016/0002-9343(87)90001-5; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Moreillon P, 2004, LANCET, V363, P139, DOI 10.1016/S0140-6736(03)15266-X; Mylonakis E, 2001, NEW ENGL J MED, V345, P1318, DOI 10.1056/NEJMra010082; NISSEN H, 1992, EUR HEART J, V13, P872, DOI 10.1093/oxfordjournals.eurheartj.a060285; Roder BL, 1999, ARCH INTERN MED, V159, P462, DOI 10.1001/archinte.159.5.462; STECKELBERG JM, 1990, AM J MED, V88, P582, DOI 10.1016/0002-9343(90)90521-E; Targonski P, 2001, ANN EPIDEMIOL, V11, P264, DOI 10.1016/S1047-2797(00)00220-9; VANDERMEER JTM, 1992, ARCH INTERN MED, V152, P1863, DOI 10.1001/archinte.152.9.1863; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505; WHITBY M, 1985, INT J CARDIOL, V7, P391, DOI 10.1016/0167-5273(85)90093-2	22	229	241	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 22	2005	293	24					3022	3028		10.1001/jama.293.24.3022	http://dx.doi.org/10.1001/jama.293.24.3022			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937SG	15972564	Bronze			2022-12-28	WOS:000229945200017
J	Bravata, DM; McDonald, KM; Shojania, KG; Sundaram, V; Owens, DK				Bravata, DM; McDonald, KM; Shojania, KG; Sundaram, V; Owens, DK			Challenges in systematic reviews: Synthesis of topics related to the delivery, organization, and financing of health care	ANNALS OF INTERNAL MEDICINE			English	Article							DECISION-SUPPORT-SYSTEMS; INTERVENTIONS; METAANALYSIS	Some important health policy topics, such as those related to the delivery, organization, and financing of health care, present substantial challenges to established methods for evidence synthesis. For example, such reviews may ask: What is the effect of for profit versus not-for-profit delivery of care on patient outcomes? Or, which strategies are the most effective for promoting preventive care? This paper describes innovative methods for synthesizing evidence related to the delivery, organization, and financing of health care. We found 13 systematic reviews on these topics that described novel methodologic approaches. Several of these syntheses used 3 approaches: conceptual frameworks to inform problem formulation, systematic searches that included nontraditional literature sources, and hybrid synthesis methods that included simulations to address key gaps in the literature. As the primary literature on these topics expands, so will opportunities to develop additional novel methods for performing high-quality comprehensive syntheses.	Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1N 6N5, Canada; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA	Stanford University; University of Ottawa; Ottawa Hospital Research Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Bravata, DM (corresponding author), Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, 117 Encina Commons, Stanford, CA 94305 USA.	dbravata@stanford.edu	Young, Alexander/A-1523-2009; Greiver, Michelle/N-8764-2015	Young, Alexander/0000-0002-9367-9213; Greiver, Michelle/0000-0001-8957-0285				ANDERSON R M, 1991; Bailey NTJ, 1975, MATH THEORY INFECT D; BERKMAN N, 2004, AHRQ PUBLICATION; Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007; Bravata D., 2002, AHRQ PUBLICATION; Bravata DM, 2004, MED DECIS MAKING, V24, P192, DOI 10.1177/0272989X04263254; Bravata DM, 2004, AHRQ PUBLICATION; BUNTIN MB, 2003, AHRQ PUBLICATION; COOPER HM, 1982, REV EDUC RES, V52, P291, DOI 10.3102/00346543052002291; Devereaux PJ, 2002, CAN MED ASSOC J, V166, P1399; Dixon-Woods Mary, 2005, J Health Serv Res Policy, V10, P45, DOI 10.1258/1355819052801804; Donaldson C, 2002, EVIDENCE BASED HLTH; DUDLEY RA, 2004, AHRQ PUBLICATION; Egger M, 2001, SYSTEMATIC REV HLTH; ELLIS P, 2003, AHRQ PUBLICATION; *EPOC GROUP, 2005, COCHR COLL; Fitch K., 2001, RAND UCLA APPROPRIAT; *GAO, 2003, GAO03139; Greenhalgh T, 2004, MILBANK Q, V82, P581, DOI 10.1111/j.0887-378X.2004.00325.x; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; HERSH WR, 2001, AHRQ PUBLICATION; Hickam DH, 2003, AHRQ PUBLICATION; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0; McDonald KM, 2002, AHRQ PUBLICATION, V02-0038; Mowatt G, 2001, J Contin Educ Health Prof, V21, P55, DOI 10.1002/chp.1340210109; Orwin R.G., 1994, HDB RES SYNTHESIS; POPAY J, 2005, COCHRANE QUALITATIVE; SHOJANIA K, 2001, AHRQ PUBLICATION; Shojania KG, 2004, AHRQ PUBLICATION, V04-0051-2; Stone EG, 2002, ANN INTERN MED, V136, P641, DOI 10.7326/0003-4819-136-9-200205070-00006; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Thomson O'Brien MA., 2000, COCHRANE DB SYST REV, V2; *U YORK CTR REV DI, 2005, DEV METH NARR SYNTH; *U YORK INF SERV R, 2005, INF RES HLTH EC; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; West S, 2002, AHRQ PUBLICATION, V02-E016; 2005, SEARCH TRIALS REGIST	40	37	37	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1056	1065		10.7326/0003-4819-142-12_Part_2-200506211-00005	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938CN	15968030				2022-12-28	WOS:000229977600005
J	Bricknell, MCM; MacCormack, T				Bricknell, MCM; MacCormack, T			ABC of conflict and disaster - Military approach to medical planning in humanitarian operations	BRITISH MEDICAL JOURNAL			English	Review									Canadian Forces Hlth Serv Grp Headquarters, Ottawa, ON, Canada				Bricknell, Martin/T-2970-2019	Bricknell, Martin/0000-0002-5080-0095				Ronald C, 1999, BMJ, V318; *UN OFF COORD HUM, 2003, GUID US MIL CIV DEF; World Health Organization, 1999, RAP HLTH ASS PROT EM	3	7	7	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 18	2005	330	7505					1437	1439		10.1136/bmj.330.7505.1437	http://dx.doi.org/10.1136/bmj.330.7505.1437			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938NP	15961817	Green Published			2022-12-28	WOS:000230010400021
J	Scolding, N				Scolding, N			Stem-cell therapy: hope and hype	LANCET			English	Editorial Material							PURKINJE NEURONS; REPAIR		Univ Bristol, Frenchay Hosp, Dept Neurol, Inst Clin Neurosci, Bristol BS16 1LE, Avon, England	University of Bristol	Scolding, N (corresponding author), Univ Bristol, Frenchay Hosp, Dept Neurol, Inst Clin Neurosci, Bristol BS16 1LE, Avon, England.	n.j.scolding@bristol.ac.uk						Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; Cogle CR, 2004, LANCET, V363, P1432, DOI 10.1016/S0140-6736(04)16102-3; Devine SM, 2003, BLOOD, V101, P2999, DOI 10.1182/blood-2002-06-1830; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Gussoni E, 2002, J CLIN INVEST, V110, P807, DOI 10.1172/JCI200216098; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; KITE M, 2000, TIMES LOND      1216; Klimanskaya I, 2005, LANCET, V365, P1636, DOI 10.1016/S0140-6736(05)66473-2; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; LAPHAM LW, 1968, SCIENCE, V159, P310, DOI 10.1126/science.159.3812.310; Pochampally RR, 2004, P NATL ACAD SCI USA, V101, P9282, DOI 10.1073/pnas.0401558101; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Rehen SK, 2005, J NEUROSCI, V25, P2176, DOI 10.1523/JNEUROSCI.4560-04.2005; Rice CM, 2004, LANCET, V364, P193, DOI 10.1016/S0140-6736(04)16633-6; Rice CM, 2003, TRANSFUSION MED, V13, P351, DOI 10.1111/j.1365-3148.2003.00463.x; SAMPLE I, 2004, GUARDIAN        0819; Sigurjonsson OE, 2005, P NATL ACAD SCI USA, V102, P5227, DOI 10.1073/pnas.0501029102; Smith LC, 2004, CLONING STEM CELLS, V6, P126, DOI 10.1089/1536230041372319; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9; 2001, LANCET, V358, P163	22	10	11	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2073	2075		10.1016/S0140-6736(05)66554-3	http://dx.doi.org/10.1016/S0140-6736(05)66554-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964432				2022-12-28	WOS:000229858800009
J	Taylor, MJ; Makunde, WH; McGarry, HF; Turner, JD; Mand, S; Hoerauf, A				Taylor, MJ; Makunde, WH; McGarry, HF; Turner, JD; Mand, S; Hoerauf, A			Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-control led trial	LANCET			English	Article							ENDOSYMBIOTIC WOLBACHIA-BACTERIA; FILARIAL NEMATODES; LYMPHATIC FILARIASIS; BRUGIA-MALAYI; ONCHOCERCA-VOLVULUS; ANTIBIOTICS; WORMS; DIETHYLCARBAMAZINE; CHEMOTHERAPY; TETRACYCLINE	Background Wolbachia endosymbionts of filarial nematodes are vital for larval development and adult-worm fertility and viability. This essential dependency on the bacterium for survival of the parasites has provided a new approach to treat filariasis with antibiotics. We used this strategy to investigate the effects of doxycycline treatment on the major cause of lymphatic filariasis, Wuchereria bancrofti. Methods We undertook a double-blind, randomised, placebo-controlled field trial of doxycycline (200 mg per day) for 8 weeks in 72 individuals infected with W bancrofti from Kimang'a village, Pangani, Tanzania. Participants were randomly assigned by block randomisation to receive capsules of doxycycline (n=34) or placebo (n=38). We assessed treatment efficacy by monitoring microfilaraemia, antigenaemia, and ultrasound detection of adult worms. Followup assessments were done at 5, 8, 11, and 14 months after the start of treatment. Analysis was per protocol. Findings One person from the doxycycline group died from HIV infection. Five (doxycycline) and 11 (placebo) individuals were absent at the time of ultrasound analysis. Doxycycline treatment almost completely eliminated microfilaraemia at 8-14 months' follow-up (for all timepoints p<0.001). Ultrasonography detected adult worms in only six (22%) of 27 individuals treated with doxycycline compared with 24 (88%) of 27 with placebo at 14 months after the start of treatment (p<0.0001). At the same timepoint, filarial antigenaemia in the doxycycline group fell to about half of that before treatment (p=0.015). Adverse events were few and mild. Interpretation An 8-week course of doxycycline is a safe and well-tolerated treatment for lymphatic filariasis with significant activity against adult worms and microfilaraemia.	Univ Liverpool, Liverpool Sch Trop Med, Filariasis Res Grp, Liverpool L3 5QA, Merseyside, England; Natl Inst Med Res, Bombo Res Stn, Tanga, Tanzania; Univ Bonn, Inst Med Parasitol, D-5300 Bonn, Germany; Bernhard Nocht Inst Trop Med, Hamburg, Germany	Liverpool School of Tropical Medicine; University of Liverpool; University of Bonn; Bernhard Nocht Institut fur Tropenmedizin	Taylor, MJ (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Filariasis Res Grp, Liverpool L3 5QA, Merseyside, England.	mark.taylor@liv.ac.uk		Taylor, Mark/0000-0003-3396-9275; Turner, Joseph/0000-0002-2185-5476				Bandi C, 1998, P ROY SOC B-BIOL SCI, V265, P2407, DOI 10.1098/rspb.1998.0591; Bockarie MJ, 2002, NEW ENGL J MED, V347, P1841, DOI 10.1056/NEJMoa021309; Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232-260.2001; Chrigwin SR, 2003, EXP PARASITOL, V103, P16, DOI 10.1016/S0014-4894(03)00063-8; Cross HF, 2001, LANCET, V358, P1873, DOI 10.1016/S0140-6736(01)06899-4; Dreyer G, 1998, T ROY SOC TROP MED H, V92, P219, DOI 10.1016/S0035-9203(98)90754-4; Faris R, 1998, AM J TROP MED HYG, V59, P864, DOI 10.4269/ajtmh.1998.59.864; Figueredo-Silva J, 2002, ANN TROP MED PARASIT, V96, P531, DOI 10.1179/000349802125001348; Freedman DO, 2001, TROP MED INT HEALTH, V6, P37, DOI 10.1046/j.1365-3156.2001.00666.x; Hoerauf A, 2000, LANCET, V355, P1242, DOI 10.1016/S0140-6736(00)02095-X; Hoerauf A, 2003, MED MICROBIOL IMMUN, V192, P211, DOI 10.1007/s00430-002-0174-6; Hoerauf A, 2003, MICROBES INFECT, V5, P261, DOI 10.1016/S1286-4579(03)00026-1; Hoerauf A, 2001, LANCET, V357, P1415, DOI 10.1016/S0140-6736(00)04581-5; Hoerauf Achim, 2002, Curr Opin Investig Drugs, V3, P533; Keiser PB, 2002, J INFECT DIS, V185, P805, DOI 10.1086/339344; Langworthy NG, 2000, P ROY SOC B-BIOL SCI, V267, P1063, DOI 10.1098/rspb.2000.1110; Mand Sabine, 2003, Filaria J, V2, P3, DOI 10.1186/1475-2883-2-3; Molyneux DH, 2003, TRENDS PARASITOL, V19, P516, DOI 10.1016/j.pt.2003.09.004; Ottesen EA, 1997, B WORLD HEALTH ORGAN, V75, P491; Punkosdy GA, 2003, INFECT IMMUN, V71, P5104, DOI 10.1128/IAI.71.9.5104-5114.2003; Rao R, 2002, J PARASITOL, V88, P605, DOI 10.1645/0022-3395(2002)088[0605:IVEOAO]2.0.CO;2; Saint Andre AV, 2002, SCIENCE, V295, P1892, DOI 10.1126/science.1068732; Taylor MJ, 1999, EXP PARASITOL, V91, P356, DOI 10.1006/expr.1998.4383; Taylor MJ, 2000, J EXP MED, V191, P1429, DOI 10.1084/jem.191.8.1429; Taylor MJ, 1999, PARASITOL TODAY, V15, P437, DOI 10.1016/S0169-4758(99)01533-1; Taylor MJ, 2001, CURR OPIN INFECT DIS, V14, P727, DOI 10.1097/00001432-200112000-00011; Townson S, 2000, ANN TROP MED PARASIT, V94, P801, DOI 10.1080/00034980020027988; *WHO, ANN REP LYMPH FIL	28	171	176	0	34	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2116	2121		10.1016/S0140-6736(05)66591-9	http://dx.doi.org/10.1016/S0140-6736(05)66591-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964448				2022-12-28	WOS:000229858800028
J	Leyser, O				Leyser, O			Auxin distribution and plant pattern formation: How many angels can dance on the point of PIN?	CELL			English	Review							ARABIDOPSIS; TRANSPORT; GRADIENTS	The plant hormone auxin is central in patterning diverse plant tissues. The direction of auxin flow and the distribution of auxin within tissues are regulated by auxin efflux transporters that are polarly localized in cells. Feedback regulation between auxin and its transporters establishes homeostatic patterns of auxin accumulation but allows dynamic repatterning in response to developmental or environmental cues.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	University of York - UK	Leyser, O (corresponding author), Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England.	hmol1@york.ac.uk	Leyser, Ottoline/AAC-5577-2019	Leyser, Ottoline/0000-0003-2161-3829	Biotechnology and Biological Sciences Research Council [BBS/B/09392] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aida M, 2004, CELL, V119, P109, DOI 10.1016/j.cell.2004.09.018; Bauly JM, 2000, PLANT PHYSIOL, V124, P1229, DOI 10.1104/pp.124.3.1229; Benjamins R, 2001, DEVELOPMENT, V128, P4057; Benkova E, 2003, CELL, V115, P591, DOI 10.1016/S0092-8674(03)00924-3; Bhalerao RP, 2002, PLANT J, V29, P325, DOI 10.1046/j.0960-7412.2001.01217.x; BILIOU I, 2005, NATURE, V433, P39; CARLES CC, 2003, NATURE, V415, P806; Friml J, 2004, SCIENCE, V306, P862, DOI 10.1126/science.1100618; Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6; Friml J, 2003, NATURE, V426, P147, DOI 10.1038/nature02085; Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571; Leyser O, 2002, ANNU REV PLANT BIOL, V53, P377, DOI 10.1146/annurev.arplant.53.100301.135227; Lomax Terri L., 1995, P509; Ottenschlager I, 2003, P NATL ACAD SCI USA, V100, P2987, DOI 10.1073/pnas.0437936100; Paponov IA, 2005, TRENDS PLANT SCI, V10, P170, DOI 10.1016/j.tplants.2005.02.009; Reinhardt D, 2003, NATURE, V426, P255, DOI 10.1038/nature02081; Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4; Sieberer T, 2000, CURR BIOL, V10, P1595, DOI 10.1016/S0960-9822(00)00861-7; Swarup R, 2001, GENE DEV, V15, P2648, DOI 10.1101/gad.210501	19	106	116	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	2005	121	6					819	822		10.1016/j.cell.2005.06.005	http://dx.doi.org/10.1016/j.cell.2005.06.005			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960970	Bronze			2022-12-28	WOS:000230011200005
J	Schernhammer, E				Schernhammer, E			Taking their own lives - The high rate of physician suicide.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Boston, MA 02114 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Schernhammer, E (corresponding author), Harvard Univ, Sch Med, Boston, MA 02114 USA.		Schernhammer, Eva S/L-7898-2018	Schernhammer, Eva S/0000-0002-4337-9415				Frank E, 1998, ARCH INTERN MED, V158, P352, DOI 10.1001/archinte.158.4.352; KIRSLING RA, 1989, PSYCHOL REP, V64, P951, DOI 10.2466/pr0.1989.64.3.951; LITMAN RE, 1987, SUICIDE LIFE-THREAT, V17, P85; PEPITONEARREOLAROCKWELL F, 1981, AM J PSYCHIAT, V138, P198; Schernhammer ES, 2004, AM J PSYCHIAT, V161, P2295, DOI 10.1176/appi.ajp.161.12.2295	5	134	138	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2005	352	24					2473	2476		10.1056/NEJMp058014	http://dx.doi.org/10.1056/NEJMp058014			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	935RH	15958803				2022-12-28	WOS:000229798900002
J	Hackel, J				Hackel, J			Informed consent	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	2005	293	23					2838	2838		10.1001/jama.293.23.2838	http://dx.doi.org/10.1001/jama.293.23.2838			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935MD	15956615				2022-12-28	WOS:000229785500001
J	Scholte, EJ; Ng'habi, K; Kihonda, J; Takken, W; Paaijmans, K; Abdulla, S; Killeen, GF; Knols, BGJ				Scholte, EJ; Ng'habi, K; Kihonda, J; Takken, W; Paaijmans, K; Abdulla, S; Killeen, GF; Knols, BGJ			An entomopathogenic fungus for control of adult African malaria mosquitoes	SCIENCE			English	Article							INSECTICIDE-TREATED NETS; SOUTH-AFRICA	Biological control of malaria mosquitoes in Africa has rarely been used in vector control programs. Recent developments in this field show that certain fungi are virulent to adult Anopheles mosquitoes. Practical delivery of an entomopathogenic fungus that infected and killed adult Anopheles gambiae, Africa's main malaria vector, was achieved in rural African village houses. An entomological inoculation rate model suggests that implementation of this vector control method, even at the observed moderate coverage during a field study in Tanzania, would significantly reduce malaria transmission intensity.	Univ Wageningen & Res Ctr, Entomol Lab, NL-6700 EH Wageningen, Netherlands; Ifakara Hlth Res & Dev Ctr, Ifakara, Tanzania; Swiss Trop Inst, Dept Epidemiol & Publ Hlth, CH-4002 Basel, Switzerland; IAEA, Agcy Labs Seibersdorf, A-2444 Seibersdorf, Austria	Wageningen University & Research; Ifakara Health Institute; University of Basel; Swiss Tropical & Public Health Institute; International Atomic Energy Agency	Knols, BGJ (corresponding author), Univ Wageningen & Res Ctr, Entomol Lab, POB 8031, NL-6700 EH Wageningen, Netherlands.	B.Knols@IAEA.org	Paaijmans, Krijn/ABC-9928-2020					[Anonymous], 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000363.PUB2; Blanford S, 2005, SCIENCE, V308, P1638, DOI 10.1126/science.1108423; Boucias D.G., 1998, PRINCIPLES INSECT PA, P177; Curtis CF, 2000, B WORLD HEALTH ORGAN, V78, P1389; Fillinger U, 2003, TROP MED INT HEALTH, V8, P37, DOI 10.1046/j.1365-3156.2003.00979.x; Hargreaves K, 2000, MED VET ENTOMOL, V14, P181, DOI 10.1046/j.1365-2915.2000.00234.x; Hargreaves K, 2003, MED VET ENTOMOL, V17, P417, DOI 10.1111/j.1365-2915.2003.00460.x; Killeen GF, 2000, AM J TROP MED HYG, V62, P535, DOI 10.4269/ajtmh.2000.62.535; Kouznetsov R L, 1977, Trop Doct, V7, P81; Mabaso MLH, 2004, TROP MED INT HEALTH, V9, P846, DOI 10.1111/j.1365-3156.2004.01263.x; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; PAPIEROK B, 2001, P 8 EUR M IOBC WPRS; Schellenberg JRMA, 2001, LANCET, V357, P1241, DOI 10.1016/S0140-6736(00)04404-4; Scholte EJ, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-29; SCHOLTE EJ, IN PRESS J INVERTEBR; *WHO, 1993, WHO TECH REP SER, V839; World Health Organization (WHO), 1975, WHO OFFS PUBL, V13	17	254	268	1	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1641	1642		10.1126/science.1108639	http://dx.doi.org/10.1126/science.1108639			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947190				2022-12-28	WOS:000229827000061
J	Main, CJ				Main, CJ			Commentary: Early psychosocial interventions for low back pain in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Manchester, Calderbank Res Unit, Manchester M20 3JQ, Lancs, England	University of Manchester	Main, CJ (corresponding author), Univ Manchester, Calderbank Res Unit, Manchester M20 3JQ, Lancs, England.	cjmain@gmail.com						Jellema P, 2005, BMJ-BRIT MED J, V331, P84, DOI 10.1136/bmj.38495.686736.E0; Linton SJ, 2000, SPINE, V25, P1148, DOI 10.1097/00007632-200005010-00017; Main C., 2000, PAIN MANAGEMENT INTE; Main CJ, 2002, BMJ-BRIT MED J, V325, P534, DOI 10.1136/bmj.325.7363.534; Morley S, 1999, PAIN, V80, P1, DOI 10.1016/S0304-3959(98)00255-3	5	2	2	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 9	2005	331	7508					88	88		10.1136/bmj.38498.495000.E0	http://dx.doi.org/10.1136/bmj.38498.495000.E0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	945XR	15967763	Bronze, Green Published			2022-12-28	WOS:000230536800016
J	Lyden, SD; Nojadera, L				Lyden, SD; Nojadera, L			Ruptured ectopic pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Hawaii, Honolulu, HI 96813 USA; Kaiser Permanente, Honolulu, HI 96819 USA	University of Hawaii System; Kaiser Permanente	Lyden, SD (corresponding author), Univ Hawaii, Honolulu, HI 96813 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2005	353	1					74	74		10.1056/NEJMicm050182	http://dx.doi.org/10.1056/NEJMicm050182			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942FC	16000357				2022-12-28	WOS:000230267300010
J	van Dam, RM; Hu, FB				van Dam, RM; Hu, FB			Coffee consumption and risk of type 2 diabetes - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CAFFEINE-INDUCED IMPAIRMENT; GLUCOSE-TOLERANCE; CHLOROGENIC ACID; BLOOD-GLUCOSE; INSULIN ACTION; LIFE-STYLE; METAANALYSIS; INGESTION; PLASMA; MEN	Context Emerging epidemiological evidence suggests that higher coffee consumption may reduce the risk of type 2 diabetes. Objective To examine the association between habitual coffee consumption and risk of type 2 diabetes and related outcomes. Data Sources and Study Selection We searched MEDLINE through January 2005 and examined the reference lists of the retrieved articles. Because this review focuses on studies of habitual coffee consumption and risk of type 2 diabetes, we excluded studies of type 1 diabetes, animal studies, and studies of short-term exposure to coffee or caffeine, leaving 15 epidemiological studies (cohort or cross-sectional). Data Extraction Information on study design, participant characteristics, measurement of coffee consumption and outcomes, adjustment for potential confounders, and estimates of associations was abstracted independently by 2 investigators. Data Synthesis We identified 9 cohort studies of coffee consumption and risk of type 2 diabetes, including 193 473 participants and 8394 incident cases of type 2 diabetes, and calculated summary relative risks (RRs) using a random-effects model. The RR of type 2 diabetes was 0.65 (95% confidence interval [CI], 0. 54-0.78) for the highest (>= 6 or >= 7 cups per day) and 0.72 (95% Cl, 0.62-0.83) for the second highest (4-6 cups per day) category of coffee-consumption compared with the lowest consumption category (0 or <= 2 cups per day). These associations did not differ substantially by sex, obesity, or region (United States and Europe). In the cross-sectional studies conducted in northern Europe, southern Europe, and Japan, higher coffee consumption was consistently associated with a lower prevalence of newly detected hyperglycemia, particularly postprandial hyperglycemia. Conclusions This systematic review supports the hypothesis that habitual coffee consumption is associated with a substantially lower risk of type 2 diabetes. Longer-term intervention studies of coffee consumption and glucose metabolism are warranted to examine the mechanisms underlying the relationship between coffee consumption and type 2 diabetes.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Nutr & Hlth, Amsterdam, Netherlands	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Vrije Universiteit Amsterdam	van Dam, RM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave,Bldg 2, Boston, MA 02115 USA.	rvan-dam@hsph.harvard.edu	van Dam, Rob M/F-9674-2010	van Dam, Rob M/0000-0002-7354-8734	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058845] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58845] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agardh EE, 2004, J INTERN MED, V255, P645, DOI 10.1111/j.1365-2796.2004.01331.x; Andrade-Cetto A, 2001, J ETHNOPHARMACOL, V78, P145, DOI 10.1016/S0378-8741(01)00335-X; Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874; Arnlov J, 2004, JAMA-J AM MED ASSOC, V291, P1199, DOI 10.1001/jama.291.10.1199-a; ASTRUP A, 1992, INT J OBESITY, V16, P269; Bracken MB, 2002, EPIDEMIOLOGY, V13, P165, DOI 10.1097/00001648-200203000-00011; BROWN CR, 1989, PHARMACOL BIOCHEM BE, V34, P565, DOI 10.1016/0091-3057(89)90559-5; Carlsson S, 2004, INT J EPIDEMIOL, V33, P616, DOI 10.1093/ije/dyh185; Ceriello A, 2004, ARTERIOSCL THROM VAS, V24, P816, DOI 10.1161/01.ATV.0000122852.22604.78; de Paulis T, 2002, EUR J PHARMACOL, V442, P215, DOI 10.1016/S0014-2999(02)01540-6; de Sotillo DVR, 2002, J NUTR BIOCHEM, V13, P717, DOI 10.1016/S0955-2863(02)00231-0; de Valk HW, 1999, NETH J MED, V54, P139, DOI 10.1016/S0300-2977(99)00005-4; deGroot JGAJ, 1996, EUR J CLIN NUTR, V50, pS101; DENARO CP, 1991, EUR J CLIN PHARMACOL, V40, P273, DOI 10.1007/BF00315208; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; Graham TE, 1998, J APPL PHYSIOL, V85, P883, DOI 10.1152/jappl.1998.85.3.883; GREENLAND S, 1998, MODERN EPIDEMIOLOGY, P643; Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349; Isogawa A, 2003, LANCET, V361, P703, DOI 10.1016/S0140-6736(03)12586-X; Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728; KAWACHI I, 1994, BRIT HEART J, V72, P269; Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Koppes LLJ, 2005, DIABETES CARE, V28, P719, DOI 10.2337/diacare.28.3.719; Lane JD, 2004, DIABETES CARE, V27, P2047, DOI 10.2337/diacare.27.8.2047; *NAT COFF ASS, 2002, NAT COFF DRINK TREND; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306; PIETINEN P, 1988, PREV MED, V17, P183, DOI 10.1016/0091-7435(88)90062-X; Pizziol A, 1998, EUR J CLIN NUTR, V52, P846, DOI 10.1038/sj.ejcn.1600657; Pulido R, 2003, EUR J CLIN NUTR, V57, P1275, DOI 10.1038/sj.ejcn.1601685; Reunanen A, 2003, LANCET, V361, P702, DOI 10.1016/S0140-6736(03)12583-4; ROBERTSON D, 1981, J CLIN INVEST, V67, P1111, DOI 10.1172/JCI110124; Robinson LE, 2004, J NUTR, V134, P2528, DOI 10.1093/jn/134.10.2528; Rosenberg MS, 2005, EVOLUTION, V59, P464, DOI 10.1554/04-602; Rosengren A, 2004, J INTERN MED, V255, P89, DOI 10.1046/j.1365-2796.2003.01260.x; Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; Saremi A, 2003, DIABETES CARE, V26, P2211, DOI 10.2337/diacare.26.7.2211; Schaafsma G., 1989, Voeding, V50, P223; Schaefer B, 2004, ANN INTERN MED, V141, P321, DOI 10.7326/0003-4819-141-4-200408170-00016; Shearer J, 2003, J NUTR, V133, P3529, DOI 10.1093/jn/133.11.3529; Soriguer F, 2004, ANN INTERN MED, V141, P321, DOI 10.7326/0003-4819-141-4-200408170-00017; Sutton AJ, 2000, STAT METHODS MED RES, V9, P421, DOI 10.1191/096228000701555244; Svilaas A, 2004, J NUTR, V134, P562, DOI 10.1093/jn/134.3.562; Tavani A, 2000, EUR J CANCER PREV, V9, P241, DOI 10.1097/00008469-200008000-00004; Thong FSL, 2002, J APPL PHYSIOL, V92, P2347, DOI 10.1152/japplphysiol.01229.2001; Thong FSL, 2002, DIABETES, V51, P583, DOI 10.2337/diabetes.51.3.583; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213; Urgert R, 1996, BRIT MED J, V313, P1362, DOI 10.1136/bmj.313.7069.1362; van Dam RM, 2004, DIABETOLOGIA, V47, P2152, DOI 10.1007/s00125-004-1573-6; Van Dam RM, 2004, DIABETES CARE, V27, P2990, DOI 10.2337/diacare.27.12.2990; van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X; van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040; VANDAM RM, 2003, ANN NUTR METAB, V47, P627; WACHMAN A, 1970, METABOLIS, V19, P539, DOI 10.1016/0026-0495(70)90009-0; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Yamaji T, 2004, DIABETOLOGIA, V47, P2145, DOI 10.1007/s00125-004-1590-5; Yoshioka K, 2003, LANCET, V361, P703, DOI 10.1016/S0140-6736(03)12585-8	62	474	488	1	88	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2005	294	1					97	104		10.1001/jama.294.1.97	http://dx.doi.org/10.1001/jama.294.1.97			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941JD	15998896				2022-12-28	WOS:000230210200030
J	Nowotny, M; Gaidamakov, SA; Crouch, RJ; Yang, W				Nowotny, M; Gaidamakov, SA; Crouch, RJ; Yang, W			Crystal structures of RNase H bound to an RNA/DNA hybrid: Substrate specificity and metal-dependent catalysis	CELL			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; COLI RIBONUCLEASE HI; SINGLE ACTIVE-SITE; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; SYNAPTIC COMPLEX; POLYPURINE TRACT; SLICER ACTIVITY; DNA; TRANSPOSITION	RNase H belongs to a nucleotidyl-transferase superfamily, which includes transposase, retroviral integrase, Holliday junction resolvase, and RISC nuclease Argonaute. We report the crystal structures of RNase H complexed with an RNA/DNA hybrid and a mechanism for substrate recognition and two-metal-ion-dependent catalysis. RNase H specifically recognizes the A form RNA strand and the B form DNA strand. Structure comparisons lead us to predict the catalytic residues of Argonaute and conclude that two-metal-ion catalysis is a general feature of the superfamily. In nucleases, the two metal ions are asymmetrically coordinated and have distinct roles in activating the nucleophile and stabilizing the transition state. In transposases, they are symmetrically coordinated and exchange roles to alternately activate a water and a 3'-OH for successive strand cleavage and transfer by a ping-pong mechanism.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NICHHD, Genet Mol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Yang, W (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	wei.yang@nih.gov	Yang, Wei/D-4926-2011; Yang, Wei/ABB-4785-2020	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000068] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK036119, Z01DK036119] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Arudchandran A, 2000, GENES CELLS, V5, P789, DOI 10.1046/j.1365-2443.2000.00373.x; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; Broccoli S, 2004, MOL MICROBIOL, V52, P1769, DOI 10.1111/j.1365-2958.2004.04092.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1; Ceschini S, 2001, EMBO J, V20, P6601, DOI 10.1093/emboj/20.23.6601; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; Goedken ER, 2001, J BIOL CHEM, V276, P7266, DOI 10.1074/jbc.M009626200; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; Haren L, 1999, ANNU REV MICROBIOL, V53, P245, DOI 10.1146/annurev.micro.53.1.245; Haruki M, 2000, BIOCHEMISTRY-US, V39, P13939, DOI 10.1021/bi001469+; Haruki M, 1997, J BIOL CHEM, V272, P22015, DOI 10.1074/jbc.272.35.22015; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Hughes SH, 1998, RESEARCH IN, P195; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Julias JG, 2002, P NATL ACAD SCI USA, V99, P9515, DOI 10.1073/pnas.142123199; Kanaya S, 1998, RESEARCH IN, P1; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; Keck JL, 1998, J BIOL CHEM, V273, P34128, DOI 10.1074/jbc.273.51.34128; Kennedy AK, 2000, CELL, V101, P295, DOI 10.1016/S0092-8674(00)80839-9; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kogoma T, 1998, RESEARCH IN, P39; Kopka ML, 2003, J MOL BIOL, V334, P653, DOI 10.1016/j.jmb.2003.09.057; Krakowiak A, 2002, CHEMBIOCHEM, V3, P1242, DOI 10.1002/1439-7633(20021202)3:12<1242::AID-CBIC1242>3.0.CO;2-Y; Lai LH, 2000, STRUCTURE, V8, P897, DOI 10.1016/S0969-2126(00)00179-9; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; Lovell S, 2002, NAT STRUCT BIOL, V9, P278, DOI 10.1038/nsb778; ODA Y, 1993, J BIOL CHEM, V268, P88; Ohtani N, 1999, BIOCHEMISTRY-US, V38, P605, DOI 10.1021/bi982207z; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parker JS, 2004, EMBO J, V23, P4727, DOI 10.1038/sj.emboj.7600488; REPASKE R, 1989, J VIROL, V63, P1460, DOI 10.1128/JVI.63.3.1460-1464.1989; Rice PA, 2001, NAT STRUCT BIOL, V8, P302, DOI 10.1038/86166; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Steiniger-White M, 2004, CURR OPIN STRUC BIOL, V14, P50, DOI 10.1016/j.sbi.2004.01.008; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; Tsunaka Y, 2005, J MOL BIOL, V345, P1171, DOI 10.1016/j.jmb.2004.11.007; Wu HJ, 2004, J BIOL CHEM, V279, P17181, DOI 10.1074/jbc.M311683200; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; Zhou LQ, 2004, NATURE, V432, P995, DOI 10.1038/nature03157	46	474	496	6	57	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	2005	121	7					1005	1016		10.1016/j.cell.2005.04.024	http://dx.doi.org/10.1016/j.cell.2005.04.024			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989951	Bronze			2022-12-28	WOS:000230448000008
J	Seligson, DB; Horvath, S; Shi, T; Yu, H; Tze, S; Grunstein, M; Kurdistani, SK				Seligson, DB; Horvath, S; Shi, T; Yu, H; Tze, S; Grunstein, M; Kurdistani, SK			Global histone modification patterns predict risk of prostate cancer recurrence	NATURE			English	Article							TARGETED RECRUITMENT; ACETYLATION; CHROMATIN; ANTIGEN; P300	Aberrations in post-translational modifications of histones have been shown to occur in cancer cells but only at individual promoters(1); they have not been related to clinical outcome. Other than being targeted to promoters, modifications of histones, such as acetylation and methylation of lysine and arginine residues, also occur over large regions of chromatin including coding regions and non-promoter sequences, which are referred to as global histone modifications(2). Here we show that changes in global levels of individual histone modifications are also associated with cancer and that these changes are predictive of clinical outcome. Through immunohistochemical staining of primary prostatectomy tissue samples, we determined the percentage of cells that stained for the histone acetylation and dimethylation of five residues in histones H3 and H4. Grouping of samples with similar patterns of modifications identified two disease subtypes with distinct risks of tumour recurrence in patients with low-grade prostate cancer. These histone modification patterns were predictors of outcome independently of tumour stage, preoperative prostate-specific antigen levels, and capsule invasion. Thus, widespread changes in specific histone modifications indicate previously undescribed molecular heterogeneity in prostate cancer and might underlie the broad range of clinical behaviour in cancer patients.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Kurdistani, SK (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.	skurdistani@mednet.ucla.edu		, Tao/0000-0001-5489-2655; Kurdistani, Siavash/0000-0003-3295-3511				Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Breiman L., 1984, CLASSIFICATION REGRE; Bunting PS, 2002, CLIN CHIM ACTA, V315, P71, DOI 10.1016/S0009-8981(01)00717-3; Cleveland WS., 1993, VISUALIZING DATA; Debes JD, 2003, CANCER RES, V63, P7638; Farkas A, 1998, UROLOGY, V52, P444, DOI 10.1016/S0090-4295(98)00242-8; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125; Han M, 2001, J UROLOGY, V166, P416, DOI 10.1016/S0022-5347(05)65955-1; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Muraoka M, 1996, ONCOGENE, V12, P1565; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Rezai-Zadeh N, 2003, GENE DEV, V17, P1019, DOI 10.1101/gad.1068003; Shi T, 2005, MODERN PATHOL, V18, P547, DOI 10.1038/modpathol.3800322; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127	24	781	848	1	76	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1262	1266		10.1038/nature03672	http://dx.doi.org/10.1038/nature03672			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988529				2022-12-28	WOS:000230140500049
J	Ramchandani, P; Stein, A; Evans, J; O'Connor, TG				Ramchandani, P; Stein, A; Evans, J; O'Connor, TG		ALSPAC Study Team	Paternal depression in the postnatal period and child development: a prospective population study	LANCET			English	Article							POSTPARTUM DEPRESSION; PSYCHIATRIC-DISORDER; BEHAVIOR; IMPACT; VALIDATION; PARENTS; SCALE; STRENGTHS; MEN	Background Depression is common and frequently affects mothers and fathers of young children. Postnatal depression in mothers affects the quality of maternal care, and can lead to disturbances in their children's social, behavioural, cognitive, and physical development. However, the effect of depression in fathers during the early years of a child's life has received little attention. Methods As part of a large, population-based study of childhood, we assessed the presence of depressive symptoms in mothers (n=13 351) and fathers (n=12 884) 8 weeks after the birth of their child with the Edinburgh postnatal depression scale (EPDS). Fathers were reassessed at 21 months. We identified any subsequent development of behavioural and emotional problems in their children (n=10 024) at age 3.5 years with maternal reports on the Rutter revised preschool scales. Findings Information was available for 8431 fathers, 11833 mothers, and 10 024 children. Depression in fathers during the postnatal period was associated with adverse emotional and behavioural outcomes in children aged 3.5 years (adjusted odds ratio 2.09, 95% CI 1.42-3.08), and an increased risk of conduct problems in boys (2.66, 1.67-4.25). These effects remained even after controlling for maternal postnatal depression and later paternal depression. Interpretation Our findings indicate that paternal depression has a specific and persisting detrimental effect on their children's early behavioural and emotional development.	Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; Univ Bristol, Acad Unit Psychiat, Bristol, Avon, England; Univ Bristol, Dept Community Based Med, Bristol, Avon, England; Univ Rochester, Dept Psychiat, Rochester, NY USA	University of Oxford; University of Bristol; University of Bristol; University of Rochester	Ramchandani, P (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	paul.ramchandani@psych.ox.ac.uk	Ramchandani, Paul/O-5340-2014; O'Connor, Tom/AAG-1598-2020	Ramchandani, Paul/0000-0003-3646-2410; O'Connor, Tom/0000-0002-8590-5057; Evans, Jonathan/0000-0003-3171-640X; Stein, Alan/0000-0001-8207-2822	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEARDSLEE WR, 1993, J AM ACAD CHILD PSY, V32, P723, DOI 10.1097/00004583-199307000-00004; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Cox JL, 1996, J AFFECT DISORDERS, V39, P185, DOI 10.1016/0165-0327(96)00008-0; Deater-Deckard K, 1998, AM J PSYCHIAT, V155, P818; DOWNEY G, 1990, PSYCHOL BULL, V108, P50, DOI 10.1037/0033-2909.108.1.50; Elander J, 1996, INT J METHOD PSYCH, V6, P63, DOI 10.1002/(SICI)1234-988X(199607)6:2<63::AID-MPR151>3.3.CO;2-M; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Goodman JH, 2004, J ADV NURS, V45, P26, DOI 10.1046/j.1365-2648.2003.02857.x; Goodman R, 2001, J AM ACAD CHILD PSY, V40, P1337, DOI 10.1097/00004583-200111000-00015; Goodman R, 1999, J ABNORM CHILD PSYCH, V27, P17, DOI 10.1023/A:1022658222914; GOODMAN SH, 1993, CHILD DEV, V64, P516, DOI 10.1111/j.1467-8624.1993.tb02925.x; Kane P, 2004, CLIN PSYCHOL REV, V24, P339, DOI 10.1016/j.cpr.2004.03.004; Lamb M. E., 2004, ROLE FATHER CHILD DE, V4th; Matthey S, 2001, J AFFECT DISORDERS, V64, P175, DOI 10.1016/S0165-0327(00)00236-6; Meltzer H., 2000, MENTAL HLTH CHILDREN; Murray CJL, 1997, LANCET, V349, P1347, DOI 10.1016/S0140-6736(96)07494-6; MURRAY L, 1990, BRIT J PSYCHIAT, V157, P288, DOI 10.1192/bjp.157.2.288; Murray L., 2003, UNIPOLAR DEPRESSION; Newport DJ, 2002, AM J PSYCHIAT, V159, P1265, DOI 10.1176/appi.ajp.159.8.1265; O'Connor TG, 2003, DEV PSYCHOPATHOL, V15, P19, DOI 10.1017/S0954579403000026; OHara MW, 1996, INT REV PSYCHIATR, V8, P37, DOI 10.3109/09540269609037816; Plomin R, 2002, J CHILD PSYCHOL PSYC, V43, P619, DOI 10.1111/1469-7610.00051; Rahman A, 2004, ARCH GEN PSYCHIAT, V61, P946, DOI 10.1001/archpsyc.61.9.946; Ramchandani P, 2003, BRIT MED J, V327, P242, DOI 10.1136/bmj.327.7409.242; Rutter M, 2004, DEV PSYCHOL, V40, P81, DOI 10.1037/0012-1649.40.1.81; Sharp D, 1995, J CHILD PSYCHOL PSYC, V36, P1315, DOI 10.1111/j.1469-7610.1995.tb01666.x; Sinclair D, 1998, BRIT J PSYCHIAT, V172, P58, DOI 10.1192/bjp.172.1.58; Stein A, 2001, BRIT J PSYCHIAT, V179, P157, DOI 10.1192/bjp.179.2.157; Suomi SJ, 1997, BRIT MED BULL, V53, P170; Western Australia Commissioner for Children and Young People, 2020, NAT SERV FRAM CHILDR; ZAHNWAXLER C, 1993, DEV PSYCHOPATHOL, V5, P79, DOI 10.1017/S0954579400004272	31	550	567	1	91	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	2005	365	9478					2201	2205		10.1016/S0140-6736(05)66778-5	http://dx.doi.org/10.1016/S0140-6736(05)66778-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	938WT	15978928				2022-12-28	WOS:000230034800030
J	Miller, RA				Miller, RA			The anti-aging sweepstakes: Catalase runs for the ROSes	SCIENCE			English	Editorial Material							LIFE-SPAN; RESISTANCE; LONGEVITY; STRESS; LIMITS; MICE		Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Geriatr Ctr, Ann Arbor, MI 48109 USA; Ann Arbor DVA Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Miller, RA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.	millerr@umich.edu						Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Kapahi P, 1999, FREE RADICAL BIO MED, V26, P495, DOI 10.1016/S0891-5849(98)00323-2; Lithgow GJ, 2002, MECH AGEING DEV, V123, P765, DOI 10.1016/S0047-6374(01)00422-5; MILLER RA, HDB BIOL AGING; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; SALMON AB, IN PRESS AM J PHYSL; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003	10	13	14	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 24	2005	308	5730					1875	1876		10.1126/science.1114393	http://dx.doi.org/10.1126/science.1114393			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976292				2022-12-28	WOS:000230120000027
J	Baum, K				Baum, K			Independent medical examinations: An expanding source of physician liability	ANNALS OF INTERNAL MEDICINE			English	Article								Employers frequently ask physicians to conduct medical examinations and review radiology films and other diagnostic tests of employees. Physicians also provide such services at the request of other third parties. These examinations are commonly called independent medical examinations. Increasingly, patients are bringing and prevailing in medical malpractice lawsuits against physicians who conduct independent medical examinations, in part because of physicians' misconceptions of their legal duties in this context. Despite the absence of a traditional physician-patient relationship, physicians who conduct independent medical examinations still owe various legal duties to the examinee patient, although the precise scope of those duties is a source of constant debate and change. Since 2001 alone, 4 state supreme courts have exercised their discretion to hear cases on this issue, bearing witness to its medical, legal, and social significance. Given the current medical malpractice climate, it is imperative that physicians understand the potential liability inherent in conducting independent medical examinations. This article summarizes controlling law, clarifying an otherwise muddied legal picture. It also offers practical suggestions for limiting physician liability in independent medical examinations.	Wiggin & Dana LLP, New Haven, CT 06510 USA		Baum, K (corresponding author), Wiggin & Dana LLP, 265 Church St, New Haven, CT 06510 USA.	kbaum@wiggin.com							0	10	10	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	1				974	978		10.7326/0003-4819-142-12_Part_1-200506210-00007	http://dx.doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937IN	15968012				2022-12-28	WOS:000229917900004
J	Hodson, EM; Jones, CA; Webster, AC; Strippoli, GF; Barclay, PG; Kable, K; Vimalachandra, D; Craig, JC				Hodson, EM; Jones, CA; Webster, AC; Strippoli, GF; Barclay, PG; Kable, K; Vimalachandra, D; Craig, JC			Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials	LANCET			English	Article							HIGH-DOSE ACYCLOVIR; PREEMPTIVE GANCICLOVIR THERAPY; PLACEBO-CONTROLLED TRIAL; LONG-TERM PROPHYLAXIS; ORAL GANCICLOVIR; LIVER-TRANSPLANTATION; INTRAVENOUS GANCICLOVIR; RENAL-TRANSPLANTATION; HEART-TRANSPLANTATION; DEFERRED THERAPY	Background Antiviral prophylaxis is commonly used in recipients of solid-organ transplants with the aim of preventing the clinical syndrome associated with cytomegalovirus infection. We undertook a systematic review to investigate whether this approach affects risks of cytomegalovirus disease and death. Methods Randomised controlled trials of prophylaxis with antiviral medications for cytomegalovirus disease in solid-organ-transplant recipients were identified. Data were combined in meta-analyses by a random-effects model. Findings Compared with placebo or no treatment, prophylaxis with aciclovir, ganciclovir, or valaciclovir significantly reduced the risks of cytomegalovirus disease (19 trials, 1981 patients; relative risk 0.42 [95% CI 0.34-0.52]), cytomegalovirus infection (17 trials, 1786 patients; 0.61 [0.48-0.77]), and all-cause mortality (17 trials, 1838 patients; 0.63 [0.43-0.92]), mainly owing to lower mortality from cytomegalovirus disease (seven trials, 1300 patients; 0.26 [0.08-0.78]). Prophylaxis also lowered the risks of disease caused by herpes simplex or zoster virus, bacterial infections, and protozoal infections, but not fungal infection, acute rejection, or graft loss. Meta-regression showed no significant difference in the risk of cytomegalovirus disease or all-cause mortality by organ transplanted or cytomegalovirus serostatus; no conclusions were possible for cytomegalovirus-negative recipients of negative organs. in trials of direct comparisons, ganciclovir was more effective than aciclovir in preventing cytomegalovirus disease. Valganciclovir and intravenous ganciclovir were as effective as oral ganciclovir. Interpretation Prophylaxis with antiviral medications reduces the risk of cytomegalovirus disease and associated mortality in recipients of solid-organ transplants. This approach should be used routinely in cytomegalovirus-positive recipients and in cytomegalovirus-negative recipients of organs positive for the virus.	Childrens Hosp Westmead, Natl Hlth & Med Res Council Ctr Clin Res Excellen, Ctr Kidney Res, Sydney, NSW, Australia; Childrens Hosp Westmead, Herpesvirus Res Unit, Sydney, NSW, Australia; Westmead Hosp, Dept Pharm, Sydney, NSW, Australia; Westmead Hosp, Dept Renal Med, Sydney, NSW, Australia; Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia; Univ Sydney, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia; Univ Bari, Nephrol Sect, Dept Emergency & Organ Transplantat, I-70121 Bari, Italy	University of Sydney; University of Sydney; University of Sydney; University of Sydney; University of Sydney; University of Sydney; Universita degli Studi di Bari Aldo Moro	Hodson, EM (corresponding author), Childrens Hosp Westmead, Ctr Kidney Res, Locked Bag 4001, Westmead, NSW 2145, Australia.	Elisah@chw.edu.au	Craig, Jonathan/E-2813-2013; Hodson, Elisabeth/S-4590-2019; Webster, Angela/J-2186-2012; Jones, Cheryl/A-4985-2011	Craig, Jonathan/0000-0002-2548-4035; Webster, Angela/0000-0001-7509-0512; Jones, Cheryl/0000-0001-5363-3694; Strippoli, Giovanni/0000-0002-6936-0616				Ahsan N, 1997, CLIN TRANSPLANT, V11, P633; Badley AD, 1997, TRANSPLANTATION, V64, P66, DOI 10.1097/00007890-199707150-00013; BALFOUR HH, 1989, NEW ENGL J MED, V320, P1381, DOI 10.1056/NEJM198905253202105; Baliga RS, 2004, AM J TRANSPLANT, V4, P495; Barkholt L, 1999, Transpl Infect Dis, V1, P89, DOI 10.1034/j.1399-3062.1999.010202.x; Bonet LA, 2003, TRANSPL P, V35, P1946, DOI 10.1016/S0041-1345(03)00648-1; Brennan DC, 1997, TRANSPLANTATION, V64, P1843, DOI 10.1097/00007890-199712270-00036; COHEN AT, 1993, J MED VIROL, V40, P5, DOI 10.1002/jmv.1890400103; CONTI DJ, 1995, ARCH SURG-CHICAGO, V130, P1217; Couchoud C., 2000, COCHRANE DB SYST REV; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; DUNCAN SR, 1994, AM J RESP CRIT CARE, V150, P146, DOI 10.1164/ajrccm.150.1.8025741; Egan JJ, 2002, J HEART LUNG TRANSPL, V21, P460, DOI 10.1016/S1053-2498(01)00399-0; Falagas ME, 1997, ANN INTERN MED, V126, P275, DOI 10.7326/0003-4819-126-4-199702150-00003; Falagas ME, 1998, TRANSPLANTATION, V66, P1020, DOI 10.1097/00007890-199810270-00010; Fiddian P, 2002, J INFECT DIS, V186, pS110, DOI 10.1086/342965; Flechner SM, 1998, TRANSPLANTATION, V66, P1682, DOI 10.1097/00007890-199812270-00019; Gane E, 1997, LANCET, V350, P1729, DOI 10.1016/S0140-6736(97)05535-9; Gavalda J, 1997, TRANSPL INT, V10, P462; George MJ, 1997, AM J MED, V103, P106, DOI 10.1016/S0002-9343(97)80021-6; Gourishankar S, 2001, TRANSPLANT P, V33, P1870, DOI 10.1016/S0041-1345(00)02730-5; Green M, 1997, CLIN INFECT DIS, V25, P1344, DOI 10.1086/516139; Hertz MI, 1998, J HEART LUNG TRANSPL, V17, P913; HIBBERD PL, 1995, ANN INTERN MED, V123, P18, DOI 10.7326/0003-4819-123-1-199507010-00002; HIBBERD PL, 1992, TRANSPLANTATION, V53, P68, DOI 10.1097/00007890-199201000-00013; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HO M, 1994, TRANSPL P, V26, P7; Jassal SV, 1998, J AM SOC NEPHROL, V9, P1697; Kletzmayr J, 1996, J AM SOC NEPHROL, V7, P325; LEFEBVRE C, 1996, P 4 INT COCHR C OCT; LERAY H, 1995, TRANSPLANT P, V27, P2448; Lowance D, 1999, NEW ENGL J MED, V340, P1462, DOI 10.1056/NEJM199905133401903; MACDONALD PS, 1995, J HEART LUNG TRANSPL, V14, P32; MARTIN M, 1994, TRANSPLANTATION, V58, P779; MERIGAN TC, 1992, NEW ENGL J MED, V326, P1182, DOI 10.1056/NEJM199204303261803; NAKAZATO PZ, 1993, TRANSPLANT P, V25, P1935; Paya C, 2004, AM J TRANSPLANT, V4, P611, DOI 10.1111/j.1600-6143.2004.00382.x; PouteilNoble C, 1996, TRANSPLANT P, V28, P2811; Reischig T, 2004, AM J TRANSPLANT, V4, P493; Reischig T, 2002, TRANSPL INT, V15, P615, DOI 10.1007/s00147-002-0475-0; RONDEAU E, 1993, NEPHROL DIAL TRANSPL, V8, P858; Rostaing L, 1994, Transpl Int, V7 Suppl 1, pS331; Rubin R H, 2000, Transpl Infect Dis, V2, P112, DOI 10.1111/j.1399-3062.2000.020303.x; SALIBA F, 1993, TRANSPLANT P, V25, P1444; Schnitzler MA, 2003, AM J TRANSPLANT, V3, P445, DOI 10.1034/j.1600-6143.2003.00069.x; Shapiro R, 1999, TRANSPLANTATION, V67, P411, DOI 10.1097/00007890-199902150-00012; Singh N, 1997, ANN INTERN MED, V127, P412, DOI 10.7326/0003-4819-127-5-199709010-00020; Smith SR, 1998, TRANSPLANT P, V30, P2097, DOI 10.1016/S0041-1345(98)00551-X; Trulock EP, 2003, J HEART LUNG TRANSPL, V22, P625, DOI 10.1016/S1053-2498(03)00182-7; Valantine H A, 1999, Transpl Infect Dis, V1 Suppl 1, P25; van der Bij W, 2001, CLIN INFECT DIS, V33, pS32, DOI 10.1086/320902; Waiser J, 1998, TRANSPLANT P, V30, P2083, DOI 10.1016/S0041-1345(98)00547-8; Winston DJ, 2004, TRANSPLANTATION, V77, P305, DOI 10.1097/01.TP.0000093463.86584.AC; Winston DJ, 2003, TRANSPLANTATION, V75, P229, DOI 10.1097/01.TP.0000040601.60276.96; WINSTON DJ, 1995, LANCET, V346, P69, DOI 10.1016/S0140-6736(95)92110-9	55	268	282	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2105	2115		10.1016/S0140-6736(05)66553-1	http://dx.doi.org/10.1016/S0140-6736(05)66553-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964447				2022-12-28	WOS:000229858800027
J	Hay, EM; Mullis, R; Lewis, M; Vohora, K; Main, CJ; Watson, P; Dziedzic, KS; Sim, J; Lowe, CM; Croft, PR				Hay, EM; Mullis, R; Lewis, M; Vohora, K; Main, CJ; Watson, P; Dziedzic, KS; Sim, J; Lowe, CM; Croft, PR			Comparison of physical treatments versus a brief pain-management programme for back pain in primary care: a randomised clinical trial in physiotherapy practice	LANCET			English	Article							LOCAL CORTICOSTEROID INJECTION; INTERVENTION; MANIPULATION; DISABILITY; DISTRESS; THERAPY	Background Recommendations for the management of low back pain in primary care emphasise the importance of recognising and addressing psychosocial factors at an early stage. We compared the effectiveness of a brief pain-management programme with physiotherapy incorporating manual therapy for the reduction of disability at 12 months in patients consulting primary care with subacute low back pain. Methods For this pragmatic, multicentre, randomised clinical trial, eligible participants consulted primary care with non-specific low back pain of less than 12 weeks' duration. They were randomly assigned either a programme of pain management (n=201) or manual therapy (n=201). The primary outcome was change in the score on the Roland and Morris disability questionnaire at 12 months. Analysis was by intention to treat. Findings Of 544 patients assessed for eligibility, 402 were recruited (mean age 40.6 years) and 329 (82%) reached 12-month follow-up. Mean disability scores were 13.8 (SD 4.8) for the pain-management group and 13.3 (4.9) for the manual-therapy group. The mean decreases in disability scores were 8.8 (6.4) and 8.8 (6.1) at 12 months (difference 0 [95% CI -1.3 to 1.41, p=0.99), and median numbers of physiotherapy visits per patient were three (IQR one to five) and four (two to five), respectively (p=0.001). One adverse reaction (an exacerbation of pain after the initial assessment) was recorded. Interpretation Brief pain management techniques delivered by appropriately trained clinicians offer an alternative to physiotherapy incorporating manual therapy and could provide a more efficient first-line approach for management of non-specific subacute low back pain in primary care.	Keele Univ, Primary Care Serv Res Ctr, Keele ST5 5BG, Staffs, England; Staffordshire Rheumatol Ctr, Stoke On Trent, Staffs, England; Univ Manchester, Unit Chron Dis Epidemiol, Manchester, Lancs, England; Univ Leicester, Dept Anaesthesia & Pain Management, Leicester, Leics, England; Nuffield Orthopaed Ctr NHS Trust, Physiotherapy Res Unit, Oxford, England	Keele University; University of Manchester; University of Leicester; Nuffield Orthopaedic Centre; University of Oxford	Hay, EM (corresponding author), Keele Univ, Primary Care Serv Res Ctr, Keele ST5 5BG, Staffs, England.	e.m.hay@cphc.keele.ac.uk						Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; Bombardier C, 2001, J RHEUMATOL, V28, P431; Bronfort Gert, 2004, Spine J, V4, P335, DOI 10.1016/j.spinee.2003.06.002; BURTON AK, 1995, SPINE, V20, P722, DOI 10.1097/00007632-199503150-00014; Cherkin DC, 2003, ANN INTERN MED, V138, P898, DOI 10.7326/0003-4819-138-11-200306030-00011; Clinical Standards Advisory Group on Back Pain, 1994, BACK PAIN; Croft PR, 1995, SPINE, V20, P2731, DOI 10.1097/00007632-199512150-00015; Damush TM, 2003, ARCH INTERN MED, V163, P2632, DOI 10.1001/archinte.163.21.2632; DUNN KM, IN PRESS SPINE; Frost H, 1998, PAIN, V75, P273, DOI 10.1016/S0304-3959(98)00005-0; Guzman J, 2002, COCHRANE DB SYST REV, V1, P1, DOI [10.1002/14651858.CD000963, DOI 10.1002/14651858.CD000963]; Hay EM, 1999, BRIT MED J, V319, P964, DOI 10.1136/bmj.319.7215.964; Hay EM, 2003, ANN RHEUM DIS, V62, P394, DOI 10.1136/ard.62.5.394; Karjalainen K, 2003, SPINE, V28, P533, DOI 10.1097/00007632-200303150-00004; KENDALL NA, GUIDE ASSESSING PSYC; KLENERMAN L, 1995, SPINE, V20, P478, DOI 10.1097/00007632-199502001-00012; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; Kori S, 1990, PAIN MANAG, V3, P35; Linton SJ, 2000, SPINE, V25, P2825, DOI 10.1097/00007632-200011010-00017; MAIN CJ, 1992, SPINE, V17, P42, DOI 10.1097/00007632-199201000-00007; Main CJ, 2002, BMJ-BRIT MED J, V325, P534, DOI 10.1136/bmj.325.7363.534; Main CJ, 1984, CURR CONCEPTS PAIN, V2, P10; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Moore JE, 2000, PAIN, V88, P145, DOI 10.1016/S0304-3959(00)00314-6; Mullis R, 2004, RHEUMATOLOGY, V43, P86; *RCGP, 1996, GUID MAN AC LOW BACK; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROSENSTIEL AK, 1983, PAIN, V17, P33, DOI 10.1016/0304-3959(83)90125-2; Underwood M, 2004, BMJ-BRIT MED J, V329, P1377, DOI 10.1136/bmj.38282.669225AE	29	146	147	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2005	365	9476					2024	2030		10.1016/S0140-6736(05)66696-2	http://dx.doi.org/10.1016/S0140-6736(05)66696-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950716				2022-12-28	WOS:000229701400024
J	Turner, JW; Pien, BC; Ardoin, SA; Anderson, AM; Shieh, WJ; Zaki, SR; Bhatnagar, J; Guarner, J; Howell, DN; Woods, CW				Turner, JW; Pien, BC; Ardoin, SA; Anderson, AM; Shieh, WJ; Zaki, SR; Bhatnagar, J; Guarner, J; Howell, DN; Woods, CW			A man with chest pain and glomerulonephritis	LANCET			English	Editorial Material							ANCA		Durham Vet Affairs Med Ctr, Durham, NC 27705 USA; Duke Univ, Med Ctr, Durham, NC USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Atlanta, GA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; Centers for Disease Control & Prevention - USA	Woods, CW (corresponding author), Durham Vet Affairs Med Ctr, Durham, NC 27705 USA.	woods004@mc.duke.edu	Guarner, Jeannette/B-8273-2013; Turner, Joshua/GXF-3437-2022	Guarner, Jeannette/0000-0001-5610-3541; 				Haas M, 2000, AM J KIDNEY DIS, V36, P709, DOI 10.1053/ajkd.2000.17615; LaScola B, 1996, J CLIN MICROBIOL, V34, P2270, DOI 10.1128/JCM.34.9.2270-2274.1996; Raoult D, 2003, ARCH INTERN MED, V163, P226, DOI 10.1001/archinte.163.2.226; Rowshani AT, 2004, LANCET, V363, P782, DOI 10.1016/S0140-6736(04)15694-8; Vassilopoulos D, 1999, CLIN DIAGN LAB IMMUN, V6, P645, DOI 10.1128/CDLI.6.5.645-651.1999	5	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2005	365	9476					2062	2062		10.1016/S0140-6736(05)66701-3	http://dx.doi.org/10.1016/S0140-6736(05)66701-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950721				2022-12-28	WOS:000229701400029
J	Wei, WI; Sham, JST				Wei, WI; Sham, JST			Nasopharyngeal carcinoma	LANCET			English	Review							EPSTEIN-BARR-VIRUS; INTENSITY-MODULATED RADIOTHERAPY; POSITRON-EMISSION-TOMOGRAPHY; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; COMPARING NEOADJUVANT CHEMOTHERAPY; PROSPECTIVE RANDOMIZED TRIAL; GOLD GRAIN IMPLANTATION; IMPROVED LOCAL-CONTROL; LONG-TERM SURVIVAL; PHASE-II TRIAL	Incidence of nasopharyngeal carcinoma has remained high in endemic regions. Diagnosing the disease in the early stages requires a high index of clinical acumen and, although most cross-sectional imaging investigations show the tumour with precision, confirmation is dependent on histology. Epstein-Barr virus (EBV)-encoded RNA signal is present in all nasopharyngeal carcinoma cells, and early diagnosis of the disease is possible through the detection of raised antibodies against EBV. The quantity of EBV DNA detected in blood indicates the stage and prognosis of the disease. Radiotherapy with concomitant chemotherapy has increased survival, and improved techniques (such as intensity-modulated radiotherapy), early detection of recurrence, and application of appropriate surgical salvage procedures have contributed to improved therapeutic results. Screening of high-risk individuals in endemic regions together with developments in gene therapy and immunotherapy might further improve outcome.	Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Wei, WI (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China.	hrmswwi@hkucc.hku.hk	Wei, William Ignace/C-4435-2009	wei, william/0000-0002-6281-7126				Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; BOUSSEN H, 1991, J CLIN ONCOL, V9, P1675, DOI 10.1200/JCO.1991.9.9.1675; BUELL P, 1974, CANCER RES, V34, P1189; CELLAI E, 1990, INT J RADIAT ONCOL, V19, P1177, DOI 10.1016/0360-3016(90)90225-9; CHAN AT, 2004, P AN M AM SOC CLIN, P492; Chan ATC, 2002, JNCI-J NATL CANCER I, V94, P1614, DOI 10.1093/jnci/94.21.1614; Chan ATC, 2002, J CLIN ONCOL, V20, P2038, DOI 10.1200/JCO.2002.08.149; Chang CC, 2002, HEAD NECK-J SCI SPEC, V24, P940, DOI 10.1002/hed.10151; Chang YC, 2003, DYSPHAGIA, V18, P135, DOI 10.1007/s00455-002-0096-x; Cheng JCH, 2001, INT J CANCER, V96, P126, DOI 10.1002/ijc.1004; Cheng LC, 1996, AUST NZ J SURG, V66, P71, DOI 10.1111/j.1445-2197.1996.tb01114.x; Cheng SH, 2000, INT J RADIAT ONCOL, V48, P1323, DOI 10.1016/S0360-3016(00)00779-3; Cheng SH, 2000, J CLIN ONCOL, V18, P2040, DOI 10.1200/JCO.2000.18.10.2040; Cheng SH, 1998, INT J RADIAT ONCOL, V41, P755, DOI 10.1016/S0360-3016(98)00092-3; Cheng SH, 2001, INT J RADIAT ONCOL, V50, P717, DOI 10.1016/S0360-3016(01)01509-7; Cheng SWK, 2000, ARCH OTOLARYNGOL, V126, P517, DOI 10.1001/archotol.126.4.517; Cheng WM, 2002, INT J CANCER, V97, P489, DOI 10.1002/ijc.1641; Cheung MC, 2000, ARCH NEUROL-CHICAGO, V57, P1347, DOI 10.1001/archneur.57.9.1347; Chi KH, 2002, INT J RADIAT ONCOL, V52, P1238, DOI 10.1016/S0360-3016(01)02781-X; Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610; Chiesa F, 2001, ORL J OTO-RHINO-LARY, V63, P214, DOI 10.1159/000055743; Chong VFH, 1996, J COMPUT ASSIST TOMO, V20, P563, DOI 10.1097/00004728-199607000-00012; Chong VFH, 1997, RADIOLOGY, V202, P463, DOI 10.1148/radiology.202.2.9015075; Chong VFH, 1999, J COMPUT ASSIST TOMO, V23, P984, DOI 10.1097/00004728-199911000-00032; CHOY D, 1993, INT J RADIAT ONCOL, V25, P505, DOI 10.1016/0360-3016(93)90073-5; Chua D, 2001, INT J CANCER, V94, P73, DOI 10.1002/ijc.1430; Chua DTT, 2000, EUR J CANCER, V36, P736, DOI 10.1016/S0959-8049(00)00008-3; Chua DTT, 1996, CANCER, V78, P202, DOI 10.1002/(SICI)1097-0142(19960715)78:2<202::AID-CNCR3>3.0.CO;2-N; Chua DTT, 2004, HEAD NECK-J SCI SPEC, V26, P118, DOI 10.1002/hed.10362; Chua DTT, 2003, INT J RADIAT ONCOL, V56, P177, DOI 10.1016/S0360-3016(03)00074-9; Chua DTT, 1998, INT J RADIAT ONCOL, V41, P379, DOI 10.1016/S0360-3016(98)00063-7; Chua DTT, 2003, ORAL ONCOL, V39, P361, DOI 10.1016/S1368-8375(02)00120-3; Chua DTT, 2003, HEAD NECK-J SCI SPEC, V25, P585, DOI 10.1002/hed.10242; Chua DTT, 2003, CANCER-AM CANCER SOC, V98, P74, DOI 10.1002/cncr.11485; Chua DTT, 1997, INT J RADIAT ONCOL, V39, P711, DOI 10.1016/S0360-3016(97)00374-X; Chua DTT, 1998, CANCER, V83, P2270, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2270::AID-CNCR6>3.3.CO;2-K; Chua DTT, 2001, CANCER-AM CANCER SOC, V92, P2845, DOI 10.1002/1097-0142(20011201)92:11<2845::AID-CNCR10133>3.0.CO;2-7; CHUA DTT, 2004, P AN M AM SOC CLIN, P492; Cooper JS, 1998, CANCER-AM CANCER SOC, V83, P213, DOI 10.1002/(SICI)1097-0142(19980715)83:2<213::AID-CNCR3>3.0.CO;2-R; DICKSON RI, 1985, LARYNGOSCOPE, V95, P276; Digby KH, 1941, BRIT J SURG, V28, P517, DOI 10.1002/bjs.18002811202; DILLON WP, 1984, RADIOLOGY, V152, P731, DOI 10.1148/radiology.152.3.6463254; Duraiswamy J, 2003, BLOOD, V101, P3150, DOI 10.1182/blood-2002-10-3092; Emami B, 2003, INT J RADIAT ONCOL, V57, P481, DOI 10.1016/S0360-3016(03)00570-4; Fandi A, 2000, J CLIN ONCOL, V18, P1324, DOI 10.1200/JCO.2000.18.6.1324; Fang FM, 2002, INT J RADIAT ONCOL, V53, P959, DOI 10.1016/S0360-3016(02)02838-9; Fang FM, 1999, INT J RADIAT ONCOL, V44, P305, DOI 10.1016/S0360-3016(99)00004-8; FEE WE, 1991, ARCH OTOLARYNGOL, V117, P1233; Fee WE, 2002, ARCH OTOLARYNGOL, V128, P280; FISCH U, 1983, LARYNGOSCOPE, V93, P36; Fleming ID, 1997, AJCC CANC STAGING MA, P33; Franchin G, 2002, ORAL ONCOL, V38, P137, DOI 10.1016/S1368-8375(01)00034-3; GODTFREDSEN E, 1944, ACTA PATH MICROBIO S, V55, P38; Gulley ML, 2001, J MOL DIAGN, V3, P1, DOI 10.1016/S1525-1578(10)60642-3; Hareyama M, 2002, CANCER, V94, P2217, DOI 10.1002/cncr.10473; HARRISON LB, 1987, INT J RADIAT ONCOL, V13, P451, DOI 10.1016/0360-3016(87)90019-8; Ho J H, 1978, IARC Sci Publ, P99; HO JHC, 1978, INT J RADIAT ONCOL, V4, P182; Ho WK, 1999, HEAD NECK-J SCI SPEC, V21, P547, DOI 10.1002/(SICI)1097-0347(199909)21:6<547::AID-HED8>3.0.CO;2-Y; Hong RL, 2004, CANCER, V100, P1429, DOI 10.1002/cncr.20129; HOPPE RT, 1976, CANCER, V37, P2605, DOI 10.1002/1097-0142(197606)37:6<2605::AID-CNCR2820370607>3.0.CO;2-W; Hsiung CY, 2002, INT J RADIAT ONCOL, V53, P638, DOI 10.1016/S0360-3016(02)02760-8; HUANG SC, 1985, INT J RADIAT ONCOL, V11, P1789, DOI 10.1016/0360-3016(85)90033-1; International Nasopharynx Cancer Study Group, 1996, Int J Radiat Oncol Biol Phys, V35, P463; Jackson C, 1901, J AMER MED ASSOC, V37, P371; Jian JJM, 2002, INT J RADIAT ONCOL, V53, P344, DOI 10.1016/S0360-3016(02)02709-8; Kao CH, 2001, CANCER-AM CANCER SOC, V92, P434, DOI 10.1002/1097-0142(20010715)92:2<434::AID-CNCR1339>3.0.CO;2-O; KRAIPHIBUL P, 1991, Journal of the Medical Association of Thailand, V74, P276; Kumar MB, 2004, INT J RADIAT ONCOL, V58, P688, DOI 10.1016/S0360-3016(03)01618-3; Kwan W H, 1996, Clin Oncol (R Coll Radiol), V8, P55, DOI 10.1016/S0936-6555(05)80041-X; KWONG D, 1994, INT J RADIAT ONCOL, V30, P1029, DOI 10.1016/0360-3016(94)90306-9; Kwong DLW, 2004, J CLIN ONCOL, V22, P2643, DOI 10.1200/JCO.2004.05.173; Kwong DLW, 2001, CANCER, V91, P1105, DOI 10.1002/1097-0142(20010315)91:6<1105::AID-CNCR1106>3.0.CO;2-Z; Kwong DLW, 2004, CANCER, V101, P1584, DOI 10.1002/cncr.20552; Kwong DLW, 1999, CANCER, V85, P1446, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1446::AID-CNCR4>3.0.CO;2-3; Kwong DLW, 1997, INT J RADIAT ONCOL, V39, P703, DOI 10.1016/S0360-3016(97)00339-8; LAM KSL, 1991, Q J MED, V78, P165; Lam LCW, 2003, J NEUROPSYCH CLIN N, V15, P90, DOI 10.1176/appi.neuropsych.15.1.90; Law SCK, 2002, INT J RADIAT ONCOL, V54, P1095, DOI 10.1016/S0360-3016(02)03009-2; Le QT, 2003, INT J RADIAT ONCOL, V56, P1046, DOI 10.1016/S0360-3016(03)00117-2; Lee A. W. M., 1997, Hong Kong Medical Journal, V3, P355; LEE AWM, 1992, BRIT J RADIOL, V65, P918, DOI 10.1259/0007-1285-65-778-918; Lee AWM, 2002, INT J RADIAT ONCOL, V53, P75, DOI 10.1016/S0360-3016(02)02711-6; LEE AWM, 1989, INT J RADIAT ONCOL, V17, P1183, DOI 10.1016/0360-3016(89)90524-5; LEE AWM, 1993, INT J RADIAT ONCOL, V26, P773, DOI 10.1016/0360-3016(93)90491-D; LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9; Lee AWM, 1999, INT J CANCER, V84, P179, DOI 10.1002/(SICI)1097-0215(19990420)84:2<179::AID-IJC15>3.0.CO;2-6; Lee AWM, 2001, RADIOTHER ONCOL, V58, P121, DOI 10.1016/S0167-8140(00)00312-1; LEE AWM, 2004, P AN M AM SOC CLIN, P488; Lee N, 2002, INT J RADIAT ONCOL, V53, P12, DOI 10.1016/S0360-3016(02)02724-4; LEE PWH, 1989, J NEUROL NEUROSUR PS, V52, P488, DOI 10.1136/jnnp.52.4.488; LEUNG S F, 1991, Australasian Radiology, V35, P31, DOI 10.1111/j.1440-1673.1991.tb02987.x; Leung SF, 2003, CLIN CANCER RES, V9, P3431; Leung SF, 2002, CANCER-AM CANCER SOC, V95, P656, DOI 10.1002/cncr.10700; Leung TW, 2000, INT J RADIAT ONCOL, V47, P405, DOI 10.1016/S0360-3016(00)00463-6; Leung TW, 2000, INT J RADIAT ONCOL, V48, P1331, DOI 10.1016/S0360-3016(00)00776-8; Leung TW, 1996, ACTA ONCOL, V35, P43, DOI 10.3109/02841869609098478; Levendag PC, 2002, RADIOTHER ONCOL, V63, P67, DOI 10.1016/S0167-8140(02)00008-7; Li JH, 2002, CANCER RES, V62, P171; Lin JC, 2004, NEW ENGL J MED, V350, P2461, DOI 10.1056/NEJMoa032260; Lin JC, 2003, BRIT J CANCER, V88, P187, DOI 10.1038/sj.bjc.6600716; Lin JC, 2003, J CLIN ONCOL, V21, P631, DOI 10.1200/JCO.2003.06.158; Lin YS, 2002, CANCER, V95, P404, DOI 10.1002/cncr.10668; LO DYM, 2000, CANCER RES, V60, P2351; Lo YMD, 2001, ANN NY ACAD SCI, V945, P68; Lopes Victor, 2003, Herpes, V10, P78; Lu TX, 2004, INT J RADIAT ONCOL, V58, P682, DOI 10.1016/S0360-3016(03)01508-6; Lu TX, 2001, INT J RADIAT ONCOL, V51, P589, DOI 10.1016/S0360-3016(01)01678-9; Ma J, 2001, J CLIN ONCOL, V19, P1350, DOI 10.1200/JCO.2001.19.5.1350; Marks JE, 1998, CANCER, V83, P582, DOI 10.1002/(SICI)1097-0142(19980801)83:3<582::AID-CNCR29>3.0.CO;2-R; MESIC JB, 1981, INT J RADIAT ONCOL, V7, P447, DOI 10.1016/0360-3016(81)90129-2; MICHEAU C, 1978, TUMORI, V64, P513, DOI 10.1177/030089167806400509; MILLAN AS, 2004, J ORAL REHABIL, V31, P600; Morton RP, 1996, HEAD NECK-J SCI SPEC, V18, P352, DOI 10.1002/(SICI)1097-0347(199607/08)18:4<352::AID-HED7>3.0.CO;2-X; Mutirangura A, 1998, CLIN CANCER RES, V4, P665; Nakamoto Y, 2003, CLIN NUCL MED, V28, P302, DOI 10.1097/01.RLU.0000057556.54046.7A; NEW GB, 1992, JAMA-J AM MED ASSOC, V79, P10; Ng SH, 1999, NEURORADIOLOGY, V41, P855, DOI 10.1007/s002340050857; Ngan RKC, 2002, ANN ONCOL, V13, P1252, DOI 10.1093/annonc/mdf200; Nicholls JM, 1997, ADV ANAT PATHOL, V4, P71; NIELSEN NH, 1977, ACTA PATH MICRO IM A, V85, P850; Oh JL, 2003, ANN ONCOL, V14, P564, DOI 10.1093/annonc/mdg163; OLMI P, 1995, INT J RADIAT ONCOL, V32, P795, DOI 10.1016/0360-3016(94)00535-S; Ozyar E, 1999, INT J RADIAT ONCOL, V44, P1079, DOI 10.1016/S0360-3016(99)00098-X; Ozyar E, 1994, Radiat Med, V12, P65; Parkin DM, 1997, IARC SCI PUBL, V143, P814; PEREZ CA, 1992, INT J RADIAT ONCOL, V23, P271, DOI 10.1016/0360-3016(92)90741-Y; Poon D, 2004, INT J RADIAT ONCOL, V59, P1312, DOI 10.1016/j.ijrobp.2004.01.037; Pow EHN, 2003, CLIN ORAL INVEST, V7, P230, DOI 10.1007/s00784-003-0215-6; Pow EHN, 2003, ORAL DIS, V9, P196, DOI 10.1034/j.1601-0825.2003.02924.x; PRASAD U, 1974, J LARYNGOL OTOL, V88, P1087, DOI 10.1017/S0022215100079779; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; REDDY SP, 1995, AM J OTOLARYNG, V16, P103, DOI 10.1016/0196-0709(95)90040-3; ROSSI A, 1988, J CLIN ONCOL, V6, P1401, DOI 10.1200/JCO.1988.6.9.1401; Sanguineti G, 2003, CLIN ONCOL-UK, V15, P451, DOI 10.1016/S0936-6555(03)00201-2; SHAM J, 1994, INT J RADIAT ONCOL, V29, P699, DOI 10.1016/0360-3016(94)90556-8; SHAM J S T, 1991, Australasian Radiology, V35, P370, DOI 10.1111/j.1440-1673.1991.tb03050.x; SHAM JST, 1990, LANCET, V335, P371, DOI 10.1016/0140-6736(90)90206-K; SHAM JST, 1991, CLIN NUCL MED, V16, P27, DOI 10.1097/00003072-199101000-00007; SHAM JST, 1991, ONCOLOGY, V48, P480; SHAM JST, 1991, CANCER, V68, P422, DOI 10.1002/1097-0142(19910715)68:2<422::AID-CNCR2820680235>3.0.CO;2-F; SHAM JST, 1991, HEAD NECK-J SCI SPEC, V13, P298, DOI 10.1002/hed.2880130406; SHAM JST, 1991, AM J NEURORADIOL, V12, P265; SHAM JST, 1990, BRIT J RADIOL, V63, P51, DOI 10.1259/0007-1285-63-745-51; SHAM JST, 1990, CANCER, V65, P2606, DOI 10.1002/1097-0142(19900601)65:11<2606::AID-CNCR2820651135>3.0.CO;2-U; SHAM JST, 1992, HEAD NECK-J SCI SPEC, V14, P208, DOI 10.1002/hed.2880140308; Shanmugaratnam K, 1991, INT HISTOLOGICAL TYP, P32; Siu LL, 1998, J CLIN ONCOL, V16, P2514, DOI 10.1200/JCO.1998.16.7.2514; Sobin LH, 1997, TNM CLASSIFICATION M, P25; SVOBODA D, 1965, EXP MOL PATHOL, V4, P189, DOI 10.1016/0014-4800(65)90032-8; Sze WM, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.10.027; Taamma A, 1999, CANCER-AM CANCER SOC, V86, P1101, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1101::AID-CNCR2>3.0.CO;2-R; Tan EH, 1999, ANN ONCOL, V10, P235, DOI 10.1023/A:1008390929826; Teo P, 1996, INT J RADIAT ONCOL, V36, P291, DOI 10.1016/S0360-3016(96)00323-9; Teo PML, 2000, INT J RADIAT ONCOL, V48, P1311, DOI 10.1016/S0360-3016(00)00786-0; Waldron J, 2003, RADIOTHER ONCOL, V68, P153, DOI 10.1016/S0167-8140(02)00370-5; WANG CC, 1991, AM J CLIN ONCOL-CANC, V14, P5, DOI 10.1097/00000421-199102000-00002; WANG CC, 1975, RADIOLOGY, V115, P737, DOI 10.1148/15.3.737; Wang T L, 1991, Ann Acad Med Singap, V20, P601; WEE J, 2004, P AN M AM SOC CLIN, P487; WEI WI, 1992, ARCH OTOLARYNGOL, V118, P923; Wei WI, 2004, HEAD NECK-J SCI SPEC, V26, P878, DOI 10.1002/hed.20066; WEI WI, 1990, ARCH OTOLARYNGOL, V116, P578; WEI WI, 1991, HEAD NECK-J SCI SPEC, V13, P200, DOI 10.1002/hed.2880130306; Wei WI, 2001, ARCH OTOLARYNGOL, V127, P766; WEI WI, 1990, AM J SURG, V160, P439, DOI 10.1016/S0002-9610(05)80561-6; Wei WI, 2001, ARCH OTOLARYNGOL, V127, P1457, DOI 10.1001/archotol.127.12.1457; Wolden SL, 2001, J CLIN ONCOL, V19, P1105, DOI 10.1200/JCO.2001.19.4.1105; Wolden SL, 2001, INT J RADIAT ONCOL, V49, P1229, DOI 10.1016/S0360-3016(00)01588-1; Wu VWC, 2004, RADIOTHER ONCOL, V71, P201, DOI 10.1016/j.radonc.2004.03.004; Xiao JP, 2001, INT J RADIAT ONCOL, V51, P164, DOI 10.1016/S0360-3016(01)01623-6; YAN JH, 1990, INT J RADIAT ONCOL, V18, P295, DOI 10.1016/0360-3016(90)90092-X; Yen RF, 2003, CANCER, V98, P283, DOI 10.1002/cncr.11519; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; ZENG Y, 1985, INT J CANCER, V36, P545, DOI 10.1002/ijc.2910360505; ZONG YS, 1992, CANCER, V69, P3, DOI 10.1002/1097-0142(19920101)69:1&lt;3::AID-CNCR2820690104&gt;3.0.CO;2-7	176	1073	1132	2	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2005	365	9476					2041	2054		10.1016/S0140-6736(05)66698-6	http://dx.doi.org/10.1016/S0140-6736(05)66698-6			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950718				2022-12-28	WOS:000229701400026
J	Sharland, M; Kendall, H; Yeates, D; Randall, A; Hughes, G; Glasziou, P; Mant, D				Sharland, M; Kendall, H; Yeates, D; Randall, A; Hughes, G; Glasziou, P; Mant, D			Antibiotic prescribing in general practice and hospital admissions for peritonsillar abscess, mastoiditis, and rheumatic fever in children: time trend analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-TRACT INFECTIONS		Univ Oxford, Div Publ Hlth & Primary Care, Hlth Care Epidemiol Unit, Oxford OX3 7LF, England; Univ London St Georges Hosp, Paediat Infect Dis Unit, London SW17 0QT, England; Prescript Pricing Author, Pharmaceut Directorate, Newcastle Upon Tyne NE1 6SN, Tyne & Wear, England; Med & Healthcare Prod Regulatory Agcy, GPRD Div, London SW8 5NQ, England	University of Oxford; St Georges University London; The Medicines & Healthcare Products Regulatory Agency	Mant, D (corresponding author), Univ Oxford, Div Publ Hlth & Primary Care, Hlth Care Epidemiol Unit, Oxford OX3 7LF, England.	david.mant@dphpc.ox.ac.uk	Mant, David CA/C-7763-2009; Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X; Hughes, Gwenda/0000-0003-2090-7702; sharland, mike/0000-0001-8626-8291	MRC [G0000340] Funding Source: UKRI; Medical Research Council [G0000340] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arroll B, 2003, BRIT J GEN PRACT, V53, P871; *DEP HLTH STAND ME, 2000, PATH LEAST RES MAIN; Little P, 2002, BRIT J GEN PRACT, V52, P187; Majeed A, 2004, BRIT MED J, V329, P879, DOI 10.1136/bmj.329.7471.879; Van Zuijlen DA, 2001, PEDIATR INFECT DIS J, V20, P140, DOI 10.1097/00006454-200102000-00004	5	110	110	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	2005	331	7512					328	329		10.1136/bmj.38503.706887.AE1	http://dx.doi.org/10.1136/bmj.38503.706887.AE1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955WZ	15967760	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000231259800020
J	Vetter, NJ				Vetter, NJ			Effects of locality based community hospital care on independence in older people needing rehabilitation: randomised controlled trial - Commentary: Intermediate care: policy before evidence	BRITISH MEDICAL JOURNAL			English	Editorial Material									Cardiff Univ, Sch Med, Cardiff CF14 4XL, Wales	Cardiff University	Vetter, NJ (corresponding author), Cardiff Univ, Sch Med, Cardiff CF14 4XL, Wales.	njvetter@hotmail.com						Green J, 2005, BMJ-BRIT MED J, V331, P317, DOI 10.1136/bmj.38498.387569.8F; Griffiths P, 2005, INT J NURS STUD, V42, P107, DOI 10.1016/j.ijnurstu.2004.07.010; GRIMLEY EJ, 2001, BMJ-BRIT MED J, V322, P807; Walker L, 2005, AGE AGEING, V34, P238, DOI 10.1093/ageing/afi055; Walsh B, 2005, BRIT MED J, V330, P699, DOI 10.1136/bmj.38397.633588.8F	5	8	8	1	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 6	2005	331	7512					320	320		10.1136/bmj.38524.543137.7C	http://dx.doi.org/10.1136/bmj.38524.543137.7C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955WZ	15994658	Green Published, Bronze			2022-12-28	WOS:000231259800014
J	Tarnopolsky, A; Fletcher, N; Hollenberg, L; Lange, B; Smith, J; Wolfe, J				Tarnopolsky, A; Fletcher, N; Hollenberg, L; Lange, B; Smith, J; Wolfe, J			Acoustics: The vocal tract and the sound of a didgeridoo	NATURE			English	Editorial Material									Univ New S Wales, Sch Phys, Sydney, NSW 2052, Australia; Australian Natl Univ, Res Sch Phys Sci, Canberra, ACT 0200, Australia; Univ Melbourne, Sch Phys, Parkville, Vic 3010, Australia	University of New South Wales Sydney; Australian National University; University of Melbourne	Tarnopolsky, A (corresponding author), Univ New S Wales, Sch Phys, Sydney, NSW 2052, Australia.	j.wolfe@unsw.edu.au	Hollenberg, Lloyd/B-2296-2010	Wolfe, Joe/0000-0001-8030-0561; HOLLENBERG, LLOYD/0000-0001-7672-6965				Epps J, 1997, MEAS SCI TECHNOL, V8, P1112, DOI 10.1088/0957-0233/8/10/012; Fletcher N., 1983, AUSTR ABORIGINAL STU, V1, P28; Fletcher Neville., 1998, PHYS MUSICAL INSTRUM; Mukai S, 1989, J OTOLARYNGOL JPN, V92, P260; Smith J. R., 1997, P I ACOUSTICS, V19, P315; Sundberg J., 1987, SCI SINGING VOICE; Wolfe J, 2003, P STOCKH MUS AC C SM, P307	7	22	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 7	2005	436	7047					39	39		10.1038/43639a	http://dx.doi.org/10.1038/43639a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	942QJ	16001056	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000230296600032
J	Cadwell, K; Coscoy, L				Cadwell, K; Coscoy, L			Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase	SCIENCE			English	Article							MHC CLASS-I; COMPLEX CLASS-I; DOWN-REGULATION; HERPESVIRUS K3; IMMUNE EVASION; PROTEINS; ENDOCYTOSIS	Ubiquitination controls a broad range of cellular functions. The last step of the ubiquitination pathway is regulated by enzyme type 3 (E3) ubiquitin ligases. E3 enzymes are responsible for substrate specificity and catalyze the formation of an isopeptide bond between a lysine residue of the substrate (or the N terminus of the substrate) and ubiquitin. MIR1 and MIR2 are two E3 ubiquitin ligases encoded by Kaposi's sarcoma-associated herpesvirus that mediate the ubiquitination of major histocompatibility complex class I (MHC 1) molecules and subsequent internalization. Here, we found that MIR1, but not MIR2, promoted down-regulation of MHC I molecules lacking lysine residues in their intracytoplasmic domain. In the presence of MIR1, these MHC I molecules were ubiquitinated, and their association with ubiquitin was sensitive to P beta(2)-mercaptoethanol, unlike lysine-ubiquitin bonds. This form of ubiquitination required a cysteine residue in the intracytoplasmic tail of MHC I molecules. An MHC I molecule containing a single cysteine residue in an artificial glycine and atanine intracytoplasmic domain was endocytosed and degraded in the presence of MIR1. Thus, ubiquitination can occur on proteins lacking accessible lysines or an accessible N terminus.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Coscoy, L (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 142 Life Sci Addit Room 3200, Berkeley, CA 94720 USA.	lcoscoy@berkeley.edu		Cadwell, Ken/0000-0002-5860-0661	NCI NIH HHS [1R01CA108447-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA108447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; Coscoy L, 2000, P NATL ACAD SCI USA, V97, P8051, DOI 10.1073/pnas.140129797; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; Coscoy L, 2001, J CLIN INVEST, V107, P1599, DOI 10.1172/JCI12432; Fruh K, 2002, VIRUS RES, V88, P55, DOI 10.1016/S0168-1702(02)00120-X; Furman MH, 2002, J CLIN INVEST, V110, P875, DOI 10.1172/JCI200216831; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Ishido S, 2000, J VIROL, V74, P5300, DOI 10.1128/JVI.74.11.5300-5309.2000; Lorenzo ME, 2002, J VIROL, V76, P5522, DOI 10.1128/JVI.76.11.5522-5531.2002; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Sanchez DJ, 2002, J BIOL CHEM, V277, P6124, DOI 10.1074/jbc.M110265200; Stevenson PG, 2000, P NATL ACAD SCI USA, V97, P8455, DOI 10.1073/pnas.150240097	15	299	312	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					127	130		10.1126/science.1110340	http://dx.doi.org/10.1126/science.1110340			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994556				2022-12-28	WOS:000230212800074
J	Greenhalgh, RM; Brown, LC; Epstein, D; Kwong, GPS; Powell, JT; Sculpher, MJ; Thompson, SG				Greenhalgh, RM; Brown, LC; Epstein, D; Kwong, GPS; Powell, JT; Sculpher, MJ; Thompson, SG		EVAR Trial Participants	Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial	LANCET			English	Article							RISK-FACTORS; MORTALITY; REGISTRY; DEATH; COST	Background Although endovascular aneurysm repair (EVAR) has a lower 30-day operative mortality than open repair, the long-term results of EVAR are uncertain. We instigated EVAR trial 1 to compare these two treatments in terms of mortality, durability, health-related quality of life (HRQL), and costs for patients with large abdominal aortic aneurysm (AAA). Methods We did a randomised controlled trial of 1082 patients aged 60 years or older who had aneurysms of at least 5.5 cm in diameter and who had been referred to one of 34 hospitals proficient in the EVAR technique. We assigned patients who were anatomically suitable for EVAR and fit for an open repair to EVAR (n=543) or open repair (n=539). Our primary endpoint was all-cause mortality, with secondary endpoints of aneurysm-related mortality, HRQL, postoperative complications, and hospital costs. Analyses were by intention to treat. Findings 94% (1017 of 1082) of patients complied with their allocated treatment and 209 died by the end of follow-up on Dec 31, 2004 (53 of aneurysm-related causes). 4 years after randomisation, all-cause mortality was similar in the two groups (about 28%; hazard ratio 0.90, 95% CI 0.69-1.18, p=0.46), although there was a persistent reduction in aneurysm-related deaths in the EVAR group (4% vs 7%; 0.55, 0.31-0.96, p=0.04). The proportion of patients with postoperative complications within 4 years of randomisation was 41% in the EVAR group and 9% in the open repair group (4.9, 3.5-6.8, p<0.0001). After 12 months there was negligible difference in HRQL between the two groups. The mean hospital costs per patient up to 4 years were UK 13257 pound for the EVAR group versus 9946 pound for the open repair group (mean difference 13311, S E 690). Interpretation Compared with open repair, EVAR offers no advantage with respect to all-cause mortality and HRQL, is more expensive, and leads to a greater number of complications and reinterventions. However, it does result in a 3% better aneurysm-related survival. The continuing need for interventions mandates ongoing surveillance and longer follow-up of EVAR for detailed cost-effectiveness assessment.	Univ London Imperial Coll Sci Technol & Med, Dept Vasc Surg, London W6 8RP, England	Imperial College London	Greenhalgh, RM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Vasc Surg, Charing Cross Campus, London W6 8RP, England.	r.greenhalgh@imperial.ac.uk	Zeleňák, Kamil/X-6293-2018; Morgan, Robert Anthony/AAH-9104-2021; Epstein, David/I-2839-2019; Russell, Ian T/H-1181-2012	Zeleňák, Kamil/0000-0002-0416-2985; Morgan, Robert Anthony/0000-0002-8108-5258; Epstein, David/0000-0002-2275-0916; Lee, Cheong/0000-0003-1439-5659; Halliday, Alison/0000-0001-9828-3579; Hooper, Richard/0000-0002-1063-0917				Brady AR, 2000, BRIT J SURG, V87, P742, DOI 10.1046/j.1365-2168.2000.01410.x; Brown LC, 2004, EUR J VASC ENDOVASC, V27, P372, DOI 10.1016/j.ejvs.2003.12.019; BROWN LC, 2004, ENDOVASCULAR INTERVE, P27; Carpenter JP, 2001, J VASC SURG, V34, P1050, DOI 10.1067/mva.2001.120037; *DEP HLTH, 2003, INCR NAT PAY SCAL; *DEP HLTH, 2004, NHS REF COSTS 2003 N; Efron B., 1994, MONOGRAPHS STAT APPL; Greenhalgh RM, 2004, LANCET, V364, P843, DOI 10.1016/S0140-6736(04)16979-1; Greenhalgh RM, 2005, LANCET, V365, P2187, DOI 10.1016/S0140-6736(05)66628-7; Hardman G, 1999, UK POPULATION NORMS; Harris PL, 2000, J VASC SURG, V32, P739, DOI 10.1067/mva.2000.109990; HM Treasury, 2003, GREEN BOOK APPR EV C; Kertai MD, 2004, EUR J VASC ENDOVASC, V28, P343, DOI 10.1016/j.ejvs.2004.07.008; Kertai MD, 2004, AM J MED, V116, P96, DOI 10.1016/j.amjmed.2003.08.029; *NAT BLOOD SERV, 2004, NAT PRIC 2004 2005 I; Prinssen M, 2004, EUR J VASC ENDOVASC, V27, P121, DOI 10.1016/j.ejvs.2003.11.006; Prinssen M, 2004, NEW ENGL J MED, V351, P1607, DOI 10.1056/NEJMoa042002; Simons P, 2003, J VASC SURG, V38, P758, DOI 10.1016/S0741-5214(03)00715-8; Sternbergh WC, 2000, J VASC SURG, V31, P237, DOI 10.1016/S0741-5214(00)90154-X; Thomas SM, 2005, EUR J VASC ENDOVASC, V29, P563, DOI 10.1016/j.ejvs.2005.03.012; Torella F, 2004, J VASC SURG, V40, P216, DOI 10.1016/j.jvs.2004.04.017; Vallabhaneni SR, 2001, EUR J RADIOL, V39, P34, DOI 10.1016/S0720-048X(01)00340-0; van Marrewijk C, 2002, J VASC SURG, V35, P461, DOI 10.1067/mva.2002.118823; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WHITE GH, 1999, DURABILITY VASCULAR; White IR, 2005, STAT MED, V24, P993, DOI 10.1002/sim.1981; WHO, 1996, INT STAT CLASS DIS R; Willan AR, 2005, STAT MED, V24, P131, DOI 10.1002/sim.1794; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	29	1047	1101	0	38	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	2005	365	9478					2179	2186		10.1016/S0140-6736(05)66627-5	http://dx.doi.org/10.1016/S0140-6736(05)66627-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978925				2022-12-28	WOS:000230034800027
J	Henshaw, D				Henshaw, D			Tension pneumothoraces	LANCET			English	Editorial Material									Kalgoorlie Reg Hosp, Kalgoorlie, WA 6430, Australia		Henshaw, D (corresponding author), Kalgoorlie Reg Hosp, Kalgoorlie, WA 6430, Australia.	David.Henshaw@health.wa.gov.au							0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 25	2005	365	9478					2243	2243		10.1016/S0140-6736(05)66784-0	http://dx.doi.org/10.1016/S0140-6736(05)66784-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978934				2022-12-28	WOS:000230034800036
J	Lipton, SA; Nakamura, T; Yao, DD; Shi, ZQ; Uehara, T; Gu, ZZ				Lipton, SA; Nakamura, T; Yao, DD; Shi, ZQ; Uehara, T; Gu, ZZ			Comment on "S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function"	SCIENCE			English	Editorial Material									Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Lipton, SA (corresponding author), Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA.	slipton@burnham.org		Lipton, Stuart/0000-0002-3490-1259; Uehara, Takashi/0000-0002-8545-4006				Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Yao DD, 2004, P NATL ACAD SCI USA, V101, P10810, DOI 10.1073/pnas.0404161101	2	38	40	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 24	2005	308	5730								10.1126/science.1110135	http://dx.doi.org/10.1126/science.1110135			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976289				2022-12-28	WOS:000230120000022
J	Mirica, LM; Vance, M; Rudd, DJ; Hedman, B; Hodgson, KO; Solomon, EI; Stack, TDP				Mirica, LM; Vance, M; Rudd, DJ; Hedman, B; Hodgson, KO; Solomon, EI; Stack, TDP			Tyrosinase reactivity in a model complex: An alternative hydroxylation mechanism	SCIENCE			English	Article							SIDE-ON PEROXO; <CU-2(MU-O)(2)>(2+) CORE; PHENOLASE ACTIVITY; DIOXYGEN; OXYGENATION; BINDING; LIGAND; INTERMEDIATE; REDUCTION; CHEMISTRY	The binuclear copper enzyme tyrosinase activates O-2 to form a mu-eta(2):eta(2)-peroxodicopper(II) complex, which oxidizes phenols to catechols. Here, a synthetic mu-eta(2):eta(2)-peroxodicopper(II) complex, with an absorption spectrum similar to that of the enzymatic active oxidant, is reported to rapidly hydroxylate phenolates at -80 degrees C. Upon phenolate addition at extreme temperature in solution (-120 degrees C), a reactive intermediate consistent with a bis-mu-oxodicopper(III)phenolate complex, with the O-O bond fully cleaved, is observed experimentally. The subsequent hydroxylation step has the hallmarks of an electrophilic aromatic substitution mechanism, similar to tyrosinase. Overall, the evidence for sequential O-O bond cleavage and C-O bond formation in this synthetic complex suggests an alternative intimate mechanism to the concerted or late stage O-O bond scission generally accepted for the phenol hydroxylation reaction performed by tyrosinase.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA	Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Hedman, B (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.	hedman@ssrl.slac.stanford.edu; hodgson@ssrl.slac.stanford.edu; edward.solomon@stanford.edu; stack@stanford.edu	Mirica, Liviu M./R-1978-2017	Mirica, Liviu M./0000-0003-0584-9508; Solomon, Edward/0000-0003-0291-3199	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031450, R01DK031450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050730, R01GM050730] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01209] Funding Source: Medline; NIDDK NIH HHS [DK31450] Funding Source: Medline; NIGMS NIH HHS [GM50730] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen P, 2002, J INORG BIOCHEM, V88, P368, DOI 10.1016/S0162-0134(01)00349-X; Decker H, 2000, ANGEW CHEM INT EDIT, V39, P1591, DOI 10.1002/(SICI)1521-3773(20000502)39:9<1591::AID-ANIE1591>3.0.CO;2-H; DuBois JL, 1997, J AM CHEM SOC, V119, P8578, DOI 10.1021/ja9717673; DuBois JL, 2000, J AM CHEM SOC, V122, P5775, DOI 10.1021/ja993134p; Green MT, 2004, SCIENCE, V304, P1653, DOI 10.1126/science.1096897; Halfen JA, 1996, SCIENCE, V271, P1397, DOI 10.1126/science.271.5254.1397; Henson MJ, 1999, J AM CHEM SOC, V121, P10332, DOI 10.1021/ja9918425; Holland PL, 1999, ANGEW CHEM INT EDIT, V38, P1139, DOI 10.1002/(SICI)1521-3773(19990419)38:8<1139::AID-ANIE1139>3.0.CO;2-0; Itoh S, 2001, J AM CHEM SOC, V123, P6708, DOI 10.1021/ja015702i; Kim M, 2002, NAT STRUCT BIOL, V9, P591, DOI 10.1038/nsb824; Lewis EA, 2004, CHEM REV, V104, P1047, DOI 10.1021/cr020633r; Mahadevan V, 2000, J AM CHEM SOC, V122, P10249, DOI 10.1021/ja002527h; Mahadevan V, 1997, J AM CHEM SOC, V119, P11996, DOI 10.1021/ja972946n; Mahapatra S, 1997, ANGEW CHEM INT EDIT, V36, P130, DOI 10.1002/anie.199701301; Mandal S, 2000, J ORG CHEM, V65, P4804, DOI 10.1021/jo991625m; Mirica LM, 2004, CHEM REV, V104, P1013, DOI 10.1021/cr020632z; Mirica LM, 2002, J AM CHEM SOC, V124, P9332, DOI 10.1021/ja026905p; Pidcock E, 1998, J AM CHEM SOC, V120, P7841, DOI 10.1021/ja980687b; Price JC, 2003, BIOCHEMISTRY-US, V42, P7497, DOI 10.1021/bi030011f; Santagostini L, 2000, CHEM-EUR J, V6, P519, DOI 10.1002/(SICI)1521-3765(20000204)6:3<519::AID-CHEM519>3.0.CO;2-I; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; Siegbahn PEM, 2003, J BIOL INORG CHEM, V8, P567, DOI 10.1007/s00775-003-0449-4; Solomon EI, 2001, ANGEW CHEM INT EDIT, V40, P4570, DOI 10.1002/1521-3773(20011217)40:24<4570::AID-ANIE4570>3.0.CO;2-4; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; WILCOX DE, 1985, J AM CHEM SOC, V107, P4015, DOI 10.1021/ja00299a043; Yamazaki S, 2003, J AM CHEM SOC, V125, P13034, DOI 10.1021/ja036425d	26	256	259	4	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	2005	308	5730					1890	1892		10.1126/science.1112081	http://dx.doi.org/10.1126/science.1112081			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	940BZ	15976297				2022-12-28	WOS:000230120000034
J	Cote, ML; Kardia, SLR; Wenzlaff, AS; Ruckdeschel, JC; Schwartz, AG				Cote, ML; Kardia, SLR; Wenzlaff, AS; Ruckdeschel, JC; Schwartz, AG			Risk of lung cancer among white and black relatives of individuals with early-onset lung cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; CHRONIC-BRONCHITIS; FAMILIAL RISK; AGE; AGGREGATION; INFORMATION	Context Evidence exists that lung cancer aggregates in families and recent findings of a chromosomal region linked to lung cancer susceptibility support a genetic component to risk. Family studies of early-onset lung cancer patients offer a unique opportunity to evaluate lifetime risk of lung cancer in relatives. Objective To measure lung cancer aggregation and estimate lifetime risk among relatives of early-onset cases and population-based controls. Design and Setting Familial aggregation and cumulative risk estimates from interview data of incident cases and concurrently ascertained controls between 1990 and 2003 in metropolitan Detroit, Mich. Participants The study included 7576 biological mothers, fathers, and siblings of 692 early-onset cases and 773 frequency-matched controls. One third of the population was black. Main Outcome Measures Cumulative lifetime risk of lung cancer, stratified by race and smoking behavior in relatives of early-onset cases and controls. Results Smokers with a family history of early-onset lung cancer in a first-degree relative had a higher risk of developing lung cancer with increasing age than smokers without a family history. An increase in risk occurs after age 60 years in these individuals, with 17.1% (SE 2.4%) of white case relatives and 25.1% (SE 5.8%) of black case relatives diagnosed with lung cancer by age 70 years. Relatives of black cases were at statistically significant increased risk of lung cancer compared with relatives of white cases (odds ratio, 2.07, 95% confidence interval, 1.29-3.32) after adjusting for age, sex, pack-years, pneumonia, and chronic obstructive lung disease. Conclusions First-degree relatives of black individuals with early-onset lung cancer have greater risk of lung cancer than their white counterparts, and these risks are further amplified by cigarette smoking. These data provide estimates of lung cancer risk that can be used to offer counseling to family members of patients with early-onset lung cancer.	Wayne State Univ, Karmanos Canc Inst, Populat Studies & Prevent Program, Detroit, MI USA; Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; University of Michigan System; University of Michigan	Cote, ML (corresponding author), 110 E Warren Ave, Detroit, MI 48201 USA.	cotem@med.wayne.edu	Ruckdeschel, John/AAU-2137-2020	Ruckdeschel, John/0000-0002-7977-4257	NCI NIH HHS [R01-CA60691, N01 CN65064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060691] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM CANC SOC, WHAT ARE KEY STAT LU; Bailey-Wilson JE, 2004, AM J HUM GENET, V75, P460, DOI 10.1086/423857; Bromen K, 2000, AM J EPIDEMIOL, V152, P497, DOI 10.1093/aje/152.6.497; CUPPLES LA, 1991, AM J HUM GENET, V49, P76; DOLL R, 1952, BMJ-BRIT MED J, V2, P1271, DOI 10.1136/bmj.2.4797.1271; Etzel CJ, 2003, CANCER RES, V63, P8531; Gauderman WJ, 2000, AM J EPIDEMIOL, V151, P41, DOI 10.1093/oxfordjournals.aje.a010120; Kreuzer M, 1998, AM J EPIDEMIOL, V147, P1028; Li XJ, 2004, INT J CANCER, V112, P451, DOI 10.1002/ijc.20436; Mayne ST, 1999, CANCER EPIDEM BIOMAR, V8, P1065; McLaughlin J K, 1990, Epidemiology, V1, P408, DOI 10.1097/00001648-199009000-00013; Murff HJ, 2004, JAMA-J AM MED ASSOC, V292, P1480, DOI 10.1001/jama.292.12.1480; OOI WL, 1986, J NATL CANCER I, V76, P217; PICKLE LW, 1983, AM J EPIDEMIOL, V118, P99, DOI 10.1093/oxfordjournals.aje.a113621; Ries LAG, SEER CANC STAT REV 1; *SAS I INC, 1999, SAS SYST WIND COMP P; Schwartz AG, 1996, AM J EPIDEMIOL, V144, P554, DOI 10.1093/oxfordjournals.aje.a008965; Schwartz AG, 1999, GENET EPIDEMIOL, V17, P1, DOI 10.1002/(SICI)1098-2272(1999)17:1<1::AID-GEPI1>3.0.CO;2-C; Silverman EK, 1998, AM J RESP CRIT CARE, V157, P1770, DOI 10.1164/ajrccm.157.6.9706014; Silverman EK, 2002, HUM MOL GENET, V11, P623, DOI 10.1093/hmg/11.6.623; SKILLRUD DM, 1986, ANN INTERN MED, V105, P503, DOI 10.7326/0003-4819-105-4-503; Sullivan F, 1999, COMPUT SCI ENG, V1, P2; TAGER I, 1978, INT J EPIDEMIOL, V7, P55, DOI 10.1093/ije/7.1.55; Theis B, 1994, Eur J Cancer Prev, V3, P321, DOI 10.1097/00008469-199407000-00004; TOCKMAN MS, 1987, ANN INTERN MED, V106, P512, DOI 10.7326/0003-4819-106-4-512; TOKUHATA GEORGE K., 1963, JOUR NATL CANCER INST, V30, P289; Vink JM, 2003, ADDICTION, V98, P923, DOI 10.1046/j.1360-0443.2003.00405.x; Yang P, 1999, GENET EPIDEMIOL, V17, P253, DOI 10.1002/(SICI)1098-2272(199911)17:4<253::AID-GEPI2>3.0.CO;2-K; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	29	70	77	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 22	2005	293	24					3036	3042		10.1001/jama.293.24.3036	http://dx.doi.org/10.1001/jama.293.24.3036			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937SG	15972566	Bronze			2022-12-28	WOS:000229945200019
J	Shekelle, PG; Morton, SC; Suftorp, MJ; Buscemi, N; Friesen, C				Shekelle, PG; Morton, SC; Suftorp, MJ; Buscemi, N; Friesen, C			Challenges in systematic reviews of complementary and alternative medicine topics	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-BACK-PAIN; CLINICAL-TRIALS; MANIPULATIVE THERAPY; PUBLICATION BIAS; PLACEBO; METAANALYSIS; ACUPUNCTURE; DEPRESSION; STROKE	The use of complementary and alternative medicine (CAM) continues to grow in the United States. The Agency for Healthcare Research and Quality has devoted a substantial proportion of the Evidence-based Practice Center (EPC) program to systematic reviews of CAM. Such syntheses present different challenges from those conducted on western medicine topics, and in many ways are more difficult. We discuss 3 challenges: identifying evidence about CAM, assessing the quality of individual studies, and addressing rare serious adverse events. We use illustrations from EPC evidence reports to show readers approaches to the 3 areas and then present specific recommendations for each issue.	RAND Corp, So Calif Evidence Based Pract Ctr, Santa Monica, CA 90401 USA; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Shekelle, PG (corresponding author), RAND Corp, So Calif Evidence Based Pract Ctr, 1776 Main St, Santa Monica, CA 90401 USA.	Paul_Shekelle@rand.org		Friesen, Carol/0000-0001-6437-9126				ALDERSON P, 2004, HANDSEARCHING COCHRA; Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1997, NATURE, V385, P480, DOI 10.1038/385480c0; Ezzo J, 1998, JAMA-J AM MED ASSOC, V280, P1628, DOI 10.1001/jama.280.18.1628; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Kalauokalani D, 2001, SPINE, V26, P1418, DOI 10.1097/00007632-200107010-00005; Kernan WN, 2000, NEW ENGL J MED, V343, P1826, DOI 10.1056/NEJM200012213432501; KLEIJNEN J, 1992, PHARM WEEKBLAD, V14, P316, DOI 10.1007/BF01977620; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; Moher D, 2003, Health Technol Assess, V7, P1; Moher David, 2002, BMC Pediatr, V2, P3, DOI 10.1186/1471-2431-2-3; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; Murphy Linda S, 2003, BMC Complement Altern Med, V3, P3, DOI 10.1186/1472-6882-3-3; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; Rochon PA, 1999, J CLIN EPIDEMIOL, V52, P113, DOI 10.1016/S0895-4356(98)00149-8; Rothwell DM, 2001, STROKE, V32, P1054, DOI 10.1161/01.STR.32.5.1054; Sampson Margaret, 2003, BMC Pediatr, V3, P1, DOI 10.1186/1471-2431-3-1; Shekelle P, 2003, AHRQ PUBLICATION, V03-E023; Shekelle PG, 2003, JAMA-J AM MED ASSOC, V289, P1537, DOI 10.1001/jama.289.12.1537; Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755; Sherman KJ, 2002, J ALTERN COMPLEM MED, V8, P11, DOI 10.1089/107555302753507140; TRIANO JJ, 1995, SPINE, V20, P948, DOI 10.1097/00007632-199504150-00013; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; *US NAT LIB MED, 2005, FACT SHEET RESP INQ; Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5; Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840; 2000, JAMA, V283, P2228	33	57	58	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1042	1047		10.7326/0003-4819-142-12_Part_2-200506211-00003	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938CN	15968028				2022-12-28	WOS:000229977600003
J	Downward, J				Downward, J			RNA interference libraries prove their worth in hunt for tumor suppressor genes	CELL			English	Editorial Material							PROTEIN	RNA interference has been promoted as an ideal tool for functional genomics, but to date the success stories have principally been in model organisms. Two papers in this issue of Cell change all that: Westbrook et al. (2005) and Kolfschoten et al. (2005) use RNA interference libraries targeting large proportions of the human genome to uncover two novel tumor suppressor genes. REST is a transcriptional repressor that silences neuron-specific gene expression, and PITX1 is a homeodomain transcription factor that promotes the expression of a negative regulator of Ras.	Canc Res UK, London Res Inst, Signal Transduct Lab, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Canc Res UK, London Res Inst, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				Albert ML, 2004, NAT REV CANCER, V4, P36, DOI 10.1038/nrc1255; Brummelkamp TR, 2003, NAT REV CANCER, V3, P781, DOI 10.1038/nrc1191; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Walker SA, 2004, EMBO J, V23, P1749, DOI 10.1038/sj.emboj.7600197; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033	8	11	15	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 17	2005	121	6					813	815		10.1016/j.cell.2005.06.002	http://dx.doi.org/10.1016/j.cell.2005.06.002			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960967	Bronze			2022-12-28	WOS:000230011200002
J	Wysocka, J; Swigut, T; Milne, TA; Dou, YL; Zhang, X; Burlingame, AL; Roeder, RG; Brivanlou, AH; Allis, CD				Wysocka, J; Swigut, T; Milne, TA; Dou, YL; Zhang, X; Burlingame, AL; Roeder, RG; Brivanlou, AH; Allis, CD			WDR5 associates with histone H3 methylated at K4 and is essential for H3K4 methylation and vertebrate development	CELL			English	Article							METHYLTRANSFERASE COMPLEX; SACCHAROMYCES-CEREVISIAE; LYSINE-4 METHYLATION; PROTEINS; HETEROCHROMATIN; RECOGNITION; MAINTENANCE; BINDING; GROWTH; MENIN	Histone H3 lysine 4 (K4) methylation has been linked to the transcriptional activation in a variety of eukaryotic species. Here we show that a common component of MLL1, MLL2, and hSetl H3 K4 methyltransferase complexes, the WD40-repeat protein WDR5, directly associates with histone H3 di- and trimethylated at K4 and with H3-K4-dimethylated nucleosomes. WDR5 is required for binding of the methyltransferase complex to the K4-dimethylated H3 tail as well as for global H3 K4 trimethylation and HOX gene activation in human cells. WDR5 is essential for vertebrate development, in that WDR5-depleted X. laevis tadpoles exhibit a variety of developmental defects and abnormal spatial Hox gene expression. Our results are the first demonstration that a WD40-repeat protein acts as a module for recognition of a specific histone modification and suggest a mechanism for reading and writing an epigenetic mark for gene activation.	Rockefeller Univ, Lab Chromatin Biol, New York, NY 10021 USA; Rockefeller Univ, Lab Mol Vertebrate Embryol, New York, NY 10021 USA; Rockefeller Univ, Lab Biochem & Mol Biol, New York, NY 10021 USA; Univ Calif San Francisco, Mass Spectrometry Facil, San Francisco, CA 94143 USA	Rockefeller University; Rockefeller University; Rockefeller University; University of California System; University of California San Francisco	Allis, CD (corresponding author), Rockefeller Univ, Lab Chromatin Biol, New York, NY 10021 USA.	alliscd@rockefeller.edu	Milne, Tom/E-1872-2016	Milne, Tom/0000-0002-0413-4271; Swigut, Tomek/0000-0002-7649-6781	NCRR NIH HHS [RR001614, RR015804] Funding Source: Medline; NIGMS NIH HHS [GM 53512, R01 GM066977] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015804, P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066977, R01GM053512, R37GM053512] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; BRIVANLOU AH, 1989, DEVELOPMENT, V106, P611; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Elgin SCR, 2003, CURR BIOL, V13, pR895, DOI 10.1016/j.cub.2003.11.006; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hollmann M, 2002, MOL GENET GENOMICS, V268, P425, DOI 10.1007/s00438-002-0768-0; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Ko C, 2003, BIOCHEM BIOPH RES CO, V300, P9, DOI 10.1016/S0006-291X(02)02699-2; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; *R DEV COR TEAM, 2004, LANG ENV STAT COMP; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Sive Hazel L., 2000, EARLY DEV XENOPUS LA; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004	32	617	641	3	60	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	2005	121	6					859	872		10.1016/j.cell.2005.03.036	http://dx.doi.org/10.1016/j.cell.2005.03.036			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960974	Bronze			2022-12-28	WOS:000230011200009
J	Wadman, M				Wadman, M			No longer the upstart	NATURE			English	Editorial Material																		2004, NATURE, V430, P495	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 16	2005	435	7044					879	879		10.1038/435879a	http://dx.doi.org/10.1038/435879a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959487	Bronze			2022-12-28	WOS:000229799700016
J	Miola, J				Miola, J			Medicine and the law	LANCET			English	Article									Univ Leicester, Fac Law, Leicester LE1 7RH, Leics, England	University of Leicester	Miola, J (corresponding author), Univ Leicester, Fac Law, Univ Rd, Leicester LE1 7RH, Leics, England.	jm83@leicester.ac.uk	Miola, Jose/AAK-1691-2020	Miola, Jose/0000-0001-9682-2284				DYER C, 2004, GUARDIAN        0406; GIBB F, 2004, TIMES           0421; Woolf Harry, 2001, Med Law Rev, V9, P1	3	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC	2004	364				SI		48	49		10.1016/S0140-6736(04)17640-X	http://dx.doi.org/10.1016/S0140-6736(04)17640-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	880OU	15967152	Bronze			2022-12-28	WOS:000225799900025
J	Yuan, GC; Liu, YJ; Dion, MF; Slack, MD; Wu, LF; Altschuler, SJ; Rando, OJ				Yuan, GC; Liu, YJ; Dion, MF; Slack, MD; Wu, LF; Altschuler, SJ; Rando, OJ			Genome-scale identification of nucleosome positions in S-cerevisiae	SCIENCE			English	Article							RNA-POLYMERASE-II; DNA TARGET SITES; IN-VIVO; EQUILIBRIUM ACCESSIBILITY; CHROMATIN-STRUCTURE; PROMOTER ELEMENTS; CHROMOSOME-III; YEAST; TRANSCRIPTION; GENE	The positioning of nucleosomes along chromatin has been implicated in the regulation of gene expression in eukaryotic cells, because packaging DNA into nucleosomes affects sequence accessibility. We developed a tiled microarray approach to identify at high resolution the translational positions of 2278 nucleosomes over 482 kilobases of Saccharomyces cerevisiae DNA, including almost all of chromosome III and 223 additional regulatory regions. The majority of the nucleosomes identified were well-positioned. We found a stereotyped chromatin organization at Pol II promoters consisting of a nucleosome-free region similar to 200 base pairs upstream of the start codon flanked on both sides by positioned nucleosomes. The nucleosome-free sequences were evolutionarily conserved and were enriched in poly-deoxyadenosine or poly-deoxythymidine sequences. Most occupied transcription factor binding motifs were devoid of nucleosomes, strongly suggesting that nucleosome positioning is a global determinant of transcription factor access.	Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA	Harvard University	Rando, OJ (corresponding author), Harvard Univ, Bauer Ctr Genom Res, 7 Divin Ave, Cambridge, MA 02138 USA.	orando@cgr.harvard.edu		Dion, Michael/0000-0002-0434-4236				Anderson JD, 2000, J MOL BIOL, V296, P979, DOI 10.1006/jmbi.2000.3531; Anderson JD, 2001, MOL CELL BIOL, V21, P3830, DOI 10.1128/MCB.21.11.3830-3839.2001; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Durbin R., 1998, BIOL SEQUENCE ANAL P; Ercan S, 2004, MOL CELL BIOL, V24, P10026, DOI 10.1128/MCB.24.22.10026-10035.2004; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; HORZ W, 1981, NUCLEIC ACIDS RES, V9, P2643, DOI 10.1093/nar/9.12.2643; KARLIN S, 1993, NUCLEIC ACIDS RES, V21, P703, DOI 10.1093/nar/21.3.703; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; KORNBERG RD, 1988, NUCLEIC ACIDS RES, V16, P6677, DOI 10.1093/nar/16.14.6677; Kristjuhan A, 2004, EMBO J, V23, P4243, DOI 10.1038/sj.emboj.7600433; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Lowary PT, 1997, P NATL ACAD SCI USA, V94, P1183, DOI 10.1073/pnas.94.4.1183; Moreira JMA, 1998, EMBO J, V17, P6028, DOI 10.1093/emboj/17.20.6028; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; Osherovich LZ, 2002, DEV CELL, V2, P143, DOI 10.1016/S1534-5807(02)00118-1; SAUNDERS MJ, 1990, MOL CELL BIOL, V10, P5721, DOI 10.1128/MCB.10.11.5721; Schwabish MA, 2004, MOL CELL BIOL, V24, P10111, DOI 10.1128/MCB.24.23.10111-10117.2004; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; Stunkel W, 1997, MOL CELL BIOL, V17, P4397; Teng Y, 2001, Nucleic Acids Res, V29, pE64, DOI 10.1093/nar/29.13.e64; van Holde KE., 1989, SPRINGER SERIES MOL; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; WALTZ RD, 1994, AQUAT INSECT, V16, P165, DOI 10.1080/01650429409361551	28	893	921	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 22	2005	309	5734					626	630		10.1126/science.1112178	http://dx.doi.org/10.1126/science.1112178			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948SE	15961632				2022-12-28	WOS:000230735200053
J	Manoli, DS; Foss, M; Villella, A; Taylor, BJ; Hall, JC; Baker, BS				Manoli, DS; Foss, M; Villella, A; Taylor, BJ; Hall, JC; Baker, BS			Male-specific fruitless specifies the neural substrates of Drosophila courtship behaviour	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; EXPRESSION PATTERNS; GENETIC DISSECTION; SEXUAL-DIMORPHISM; MELANOGASTER; NEURONS; IDENTIFICATION; ABLATION; MUTANTS; COMPLEX	Robust innate behaviours are attractive systems for genetically dissecting how environmental cues are perceived and integrated to generate complex behaviours. During courtship, Drosophila males engage in a series of innate, stereotyped behaviours that are coordinated by specific sensory cues. However, little is known about the specific neural substrates mediating this complex behavioural programme(1). Genetic, developmental and behavioural studies have shown that the fruitless (fru) gene encodes a set of male-specific transcription factors (Fru(M)) that act to establish the potential for courtship in Drosophila(2). Fru(M) proteins are expressed in similar to 2% of central nervous system neurons, at least one subset of which coordinates the component behaviours of courtship(3,4). Here we have inserted the yeast GAL4 gene into the fru locus by homologous recombination and show that ( 1) Fru(M) is expressed in subsets of all peripheral sensory systems previously implicated in courtship, ( 2) inhibition of Fru(M) function in olfactory system components reduces olfactory-dependent changes in courtship behaviour, ( 3) transient inactivation of all Fru(M)-expressing neurons abolishes courtship behaviour, with no other gross changes in general behaviour, and ( 4) 'masculinization' of Fru(M)-expressing neurons in females is largely sufficient to confer male courtship behaviour. Together, these data demonstrate that Fru(M) proteins specify the neural substrates of male courtship.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Neurosci Program, Stanford, CA 94305 USA; Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA	Stanford University; Stanford University; Oregon State University; Brandeis University	Baker, BS (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	bbaker@pmgm2.stanford.edu		Manoli, Devanand/0000-0002-7238-2330				Acebes A, 2004, CURR BIOL, V14, P704, DOI 10.1016/j.cub.2004.04.003; Acebes A, 2003, J EXP BIOL, V206, P3095, DOI 10.1242/jeb.00522; Anand A, 2001, GENETICS, V158, P1569; Baker BS, 2001, CELL, V105, P13, DOI 10.1016/S0092-8674(01)00293-8; Billeter JC, 2004, J COMP NEUROL, V475, P270, DOI 10.1002/cne.20177; Boekhoff-Falk G, 2005, DEV DYNAM, V232, P550, DOI 10.1002/dvdy.20207; Eberl DF, 1997, P NATL ACAD SCI USA, V94, P14837, DOI 10.1073/pnas.94.26.14837; EWING AW, 1979, J COMP PHYSIOL, V130, P87, DOI 10.1007/BF02582977; Gong WJ, 2003, P NATL ACAD SCI USA, V100, P2556, DOI 10.1073/pnas.0535280100; Goodwin SF, 2000, GENETICS, V154, P725; Greenspan RJ, 2000, ANNU REV GENET, V34, P205, DOI 10.1146/annurev.genet.34.1.205; KEIL TA, 1989, TISSUE CELL, V21, P139, DOI 10.1016/0040-8166(89)90028-1; Kitamoto T, 2002, P NATL ACAD SCI USA, V99, P13232, DOI 10.1073/pnas.202489099; Kondoh Y, 2003, P ROY SOC B-BIOL SCI, V270, P1005, DOI 10.1098/rspb.2003.2331; Larsson MC, 2004, NEURON, V43, P703, DOI 10.1016/j.neuron.2004.08.019; Lee G, 2001, J NEUROSCI, V21, P513, DOI 10.1523/JNEUROSCI.21-02-00513.2001; Lee G, 2000, J NEUROBIOL, V43, P404, DOI 10.1002/1097-4695(20000615)43:4<404::AID-NEU8>3.0.CO;2-D; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; Manoli DS, 2004, NATURE, V430, P564, DOI 10.1038/nature02713; McBride SMJ, 1999, NEURON, V24, P967, DOI 10.1016/S0896-6273(00)81043-0; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; Scott KC, 1999, GENETICS, V153, P787; Shah NM, 2004, NEURON, V43, P313, DOI 10.1016/j.neuron.2004.07.008; Shyamala BV, 1999, J GENET, V78, P87, DOI 10.1007/BF02924560; Smith SA, 1996, J COMP NEUROL, V364, P311; Song HJ, 2002, GENETICS, V162, P1703; SPIETH HT, 1974, ANNU REV ENTOMOL, V19, P385, DOI 10.1146/annurev.en.19.010174.002125; Strauss R, 2002, CURR OPIN NEUROBIOL, V12, P633, DOI 10.1016/S0959-4388(02)00385-9; VAIAS LJ, 1993, BEHAV GENET, V23, P91, DOI 10.1007/BF01067558; Wolfner MF, 2002, HEREDITY, V88, P85, DOI 10.1038/sj.hdy.6800017	30	290	298	6	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 21	2005	436	7049					395	400		10.1038/nature03859	http://dx.doi.org/10.1038/nature03859			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	947DK	15959468				2022-12-28	WOS:000230623400043
J	Saad, DF; Gow, KW				Saad, DF; Gow, KW			Small-bowel prolapse through a persistent omphalomesenteric duct	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Emory Univ, Sch Med, Atlanta, GA 30322 USA	Emory University	Saad, DF (corresponding author), Emory Univ, Sch Med, Atlanta, GA 30322 USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2005	353	1					E1	E1		10.1056/NEJMicm041171	http://dx.doi.org/10.1056/NEJMicm041171			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942FC	16000349				2022-12-28	WOS:000230267300011
J	Mesecke, N; Terziyska, N; Kozany, C; Baumann, F; Neupert, W; Hell, K; Herrmann, JM				Mesecke, N; Terziyska, N; Kozany, C; Baumann, F; Neupert, W; Hell, K; Herrmann, JM			A disulfide relay system in the intermembrane space of mitochondria that mediates protein import	CELL			English	Article							SMALL TIM PROTEINS; SUPEROXIDE-DISMUTASE; SULFHYDRYL OXIDASE; BOND FORMATION; YEAST; GENE; COMPLEX; TRANSLOCATION; MEMBRANE; MIA40	We describe here a pathway for the import of proteins into the intermembrane space (IMS) of mitochondria. Substrates of this pathway are proteins with conserved cysteine motifs, which are critical for import. After passage through the TOM channel, these proteins are covalently trapped by Mia40 via disulfide bridges. Mia40 contains cysteine residues, which are oxidized by the sulfhydryl oxidase Erv1. Depletion of Erv1 or conditions reducing Mia40 prevent protein import. We propose that Erv1 and Mia40 function as a disulfide relay system that catalyzes the import of proteins into the IMS by an oxidative folding mechanism. The existence of a disulfide exchange system in the IMS is unexpected in view of the free exchange of metabolites between IMS and cytosol via porin channels. We suggest that this process reflects the evolutionary origin of the IMS from the periplasmic space of the prokaryotic ancestors of mitochondria.	Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany	University of Munich	Herrmann, JM (corresponding author), Univ Munich, Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.	hannes.herrmann@bio.med.uni-muenchen.de	Wagener, Nikola/L-3202-2017; Baumann, Frank/F-7737-2016					Banci L, 2004, J BIOL CHEM, V279, P34833, DOI 10.1074/jbc.M403655200; Becher D, 1999, YEAST, V15, P1171, DOI 10.1002/(SICI)1097-0061(19990915)15:12<1171::AID-YEA443>3.0.CO;2-T; Chacinska A, 2004, EMBO J, V23, P3735, DOI 10.1038/sj.emboj.7600389; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; Curran SP, 2004, J BIOL CHEM, V279, P43744, DOI 10.1074/jbc.M404878200; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Endo T, 2002, BBA-MOL CELL RES, V1592, P3, DOI 10.1016/S0167-4889(02)00259-8; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Gerber J, 2001, J BIOL CHEM, V276, P23486, DOI 10.1074/jbc.M100134200; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Grossman SD, 2002, NEUROMOL MED, V2, P61, DOI 10.1385/NMM:2:1:61; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Herrmann JM, 2005, TRENDS BIOCHEM SCI, V30, P205, DOI 10.1016/j.tibs.2005.02.005; Herrmann JM, 2001, METHOD CELL BIOL, V65, P217, DOI 10.1016/S0091-679X(01)65013-1; Hiniker A, 2004, TRENDS BIOCHEM SCI, V29, P516, DOI 10.1016/j.tibs.2004.08.002; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; Jensen RE, 2002, BBA-MOL CELL RES, V1592, P25, DOI 10.1016/S0167-4889(02)00261-6; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; KOCHLER CM, 2004, ANNU REV CELL DEV BI, V20, P309; Koehler CM, 2004, TRENDS BIOCHEM SCI, V29, P1, DOI 10.1016/j.tibs.2003.11.003; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Lee JE, 2000, FEBS LETT, V477, P62, DOI 10.1016/S0014-5793(00)01767-1; Levitan A, 2004, J BIOL CHEM, V279, P20002, DOI 10.1074/jbc.M312877200; LISOWSKY T, 1992, MOL GEN GENET, V232, P58, DOI 10.1007/BF00299137; Lu H, 2004, J BIOL CHEM, V279, P18952, DOI 10.1074/jbc.M313045200; Lutz T, 2003, EMBO J, V22, P4400, DOI 10.1093/emboj/cdg421; Naoe M, 2004, J BIOL CHEM, V279, P47815, DOI 10.1074/jbc.M410272200; Ostergaard H, 2004, J CELL BIOL, V166, P337, DOI 10.1083/jcb.200402120; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Terziyska N, 2005, FEBS LETT, V579, P179, DOI 10.1016/j.febslet.2004.11.072; Williams JC, 2005, J BIOL CHEM, V280, P15202, DOI 10.1074/jbc.M410705200	40	432	445	2	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	2005	121	7					1059	1069		10.1016/j.cell.2005.04.011	http://dx.doi.org/10.1016/j.cell.2005.04.011			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989955	Bronze			2022-12-28	WOS:000230448000012
J	Nemhauser, JL; Chory, J				Nemhauser, JL; Chory, J			A new FronTIR in targeted protein degradation and plant development	CELL			English	Editorial Material							AUXIN; TIR1	Three papers, two in a recent issue of Nature and one in the July issue of Developmental Cell, identify a family of F box proteins as the long-sought receptors for the plant growth hormone auxin. The new studies reveal that auxin, a small molecule, regulates F box proteins, which are involved in ubiquitin-mediated protein degradation. This finding has profound implications for understanding plant physiology and development and for defining new modes of regulation of SCF ubiquitin ligase complexes.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA	Salk Institute; Howard Hughes Medical Institute; Salk Institute	Nemhauser, JL (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA.							Dharmasiri N, 2003, CURR BIOL, V13, P1418, DOI 10.1016/S0960-9822(03)00536-0; Dharmasiri N, 2005, DEV CELL, V9, P109, DOI 10.1016/j.devcel.2005.05.014; Dharmasiri N, 2005, NATURE, V435, P441, DOI 10.1038/nature03543; Friml J, 2003, NATURE, V426, P147, DOI 10.1038/nature02085; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; Kepinski S, 2004, P NATL ACAD SCI USA, V101, P12381, DOI 10.1073/pnas.0402868101; Kepinski S, 2005, NATURE, V435, P446, DOI 10.1038/nature03542; Napier RM, 2002, PLANT MOL BIOL, V49, P339, DOI 10.1023/A:1015259130955; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Weijers D, 2005, EMBO J, V24, P1874, DOI 10.1038/sj.emboj.7600659; Woodward AW, 2005, ANN BOT-LONDON, V95, P707, DOI 10.1093/aob/mci083	11	7	9	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	2005	121	7					970	972		10.1016/j.cell.2005.06.020	http://dx.doi.org/10.1016/j.cell.2005.06.020			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989947	Bronze			2022-12-28	WOS:000230448000004
J	Russo, T; Volterra, V				Russo, T; Volterra, V			Comment on "Children creating core properties of language: Evidence from an emerging sign language in Nicaragua"	SCIENCE			English	Editorial Material							FACULTY		Univ Calabria, Dept Philosophy, I-87036 Arcavacata Di Rende, CS, Italy; CNR, Inst Cognit Sci & Technol, I-00161 Rome, Italy	University of Calabria; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze e Tecnologie della Cognizione (ISTC-CNR)	Russo, T (corresponding author), Univ Calabria, Dept Philosophy, Via Piero Bucci, I-87036 Arcavacata Di Rende, CS, Italy.	t.russo@mclink.it; virginia.volterra@istc.cnr.it	volterra, virginia/C-4322-2015	VOLTERRA, VIRGINIA/0000-0003-3018-9951				BATES E, 1984, MONOGR SOC RES CHILD, V49, P130; Boyes-Braem P., 2001, HANDS ARE HEAD MOUTH; Fusellier-Souza I., 2001, ACQUISITION INTERACT, V15, P61; Fusellier-Souza Ivani., 2004, THESIS U PARIS FRANC; Hauser MD, 2002, SCIENCE, V298, P1569, DOI 10.1126/science.298.5598.1569; LAUDANNA A, 1991, APPL PSYCHOLINGUIST, V12, P135, DOI 10.1017/S0142716400009115; McNeill D, 1992, HAND MIND WHAT GESTU; McNeill D., 2002, ACTA LINGUIST HAF, V34, P7, DOI DOI 10.1080/03740463.2002.10414607; Pinker S, 2005, COGNITION, V95, P201, DOI 10.1016/j.cognition.2004.08.004; PIZZUTO E, 2003, COARTICOLAZIONE, P59; Senghas A, 2004, SCIENCE, V305, P1779, DOI 10.1126/science.1100199; Volterra V., 1994, GESTURE LANGUAGE HEA	12	9	9	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 1	2005	309	5731								10.1126/science.1107876	http://dx.doi.org/10.1126/science.1107876			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	941KD	15994513				2022-12-28	WOS:000230212800028
J	Shmueli, A; Oren, M				Shmueli, A; Oren, M			Life, death, and ubiquitin: Taming the mule	CELL			English	Editorial Material							P53; LIGASE; MCL-1	Ubiquitin-mediated protein degradation is an efficient way for the cell to get rid of unwanted proteins. A key player in this process is the E3 ubiquitin ligase. In this issue of Cell, Chen et al. (2005) and Zhong et al. (2005) describe a new E3 ligase, ARF-BP1/Mule, which targets two very different substrates, p53 and Mcl-1, with completely different cellular outcomes.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shmueli, A (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			Oren, Moshe/0000-0003-4311-7172				Cans C, 2003, P NATL ACAD SCI USA, V100, P13892, DOI 10.1073/pnas.2335950100; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Liu H, 2005, MOL CELL BIOL, V25, P3117, DOI 10.1128/MCB.25.8.3117-3126.2005; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	10	38	41	2	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 1	2005	121	7					963	965		10.1016/j.cell.2005.06.018	http://dx.doi.org/10.1016/j.cell.2005.06.018			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	944RZ	15989944	Bronze			2022-12-28	WOS:000230448000001
J	Hadziyannis, SJ; Tassopoulos, NC; Heathcote, EJ; Chang, TT; Kitis, G; Rizzetto, M; Marcellin, P; Lim, SG; Goodman, Z; Ma, J; Arterburn, S; Xiong, S; Currie, G; Brosgart, CL				Hadziyannis, SJ; Tassopoulos, NC; Heathcote, EJ; Chang, TT; Kitis, G; Rizzetto, M; Marcellin, P; Lim, SG; Goodman, Z; Ma, J; Arterburn, S; Xiong, S; Currie, G; Brosgart, CL		Adefovir Dipivoxil 438 Study Grp	Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							E-ANTIGEN; VIRUS DNA; RESISTANCE; LAMIVUDINE; PRECORE; EFFICACY	BACKGROUND: Treatment with adefovir dipivoxil for 48 weeks resulted in histologic, virologic, and biochemical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. We evaluated the effect of continued therapy as compared with cessation of therapy. METHODS: One hundred eighty-five HBeAg-negative patients with chronic hepatitis B were assigned to receive 10 mg of adefovir dipivoxil or placebo once daily for 48 weeks (ratio, 2:1). After week 48, patients receiving adefovir dipivoxil were again randomly assigned either to receive an additional 48 weeks of the drug or to switch to placebo. Patients originally assigned to placebo were switched to adefovir dipivoxil. Patients treated with adefovir dipivoxil during weeks 49 through 96 were subsequently offered continued therapy. The primary end points were changes in hepatitis B virus (HBV) DNA and alanine aminotransferase levels. RESULTS: Treatment with adefovir dipivoxil resulted in a median decrease in serum HBV DNA of 3.47 log copies per milliliter (on a base-10 scale) at 96 weeks and 3.63 log copies per milliliter at 144 weeks. HBV DNA levels were less than 1000 copies per milliliter in 71 percent of patients at week 96 and 79 percent at week 144. In the majority of patients who were switched from adefovir dipivoxil to placebo, the benefit of treatment was lost (median change in HBV DNA levels from baseline, -1.09 log copies per milliliter; only 8 percent of patients had levels below 1000 copies per milliliter at week 96). Side effects during weeks 49 through 144 were similar to those during the initial 48 weeks. Resistance mutations rtN236T and rtA181V were identified in 5.9 percent of patients after 144 weeks. CONCLUSIONS: In patients with HBeAg-negative chronic hepatitis B, the benefits achieved from 48 weeks of adefovir dipivoxil were lost when treatment was discontinued. In patients treated for 144 weeks, benefits were maintained, with infrequent emergence of viral resistance.	Henry Dunant Hosp, Dept Med & Hepatol, Athens, Greece; Western Attica Gen Hosp, Athens, Greece; Univ Toronto, Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; Natl Chen Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan; Georgios Papanikolaou Hosp, Thessaloniki, Greece; Azienda Osped San Giovanni Battista, Turin, Italy; Hop Beaujon, INSERM, U481, Serv Hepatol, Clichy, France; Hop Beaujon, Ctr Rech Claude Bernard Hepatites Virales, Clichy, France; Natl Univ Singapore Hosp, Div Gastroenterol, Singapore 117548, Singapore; Armed Forces Inst Pathol, Washington, DC 20306 USA; Gilead Sci Inc, Foster City, CA 94404 USA	Henry Dunant Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; National Cheng Kung University; George Papanikolaou General Hospital of Thessaloniki; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; National University of Singapore; United States Department of Defense; Gilead Sciences	Hadziyannis, SJ (corresponding author), Henry Dunant Hosp, Dept Med, 107 Mesog Ave, Athens 11526, Greece.	hadziyannis@ath.forthnet.gr	LIM, Seng Gee/AAD-9040-2020; Chang, Ting-Tsung/B-4306-2009	LIM, Seng Gee/0000-0003-0994-4932; 				Angus P, 2003, GASTROENTEROLOGY, V125, P292, DOI 10.1016/S0016-5085(03)00939-9; BRUNETTO MR, 1989, ITAL J GASTROENTEROL, V21, P151; Di Marco V, 2004, HEPATOLOGY, V40, P883, DOI 10.1002/hep.20381; EASL, 2003, J HEPATOL S1, V39, pS1; Funk ML, 2002, J VIRAL HEPATITIS, V9, P52, DOI 10.1046/j.1365-2893.2002.00304.x; HADZIYANNIS S, 1990, J HEPATOL, V11, pS133, DOI 10.1016/0168-8278(90)90180-Y; Hadziyannis SJ, 2000, HEPATOLOGY, V32, P847, DOI 10.1053/jhep.2000.17915; Hadziyannis SJ, 2003, NEW ENGL J MED, V348, P800, DOI 10.1056/NEJMoa021812; HADZIYANNIS SJ, 1995, VIRAL HEPATITIS REV, V1, P7; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Lampertico P, 1997, HEPATOLOGY, V26, P1621, DOI 10.1002/hep.510260634; Marcellin P, 2004, NEW ENGL J MED, V351, P1206, DOI 10.1056/NEJMoa040431; Papatheodoridis GV, 2001, J HEPATOL, V34, P306, DOI 10.1016/S0168-8278(00)00094-5; Richman DD, 2000, HEPATOLOGY, V32, P866, DOI 10.1053/jhep.2000.18194; Santantonio T, 2000, J HEPATOL, V32, P300, DOI 10.1016/S0168-8278(00)80076-8; Tassopoulos NC, 1999, HEPATOLOGY, V29, P889, DOI 10.1002/hep.510290321; Wai CT, 2002, J GASTROENTEROL, V37, P771, DOI 10.1007/s005350200129; Westland CE, 2003, HEPATOLOGY, V38, P96, DOI 10.1053/jhep.2003.50288; *WHO, 2000, 204 WHO	19	409	469	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					2673	2681		10.1056/NEJMoa042957	http://dx.doi.org/10.1056/NEJMoa042957			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	940HH	15987916	Bronze			2022-12-28	WOS:000230133800004
J	Akram, R				Akram, R			I am a better doctor now	LANCET			English	Editorial Material									Univ Hosp Aintree, Aintree Cardiac Ctr, Liverpool L9 7AL, Merseyside, England		Akram, R (corresponding author), Univ Hosp Aintree, Aintree Cardiac Ctr, Liverpool L9 7AL, Merseyside, England.	razasida@hotmail.com							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2149	2149		10.1016/S0140-6736(05)66740-2	http://dx.doi.org/10.1016/S0140-6736(05)66740-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964455				2022-12-28	WOS:000229858800034
J	Hillis, GS; Bloomfield, P				Hillis, GS; Bloomfield, P			Basic transthoracic echocardiography	BRITISH MEDICAL JOURNAL			English	Review							VENTRICULAR SYSTOLIC DYSFUNCTION; ASSOCIATION TASK-FORCE; CONGESTIVE-HEART-FAILURE; AMERICAN-COLLEGE; CLINICAL-APPLICATION; ATRIAL-FIBRILLATION; PRACTICE GUIDELINES; PREVALENCE; MORTALITY; COMMITTEE		Univ Aberdeen, Aberdeen Royal Infirm, Aberdeen AB25 2ZN, Scotland; Royal Infirm, Edinburgh, Midlothian, Scotland	University of Aberdeen; Royal Infirmary of Edinburgh	Hillis, GS (corresponding author), Univ Aberdeen, Aberdeen Royal Infirm, Aberdeen AB25 2ZN, Scotland.	g.hillis@abdn.ac.uk						Adams JN, 1998, LANCET, V352, P1722, DOI 10.1016/S0140-6736(05)79822-6; *AM SOC ECH COMM S, 1989, J AM SOC ECHOCARDIOG, V2, P358; Cheitlin MD, 2003, CIRCULATION, V108, P1146, DOI 10.1161/01.CIR.0000073597.57414.A9; Cheitlin MD, 1997, CIRCULATION, V95, P1686; Davie AP, 1996, BRIT MED J, V312, P222; Doughty RN, 1997, EUR HEART J, V18, P560; Enriquez-Sarano M, 2004, NEW ENGL J MED, V351, P1539, DOI 10.1056/NEJMcp030912; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; FURBERG CD, 1994, AM J CARDIOL, V74, P236, DOI 10.1016/0002-9149(94)90363-8; Gillespie N D, 1996, Health Bull (Edinb), V54, P395; Gillespie ND, 1997, BMJ-BRIT MED J, V314, P936, DOI 10.1136/bmj.314.7085.936; HOGLUND C, 1985, ACTA MED SCAND, V217, P411; KIRKLIN JW, 1991, CIRCULATION, V83, P1125; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; *NAT I HLTH CLIN E, 2003, MAN CHRON HEART FAIL; Nielsen OW, 2000, BRIT MED J, V320, P220, DOI 10.1136/bmj.320.7229.220; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; Senni M, 1998, CIRCULATION, V98, P2282, DOI 10.1161/01.CIR.98.21.2282; Vasan RS, 1999, J AM COLL CARDIOL, V33, P1948, DOI 10.1016/S0735-1097(99)00118-7; WILKINS GT, 1988, BRIT HEART J, V60, P299; XU MS, 1992, NEW ZEAL MED J, V105, P120	21	25	25	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 18	2005	330	7505					1432	1436		10.1136/bmj.330.7505.1432	http://dx.doi.org/10.1136/bmj.330.7505.1432			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938NP	15961816	Green Published			2022-12-28	WOS:000230010400020
J	Luan, BQ; Robbins, MO				Luan, BQ; Robbins, MO			The breakdown of continuum models for mechanical contacts	NATURE			English	Article							ATOMIC-FORCE MICROSCOPY; FRICTION; ADHESION; TRIBOLOGY; SURFACES; TRANSITION; SOLIDS; SCALE; WEAR; LAWS	Forces acting within the area of atomic contact between surfaces play a central role in friction and adhesion. Such forces are traditionally calculated using continuum contact mechanics(1), which is known to break down as the contact radius approaches atomic dimensions. Yet contact mechanics is being applied at ever smaller lengths, driven by interest in shrinking devices to nano-metre scales(2,3), creating nanostructured materials with optimized mechanical properties(3,4), and understanding the molecular origins of macroscopic friction and adhesion(5,6). Here we use molecular simulations to test the limits of contact mechanics under ideal conditions. Our findings indicate that atomic discreteness within the bulk of the solids does not have a significant effect, but that the atomic-scale surface roughness that is always produced by discrete atoms leads to dramatic deviations from continuum theory. Contact areas and stresses may be changed by a factor of two, whereas friction and lateral contact stiffness change by an order of magnitude. These variations are likely to affect continuum predictions for many macroscopic rough surfaces, where studies(7,8) show that the total contact area is broken up into many separate regions with very small mean radius.	Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA	Johns Hopkins University	Robbins, MO (corresponding author), Johns Hopkins Univ, Dept Phys & Astron, 3400 N Charles St, Baltimore, MD 21218 USA.	mr@jhu.edu		Robbins, Mark Owen/0000-0001-7160-3608				BHUSHAN B, 1995, NATURE, V374, P607, DOI 10.1038/374607a0; Bhushan B., 2003, SPRINGER HDB NANOTEC; Carpick RW, 2004, MRS BULL, V29, P472, DOI 10.1557/mrs2004.141; Carpick RW, 1997, CHEM REV, V97, P1163, DOI 10.1021/cr960068q; Dienwiebel M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.126101; Enachescu M, 1998, PHYS REV LETT, V81, P1877, DOI 10.1103/PhysRevLett.81.1877; GREENWOOD JA, 1984, P ROY SOC LOND A MAT, V393, P133, DOI 10.1098/rspa.1984.0050; Hirano M, 1997, PHYS REV LETT, V78, P1448, DOI 10.1103/PhysRevLett.78.1448; HOMOLA AM, 1990, WEAR, V136, P65, DOI 10.1016/0043-1648(90)90072-I; HORN RG, 1987, J COLLOID INTERF SCI, V115, P480, DOI 10.1016/0021-9797(87)90065-8; Hyun S, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.026117; JOHNSON KL, 1985, CONTACT MECH, pCH4; Kiely JD, 1998, PHYS REV B, V57, P12588, DOI 10.1103/PhysRevB.57.12588; Landman U, 1996, LANGMUIR, V12, P4514, DOI 10.1021/la950890+; Lantz MA, 1997, PHYS REV B, V56, P15345, DOI 10.1103/PhysRevB.56.15345; Maeda N, 2002, SCIENCE, V297, P379, DOI 10.1126/science.1072378; MAUGIS D, 1992, J COLLOID INTERF SCI, V150, P243, DOI 10.1016/0021-9797(92)90285-T; Miller R, 1996, PHILOS MAG A, V73, P803, DOI 10.1080/01418619608243690; Muser MH, 2001, PHYS REV LETT, V86, P1295, DOI 10.1103/PhysRevLett.86.1295; NEWBY BMZ, 1995, SCIENCE, V269, P1407, DOI 10.1126/science.269.5229.1407; Persson BNJ, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.116101; Schwarz UD, 1997, PHYS REV B, V56, P6987, DOI 10.1103/PhysRevB.56.6987; Shull KR, 2002, MAT SCI ENG R, V36, P1, DOI 10.1016/S0927-796X(01)00039-0; Socoliuc A, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.134301; Urbakh M, 2004, NATURE, V430, P525, DOI 10.1038/nature02750; Vafek O, 1999, PHYS REV B, V60, P12002, DOI 10.1103/PhysRevB.60.12002; Valiev R, 2002, NATURE, V419, P887, DOI 10.1038/419887a; Wenning L, 2001, EUROPHYS LETT, V54, P693, DOI 10.1209/epl/i2001-00371-6; 2001, SCI AM, V285, P32	29	497	512	9	234	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					929	932		10.1038/nature03700	http://dx.doi.org/10.1038/nature03700			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959512				2022-12-28	WOS:000229799700043
J	Muotri, AR; Chu, VT; Marchetto, MCN; Deng, W; Moran, JV; Gage, FH				Muotri, AR; Chu, VT; Marchetto, MCN; Deng, W; Moran, JV; Gage, FH			Somatic mosaicism in neuronal precursor cells mediated by L1 retrotransposition	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; LINE-1; GENE; TRANSCRIPTION; NEUROGENESIS; EXPRESSION; SEQUENCE; DIFFERENTIATION; DISRUPTION	Revealing the mechanisms for neuronal somatic diversification remains a central challenge for understanding individual differences in brain organization and function. Here we show that an engineered human LINE-1 (for long interspersed nuclear element-1; also known as L1) element can retrotranspose in neuronal precursors derived from rat hippocampus neural stem cells. The resulting retrotransposition events can alter the expression of neuronal genes, which, in turn, can influence neuronal cell fate in vitro. We further show that retrotransposition of a human L1 in transgenic mice results in neuronal somatic mosaicism. The molecular mechanism of action is probably mediated through Sox2, because a decrease in Sox2 expression during the early stages of neuronal differentiation is correlated with increases in both L1 transcription and retrotransposition. Our data therefore indicate that neuronal genomes might not be static, but some might be mosaic because of de novo L1 retrotransposition events.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Univ Michigan, Sch Med, Dept Human Genet & Internal Med, Ann Arbor, MI 48109 USA	Salk Institute; University of Michigan System; University of Michigan	Gage, FH (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gage@salk.edu						Athanikar JN, 2004, NUCLEIC ACIDS RES, V32, P3846, DOI 10.1093/nar/gkh698; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Brouha B, 2002, AM J HUM GENET, V71, P327, DOI 10.1086/341722; D'Amour KA, 2003, P NATL ACAD SCI USA, V100, P11866, DOI 10.1073/pnas.1834200100; DeBerardinis RJ, 1998, NAT GENET, V20, P288, DOI 10.1038/3104; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; Goodier JL, 2001, GENOME RES, V11, P1677, DOI 10.1101/gr.198301; GRIMALDI G, 1984, EMBO J, V3, P1753, DOI 10.1002/j.1460-2075.1984.tb02042.x; Han JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536; HOGAN J, 1994, MANIPULATING MOUSE E; Hsieh J, 2004, CURR OPIN GENET DEV, V14, P461, DOI 10.1016/j.gde.2004.07.006; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Lietz M, 2003, EUR J BIOCHEM, V270, P2, DOI 10.1046/j.1432-1033.2003.03360.x; MIKI Y, 1992, CANCER RES, V52, P643; Moran J.V., 2002, MOBILE DNA, P836; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Morrish TA, 2002, NAT GENET, V31, P159, DOI 10.1038/ng898; Naef F, 2002, GENOME BIOL, V3; Ostertag EM, 2000, NUCLEIC ACIDS RES, V28, P1418, DOI 10.1093/nar/28.6.1418; Ostertag EM, 2002, NAT GENET, V32, P655, DOI 10.1038/ng1022; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Perepelitsa-Belancio V, 2003, NAT GENET, V35, P363, DOI 10.1038/ng1269; Prak ETL, 2003, P NATL ACAD SCI USA, V100, P1832, DOI 10.1073/pnas.0337627100; Schwahn U, 1998, NAT GENET, V19, P327, DOI 10.1038/1214; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Tchenio T, 2000, NUCLEIC ACIDS RES, V28, P411, DOI 10.1093/nar/28.2.411; TRELOGAN SA, 1995, P NATL ACAD SCI USA, V92, P1520, DOI 10.1073/pnas.92.5.1520; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Yang N, 2003, NUCLEIC ACIDS RES, V31, P4929, DOI 10.1093/nar/gkg663; Zapala MA, 2002, GENOME BIOL, V3; Zappone MV, 2000, DEVELOPMENT, V127, P2367	44	657	681	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					903	910		10.1038/nature03663	http://dx.doi.org/10.1038/nature03663			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959507	Green Published			2022-12-28	WOS:000229799700037
J	Richardson, PG; Sonneveld, P; Schuster, MW; Irwin, D; Stadtmauer, EA; Facon, T; Harousseau, JL; Ben-Yehuda, D; Lonial, S; Goldschmidt, H; Reece, D; San-Miguel, JF; Blade, J; Boccadoro, M; Cavenagh, J; Dalton, WS; Boral, AL; Esseltine, DL; Porter, JB; Schenkein, D; Anderson, KC				Richardson, PG; Sonneveld, P; Schuster, MW; Irwin, D; Stadtmauer, EA; Facon, T; Harousseau, JL; Ben-Yehuda, D; Lonial, S; Goldschmidt, H; Reece, D; San-Miguel, JF; Blade, J; Boccadoro, M; Cavenagh, J; Dalton, WS; Boral, AL; Esseltine, DL; Porter, JB; Schenkein, D; Anderson, KC		APEX Investigators	Bortezomib or high-dose dexamethasone for relapsed multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED PHASE-III; THALIDOMIDE; THERAPY; VAD; CHEMOTHERAPY; VINCRISTINE; RESISTANT; SURVIVAL; DOXORUBICIN; ADRIAMYCIN	BACKGROUND: This study compared bortezomib with high-dose dexamethasone in patients with relapsed multiple myeloma who had received one to three previous therapies. METHODS: We randomly assigned 669 patients with relapsed myeloma to receive either an intravenous bolus of bortezomib (1.3 mg per square meter of body-surface area) on days 1, 4, 8, and 11 for eight three-week cycles, followed by treatment on days 1, 8, 15, and 22 for three five-week cycles, or high-dose dexamethasone (40 mg orally) on days 1 through 4, 9 through 12, and 17 through 20 for four five-week cycles, followed by treatment on days 1 through 4 for five four-week cycles. Patients who were assigned to receive dexamethasone were permitted to cross over to receive bortezomib in a companion study after disease progression. RESULTS: Patients treated with bortezomib had higher response rates, a longer time to progression (the primary end point), and a longer survival than patients treated with dexamethasone. The combined complete and partial response rates were 38 percent for bortezomib and 18 percent for dexamethasone (P<0.001), and the complete response rates were 6 percent and less than 1 percent, respectively (P<0.001). Median times to progression in the bortezomib and dexamethasone groups were 6.22 months (189 days) and 3.49 months (106 days), respectively (hazard ratio, 0.55; P<0.001). The one-year survival rate was 80 percent among patients taking bortezomib and 66 percent among patients taking dexamethasone (P=0.003), and the hazard ratio for overall survival with bortezomib was 0.57 (P=0.001). Grade 3 or 4 adverse events were reported in 75 percent of patients treated with bortezomib and in 60 percent of those treated with dexamethasone. CONCLUSIONS: Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.	Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Rotterdam Hosp, Rotterdam, Netherlands; New York Presbyterian Hosp, New York, NY USA; Alta Bates Canc Ctr, Berkeley, CA USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Hosp Claude Huriez, Lille, France; Hop Hotel Dieu, Nantes, France; Hadassah Univ Hosp, IL-91120 Jerusalem, Israel; Emory Univ, Atlanta, GA 30322 USA; Univ Klinikum Heidelberg, Heidelberg, Germany; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; Hosp Univ Salamanca, Salamanca, Spain; Inst Invest Biomed Agusti Pi & Sunyer, Barcelona, Spain; Univ Turin, Turin, Italy; St Bartholomews Hosp, London, England; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA; Millennium Pharmaceut Inc, Cambridge, MA USA	Harvard University; Dana-Farber Cancer Institute; Erasmus University Rotterdam; Erasmus MC; NewYork-Presbyterian Hospital; University of Pennsylvania; Universite de Lille - ISITE; CHU Lille; Nantes Universite; CHU de Nantes; Hebrew University of Jerusalem; Emory University; Ruprecht Karls University Heidelberg; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Salamanca; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Turin; University of London; Queen Mary University London; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Richardson, PG (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	paul_richardson@dfci.harvard.edu	San-Miguel, Jesús F./V-8977-2018; Kovacs, Michael/G-3315-2011	San-Miguel, Jesús F./0000-0002-9183-4857; Boccadoro, Mario/0000-0001-8130-5209				Alexanian R, 2000, SEMIN HEMATOL, V37, P35, DOI 10.1016/S0037-1963(00)90081-7; ALEXANIAN R, 1986, ANN INTERN MED, V105, P8, DOI 10.7326/0003-4819-105-1-8; ALEXANIAN R, 1992, BLOOD, V80, P887; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; BARLOGIE B, 1986, ONKOLOGIE, V9, P210, DOI 10.1159/000216008; Barlogie B, 2001, BLOOD, V98, P492, DOI 10.1182/blood.V98.2.492; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; BROWMAN GP, 1992, BRIT J HAEMATOL, V82, P555, DOI 10.1111/j.1365-2141.1992.tb06466.x; CALHOUN EA, 2000, P AN M AM SOC CLIN, V19, pA446; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340; Durie BGM, 1999, BLOOD, V94, p316A; FRIEDENBERG WR, 1991, AM J HEMATOL, V36, P171, DOI 10.1002/ajh.2830360303; Gertz MA, 1995, AM J CLIN ONCOL-CANC, V18, P475; Grosbois B, 2001, BLOOD, V98, p163A; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hus M, 2001, HAEMATOLOGICA, V86, P404; Jagannath S, 2004, BRIT J HAEMATOL, V127, P165, DOI 10.1111/j.1365-2141.2004.05188.x; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Juliusson G, 2000, BRIT J HAEMATOL, V109, P89, DOI 10.1046/j.1365-2141.2000.01983.x; Kumar A, 2003, LANCET ONCOL, V4, P293, DOI 10.1016/S1470-2045(03)01077-5; Kumar SK, 2004, MAYO CLIN PROC, V79, P867, DOI 10.4065/79.7.867; LeBlanc R, 2002, CANCER RES, V62, P4996; LONIAL S, 2004, J HEMATOL S2, V5, pS130; Mineur P, 1998, BRIT J HAEMATOL, V103, P512; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Neben K, 2002, CLIN CANCER RES, V8, P3377; NIESVIZKY R, 2003, P AN M AM SOC CLIN, V22, P582; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; RAJKUMAR S, 2000, BLOOD, V96, P168; Rajkumar SV, 2004, J CLIN ONCOL, V22, p560S; Raza SN, 2000, BLOOD, V96, p168A; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Richardson PG, 2003, BLOOD, V102, p149A; RICHARDSON PG, 2004, HEMATOL J, V5, pS103; Sonneveld P, 2001, BRIT J HAEMATOL, V115, P895, DOI 10.1046/j.1365-2141.2001.03171.x; Tosi P, 2002, HAEMATOLOGICA, V87, P408; Weber D, 2003, J CLIN ONCOL, V21, P16, DOI 10.1200/JCO.2003.03.139; Yakoub-Agha Ibrahim, 2002, Hematol J, V3, P185, DOI 10.1038/sj.thj.6200175	40	2010	2093	1	129	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2005	352	24					2487	2498		10.1056/NEJMoa043445	http://dx.doi.org/10.1056/NEJMoa043445			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935RH	15958804				2022-12-28	WOS:000229798900004
J	Gow, AJ; Whiteman, MC; Pattie, A; Whalley, L; Starr, J; Deary, IJ				Gow, AJ; Whiteman, MC; Pattie, A; Whalley, L; Starr, J; Deary, IJ			Lifetime intellectual function and satisfaction with life in old age: longitudinal cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Edinburgh, Dept Psychol, Edinburgh EH8 9JZ, Midlothian, Scotland; Univ Aberdeen, Dept Mental Hlth, Clin Res Ctr, Aberdeen AB25 2ZH, Scotland; Univ Edinburgh, Dept Geriatr Med, Edinburgh EH16 4SB, Midlothian, Scotland	University of Edinburgh; University of Aberdeen; University of Edinburgh	Deary, IJ (corresponding author), Univ Edinburgh, Dept Psychol, 7 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.	Ian.Deary@ed.ac.uk	Deary, Ian J/C-6297-2009; Gow, Alan J/A-6070-2009; whalley, lawrence j/E-9019-2011; Starr, John/C-8951-2011	Deary, Ian J/0000-0002-1733-263X; Gow, Alan J/0000-0002-3320-4531; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Deary IJ, 2004, J PERS SOC PSYCHOL, V86, P130, DOI 10.1037/0022-3514.86.1.130; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Fillit HM, 2002, MAYO CLIN PROC, V77, P681, DOI 10.4065/77.7.681; GOW AJ, 2005, IN PRESS PERS INDIVI	5	28	29	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 16	2005	331	7509					141	142		10.1136/bmj.38531.675660.F7	http://dx.doi.org/10.1136/bmj.38531.675660.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	947GV	16000314	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000230632300017
J	Okie, S				Okie, S			Stem-cell research - Signposts and roadblocks	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Hoffman DI, 2003, FERTIL STERIL, V79, P1063, DOI 10.1016/S0015-0282(03)00172-9; Perry ACF, 2005, NEW ENGL J MED, V353, P87, DOI 10.1056/NEJMcibr052068; Practice Committe of the American Society for Reproductive Medicine, 2003, Fertil Steril, V80, P1309; 2005, DAILY PENNSYLVA 0527; 2005, NY TIMES        0526, pA28	5	11	11	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2005	353	1					1	5		10.1056/NEJMp058129	http://dx.doi.org/10.1056/NEJMp058129			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942FC	16000350				2022-12-28	WOS:000230267300001
J	Tsimikas, S; Brilakis, ES; Miller, ER; McConnell, JP; Lennon, RJ; Kornman, KS; Witztum, JL; Berger, PB				Tsimikas, S; Brilakis, ES; Miller, ER; McConnell, JP; Lennon, RJ; Kornman, KS; Witztum, JL; Berger, PB			Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; ELEVATED LIPOPROTEIN(A); MYOCARDIAL-INFARCTION; RISK-FACTOR; APOPTOTIC CELLS; HEART-DISEASE; HUMAN PLASMA; LDL; APOLIPOPROTEIN(A); ATHEROSCLEROSIS	Background: Lp(a) lipoprotein binds proinflammatory oxidized phospholipids. We investigated whether levels of oxidized low-density lipoprotein (LDL) measured with use of monoclonal antibody E06 reflect the presence and extent of obstructive coronary artery disease, defined as a stenosis of more than 50 percent of the luminal diameter. Methods: Levels of oxidized LDL and Lp(a) lipoprotein were measured in a total of 504 patients immediately before coronary angiography. Levels of oxidized LDL are reported as the oxidized phospholipid content per particle of apolipoprotein B-100 (oxidized phospholipid:apo B-100 ratio). Results: Measurements of the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels were skewed toward lower values, and the values for the oxidized phospholipid:apo B-100 ratio correlated strongly with those for Lp(a) lipoprotein (r=0.83, P<0.001). In the entire cohort, the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels showed a strong and graded association with the presence and extent of coronary artery disease (i.e., the number of vessels with a stenosis of more than 50 percent of the luminal diameter) (P<0.001). Among patients 60 years of age or younger, those in the highest quartiles for the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels had odds ratios for coronary artery disease of 3.12 (P<0.001) and 3.64 (P<0.001), respectively, as compared with patients in the lowest quartile. The combined effect of hypercholesterolemia and being in the highest quartiles of the oxidized phospholipid:apo B-100 ratio (odds ratio, 16.8; P<0.001) and Lp(a) lipoprotein levels (odds ratio, 14.2; P<0.001) significantly increased the probability of coronary artery disease among patients 60 years of age or younger. In the entire study group, the association of the oxidized phospholipid:apo B-100 ratio with obstructive coronary artery disease was independent of all clinical and lipid measures except one, Lp(a) lipoprotein. However, among patients 60 years of age or younger, the oxidized phospholipid:apo B-100 ratio remained an independent predictor of coronary artery disease. Conclusions: Circulating levels of oxidized LDL are strongly associated with angiographically documented coronary artery disease, particularly in patients 60 years of age or younger. These data suggest that the atherogenicity of Lp(a) lipoprotein may be mediated in part by associated proinflammatory oxidized phospholipids.	Univ Calif San Diego, Vasc Med Program, Div Cardiovasc Dis, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Biostat, Rochester, MN 55905 USA; Interleukin Genet, Waltham, MA USA; Duke Clin Res Inst, Div Cardiovasc Dis, Durham, NC USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Mayo Clinic; Mayo Clinic; Duke University	Tsimikas, S (corresponding author), Univ Calif San Diego, Vasc Med Program, Div Cardiovasc Dis, 9500 Gilman Dr,Basic Sci Bldg,Rm 1080, La Jolla, CA 92093 USA.	stsimikas@ucsd.edu	Brilakis, Emmanouil/B-5282-2009	Brilakis, Emmanouil/0000-0001-9416-9701	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057505, P50HL056989, F32HL069646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57505, HL69646, HL56989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Assmann G, 1996, AM J CARDIOL, V77, P1179, DOI 10.1016/S0002-9149(96)00159-2; Berg K, 1997, CLIN GENET, V52, P254; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Binder CJ, 2004, J CLIN INVEST, V114, P427, DOI 10.1172/jci200420479; Binder CJ, 2003, NAT MED, V9, P736, DOI 10.1038/nm876; Blencowe C, 1995, J BIOL CHEM, V270, P31151, DOI 10.1074/jbc.270.52.31151; Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699; Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; Danesh J, 2000, CIRCULATION, V102, P1082, DOI 10.1161/01.CIR.102.10.1082; Dangas G, 1998, J AM COLL CARDIOL, V32, P2035, DOI 10.1016/S0735-1097(98)00469-0; Edelstein C, 2003, J BIOL CHEM, V278, P52841, DOI 10.1074/jbc.M310425200; Ehara S, 2001, CIRCULATION, V103, P1955, DOI 10.1161/01.cir.103.15.1955; Foody JM, 2000, ARTERIOSCL THROM VAS, V20, P493, DOI 10.1161/01.ATV.20.2.493; HEARN JA, 1990, AM J CARDIOL, V66, P1176, DOI 10.1016/0002-9149(90)91094-M; Hobbs HH, 1999, CURR OPIN LIPIDOL, V10, P225, DOI 10.1097/00041433-199906000-00005; Holvoet P, 1998, CIRCULATION, V98, P1487, DOI 10.1161/01.CIR.98.15.1487; Holvoet P, 2001, ARTERIOSCL THROM VAS, V21, P844, DOI 10.1161/01.ATV.21.5.844; Holvoet P, 1999, JAMA-J AM MED ASSOC, V281, P1718, DOI 10.1001/jama.281.18.1718; KARABINA SAP, 1994, BBA-LIPID LIPID MET, V1213, P34, DOI 10.1016/0005-2760(94)90219-4; Klezovitch O, 2001, J BIOL CHEM, V276, P46864, DOI 10.1074/jbc.M107943200; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; McConnell JP, 2002, CLIN CHEM LAB MED, V40, P56, DOI 10.1515/CCLM.2002.011; Nishi K, 2002, ARTERIOSCL THROM VAS, V22, P1649, DOI 10.1161/01.ATV.0000033829.14012.18; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; SANDKAMP M, 1990, CLIN CHEM, V36, P20; Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472; Sunayama S, 1996, CIRCULATION, V94, P1263, DOI 10.1161/01.CIR.94.6.1263; Thillet J, 1998, ATHEROSCLEROSIS, V136, P389, DOI 10.1016/S0021-9150(97)00217-7; Toshima S, 2000, ARTERIOSCL THROM VAS, V20, P2243, DOI 10.1161/01.ATV.20.10.2243; Trieu VN, 1999, BIOCHEM BIOPH RES CO, V257, P714, DOI 10.1006/bbrc.1999.0519; Tsimikas S, 2004, CIRCULATION, V110, P1406, DOI 10.1161/01.CIR.0000141728.23033.B5; Tsimikas S, 2003, J AM COLL CARDIOL, V41, P360, DOI 10.1016/S0735-1097(02)02769-9; Tsimikas S, 2004, CIRCULATION, V109, P3164, DOI 10.1161/01.CIR.0000130844.01174.55; Tsimikas S, 2001, CIRCULATION, V103, P1930; Tsimikas S, 2004, MOL BASIS CARDIOVASC, P385; Wolk R, 2003, CIRCULATION, V108, P2206, DOI 10.1161/01.CIR.0000095270.85646.E8; Yano Y, 1997, J HISTOCHEM CYTOCHEM, V45, P559, DOI 10.1177/002215549704500408	40	534	560	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2005	353	1					46	57		10.1056/NEJMoa043175	http://dx.doi.org/10.1056/NEJMoa043175			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942FC	16000355	Bronze			2022-12-28	WOS:000230267300007
J	Lee, IM; Cook, NR; Gaziano, JM; Gordon, D; Ridker, PM; Manson, JE; Hennekens, CH; Buring, JE				Lee, IM; Cook, NR; Gaziano, JM; Gordon, D; Ridker, PM; Manson, JE; Hennekens, CH; Buring, JE			Vitamin E in the primary prevention of cardiovascular disease and cancer - The Women's Health Study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BETA-CAROTENE SUPPLEMENTATION; NUTRITION INTERVENTION TRIALS; CORONARY-HEART-DISEASE; ANTIOXIDANT VITAMINS; ALPHA-TOCOPHEROL; CLINICAL-TRIAL; E CONSUMPTION; MORTALITY; RISK; EVENTS	Context Basic research provides plausible mechanisms and observational studies suggest that apparently healthy persons, who self-select for high intakes of vitamin E through diet or supplements, have decreased risks of cardiovascular disease and cancer. Randomized trials do not generally support benefits of vitamin E, but there are few trials of long duration among initially healthy persons. Objective To test whether vitamin E supplementation decreases risks of cardiovascular disease and cancer among healthy women. Design, Setting, and Participants In the Women's Health Study conducted between 1992 and 2004, 39 876 apparently healthy US women aged at least 45 years were randomly assigned to receive vitamin E or placebo and aspirin or placebo, using a 2 X 2 factorial design, and were followed up for an average of 10.1 years. Intervention Administration of 600 IU of natural-source vitamin E on alternate days. Main Outcome Measures Primary outcomes were a composite end point of first major cardiovascular event (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and total invasive cancer. Results During follow-up, there were 482. major cardiovascular events in the vitamin E group and 517 in the placebo group, a nonsignificant 7% risk reduction (relative risk [RR], 0.93; 95% confidence interval [CI], 0.82-1.05; P=.26). There were no significant effects on the incidences of myocardial infarction (RR, 1.01; 95% Cl, 0.82-1.23; P=.96) or stroke (RR, 0.98; 95% Cl, 0.82-1.17; P=.82), as well as ischemic or hemorrhagic stroke. For cardiovascular death, there was a significant 24% reduction (RR, 0.76; 95% Cl, 0.59-0.98; P=.03). There was no significant effect on the incidences of total cancer (1437 cases in the vitamin E group and 1428 in the placebo group; RR, 1.01; 95% Cl, 0.94-1.08; P=.87) or breast (RR, 1.00; 95% Cl, 0.90-1.12; P=.95), lung (RR, 1.09; 95% Cl, 0.83-1.44; P=.52), or colon cancers (RR, 1.00; 95% Cl, 0.77-1.31; P=.99). Cancer deaths also did not differ significantly between groups. There was no significant effect of vitamin E on total mortality (636 in the vitamin E group and 615 in the placebo group; RR, 1.04; 95% Cl, 0.93-1.16; P=.53). Conclusions The data from this large trial indicated that 600 IU of natural-source vitamin E taken every other day provided no overall benefit for major cardiovascular events or cancer, did not affect total mortality, and decreased cardiovascular mortality in healthy women. These data do not support recommending vitamin E supplementation for cardiovascular disease or cancer prevention among healthy women.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Prevent Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Cardiovasc Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Aging, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, Boston, MA USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Univ Miami, Sch Med, Dept Med, Miami, FL USA; Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL USA; Florida Atlantic Univ, Ctr Excellence, Dept Biomed Sci, Boca Raton, FL 33431 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Harvard Medical School; University of Miami; University of Miami; State University System of Florida; Florida Atlantic University	Lee, IM (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.	ilee@rics.bwh.harvard.edu	Lee, I-Min/ABD-5409-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043851] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47988] Funding Source: Medline; NHLBI NIH HHS [HL-43851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; Atiya M, 2003, STROKE, V34, P565, DOI 10.1161/01.STR.0000054159.21017.7C; Bairati I, 2005, JNCI-J NATL CANCER I, V97, P481, DOI 10.1093/jnci/dji095; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Boaz M, 2000, LANCET, V356, P1213, DOI 10.1016/S0140-6736(00)02783-5; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; CERUTTI PA, 1994, LANCET, V344, P862, DOI 10.1016/S0140-6736(94)92832-0; Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3; Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Eidelman RS, 2004, ARCH INTERN MED, V164, P1552, DOI 10.1001/archinte.164.14.1552; GEY KF, 1991, AM J CLIN NUTR, V53, pS326, DOI 10.1093/ajcn/53.1.326S; Girodon F, 1999, ARCH INTERN MED, V159, P748, DOI 10.1001/archinte.159.7.748; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; Halliwell B, 2000, LANCET, V355, P1179, DOI 10.1016/S0140-6736(00)02075-4; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; Hennekens C.H., 1987, EPIDEMIOLOGY MED; Hensley K, 2004, FREE RADICAL BIO MED, V36, P1, DOI 10.1016/j.freeradbiomed.2003.10.009; Hercberg S, 2004, ARCH INTERN MED, V164, P2335, DOI 10.1001/archinte.164.21.2335; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439; Kris-Etherton PM, 2004, CIRCULATION, V110, P637, DOI 10.1161/01.CIR.0000137822.39831.F1; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102; LI JY, 1993, J NATL CANCER I, V85, P1492, DOI 10.1093/jnci/85.18.1492; Linfante A, 2004, CIRCULATION, V110, P664; Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338; Manson JE, 2003, J WOMEN HEALTH GEN-B, V12, P123, DOI 10.1089/154099903321576510; McNeil JJ, 2004, OPHTHALMOLOGY, V111, P75, DOI 10.1016/j.ophtha.2003.04.009; Mehta J, 1997, AM J CARDIOL, V79, P1558, DOI 10.1016/S0002-9149(97)00196-3; MEYDANI M, 1995, LANCET, V345, P170, DOI 10.1016/S0140-6736(95)90172-8; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; Ogita H, 2004, ENDOTHELIUM-J ENDOTH, V11, P123, DOI 10.1080/10623320490482664; Patterson RE, 1997, CANCER CAUSE CONTROL, V8, P786, DOI 10.1023/A:1018443724293; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; Rexrode KM, 2000, J WOMEN HEALTH GEN-B, V9, P19, DOI 10.1089/152460900318911; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RITENBAUGH C, SUMMARY EVIDENCE RAN; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SHETTY P, UPDATE EVIDENCE RAND; Shoulson I, 1998, ANN NEUROL, V43, P318; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1995, LANCET, V346, P36, DOI 10.1016/S0140-6736(95)92657-7; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steiner M, 1999, NUTR REV, V57, P306, DOI 10.1111/j.1753-4887.1999.tb06903.x; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Upston JM, 1999, FASEB J, V13, P977, DOI 10.1096/fasebj.13.9.977; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Virtamo J, 1998, ARCH INTERN MED, V158, P668, DOI 10.1001/archinte.158.6.668; Virtamo J, 2003, JAMA-J AM MED ASSOC, V290, P476, DOI 10.1001/jama.290.4.476; Vivekananthan DP, 2003, LANCET, V361, P2017, DOI 10.1016/S0140-6736(03)13637-9; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; You WC, 2001, EUR J CANCER PREV, V10, P257, DOI 10.1097/00008469-200106000-00009; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Zureik M, 2004, ARTERIOSCL THROM VAS, V24, P1485, DOI 10.1161/01.ATV.0000136648.62973.c8	57	808	833	0	61	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2005	294	1					56	65		10.1001/jama.294.1.56	http://dx.doi.org/10.1001/jama.294.1.56			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941JD	15998891	Bronze			2022-12-28	WOS:000230210200025
J	Chan, JL; Mantzoros, CS				Chan, JL; Mantzoros, CS			Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa	LANCET			English	Review							BONE-MINERAL DENSITY; GONADOTROPIN-RELEASING-HORMONE; ENDOCRINE-METABOLIC ABERRATIONS; HUMAN PITUITARY-ADENOMAS; HUMAN RECOMBINANT LEPTIN; MULTIPLE SKELETAL SITES; WOMEN DISTANCE RUNNERS; SERUM LEPTIN; PLASMA LEPTIN; BODY-COMPOSITION	Leptin is an adipocyte-secreted hormone that plays a key part in energy homoeostasis. Advances in leptin physiology have established that the main role of this hormone is to signal energy availability in energy-deficient states. Studies in animals and human beings have shown that low concentrations of leptin are fully or partly responsible for starvation-induced changes in neuroendocrine axes, including low reproductive, thyroid, and insulin-like growth factor (IGF) hormones. Disease states such as exercise-induced hypothalamic amenorrhoea and anorexia nervosa are also associated with low concentrations of leptin and a similar spectrum of neuroendocrine abnormalities. We have recently shown in an interventional, proof-of-concept study that leptin can restore ovulatory menstrual cycles and improve reproductive, thyroid, and IGF hormones and bone markers in hypothalamic amenorrhoea. Further studies are warranted to establish the safety and effectiveness of leptin for the infertility and osteoporosis associated with hypothalamic amenorrhoea, and to clarify its role in anorexia nervosa.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Endocrinol Diabet & Metab, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Mantzoros, CS (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Endocrinol Diabet & Metab, 330 Brookline Ave,Stoneman 816, Boston, MA 02215 USA.	cmantzor@bidmc.harvard.edu	Mantzoros, Christos/Y-2902-2019		NCRR NIH HHS [K23 RR018860] Funding Source: Medline; PHS HHS [R01 58785] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR018860] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Aloi JA, 1997, J CLIN ENDOCR METAB, V82, P1543, DOI 10.1210/jc.82.5.1543; Audi L, 1998, MOL PSYCHIATR, V3, P544, DOI 10.1038/sj.mp.4000418; BACHRACH LK, 1990, PEDIATRICS, V86, P440; Ballauff A, 1999, MOL PSYCHIATR, V4, P71, DOI 10.1038/sj.mp.4000478; Balligand JL, 1998, EUR J ENDOCRINOL, V138, P415, DOI 10.1530/eje.0.1380415; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; BERGA SL, 1995, ENDOCRINOLOGIST, V5, P416, DOI 10.1097/00019616-199511000-00005; BERGA SL, 1989, J CLIN ENDOCR METAB, V68, P301, DOI 10.1210/jcem-68-2-301; BERGA SL, 1989, PSYCHIAT CLIN N AM, V12, P105; BILLER BMK, 1991, OBSTET GYNECOL, V78, P996; BILLER BMK, 1990, J CLIN ENDOCR METAB, V70, P311, DOI 10.1210/jcem-70-2-311; Blain H, 2002, J CLIN ENDOCR METAB, V87, P1030, DOI 10.1210/jc.87.3.1030; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; BULLEN BA, 1985, NEW ENGL J MED, V312, P1349, DOI 10.1056/NEJM198505233122103; Burguera B, 2001, ENDOCRINOLOGY, V142, P3546, DOI 10.1210/en.142.8.3546; Calandra C, 2003, Eat Weight Disord, V8, P130; CAMERON JL, 1991, J CLIN ENDOCR METAB, V73, P35, DOI 10.1210/jcem-73-1-35; Casanueva FF, 1997, BIOCHEM MOL MED, V60, P116, DOI 10.1006/bmme.1996.2564; Chan JL, 2003, J CLIN INVEST, V111, P1409, DOI 10.1172/JCI200317490; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen C, 2001, ENDOCRINE, V14, P73, DOI 10.1385/ENDO:14:1:073; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cock TA, 2003, LANCET, V362, P1572, DOI 10.1016/S0140-6736(03)14747-2; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405; Couzinet B, 1999, CLIN ENDOCRINOL, V50, P229, DOI 10.1046/j.1365-2265.1999.00649.x; CUMMING DC, 1985, J CLIN ENDOCR METAB, V60, P810, DOI 10.1210/jcem-60-4-810; DAVIES KM, 1990, BONE, V11, P143, DOI 10.1016/8756-3282(90)90207-F; DAVIES MC, 1990, BRIT MED J, V301, P790, DOI 10.1136/bmj.301.6755.790; DESOUZA MJ, 1991, MED SCI SPORT EXER, V23, P995; Di Carlo C, 2002, FERTIL STERIL, V78, P376, DOI 10.1016/S0015-0282(02)03221-1; DING JH, 1988, ANN INTERN MED, V108, P530, DOI 10.7326/0003-4819-108-4-530; Dominguez CE, 1997, FERTIL STERIL, V68, P992, DOI 10.1016/S0015-0282(97)00393-2; DRINKWATER BL, 1984, NEW ENGL J MED, V311, P277, DOI 10.1056/NEJM198408023110501; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Eckert ED, 1998, J CLIN ENDOCR METAB, V83, P791, DOI 10.1210/jc.83.3.791; Elefteriou F, 2004, P NATL ACAD SCI USA, V101, P3258, DOI 10.1073/pnas.0308744101; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; Farooqi IS, 2001, NATURE, V414, P34, DOI 10.1038/35102112; FRISCH RE, 1974, SCIENCE, V185, P949, DOI 10.1126/science.185.4155.949; GILES DE, 1993, FERTIL STERIL, V60, P486; Giusti M, 2002, CLIN ENDOCRINOL, V57, P449, DOI 10.1046/j.1365-2265.2002.01612.x; Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156; Gordon C M, 2000, Eat Weight Disord, V5, P175; Gordon CM, 2002, J CLIN ENDOCR METAB, V87, P4935, DOI 10.1210/jc.2002-020545; Goulding A, 1998, CALCIFIED TISSUE INT, V63, P456, DOI 10.1007/s002239900557; Grinspoon S, 2002, J CLIN ENDOCR METAB, V87, P2883, DOI 10.1210/jc.87.6.2883; Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P3861, DOI 10.1210/jc.81.11.3861; GULEKLI B, 1994, CLIN ENDOCRINOL, V41, P275, DOI 10.1111/j.1365-2265.1994.tb02545.x; HEBEBRAND J, 1995, LANCET, V346, P1624, DOI 10.1016/S0140-6736(95)91955-4; Hebebrand J, 1997, MOL PSYCHIATR, V2, P330, DOI 10.1038/sj.mp.4000282; Heiman ML, 1997, ENDOCRINOLOGY, V138, P3859, DOI 10.1210/en.138.9.3859; Hergenroeder AC, 1997, AM J OBSTET GYNECOL, V176, P1017, DOI 10.1016/S0002-9378(97)70396-X; Herpertz S, 2000, EUR J ENDOCRINOL, V142, P373, DOI 10.1530/eje.0.1420373; Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568; HIGHET R, 1989, SPORTS MED, V7, P82, DOI 10.2165/00007256-198907020-00002; Hoek HW, 2003, INT J EAT DISORDER, V34, P383, DOI 10.1002/eat.10222; Holtkamp K, 2004, PSYCHONEUROENDOCRINO, V29, P791, DOI 10.1016/S0306-4530(03)00143-4; Holtkamp K, 2003, J NEURAL TRANSM, V110, P427, DOI 10.1007/s00702-002-0800-x; Holtkamp K, 2003, J PSYCHIATR RES, V37, P165, DOI 10.1016/S0022-3956(02)00100-0; Jin L, 2000, ENDOCRINOLOGY, V141, P333, DOI 10.1210/en.141.1.333; Karlsson C, 1997, J CLIN ENDOCR METAB, V82, P4144, DOI 10.1210/jc.82.12.4144; Keen AD, 1997, OSTEOPOROSIS INT, V7, P311, DOI 10.1007/BF01623770; Kim MS, 2000, J CLIN INVEST, V105, P1005, DOI 10.1172/JCI8857; Kitawaki J, 2000, J CLIN ENDOCR METAB, V85, P1946, DOI 10.1210/jc.85.5.1946; KLIBANSKI A, 1995, J CLIN ENDOCR METAB, V80, P898, DOI 10.1210/jc.80.3.898; Kolaczynski JW, 1996, DIABETES, V45, P699, DOI 10.2337/diabetes.45.5.699; Kopp W, 1998, HORM METAB RES, V30, P272, DOI 10.1055/s-2007-978882; Kopp W, 1997, MOL PSYCHIATR, V2, P335, DOI 10.1038/sj.mp.4000287; Korbonits M, 2001, CLIN ENDOCRINOL, V54, P781, DOI 10.1046/j.1365-2265.2001.01279.x; Kratzsch J, 2002, J CLIN ENDOCR METAB, V87, P4587, DOI 10.1210/jc.2002-020001; Krizova J, 2002, ENDOCR RES, V28, P199, DOI 10.1081/ERC-120015058; Kyle UG, 2003, NUTRITION, V19, P597, DOI 10.1016/S0899-9007(03)00061-3; LaPaglia N, 1998, J ENDOCRINOL, V159, P79, DOI 10.1677/joe.0.1590079; Laughlin GA, 1997, J CLIN ENDOCR METAB, V82, P318, DOI 10.1210/jc.82.1.318; Laughlin GA, 1998, J CLIN ENDOCR METAB, V83, P25, DOI 10.1210/jc.83.1.25; Laughlin GA, 1996, J CLIN ENDOCR METAB, V81, P4301, DOI 10.1210/jc.81.12.4301; Lear SA, 1999, INT J EAT DISORDER, V26, P283, DOI 10.1002/(SICI)1098-108X(199911)26:3&lt;283::AID-EAT5&gt;3.0.CO;2-K; Lebrethon MC, 2000, ENDOCRINOLOGY, V141, P1464, DOI 10.1210/en.141.4.1464; Legradi G, 1997, ENDOCRINOLOGY, V138, P2569, DOI 10.1210/en.138.6.2569; Licinio J, 2004, P NATL ACAD SCI USA, V101, P4531, DOI 10.1073/pnas.0308767101; Licinio J, 1998, P NATL ACAD SCI USA, V95, P2541, DOI 10.1073/pnas.95.5.2541; Licinio J, 1997, NAT MED, V3, P575, DOI 10.1038/nm0597-575; LIU JH, 1990, AM J OBSTET GYNECOL, V163, P1732, DOI 10.1016/0002-9378(90)91437-H; Lob S, 2003, EXP CLIN ENDOCR DIAB, V111, P278, DOI 10.1055/s-2003-41286; LOUCKS AB, 1992, J CLIN ENDOCR METAB, V75, P514, DOI 10.1210/jc.75.2.514; LOUCKS AB, 1989, J CLIN ENDOCR METAB, V68, P402, DOI 10.1210/jcem-68-2-402; Loucks AB, 1998, J APPL PHYSIOL, V84, P37, DOI 10.1152/jappl.1998.84.1.37; Lucas AR, 1999, MAYO CLIN PROC, V74, P972; Magni P, 1999, ENDOCRINOLOGY, V140, P1581, DOI 10.1210/en.140.4.1581; Mantzoros C, 1997, J CLIN ENDOCR METAB, V82, P1845, DOI 10.1210/jc.82.6.1845; Mantzoros CS, 2001, J CLIN ENDOCR METAB, V86, P3284, DOI 10.1210/jc.86.7.3284; Mantzoros CS, 1999, ANN INTERN MED, V130, P671, DOI 10.7326/0003-4819-130-8-199904200-00014; Mantzoros CS, 1998, CLIN ENDOCRINOL, V49, P551, DOI 10.1046/j.1365-2265.1998.00571.x; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P1066, DOI 10.1210/jc.82.4.1066; Maor G, 2002, J BONE MINER RES, V17, P1034, DOI 10.1359/jbmr.2002.17.6.1034; MARCUS R, 1985, ANN INTERN MED, V102, P158, DOI 10.7326/0003-4819-102-2-158; Matejek N, 1999, INT J SPORTS MED, V20, P451; Mehler PS, 2003, INT J EAT DISORDER, V33, P113, DOI 10.1002/eat.10119; Miller KK, 1998, J CLIN ENDOCR METAB, V83, P2309, DOI 10.1210/jc.83.7.2309; Miller KK, 1999, J CLIN ENDOCR METAB, V84, P1775, DOI 10.1210/jc.84.6.1775; Misra M, 2004, J CLIN ENDOCR METAB, V89, P3486, DOI 10.1210/jc.2003-032251; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Monteleone P, 2002, MOL PSYCHIATR, V7, P641, DOI 10.1038/sj.mp.4001043; Moschos S, 2002, FERTIL STERIL, V77, P433, DOI 10.1016/S0015-0282(01)03010-2; Mounzih K, 1997, ENDOCRINOLOGY, V138, P1190, DOI 10.1210/en.138.3.1190; MYBURGH KH, 1990, ANN INTERN MED, V113, P754, DOI 10.7326/0003-4819-113-10-754; MYBURGH KH, 1993, MED SCI SPORT EXER, V25, P1197; Nedvidkova J, 2000, ENDOCR RES, V26, P219, DOI 10.3109/07435800009066163; Odabasi E, 2000, EUR J ENDOCRINOL, V142, P170, DOI 10.1530/eje.0.1420170; Ozata M, 1999, J CLIN ENDOCR METAB, V84, P3686, DOI 10.1210/jc.84.10.3686; Pasco JA, 2001, J CLIN ENDOCR METAB, V86, P1884, DOI 10.1210/jc.86.5.1884; Perkins RB, 1999, J CLIN ENDOCR METAB, V84, P1905, DOI 10.1210/jc.84.6.1905; Pettersson U, 1999, CALCIFIED TISSUE INT, V64, P117, DOI 10.1007/s002239900589; Polito A, 2000, AM J CLIN NUTR, V71, P1495; Rauch F, 1998, CALCIFIED TISSUE INT, V63, P453, DOI 10.1007/s002239900556; REAME NE, 1985, J CLIN ENDOCR METAB, V61, P851, DOI 10.1210/jcem-61-5-851; Rencken ML, 1996, JAMA-J AM MED ASSOC, V276, P238, DOI 10.1001/jama.276.3.238; Robinson E, 2000, J ADOLESCENT HEALTH, V26, P343, DOI 10.1016/S1054-139X(99)00121-4; Roemmich JN, 2003, J CLIN ENDOCR METAB, V88, P599, DOI 10.1210/jc.2001-012025; Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424; Rosenbaum M, 2002, J CLIN ENDOCR METAB, V87, P2391, DOI 10.1210/jc.87.5.2391; Ruhl CE, 2002, J BONE MINER RES, V17, P1896, DOI 10.1359/jbmr.2002.17.10.1896; Saad MF, 1997, J CLIN ENDOCR METAB, V82, P579, DOI 10.1210/jc.82.2.579; SANTORO N, 1986, ENDOCR REV, V7, P11, DOI 10.1210/edrv-7-1-11; SEEMAN E, 1992, J BONE MINER RES, V7, P1467; Seoane LM, 2000, REGUL PEPTIDES, V92, P25, DOI 10.1016/S0167-0115(00)00145-2; Simha V, 2002, J CLIN ENDOCR METAB, V87, P4942, DOI 10.1210/jc.2002-020792; Simon C, 1998, J CLIN ENDOCR METAB, V83, P1893, DOI 10.1210/jc.83.6.1893; Sinha MK, 1996, J CLIN INVEST, V97, P1344, DOI 10.1172/JCI118551; Steppan CM, 2000, REGUL PEPTIDES, V92, P73, DOI 10.1016/S0167-0115(00)00152-X; Stoving RK, 1998, CLIN ENDOCRINOL, V48, P761; Stoving RK, 1999, J PSYCHIATR RES, V33, P139, DOI 10.1016/S0022-3956(98)00049-1; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; Thomas T, 2001, BONE, V29, P114, DOI 10.1016/S8756-3282(01)00487-2; Thong FSL, 2000, J APPL PHYSIOL, V88, P2037, DOI 10.1152/jappl.2000.88.6.2037; VELDHUIS JD, 1993, J CLIN ENDOCR METAB, V76, P587, DOI 10.1210/jcem.76.3.8445014; VELDHUIS JD, 1985, J CLIN ENDOCR METAB, V61, P557, DOI 10.1210/jcem-61-3-557; VILLANUEVA AL, 1986, J CLIN ENDOCR METAB, V63, P133, DOI 10.1210/jcem-63-1-133; WAKAT DK, 1982, MED SCI SPORT EXER, V14, P263, DOI 10.1249/00005768-198204000-00002; WARREN MP, 1994, J SOC GYNECOL INVEST, V1, P84, DOI 10.1177/107155769400100117; Warren MP, 1999, J CLIN ENDOCR METAB, V84, P873, DOI 10.1210/jc.84.3.873; WARREN MP, 1986, NEW ENGL J MED, V314, P1348, DOI 10.1056/NEJM198605223142104; Warren MP, 1996, J CLIN ENDOCR METAB, V81, P437, DOI 10.1210/jc.81.2.437; WARREN MP, 1992, J CLIN ENDOCR METAB, V75, P1393, DOI 10.1210/jc.75.6.1393; Warren MP, 1999, J CLIN ENDOCR METAB, V84, P1892, DOI 10.1210/jc.84.6.1892; Weimann E, 1999, EUR J CLIN INVEST, V29, P853; Welt CK, 2004, NEW ENGL J MED, V351, P987, DOI 10.1056/NEJMoa040388; Woods AJ, 1996, NATURE, V381, P745, DOI 10.1038/381745a0; Yamauchi M, 2001, CLIN ENDOCRINOL, V55, P341, DOI 10.1046/j.1365-2265.2001.01361.x; YEN SCC, 1999, REPROD ENDOCRINOLOGY, P536; YEN SSC, 1993, ENDOCRIN METAB CLIN, V22, P29, DOI 10.1016/S0889-8529(18)30179-8; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	156	230	240	0	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	2005	366	9479					74	85		10.1016/S0140-6736(05)66830-4	http://dx.doi.org/10.1016/S0140-6736(05)66830-4			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993236				2022-12-28	WOS:000230277600037
J	Kennedy, D; Norman, C				Kennedy, D; Norman, C			What don't we know? Introduction	SCIENCE			English	Editorial Material																			0	291	343	7	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 1	2005	309	5731					75	75		10.1126/science.309.5731.75	http://dx.doi.org/10.1126/science.309.5731.75			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994521				2022-12-28	WOS:000230212800038
J	Gill, P				Gill, P			DNA as evidence - The technology of identification	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Forens Sci Serv Inc, Birmingham, W Midlands, England	Forensic Science Service UK	Gill, P (corresponding author), Forens Sci Serv Inc, Birmingham, W Midlands, England.		Gill, Peter/C-3056-2009					Gill P, 2000, FORENSIC SCI INT, V112, P17, DOI 10.1016/S0379-0738(00)00158-4; Marchi E, 2004, AM LAB, V36, P30; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Wambaugh J., 1989, BLOODING; WERRETT D, 1998, PROF DNA, V2, P1	5	16	16	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					2669	2671		10.1056/NEJMp048359	http://dx.doi.org/10.1056/NEJMp048359			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	940HH	15987914				2022-12-28	WOS:000230133800002
J	Batlle, E; Bacani, J; Begthel, H; Jonkeer, S; Gregorieff, A; van de Born, M; Malats, N; Sancho, E; Boon, E; Pawson, T; Gallinger, S; Pals, S; Clevers, H				Batlle, E; Bacani, J; Begthel, H; Jonkeer, S; Gregorieff, A; van de Born, M; Malats, N; Sancho, E; Boon, E; Pawson, T; Gallinger, S; Pals, S; Clevers, H			EphB receptor activity suppresses colorectal cancer progression	NATURE			English	Article							MULTIPLE INTESTINAL NEOPLASIA; BETA-CATENIN; APC; COLON; ACTIVATION; MICE; EPITHELIUM; EXPRESSION; MUTATIONS; PATHWAY	Most sporadic colorectal cancers are initiated by activating Wnt pathway mutations(1), characterized by the stabilization of beta-catenin and constitutive transcription by the beta-catenin/T cell factor-4 (Tcf-4) complex(2,3). EphB guidance receptors are Tcf4 target genes that control intestinal epithelial architecture through repulsive interactions with Ephrin-B ligands(4,5). Here we show that, although Wnt signalling remains constitutively active, most human colorectal cancers lose expression of EphB at the adenoma-carcinoma transition. Loss of EphB expression strongly correlates with degree of malignancy. Furthermore, reduction of EphB activity accelerates tumorigenesis in the colon and rectum of Apc(Min/+) mice, and results in the formation of aggressive adenocarcinomas. Our data demonstrate that loss of EphB expression represents a critical step in colorectal cancer progression.	Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands; Biomed Res Inst, Barcelona 08028, Spain; ICREA, Barcelona 08010, Spain; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Inst Municipal Invest Med, E-08003 Barcelona, Spain	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Clevers, H (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	clevers@niob.knaw.nl	Batlle, Eduard/K-8080-2014; Pawson, Tony J/E-4578-2013; Sancho, Elena/ABH-4867-2020; Gallinger, Steven/E-4575-2013; Malats, Nuria/H-7041-2015	Batlle, Eduard/0000-0003-2422-0326; Sancho, Elena/0000-0002-8182-513X; Pals, Steven/0000-0002-1419-0939; Malats, Nuria/0000-0003-2538-3784	ICREA Funding Source: Custom	ICREA(ICREA)		Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Gregorieff A, 2004, EMBO J, V23, P1825, DOI 10.1038/sj.emboj.7600191; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Lal G, 2001, CANCER RES, V61, P6131; Mao WG, 2004, CANCER RES, V64, P781, DOI 10.1158/0008-5472.CAN-03-1047; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Munarini N, 2002, J CELL SCI, V115, P25; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Shitoh K, 2001, GENE CHROMOSOME CANC, V30, P32, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1065>3.0.CO;2-I; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Yamada Y, 2002, CANCER RES, V62, P6367	20	329	354	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1126	1130		10.1038/nature03626	http://dx.doi.org/10.1038/nature03626			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973414				2022-12-28	WOS:000229970400055
J	Majmudar, TS; Behringer, RP				Majmudar, TS; Behringer, RP			Contact force measurements and stress-induced anisotropy in granular materials	NATURE			English	Article								Interparticle forces in granular media form an inhomogeneous distribution of filamentary force chains. Understanding such forces and their spatial correlations, specifically in response to forces at the system boundaries(1,2), represents a fundamental goal of granular mechanics. The problem is of relevance to civil engineering, geophysics and physics(3-5), being important for the understanding of jamming, shear-induced yielding and mechanical response. Here we report measurements of the normal and tangential grain-scale forces inside a two-dimensional system of photoelastic disks that are subject to pure shear and isotropic compression. Various statistical measures show the underlying differences between these two stress states. These differences appear in the distributions of normal forces (which are more rounded for compression than shear), although not in the distributions of tangential forces (which are exponential in both cases). Sheared systems show anisotropy in the distributions of both the contact network and the contact forces. Anisotropy also occurs in the spatial correlations of forces, which provide a quantitative replacement for the idea of force chains. Sheared systems have long-range correlations in the direction of force chains, whereas isotropically compressed systems have short-range correlations regardless of the direction.	Duke Univ, Dept Phys, Durham, NC 27708 USA; Duke Univ, Ctr Nonlinear & Complex Syst, Durham, NC 27708 USA	Duke University; Duke University	Behringer, RP (corresponding author), Duke Univ, Dept Phys, Durham, NC 27708 USA.	bob@phy.duke.edu	Majmudar, Trushant/A-3067-2012					Behringer R. P., 1997, POWDERS GRAINS, V97; Cambou B, 2004, MECH MATER, V36, P1185, DOI 10.1016/j.mechmat.2002.12.002; DRESCHER A, 1972, J MECH PHYS SOLIDS, V20, P337, DOI 10.1016/0022-5096(72)90029-4; DURELLI AJ, 1983, J APPL MECH-T ASME, V50, P288, DOI 10.1115/1.3167034; Frocht MM, 1941, PHOTOELASTICITY, V1; Frocht MM, 1948, PHOTOELASTICITY, V2; Geng JF, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.035506; Goldenberg C, 2004, GRANUL MATTER, V6, P87, DOI 10.1007/s10035-004-0165-y; Jaeger HM, 1996, REV MOD PHYS, V68, P1259, DOI 10.1103/RevModPhys.68.1259; Landau L. D., 1959, THEORY ELASTICITY; Landry JW, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.041303; Lovoll G, 1999, PHYS REV E, V60, P5872, DOI 10.1103/PhysRevE.60.5872; Mueth DM, 1998, PHYS REV E, V57, P3164, DOI 10.1103/PhysRevE.57.3164; Nedderman R.M., 1992, STATICS KINEMATICS G; Paikowsky S.G., 1993, 2 INT C DISCR EL MET, P449; PRESS WH, 1992, NUMERICAL RECIPES; Radjai F, 1997, POWDERS & GRAINS 97, P211; Reydellet G, 2001, PHYS REV LETT, V86, P3308, DOI 10.1103/PhysRevLett.86.3308; SHUKLA A, 1985, J STRAIN ANAL ENG, V20, P241, DOI 10.1243/03093247V204241; Silbert LE, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.061303; Snoeijer JH, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.061306; Snoeijer JH, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.054302; TIGHE BP, 2005, FORCE DISTRIBUTIONS; TSOUNGUI O, 1998, GRANUL MATTER, V1, P65, DOI DOI 10.1007/S100350050010	24	861	896	17	310	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1079	1082		10.1038/nature03805	http://dx.doi.org/10.1038/nature03805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973358				2022-12-28	WOS:000229970400044
J	van Wijk, I; Kappelle, LJ; van Gijn, J; Koudstaal, PJ; Franke, CL; Vermeulen, M; Gorter, JW; Algra, A				van Wijk, I; Kappelle, LJ; van Gijn, J; Koudstaal, PJ; Franke, CL; Vermeulen, M; Gorter, JW; Algra, A		LiLAC Study Grp	Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study	LANCET			English	Article							FOLLOW-UP; INTEROBSERVER AGREEMENT; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; CEREBRAL-ISCHEMIA; RECURRENT STROKE; PROGNOSIS; MORTALITY; HANDICAP	Background Determinants of survival and of risk of vascular events after transient ischaemic attack (TIA) or minor ischaemic stroke are not well defined in the long term. We aimed to restudy these risks in a prospective cohort of patients after TIA or minor ischaemic stroke (Rankin grade <= 3), after 10 years or more. Methods We assessed the survival status and occurrence of vascular events in 2473 participants of the Dutch TIA Trial (recruitment in 1986-89; arterial cause of cerebral ischaemia). We included 24 hospitals in the Netherlands that recruited at least 50 patients. Primary outcomes were all-cause mortality and the composite event of death from all vascular causes, non-fatal stroke, and non-fatal myocardial infarction. We assessed cumulative risks by Kaplan-Meier analysis and prognostic factors with Cox univariate and multivariate analysis. Findings Follow-up was complete in 2447 (99%) patients. After a mean follow-up of 10.1 years, 1489 (60%) patients had died and 1336 (54%) had had at least one vascular event. 10-year risk of death was 42.7% (95% CI 40.8-44.7). Age and sex-adjusted hazard ratios were 3.33 (2.97-3.73) for age over 65 years, 2.10 (1.79-2.48) for diabetes, 1.77 (1.45-2.15) for claudication, 1.94 (1.42-2.65) for previous peripheral vascular surgery, and 1.50 (1.31-1.71) for pathological Q waves on baseline electrocardiogram. 10-year risk of a vascular event was 44.1% (42.0-46.1). After falling in the first 3 years, yearly risk of a vascular event increased over time. Predictive factors for risk of vascular events were similar to those for risk of death. Interpretation Long-term secondary prevention in patients with cerebral ischaemia still has room for further improvement.	Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurol, Utrecht, Netherlands; Rehabil Ctr Hoogstr, Utrecht, Netherlands; Erasmus MC, Dept Neurol, Rotterdam, Netherlands; Atrium Med Ctr, Dept Neurol, Heerlen, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; Atrium Medical Center; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center	Algra, A (corresponding author), Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurol, Utrecht, Netherlands.	a.algra@umcutrecht.nl	Gorter, Jan Willem/AAK-8784-2021; van Gijn, Jan/A-9444-2008	Gorter, Jan Willem/0000-0002-3012-2119; 				Algra A, 1996, J NEUROL NEUROSUR PS, V60, P197, DOI 10.1136/jnnp.60.2.197; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Anderson CS, 2004, STROKE, V35, P1920, DOI 10.1161/01.STR.0000133130.20322.9f; [Anonymous], 1993, Stroke, V24, P527; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Bravata DM, 2003, STROKE, V34, P699, DOI 10.1161/01.STR.0000057578.26828.78; Bronnum-Hansen H, 2001, STROKE, V32, P2131, DOI 10.1161/hs0901.094253; BURN J, 1994, STROKE, V25, P333, DOI 10.1161/01.STR.25.2.333; Clark TG, 2003, J NEUROL NEUROSUR PS, V74, P577, DOI 10.1136/jnnp.74.5.577; Coull AJ, 2004, BMJ-BRIT MED J, V328, P326, DOI 10.1136/bmj.37991.635266.44; De Schryver ELLM, 2000, CEREBROVASC DIS, V10, P147, DOI 10.1159/000016044; Eriksson SE, 2001, CEREBROVASC DIS, V12, P171, DOI 10.1159/000047700; Gresham GE, 1998, STROKE, V29, P793, DOI 10.1161/01.STR.29.4.793; HANKEY GJ, 1992, J NEUROL NEUROSUR PS, V55, P640, DOI 10.1136/jnnp.55.8.640; HANKEY GJ, 1991, J NEUROL NEUROSUR PS, V54, P793, DOI 10.1136/jnnp.54.9.793; Hankey GJ, 1998, STROKE, V29, P2491, DOI 10.1161/01.STR.29.12.2491; Hardie K, 2003, STROKE, V34, P1842, DOI 10.1161/01.STR.0000082382.42061.EE; Jorgensen HS, 1997, NEUROLOGY, V48, P891; KERNAN WN, 1991, STROKE, V22, P1108, DOI 10.1161/01.STR.22.9.1108; KERNAN WN, 1991, ANN INTERN MED, V114, P552, DOI 10.7326/0003-4819-114-7-552; Marini C, 1999, STROKE, V30, P2320, DOI 10.1161/01.STR.30.11.2320; Peltonen M, 1998, STROKE, V29, P1358, DOI 10.1161/01.STR.29.7.1358; Prencipe M, 1998, STROKE, V29, P126, DOI 10.1161/01.STR.29.1.126; Reitsma JB, 1999, HEART, V82, P52, DOI 10.1136/hrt.82.1.52; SAEKI S, 1995, STROKE, V26, P399, DOI 10.1161/01.STR.26.3.399; SANDERCOCK P, 1992, BRIT MED J, V305, P1460, DOI 10.1136/bmj.305.6867.1460; Shah PK, 2003, J AM COLL CARDIOL, V41, p15S, DOI 10.1016/S0735-1097(02)02834-6; Staaf G, 2001, STROKE, V32, P2592, DOI 10.1161/hs1101.098355; TUOMILEHTO J, 1995, STROKE, V26, P971, DOI 10.1161/01.STR.26.6.971; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vernino S, 2003, STROKE, V34, P1828, DOI 10.1161/01.STR.0000080534.98416.A0; WARLOW C, 1992, LANCET, V339, P724, DOI 10.1016/0140-6736(92)90608-6; Wilkinson PR, 1997, STROKE, V28, P507, DOI 10.1161/01.STR.28.3.507; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	36	214	214	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2098	2104		10.1016/S0140-6736(05)66734-7	http://dx.doi.org/10.1016/S0140-6736(05)66734-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964446				2022-12-28	WOS:000229858800026
J	Kaiser, J				Kaiser, J			Meeting - American Society of Gene Therapy - Retroviral vectors: A double-edged sword	SCIENCE			English	News Item																			0	7	8	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 17	2005	308	5729					1735	1736						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961648				2022-12-28	WOS:000229926800015
J	Glikman, D; Baroody, FM				Glikman, D; Baroody, FM			Recurrent respiratory papillomatosis with lung involvement	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Chicago, Chicago, IL 60637 USA	University of Chicago	Glikman, D (corresponding author), Univ Chicago, Chicago, IL 60637 USA.			Glikman, Daniel/0000-0002-8006-5845					0	7	7	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2005	352	24					E22	E22		10.1056/NEJMicm040850	http://dx.doi.org/10.1056/NEJMicm040850			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935RH	15958801				2022-12-28	WOS:000229798900010
J	Noji, EK				Noji, EK			ABC of conflict and disaster - Public health in the aftermath of disasters	BRITISH MEDICAL JOURNAL			English	Review								In the aftermath of disasters, public health services must address the effects of civil strife, armed conflict, population migration, economic collapse, and famine. In modern conflicts civilians are targeted deliberately, and affected populations may face severe public health consequences, even without displacement from their homes. For displaced people, damage to health, sanitation, water supplies, housing, and agriculture may lead to a rapid increase in malnutrition and communicable diseases. Fortunately, the provision of adequate clean water and sanitation, timely measles immunisation, simple treatment of dehydration from diarrhoea, supplementary feeding for the malnourished, micronutrient supplements, and the establishment of an adequate public health surveillance system greatly reduces the health risks associated with the harsh environments of refugee camps.	Ctr Dis Control & Prevent, Washington, DC USA	Centers for Disease Control & Prevention - USA	Noji, EK (corresponding author), Ctr Dis Control & Prevent, Washington, DC USA.							[Anonymous], 1997, PUBLIC HLTH CONSEQUE; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Pan American Health Organization, 2000, NAT DIS PROT PUBL HL; Perrin P., 1996, HDB WAR PUBLIC HLTH; Ronald C, 1999, BMJ, V318; The Sphere Project, 2000, HUM CHART MIN STAND; World Health Organization, 2000, MAN NUTR MAJ EM; World Health Organization, 1999, RAP HLTH ASS PROT EM	8	29	32	0	17	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 11	2005	330	7504					1379	1381		10.1136/bmj.330.7504.1379	http://dx.doi.org/10.1136/bmj.330.7504.1379			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936FE	15947402	Green Published			2022-12-28	WOS:000229840100031
J	Holt, BF; Belkhadir, Y; Dangl, JL				Holt, BF; Belkhadir, Y; Dangl, JL			Antagonistic control of disease resistance protein stability in the plant immune system	SCIENCE			English	Article							DOWNY MILDEW RESISTANCE; SCF UBIQUITIN-LIGASE; TOBACCO-MOSAIC-VIRUS; MOLECULAR CHAPERONE; MEDIATED RESISTANCE; ESSENTIAL COMPONENT; ARABIDOPSIS; HSP90; GENE; SGT1	Pathogen recognition by the plant immune system is governed by structurally related, polymorphic products of disease resistance (R) genes. RAR1 and/or SGT1b mediate the function of many R proteins. RAR1 controls preactivation R protein accumulation by an unknown mechanism. We demonstrate that Arabidopsis SGT1b has two distinct, genetically separable functions in the plant immune system: SGT1b antagonizes RAR1 to negatively regulate R protein accumulation before infection, and SGT1b has a RAR1-independent function that regulates programmed cell death during infection. The balanced activities of RAR1 and SGT1, in concert with cytosolic HSP90, modulate preactivation R protein accumulation and signaling competence.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Dangl, JL (corresponding author), Univ N Carolina, Dept Biol, 108 Coker Hall,CB 3280, Chapel Hill, NC 27599 USA.	dangl@email.unc.edu	Holt, Ben F/D-1513-2011; Belkhadir, Youssef/GXM-6743-2022	Belkhadir, Youssef/0000-0001-7149-7139				Austin MJ, 2002, SCIENCE, V295, P2077, DOI 10.1126/science.1067747; Axtell MJ, 2003, CELL, V112, P369, DOI 10.1016/S0092-8674(03)00036-9; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Bansal PK, 2004, MOL CELL BIOL, V24, P8069, DOI 10.1128/MCB.24.18.8069-8079.2004; Belbahri L, 2001, PLANT J, V28, P419, DOI 10.1046/j.1365-313X.2001.01155.x; Belkhadir Y, 2004, CURR OPIN PLANT BIOL, V7, P391, DOI 10.1016/j.pbi.2004.05.009; Belkhadir Y, 2004, PLANT CELL, V16, P2822, DOI 10.1105/tpc.104.024117; Bieri S, 2004, PLANT CELL, V16, P3480, DOI 10.1105/tpc.104.026682; Boyes DC, 1998, P NATL ACAD SCI USA, V95, P15849, DOI 10.1073/pnas.95.26.15849; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; Dubacq C, 2002, EUKARYOT CELL, V1, P568, DOI 10.1128/EC.1.4.568-582.2002; FREIALDENHOVEN A, 1994, PLANT CELL, V6, P983; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Hubert DA, 2003, EMBO J, V22, P5679, DOI 10.1093/emboj/cdg547; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Lingelbach LB, 2004, MOL CELL BIOL, V24, P8938, DOI 10.1128/MCB.24.20.8938-8950.2004; Liu Y, 2002, PLANT CELL, V14, P1483, DOI 10.1105/tpc.002493; Liu YL, 2004, J BIOL CHEM, V279, P2101, DOI 10.1074/jbc.M310029200; Liu YL, 2002, PLANT J, V30, P415, DOI 10.1046/j.1365-313X.2002.01297.x; Lu R, 2003, EMBO J, V22, P5690, DOI 10.1093/emboj/cdg546; Mackey D, 2002, CELL, V108, P743, DOI 10.1016/S0092-8674(02)00661-X; McDowell JM, 1998, PLANT CELL, V10, P1861, DOI 10.1105/tpc.10.11.1861; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Muskett PR, 2002, PLANT CELL, V14, P979, DOI 10.1105/tpc.001040; Peart JR, 2002, P NATL ACAD SCI USA, V99, P10865, DOI 10.1073/pnas.152330599; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Sangster TA, 2005, CURR OPIN PLANT BIOL, V8, P86, DOI 10.1016/j.pbi.2004.11.012; Shirasu K, 2003, TRENDS PLANT SCI, V8, P252, DOI 10.1016/S1360-1385(03)00104-3; Shirasu K, 1999, CELL, V99, P355, DOI 10.1016/S0092-8674(00)81522-6; SIMONICH MT, 1995, MOL PLANT MICROBE IN, V8, P637, DOI 10.1094/MPMI-8-0637; Steensgaard P, 2004, EMBO REP, V5, P626, DOI 10.1038/sj.embor.7400154; Takahashi A, 2003, P NATL ACAD SCI USA, V100, P11777, DOI 10.1073/pnas.2033934100; Tor M, 2002, PLANT CELL, V14, P993, DOI 10.1105/tpc.001123; Tornero P, 2002, PLANT CELL, V14, P1005, DOI 10.1105/tpc.001032; Warren RF, 1999, GENETICS, V152, P401; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zhang Y, 2004, PLANT J, V40, P213, DOI 10.1111/j.1365-313X.2004.02201.x	38	199	208	5	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	2005	309	5736					929	932		10.1126/science.1109977	http://dx.doi.org/10.1126/science.1109977			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953SS	15976272				2022-12-28	WOS:000231101400045
J	Richards, D; Toop, L; Chambers, S; Fletcher, L				Richards, D; Toop, L; Chambers, S; Fletcher, L			Response to antibiotics of women with symptoms of urinary tract infection but negative dipstick urine test results: double blind randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MANAGEMENT; DIAGNOSIS; COUNT	Objective To assess the effectiveness of antibiotic treatment of women with symptoms of urinary tract infection but negative urine dipstick testing. Design Prospective, double blind, randomised, placebo controlled trial. Setting Primary care, among a randomly selected group of general practitioners in Christchurch, New Zealand. Participants 59 women aged 16-50 years presenting with a history of dysuria and frequency in whom a dipstick test of midstream urine was negative for both nitrites and leucocytes. Participants with complicated urinary tract infection were excluded. Intervention Trimethoprim 300 mg daily for three days or placebo. Main outcome measures Self reported diary of symptoms for seven days, recording the presence or absence of individual symptoms each day, followed by a structured telephone questionnaire after seven days. The main clinical outcome was resolution of dysuria at three and seven days and median time to resolution. Secondary outcomes were resolution of other symptoms. Results The median time for resolution of dysuria was three days for trimethoprim compared with five days for placebo (P = 0.002). At day 3, five (24%) of patients in the treatment group had ongoing dysuria compared with 20 (74%) in the placebo group (P = 0.005). This difference persisted until day 7: two patients (10%) in the treatment group vs 11 (41%) in the placebo group; P = 0.02. The number needed to treat was 4. The median duration of constitutional symptoms (feverishness, shivers) was reduced by four days. Conclusions Although a negative dipstick test for leucocytes and nitrites accurately predicted absence of infection when standard microbiological definitions were used (negative predictive value 92%), it did not predict response to antibiotic treatment. Three days' treatment with trimethoprim significantly reduced dysuria in women whose urine dipstick test was negative. These results support the practice of empirical antibiotic use guided by symptoms. Balancing the competing interests of symptom relief and the minimisation of antibiotic use remains a dilemma-further research is needed to determine clinical predictors of response to antibiotics.	Christchurch Sch Med & Hlth Sci, Dept Publ Hlth & Gen Practice, Christchurch, New Zealand; Christchurch Sch Med & Hlth Sci, Dept Pathol, Christchurch, New Zealand	University of Otago; University of Otago	Richards, D (corresponding author), Christchurch Sch Med & Hlth Sci, Dept Publ Hlth & Gen Practice, POB 4345, Christchurch, New Zealand.	derelie.richards@chmeds.ac.nz		Mangin, Dee/0000-0003-2149-9376; Chambers, Stephen/0000-0002-0698-3285				BROOKS D, 1990, BRIT J GEN PRACT, V40, P399; Car J, 2003, BRIT MED J, V327, P1204, DOI 10.1136/bmj.327.7425.1204; *DEP HLTH, 2000, UK ANT RES STRAT ACT, P1; DITCHBURN RK, 1990, BRIT J GEN PRACT, V40, P406; Fenwick EAL, 2000, BRIT J GEN PRACT, V50, P635; Foxman B, 2000, ANN EPIDEMIOL, V10, P509, DOI 10.1016/S1047-2797(00)00072-7; Hummers-Pradier E, 2002, BRIT J GEN PRACT, V52, P752; *INF POEMS, 2003, NAT ANT CAMP INF PRI, P1; KUNIN CM, 1993, ANN INTERN MED, V119, P454, DOI 10.7326/0003-4819-119-6-199309150-00002; Kunin CM., 1997, URINARY TRACT INFECT, P28; MOORE T, 1965, LANCET, V1, P626; Richards DA, 2002, NEW ZEAL MED J, V115, P12; STAMM WE, 1980, NEW ENGL J MED, V303, P409, DOI 10.1056/NEJM198008213030801; STAMM WE, 1981, NEW ENGL J MED, V304, P956, DOI 10.1056/NEJM198104163041608; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; *US DEP HHS, 2003, CLIN COURIER, V21, P11; Verest LFHM, 2000, BRIT J GEN PRACT, V50, P309	17	49	49	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 16	2005	331	7509					143	146B		10.1136/bmj.38496.452581.8F	http://dx.doi.org/10.1136/bmj.38496.452581.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947GV	15972728	Green Published, Bronze			2022-12-28	WOS:000230632300019
J	Diethelm, PA; Rielle, JC; McKee, M				Diethelm, PA; Rielle, JC; McKee, M			The whole truth and nothing but the truth? The research that Philip Morris did not want you to see	LANCET			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; NICOTINE; INGREDIENTS; CIGARETTES; INDUSTRY; RATS	The tobacco industry maintained, for many years, that it was unaware of research about the toxic effects of smoking. By the 1970s, however, the industry decided that it needed this information but they were unwilling to seek it in a way that was open to public scrutiny. By means of material from internal industry documents it can be revealed that one company, Philip Morris, acquired a research facility, INBIFO, in Germany and created a complex mechanism seeking to ensure that the work done in the facility could not be linked to Philip Morris. In particular it involved the appointment of a Swedish professor as a 'co-ordinator', who would synthesise reports for onward transmission to the USA. Various arrangements were made to conceal this process, not only from the wider public, but also from many within Philip Morris, although it was known to some senior executives. INBIFO appears to have published only a small amount of its research and what was published appears to differ considerably from what was not. In particular, the unpublished reports provided evidence of the greater toxicity of sidestream. than mainstream smoke, a finding of particular relevance given the industry's continuing denial of the harmful effects of passive smoking. By contrast, much of its published work comprises papers that convey a message that could be considered useful to the industry, in particular casting doubt on methods used to assess the effects of passive smoking.	OxyRomandie, Geneva, Switzerland; Carrefour Prevent, CIPRET Geneve, Geneva, Switzerland; London Sch Hyg & Trop Med, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Diethelm, PA (corresponding author), OxyRomandie, Geneva, Switzerland.	diethelm@libertysurf.fr	McKee, Marc D/E-2187-2011; Mckee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Mckee, Martin/0000-0002-0121-9683				*AM TOB CO, 1967, NIC PROD FEAS STUD; Barnes DE, 1996, J HEALTH POLIT POLIC, V21, P515, DOI 10.1215/03616878-21-3-515; CARCHMAN RA, 1997, SCI PUBLICATION; CRAMPTON WJ, 1990, RE DISCOVERY RES DOC; CULLMAN JF, 1969, COMMUNICATION   1007; CULLMAN JF, 1970, COMMUNICATION   0224; Drope J, 2001, J EPIDEMIOL COMMUN H, V55, P588, DOI 10.1136/jech.55.8.588; DUNN WL, 1980, NICOTINE RECEPTOR PR; Enstrom JE, 2003, BMJ-BRIT MED J, V326, P1057, DOI 10.1136/bmj.326.7398.1057; Gebel S, 2001, TOXICOL SCI, V59, P75, DOI 10.1093/toxsci/59.1.75; GERSTENBERG B, 1995, DRUG METAB DISPOS, V23, P143; GUGEL H, 1982, A05003047 INBIFO; HAUSSMANN HJ, 1994, INBIFO I BIOL FORSCH; *HC UK HLTH SEL CO, 2000, TOB IND HLTH RISKS S; Hirschhorn N, 2001, TOB CONTROL, V10, P247, DOI 10.1136/tc.10.3.247; HOEL D, 1981, ENV TOBACCO SMOKE EF, V2; Hong MK, 2002, BRIT MED J, V325, P1413, DOI 10.1136/bmj.325.7377.1413; MIES M, 1982, 05003061 PY INBIFO; OSDENE TS, 1972, COMMUNICATION   0728; OSDENE TS, 1972, OUR TECHNICAL PROGRA; PAGES R, 1989, TENTATIVE AGENDA VIS; Roemer E, 2002, FOOD CHEM TOXICOL, V40, P105, DOI 10.1016/S0278-6915(01)00086-2; ROMER E, 1982, 05003061 IB INBIFO; Rustemeier K, 2002, FOOD CHEM TOXICOL, V40, P93, DOI 10.1016/S0278-6915(01)00085-0; RYLANDER R, 1982, COMMUNICATION   0126; SCHEPERS G, 1988, ARCH TOXICOL, V62, P395, DOI 10.1007/BF00293630; SCHEPERS G, 1993, EUR J DRUG METAB PH, V18, P187, DOI 10.1007/BF03188795; SELIGMAN RB, 1977, COMMUNICATION   0331; SELIGMAN RB, 1976, ENRICHED FLAVOR; Stabbert R, 2001, ADV EXP MED BIOL, V500, P153; STANFORD LE, 1993, RE INBIFO CRC; TEWES FJ, 1990, ENVIRON RES, V52, P23, DOI 10.1016/S0013-9351(05)80148-3; UYDESS IL, 1996, COMMUNICATION   0301; WAKEHAM H, 1968, NEED BIOL TESTING RE; WAKEHAM H, 1970, ACQUISITION INBIFO; WAKEHAM H, 1970, BEST PROGRAM CTR; WAKEHAM H, 1969, PROPOSAL BIOL RES PR; Yeaman A, 1963, IMPLICATIONS BATTELL; 1989, REFLECTIONS ROLE PMU; 1954, TOBACCO LEAF     JAN	40	75	75	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 2	2005	366	9479					86	92		10.1016/S0140-6736(05)66474-4	http://dx.doi.org/10.1016/S0140-6736(05)66474-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993237				2022-12-28	WOS:000230277600038
J	McPake, B				McPake, B			Saving the lives of vulnerable children	LANCET			English	Editorial Material							GLOBAL FUND; HEALTH		London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1 7HT, England	University of London; London School of Hygiene & Tropical Medicine	McPake, B (corresponding author), London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1 7HT, England.	barbara.mcpake@lshtm.ac.uk	McPake, Barbara/AAE-8655-2021	McPake, Barbara/0000-0002-9904-1077				Brugha R, 2004, LANCET, V364, P95, DOI 10.1016/S0140-6736(04)16595-1; Brugha R, 2002, LANCET, V359, P435, DOI 10.1016/S0140-6736(02)07607-9; *GLOB HLTH TRUST, 2003, HUM RES HLTH DEV JOI; HANSON K, 2001, 14 CMH WG5; Hongoro C, 2004, LANCET, V364, P1451, DOI 10.1016/S0140-6736(04)17229-2; Johns B, 2004, HEALTH ECON, V13, P1117, DOI 10.1002/hec.880; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; MUKASA S, 4 CVO; OLIVEIRACRUZ V, 2001, 15 CMH WG5; Wibulpolprasert Suwit, 2003, Hum Resour Health, V1, P12, DOI 10.1186/1478-4491-1-12; World Health Organization, 2004, MEX STAT HLTH RES	11	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 25	2005	365	9478					2154	2156		10.1016/S0140-6736(05)66753-0	http://dx.doi.org/10.1016/S0140-6736(05)66753-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978907				2022-12-28	WOS:000230034800005
J	Reedijk, J				Reedijk, J			Dioxygen surprises	SCIENCE			English	Editorial Material							COMPLEXES; LIGAND; REACTIVITY; HEMOCYANIN; ACTIVATION; BINDING; PEROXO; OXO		Leiden Univ, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Reedijk, J (corresponding author), Leiden Univ, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands.	reedijk@chem.leidenuniv.nl	Reedijk, Jan/F-1992-2010	Reedijk, Jan/0000-0002-6739-8514				Berreau LM, 1999, ANGEW CHEM INT EDIT, V38, P207, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<207::AID-ANIE207>3.0.CO;2-U; Bol JE, 1997, ANGEW CHEM INT EDIT, V36, P998, DOI 10.1002/anie.199709981; Gamez P, 2004, DALTON T, P4079, DOI 10.1039/b413535k; Halfen JA, 1996, SCIENCE, V271, P1397, DOI 10.1126/science.271.5254.1397; KARLIN KD, 1987, PROG INORG CHEM, V35, P219, DOI 10.1002/9780470166369.ch3; KITAJIMA N, 1992, ADV INORG CHEM, V39, P1, DOI 10.1016/S0898-8838(08)60258-5; Liang HC, 2004, INORG CHEM, V43, P4115, DOI 10.1021/ic0498283; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; Mahapatra S, 1997, INORG CHEM, V36, P6343, DOI 10.1021/ic970718o; Mirica LM, 2005, SCIENCE, V308, P1890, DOI 10.1126/science.1112081; Obias HV, 1998, J AM CHEM SOC, V120, P12960, DOI 10.1021/ja981878h; Zhang CX, 2003, J AM CHEM SOC, V125, P634, DOI 10.1021/ja028779v	12	8	8	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 24	2005	308	5730					1876	1877		10.1126/science.1113708	http://dx.doi.org/10.1126/science.1113708			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976293				2022-12-28	WOS:000230120000028
J	Kalas, P; Graham, JR; Clampin, M				Kalas, P; Graham, JR; Clampin, M			A planetary system as the origin of structure in Fomalhaut's dust belt	NATURE			English	Article							KUIPER-BELT; CIRCUMSTELLAR DISK; DEBRIS; SIGNATURES; COBE	The Sun and >15 per cent of nearby stars are surrounded by dusty disks that must be collisionally replenished by asteroids and comets, as the dust would otherwise be depleted on timescales <10(7) years (ref. 1). Theoretical studies show that the structure of a dusty disk can be modified by the gravitational influence of planets(2-4), but the observational evidence is incomplete, at least in part because maps of the thermal infrared emission from the disks have low linear resolution (35 AU in the best case(5)). Optical images provide higher resolution, but the closest examples (AU Mic and beta Pic) are edge-on(6,7), preventing the direct measurement of the azimuthal and radial disk structure that is required for fitting theoretical models of planetary perturbations. Here we report the detection of optical light reflected from the dust grains orbiting Fomalhaut (HD 216956). The system is inclined 248 away from edge-on, enabling the measurement of disk structure around its entire circumference, at a linear resolution of 0.5 AU. The dust is distributed in a belt 25 AU wide, with a very sharp inner edge at a radial distance of 133 AU, and we measure an offset of 15 AU between the belt's geometric centre and Fomalhaut. Taken together, the sharp inner edge and offset demonstrate the presence of planetary-mass objects orbiting Fomalhaut.	Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	University of California System; University of California Berkeley; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Kalas, P (corresponding author), Univ Calif Berkeley, Dept Astron, 601 Campbell Hall, Berkeley, CA 94720 USA.	kalas@astron.berkeley.edu	Clampin, mark/D-2738-2012	Kalas, Paul/0000-0002-6221-5360				Artymowicz P, 1997, ASTROPHYS J, V490, P863, DOI 10.1086/304889; AUMANN HH, 1985, PUBL ASTRON SOC PAC, V97, P885, DOI 10.1086/131620; Backman D. E., 1993, PROTOSTARS PLANETS, P1253; Chiang EI, 2000, ASTROPHYS J, V540, P1084, DOI 10.1086/309372; CLAMPIN M, 2003, ASTROPHYS J, V126, P358; Dent WRF, 2000, MON NOT R ASTRON SOC, V314, P702, DOI 10.1046/j.1365-8711.2000.03331.x; Fixsen DJ, 2002, ASTROPHYS J, V578, P1009, DOI 10.1086/342658; Gillett F., 1986, LIGHT DARK MATTER, P61; Greaves JS, 2005, ASTROPHYS J, V619, pL187, DOI 10.1086/428348; Holland WS, 1998, NATURE, V392, P788, DOI 10.1038/33874; Holland WS, 2003, ASTROPHYS J, V582, P1141, DOI 10.1086/344819; Kalas P, 2004, SCIENCE, V303, P1990, DOI 10.1126/science.1093420; KALAS P, 1995, ASTRON J, V110, P794, DOI 10.1086/117565; Kalas P, 1996, ASTRON J, V111, P1347, DOI 10.1086/117881; Kelsall T, 1998, ASTROPHYS J, V508, P44, DOI 10.1086/306380; Krist JE, 2005, ASTRON J, V129, P1008, DOI 10.1086/426755; Kuchner MJ, 2003, ASTROPHYS J, V588, P1110, DOI 10.1086/374213; Liou JC, 1999, ASTRON J, V118, P580, DOI 10.1086/300938; Luu JX, 2002, ANNU REV ASTRON ASTR, V40, P63, DOI 10.1146/annurev.astro.40.060401.093818; Navascues DB, 1998, ASTRON ASTROPHYS, V339, P831; Ozernoy LM, 2000, ASTROPHYS J, V537, pL147, DOI 10.1086/312779; ROQUES F, 1994, ICARUS, V108, P37, DOI 10.1006/icar.1994.1040; Smart WM, 1929, MON NOT R ASTRON SOC, V90, P0534; SMITH BA, 1984, SCIENCE, V226, P1421, DOI 10.1126/science.226.4681.1421; Stapelfeldt KR, 2004, ASTROPHYS J SUPPL S, V154, P458, DOI 10.1086/423135; Wyatt MC, 1999, ASTROPHYS J, V527, P918, DOI 10.1086/308093; Wyatt MC, 2002, MON NOT R ASTRON SOC, V334, P589, DOI 10.1046/j.1365-8711.2002.05533.x	28	325	327	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1067	1070		10.1038/nature03601	http://dx.doi.org/10.1038/nature03601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973402				2022-12-28	WOS:000229970400041
J	Jull, A; Bennett, D				Jull, A; Bennett, D			Do n-of-1 trials really tailor treatment?	LANCET			English	Editorial Material							QUININE; CRAMPS		Univ Oxford, Clin Trial Serv Unit, Oxford, England; Univ Oxford, Epidemiol Studies Unit, Oxford, England	University of Oxford; University of Oxford	Jull, A (corresponding author), Univ Auckland, Clin Trials Res Unit, Auckland 1, New Zealand.	a.jull@ctru.auckland.ac.nz	Jull, Andrew/I-1737-2013	Jull, Andrew/0000-0002-8484-3771; Bennett, Derrick/0000-0002-9170-8447				Coxeter PD, 2003, COMPLEMENT THER MED, V11, P215, DOI 10.1016/S0965-2299(03)00122-5; Guyatt G., 2015, USERS GUIDES MED LIT; Karnon J, 2001, HEALTH ECON, V10, P79, DOI 10.1002/1099-1050(200101)10:1<79::AID-HEC567>3.0.CO;2-Z; Man-Son-Hing M, 1998, J GEN INTERN MED, V13, P600, DOI 10.1046/j.1525-1497.1998.00182.x; Nikles CJ, 2005, BRIT J GEN PRACT, V55, P175; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Wegman ACM, 2003, ANN RHEUM DIS, V62, P1156, DOI 10.1136/ard.2002.002865; Woodfield R, 2005, BRIT J GEN PRACT, V55, P181; Zucker DR, 1997, J CLIN EPIDEMIOL, V50, P401, DOI 10.1016/S0895-4356(96)00429-5	9	11	12	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2005	365	9476					1992	1994		10.1016/S0140-6736(05)66678-0	http://dx.doi.org/10.1016/S0140-6736(05)66678-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	934IB	15950705				2022-12-28	WOS:000229701400009
J	Franklyn, JA; Sheppard, MC; Maisonneuve, P				Franklyn, JA; Sheppard, MC; Maisonneuve, P			Thyroid function and mortality in patients treated for hyperthyroidism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY-DISEASE; ISCHEMIC-HEART-DISEASE; RISK-FACTOR; FOLLOW-UP; ATRIAL-FIBRILLATION; ALL-CAUSE; HYPOTHYROIDISM; WOMEN; TSH	Context Hyperthyroidism has been reported to cause excess all-cause and circulatory mortality. Whether this can be reversed is unknown, as is the influence of mild persisting thyroid dysfunction and treatment-induced hypothyroidism. Objectives To determine whether radioiodine treatment is associated with increased mortality and to determine the influences of mild thyroid dysfunction and the development of overt hypothyroidism treated with thyroxine (T-4). Design, Setting, and Participants A population -based study of 2668 individuals aged 40 years or older treated for overt hyperthyroidism with radioiodine in the West Midlands region of England from 1984-2002. Main Outcome Measures Cause of death compared with age- and period-specific mortality in England and Wales and assessment of the influence of T-4 therapy for radioiodine-induced hypothyroidism and subclinical thyroid dysfunction on mortality. Results In 15 968 person -years of follow-up, 554 died vs 487 expected deaths (standardized mortality ratio [SMR], 1.14; 95% confidence interval [CI], 1.04-1.24, P=.002). Increased risks of all-cause and circulatory deaths vs age- and period-specific mortality were observed in follow-up in those not requiring, or prior to, T-4 therapy. These increased risks were not observed during follow-up on T-4 therapy (circulatory disease SMR prior to T-4, 1.33; 95% Cl, 1.14-1.53 vs SMR, 0.91; 95% Cl, 0.70-1.17 during T-4)- Patients receiving T-4 had decreased risk of mortality vs risk in the period not requiring, or prior to, T-4 therapy (all-cause mortality hazard ratio [HR], 0.65; 95 % Cl, 0.54-0.79; circulatory mortality HR, 0.65; 95% Cl, 0.48-0.87). Increased all-cause mortality vs the background population was observed in the period prior to T-4 therapy in follow-up associated with low, normal, and high serum thyrotropin. The SMR for ischemic heart disease increased slightly when analyzed by serum thyrotropin, high serum thyrotropin being the highest SMR (low thyrotropin SMR, 1.06; 95% Cl, 0.75-1.45; normal thyrotropin SMR, 1.17; 95% Cl, 0.76-1.71; high thyrotropin SMR, 1.48; 95% Cl, 0.86-2.37). Comparison within the cohort showed that mild hypothyroidism prior to T-4 therapy was associated with increased risk of mortality from ischemic heart disease vs biochemical euthyroidism (HR, 2.08; 95% Cl, 1.04-4.19). Conclusions Patients treated with radioiodine for hyperthyroidism had increased mortality vs age- and period-specific mortality in England and Wales, a finding no longer evident during T-4 therapy. This supports treating hyperthyroidism with doses of radioiodine sufficient to induce overt hypothyroidism. The association within the cohort of mortality from ischemic heart disease with subclinical hypothyroidism suggests T-4 replacement should be considered should this biochemical abnormality develop after radioiodine therapy.	Univ Birmingham, Sch Med, Inst Biomed Res,Dept Med, Div Med Sci, Birmingham B15 2TT, W Midlands, England; European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy	University of Birmingham; IRCCS European Institute of Oncology (IEO)	Franklyn, JA (corresponding author), Univ Birmingham, Sch Med, Inst Biomed Res,Dept Med, Div Med Sci, Birmingham B15 2TT, W Midlands, England.	j.a.franklyn@bham.ac.uk	Maisonneuve, Patrick/U-9789-2018	Maisonneuve, Patrick/0000-0002-5309-4704				Auer J, 2001, AM HEART J, V142, P838, DOI 10.1067/mhj.2001.119370; BARBER SG, 1977, LANCET, V2, P967; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Cappola AR, 2003, J CLIN ENDOCR METAB, V88, P2438, DOI 10.1210/jc.2003-030398; Danese ND, 2000, J CLIN ENDOCR METAB, V85, P2993, DOI 10.1210/jcem.85.9.6841; DELIT C, 1961, JAMA-J AM MED ASSOC, V176, P262, DOI 10.1001/jama.1961.03040170008003; Fisher LD, 1999, ANNU REV PUBL HEALTH, V20, P145, DOI 10.1146/annurev.publhealth.20.1.145; FRANKLYN JA, 1991, CLIN ENDOCRINOL, V34, P71, DOI 10.1111/j.1365-2265.1991.tb01738.x; Franklyn JA, 1998, NEW ENGL J MED, V338, P712, DOI 10.1056/NEJM199803123381103; GOLDMAN MB, 1990, CANCER RES, V50, P2283; Gussekloo J, 2004, JAMA-J AM MED ASSOC, V292, P2591, DOI 10.1001/jama.292.21.2591; Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004; HALL P, 1993, ACTA ENDOCRINOL-COP, V128, P230, DOI 10.1530/acta.0.1280230; Imaizumi M, 2004, J CLIN ENDOCR METAB, V89, P3365, DOI 10.1210/jc.2003-031089; KEATING FR, 1961, PROG CARDIOVASC DIS, V3, P364, DOI 10.1016/S0033-0620(61)90004-4; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; Parle JV, 2001, LANCET, V358, P861, DOI 10.1016/S0140-6736(01)06067-6; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; Ringel MD, 2005, J CLIN ENDOCR METAB, V90, P588, DOI 10.1210/jc.2004-2173; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; STEINBERG AD, 1968, ANN INTERN MED, V68, P338, DOI 10.7326/0003-4819-68-2-338; Surks MI, 2004, JAMA-J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; Vanderpump MPJ, 1996, THYROID, V6, P155; VANHAELST L, 1967, LANCET, V2, P800, DOI 10.1016/S0140-6736(67)92235-0; YAMAMOTO M, 1992, ENDOCRINOL JAPON, V39, P223	27	109	120	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2005	294	1					71	80		10.1001/jama.294.1.71	http://dx.doi.org/10.1001/jama.294.1.71			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941JD	15998893				2022-12-28	WOS:000230210200027
J	Bai, CL				Bai, CL			Ascent of nanoscience in China	SCIENCE			English	Editorial Material									Chinese Acad Sci, Inst Chem, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Chemistry, CAS	Bai, CL (corresponding author), Chinese Acad Sci, Inst Chem, Beijing 100080, Peoples R China.	clbai@iccas.ac.cn						Gong JR, 2005, P NATL ACAD SCI USA, V102, P971, DOI 10.1073/pnas.0409145102; Kosto RN, 2004, SCIENTIST, V18, P10; Qiu XH, 2000, J AM CHEM SOC, V122, P5550, DOI 10.1021/ja994271p; 2003, SCI WATCH, V14	4	76	83	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 1	2005	309	5731					61	63		10.1126/science.1115172	http://dx.doi.org/10.1126/science.1115172			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994515				2022-12-28	WOS:000230212800032
J	Siegfried, T				Siegfried, T			In praise of hard questions	SCIENCE			English	News Item																			0	13	13	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 1	2005	309	5731					76	77		10.1126/science.309.5731.76	http://dx.doi.org/10.1126/science.309.5731.76			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994522				2022-12-28	WOS:000230212800039
J	Solantaus, T; Salo, S				Solantaus, T; Salo, S			Paternal postnatal depression: fathers emerge from the wings	LANCET			English	Editorial Material									Natl Res & Dev Ctr Welf & Hlth, FIN-00531 Helsinki, Finland; Univ Helsinki, Childrens Hosp, Helsinki, Finland	University of Helsinki	Solantaus, T (corresponding author), Natl Res & Dev Ctr Welf & Hlth, FIN-00531 Helsinki, Finland.	Tytti.Solantaus@stakes.fi						Braungart-Rieker J, 1998, DEV PSYCHOL, V34, P1428, DOI 10.1037/0012-1649.34.6.1428; Feldman R, 2003, INFANT MENT HEALTH J, V24, P1, DOI 10.1002/imhj.10041; Gavin LE, 2002, J ADOLESCENT HEALTH, V31, P266, DOI 10.1016/S1054-139X(02)00366-X; Grych JH, 1999, DEV PSYCHOL, V35, P893, DOI 10.1037/0012-1649.35.4.893; *SOC INS I, 2004, STAT YB SOC INS I FI	5	15	15	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 25	2005	365	9478					2158	2159		10.1016/S0140-6736(05)66754-2	http://dx.doi.org/10.1016/S0140-6736(05)66754-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978909				2022-12-28	WOS:000230034800007
J	Fox, RC; Scott, CS				Fox, RC; Scott, CS			First evidence of a venom delivery apparatus in extinct mammals	NATURE			English	Article								Numerous non-mammalian vertebrates have evolved lethal venoms to aid either in securing prey or as protection from predators, but modern mammals that use venoms in these ways are rare, including only the duck-billed platypus (Ornithorhynchus), the Caribbean Solenodon, and a few shrews (Soricidae) (Order Insectivora)(1). Here we report evidence of a venom delivery apparatus in extinct mammals, documented by well-preserved specimens recovered from late Palaeocene rocks in Alberta, Canada(2,3). Although classified within Eutheria, these mammals are phylogenetically remote from modern Insectivora(4) and have evolved specialized teeth as salivary venom delivery systems (VDSs) that differ markedly from one another and from those of Solenodon and shrews. Our discoveries therefore show that mammals have been much more flexible in the evolution of VDSs than previously believed, contradicting currently held notions that modern insectivorans are representative of the supposedly limited role of salivary venoms in mammalian history. Evidently, small predatory eutherians have paralleled colubroid snakes(5) in evolving salivary venoms and their delivery systems several times independently.	Univ Alberta, Dept Biol Sci, Paleontol Vertebres Lab, Edmonton, AB T6G 2E9, Canada	University of Alberta	Fox, RC (corresponding author), Univ Alberta, Dept Biol Sci, Paleontol Vertebres Lab, Edmonton, AB T6G 2E9, Canada.	richard.fox@ualberta.ca						BELLAIRS AD, 1957, REPTILES LIFE HIST E; DUFTON MJ, 1992, PHARMACOL THERAPEUT, V53, P199, DOI 10.1016/0163-7258(92)90009-O; FOX RC, 1990, DAWN AGE MAMMALS NO, P51; Gazin C. L., 1956, SMITHSONIAN MISCELLA, V131, P1; GINGERICH P D, 1983, Contributions from the Museum of Paleontology University of Michigan, V26, P227; GOIN CJ, 1972, INTRO HERPETOLOGY; Jackson K, 2003, ZOOL J LINN SOC-LOND, V137, P337, DOI 10.1046/j.1096-3642.2003.00052.x; Kita M, 2004, P NATL ACAD SCI USA, V101, P7542, DOI 10.1073/pnas.0402517101; Lake AR, 1996, S AFR J SCI, V92, P167; Lofgren Donald L., 2004, P43; MacDonald D., 1984, ENCY MAMMALS; MCDOWELL SAMUEL BOOKER, 1958, BULL AMER MUS NAT HIST, V115, P113; McKenna MC, 1997, CLASSIFICATION MAMMA; Rabb G.B., 1959, NAT HIST MISC, V170, P1; Scott C, 2004, J VERTEBR PALEONTOL, V24, p111A	15	37	39	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 23	2005	435	7045					1091	1093		10.1038/nature03646	http://dx.doi.org/10.1038/nature03646			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973406				2022-12-28	WOS:000229970400047
J	Mangia, A; Santoro, R; Minerva, N; Ricci, GL; Carretta, V; Persico, M; Vinelli, F; Scotto, G; Bacca, D; Annese, M; Romano, M; Zechini, F; Sogari, F; Spirito, F; Andriulli, A				Mangia, A; Santoro, R; Minerva, N; Ricci, GL; Carretta, V; Persico, M; Vinelli, F; Scotto, G; Bacca, D; Annese, M; Romano, M; Zechini, F; Sogari, F; Spirito, F; Andriulli, A			Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC HEPATITIS-C; SUSTAINED VIROLOGICAL RESPONSE; PLUS RIBAVIRIN; COMBINATION THERAPY; VIRAL DYNAMICS; INTERFERON; MULTICENTER; STANDARD; KINETICS; DECLINE	Background We hypothesized that in patients with hepatitis C virus (HCV) genotype 2 or 3 in whom HCV RNA is not detectable after 4 weeks of therapy, 12 weeks of treatment is as effective as 24 weeks. Methods A total of 283 patients were randomly assigned to a standard 24-week regimen of peginterferon alfa-2b at a dose of 1.0 mu g per kilogram weekly plus ribavirin at a dose of 1000 mg or 1200 mg daily, on the basis of body weight. Of these, 70 patients were assigned to the 24-week regimen (standard-duration group) and 213 patients to a variable regimen (variable-duration group) of 12 or 24 weeks, depending on whether tests for HCV RNA were negative or positive at week 4. The primary end point was HCV that was not detectable by polymerase-chain-reaction (PCR) assay 24 weeks after the completion of therapy. Results In the standard-duration group, 45 (64 percent) patients had HCV that was not detectable by PCR assay at week 4, as compared with 133 (62 percent) in the variable-duration group (difference [the rate in the standard-duration group minus that in the variable-duration group], 2 percent; 95 percent confidence interval, -11 to 15 percent). Fifty-three patients (76 percent) in the standard-duration group and 164 patients (77 percent) in the variable-duration group had a sustained virologic response (difference, -1 percent; 95 percent confidence interval, -13 to 10 percent). Fewer patients in the variable-duration group receiving the 12-week regimen had adverse events and withdrew than in the group receiving the 24-week regimen (P=0.045). The rate of relapse (defined as HCV not detectable at the end of treatment but detectable at the end of follow-up) was 3.6 percent in the standard-duration group and 8.9 percent in the variable-duration group (P=0.16). Overall, the rate of sustained virologic response was 80 percent among patients with HCV genotype 2 and 66 percent among those with genotype 3 (P<0.001). Conclusions A shorter course of therapy over 12 weeks with peginterferon alfa-2b and ribavirin is as effective as a 24-week course for patients with HCV genotype 2 or 3 who have a response to treatment at 4 weeks.	IRCCS, Casa Sollievo Sofferenza Hosp, Gastroenterol Unit, I-71013 San Giovanni Rotondo, Italy; Hosp Canosa, Dept Internal Med, Canosa, Italy; Univ Roma La Sapienza, Dept Internal Med, Rome, Italy; Hosp Venosa, Dept Internal Med, Venosa, Italy; Univ Naples Federico II, Dept Internal Med, Naples, Italy; Osped Riuniti Foggia, Dept Gastroenterol, Foggia, Italy; Univ Foggia, Dept Infect Dis, Foggia, Italy; Hosp Casarano, Dept Internal Med, Casarano, Italy; Hosp Policoro, Dept Internal Med, Policoro, Italy; SantAndrea Hosp, Dept Internal Med, Rome, Italy; Sovrano Ordine Malta, Liver Unit, Rome, Italy; Santissima Annunziata Hosp, Dept Internal Med, Taranto, Italy	IRCCS Casa Sollievo Della Sofferenza; Sapienza University Rome; University of Naples Federico II; University of Foggia; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea	Mangia, A (corresponding author), IRCCS, Casa Sollievo Sofferenza Hosp, Gastroenterol Unit, I-71013 San Giovanni Rotondo, Italy.	a.mangia@tin.it	Andriulli, Angelo/B-5027-2017; SANTORO, ROSANNA/C-3941-2017; persico, marcello/AAB-3562-2019; Mangia, A/AAL-5357-2020	Andriulli, Angelo/0000-0001-8862-7083; SANTORO, ROSANNA/0000-0001-6516-1305; Mangia, A/0000-0002-2600-3555; Persico, Marcello/0000-0002-1399-6498; , Gaetano/0000-0002-1406-7797				[Anonymous], 2002, HEPATOLOGY, V36, pS3, DOI 10.1053/jhep.2002.37117; Cheng DM, 2000, BIOMETRICS, V56, P626, DOI 10.1111/j.0006-341X.2000.00626.x; Dalgard O, 2004, HEPATOLOGY, V40, P1260, DOI 10.1002/hep.20467; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010; *IT ASS STUD LIV, GUID ONL FIN STAT; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; McHutchison JG, 2002, GASTROENTEROLOGY, V123, P1061, DOI 10.1053/gast.2002.35950; Neumann A, 2002, J HEPATOL, V36, P121, DOI 10.1016/S0168-8278(02)80430-5; Neumann AU, 2000, HEPATOLOGY, V32, p318A; Neumann AU, 2000, J INFECT DIS, V182, P28, DOI 10.1086/315661; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Nousbaum JB, 2003, J HEPATOL, V39, P655, DOI 10.1016/S0168-8278(03)00403-3; SCHEUER PJ, 1991, J HEPATOL, V13, P372, DOI 10.1016/0168-8278(91)90084-O; von Wagner M, 2004, HEPATOLOGY, V40, p725A; Zeuzem S, 2004, J HEPATOL, V40, P993, DOI [10.1016/S0168-8278(04)00060-1, 10.1016/j.jhep.2004.02.007]; Zeuzem S, 2005, J HEPATOL, V42, P434, DOI 10.1016/j.jhep.2005.01.006; Zeuzem S, 2003, HEPATOLOGY, V38, p310A; Zeuzem S, 2001, GASTROENTEROLOGY, V120, P1438, DOI 10.1053/gast.2001.24006; Zeuzem S, 1998, HEPATOLOGY, V27, P1149, DOI 10.1002/hep.510270433	20	503	530	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					2609	2617		10.1056/NEJMoa042608	http://dx.doi.org/10.1056/NEJMoa042608			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972867				2022-12-28	WOS:000229953700008
J	Atkins, D; Fink, K; Slutsky, J				Atkins, D; Fink, K; Slutsky, J			Better information for better health care: The evidence-based practice center program and the agency for healthcare research and quality	ANNALS OF INTERNAL MEDICINE			English	Article							IMPLEMENTATION; GUIDELINE; STRENGTH; OUTCOMES	To provide decision makers with the best available evidence, the Agency for Healthcare Research and Quality established a network of Evidence-based Practice Centers across North America. The centers perform systematic reviews on important questions posed by partner organizations about clinical, organizational, and policy interventions in health care. The Agency works closely with partners and other decision makers to help translate that evidence into practice or policy. In this paper, we review important lessons we have learned over the past 7 years about how to increase the efficiency and impact of systematic reviews. Lessons concern selecting the right topics and scope, working effectively with partners, and balancing consistency and flexibility in methods. We examine continuing evolutions of the program and the impact of planned work on comparative effectiveness performed as part of the Medicare Modernization Act of 2003.	Agcy Healthcare Res & Qual, Rockville, MD 20850 USA	Agency for Healthcare Research & Quality	Atkins, D (corresponding author), Agcy Healthcare Res & Qual, 540 Gaither Rd, Rockville, MD 20850 USA.	datkins@ahrq.gov						Adams K., 2003, PRIORITY AREAS NATL; [Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; BERKMAN N, 2004, AHRQ PUBLICATION; BROWN JB, 1995, JOINT COMM J QUAL IM, V21, P5, DOI 10.1016/S1070-3241(16)30123-7; Deeks J J, 2003, Health Technol Assess, V7, piii; Ebell MH, 2004, AM FAM PHYSICIAN, V69, P548; Gaynes B. N., 2005, AHRQ PUBLICATION; GRADY D, 2003, AHRQ PUBLICATION; GRAY BH, 1992, HEALTH AFFAIR, V11, P38, DOI 10.1377/hlthaff.11.4.38; GRAY BH, 2003, AHCPR CHANGING POLIT, DOI DOI 10.1377/HLTHAFF.W3.283; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; Kosterlitz J, 1991, Natl J (Wash), V23, P574; Lieberthal AS, 2004, PEDIATRICS, V113, P1451, DOI 10.1542/peds.113.5.1451; Matchar DB, 2005, ANN INTERN MED, V142, P1120, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00012; MCCRORY DC, AHCPR PUBLICATION; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; MEENAN RT, 2002, 290970018 OR HLTH SC; Norris SL, 2005, ANN INTERN MED, V142, P1112, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00011; NUTTING PA, 1992, AM FAM PHYSICIAN, V46, P57; SALIVE ME, 1990, HEALTH SERV RES, V25, P697; Shekelle P, 2003, AHRQ PUBLICATION, V03-E023; SHEKELLE PG, 2004, AHRQ PUBLICATION; Shojania KG, 2004, AHRQ PUBLICATION, V04-0051-2; Stryer D, 2000, HEALTH SERV RES, V35, P977; Von Knoop C, 2003, VITAL SIGNS E HLTH U; WENNBERG JE, 1994, SCIENCE, V264, P758, DOI 10.1126/science.7513442; West S, 2002, AHRQ PUBLICATION, V02-E016	28	66	67	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1035	1041		10.7326/0003-4819-142-12_Part_2-200506211-00002	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	938CN	15968027				2022-12-28	WOS:000229977600002
J	Tatsioni, A; Zarin, DA; Aronson, N; Samson, DJ; Flamm, CR; Schmid, C; Lau, J				Tatsioni, A; Zarin, DA; Aronson, N; Samson, DJ; Flamm, CR; Schmid, C; Lau, J			Challenges in systematic reviews of diagnostic technologies	ANNALS OF INTERNAL MEDICINE			English	Article							PUBLICATION BIAS; TEST ACCURACY; TESTS; METAANALYSIS; LESSONS; QUALITY; CURVE	Diagnostic tests are critical components of effective health care. They help determine treatments that are most beneficial for a given patient. Their assessment is a complex process that includes such challenges as a dearth of studies that evaluate clinical outcomes and lack of data on use of the test in realistic clinical settings. The methodologic quality of studies of diagnostic tests also lags behind the quality of studies of therapeutic interventions. Statistical methods to combine diagnostic accuracy data are more complex and not as well developed, leading to difficulties in the interpretation of results. The Agency for Healthcare Research and Quality Technology Assessment Program has adopted a 6-level framework for evaluating diagnostic technologies. The model emphasizes the need for systematic reviews of diagnostic test studies to go beyond the assessment of technical feasibility and accuracy to examine the impact of the test on health outcomes. In this paper, we use examples from 3 Evidence-based Practice Center reports to illustrate 3 challenges reviewers may face when reviewing diagnostic test literature: finding relevant studies, assessing methodologic quality of diagnostic accuracy studies, and synthesizing studies that evaluate tests in different patient populations or use different outcomes.	Tufts Univ New England Med Ctr, Evidence Based Pract Ctr, Boston, MA 02111 USA; Agcy Healthcare Res & Qual, Rockville, MD USA; Blue Cross & Blue Shield Assoc Technol Evaluat Ct, Chicago, IL USA	Tufts Medical Center; Agency for Healthcare Research & Quality	Lau, J (corresponding author), Tufts Univ New England Med Ctr, Evidence Based Pract Ctr, 750 Washington St, Boston, MA 02111 USA.		Schmid, Christopher H./J-2398-2014; Tatsioni, Athina/AAQ-5413-2020	Schmid, Christopher H./0000-0002-0855-5313; 	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS013328] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS13328] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALBERANI V, 1990, B MED LIBR ASSOC, V78, P358; ARROLL B, 1988, J GEN INTERN MED, V3, P443, DOI 10.1007/BF02595920; Bafounta ML, 2004, LANCET ONCOL, V5, P673, DOI 10.1016/S1470-2045(04)01609-2; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; Banta HD, 2002, INT J TECHNOL ASSESS, V18, P762, DOI 10.1017/S0266462302000570; Blackmore C C, 1999, Acad Radiol, V6 Suppl 1, pS8, DOI 10.1016/S1076-6332(99)80078-6; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; *COCHR METH GROUP, 2004, COCHR METH WORK GROU; De Angelis C, 2004, NEW ENGL J MED, V351, P1250, DOI 10.1056/NEJMe048225; Deeks JJ, 2001, BRIT MED J, V323, P157, DOI 10.1136/bmj.323.7305.157; Deville Walter L, 2002, BMC Med Res Methodol, V2, P9, DOI 10.1186/1471-2288-2-9; *DUK CTR CLIN HLTH, 2005, POS EM TOM SINGL PHO; FINEBERG HV, 1977, JAMA-J AM MED ASSOC, V238, P224, DOI 10.1001/jama.238.3.224; FRYBACK DG, 1991, MED DECIS MAKING, V11, P88, DOI 10.1177/0272989X9101100203; FRYBACK DG, 1983, J NEURORADIOLOGY, V10, P94; Haynes RB, 2004, BMJ-BRIT MED J, V328, P1040, DOI 10.1136/bmj.38068.557998.EE; Imran Muhammad Babar, 2003, J Coll Physicians Surg Pak, V13, P465; Irwig I, 1995, J CLIN EPIDEMIOL, V48, P131; IRWIG L, 1995, J CLIN EPIDEMIOL, V48, P119, DOI 10.1016/0895-4356(94)00099-C; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; LAU J, 2001, AHRQ PUBLICATION; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; Lohr K N, 1999, Jt Comm J Qual Improv, V25, P470; MCNEIL BJ, 1976, J NUCL MED, V17, P439; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; MULROW CD, 1989, J GEN INTERN MED, V4, P288, DOI 10.1007/BF02597398; Mushlin A I, 1999, Acad Radiol, V6 Suppl 1, pS128, DOI 10.1016/S1076-6332(99)80107-X; Mushlin AI, 2001, LANCET, V358, P1353, DOI 10.1016/S0140-6736(01)06417-0; *NEW ENGL MED CTR, 2005, MAGN RES SPECTR BRAI; NIERENBERG AA, 1988, JAMA-J AM MED ASSOC, V259, P1699, DOI 10.1001/jama.259.11.1699; Oei EHG, 2003, RADIOLOGY, V226, P837, DOI 10.1148/radiol.2263011892; Oosterhuis WP, 2000, CLIN CHEM LAB MED, V38, P577, DOI 10.1515/CCLM.2000.084; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; Romagnuolo J, 2003, ANN INTERN MED, V139, P547, DOI 10.7326/0003-4819-139-7-200310070-00006; Rutter CM, 2001, STAT MED, V20, P2865, DOI 10.1002/sim.942; Schmid CH, 2004, J CLIN EPIDEMIOL, V57, P683, DOI 10.1016/j.jclinepi.2003.12.001; SHEPS SB, 1984, JAMA-J AM MED ASSOC, V252, P2418, DOI 10.1001/jama.252.17.2418; Siadaty MS, 2004, J CLIN EPIDEMIOL, V57, P698, DOI 10.1016/j.jclinepi.2003.12.007; Tang JL, 2000, J CLIN EPIDEMIOL, V53, P477, DOI 10.1016/S0895-4356(99)00204-8; Terrin N, 2003, STAT MED, V22, P2113, DOI 10.1002/sim.1461; THORNBURY JR, 1975, RADIOLOGY, V114, P561, DOI 10.1148/114.3.561; Thornton A, 2000, J CLIN EPIDEMIOL, V53, P207, DOI 10.1016/S0895-4356(99)00161-4; Vamvakas EC, 1998, ARCH PATHOL LAB MED, V122, P675; Vasbinder GBC, 2001, ANN INTERN MED, V135, P401, DOI 10.7326/0003-4819-135-6-200109180-00009; Walter SD, 2002, STAT MED, V21, P1237, DOI 10.1002/sim.1099; Whiting P, 2004, ANN INTERN MED, V140, P189, DOI 10.7326/0003-4819-140-3-200402030-00010; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25	47	134	136	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1048	1055		10.7326/0003-4819-142-12_Part_2-200506211-00004	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938CN	15968029				2022-12-28	WOS:000229977600004
J	Martin, J				Martin, J			Collaboration in cardiovascular stem-cell research	LANCET			English	Editorial Material							BONE-MARROW-CELLS; MYOCARDIAL-INFARCTION; TRANSPLANTATION; HUMANS; REPAIR		UCL, Dept Med, British Heart Fdn Labs, London WC1E 6JJ, England	University of London; University College London	Martin, J (corresponding author), UCL, Dept Med, British Heart Fdn Labs, London WC1E 6JJ, England.	john.martin@ucl.ac.uk						Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Fernandez-Aviles F, 2004, CIRC RES, V95, P742, DOI 10.1161/01.RES.0000144798.54040.ed; Galinanes M, 2004, CELL TRANSPLANT, V13, P7, DOI 10.3727/000000004772664842; Mathur A, 2004, LANCET, V364, P183, DOI 10.1016/S0140-6736(04)16632-4; Menasche P, 2003, J AM COLL CARDIOL, V41, P1078, DOI 10.1016/S0735-1097(03)00092-5; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9; Yla-Herttuala S, 2000, LANCET, V355, P213, DOI 10.1016/S0140-6736(99)04180-X	9	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 18	2005	365	9477					2070	2071		10.1016/S0140-6736(05)66626-3	http://dx.doi.org/10.1016/S0140-6736(05)66626-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964430				2022-12-28	WOS:000229858800007
J	Berns, A				Berns, A			Stem cells for lung cancer?	CELL			English	Editorial Material							K-RAS; LEUKEMIA	Stem cells are believed to be crucial players in tumor development. There is much interest in identifying those compartments that harbor stem cells involved in lung cancer, given the high incidence and recurrence rate of this disease. In this issue of Cell, Kim and colleagues describe a niche in the bronchioal-veolar duct junction of adult mouse lung that harbors stem cells from which adenocarcinomas are likely to arise (Kim et al., 2005). They enriched, propagated, and differentiated these stem cells in vitro and found that they were activated by the oncogenic protein K-ras. This study provides exciting insights into how the stem cell compartment operates during both normal lung-tissue homeostasis and the development of lung cancer. The new work offers perspectives on possible therapeutic interventions to combat lung cancer.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands.							Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Giangreco A, 2002, AM J PATHOL, V161, P173, DOI 10.1016/S0002-9440(10)64169-7; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hong KU, 2004, AM J PATHOL, V164, P577, DOI 10.1016/S0002-9440(10)63147-1; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jamieson CHM, 2004, CANCER CELL, V6, P531, DOI 10.1016/S1535-6108(04)00342-3; KIM CFB, 2005, CELL, P121; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Reynolds SD, 2000, AM J PHYSIOL-LUNG C, V278, pL1256, DOI 10.1152/ajplung.2000.278.6.L1256; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128	11	51	58	1	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 17	2005	121	6					811	813		10.1016/j.cell.2005.06.004	http://dx.doi.org/10.1016/j.cell.2005.06.004			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960966	Bronze			2022-12-28	WOS:000230011200001
J	Erwin, DH				Erwin, DH			Seeds of diversity	SCIENCE			English	Editorial Material							ECOSYSTEM ENGINEERS; ORGANISMS		Natl Museum Nat Hist, Dept Paleobiol, Washington, DC 20013 USA	Smithsonian Institution; Smithsonian National Museum of Natural History	Erwin, DH (corresponding author), Natl Museum Nat Hist, Dept Paleobiol, MRC-121,POB 37012, Washington, DC 20013 USA.	erwind@si.edu	Erwin, Douglas H/A-9668-2009	Erwin, Douglas/0000-0003-2518-5614				Dawkins R, 2004, BIOL PHILOS, V19, P377, DOI 10.1023/B:BIPH.0000036180.14904.96; Dawkins R., 1982, pi; Emerson BC, 2005, NATURE, V434, P1015, DOI 10.1038/nature03450; Jones CG, 1997, ECOLOGY, V78, P1946, DOI 10.1890/0012-9658(1997)078[1946:PANEOO]2.0.CO;2; JONES CG, 1994, OIKOS, V69, P373, DOI 10.2307/3545850; Lewontin R.C., 1983, P273; MAC ARTHUR ROBERT H., 1967; Odling-Smee FJ, 2003, NICHE CONSTRUCTION N; SIGNOR PW, 1994, PALEOBIOLOGY, V20, P297, DOI 10.1017/S0094837300012793; STANLEY SM, 1990, PALEOBIOLOGY, V16, P401, DOI 10.1017/S0094837300010150; Webby B.D., 2004, GREAT ORDOVICIAN BIO, DOI DOI 10.7312/WEBB12678	11	36	36	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 17	2005	308	5729					1752	1753		10.1126/science.1113416	http://dx.doi.org/10.1126/science.1113416			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961660				2022-12-28	WOS:000229926800042
J	Hopkins, DS; Pekker, D; Goldbart, PM; Bezryadin, A				Hopkins, DS; Pekker, D; Goldbart, PM; Bezryadin, A			Quantum interference device made by DNA templating of superconducting nanowires	SCIENCE			English	Article								The application of single molecules as templates for nanodevices is a promising direction for nanotechnology. We used a pair of suspended DNA molecules as templates for superconducting two-nanowire devices. Because the resulting wires are very thin, comparable to the DNA molecules themselves, they are susceptible to thermal fluctuations typical for one-dimensional superconductors and exhibit a nonzero resistance over a broad temperature range. We observed resistance oscillations in these two-nanowire structures that are different from the usual Little-Parks oscillations. Here, we provide a quantitative explanation for the observed quantum interference phenomenon, which takes into account strong phase gradients created in the leads by the applied magnetic field.	Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Bezryadin, A (corresponding author), Univ Illinois, Dept Phys, Urbana, IL 61801 USA.	bezryadi@uiuc.edu	Bezryadin, Alexey/H-1815-2016	Bezryadin, Alexey/0000-0002-4822-6960				Bezryadin A, 2000, NATURE, V404, P971, DOI 10.1038/35010060; Braun E, 1998, NATURE, V391, P775, DOI 10.1038/35826; Braun E, 2004, ADV PHYS, V53, P441, DOI 10.1080/00018730412331294688; CLEM JR, 1972, B AM PHYS SOC, V43, P411; JAKLEVIC RC, 1964, PHYS REV LETT, V12, P159, DOI 10.1103/PhysRevLett.12.159; LANGER JS, 1967, PHYS REV, V164, P498, DOI 10.1103/PhysRev.164.498; LIKHAREV KK, 1973, SOV RADIOPHYS, V14, P722; LITTLE WA, 1967, PHYS REV, V156, P396, DOI 10.1103/PhysRev.156.396; Maksimova GM, 1998, PHYS SOLID STATE+, V40, P1607, DOI 10.1134/1.1130618; MCCUMBER DE, 1970, PHYS REV B-SOLID ST, V1, P1054, DOI 10.1103/PhysRevB.1.1054; Mertig M, 2002, NANO LETT, V2, P841, DOI 10.1021/nl025612r; Richter J, 2001, APPL PHYS LETT, V78, P536, DOI 10.1063/1.1338967; Richter J, 2002, APPL PHYS A-MATER, V74, P725, DOI 10.1007/s003390201289; Seeman NC, 1998, ANGEW CHEM INT EDIT, V37, P3220, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3220::AID-ANIE3220>3.0.CO;2-C; Stan G, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.097003; Tinkham M, 2002, APPL PHYS LETT, V80, P2946, DOI 10.1063/1.1473232; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.; Watanabe H, 2001, APPL PHYS LETT, V79, P2462, DOI 10.1063/1.1408604; Yan H, 2003, SCIENCE, V301, P1882, DOI 10.1126/science.1089389	19	130	132	4	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1762	1765		10.1126/science.1111307	http://dx.doi.org/10.1126/science.1111307			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15961664				2022-12-28	WOS:000229926800047
J	Kim, CFB; Jackson, EL; Woolfenden, AE; Lawrence, S; Babar, I; Vogel, S; Crowley, D; Bronson, RT; Jacks, T				Kim, CFB; Jackson, EL; Woolfenden, AE; Lawrence, S; Babar, I; Vogel, S; Crowley, D; Bronson, RT; Jacks, T			Identification of bronchioalveolar stem cells in normal lung and lung cancer	CELL			English	Article							ATYPICAL ADENOMATOUS HYPERPLASIA; PROGENITOR CELLS; MAMMARY-GLAND; SELF-RENEWAL; MOUSE LUNG; EXPRESSION; BLEOMYCIN; DIFFERENTIATION; ADENOCARCINOMA; POPULATIONS	Injury models have suggested that the lung contains anatomically and functionally distinct epithelial stem cell populations. We have isolated such a regional pulmonary stem cell population, termed bronchloalveolar stem cells (BASCs). Identified at the bronchioalveolar duct junction, BASCs were resistant to bronchiolar and alveolar damage and proliferated during epithelial cell renewal in vivo. BASCs exhibited self-renewal and were multipotent in clonal assays, highlighting their stem cell properties. Furthermore, BASCs expanded in response to oncogenic K-ras in culture and in precursors of lung tumors in vivo. These data support the hypothesis that BASCs are a stem cell population that maintains the bronchiolar Clara cells and alveolar cells of the distal lung and that their transformed counterparts give rise to adenocarcinoma. Although bronchiolar cells and alveolar cells are proposed to be the precursor cells of adenocarcinoma, this work points to BASCs as the putative cells of origin for this subtype of lung cancer.	MIT, Canc Res Ctr, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Jacks, T (corresponding author), MIT, Canc Res Ctr, Cambridge, MA 02139 USA.	tjacks@mit.edu						Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; ASO Y, 1976, LAB INVEST, V35, P558; BANNISTER LH, 1999, GRAYS ANATOMY, P1666; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borthwick DW, 2001, AM J RESP CELL MOL, V24, P662, DOI 10.1165/ajrcmb.24.6.4217; Bortnick AE, 2003, AM J PHYSIOL-LUNG C, V285, pL869, DOI 10.1152/ajplung.00077.2003; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Daly HE, 1997, TOXICOL APPL PHARM, V142, P303, DOI 10.1006/taap.1996.8056; Daly HE, 1998, LAB INVEST, V78, P393; Delplanque A, 2000, J CELL SCI, V113, P767; DEOME KB, 1959, CANCER RES, V19, P515; DERMER GB, 1982, CANCER, V49, P881, DOI 10.1002/1097-0142(19820301)49:5<881::AID-CNCR2820490511>3.0.CO;2-7; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Giangreco A, 2002, AM J PATHOL, V161, P173, DOI 10.1016/S0002-9440(10)64169-7; GIANGRECO A, 2003, LUNG CELL MOL PHYSL, V286, pL624; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; GUNNING WT, 1991, EXP LUNG RES, V17, P255, DOI 10.3109/01902149109064416; Hadjantonakis AK, 1998, NAT GENET, V19, P220, DOI 10.1038/896; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; Hong KU, 2001, AM J RESP CELL MOL, V24, P671, DOI 10.1165/ajrcmb.24.6.4498; HOSHINO K, 1967, NATURE, V213, P193, DOI 10.1038/213193a0; Isakson BE, 2001, AM J PHYSIOL-CELL PH, V281, pC1291, DOI 10.1152/ajpcell.2001.281.4.C1291; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kotton DN, 2001, DEVELOPMENT, V128, P5181; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kruger GM, 2002, NEURON, V35, P657, DOI 10.1016/S0896-6273(02)00827-9; Mason RJ, 2000, AM J PATHOL, V156, P175, DOI 10.1016/S0002-9440(10)64717-7; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; MORI M, 1993, CANCER, V72, P2331, DOI 10.1002/1097-0142(19931015)72:8<2331::AID-CNCR2820720808>3.0.CO;2-E; Mori M, 2001, MODERN PATHOL, V14, P72, DOI 10.1038/modpathol.3880259; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Otto WR, 2002, J PATHOL, V197, P527, DOI 10.1002/path.1160; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reynolds SD, 2000, AM J PATHOL, V156, P269, DOI 10.1016/S0002-9440(10)64727-X; Reynolds SD, 2000, AM J PHYSIOL-LUNG C, V278, pL1256, DOI 10.1152/ajplung.2000.278.6.L1256; ROSAI J, 1995, ATLAS TUMOR PATHOLOG; Seaberg RM, 2003, TRENDS NEUROSCI, V26, P125, DOI 10.1016/S0166-2236(03)00031-6; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; Summer R, 2003, AM J PHYSIOL-LUNG C, V285, pL97, DOI 10.1152/ajplung.00009.2003; THAETE LG, 1991, EXP LUNG RES, V17, P219, DOI 10.3109/01902149109064413; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; Wuenschell CW, 1996, J HISTOCHEM CYTOCHEM, V44, P113, DOI 10.1177/44.2.8609367	58	1601	1770	1	124	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	2005	121	6					823	835		10.1016/j.cell.2005.03.032	http://dx.doi.org/10.1016/j.cell.2005.03.032			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960971	Bronze			2022-12-28	WOS:000230011200006
J	Fre, S; Huyghe, M; Mourikis, P; Robine, S; Louvard, D; Artavanis-Tsakonas, S				Fre, S; Huyghe, M; Mourikis, P; Robine, S; Louvard, D; Artavanis-Tsakonas, S			Notch signals control the fate of immature progenitor cells in the intestine	NATURE			English	Article							VILLIN GENE; EPITHELIAL-CELLS; STEM-CELLS; EXPRESSION; DIFFERENTIATION; MICE; PROLIFERATION; NEUROGENIN3; MATH1; HES5	The Notch signalling pathway plays a crucial role in specifying cellular fates in metazoan development by regulating communication between adjacent cells(1,2). Correlative studies suggested an involvement of Notch in intestinal development. Here, by modulating Notch activity in the mouse intestine, we directly implicate Notch signals in intestinal cell lineage specification. We also show that Notch activation is capable of amplifying the intestinal progenitor pool while inhibiting cell differentiation. We conclude that Notch activity is required for the maintenance of proliferating crypt cells in the intestinal epithelium.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Canc Ctr,Dept Cell Biol, Charlestown, MA 02129 USA; Inst Curie, CNRS, F-75231 Paris, France; Univ Paris 11, Fac Sci Orsay, F-91405 Orsay, France; Coll France, F-75231 Paris, France	Harvard University; Massachusetts General Hospital; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; College de France	Artavanis-Tsakonas, S (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Canc Ctr,Dept Cell Biol, Charlestown, MA 02129 USA.	tsakonas@helix.mgh.harvard.edu	Mourikis, Philippos/AAM-2458-2020; Fre, Silvia/C-7540-2017	Fre, Silvia/0000-0002-7209-7636; huyghe, mathilde/0000-0002-8473-2924; Mourikis, Philippos/0000-0003-3164-7109				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Crosnier C, 2005, DEVELOPMENT, V132, P1093, DOI 10.1242/dev.01644; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; FATH KR, 1990, DEVELOPMENT, V109, P449; Galceran J, 2004, GENE DEV, V18, P2718, DOI 10.1101/gad.1249504; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Go MJ, 1998, DEVELOPMENT, V125, P2031; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hofer D, 1996, HISTOCHEM CELL BIOL, V105, P405, DOI 10.1007/BF01463662; Ito T, 2000, DEVELOPMENT, V127, P3913; Jenny M, 2002, EMBO J, V21, P6338, DOI 10.1093/emboj/cdf649; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Lee JC, 2001, DIABETES, V50, P928, DOI 10.2337/diabetes.50.5.928; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cb.08.110192.001105; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; MAUNOURY R, 1988, EMBO J, V7, P3321, DOI 10.1002/j.1460-2075.1988.tb03203.x; MAUNOURY R, 1992, DEVELOPMENT, V115, P717; Murtaugh LC, 2003, P NATL ACAD SCI USA, V100, P14920, DOI 10.1073/pnas.2436557100; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Zine A, 2002, HEARING RES, V170, P22, DOI 10.1016/S0378-5955(02)00449-5	30	675	726	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					964	968		10.1038/nature03589	http://dx.doi.org/10.1038/nature03589			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959516				2022-12-28	WOS:000229799700051
J	Fridmann, J; Wiedenhover, I; Gade, A; Baby, LT; Bazin, D; Brown, BA; Campbell, CM; Cook, JM; Cottle, PD; Diffenderfer, E; Dinca, DC; Glasmacher, T; Hansen, PG; Kemper, KW; Lecouey, JL; Mueller, WF; Olliver, H; Rodriguez-Vieitez, E; Terry, JR; Tostevin, JA; Yoneda, K				Fridmann, J; Wiedenhover, I; Gade, A; Baby, LT; Bazin, D; Brown, BA; Campbell, CM; Cook, JM; Cottle, PD; Diffenderfer, E; Dinca, DC; Glasmacher, T; Hansen, PG; Kemper, KW; Lecouey, JL; Mueller, WF; Olliver, H; Rodriguez-Vieitez, E; Terry, JR; Tostevin, JA; Yoneda, K			'Magic' nucleus Si-42	NATURE			English	Article							N=28 SHELL CLOSURE; NEUTRON; FRAGMENTATION	Nuclear shell structures-the distribution of the quantum states of individual protons and neutrons-provide one of our most important guides for understanding the stability of atomic nuclei. Nuclei with 'magic numbers' of protons and/or neutrons (corresponding to closed shells of strongly bound nucleons) are particularly stable(1,2). Whether the major shell closures and magic numbers change in very neutron-rich nuclei (potentially causing shape deformations) is a fundamental, and at present open, question(3,4). A unique opportunity to study these shell effects is offered by the Si-42 nucleus, which has 28 neutrons-a magic number in stable nuclei-and 14 protons. This nucleus has a 12-neutron excess over the heaviest stable silicon nuclide, and has only one neutron fewer than the heaviest silicon nuclide observed so far(5). Here we report measurements of Si-42 and two neighbouring nuclei using a technique involving one- and two-nucleon knockout from beams of exotic nuclei(6,7). We present strong evidence for a well-developed proton subshell closure at Z = 14 (14 protons), the near degeneracy of two different (s(1/2) and d(3/2)) proton orbits in the vicinity of Si-42, and a nearly spherical shape for Si-42.	Florida State Univ, Dept Phys, Tallahassee, FL 32306 USA; Michigan State Univ, Natl Superconducting Cyclotron Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Phys & Astron, E Lansing, MI 48824 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Nucl Sci, Berkeley, CA 94720 USA; Univ Surrey, Sch Elect & Phys Sci, Dept Phys, Surrey GU2 7XH, England	State University System of Florida; Florida State University; Michigan State University; Michigan State University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Surrey	Cottle, PD (corresponding author), Florida State Univ, Dept Phys, Tallahassee, FL 32306 USA.	cottle@phy.fsu.edu	Glasmacher, Thomas/H-9673-2014; Gade, Alexandra/A-6850-2008; Bazin, Daniel/N-1226-2019; Campbell, Christopher/B-9429-2008; Glasmacher, Thomas/C-4462-2008	Glasmacher, Thomas/0000-0001-9436-2448; Gade, Alexandra/0000-0001-8825-0976; Bazin, Daniel/0000-0002-5663-9693; Campbell, Christopher/0000-0003-3577-4316; 				Bazin D, 2003, NUCL INSTRUM METH B, V204, P629, DOI 10.1016/S0168-583X(02)02142-0; Bazin D, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.012501; Brown B.A, 2004, 1289 MSUNSCL; Caurier E, 2004, NUCL PHYS A, V742, P14, DOI 10.1016/j.nuclphysa.2004.06.032; Cottle PD, 1998, PHYS REV C, V58, P3761, DOI 10.1103/PhysRevC.58.3761; DOLL P, 1976, NUCL PHYS A, V263, P210, DOI 10.1016/0375-9474(76)90169-X; Duflo J, 1999, PHYS REV C, V59, pR2347, DOI 10.1103/PhysRevC.59.R2347; Gade A, 2004, PHYS REV C, V69, DOI 10.1103/PhysRevC.69.034311; Grevy S, 2004, PHYS LETT B, V594, P252, DOI 10.1016/j.physletb.2004.06.005; Hansen PG, 2003, ANNU REV NUCL PART S, V53, P219, DOI 10.1146/annurev.nucl.53.041002.110406; HAXEL O, 1949, PHYS REV, V75, P1766, DOI 10.1103/PhysRev.75.1766.2; Lalazissis GA, 1999, PHYS REV C, V60, DOI 10.1103/PhysRevC.60.014310; Lalazissis GA, 1998, NUCL PHYS A, V628, P221, DOI 10.1016/S0375-9474(97)00630-1; MAYER MG, 1949, PHYS REV, V75, P1969, DOI 10.1103/PhysRev.75.1969; Morrissey DJ, 2003, NUCL INSTRUM METH B, V204, P90, DOI 10.1016/S0168-583X(02)01895-5; Mueller WF, 2001, NUCL INSTRUM METH A, V466, P492, DOI 10.1016/S0168-9002(01)00257-1; Nazarewicz W, 2001, NUCL PHYS A, V682, p295C, DOI 10.1016/S0375-9474(00)00659-X; Notani M, 2002, PHYS LETT B, V542, P49, DOI 10.1016/S0370-2693(02)02337-7; Nummela S, 2001, PHYS REV C, V63, DOI 10.1103/PhysRevC.63.044316; Peru S, 2000, EUR PHYS J A, V9, P35, DOI 10.1007/s100500070053; Rodriguez-Guzman R, 2002, PHYS REV C, V65, DOI 10.1103/PhysRevC.65.024304; Schiffer JP, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.162501; Terasaki J, 1997, NUCL PHYS A, V621, P706, DOI 10.1016/S0375-9474(97)00183-8; Tostevin JA, 2004, PHYS REV C, V70, DOI 10.1103/PhysRevC.70.064602; Tostevin JA, 2001, NUCL PHYS A, V682, p320C, DOI 10.1016/S0375-9474(00)00656-4; Warner D, 2004, NATURE, V430, P517, DOI 10.1038/430517a; WERNER TR, 1994, PHYS LETT B, V333, P303, DOI 10.1016/0370-2693(94)90146-5; Werner TR, 1996, NUCL PHYS A, V597, P327, DOI 10.1016/0375-9474(95)00476-9	28	92	95	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					922	924		10.1038/nature03619	http://dx.doi.org/10.1038/nature03619			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15959511	Green Submitted			2022-12-28	WOS:000229799700041
J	Cyranoski, D				Cyranoski, D			Masking our ignorance	NATURE			English	News Item																			0	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2005	435	7041					408	408						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15952257				2022-12-28	WOS:000229337800018
J	Kim, TH; Barrera, LO; Zheng, M; Qu, CX; Singer, MA; Richmond, TA; Wu, YN; Green, RD; Ren, B				Kim, TH; Barrera, LO; Zheng, M; Qu, CX; Singer, MA; Richmond, TA; Wu, YN; Green, RD; Ren, B			A high-resolution map of active promoters in the human genome	NATURE			English	Article							EXPRESSED GENES; IDENTIFICATION; TRANSCRIPTOME; SEQUENCE; UPDATE; MOUSE	In eukaryotic cells, transcription of every protein-coding gene begins with the assembly of an RNA polymerase II preinitiation complex (PIC) on the promoter(1). The promoters, in conjunction with enhancers, silencers and insulators, define the combinatorial codes that specify gene expression patterns(2). Our ability to analyse the control logic encoded in the human genome is currently limited by a lack of accurate information regarding the promoters for most genes(3). Here we describe a genome-wide map of active promoters in human fibroblast cells, determined by experimentally locating the sites of PIC binding throughout the human genome. This map defines 10,567 active promoters corresponding to 6,763 known genes and at least 1,196 un-annotated transcriptional units. Features of the map suggest extensive use of multiple promoters by the human genes and widespread clustering of active promoters in the genome. In addition, examination of the genome-wide expression profile reveals four general classes of promoters that define the transcriptome of the cell. These results provide a global view of the functional relationships among transcriptional machinery, chromatin structure and gene expression in human cells.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Moores Canc Ctr, La Jolla, CA 92093 USA; Univ Calif Los Angeles, Dept Stat, Los Angeles, CA 90095 USA; NimbleGen Syst Inc, Madison, WI 53711 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California Los Angeles; Roche Holding; Roche NimbleGen	Ren, B (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, 9500 Gilman Dr, La Jolla, CA 92093 USA.	biren@ucsd.edu		Soriaga, Leah/0000-0001-5852-741X; Kim, Tae Hoon/0000-0003-3950-7557	NCI NIH HHS [R33 CA105829, R21 CA105829, F32 CA108313] Funding Source: Medline; NHGRI NIH HHS [U01 HG003151] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA105829, R33CA105829] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG003151] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Benson DA, 2004, NUCLEIC ACIDS RES, V32, pD23, DOI 10.1093/nar/gkh045; Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388; Birney E, 2004, NUCLEIC ACIDS RES, V32, pD468, DOI 10.1093/nar/gkh038; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; *ENCODE PROJ CONS, 2001, SCIENCE, V306, P636; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kim TH, 2005, GENOME RES, V15, P830, DOI 10.1101/gr.3430605; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Ohler U., 2002, GENOME BIOL, V3, pRESEARCH0087, DOI [10.1186/gb-2002-3-12-research0087, DOI 10.1186/GB-2002-3-12-RESEARCH0087]; Pruitt KD, 2003, NUCLEIC ACIDS RES, V31, P34, DOI 10.1093/nar/gkg111; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Roy PJ, 2002, NATURE, V418, P975, DOI 10.1038/nature01012; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Singh-Gasson S, 1999, NAT BIOTECHNOL, V17, P974, DOI 10.1038/13664; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Spellman Paul T, 2002, J Biol, V1, P5, DOI 10.1186/1475-4924-1-5; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Suzuki Y, 2004, NUCLEIC ACIDS RES, V32, pD78, DOI 10.1093/nar/gkh076; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Trinklein ND, 2003, GENOME RES, V13, P308, DOI 10.1101/gr.794803; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896	30	727	759	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	2005	436	7052					876	880		10.1038/nature03877	http://dx.doi.org/10.1038/nature03877			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953XG	15988478	Green Accepted			2022-12-28	WOS:000231116500052
J	Shakarishvili, A; Dubovskaya, LK; Zohrabyan, LS; St Lawrence, JS; Aral, SO; Dugasheva, LG; Okan, SA; Lewis, JS; Parker, KA; Ryan, CA				Shakarishvili, A; Dubovskaya, LK; Zohrabyan, LS; St Lawrence, JS; Aral, SO; Dugasheva, LG; Okan, SA; Lewis, JS; Parker, KA; Ryan, CA		LIBRA Project Investigation Team	Sex work, drug use, HIV infection, and spread of sexually transmitted infections in Moscow, Russian Federation	LANCET			English	Article								Rates of HIV-1 infection are growing rapidly, and the epidemic of sexually transmitted infections is continuing at an alarming rate, in the Russian Federation. We did a cross-sectional study of sexually transmitted infections, HIV infection, and drug use in street youth at a juvenile detention facility, adults at homeless detention centres, and women and men at a remand Centre in Moscow. 160 (79%) women at the remand Centre were sex workers. 91 (51%) homeless women had syphilis. At least one bacterial sexually transmitted infection was present in 97 (58%) female juvenile detainees, 120 (64%) women at the remand Centre, and 133 (75%) homeless women. HIV seroprevalence was high in women at the remand Centre (n=7 [4%]), adolescent male detainees (5 [3%]), and homeless women (4 [2%]). In view of the interaction between sexually transmitted infections and HIV infection, these findings of high prevalence of sexually transmitted infections show that these disenfranchised populations have the potential to make a disproportionately high contribution to the explosive growth of the HIV epidemic unless interventions targeting these groups are implemented in the Russian Federation.	US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Russian Assoc Prevent STIs Sanam, Moscow, Russia; Sechenov Moscow Med Acad, Moscow, Russia	Centers for Disease Control & Prevention - USA; Sechenov First Moscow State Medical University	Shakarishvili, A (corresponding author), US Ctr Dis Control & Prevent, Mail Stop E-04,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	afsg@cdc.gov						Aral SO, 2003, SEX TRANSM DIS, V30, P39, DOI 10.1097/00007435-200301000-00009; Field MG, 2004, NEW ENGL J MED, V351, P117, DOI 10.1056/NEJMp048066; Lowndes C. M., 2003, International Journal of Drug Policy, V14, P45, DOI 10.1016/S0955-3959(02)00208-6; *MOSC CIT HLTH COM, 2002, SAN EP SURV REP HIV; *MOSC CIT HLTH COM, 2001, SAN EP SURV REP HIV; *UN, 2004, HIV AIDS E EUR COMM	6	54	54	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	2005	366	9479					57	60		10.1016/S0140-6736(05)66828-6	http://dx.doi.org/10.1016/S0140-6736(05)66828-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993234				2022-12-28	WOS:000230277600035
J	Pain, A; Renauld, H; Berriman, M; Murphy, L; Yeats, CA; Weir, W; Kerhornou, A; Aslett, M; Bishop, R; Bouchier, C; Cochet, M; Coulson, RMR; Cronin, A; de Villiers, EP; Fraser, A; Fosker, N; Gardner, M; Goble, A; Griffiths-Jones, S; Harris, DE; Katzer, F; Larke, N; Lord, A; Maser, P; McKellar, S; Mooney, P; Morton, F; Nene, V; O'Neil, S; Price, C; Quail, MA; Rabbinowitsch, E; Rawlings, ND; Rutter, S; Saunders, D; Seeger, K; Shah, T; Squares, R; Squares, S; Tivey, A; Walker, AR; Woodard, J; Dobbelaere, DAE; Langsley, G; Rajandream, MA; McKeever, D; Shiels, B; Tait, A; Barrell, B; Hall, N				Pain, A; Renauld, H; Berriman, M; Murphy, L; Yeats, CA; Weir, W; Kerhornou, A; Aslett, M; Bishop, R; Bouchier, C; Cochet, M; Coulson, RMR; Cronin, A; de Villiers, EP; Fraser, A; Fosker, N; Gardner, M; Goble, A; Griffiths-Jones, S; Harris, DE; Katzer, F; Larke, N; Lord, A; Maser, P; McKellar, S; Mooney, P; Morton, F; Nene, V; O'Neil, S; Price, C; Quail, MA; Rabbinowitsch, E; Rawlings, ND; Rutter, S; Saunders, D; Seeger, K; Shah, T; Squares, R; Squares, S; Tivey, A; Walker, AR; Woodard, J; Dobbelaere, DAE; Langsley, G; Rajandream, MA; McKeever, D; Shiels, B; Tait, A; Barrell, B; Hall, N			Genome of the host-cell transforming parasite Theileria annulata compared with T-parva	SCIENCE			English	Article							DNA-BINDING PROTEIN; GENES; PATHOGEN; NUCLEUS	Theileria annulata and T. parva are closely related protozoan parasites that cause lymphoproliferative diseases of cattle. We sequenced the genome of T. annulata and compared it with that of T. parva to understand the mechanisms underlying transformation and tropism. Despite high conservation of gene sequences and synteny, the analysis reveals unequally expanded gene families and species-specific genes. We also identify divergent families of putative secreted polypeptides that may reduce immune recognition, candidate regulators of host-cell transformation, and a Theileria-specific protein domain [frequently associated in Theileria (FAINT)] present in a large number of secreted proteins.	Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Moredun Res Inst, Penicuik EH26 0PZ, Midlothian, Scotland; Univ Bern, Inst Anim Pathol, CH-3012 Bern, Switzerland; Univ Bern, Inst Cell Biol, CH-3012 Bern, Switzerland; Easter Bush Vet Ctr, Royal Sch Vet Studies, Div Vet Clin Studies, Roslin EH25 9RG, Midlothian, Scotland; Inst Genom Res, TIGR, Rockville, MD 20850 USA; European Bioinformat Inst, European Mol Biol Lab, Cambridge CB10 1SD, England; Inst Pasteur, Dept Parasitol, CNRS, URA 2581, F-75724 Paris, France; Inst Pasteur, Plate Forme Genom Pasteur Genopole Ile France, F-75724 Paris, France; Int Livestock Res Inst, Nairobi, Kenya; Fac Vet Med, Inst Comparat Med, Parasitol Grp, Div Vet Infect & Immun, Glasgow G61 1QH, Lanark, Scotland	Wellcome Trust Sanger Institute; Moredun Research Institute; University of Bern; University of Bern; University of Edinburgh; J. Craig Venter Institute; European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CGIAR; International Livestock Research Institute (ILRI); University of Glasgow	Pain, A (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	ap2@sanger.ac.uk	Rawlings, Neil/M-5566-2013; Katzer, Frank/AAG-2042-2020; Quail, michael/ABE-6131-2020; Dobbelaere, Dirk/A-3885-2013; Hall, Neil/A-8717-2013; Pain, Arnab/L-5766-2015; Rawlings, Neil D./I-4867-2012; Berriman, Matthew/A-7618-2011; Griffiths-Jones, Sam/H-2998-2014	Rawlings, Neil/0000-0001-5557-7665; Katzer, Frank/0000-0001-5902-4136; Dobbelaere, Dirk/0000-0003-0672-8468; Hall, Neil/0000-0002-7995-3810; Pain, Arnab/0000-0002-1755-2819; Berriman, Matthew/0000-0002-9581-0377; Weir, William/0000-0001-8648-666X; Shiels, Brian/0000-0001-7595-2514; Maser, Pascal/0000-0003-3122-1941; Murphy, Lee/0000-0001-6467-7449; Hall, Neil/0000-0003-2808-0009; de Villiers, Etienne/0000-0001-9878-1009; Kerhornou, Arnaud/0000-0002-2890-295X; Griffiths-Jones, Sam/0000-0001-6043-807X; Shah, Trushar/0000-0002-0091-7981; Nene, Vishvanath/0000-0001-7066-4169; Morton, Fraser/0000-0001-5328-9467	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP MTEP, 1994, PARASITOLOGY, V108, P147, DOI 10.1017/S0031182000068232; Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Barry JD, 2003, INT J PARASITOL, V33, P29, DOI 10.1016/S0020-7519(02)00247-3; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BAYLIS HA, 1991, MOL BIOCHEM PARASIT, V49, P133, DOI 10.1016/0166-6851(91)90136-T; de Molina AR, 2002, ONCOGENE, V21, P4317, DOI 10.1038/sj.onc.1205556; Dobbelaere DAE, 2004, CURR OPIN IMMUNOL, V16, P524, DOI 10.1016/j.coi.2004.05.009; Endo T, 1996, MOL BIOL EVOL, V13, P685, DOI 10.1093/oxfordjournals.molbev.a025629; Forsyth LMG, 1999, J COMP PATHOL, V120, P39, DOI 10.1053/jcpa.1998.0256; Gardner MJ, 2005, SCIENCE, V309, P134, DOI 10.1126/science.1110439; Gubbels MJ, 2001, PARASITOLOGY, V123, P553, DOI 10.1017/S0031182001008757; Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717; Kanzaki A, 2002, INT J CANCER, V97, P631, DOI 10.1002/ijc.10105; Lee I, 2004, TRENDS BIOCHEM SCI, V29, P567, DOI 10.1016/j.tibs.2004.09.005; Mehlhorn H, 1998, PARASITOL RES, V84, P467, DOI 10.1007/s004360050431; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Shiels BR, 2004, EUKARYOT CELL, V3, P495, DOI 10.1128/EC.3.2.495-505.2004; Sved P, 2004, CANCER RES, V64, P6934, DOI 10.1158/0008-5472.CAN-03-3018; Swan DG, 1999, MOL BIOCHEM PARASIT, V101, P117, DOI 10.1016/S0166-6851(99)00064-X; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682	20	236	286	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					131	133		10.1126/science.1110418	http://dx.doi.org/10.1126/science.1110418			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994557				2022-12-28	WOS:000230212800075
J	Cronenwett, JL				Cronenwett, JL			Endovascular aneurysm repair: important mid-term results	LANCET			English	Editorial Material							ABDOMINAL AORTIC-ANEURYSM; EXPERIENCE; EUROSTAR; TRIAL		Dartmouth Hitchcock Med Ctr, Vasc Surg Sect, Lebanon, NH 03755 USA	Dartmouth College	Cronenwett, JL (corresponding author), Dartmouth Hitchcock Med Ctr, Vasc Surg Sect, Lebanon, NH 03755 USA.	jack.cronenwett@hitchcock.org						Adriaensen MEAPM, 2002, RADIOLOGY, V224, P739, DOI 10.1148/radiol.2243011675; Anderson PL, 2004, J VASC SURG, V39, P10, DOI 10.1016/j.jvs.2003.07.020; Greenhalgh RM, 2004, LANCET, V364, P843, DOI 10.1016/S0140-6736(04)16979-1; Hallett JW, 1997, J VASC SURG, V25, P277, DOI 10.1016/S0741-5214(97)70349-5; Harris Peter L, 2004, Vascular, V12, P33; Harris PL, 2000, J VASC SURG, V32, P739, DOI 10.1067/mva.2000.109990; Lee WA, 2004, J VASC SURG, V39, P491, DOI 10.1016/j.jvs.2003.12.001; Peppelenbosch N, 2004, J VASC SURG, V39, P288, DOI 10.1016/j.jvs.2003.09.047; Prinssen M, 2004, NEW ENGL J MED, V351, P1607, DOI 10.1056/NEJMoa042002; Schermerhorn ML, 2002, J VASC SURG, V36, P1112, DOI 10.1067/mva.2002.129646	10	32	33	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 25	2005	365	9478					2156	2158		10.1016/S0140-6736(05)66629-9	http://dx.doi.org/10.1016/S0140-6736(05)66629-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978908				2022-12-28	WOS:000230034800006
J	Walshe, K; Benson, L				Walshe, K; Benson, L			GMC and the future of revalidation - Time for radical reform	BRITISH MEDICAL JOURNAL			English	Article								Changes to UK professional regulation have lacked strategic direction. The cur-rent reviews offer an opportunity for fundamental reform that can regain public confidence	Manchester Business Sch, Ctr Publ Policy & Management, Manchester M15 6PB, Lancs, England	University of Manchester	Walshe, K (corresponding author), Manchester Business Sch, Ctr Publ Policy & Management, Manchester M15 6PB, Lancs, England.	Kieran.Walshe@man.ac.uk		Walshe, Kieran/0000-0002-0696-480X				Allsop J., 2004, REGULATION HLTH PROF; [Anonymous], 2004, COMM INQ INV NHS HAN; *COMM HLTH IMPR, 2001, INV ISS AR CAS LOUGH; *DEP HLTH, 2004, COMM INQ IND INV NHS; *DEP HLTH, 2000, INQ QUAL PRACT NAT H; *DEP HLTH, 2000, HLTH SERV TAL; ESMAIL A, 2005, BRIT MED J, P1144; Irvine D., 2003, DOCTORS TALE PROFESS; Kennedy I, 2001, LEARNING BRISTOL REP; Oneill O., 2002, QUESTION TRUST BBC R; REID J, 2005, HOUSE COMMONS OFFICI; RREDFERN M, 2001, ROYAL LIVERPOOL CHIL; Smith J., 2004, 5 STAT OFF; Walshe K, 2002, BRIT MED J, V325, P895, DOI 10.1136/bmj.325.7369.895; Walshe K., 2003, REGULATING HEALTHCAR	15	10	10	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 25	2005	330	7506					1504	1506		10.1136/bmj.330.7506.1504	http://dx.doi.org/10.1136/bmj.330.7506.1504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942NR	15976427	Green Published			2022-12-28	WOS:000230289600027
J	Ammann, P; Sticherling, C; Kalusche, D; Eckstein, J; Bernheim, A; Schaer, B; Osswald, S				Ammann, P; Sticherling, C; Kalusche, D; Eckstein, J; Bernheim, A; Schaer, B; Osswald, S			An electrocardiogram-based algorithm to detect loss of left ventricular capture during cardiac resynchronization therapy	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC HEART-FAILURE; BUNDLE-BRANCH-BLOCK; DEFIBRILLATION; ASYNCHRONY; MORTALITY; TRIAL; SITE	Background: Loss of left ventricular capture in patients with cardiac resynchronization devices may account for worsening heart failure and can be difficult to diagnose without a programmer. Objective: To determine whether distinct morphologic changes on the surface electrocardiogram indicate loss of left ventricular capture. Design: After analysis of the R-S spike ratio in the 12-lead electrocardiogram during right ventricular and biventricular pacing in 10 patients, an algorithm to detect loss of left ventricular capture was developed. Setting: University hospital. Patients: 54 patients with a cardiac resynchronization device and underlying left bundle-branch block. Measurements: Leads V1 and I of a 12-lead electrocardiogram were assessed after biventricular pacing was confirmed and after the device was programmed to right ventricular pacing only (simulating loss of left ventricular capture). Results: The sensitivity of the algorithm to correctly identify loss of left ventricular capture was 94% (95% Cl, 88.2% to 97.7%), and the specificity was 93% (Cl, 86.3% to 95.8%). The likelihood ratio of a positive test result was 12.8 (Cl, 6.443 to 23.310), and the likelihood ratio of a negative test result was 0.06 (Cl, 0.024 to 0.137). Limitations: The algorithm was tested in patients in whom the right ventricular electrode was placed in the apex of the right ventricle only. Conclusion: Presence of biventricular capture-the prerequisite for successful cardiac resynchronization therapy-and loss of left ventricular capture can be accurately detected by an algorithm based on analysis of the R-S ratio on leads V1 and I of the surface electrocardiogram.	Univ Basel Hosp, CH-4031 Basel, Switzerland; Kantonsspital St Gallen, St Gallen, Switzerland; Herz Zentrum Bad Krozingen, Bad Krozingen, Germany	University of Basel	Ammann, P (corresponding author), Univ Basel Hosp, CH-4031 Basel, Switzerland.	peter.ammann@kssg.ch	Osswald, Stefan/A-6904-2018; Sticherling, Christian/AAY-4435-2021	Osswald, Stefan/0000-0002-9240-6731; Sticherling, Christian/0000-0001-8428-7050				Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Auricchio A, 1999, AM J CARDIOL, V83, p136D; Bradley DJ, 2003, JAMA-J AM MED ASSOC, V289, P730, DOI 10.1001/jama.289.6.730; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Bristow MR, 2000, J CARD FAIL, V6, P276, DOI 10.1054/jcaf.2000.9501; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Eriksson P, 1998, CIRCULATION, V98, P2494, DOI 10.1161/01.CIR.98.22.2494; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Garrigue S, 2001, AM J CARDIOL, V88, P1436, DOI 10.1016/S0002-9149(01)02131-2; GRINES CL, 1989, CIRCULATION, V79, P845, DOI 10.1161/01.CIR.79.4.845; Janousek J, 2004, J AM COLL CARDIOL, V44, P1927, DOI 10.1016/j.jacc.2004.08.044; Meisel E, 2001, CIRCULATION, V104, P442, DOI 10.1161/hc2901.093145; Muntwyler J, 2002, EUR HEART J, V23, P1861, DOI 10.1053/euhj.2002.3282; Pitzalis MV, 2002, J AM COLL CARDIOL, V40, P1615, DOI 10.1016/S0735-1097(02)02337-9; Ricci R, 2002, J INTERV CARD ELECTR, V6, P279, DOI 10.1023/A:1019570022647; Yee R, 2004, PACE, V27, P894, DOI 10.1111/j.1540-8159.2004.00553.x; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685	18	32	34	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	1				968	973		10.7326/0003-4819-142-12_Part_1-200506210-00006	http://dx.doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937IN	15968011				2022-12-28	WOS:000229917900003
J	Scott, TF; Schneider, AD; Cook, WD; Bowman, CN				Scott, TF; Schneider, AD; Cook, WD; Bowman, CN			Photoinduced plasticity in cross-linked polymers	SCIENCE			English	Article							RING-OPENING POLYMERIZATION; CONTROLLED MOLECULAR-WEIGHT; CYCLIC ALLYLIC SULFIDES	Chemically cross-linked polymers are inherently limited by stresses that are introduced by post-gelation volume changes during polymerization. It is also difficult to change a cross-linked polymer's shape without a corresponding loss of material properties or substantial stress development. We demonstrate a cross-linked polymer that, upon exposure to light, exhibits stress and/or strain relaxation without any concomitant change in material properties. This result is achieved by introducing radicals via photocleavage of residual photoinitiator in the polymer matrix, which then diffuse via addition-fragmentation chain transfer of midchain functional groups. These processes lead to photoinduced plasticity, actuation, and equilibrium shape changes without residual stress. Such polymeric materials are critical to the development of microdevices, biomaterials, and polymeric coatings.	Univ Colorado, Dept Biol & Chem Engn, Boulder, CO 80309 USA; Monash Univ, Sch Phys & Mat Engn, Clayton, Vic 3800, Australia	University of Colorado System; University of Colorado Boulder; Monash University	Bowman, CN (corresponding author), Univ Colorado, Dept Biol & Chem Engn, Boulder, CO 80309 USA.	christopher.bowman@colorado.edu	Bowman, Christopher N/B-1490-2008; Cook, Wayne D/A-4787-2012	Bowman, Christopher N/0000-0001-8458-7723; 	NIDCR NIH HHS [DE12998, DE10959] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010959, R29DE010959, R01DE012998] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adhikari B, 2000, PROG POLYM SCI, V25, P909, DOI 10.1016/S0079-6700(00)00020-4; BILLMEYER FW, 1984, TXB POLYM SCI, P436; Chen XX, 2002, SCIENCE, V295, P1698, DOI 10.1126/science.1065879; Cramer NB, 2001, J POLYM SCI POL CHEM, V39, P3311, DOI 10.1002/pola.1314; Evans RA, 2001, J POLYM SCI POL CHEM, V39, P202, DOI 10.1002/1099-0518(20010101)39:1<202::AID-POLA230>3.0.CO;2-6; Evans RA, 1996, MACROMOLECULES, V29, P6983, DOI 10.1021/ma960573p; EVANS RA, 1994, MACROMOLECULES, V27, P7935, DOI 10.1021/ma00104a062; Evans RA, 2000, MACROMOLECULES, V33, P6722, DOI 10.1021/ma9917646; Kim BK, 1996, POLYMER, V37, P5781, DOI 10.1016/S0032-3861(96)00442-9; Lendlein A, 2001, P NATL ACAD SCI USA, V98, P842, DOI 10.1073/pnas.031571398; MEIJS GF, 1991, MACROMOLECULES, V24, P3689, DOI 10.1021/ma00012a033; MEIJS GF, 1988, MACROMOLECULES, V21, P3122, DOI 10.1021/ma00188a039; Sanda F, 2001, J POLYM SCI POL CHEM, V39, P265, DOI 10.1002/1099-0518(20010115)39:2<265::AID-POLA20>3.3.CO;2-4; Sunder A, 1999, MACROMOL CHEM PHYSIC, V200, P58, DOI 10.1002/(SICI)1521-3935(19990101)200:1<58::AID-MACP58>3.0.CO;2-C	14	546	562	16	369	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1615	1617		10.1126/science.1110505	http://dx.doi.org/10.1126/science.1110505			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947185				2022-12-28	WOS:000229827000053
J	DiLuzio, WR; Turner, L; Mayer, M; Garstecki, P; Weibel, DB; Berg, HC; Whitesides, GM				DiLuzio, WR; Turner, L; Mayer, M; Garstecki, P; Weibel, DB; Berg, HC; Whitesides, GM			Escherichia coli swim on the right-hand side	NATURE			English	Article							3-DIMENSIONAL TRACKING; FLAGELLAR FILAMENTS; MOTILITY; CHEMOTAXIS; BACTERIA; SURFACE; DIFFERENTIATION; TYPHIMURIUM; MICROSCOPY; MUTANTS	The motion of peritrichously flagellated bacteria close to surfaces is relevant to understanding the early stages of biofilm formation and of pathogenic infection(1-4). This motion differs from the random-walk trajectories(5) of cells in free solution. Individual Escherichia coli cells swim in clockwise, circular trajectories near planar glass surfaces(6,7). On a semi-solid agar substrate, cells differentiate into an elongated, hyperflagellated phenotype and migrate cooperatively over the surface(8), a phenomenon called swarming. We have developed a technique for observing isolated E. coli swarmer cells(9) moving on an agar substrate and confined in shallow, oxidized poly( dimethylsiloxane) ( PDMS) microchannels. Here we show that cells in these microchannels preferentially 'drive on the right', swimming preferentially along the right wall of the microchannel ( viewed from behind the moving cell, with the agar on the bottom). We propose that when cells are confined between two interfaces - one an agar gel and the second PDMS they swim closer to the agar surface than to the PDMS surface ( and for much longer periods of time), leading to the preferential movement on the right of the microchannel. Thus, the choice of materials guides the motion of cells in microchannels.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Harvard Univ, Rowland Inst, Cambridge, MA 02142 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Harvard University; Harvard University; Harvard University	Whitesides, GM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	gwhitesides@gmwgroup.harvard.edu	Garstecki, Piotr/ABA-9188-2020; Mayer, Michael/C-1299-2010; Mayer, Michael/AAS-1777-2020	Garstecki, Piotr/0000-0001-9101-7163; Mayer, Michael/0000-0002-6148-5756; 				ALLISON C, 1992, MOL MICROBIOL, V6, P1583; ARMSTRONG JB, 1967, J BACTERIOL, V93, P390, DOI 10.1128/JB.93.1.390-398.1967; Berg HC, 2003, ANNU REV BIOCHEM, V72, P19, DOI 10.1146/annurev.biochem.72.121801.161737; BERG HC, 1973, NATURE, V245, P380, DOI 10.1038/245380a0; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; BERG HC, 1990, BIOPHYS J, V58, P919, DOI 10.1016/S0006-3495(90)82436-X; Biondi SA, 1998, AICHE J, V44, P1923, DOI 10.1002/aic.690440822; Brandrup J., 1999, POLYM HDB, V4th; Damiano ER, 2004, J FLUID MECH, V500, P75, DOI 10.1017/S0022112003006566; Darnton N, 2004, BIOPHYS J, V86, P1863, DOI 10.1016/S0006-3495(04)74253-8; FRYMIER PD, 1995, P NATL ACAD SCI USA, V92, P6195, DOI 10.1073/pnas.92.13.6195; Frymier PD, 1997, AICHE J, V43, P1341, DOI 10.1002/aic.690430523; Harshey RM, 2003, ANNU REV MICROBIOL, V57, P249, DOI 10.1146/annurev.micro.57.030502.091014; HARSHEY RM, 1994, P NATL ACAD SCI USA, V91, P8631, DOI 10.1073/pnas.91.18.8631; HENRICHSEN J, 1972, BACTERIOL REV, V36, P478, DOI 10.1128/MMBR.36.4.478-503.1972; Ottemann KM, 1997, MOL MICROBIOL, V24, P1109, DOI 10.1046/j.1365-2958.1997.4281787.x; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; Pernodet N, 1997, ELECTROPHORESIS, V18, P55, DOI 10.1002/elps.1150180111; Pratt LA, 1998, MOL MICROBIOL, V30, P285, DOI 10.1046/j.1365-2958.1998.01061.x; RAMIA M, 1993, BIOPHYS J, V65, P755, DOI 10.1016/S0006-3495(93)81129-9; TAYLOR G, 1952, PROC R SOC LON SER-A, V211, P225, DOI 10.1098/rspa.1952.0035; Toguchi A, 2000, J BACTERIOL, V182, P6308, DOI 10.1128/JB.182.22.6308-6321.2000; Turner L, 2000, J BACTERIOL, V182, P2793, DOI 10.1128/JB.182.10.2793-2801.2000; Vigeant MAS, 1997, APPL ENVIRON MICROB, V63, P3474, DOI 10.1128/AEM.63.9.3474-3479.1997; Vigeant MAS, 2002, APPL ENVIRON MICROB, V68, P2794, DOI 10.1128/AEM.68.6.2794-2801.2002; Visick KL, 2000, J BACTERIOL, V182, P1779, DOI 10.1128/JB.182.7.1779-1787.2000; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G	28	328	333	4	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1271	1274		10.1038/nature03660	http://dx.doi.org/10.1038/nature03660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988531				2022-12-28	WOS:000230140500051
J	Paciorek, T; Zazimalova, E; Ruthardt, N; Petrasek, J; Stierhof, YD; Kleine-Vehn, J; Morris, DA; Emans, N; Jurgens, G; Geldner, N; Friml, J				Paciorek, T; Zazimalova, E; Ruthardt, N; Petrasek, J; Stierhof, YD; Kleine-Vehn, J; Morris, DA; Emans, N; Jurgens, G; Geldner, N; Friml, J			Auxin inhibits endocytosis and promotes its own efflux from cells	NATURE			English	Article							BREFELDIN-A; ARABIDOPSIS; TRANSPORT; LOCALIZATION; GRADIENTS; GENE; ACCUMULATION; MUTATIONS; MECHANISM; HORMONE	One of the mechanisms by which signalling molecules regulate cellular behaviour is modulating subcellular protein translocation. This mode of regulation is often based on specialized vesicle trafficking, termed constitutive cycling, which consists of repeated internalization and recycling of proteins to and from the plasma membrane(1). No such mechanism of hormone action has been shown in plants although several proteins, including the PIN auxin efflux facilitators, exhibit constitutive cycling(2,3). Here we show that a major regulator of plant development, auxin, inhibits endocytosis. This effect is specific to biologically active auxins and requires activity of the Calossin-like protein BIG. By inhibiting the internalization step of PIN constitutive cycling, auxin increases levels of PINs at the plasma membrane. Concomitantly, auxin promotes its own efflux from cells by a vesicle-trafficking-dependent mechanism. Furthermore, asymmetric auxin translocation during gravitropism is correlated with decreased PIN internalization. Our data imply a previously undescribed mode of plant hormone action: by modulating PIN protein trafficking, auxin regulates PIN abundance and activity at the cell surface, providing a mechanism for the feedback regulation of auxin transport.	Univ Tubingen, Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany; ASCR, Inst Expt Bot, Prague 16502 6, Czech Republic; Rhein Westfal TH Aachen, Cellome Res Grp, D-52074 Aachen, Germany; Univ Southampton, Sch Biol Sci, Southampton SO16 7PX, Hants, England	Eberhard Karls University of Tubingen; Czech Academy of Sciences; Institute of Experimental Botany of the Czech Academy of Sciences; RWTH Aachen University; University of Southampton	Friml, J (corresponding author), Univ Tubingen, Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany.	jiri.friml@zmbp.uni-tuebingen.de	Eva, Zazimalova/G-7432-2014; Kleine-Vehn, Jürgen/C-8984-2014; Friml, Jiri/D-9511-2012; Geldner, Niko/Y-2481-2019; Petrasek, Jan/AAW-1081-2021; Petrasek, Jan/C-8240-2009	Eva, Zazimalova/0000-0002-8325-7092; Kleine-Vehn, Jürgen/0000-0002-4354-3756; Friml, Jiri/0000-0002-8302-7596; Petrasek, Jan/0000-0002-6719-2735; Petrasek, Jan/0000-0002-6719-2735; Geldner, Niko/0000-0002-2300-9644				Baluska F, 2002, PLANT PHYSIOL, V130, P422, DOI 10.1104/pp.007526; Benkova E, 2003, CELL, V115, P591, DOI 10.1016/S0092-8674(03)00924-3; Berleth T, 2001, CURR OPIN PLANT BIOL, V4, P57, DOI 10.1016/S1369-5266(00)00136-9; BOERJAN W, 1995, PLANT CELL, V7, P1405, DOI 10.1105/tpc.7.9.1405; Cutler SR, 2000, P NATL ACAD SCI USA, V97, P3718, DOI 10.1073/pnas.97.7.3718; Delarue M, 1999, PHYSIOL PLANTARUM, V107, P120, DOI 10.1034/j.1399-3054.1999.100116.x; Delbarre A, 1996, PLANTA, V198, P532, DOI 10.1007/BF00262639; Emans N, 2002, PLANT CELL, V14, P71, DOI 10.1105/tpc.010339; Friml J, 2003, CURR OPIN PLANT BIOL, V6, P7, DOI 10.1016/S1369526602000031; Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a; Friml J, 2003, PLANT J, V34, P115, DOI 10.1046/j.1365-313X.2003.01705.x; Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6; Friml J, 2003, NATURE, V426, P147, DOI 10.1038/nature02085; Gadow A. von, 1997, Journal of Agricultural and Food Chemistry, V45, P632, DOI 10.1021/jf960281n; Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571; Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5; Gil P, 2001, GENE DEV, V15, P1985, DOI 10.1101/gad.905201; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; Kanyuka K, 2003, PLANT J, V35, P57, DOI 10.1046/j.1365-313X.2003.01779.x; KARLINNEUMANN GA, 1991, PLANT CELL, V3, P573, DOI 10.1105/tpc.3.6.573; Morris DA, 2000, PLANT GROWTH REGUL, V32, P161, DOI 10.1023/A:1010701527848; Petrasek J, 2003, PLANT PHYSIOL, V131, P254, DOI 10.1104/pp.012740; Petrasek J, 2002, PLANTA, V216, P302, DOI 10.1007/s00425-002-0845-y; Pimpl P, 2000, PLANT CELL, V12, P2219, DOI 10.1105/tpc.12.11.2219; Richards S, 1996, GENETICS, V142, P1215; Royle SJ, 2003, BIOESSAYS, V25, P39, DOI 10.1002/bies.10200; Ruegger M, 1997, PLANT CELL, V9, P745, DOI 10.1105/tpc.9.5.745; Swarup R, 2001, GENE DEV, V15, P2648, DOI 10.1101/gad.210501; Xu J, 2005, PLANT CELL, V17, P525, DOI 10.1105/tpc.104.028449; Zhao YD, 2001, SCIENCE, V291, P306, DOI 10.1126/science.291.5502.306	30	574	600	1	148	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1251	1256		10.1038/nature03633	http://dx.doi.org/10.1038/nature03633			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988527				2022-12-28	WOS:000230140500047
J	Richards, PG				Richards, PG			Keiiti Aki (1930-2005) - Seismologist extraordinaire. Obituary	NATURE			English	Biographical-Item									Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA	Columbia University	Richards, PG (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, 61 Route 9W, Palisades, NY 10964 USA.	richards@ldeo.columbia.edu							0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 30	2005	435	7046					1176	1176		10.1038/4351176a	http://dx.doi.org/10.1038/4351176a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988512	Bronze			2022-12-28	WOS:000230140500030
J	Bryce, J; Victora, CG				Bryce, J; Victora, CG		Conference Organizing Grp	Child survival: countdown to 2015	LANCET			English	Editorial Material							NEONATAL SURVIVAL; MORTALITY; HEALTH; CARE		Univ Fed Pelotas, Pelotas, Brazil	Universidade Federal de Pelotas	Bryce, J (corresponding author), 2081 Danby Rd, Ithaca, NY 14850 USA.	jbrycedanby@aol.com	Victora, Cesar Gomes/Y-2455-2019; Victora, Cesar G/D-4476-2013	Victora, Cesar Gomes/0000-0002-2465-2180; Victora, Cesar G/0000-0002-2465-2180				Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; *CHILD SURV PARTN, CHILD SURV GLOB IMP; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; Gary LD, 2005, LANCET, V365, P977; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Knippenberg R, 2005, LANCET, V365, P1087, DOI 10.1016/S0140-6736(05)74233-1; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Martines J, 2005, LANCET, V365, P1189, DOI 10.1016/S0140-6736(05)71882-1; Mason E, 2005, LANCET, V365, P1286, DOI 10.1016/S0140-6736(05)61005-7; Tinker A, 2005, LANCET, V365, P822, DOI 10.1016/S0140-6736(05)71016-3; *UNICEF, 2005, JOINT HLTH NUTR STRA; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; World Health Organization, 2005, WORLD HLTH REP 2005; World Health Organization (WHO), 2005, WORLD HLTH ASS CONCL; TRACKING PROGR CHILD	17	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	2005	365	9478					2153	2154		10.1016/S0140-6736(05)66752-9	http://dx.doi.org/10.1016/S0140-6736(05)66752-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938WT	15978906				2022-12-28	WOS:000230034800004
J	Nabel, GJ				Nabel, GJ			Close to the edge Neutralizing the HIV-1 envelope	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS-INFECTION; B-CELLS; GP41		NIAID, VRC, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Nabel, GJ (corresponding author), NIAID, VRC, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	gnabel@nih.gov						Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; CANOSO RT, 1987, BRIT J HAEMATOL, V65, P495, DOI 10.1111/j.1365-2141.1987.tb04157.x; Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011; Fox RA, 1997, ARTHRITIS RHEUM-US, V40, P1168, DOI 10.1002/art.1780400623; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781; Louzoun Y, 2003, B MATH BIOL, V65, P535, DOI 10.1016/S0092-8240(03)00023-5; Meffre E, 2000, NAT IMMUNOL, V1, P207, DOI 10.1038/79739; Meffre E, 2001, J CLIN INVEST, V108, P879, DOI 10.1172/JCI13051; Nemazee D, 1996, IMMUNOL TODAY, V17, P25, DOI 10.1016/0167-5699(96)80565-2; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004; Palacios R, 2004, INT J STD AIDS, V15, P277, DOI 10.1258/095646204773557857; Raaphorst FM, 1997, INT IMMUNOL, V9, P1503, DOI 10.1093/intimm/9.10.1503; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; Trkola A, 2005, NAT MED, V11, P615, DOI 10.1038/nm1244; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Zwick MB, 2005, J VIROL, V79, P1252, DOI 10.1128/JVI.79.2.1252-1261.2005; Zwick MB, 2004, NAT MED, V10, P133, DOI 10.1038/nm0204-133	19	31	37	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	2005	308	5730					1878	1879		10.1126/science.1114854	http://dx.doi.org/10.1126/science.1114854			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15976295	Green Submitted			2022-12-28	WOS:000230120000030
J	Dyson, F				Dyson, F			Dynamic universe	NATURE			English	Editorial Material									Inst Adv Study, Princeton, NJ 08540 USA	Institute for Advanced Study - USA	Dyson, F (corresponding author), Inst Adv Study, Einstein Dr, Princeton, NJ 08540 USA.								0	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 23	2005	435	7045					1033	1033		10.1038/4351033a	http://dx.doi.org/10.1038/4351033a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973387	Bronze			2022-12-28	WOS:000229970400023
J	Fairhurst, RM; Baruch, DI; Brittain, NJ; Ostera, GR; Wallach, JS; Hoang, HL; Hayton, K; Guindo, A; Makobongo, MO; Schwartz, OM; Tounkara, A; Doumbo, OK; Diallo, DA; Fujioka, H; Ho, M; Wellems, TE				Fairhurst, RM; Baruch, DI; Brittain, NJ; Ostera, GR; Wallach, JS; Hoang, HL; Hayton, K; Guindo, A; Makobongo, MO; Schwartz, OM; Tounkara, A; Doumbo, OK; Diallo, DA; Fujioka, H; Ho, M; Wellems, TE			Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria	NATURE			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; PLASMODIUM-FALCIPARUM; RED-CELLS; SURFACE; ANTIGENS; ANTIBODIES; DISEASE; PATHOGENESIS; POPULATION; RESISTANCE	Haemoglobin C, which carries a glutamate-to-lysine mutation in the beta-globin chain, protects West African children against Plasmodium falciparum malaria(1,2). Mechanisms of protection are not established for the heterozygous (haemoglobin AC) or homozygous (haemoglobin CC) states. Here we report a marked effect of haemoglobin C on the cell-surface properties of P. falciparum-infected erythrocytes involved in pathogenesis. Relative to parasite-infected normal erythrocytes (haemoglobin AA), parasitized AC and CC erythrocytes show reduced adhesion to endothelial monolayers expressing CD36 and intercellular adhesion molecule-1 (ICAM-1). They also show impaired rosetting interactions with non-parasitized erythrocytes, and reduced agglutination in the presence of pooled sera from malaria-immune adults. Abnormal cell-surface display of the main variable cytoadherence ligand, PfEMP-1 (P. falciparum erythrocyte membrane protein-1), correlates with these findings. The abnormalities in PfEMP-1 display are associated with markers of erythrocyte senescence, and are greater in CC than in AC erythrocytes. Haemoglobin C might protect against malaria by reducing PfEMP-1-mediated adherence of parasitized erythrocytes, thereby mitigating the effects of their sequestration in the microvasculature.	NIAID, Lab Malaria & Vestor Res, NIH, Bethesda, MD 20892 USA; NIAID, Malaria Vaccine Dev Branch, NIH, Bethesda, MD 20892 USA; NIAID, Biol Imaging Facil, Res Technol Branch, NIH, Bethesda, MD 20892 USA; Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; Univ Bamako, Fac Med Pharm & Odontostomatol, Dept Parasitol, Malaria Res & Training Ctr, Bamako, Mali; Univ Bamako, Fac Med Pharm & Odontostomatol, Dept Hematol, Malaria Res & Training Ctr, Bamako, Mali; Minist Hlth, Ctr Natl Transfus Sanguine, Bamako, Mali; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Calgary; University of Bamako; University of Bamako; Case Western Reserve University	Wellems, TE (corresponding author), NIAID, Lab Malaria & Vestor Res, NIH, Bethesda, MD 20892 USA.	twellems@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000483, ZIAAI000483] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal A, 2000, BLOOD, V96, P2358, DOI 10.1182/blood.V96.7.2358.h8002358_2358_2363; ALLISON AC, 1961, ANN NY ACAD SCI, V91, P710, DOI 10.1111/j.1749-6632.1961.tb31102.x; Arie T, 2005, J STRUCT BIOL, V150, P163, DOI 10.1016/j.jsb.2005.02.008; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; BUNN HF, 1982, P NATL ACAD SCI-BIOL, V79, P7527, DOI 10.1073/pnas.79.23.7527; CHARACHE S, 1967, J CLIN INVEST, V46, P1795, DOI 10.1172/JCI105670; Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X; Fairhurst RM, 2003, BLOOD, V101, P3309, DOI 10.1182/blood-2002-10-3105; Flint J, 1998, BAILLIERE CLIN HAEM, V11, P1, DOI 10.1016/S0950-3536(98)80069-3; FRIEDMAN MJ, 1979, AM J TROP MED HYG, V28, P777, DOI 10.4269/ajtmh.1979.28.777; Gamain B, 2001, P NATL ACAD SCI USA, V98, P2664, DOI 10.1073/pnas.041602598; Giribaldi G, 2001, BRIT J HAEMATOL, V113, P492, DOI 10.1046/j.1365-2141.2001.02707.x; HUISMAN THJ, 1972, CLIN CHIM ACTA, V40, P159, DOI 10.1016/0009-8981(72)90264-1; KAUL DK, 1991, BLOOD, V78, P812; LOW PS, 1985, SCIENCE, V227, P531, DOI 10.1126/science.2578228; MACDONALD VW, 1982, BIOCHIM BIOPHYS ACTA, V701, P39, DOI 10.1016/0167-4838(82)90309-0; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; Modiano D, 2001, NATURE, V414, P305, DOI 10.1038/35104556; MURPHY JR, 1973, J LAB CLIN MED, V82, P334; Oh SS, 2000, MOL BIOCHEM PARASIT, V108, P237, DOI 10.1016/S0166-6851(00)00227-9; Ricke CH, 2000, J IMMUNOL, V165, P3309, DOI 10.4049/jimmunol.165.6.3309; ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995; Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; WILLIAMS AR, 1980, SCAND J HAEMATOL, V24, P57; Winterbourn CC, 1985, CRC HDB METHODS OXYG, P137; Yipp BG, 2000, BLOOD, V96, P2292, DOI 10.1182/blood.V96.6.2292.h8002292_2292_2298	30	143	147	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1117	1121		10.1038/nature03631	http://dx.doi.org/10.1038/nature03631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973412	Green Published, Bronze			2022-12-28	WOS:000229970400053
J	Stolk, WA; de Vlas, SJ; Habbema, JD				Stolk, WA; de Vlas, SJ; Habbema, JD			Anti-Wolbachia treatment for lymphatic filariasis	LANCET			English	Editorial Material							WUCHERERIA-BANCROFTI INFECTION; MODEL-BASED ANALYSIS; EFFICACY; DIETHYLCARBAMAZINE; ALBENDAZOLE; IVERMECTIN; INDIA; ELIMINATION; PONDICHERRY		Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Stolk, WA (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands.	w.stolk@erasmusmc.nl		Stolk, Wilma/0000-0001-9509-1328; de Vlas, Sake J./0000-0002-1830-5668				DREYER G, 1995, T ROY SOC TROP MED H, V89, P441, DOI 10.1016/0035-9203(95)90049-7; El Setouhy M, 2004, AM J TROP MED HYG, V70, P191, DOI 10.4269/ajtmh.2004.70.191; Hoerauf A, 2003, MED MICROBIOL IMMUN, V192, P211, DOI 10.1007/s00430-002-0174-6; Kshirsagar NA, 2004, T ROY SOC TROP MED H, V98, P205, DOI 10.1016/S0035-9203(03)00044-0; Molyneux DH, 2002, ANN TROP MED PARASIT, V96, pS15, DOI 10.1179/000349802125002374; Noroes J, 1997, T ROY SOC TROP MED H, V91, P78, DOI 10.1016/S0035-9203(97)90405-3; Ottesen EA, 1999, PARASITOL TODAY, V15, P382, DOI 10.1016/S0169-4758(99)01486-6; Plaisier AP, 1999, PARASITOLOGY, V119, P385, DOI 10.1017/S0031182099004783; Richard-Lenoble D, 2003, FUND CLIN PHARMACOL, V17, P199, DOI 10.1046/j.1472-8206.2003.00170.x; Stolk WA, 2003, J INFECT DIS, V188, P1371, DOI 10.1086/378354; Subramanian S, 2004, PARASITOLOGY, V128, P467, DOI 10.1017/S0031182004004822; Taylor MJ, 2000, PARASITOL TODAY, V16, P179, DOI 10.1016/S0169-4758(00)01661-6; 2004, AM J TROP MED HYG S5, V71, P1	13	19	20	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 18	2005	365	9477					2067	2068		10.1016/S0140-6736(05)66714-1	http://dx.doi.org/10.1016/S0140-6736(05)66714-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964428				2022-12-28	WOS:000229858800005
J	Litman, RS; Rosenberg, H				Litman, RS; Rosenberg, H			Malignant hyperthermia - Update on susceptibility testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CENTRAL CORE DISEASE; DEPENDENT CALCIUM-CHANNEL; VITRO CONTRACTURE-TEST; HYPOKALEMIC PERIODIC PARALYSIS; HYPERKALEMIC CARDIAC-ARREST; MUSCLE RYANODINE RECEPTOR; SKELETAL-MUSCLE; RYR1 GENE; SARCOPLASMIC-RETICULUM; CHROMOSOME 19Q12-13.2	Malignant hyperthermia (MH) is a pharmacogenetic clinical syndrome that manifests as a hypermetabolic crisis when a susceptible individual is exposed to an anesthetic triggering agent. Clinical signs include unexplained elevation of end-tidal carbon dioxide, muscle rigidity, acidosis, tachycardia, tachypnea, hyperthermia, and evidence of rhabdomyolysis. This process is a result of an abnormally increased release of calcium from the sarcoplasmic reticulum, which is often caused by an inherited mutation in the gene for the ryanodine receptor (RYR1) that resides in the membrane of the sarcoplasmic reticulum. The gold standard for determination of MH susceptibility is the caffeine-halothane contracture test. However, it is invasive, requiring skeletal muscle biopsy and is not widely available. Researchers have begun to map mutations within the ryanodine receptor gene (chromosome 19q13.1) responsible for conferring MH susceptibility. Ryanodine receptor mutations are found in at least 25% of known MH susceptible individuals in North America. Mutation analysis has recently become available in the United States and is expected to play an integral role in the diagnosis of MH susceptibility in the future.	Univ Penn, Dept Anesthesiol & Crit Care Med, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA; St Barnabas Hosp, Dept Med Educ, Livingston, NJ USA; Mt Sinai Sch Med, New York, NY USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Icahn School of Medicine at Mount Sinai	Litman, RS (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care Med, Childrens Hosp Philadelphia, Sch Med, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Lit-manr@email.chop.edu	Litman, Ron/AAK-6146-2020					Allen GC, 1998, ANESTHESIOLOGY, V88, P579, DOI 10.1097/00000542-199803000-00006; Anetseder M, 2002, LANCET, V359, P1579, DOI 10.1016/S0140-6736(02)08506-9; Bachand M, 1997, CAN J ANAESTH, V44, P696, DOI 10.1007/BF03013380; Bendahan D, 1998, ANESTHESIOLOGY, V88, P96, DOI 10.1097/00000542-199801000-00017; Bendahan D, 2001, ANESTH ANALG, V93, P683, DOI 10.1097/00000539-200109000-00030; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Davis MR, 2003, NEUROMUSCULAR DISORD, V13, P151, DOI 10.1016/S0960-8966(02)00218-3; DENBOROUGH MA, 1962, BRIT J ANAESTH, V34, P395, DOI 10.1093/bja/34.6.395; DEUFEL T, 1995, AM J HUM GENET, V56, P1334; Dirksen RT, 2004, BIOPHYS J, V87, P3193, DOI 10.1529/biophysj.104.049447; Fletcher JE, 1999, ANESTHESIOLOGY, V90, P1294, DOI 10.1097/00000542-199905000-00012; FLETCHER JE, 1991, LIFE SCI, V49, P1651, DOI 10.1016/0024-3205(91)90060-O; Fortunato G, 1999, EUR J HUM GENET, V7, P415, DOI 10.1038/sj.ejhg.5200314; GILLARD EF, 1992, GENOMICS, V13, P1247, DOI 10.1016/0888-7543(92)90042-Q; Guis S, 2004, ARCH NEUROL-CHICAGO, V61, P106, DOI 10.1001/archneur.61.1.106; ILES DE, 1994, HUM MOL GENET, V3, P969, DOI 10.1093/hmg/3.6.969; Larach MG, 1997, CLIN PEDIATR, V36, P9; LEVITT RC, 1992, GENOMICS, V14, P562, DOI 10.1016/S0888-7543(05)80152-1; Loke J, 1998, AM J MED, V104, P470, DOI 10.1016/S0002-9343(98)00108-9; LOUIS CF, 1992, ANESTHESIOLOGY, V77, P114, DOI 10.1097/00000542-199207000-00017; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; *MAL HYP ASS US WE, MH MUSCL BIOPS TEST; Marchant CL, 2004, MUSCLE NERVE, V30, P114, DOI 10.1002/mus.20068; Mathews KD, 2004, ARCH NEUROL-CHICAGO, V61, P27, DOI 10.1001/archneur.61.1.27; McCarthy T V, 2004, Biochem J, V380, pe1, DOI 10.1042/BJ20040512; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; MCCARTHY TV, 1990, NATURE, V343, P562, DOI 10.1038/343562a0; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; Monnier N, 1997, AM J HUM GENET, V60, P1316, DOI 10.1086/515454; Nathan A, 2005, ANESTH ANALG, V100, P672, DOI 10.1213/01.ANE.0000146533.21771.2F; O'Sullivan GH, 2001, BIOCHEM PHARMACOL, V61, P1479, DOI 10.1016/S0006-2952(01)00604-9; OLCKERS A, 1992, GENOMICS, V14, P829, DOI 10.1016/S0888-7543(05)80206-X; Ording H, 1997, ACTA ANAESTH SCAND, V41, P955, DOI 10.1111/j.1399-6576.1997.tb04820.x; ORDING H, 1985, ANESTH ANALG, V64, P700; Paul-Pletzer K, 2002, J BIOL CHEM, V277, P34918, DOI 10.1074/jbc.M205487200; Phillips MS, 1996, GENOMICS, V34, P24, DOI 10.1006/geno.1996.0238; POLLOCK N, 1992, ANAESTH INTENS CARE, V20, P520, DOI 10.1177/0310057X9202000427; Rajabally YA, 2002, MUSCLE NERVE, V25, P453, DOI 10.1002/mus.10069; Robinson RL, 2003, EUR J HUM GENET, V11, P342, DOI 10.1038/sj.ejhg.5200964; Robinson RL, 2002, HUM MUTAT, V20, P88, DOI 10.1002/humu.10098; Robinson RL, 1997, HUM MOL GENET, V6, P953, DOI 10.1093/hmg/6.6.953; Rosenberg H, 2002, ANESTHESIOLOGY, V96, P232, DOI 10.1097/00000542-200201000-00036; Sei Y, 2004, ANESTHESIOLOGY, V101, P824, DOI 10.1097/00000542-200410000-00005; Sei Y, 2002, ANESTHESIOLOGY, V97, P1052, DOI 10.1097/00000542-200211000-00005; Serfas KD, 1996, ANESTHESIOLOGY, V84, P322, DOI 10.1097/00000542-199602000-00009; Stewart SL, 2001, CLIN GENET, V59, P178, DOI 10.1034/j.1399-0004.2001.590306.x; Struk A, 1998, BIOPHYS J, V75, P2402, DOI 10.1016/S0006-3495(98)77684-2; SUDBRAK R, 1995, AM J HUM GENET, V56, P684; Tobin JR, 2001, JAMA-J AM MED ASSOC, V286, P168, DOI 10.1001/jama.286.2.168; Wappler F, 2001, ANESTHESIOLOGY, V94, P95, DOI 10.1097/00000542-200101000-00019; Weiss RG, 2004, AM J PHYSIOL-CELL PH, V287, pC1094, DOI 10.1152/ajpcell.00173.2004; Yang TZ, 2003, J BIOL CHEM, V278, P25722, DOI 10.1074/jbc.M302165200	52	106	117	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	2005	293	23					2918	2924		10.1001/jama.293.23.2918	http://dx.doi.org/10.1001/jama.293.23.2918			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	935MD	15956637				2022-12-28	WOS:000229785500027
J	Rudan, I; Lawn, J; Cousens, S; Rowe, AK; Boschi-Pinto, C; Tomaskovic, L; Mendoza, W; Lanata, CF; Roca-Feltrer, A; Carniero, I; Schellenberg, JA; Polasek, O; Weber, M; Bryce, J; Morris, SS; Black, RE; Campbell, H				Rudan, I; Lawn, J; Cousens, S; Rowe, AK; Boschi-Pinto, C; Tomaskovic, L; Mendoza, W; Lanata, CF; Roca-Feltrer, A; Carniero, I; Schellenberg, JA; Polasek, O; Weber, M; Bryce, J; Morris, SS; Black, RE; Campbell, H			Gaps in policy-relevant information on burden of disease in children: a systematic review	LANCET			English	Review							HEALTH; MORTALITY; DEATH; MISCLASSIFICATION; COUNTRIES	Background Valid information about cause-specific child mortality and morbidity is an essential foundation for national and international health policy. We undertook a systematic review to investigate the geographical dispersion of and time trends in publication for policy-relevant information about children's health and to assess associations between the availability of reliable data and poverty. Methods We identified data available on Jan 1, 2001, and published since 1980, for the major causes. of morbidity and mortality in young children. Studies with relevant,data were assessed against a set of inclusion criteria to identify those likely to provide unbiased estimates of the burden of childhood disease in the community. Findings Only 308 information units from more than 17 000 papers identified were regarded as possible. unbiased sources for estimates of childhood disease burden. The geographical distribution of these information units revealed a pattern of small well-researched populations surrounded by large areas with little available information. No reliable population-based data were identified from many of the world's poorest countries, which account for about a third of all deaths of children worldwide. The number of new studies diminished over the last 10 years investigated. Interpretation The number of population-based studies yielding estimates of burden of childhood disease from less developed countries was low. The decreasing trend over time suggests reductions in research investment in this sphere. Data are especially sparse from the world's least developed countries with the highest child mortality. Guidelines are needed for the conduct of burden-of-disease studies together with an international research policy that gives increased emphasis to global equity and coverage so that knowledge can be generated from all regions of the world.	Univ Edinburgh, Sch Med, Dept Community Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Zagreb, Sch Med, Sch Publ Hlth, Dept Med Stat Epidmeiol & Med Informat, Zagreb 41001, Croatia; Inst Child Hlth, Int Perinatal Care Unit, London, England; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England; London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England; Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA USA; WHO, Child & Adolescent Hlth Dept, CH-1211 Geneva, Switzerland; Inst Invest Nutr La Molina, Lima, Peru; Dept Int Dev UK Govt, Europe Middle E & Amer Div, London, England; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA	University of Edinburgh; University of Zagreb; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; Centers for Disease Control & Prevention - USA; World Health Organization; Johns Hopkins University	Campbell, H (corresponding author), Univ Edinburgh, Sch Med, Dept Publ Hlth Sci, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	Harry.Campbell@ed.ac.uk	Rudan, Igor/I-1467-2012; Polasek, Ozren/B-6002-2011; Lanata, Claudio F./N-7997-2018; Campbell, Harry/E-2959-2010; Roca-Feltrer, Arantxa/AAW-6986-2020; Pinto, Cynthia Boschi/AAA-6990-2020	Rudan, Igor/0000-0001-6993-6884; Polasek, Ozren/0000-0002-5765-1862; Lanata, Claudio F./0000-0002-6994-7425; Campbell, Harry/0000-0002-6169-6262; Pinto, Cynthia Boschi/0000-0002-0069-7974; Black, Robert/0000-0001-9926-7984; Schellenberg, Joanna/0000-0002-0708-3676; Morris, Saul/0000-0002-9372-7342; Lawn, Joy/0000-0002-4573-1443				Anker M, 1997, INT J EPIDEMIOL, V26, P1090, DOI 10.1093/ije/26.5.1090; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; BOERMA JT, 1994, DHS METHODOLOGICAL R, V2, P145; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; BUXTON M, 1996, J HEALTH SERV RES PO, V1, P25; Chandramohan D, 2001, INT J EPIDEMIOL, V30, P509, DOI 10.1093/ije/30.3.509; *CHILD AD HLTH DEV, CHILD HLTH EP WHO 20; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; Evans T, 2003, B WORLD HEALTH ORGAN, V81, P856; Global Forum for Health Research, 2005, 10 90 REP HLTH RES 2, P25; *HLTH METR NETW, HOM PAG; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; KALTER H, 1992, HEALTH POLICY PLANN, V7, P30, DOI 10.1093/heapol/7.1.30; Lanata CF, 2004, INT J EPIDEMIOL, V33, P1362, DOI 10.1093/ije/dyh229; Morris SS, 2003, INT J EPIDEMIOL, V32, P1041, DOI 10.1093/ije/dyg241; Pang T, 2003, B WORLD HEALTH ORGAN, V81, P815; RICHARDS T, 2004, BRIT MED J, V328, P310; SADANA R, 2003, B WORLD HEALTH ORGAN, V81, P81; Sibai AM, 2004, B WORLD HEALTH ORGAN, V82, P83; United Nations, 2001, REPORT SECRETARY GEN; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; Waters E, 2004, BRIT MED J, V328, P585, DOI 10.1136/bmj.328.7439.585; *WHO, 2000, WORLD HLT REP; *WHO, 2003, EST COV MORT DAT; World Health Organization, 2001, MACR HLTH INV HLTH E	25	109	111	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2005	365	9476					2031	2040		10.1016/S0140-6736(05)66697-4	http://dx.doi.org/10.1016/S0140-6736(05)66697-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950717				2022-12-28	WOS:000229701400025
J	Gasser, S; Orsulic, S; Brown, EJ; Raulet, DH				Gasser, S; Orsulic, S; Brown, EJ; Raulet, DH			The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor	NATURE			English	Article							GENOMIC INSTABILITY; NK CELLS; CHECKPOINT; ATM; TUMORIGENESIS; ACTIVATION; REPAIR; CHK1; IMMUNORECEPTOR; MACROPHAGES	Some stimulatory receptors of the innate immune system, such as the NKG2D receptor ( also called KLRK1) expressed by natural killer cells and activated CD8(+) T cells, recognize self-molecules that are upregulated in diseased cells by poorly understood mechanisms(1). Here we show that mouse and human NKG2D ligands are upregulated in non-tumour cell lines by genotoxic stress and stalled DNA replication, conditions known to activate a major DNA damage checkpoint pathway initiated by ATM ( ataxia telangiectasia, mutated) or ATR (ATM- and Rad3-related) protein kinases(2). Ligand upregulation was prevented by pharmacological or genetic inhibition of ATR, ATM or Chk1 ( a downstream transducer kinase in the pathway). Furthermore, constitutive ligand expression by a tumour cell line was inhibited by targeting short interfering RNA to ATM, suggesting that ligand expression in established tumour cells, which often harbour genomic irregularities, may be due to chronic activation of the DNA damage response pathway. Thus, the DNA damage response, previously shown to arrest the cell cycle and enhance DNA repair functions, or to trigger apoptosis, may also participate in alerting the immune system to the presence of potentially dangerous cells.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Harvard University; Massachusetts General Hospital; University of Pennsylvania	Raulet, DH (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	raulet@uclink.berkeley.edu	gasser, stephan/A-2309-2013	Raulet, David/0000-0002-1257-8649; Gasser, Stephan/0000-0002-5616-0914	NATIONAL CANCER INSTITUTE [R01CA093678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039642] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA093678] Funding Source: Medline; NIAID NIH HHS [R01 AI039642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bignami M, 2003, EUR J CANCER, V39, P2142, DOI 10.1016/S0959-8049(03)00569-0; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Diefenbach A, 2003, EUR J IMMUNOL, V33, P381, DOI 10.1002/immu.200310012; Gonzalez S, 2003, MOL CELL BIOL, V23, P8161, DOI 10.1128/MCB.23.22.8161-8171.2003; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hernandez-Hoyos G, 2003, IMMUNITY, V19, P83, DOI 10.1016/S1074-7613(03)00176-6; Jamieson AM, 2002, IMMUNITY, V17, P19, DOI 10.1016/S1074-7613(02)00333-3; Krause DR, 2003, ONCOGENE, V22, P5927, DOI 10.1038/sj.onc.1206691; LANDER MR, 1978, J NATL CANCER I, V60, P477; Lodoen M, 2003, J EXP MED, V197, P1245, DOI 10.1084/jem.20021973; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Weitzman MD, 2004, DNA REPAIR, V3, P1165, DOI 10.1016/j.dnarep.2004.03.018; Xing DY, 2005, P NATL ACAD SCI USA, V102, P6936, DOI 10.1073/pnas.0502256102; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	27	982	1030	4	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	2005	436	7054					1186	1190		10.1038/nature03884	http://dx.doi.org/10.1038/nature03884			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	958AK	15995699	Green Accepted			2022-12-28	WOS:000231416600052
J	Messenger, S; Keller, LP; Lauretta, DS				Messenger, S; Keller, LP; Lauretta, DS			Supernova olivine from cometary dust	SCIENCE			English	Article							MOLECULAR-CLOUD MATERIAL; PRESOLAR SIC GRAINS; SOLAR-SYSTEM; ISOTOPIC COMPOSITIONS; ISO SPECTROSCOPY; SILICON-CARBIDE; MASSIVE STARS; CARBON; CONDENSATION; NITROGEN	An interplanetary dust particle contains a submicrometer crystalline silicate aggregate of probable supernova origin. The grain has a pronounced enrichment in O-18/O-16 (13 times the solar value) and depletions in O-17/O-16 (one-third solar) and Si-29/Si-28 (<0.8 times solar), indicative of formation from a type 11 supernova. The aggregate contains olivine (forsterite 83) grains <100 nanometers in size, with microstructures that are consistent with minimal thermal alteration. This unusually iron-rich olivine grain could have formed by equilibrium condensation from cooling supernova ejecta if several different nucleosynthetic zones mixed in the proper proportions. The supernova grain is also partially encased in nitrogen-15-rich organic matter that likely formed in a presolar cold molecular cloud.	NASA, Lyndon B Johnson Space Ctr, Robert M Walker Lab Space Sci, Houston, TX 77058 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; University of Arizona	Messenger, S (corresponding author), NASA, Lyndon B Johnson Space Ctr, Robert M Walker Lab Space Sci, Mail Code KR, Houston, TX 77058 USA.	scott.r.messenger@nasa.gov						Alexander CMO, 1998, METEORIT PLANET SCI, V33, P603, DOI 10.1111/j.1945-5100.1998.tb01667.x; ALEXANDER CMO, 1993, GEOCHIM COSMOCHIM AC, V57, P2869, DOI 10.1016/0016-7037(93)90395-D; Amari S, 2001, ASTROPHYS J, V559, P463, DOI 10.1086/322397; Amari S, 2001, ASTROPHYS J, V546, P248, DOI 10.1086/318230; ARNARI S, 1992, ASTROPHYS J, V394, P643; ARNOULD M, 1998, AIP C P, V402, P179; BERNATOWIC TJ, 1998, AIP C P, V402; Bernstein MP, 2002, ASTROPHYS J, V576, P1115, DOI 10.1086/341863; Boothroyd AI, 1999, ASTROPHYS J, V510, P232, DOI 10.1086/306546; Bradley J. P., 1988, METEORITES EARLY SOL, P861; Bradley JP, 1999, SCIENCE, V285, P1716, DOI 10.1126/science.285.5434.1716; Busso M, 2003, PUBL ASTRON SOC AUST, V20, P356, DOI 10.1071/AS03035; Charnley SB, 2002, ASTROPHYS J, V569, pL133, DOI 10.1086/340484; Choi BG, 1998, SCIENCE, V282, P1284, DOI 10.1126/science.282.5392.1284; Choi BG, 1999, ASTROPHYS J, V522, pL133, DOI 10.1086/312239; Clayton DD, 1999, SCIENCE, V283, P1290, DOI 10.1126/science.283.5406.1290; Clayton DD, 2001, ASTROPHYS J, V562, P480, DOI 10.1086/323467; CLAYTON DD, 2004, ORIGIN EVOLUTION ELE, P297; Deneault EAN, 2003, ASTROPHYS J, V594, P312, DOI 10.1086/376863; Dunne L, 2003, NATURE, V424, P285, DOI 10.1038/nature01792; Ebel DS, 2000, GEOCHIM COSMOCHIM AC, V64, P339, DOI 10.1016/S0016-7037(99)00284-7; FEDKIN AV, 2004, LUNAR PLANET SCI, V35, pA1823; Floss C, 2004, SCIENCE, V303, P1355, DOI 10.1126/science.1093283; Floss C., 2004, LUNAR PLANET SCI, VXXXV; HOPPE P, 1994, ASTROPHYS J, V430, P870, DOI 10.1086/174458; Hoppe P, 1996, GEOCHIM COSMOCHIM AC, V60, P883, DOI 10.1016/0016-7037(95)00435-1; HOPPE P, 2005, LUNAR PLANET SCI, V36; Huss GR, 1997, GEOCHIM COSMOCHIM AC, V61, P5117, DOI 10.1016/S0016-7037(97)00299-8; Jones AP, 1996, ASTROPHYS J, V469, P740, DOI 10.1086/177823; Keller LP, 2004, GEOCHIM COSMOCHIM AC, V68, P2577, DOI 10.1016/j.gca.2003.10.044; Kemper F, 2004, ASTROPHYS J, V609, P826, DOI 10.1086/421339; Kemper F, 2002, ASTRON ASTROPHYS, V394, P679, DOI 10.1051/0004-6361:20021119; KOBAYASHI S, 2005, LUNAR PLANET SCI, V36; KRESTINA H, 2002, LUNAR PLANET SCI, V33; Lada CJ, 2003, ANNU REV ASTRON ASTR, V41, P57, DOI 10.1146/annurev.astro.41.011802.094844; Li AG, 1997, ASTRON ASTROPHYS, V323, P566; MARHAS KK, 2004, LUNAR PLANET SCI, V35; Meeus G, 2001, ASTRON ASTROPHYS, V365, P476, DOI 10.1051/0004-6361:20000144; Messenger S, 2003, SCIENCE, V300, P105, DOI 10.1126/science.1080576; Messenger S, 2000, NATURE, V404, P968, DOI 10.1038/35010053; Messenger S, 2002, METEORIT PLANET SCI, V37, P1491, DOI 10.1111/j.1945-5100.2002.tb00806.x; MESSENGER S, 1997, AIP C P, V402, P545; MEYER BS, 1995, METEORITICS, V30, P325, DOI 10.1111/j.1945-5100.1995.tb01131.x; Mostefaoui S, 2004, ASTROPHYS J, V613, pL149, DOI 10.1086/424842; Mouri H, 2000, ASTROPHYS J, V534, pL63, DOI 10.1086/312633; Nagashima K, 2004, NATURE, V428, P921, DOI 10.1038/nature02510; Nguyen AN, 2004, SCIENCE, V303, P1496, DOI 10.1126/science.1094389; NGUYEN AN, 2005, LUNAR PLANET SCI, V36; Nittler LR, 1998, NATURE, V393, P222, DOI 10.1038/30377; Nittler LR, 1997, ASTROPHYS J, V483, P475, DOI 10.1086/304234; Pasek MA, 2005, ICARUS, V175, P1, DOI 10.1016/j.icarus.2004.10.012; Rauscher T, 2002, ASTROPHYS J, V576, P323, DOI 10.1086/341728; STROUD RM, 2004, MET PLANET SCI, V39; Tachibana S, 2003, ASTROPHYS J, V588, pL41, DOI 10.1086/375362; Travaglio C, 1999, ASTROPHYS J, V510, P325, DOI 10.1086/306551; van Dishoeck EF, 2004, ANNU REV ASTRON ASTR, V42, P119, DOI 10.1146/annurev.astro.42.053102.134010; Waters LBFM, 1996, ASTRON ASTROPHYS, V315, pL361; WOODEN DH, 1998, AIP C P, V402, P317; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237; Yada T., 2005, LUNAR PLANET SCI, VXXXVI; Zinner E, 2003, GEOCHIM COSMOCHIM AC, V67, P5083, DOI 10.1016/S0016-7037(03)00261-8; Zinner EK, 2005, TREATISE GEOCHEM, V1, P17	63	133	133	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 29	2005	309	5735					737	741		10.1126/science.1109602	http://dx.doi.org/10.1126/science.1109602			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951NU	15994379				2022-12-28	WOS:000230938200040
J	Arrow, KJ; Gelband, H; Jamison, DT				Arrow, KJ; Gelband, H; Jamison, DT			Making antimalarial agents available in Africa	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stanford Univ, Palo Alto, CA 94304 USA; Natl Acad Sci, Inst Med, Washington, DC 20418 USA; Univ Calif Los Angeles, Los Angeles, CA USA	Stanford University; National Academies of Sciences, Engineering & Medicine; University of California System; University of California Los Angeles	Arrow, KJ (corresponding author), Stanford Univ, Palo Alto, CA 94304 USA.							Institute of Medicine (US) Committee on the Economics of Antimalarial Drugs, 2004, SAVING LIVES BUYING; *UNICEF, 2003, AFR MAL REP 2003	2	12	14	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 28	2005	353	4					333	335		10.1056/NEJMp058168	http://dx.doi.org/10.1056/NEJMp058168			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	949JW	16000348				2022-12-28	WOS:000230782800003
J	Benson, J; Quince, T; Hibble, A; Fanshawe, T; Emery, J				Benson, J; Quince, T; Hibble, A; Fanshawe, T; Emery, J			Impact on patients of expanded, general practice based, student teaching: observational and qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-STUDENTS; PATIENTS VIEWS; PRIMARY-CARE; CONSULTATIONS; SATISFACTION; PRACTITIONERS; ENABLEMENT; ATTITUDES	Objectives To compare patients' enablement and satisfaction after teaching and non-teaching consultations. To explore patients' views about the possible impact that increased community based teaching of student doctors in their practice may have on the delivery of service and their attitudes towards direct involvement with students. Design Observational study using validated survey instruments (patient enablement index-PET, and consultation satisfaction questionnaire-CSQ) administered after teaching consultations and non-teaching consultations. Ten focus groups (two from each practice), comprising five with patients participating in prearranged teaching sessions and five with patients not participating in these. Setting Five general practices in west Suffolk and southern Norfolk, England, that teach student doctors on the Cambridge graduate medical course. Participants 240 patients attending teaching consultations (response rate 82%,196 patients) and 409 patients attending non-teaching consultations (response rate 72%, 294 patients) received survey instruments. Ten focus groups with a total of 34 patients participating in prearranged teaching sessions and 20 patients not participating in these. Main outcome measures Scores on the patient enablement index and consultation satisfaction questionnaire, analysed at the level of all patients, allowing for age, sex, general practitioner, and practice, and at the level of the individual general practitioner teacher. Qualitative analysis of focus group data. Results Patients' enablement or satisfaction was not reduced after teaching consultations compared with non-teaching consultations (mean difference in scores on the patient enablement index and consultation satisfaction questionnaire with adjustment for confounders 2.24% and 1.70%, respectively). This held true for analysis by all patients and by general practitioner teacher. Qualitative data showed that patients generally supported the teaching of student doctors in their practice. However, this support was conditional on receiving sufficient information about reasons for doctors' absence, the characteristics of students, and the nature of teaching planned. Many patients viewed their general practice as different from hospital and expected greater control over students' presence during their consultations. Conclusions Patients' enablement and satisfaction are not impaired by students' participation in consultations. Patients generally support the teaching of student doctors in their general practice but expect to be provided with sufficient information and to have a choice about participation, so they can give informed consent. Recognising this when organising general practice based teaching is important.	Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Gen Practice Educ Grp, Cambridge CB2 2SR, England; Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Cambridge Grad Course, Cambridge CB2 2SR, England; Eastern Deanery, Cambridge CB1 5EE, England; Univ Western Australia, Discipline Gen Practice, Perth, WA 6010, Australia	University of Cambridge; University of Cambridge; University of Western Australia	Benson, J (corresponding author), Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Gen Practice Educ Grp, Cambridge CB2 2SR, England.	jab62@medschl.cam.ac.uk						Baker R, 1996, BRIT J GEN PRACT, V46, P601; Balint M., 1986, DOCTOR HIS PATIENT I; Bentham J, 1999, MED EDUC, V33, P686, DOI 10.1046/j.1365-2923.1999.00410.x; Coleman K, 2002, FAM PRACT, V19, P183, DOI 10.1093/fampra/19.2.183; Cooke F, 1996, BRIT J GEN PRACT, V46, P361; Doyal L, 2001, BRIT MED J, V322, P685, DOI 10.1136/bmj.322.7288.685; *HEADS DEP PRIM CA, 2002, NEW CENT NEW CHALL; Howe A, 2003, BRIT MED J, V327, P326, DOI 10.1136/bmj.327.7410.326; Howie JGR, 1998, FAM PRACT, V15, P165, DOI 10.1093/fampra/15.2.165; Jones S, 1996, MED EDUC, V30, P14, DOI 10.1111/j.1365-2923.1996.tb00711.x; Kinnersley P, 1996, FAM PRACT, V13, P41, DOI 10.1093/fampra/13.1.41; LEWIS JR, 1995, BRIT J GEN PRACT, V45, P249; Mead N, 2002, SOC SCI MED, V55, P283, DOI 10.1016/S0277-9536(01)00171-X; O'Flynn N, 2002, BRIT MED J, V325, P683, DOI 10.1136/bmj.325.7366.683; OFlynn N, 1997, BRIT MED J, V315, P1142; Pinheiro J, 2001, MIXED EFFECTS MODELS; *R DEV COR TEAM, 2004, R LANG ENV STAT COMP; Stacy R, 1999, MED EDUC, V33, P688, DOI 10.1046/j.1365-2923.1999.00454.x; Tarrant C, 2003, BRIT MED J, V326, P1310, DOI 10.1136/bmj.326.7402.1310; Williamson C, 1997, BRIT MED J, V315, P1108	21	54	54	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 9	2005	331	7508					89	92B		10.1136/bmj.38492.599606.8F	http://dx.doi.org/10.1136/bmj.38492.599606.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	945XR	15996965	Green Accepted, Green Published, Green Submitted, Bronze			2022-12-28	WOS:000230536800017
J	Henry, RC				Henry, RC			The mental Universe	NATURE			English	Editorial Material									Johns Hopkins Univ, Henry A Rowland Dept Phys & Astron, Baltimore, MD 21218 USA	Johns Hopkins University	Henry, RC (corresponding author), Johns Hopkins Univ, Henry A Rowland Dept Phys & Astron, Baltimore, MD 21218 USA.			Henry, Richard/0000-0003-4447-2686				HENRY RC, 1990, AM J PHYS, V58, P1087, DOI 10.1119/1.16277; MARBURGER JH, 2002, COPENHAGEN INTERPRET; Steiner M., 1998, APPL MATH PHILOS PRO	3	23	24	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 7	2005	436	7047					29	29		10.1038/436029a	http://dx.doi.org/10.1038/436029a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	942QJ	16001047	Bronze			2022-12-28	WOS:000230296600025
J	Van Meurs, KP; Wright, LL; Ehrenkranz, RA; Lemons, JA; Ball, MB; Poole, WK; Perritt, R; Higgins, RD; Oh, W; Hudak, ML; Laptook, AR; Shankaran, S; Finer, NN; Carlo, WA; Kennedy, KA; Fridriksson, JH; Steinhorn, RH; Sokol, GM; Konduri, GG; Aschner, JL; Stoll, BJ; D'Angio, CT; Stevenson, DK; Oh, W; Hensman, A; Gingras, D; Stoll, BJ; Jain, L; Hale, E; Seabrook, I; Sokol, G; Lorant, D; Appel, DD; Miller, L; Chriscinske, D; Attwood, J; Steinhorn, R; Sautel, M; Van Meurs, K; Ball, B; Proud, D; Carlo, WA; Cosby, SS; Johnson, RB; Fridriksson, J; Warner, B; Mersmann, M; Alexander, B; Shively, J; Mincey, H; Hoover, M; Sapienz, S; Stephenson, E; Finer, NN; Rasmussen, MR; Henderson, C; Demetrio, C; Rich, W; Joseph, C; Hudak, M; Osbeck, S; Case, E; Kellum, A; Hogans, L; D'Angio, CT; Reubens, L; Hutton, G; Laptook, A; Madison, S; Hensley, G; Miller, N; Metoyer, G; Kennedy, K; McDavid, G; Emerson, D; Konduri, G; Paquette, M; Wong, S; Aschner, J; O'Shea, TM; Peters, N; Hansell, BJ; Griffin, J; Adams, C; Shankaran, S; Bara, RA; Muran, G; Weekfall, W; Ehrenkranz, RA; Gettner, P; Caldwell, A; Oh, W; Fanaroff, AA; Goldberg, RN; Stoll, BJ; Lemons, JA; Stevenson, DK; Carlo, WA; Donovan, EF; Finer, NN; Duara, S; Phelps, DL; Laptook, AR; Tyson, JE; O'Shea, TM; Shankaran, S; Ehrenkranz, RA; Jobe, A; Poole, WK; Hastings, B; Petrie, C; Higgins, RD; Wright, LL; McClure, E; Bulas, D; Mertens, D; Slovis, T; Avery, G; D'Alton, M; Poole, WK; Fletcher, JC; Gleason, CA; Redmond, C				Van Meurs, KP; Wright, LL; Ehrenkranz, RA; Lemons, JA; Ball, MB; Poole, WK; Perritt, R; Higgins, RD; Oh, W; Hudak, ML; Laptook, AR; Shankaran, S; Finer, NN; Carlo, WA; Kennedy, KA; Fridriksson, JH; Steinhorn, RH; Sokol, GM; Konduri, GG; Aschner, JL; Stoll, BJ; D'Angio, CT; Stevenson, DK; Oh, W; Hensman, A; Gingras, D; Stoll, BJ; Jain, L; Hale, E; Seabrook, I; Sokol, G; Lorant, D; Appel, DD; Miller, L; Chriscinske, D; Attwood, J; Steinhorn, R; Sautel, M; Van Meurs, K; Ball, B; Proud, D; Carlo, WA; Cosby, SS; Johnson, RB; Fridriksson, J; Warner, B; Mersmann, M; Alexander, B; Shively, J; Mincey, H; Hoover, M; Sapienz, S; Stephenson, E; Finer, NN; Rasmussen, MR; Henderson, C; Demetrio, C; Rich, W; Joseph, C; Hudak, M; Osbeck, S; Case, E; Kellum, A; Hogans, L; D'Angio, CT; Reubens, L; Hutton, G; Laptook, A; Madison, S; Hensley, G; Miller, N; Metoyer, G; Kennedy, K; McDavid, G; Emerson, D; Konduri, G; Paquette, M; Wong, S; Aschner, J; O'Shea, TM; Peters, N; Hansell, BJ; Griffin, J; Adams, C; Shankaran, S; Bara, RA; Muran, G; Weekfall, W; Ehrenkranz, RA; Gettner, P; Caldwell, A; Oh, W; Fanaroff, AA; Goldberg, RN; Stoll, BJ; Lemons, JA; Stevenson, DK; Carlo, WA; Donovan, EF; Finer, NN; Duara, S; Phelps, DL; Laptook, AR; Tyson, JE; O'Shea, TM; Shankaran, S; Ehrenkranz, RA; Jobe, A; Poole, WK; Hastings, B; Petrie, C; Higgins, RD; Wright, LL; McClure, E; Bulas, D; Mertens, D; Slovis, T; Avery, G; D'Alton, M; Poole, WK; Fletcher, JC; Gleason, CA; Redmond, C		Preemie Inhaled Nitric Oxide Study	Inhaled nitric oxide for premature infants with severe respiratory failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYALINE-MEMBRANE DISEASE; PERSISTENT PULMONARY-HYPERTENSION; RANDOMIZED CONTROLLED-TRIAL; DISTRESS-SYNDROME; PLATELET-AGGREGATION; BLEEDING-TIME; NEWBORN; TERM; ENDOTHELIUM; PRESSURE	Background: Inhaled nitric oxide is a controversial treatment for premature infants with severe respiratory failure. We conducted a multicenter, randomized, blinded, controlled trial to determine whether inhaled nitric oxide reduced the rate of death or bronchopulmonary dysplasia in such infants. Methods: We randomly assigned 420 neonates, born at less than 34 weeks of gestation, with a birth weight of 401 to 1500 g, and with respiratory failure more than four hours after treatment with surfactant to receive placebo (simulated flow) or inhaled nitric oxide (5 to 10 ppm). Infants with a response (an increase in the partial pressure of arterial oxygen of more than 10 mm Hg) were weaned according to protocol. Treatment with study gas was discontinued in infants who did not have a response. Results: The rate of death or bronchopulmonary dysplasia was 80 percent in the nitric oxide group, as compared with 82 percent in the placebo group (relative risk, 0.97; 95 percent confidence interval, 0.86 to 1.06; P=0.52), and the rate of bronchopulmonary dysplasia was 60 percent versus 68 percent (relative risk, 0.90; 95 percent confidence interval, 0.75 to 1.08; P=0.26). There were no significant differences in the rates of severe intracranial hemorrhage or periventricular leukomalacia. Post hoc analyses suggest that rates of death and bronchopulmonary dysplasia are reduced for infants with a birth weight greater than 1000 g, whereas infants weighing 1000 g or less who are treated with inhaled nitric oxide have higher mortality and increased rates of severe intracranial hemorrhage. Conclusions: The use of inhaled nitric oxide in critically ill premature infants weighing less than 1500 g does not decrease the rates of death or bronchopulmonary dysplasia. Further trials are required to determine whether inhaled nitric oxide benefits infants with a birth weight of 1000 g or more.	Stanford Univ, Sch Med, Dept Pediat, Div Neonatol & Dev Med, Palo Alto, CA 94304 USA; NICHHD, NICHD, Bethesda, MD 20892 USA; Yale Univ, Sch Med, New Haven, CT USA; Indiana Univ, Sch Med, Indianapolis, IN USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; Brown Univ, Women & Infants Hosp, Providence, RI USA; Univ Florida, Jacksonville, FL USA; Wayne State Univ, Detroit, MI USA; Univ Calif San Diego, San Diego, CA 92103 USA; Univ Alabama, Birmingham, AL USA; Univ Texas, Houston, TX USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Northwestern Univ, Chicago, IL 60611 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; Emory Univ, Sch Med, Atlanta, GA USA; Univ Rochester, Rochester, NY USA	Stanford University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Yale University; Indiana University System; Indiana University-Purdue University Indianapolis; Research Triangle Institute; Brown University; Women & Infants Hospital Rhode Island; State University System of Florida; University of Florida; Wayne State University; University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham; University of Texas System; University System of Ohio; University of Cincinnati; Northwestern University; Medical College of Wisconsin; Wake Forest University; Wake Forest Baptist Medical Center; Emory University; University of Rochester	Van Meurs, KP (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Div Neonatol & Dev Med, 750 Welch Rd,Suite 315, Palo Alto, CA 94304 USA.	vanmeurs@stanford.edu	Steinhorn, Robin/A-4248-2010	Steinhorn, Robin/0000-0002-0344-2328	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD027880, U10HD027871, U10HD040461, U10HD021385, U10HD027904, U10HD027856, U10HD027853, U10HD021373, U10HD034216, U10HD027851, U10HD040689] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD040498, U10HD040521, U01HD036790] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000750, M01RR000044, M01RR008084, M01RR000039, M01RR006022, M01RR000070] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR06022, M01 RR08084, M01 RR00039, M01 RR00044, M01 RR00070, M01 RR00750] Funding Source: Medline; NICHD NIH HHS [U10 HD40461, U10 HD40498, U10 HD40521, U10 HD40689, U10 HD34216, U10 HD27904, U10 HD27880, U10 HD27871, U01 HD36790, U10 HD 21373, U10 HD21385, U10 HD27851, U10 HD27853, U10 HD27856] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1997, NEW ENGL J MED, V337, P434; BARRINGTON KJ, 2001, COCHRANE DB SYST REV, V4; Charafeddine L, 1999, PEDIATRICS, V103, P759, DOI 10.1542/peds.103.4.759; Cheung PY, 1998, LANCET, V351, P1181, DOI 10.1016/S0140-6736(05)79127-3; Christou H, 1998, PEDIATRICS, V102, P1390, DOI 10.1542/peds.102.6.1390; EVANS NJ, 1991, ARCH DIS CHILD-FETAL, V66, P6, DOI 10.1136/adc.66.1_Spec_No.6; *FRANC BELG COLL N, 1999, LANCET, V354, P1826; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; FROSTELL C, 1991, CIRCULATION, V84, P2212; FURLONG B, 1987, BRIT J PHARMACOL, V90, P687, DOI 10.1111/j.1476-5381.1987.tb11221.x; George TN, 1998, J PEDIATR-US, V132, P731, DOI 10.1016/S0022-3476(98)70370-1; HALLIDAY H, 1977, PEDIATRICS, V60, P444; HOGMAN M, 1993, LANCET, V341, P1664, DOI 10.1016/0140-6736(93)90802-N; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Kinsella JP, 1997, PEDIATR RES, V41, P457, DOI 10.1203/00006450-199704000-00002; Kinsella JP, 1999, LANCET, V354, P1061, DOI 10.1016/S0140-6736(99)03558-8; Konduri GG, 2004, PEDIATRICS, V113, P559, DOI 10.1542/peds.113.3.559; Lemons JA, 2000, PEDIATRICS, V106, P344; Mercier JC, 1999, LANCET, V354, P1066; Mestan KKL, 2005, NEW ENGL J MED, V353, P23, DOI 10.1056/NEJMoa043514; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PELIOWSKI A, 1995, J PEDIATR-US, V126, P450, DOI 10.1016/S0022-3476(95)70467-1; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; ROZE JC, 1994, LANCET, V344, P303, DOI 10.1016/S0140-6736(94)91341-2; SCHAFFER DB, 1993, OPHTHALMOLOGY, V100, P230; Schreiber MD, 2003, NEW ENGL J MED, V349, P2099, DOI 10.1056/NEJMoa031154; SKINNER JR, 1992, ARCH DIS CHILD-FETAL, V67, P366, DOI 10.1136/adc.67.4_Spec_No.366; Stork E, 1997, NEW ENGL J MED, V336, P597; SUBHEDAR NV, 1997, ARCH DIS CHILD, V77, P185; Truffert P, 2003, EUR J PEDIATR, V162, P646, DOI 10.1007/s00431-002-1134-2; VanMeurs KP, 1997, PEDIATR PULM, V24, P319; Walsh MC, 2004, PEDIATRICS, V114, P1305, DOI 10.1542/peds.2004-0204; WALTHER FJ, 1992, PEDIATRICS, V90, P899; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	35	198	201	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2005	353	1					13	22		10.1056/NEJMoa043927	http://dx.doi.org/10.1056/NEJMoa043927			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942FC	16000352				2022-12-28	WOS:000230267300004
J	He, J; Gu, DF; Wu, XG; Chen, JC; Duan, XF; Chen, J; Whelton, PK				He, J; Gu, DF; Wu, XG; Chen, JC; Duan, XF; Chen, J; Whelton, PK			Effect of soybean protein on blood pressure: A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; DIETARY-PROTEIN; SOY PROTEIN; BLADDER-CANCER; INCREASED RISK; UNITED-STATES; HYPERTENSION; METAANALYSIS; CHINESE; MEN	Background: Epidemiologic studies suggest that vegetable protein intake is inversely related to blood pressure. Objective: To examine the effect of soybean protein supplementation on blood pressure in persons with prehypertension or stage 1 hypertension. Design: Randomized, double-blind, controlled trial. Setting: Three communities in the People's Republic of China. Patients: 302 participants 35 to 64 years of age with an initial untreated systolic blood pressure of 130 to 159 mm Hg, diastolic blood pressure of 80 to 99 mm Hg, or both. Intervention: Study participants were randomly assigned to receive 40 g of isolated soybean protein supplements per day or complex carbohydrate control for 12 weeks; 91.4% completed the intervention. Measurements: Blood pressure measurements were obtained by using random-zero sphygmomanometers at baseline and at 6 and 12 weeks. Results: At baseline, the mean systolic and diastolic blood pressures were 135.0 mm Hg (SD 10.9) and 84.7 mm Hg (SD 6.9), respectively. Compared with the control group, the net changes in systolic blood pressure and diastolic blood pressure were -4.31 mm Hg (95% Cl, -2.11 to -6.51 mm Hg; P < 0.001) and -2.76 mm Hg (Cl, -1.35 to -4.16 mm Hg; P < 0.001), respectively, after the 12-week intervention. The net changes in systolic and diastolic blood pressure reductions were -7.88 mm Hg (Cl, -4.66 to -11.1 mm Hg) and -5.27 mm Hg (Cl, -3.05 to -7.49 mm Hg), respectively, in persons with hypertension and -2.34 mm Hg (Cl, 0.48 to -5.17 mm Hg) and -1.28 mm Hg (Cl, 0.52 to -3.07 mm Hg), respectively, in those without hypertension. Limitations: This trial did not examine whether the blood pressure reduction was due to protein or isoflavones in soybean. Conclusions: Soybean protein supplementation resulted in a reduction in systolic and diastolic blood pressure. These findings suggest that increased intake of soybean protein may play an important role in preventing and treating hypertension.	Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA; Chinese Acad Med Sci, Cardiovasc Inst, Beijing 100037, Peoples R China; Chinese Acad Med Sci, Fuwai Hosp, Beijing 100037, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China	Tulane University; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	He, J (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1430 Tulane Ave SL 18, New Orleans, LA 70112 USA.	jhe@tulane.edu	He, Jiang/AAF-5303-2020	He, Jiang/0000-0002-8286-9652	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068057] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON GH, 1986, CAN J PHYSIOL PHARM, V64, P863, DOI 10.1139/y86-149; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Burke V, 2001, HYPERTENSION, V38, P821, DOI 10.1161/hy1001.092614; CHEN J, 1990, DIET LFIESTYLE MORTA, P570; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; CLARK BA, 1992, HYPERTENSION, V19, P589, DOI 10.1161/01.HYP.19.6.589; Crouse JR, 1999, ARCH INTERN MED, V159, P2070, DOI 10.1001/archinte.159.17.2070; Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S; ELLIOTT P, 1992, J HYPERTENS, V10, pS141; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; Gu DF, 2002, HYPERTENSION, V40, P920, DOI 10.1161/01.HYP.0000040263.94619.D5; Gu DF, 2001, J HYPERTENS, V19, P1325, DOI 10.1097/00004872-200107000-00019; Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199; Hajjar IM, 2001, ARCH INTERN MED, V161, P589, DOI 10.1001/archinte.161.4.589; He JA, 1995, J HYPERTENS, V13, P1267, DOI 10.1097/00004872-199511000-00008; HISHIKAWA K, 1992, JPN HEART J, V33, P41; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; *I NUTR FOOD SAF C, 2002, CHIN FOOD COMP 2002; Iritani N, 1997, J NUTR, V127, P1077, DOI 10.1093/jn/127.6.1077; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; Kuchel O, 1998, AM J PHYSIOL-REG I, V275, pR1164, DOI 10.1152/ajpregu.1998.275.4.R1164; Lavigne C, 2000, AM J PHYSIOL-ENDOC M, V278, pE491, DOI 10.1152/ajpendo.2000.278.3.E491; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NAKAKI T, 1990, LANCET, V336, P696, DOI 10.1016/0140-6736(90)92196-O; Obarzanek E, 1996, JAMA-J AM MED ASSOC, V275, P1598, DOI 10.1001/jama.275.20.1598; Stamler J, 1996, CIRCULATION, V94, P1629, DOI 10.1161/01.CIR.94.7.1629; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Stamler J, 2002, HYPERTENSION, V39, P1000, DOI 10.1161/01.HYP.0000016178.80811.D9; Sun CL, 2004, INT J CANCER, V112, P319, DOI 10.1002/ijc.20384; Sun CL, 2002, CANCER EPIDEM BIOMAR, V11, P1674; Washburn S, 1999, MENOPAUSE, V6, P7; Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624; Whelton SP, 2002, ANN INTERN MED, V136, P493, DOI 10.7326/0003-4819-136-7-200204020-00006; WILLIAMS M, 1986, J CLIN INVEST, V78, P1687, DOI 10.1172/JCI112763; Xin X, 2001, HYPERTENSION, V38, P1112, DOI 10.1161/hy1101.093424; Zhao LC, 2004, HYPERTENSION, V43, P1332, DOI 10.1161/01.HYP.0000128243.06502.bc	40	140	154	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 5	2005	143	1					1	9		10.7326/0003-4819-143-1-200507050-00004	http://dx.doi.org/10.7326/0003-4819-143-1-200507050-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941XB	15998749				2022-12-28	WOS:000230246400001
J	Decullier, E; Lheritier, V; Chapuis, F				Decullier, E; Lheritier, V; Chapuis, F			Fate of biomedical research protocols and publication bias in France: retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; FOLLOW-UP; REGISTRATION; COMMITTEE	Objectives To describe the fate of protocols approved by the French research ethics committees, a national system created by the French 1988 Huriet-Serusclat Act; to assess publication bias at a national level. Design Retrospective cohort study. Setting Representative sample of 25/48 French research ethics committees in 1994. Protocols 649 research protocols approved by committees, with follow-up information. Main outcome measures Protocols' initial characteristics (design, study size, investigator) abstracted from committees' archives; follow-up information (rates of initiation, completion, and publication) obtained from mailed questionnaire to principal investigators. Results Completed questionnaires were available for 649/976 (69%) protocols. Of these, 581 (90%) studies were initiated, 501/581 (86%) were completed, and 190/501 (38%) were published. Studies with confirmatory results were more likely to be published as scientific papers than were studies with inconclusive results (adjusted odds ratio 4.59, 95% confidence interval 2.21 to 9.54). Moreover, studies with confirmatory results were published more quickly than studies with inconclusive results (hazard ratio 2.48, 1.36 to 4.55). Conclusion At a national level, too many research studies are not completed, and among those completed too many are not published. We suggest capitalising on research ethics committees to register and follow all authorised research on human participants on a systematic and prospective basis.	Hop Hotel Dieu, French Natl Confederat Res Eth Comm, F-69002 Lyon, France; Hosp Civils Lyon, DIM, Clin Res Unit, F-69424 Lyon, France; Hop Hotel Dieu, CCPPRB Lyon B, F-69002 Lyon, France	CHU Lyon; CHU Lyon; CHU Lyon	Chapuis, F (corresponding author), Hop Hotel Dieu, French Natl Confederat Res Eth Comm, F-69002 Lyon, France.	francois.chapuis@chu-lyon.fr	decullier, evelyne/AAL-5861-2021					Abbasi K, 2004, BRIT MED J, V329, P637, DOI 10.1136/bmj.329.7467.637; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; De Angelis C, 2004, MED J AUSTRALIA, V181, P293, DOI 10.5694/j.1326-5377.2004.tb06290.x; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1992, CONTROL CLIN TRIALS, V13, P170, DOI 10.1016/0197-2456(92)90022-R; EASTERBROOK P, 1987, BRIT MED J, V295, P1347, DOI 10.1136/bmj.295.6609.1347-a; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; EASTERBROOK PJ, 1992, J ROY SOC MED, V85, P71; GREENWALD AG, 1975, PSYCHOL BULL, V82, P1, DOI 10.1037/h0076157; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; Pich J, 2003, LANCET, V361, P1015, DOI 10.1016/S0140-6736(03)12799-7; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640	13	106	107	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	2005	331	7507					19	22		10.1136/bmj.38488.385995.8F	http://dx.doi.org/10.1136/bmj.38488.385995.8F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947TD	15967761	Green Published, Bronze			2022-12-28	WOS:000230668500016
J	Glass, RI; Steele, AD				Glass, RI; Steele, AD			The value of cholera vaccines reassessed	LANCET			English	Editorial Material							VACCINATION		Ctr Dis Control & Prevent, Viral Gastroenteritis Sect, Atlanta, GA 30333 USA; World Hlth Org, Initiat Vaccine Res, Geneva, Switzerland	Centers for Disease Control & Prevention - USA; World Health Organization	Glass, RI (corresponding author), Ctr Dis Control & Prevent, Viral Gastroenteritis Sect, Atlanta, GA 30333 USA.	rglass@cdc.gov		Steele, Andrew Duncan/0000-0002-4946-037X				Ali M, 2002, HEALTH PLACE, V8, P201, DOI 10.1016/S1353-8292(01)00043-0; Calain P, 2004, VACCINE, V22, P2444, DOI 10.1016/j.vaccine.2003.11.070; CLEMENS JD, 1986, LANCET, V2, P124; Connolly MA, 2004, LANCET, V364, P1974, DOI 10.1016/S0140-6736(04)17481-3; Drazen JM, 2005, NEW ENGL J MED, V352, P827, DOI 10.1056/NEJMe058031; GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498; Longini IM, 2002, STAT MED, V21, P481, DOI 10.1002/sim.994; Lucas MES, 2005, NEW ENGL J MED, V352, P757, DOI 10.1056/NEJMoa043323; *WHO GLOB TASK FOR, 2002, WHO M DEC 10 11 2002	9	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	2005	366	9479					7	9		10.1016/S0140-6736(05)66551-8	http://dx.doi.org/10.1016/S0140-6736(05)66551-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942JB	15993211				2022-12-28	WOS:000230277600006
J	Roos, DS				Roos, DS			Themes and variations in apicomplexan parasite biology	SCIENCE			English	Editorial Material							GENOME SEQUENCE; PLASMODIUM-FALCIPARUM; TOXOPLASMA-GONDII; MALARIA; VIRULENCE; PROTEINS; STRATEGIES; INVASION		Univ Penn, Genom Inst, Philadelphia, PA 19104 USA	University of Pennsylvania	Roos, DS (corresponding author), Univ Penn, Genom Inst, Philadelphia, PA 19104 USA.	droos@sas.upenn.edu		Roos, David Siker/0000-0001-6725-4089				Abrahamsen MS, 2004, SCIENCE, V304, P441, DOI 10.1126/science.1094786; Blackman MJ, 2001, MOL BIOCHEM PARASIT, V117, P11, DOI 10.1016/S0166-6851(01)00328-0; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; Deitsch KW, 2004, TRENDS PARASITOL, V20, P562, DOI 10.1016/j.pt.2004.09.002; Dobbelaere D. A. E., 2002, THEILERIA; Dobbelaere DAE, 2004, CURR OPIN IMMUNOL, V16, P524, DOI 10.1016/j.coi.2004.05.009; Gardner MJ, 2005, SCIENCE, V309, P134, DOI 10.1126/science.1110439; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; Hu K, 2002, J CELL BIOL, V156, P1039, DOI 10.1083/jcb.200112086; Jung C, 2004, INT J PARASITOL, V34, P285, DOI 10.1016/j.ijpara.2003.12.004; Kissinger JC, 2003, NUCLEIC ACIDS RES, V31, P234, DOI 10.1093/nar/gkg072; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; Li L, 2003, GENOME RES, V13, P443, DOI 10.1101/gr.693203; Lingelbach K, 1998, J CELL SCI, V111, P1467; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; Norval RAI., 1992, EPIDEMIOLOGY THEILER; Pain A, 2005, SCIENCE, V309, P131, DOI 10.1126/science.1110418; Ralph SA, 2004, NAT REV MICROBIOL, V2, P203, DOI 10.1038/nrmicro843; Shaw MK, 2003, TRENDS PARASITOL, V19, P2, DOI 10.1016/S1471-4922(02)00015-6; Sibley LD, 2004, SCIENCE, V304, P248, DOI 10.1126/science.1094717; Striepen B, 2004, P NATL ACAD SCI USA, V101, P3154, DOI 10.1073/pnas.0304686101; Templeton TJ, 2004, GENOME RES, V14, P1686, DOI 10.1101/gr.2615304; Xu P, 2004, NATURE, V431, P1107, DOI 10.1038/nature02977	25	27	27	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 1	2005	309	5731					72	73		10.1126/science.1115252	http://dx.doi.org/10.1126/science.1115252			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15994520				2022-12-28	WOS:000230212800037
J	Chao, WL; Harteneck, BD; Liddle, JA; Anderson, EH; Attwood, DT				Chao, WL; Harteneck, BD; Liddle, JA; Anderson, EH; Attwood, DT			Soft X-ray microscopy at a spatial resolution better than 15nm	NATURE			English	Article							ELECTRON-BEAM LITHOGRAPHY; MAGNETIC NANOSTRUCTURES; TRANSMISSION MICROSCOPY; WATER; TOMOGRAPHY; DOMAINS	Analytical tools that have spatial resolution at the nanometre scale are indispensable for the life and physical sciences. It is desirable that these tools also permit elemental and chemical identification on a scale of 10 nm or less, with large penetration depths. A variety of techniques(1-7) in X-ray imaging are currently being developed that may provide these combined capabilities. Here we report the achievement of sub-15-nm spatial resolution with a soft X-ray microscope - and a clear path to below 10 nm - using an overlay technique for zone plate fabrication. The microscope covers a spectral range from a photon energy of 250 eV (similar to 5 nm wavelength) to 1.8 keV (similar to 0.7 nm), so that primary K and L atomic resonances of elements such as C, N, O, Al, Ti, Fe, Co and Ni can be probed. This X-ray microscopy technique is therefore suitable for a wide range of studies: biological imaging in the water window(8,9); studies of wet environmental samples(10,11); studies of magnetic nanostructures with both elemental and spin-orbit sensitivity(12-14); studies that require viewing through thin windows, coatings or substrates ( such as buried electronic devices in a silicon chip(15)); and three-dimensional imaging of cryogenically fixed biological cells(9,16).	Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Xray Opt, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Chao, WL (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Xray Opt, 1 Cyclotron Rd,MS 2-400, Berkeley, CA 94720 USA.	wlchao@lbl.gov	Liddle, James A/A-4867-2013	Liddle, James A/0000-0002-2508-7910				Anderson EH, 2004, MICROELECTRON ENG, V73-4, P74, DOI 10.1016/j.mee.2004.02.019; Anderson EH, 2000, J VAC SCI TECHNOL B, V18, P2970, DOI 10.1116/1.1321282; Anderson EH, 1995, J VAC SCI TECHNOL B, V13, P2529, DOI 10.1116/1.588387; Attwood D., 2000, SOFT XRAYS EXTREME U; BORN M, 1999, PRINCIPLES OPTICS, P596; Chao W, 2003, J VAC SCI TECHNOL B, V21, P3108, DOI 10.1116/1.1619956; Chao WL, 2003, OPT LETT, V28, P2019, DOI 10.1364/OL.28.002019; Di Fabrizio E, 1999, NATURE, V401, P895, DOI 10.1038/44791; Eisebitt S, 2004, NATURE, V432, P885, DOI 10.1038/nature03139; Fischer P, 1996, Z PHYS B CON MAT, V101, P313, DOI 10.1007/s002570050214; Fischer P, 2002, J PHYS D APPL PHYS, V35, P2391, DOI 10.1088/0022-3727/35/19/310; Gibson EA, 2003, SCIENCE, V302, P95, DOI 10.1126/science.1088654; GOODMAN JW, 2000, STAT OPTICS, P303; Jochum E., 1995, SYNCHROTRON RAD NEWS, V8, P29; Juenger MCG, 2003, J MATER SCI LETT, V22, P1335, DOI 10.1023/A:1025731210337; Kipp L, 2001, NATURE, V414, P184, DOI 10.1038/35102526; Larabell CA, 2004, MOL BIOL CELL, V15, P957, DOI 10.1091/mbc.E03-07-0522; Larotonda MA, 2004, IEEE J SEL TOP QUANT, V10, P1363, DOI 10.1109/JSTQE.2004.838038; Marchesini S, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.140101; Meyer-Ilse W, 2001, J MICROSC-OXFORD, V201, P395, DOI 10.1046/j.1365-2818.2001.00845.x; Miao JW, 1999, NATURE, V400, P342, DOI 10.1038/22498; Miao JW, 2003, P NATL ACAD SCI USA, V100, P110, DOI 10.1073/pnas.232691299; Myneni SCB, 1999, SCIENCE, V286, P1335, DOI 10.1126/science.286.5443.1335; SCHMAHL G, 1984, XRAY MICROSCOPY; Schneider G, 2002, J VAC SCI TECHNOL B, V20, P3089, DOI 10.1116/1.1523403; Schneider G, 2002, SURF REV LETT, V9, P177, DOI 10.1142/S0218625X02001914; Stoll H, 2004, APPL PHYS LETT, V84, P3328, DOI 10.1063/1.1723698; SUSINI J, 2003, XRAY MICROSCOPY, V7; Toh K. K. H., 1987, Proceedings of the SPIE - The International Society for Optical Engineering, V772, P202, DOI 10.1117/12.967051; Vogt U, 2004, APPL PHYS B-LASERS O, V78, P53, DOI 10.1007/s00340-003-1338-9; Yasin S, 2001, APPL PHYS LETT, V78, P2760, DOI 10.1063/1.1369615	31	682	740	12	211	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 30	2005	435	7046					1210	1213		10.1038/nature03719	http://dx.doi.org/10.1038/nature03719			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988520				2022-12-28	WOS:000230140500038
J	Lyamin, O; Pryaslova, J; Lance, V; Siegel, J				Lyamin, O; Pryaslova, J; Lance, V; Siegel, J			Continuous activity in cetaceans after birth	NATURE			English	Editorial Material							SLEEP-DEPRIVATION; STATE; DROSOPHILA		Univ Calif Los Angeles, North Hills, CA 91343 USA; VA GLAHS, North Hills, CA 91343 USA; Utrish Dolphinarium, Moscow 119071, Russia; San Diego State Univ, San Diego, CA 92182 USA	University of California System; University of California Los Angeles; California State University System; San Diego State University	Siegel, J (corresponding author), Univ Calif Los Angeles, North Hills, CA 91343 USA.	jsiegel@ucla.edu	Lyamin, Oleg/AAO-4881-2020	Lyamin, Oleg/0000-0003-2049-0943	NINDS NIH HHS [R01 NS042947] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BONNET MH, 1989, PHYSIOL BEHAV, V45, P1049, DOI 10.1016/0031-9384(89)90236-9; FLANIGAN WF, 1975, SLEEP RES, V4, P139; HOPPENBROUWERS T, 1975, EXP NEUROL, V49, P822, DOI 10.1016/0014-4886(75)90062-X; Lyamin OI, 2004, ARCH ITAL BIOL, V142, P557; Lyamin OI, 2002, BEHAV BRAIN RES, V129, P125, DOI 10.1016/S0166-4328(01)00346-1; RECHTSCHAFFEN A, 1983, SCIENCE, V221, P182, DOI 10.1126/science.6857280; Rechtschaffen A, 2002, SLEEP, V25, P18, DOI 10.1093/sleep/25.1.18; ROFFWARG HP, 1966, SCIENCE, V152, P604, DOI 10.1126/science.152.3722.604; Shaw PJ, 2000, SCIENCE, V287, P1834, DOI 10.1126/science.287.5459.1834; Shaw PJ, 2002, NATURE, V417, P287, DOI 10.1038/417287a	10	96	100	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1177	1177		10.1038/4351177a	http://dx.doi.org/10.1038/4351177a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15988513	Green Accepted, Bronze			2022-12-28	WOS:000230140500031
J	O'Connor, AR; Morgan, WE				O'Connor, AR; Morgan, WE			Radiological review of pneumothorax	BMJ-BRITISH MEDICAL JOURNAL			English	Review								Spontaneous pneumothorax is relatively common in the community.(1) The incidence of iatrogenic pneumothorax is difficult to assess but is probably increasing due to the more widespread use of mechanical ventilation and interventional procedures such as central line placement and lung biopsy. Correct interpretation of chest radiographs in this clinical setting and knowledge of when to request more complex imaging techniques are essential. In this review we discuss the role of the chest radiograph in the assessment of pneumothorax before and after treatment along with the value of computed tomography and radiologically guided chest drain placement.	City Hosp Nottingham, Dept Radiol, Nottingham NG5 1PB, England; City Hosp Nottingham, Dept Thorac Surg, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital	O'Connor, AR (corresponding author), City Hosp Nottingham, Dept Radiol, Hucknall Rd, Nottingham NG5 1PB, England.	angusoconnor@hotmail.com						Baumann MH, 2001, CHEST, V119, P590, DOI 10.1378/chest.119.2.590; GLAZER HS, 1989, RADIOLOGY, V173, P707, DOI 10.1148/radiology.173.3.2813774; Henry M, 2003, THORAX S2, V58, P39, DOI DOI 10.1136/TH0RAX.58.SUPPL_21I39; Kurihara Y, 1999, RADIOGRAPHICS, V19, P105, DOI 10.1148/radiographics.19.1.g99ja02105; Laws D, 2003, THORAX, V58, pII53, DOI 10.1136/thorax.58.suppl_2.ii53; MEHOLIC A, 1996, FUNDAMENTALS CHEST R, P29; MELTON LJ, 1979, AM REV RESPIR DIS, V120, P1379; Seow A, 1996, AM J ROENTGENOL, V166, P313, DOI 10.2214/ajr.166.2.8553937	8	33	37	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 25	2005	330	7506					1493	1497		10.1136/bmj.330.7506.1493	http://dx.doi.org/10.1136/bmj.330.7506.1493			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942NR	15976424	Green Published			2022-12-28	WOS:000230289600024
J	Ruta, D; Mitton, C; Bate, A; Donaldson, C				Ruta, D; Mitton, C; Bate, A; Donaldson, C			Programme budgeting and marginal analysis: bridging the divide between doctors and managers	BRITISH MEDICAL JOURNAL			English	Article							NEEDS ASSESSMENT	Recent NHS reforms give doctors increased responsibility for efficient and fair use of resources. Programme budgeting and marginal analysis is one way to ensure the views of all stakeholders are properly represented.	Univ Newcastle, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ British Columbia, Ctr Healthcare Innovat & Improvement, Res Inst Childrens & Womens Hlth, Vancouver, BC V6H 3V4, Canada	Newcastle University - UK; University of British Columbia	Ruta, D (corresponding author), Univ Newcastle, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.	danny.ruta@ncl.ac.uk	Bate, Angela/AAR-1027-2020; Ruta, Danny A/E-4472-2013	Bate, Angela/0000-0001-5277-4188; Ruta, Danny/0000-0002-2024-3267; Donaldson, Cam/0000-0003-4670-5340	Economic and Social Research Council [RES-451-25-4087] Funding Source: researchfish	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		COHEN D, 1994, BRIT MED J, V309, P781, DOI 10.1136/bmj.309.6957.781; CRAIG N, 1995, HEALTH POLICY, V33, P107, DOI 10.1016/0168-8510(95)93672-N; Crosson FJ, 2003, BRIT MED J, V326, P654, DOI 10.1136/bmj.326.7390.654; Davies HTO, 2003, BMJ-BRIT MED J, V326, P646, DOI 10.1136/bmj.326.7390.646; DONALDSON C, 1993, HEALTH POLICY, V25, P95, DOI 10.1016/0168-8510(93)90105-X; Donaldson C, 2004, PRIORITY SETTING TOO; Greschner Donna, 2003, CANADIAN BAR REV, V82, P501; Ham C, 2003, LANCET, V361, P1978, DOI 10.1016/S0140-6736(03)13593-3; Lockett T, 1995, PRIORITY SETTING ACT; McDonald R, 2002, USING HLTH EC HLTH S; Mitton Craig, 2003, Appl Health Econ Health Policy, V2, P121; PEACOCK S, 1997, PROGRAM BUDGETING MA; Ruta D A, 1996, J Health Serv Res Policy, V1, P185	13	44	44	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 25	2005	330	7506					1501	1503		10.1136/bmj.330.7506.1501	http://dx.doi.org/10.1136/bmj.330.7506.1501			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942NR	15976426	Green Published			2022-12-28	WOS:000230289600026
J	Olsen, NJ				Olsen, NJ			Tailoring arthritis therapy in the wake of the NSAID crisis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olsen, NJ (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.								0	11	11	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					2578	2580		10.1056/NEJMp058105	http://dx.doi.org/10.1056/NEJMp058105			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972863				2022-12-28	WOS:000229953700004
J	Lakhani, A; Coles, J; Eayres, D; Spence, C; Rachet, B				Lakhani, A; Coles, J; Eayres, D; Spence, C; Rachet, B			Creative use of existing clinical and health outcomes data to assess NHS performance in England: Part 1 - performance indicators closely linked to clinical care	BRITISH MEDICAL JOURNAL			English	Article								There have been several recent calls for better data on NHS outputs and outcomes in England, which will require new data collection with long lead times. In this, the first of two articles, the authors show what can be done now with existing routine data across many sectors and raise issues about assumptions and technical aspects for discussion.	London Sch Hyg & Trop Med, Natl Ctr Hlth Outcomes Dev, London WC1E 6AZ, England; CASPE Res, London W1G 0AN, England; Northgate Informat Solut, Hemel Hempstead HP2 7HU, Herts, England; London Sch Hyg & Trop Med, Noncommunicable Dis Epidemiol Unit, London, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Lakhani, A (corresponding author), London Sch Hyg & Trop Med, Natl Ctr Hlth Outcomes Dev, London WC1E 6AZ, England.	Azim.Lakhani@lshun.ac.uk		Sanderson, Colin/0000-0002-4838-6112; Rachet, Bernard/0000-0001-5837-7773				Atkinson A., 2004, ATKINSON REV INTERIM; *CENTR HLTH MON UN, 1996, 96CC0036 NHS EX CENT; Coleman MP, 1999, SERIES SMPS, V61, P1; *DEP HLTH, 2002, HOSP EP STAT; *DEP HLTH, HLTH SURV ENGL TREND; Department of Health, 2004, CHIEF EX REP NHS; Department of Health [London], 2002, NHS PERF IND; Jarman B, 2004, BMJ-BRIT MED J, V329, P73, DOI 10.1136/bmj.329.7457.73; LAKHANI A, 2000, HARNESSING OFFICIAL; LAKHANI A, IN PRESS BMJ; LAKHANI A, 2003, COMPENDIUM CLIN HLTH; MASON A, 2000, USING CASE FATALITY; Nolte E. M. McKee, 2004, DOES HEALTHCARE SAVE; *OFF NAT STAT, ON 5 YEAR SURV PAT D; RUDD A, 1999, HLTH OUTCOME INDICAT; Smith R, 2003, BRIT MED J, V327, P1239, DOI 10.1136/bmj.327.7426.1239	16	32	32	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 18	2005	330	7505					1426	1431		10.1136/bmj.330.7505.1426	http://dx.doi.org/10.1136/bmj.330.7505.1426			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938NP	15961815	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000230010400019
J	Lin, J; Shaw, AS				Lin, J; Shaw, AS			Getting downstream without a raft	CELL			English	Editorial Material							PROTEIN-TYROSINE KINASE; T-CELL-ACTIVATION; LIPID RAFTS; PALMITOYLATION; LAT	Douglass and Vale (2005) use single-molecule fluorescence to suggest that protein-protein interactions, not detergent insolubility, regulate the assembly of signaling complexes in the plasma membrane.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL)	Lin, J (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid,Box 8118, St Louis, MO 63110 USA.			Shaw, Andrey/0000-0001-5685-0272				Douglass AD, 2005, CELL, V121, P937, DOI 10.1016/j.cell.2005.04.009; Harder T, 2004, CURR OPIN IMMUNOL, V16, P353, DOI 10.1016/j.coi.2004.03.013; He HT, 2005, SEMIN IMMUNOL, V17, P23, DOI 10.1016/j.smim.2004.09.001; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	10	14	14	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 17	2005	121	6					815	816		10.1016/j.cell.2005.06.001	http://dx.doi.org/10.1016/j.cell.2005.06.001			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	938NX	15960968	Bronze			2022-12-28	WOS:000230011200003
J	Muhlschlegel, P; Eisler, HJ; Martin, OJF; Hecht, B; Pohl, DW				Muhlschlegel, P; Eisler, HJ; Martin, OJF; Hecht, B; Pohl, DW			Resonant optical antennas	SCIENCE			English	Article							SCATTERING; FORCES	We have fabricated nanometer-scate gold dipole antennas designed to be resonant at optical frequencies. On resonance, strong field enhancement in the antenna feed gap leads to white-light supercontinuum generation. The antenna length at resonance is considerably shorter than one-half the wavelength of the incident light. This is in contradiction to classical antenna theory but in qualitative accordance with computer simulations that take into account the finite metallic conductivity at optical frequencies. Because optical. antennas link propagating radiation and confined/enhanced optical fields, they should find applications in optical characterization, manipulation of nanostructures, and optical information processing.	Univ Basel, Inst Phys, Natl Ctr Competence Nanoscale Sci, Nanoopt Grp, CH-4056 Basel, Switzerland; Ecole Polytech Fed Lausanne, Swiss Fed Inst Technol, Nanophoton & Metrol Lab, CH-1015 Lausanne, Switzerland	University of Basel; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Hecht, B (corresponding author), Univ Basel, Inst Phys, Natl Ctr Competence Nanoscale Sci, Nanoopt Grp, Klingelbergstr 82, CH-4056 Basel, Switzerland.	bert.hecht@nano-optics.ch	Hecht, Bert/B-4996-2010	Hecht, Bert/0000-0002-4883-8676; Martin, Olivier J.F./0000-0002-9574-3119				ALFANO RR, 1970, PHYS REV LETT, V24, P584, DOI 10.1103/PhysRevLett.24.584; Barnes WL, 2003, NATURE, V424, P824, DOI 10.1038/nature01937; Beversluis MR, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.115433; BOYD GT, 1986, PHYS REV B, V33, P7923, DOI 10.1103/PhysRevB.33.7923; Bozhevolnyi SI, 2001, PHYS REV LETT, V86, P3008, DOI 10.1103/PhysRevLett.86.3008; Champert PA, 2004, OPT EXPRESS, V12, P4366, DOI 10.1364/OPEX.12.004366; Crozier KB, 2003, J APPL PHYS, V94, P4632, DOI 10.1063/1.1602956; Fromm DP, 2004, NANO LETT, V4, P957, DOI 10.1021/nl049951r; Fumeaux C, 1999, OPT LETT, V24, P1629, DOI 10.1364/OL.24.001629; Grober RD, 1997, APPL PHYS LETT, V70, P1354, DOI 10.1063/1.118577; Haes AJ, 2004, NANO LETT, V4, P1029, DOI 10.1021/nl049670j; Hallock AJ, 2005, P NATL ACAD SCI USA, V102, P1280, DOI 10.1073/pnas.0408604101; Hartschuh A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.095503; Jackson JB, 2003, APPL PHYS LETT, V82, P257, DOI 10.1063/1.1534916; JOHNSTON PB, 1972, PHYS REV B, V8, P4370; Kneipp K, 1997, PHYS REV LETT, V78, P1667, DOI 10.1103/PhysRevLett.78.1667; Knoll B, 1999, NATURE, V399, P134, DOI 10.1038/20154; Krenn JR, 1999, PHYS REV LETT, V82, P2590, DOI 10.1103/PhysRevLett.82.2590; Li KR, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.227402; Maier SA, 2003, NAT MATER, V2, P229, DOI 10.1038/nmat852; Michler P, 2000, SCIENCE, V290, P2282, DOI 10.1126/science.290.5500.2282; Novotny L, 1997, PHYS REV LETT, V79, P645, DOI 10.1103/PhysRevLett.79.645; Paulus M, 2001, J OPT SOC AM A, V18, P854, DOI 10.1364/JOSAA.18.000854; Pendry JB, 2004, SCIENCE, V305, P847, DOI 10.1126/science.1098999; Pohl D.W., 1991, ADV OPT ELECTRON MIC, V12, P243, DOI [10.1016/B978-0-12-029912-6.50009-9, DOI 10.1016/B978-0-12-029912-6.50009-9]; POHL DW, 2000, NEAR FIELD OPTICS PR, P22; Qin YD, 2001, CHINESE PHYS LETT, V18, P390, DOI 10.1088/0256-307X/18/3/327; Rechberger W, 2003, OPT COMMUN, V220, P137, DOI 10.1016/S0030-4018(03)01357-9; Schuck PJ, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.017402; Xu HX, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.246802	30	1823	1861	17	532	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1607	1609		10.1126/science.1111886	http://dx.doi.org/10.1126/science.1111886			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947182	Green Published			2022-12-28	WOS:000229827000050
